Novel nicotinamide derivative or salt thereof

ABSTRACT

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1  represents a halogen atom; R 2  represents a C 1-12  alkyl group, a C 2-12  alkenyl group, a C 2-12  alkynyl group, a C 3-8  cycloalkyl group, an aryl group, an ar-C 1-6  alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3  represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4  and R 5  each independently represent a hydrogen atom; and R 2  and R 4  may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

TECHNICAL FIELD

The present invention relates to a nicotinamide derivative having Syk-inhibitory activity or a salt thereof.

BACKGROUND ART

Spleen Tyrosine Kinase (Syk), which is a non-receptor type intracellular tyrosine kinase, plays essential roles for activation of B cells and in an intracellular signaling system mediated by an Fc receptor. For example, Syk is associated with a FcεRI signal that is an immunoglobulin E receptor in mast cells, basophils and other cells, and thus it regulates generation of inflammatory mediators such as histamine or leukotrien, as well as cytokine, from these cells. At the same time, Syk plays a role in transmitting activation signals caused by stimulation of Fcγ receptor into monocytes, dendritic cells and other cells (Non Patent Documents 1 and 2). Moreover, it has been reported that Syk is also associated with cytokine signaling caused by integrin, IL-13, IL-15 and the like (Non Patent Documents 3 and 4).

In the case of a B-cell, a signal is transmitted into the cell mediated by a BCR (B-cell antigen receptor) expressed on the cell membrane, so that activation and differentiation of the cell is induced, resulting in generation of an antibody. It has been reported that Syk is essential for such an activation and differentiation process (Non Patent Document 5).

It is anticipated that it is possible to suppress various cell responses by inhibiting Syk (Non Patent Documents 5 and 6).

In the case of a type I allergy, which is an immediate-type allergy reaction, for example, immunoglobulin E (IgE) binds to FcεRI, which is a high-affinity IgE receptor, and an allergen then binds thereto to promote activation of the FcεRI and the release of inflammatory mediator. As a result, allergic symptoms are expressed. It is anticipated that inhibition of Syk activity will lead to the suppression of the activation of the FcεRI, and that it will be useful for the treatment of representative type I allergy-related diseases such as bronchial asthma, allergic rhinitis, hives, and atopic dermatitis.

Moreover, it is considered that inhibition of Syk activity leads to the suppression of the activation and/or maturation of immune B cells and the generation of antibodies, and that such inhibition of Syk activity can also regulate immune reactions other than type I allergy. Accordingly, it is also anticipated that inhibition of Syk activity will be effective for autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.), autoimmune hemolytic anemia, nephrotic syndrome, contact dermatitis, and the like. Furthermore, since inhibition of Syk activity also leads to the suppression of the activation of macrophages, it is anticipated that inhibition of Syk will be also effective for idiopathic thrombocytopenic purpura.

Further, inhibition of Syk activity suppresses not only immune and/or inflammatory diseases, but also activation and proliferation of lymphocytes, including B-cells as typical examples. Thus, it is anticipated that inhibition of Syk will be also effective for the treatment of various types of proliferative diseases such as lymphoma and lymphocytic leukemia. Still further, since inhibition of Syk activity regulates proliferation and differentiation of bone marrow cells, it is anticipated that it will be also effective for acute myelocytic leukemia.

On the other hand, Syk has been known to be involved in signaling mediated by integrin which is a cell adhesion molecule. Since Syk is expressed in blood platelets and is involved in the activation thereof, an inhibitor of such Syk is anticipated to be effective as a therapeutic agent for diseases associated with the activation of blood platelets.

A large number of compounds having Syk-inhibitory activity have been reported (Patent Documents 1 to 4). In clinical tests in which rheumatoid arthritis and idiopathic thrombocytopenic purpura have been targeted, useful compounds (Non Patent Document 7) and compounds having Syk and/or JAK inhibitory activity (Patent Documents 5 to 8) have been reported.

PRIOR ART DOCUMENTS Patent Documents [Patent Document 1] International Publication WO00/75113

-   [Patent Document 2] JP Patent Publication (Kokai) No. 2008-013499 A -   [Patent Document 3] International Publication WO07/120,980 -   [Patent Document 4] International Publication WO07/124,221 -   [Patent Document 5] International Publication WO09/026,107 -   [Patent Document 6] International Publication WO09/131,687 -   [Patent Document 7] International Publication WO09/136,995 -   [Patent Document 8] International Publication WO09/145,856

Non Patent Documents

-   [Non Patent Document 1] The Journal of Biological Chemistry, Vol.     266, pp. 15790-15796, 1991 -   [Non Patent Document 2] International Journal of Hematology, Vol.     75, No. 4, pp. 357-362, 2002 -   [Non Patent Document 3] The Journal of Biological Chemistry, Vol.     270, pp. 16189-16197, 1995 -   [Non Patent Document 4] The Journal of Immunology, Vol. 167, No. 11,     pp. 6292-6302, 2001 -   [Non Patent Document 5] Expert Opinion on Investigational Drugs,     Vol. 13, No. 7, pp. 743-762, 2004 -   [Non Patent Document 6] Expert Opinion on Therapeutic Targets, Vol.     9, No. 5, pp. 901-921, 2005 -   [Non Patent Document 7] IDrugs, Vol. 12, No. 3, pp. 174-185, 2009

SUMMARY OF INVENTION Object to be Solved by the Invention

To date, various Syk inhibitors have been reported, but they have not been placed on the market yet. It has been desired to develop a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity.

Means for Solving the Object

As a result of intensive studies directed towards achieving the aforementioned object, the present inventors have found that a nicotinamide derivative having a specific structure or a salt thereof has excellent Syk-inhibitory activity, thereby completing the present invention.

Specifically, the nicotinamide derivative of the present invention or a pharmaceutically acceptable salt thereof is characterized in that it is represented by the following formula (I):

wherein R¹ represents a halogen atom; R² represents a C₁₋₁₂ alkyl group optionally having at least one substituent, a C₂₋₁₂ alkenyl group optionally having at least one substituent, a C₂₋₁₂ alkynyl group optionally having at least one substituent, a C₃₋₈ cycloalkyl group optionally having at least one substituent, an aryl group optionally having at least one substituent, an ar-C₁₋₆ alkyl group optionally having at least one substituent or a heterocyclic group optionally having at least one substituent; R³ represents an aryl group optionally having at least one substituent or a heterocyclic group optionally having at least one substituent; and R⁴ and R⁵ each independently represent a hydrogen atom, a C₁₋₁₂ alkyl group optionally having at least one substituent, a C₂₋₁₂ alkenyl group optionally having at least one substituent, or a C₂₋₁₂ alkynyl group optionally having at least one substituent.

In addition, the present invention provides a pharmaceutical composition comprising the above-described nicotinamide derivative or a salt thereof, particularly, a pharmaceutical composition for use in the treatment of a Syk-related disease, which comprises the above-described nicotinamide derivative or a salt thereof, and a pharmaceutical composition for use in the treatment of a disease selected from the group consisting of rheumatism and idiopathic thrombocytopenic purpura, which comprises the above-described nicotinamide derivative or a salt thereof.

From a further viewpoint, the present invention provides: use of the above-described nicotinamide derivative or a salt thereof for production of the above-described pharmaceutical composition; a method for treating a Syk-related disease, which comprises a step of administering a therapeutically effective amount of the above-described nicotinamide derivative or a salt thereof to mammals including a human; and a method for treating a disease selected from the group consisting of rheumatism and idiopathic thrombocytopenic purpura, which comprises a step of administering a therapeutically effective amount of the above-described nicotinamide derivative or a salt thereof to mammals including a human.

Effects of the Invention

The nicotinamide derivative of the present invention or a salt thereof has excellent Syk-inhibitory activity, and it is useful as a pharmaceutical composition for use in the treatment of a Syk-related disease.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows the results of an intracellular phosphorylation signaling assay.

FIG. 2 shows the results of an osteoclast differentiation assay.

DESCRIPTION OF EMBODIMENTS

Hereinafter, the compound of the present invention will be described in detail.

The following definitions are applied in the present specification, unless otherwise specified.

The term “halogen atom” is used herein to mean a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.

The term “C₁₋₁₂ alkyl group” is used herein to mean a linear or branched C₁₋₁₂ alkyl group, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl, hexyl, heptyl and octyl groups.

The term “C₁₋₆ alkyl group” is used herein to mean a linear or branched C₁₋₆ alkyl group, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl and hexyl groups.

The term “C₂₋₁₂ alkenyl group” is used herein to mean a linear or branched C₂₋₁₂ alkenyl group, such as vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, 1,3-butadienyl, pentenyl, hexenyl, heptenyl and octenyl groups.

The term “C₂₋₆ alkenyl group” is used herein to mean a linear or branched C₂₋₆ alkenyl group, such as vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, 1,3-butadienyl, pentenyl and hexenyl groups.

The term “C₂₋₁₂ alkynyl group” is used herein to mean a linear or branched C₂₋₁₂ alkynyl group, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl and octynyl groups.

The term “C₂₋₆ alkynyl group” is used herein to mean a linear or branched C₂₋₆ alkynyl group, such as ethynyl, propynyl, butynyl, pentynyl and hexynyl groups.

The term “C₃₋₈ cycloalkyl group” is used herein to mean a C₃₋₈ cycloalkyl group, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.

The term “C₅₋₇ cycloalkyl group” is used herein to mean a cyclopentyl, cyclohexyl or cycloheptyl group.

The term “aryl group” is used herein to mean a phenyl, naphthyl, indanyl or indenyl group.

The term “ar-C₁₋₆ alkyl group” is used herein to mean an ar-C₁₋₆ alkyl group, such as benzyl, 2-phenylpropan-2-yl, diphenylmethyl, trityl, phenethyl and naphthylmethyl groups.

The term “C₁₋₆ alkylene group” is used herein to mean a linear or branched C₁₋₆ alkylene group, such as methylene, ethylene, propylene, butylene and hexylene groups.

The term “C₂₋₆ alkenylene group” is used herein to mean a linear or branched C₂₋₆ alkenylene group, such as vinylene, propenylene, butenylene and pentenylene groups.

The term “C₂₋₆ alkynylene group” is used herein to mean a linear or branched C₂₋₆ alkynylene group, such as ethynylene, propynylene, butynylene and pentynylene groups.

The term “C₁₋₆ alkoxy group” is used herein to mean a linear or branched C₁₋₆ alkyloxy group, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy and hexyloxy groups.

The term “ar-C₁₋₆ alkoxy group” is used herein to mean an ar-C₁₋₆ alkyloxy group, such as benzyloxy, phenethyloxy and naphthylmethyloxy groups.

The term “aryloxy group” is used herein to mean a phenoxy or naphthyloxy group.

The term “C₁₋₆ alkoxy C₁₋₆ alkyl group” is used herein to mean a C₁₋₆ alkyloxy C₁₋₆ alkyl group, such as methoxymethyl and 1-ethoxyethyl groups.

The term “ar-C₁₋₆ alkoxy C₁₋₆ alkyl group” is used herein to mean an ar-C₁₋₆ alkyloxy C₁₋₆ alkyl group, such as benzyloxymethyl and phenethyloxymethyl groups.

The term “C₂₋₁₂ alkanoyl group” is used herein to mean a linear or branched C₂₋₁₂ alkanoyl group, such as acetyl, propionyl, valeryl, isovaleryl and pivaloyl groups.

The term “aroyl group” is used herein to mean a benzoyl or naphthoyl group.

The term “heterocyclic carbonyl group” is used herein to mean a nicotinoyl, thenoyl, pyrrolidinocarbonyl or furoyl group.

The term “(α-substituted) amino acetyl group” is used herein to mean an (α-substituted) amino acetyl group having an optionally protected N-terminus, which is derived from amino acids (wherein the amino acids include glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, aspartic acid, glutamic acid, asparagine, glutamine, arginine, lysine, histidine, hydroxylysine, phenylalanine, tyrosine, tryptophan, proline and hydroxyproline).

The term “acyl group” is used herein to mean a formyl group, a succinyl group, a glutaryl group, a maleoyl group, a phthaloyl group, a C₂₋₁₂ alkanoyl group, an aroyl group, a heterocyclic carbonyl group or an (α-substituted) amino acetyl group.

The term “acyl C₁₋₆ alkyl group” is used herein to mean an acyl C₁₋₆ alkyl group, such as acetylmethyl, benzoylmethyl and 1-benzoylethyl groups.

The term “C₂₋₆ alkanoyloxy group” is used herein to mean a linear or branched C₂₋₆ alkanoyloxy group, such as acetyloxy and propionyloxy groups.

The term “aroyloxy group” is used herein to mean a benzoyloxy or naphthoyloxy group.

The term “acyloxy group” is used herein to mean a C₂₋₆ alkanoyloxy group or aroyloxy group.

The term “acyloxy C₁₋₆ alkyl group” is used herein to mean an acyloxy C₁₋₆ alkyl group, such as acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl, benzoyloxymethyl and 1-(benzoyloxy)ethyl groups.

The term “C₁₋₆ alkoxycarbonyl group” (wherein C₁₋₆ means the number of carbon atoms contained in the alkoxy group) is used herein to mean a linear or branched C₁₋₆ alkyloxycarbonyl group, such as methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl and 1,1-dimethylpropoxycarbonyl groups.

The term “ar-C₁₋₆ alkoxycarbonyl group” (wherein C₁₋₆ means the number of carbon atoms contained in the alkoxy group) is used herein to mean an ar-C₁₋₆ alkyloxycarbonyl group, such as benzyloxycarbonyl and phenethyloxycarbonyl groups.

The term “aryloxycarbonyl group” is used herein to mean a phenyloxycarbonyl or naphthyloxycarbonyl group.

The term “C₁₋₆ alkylsulfonyl group” is used herein to mean a C₁₋₆ alkylsulfonyl group, such as methylsulfonyl, ethylsulfonyl and propylsulfonyl groups.

The term “arylsulfonyl group” is used herein to mean a benzenesulfonyl, p-toluenesulfonyl or naphthalenesulfonyl group.

The term “silyl group” is used herein to mean a trimethylsilyl, triethylsilyl or tributylsilyl group.

The term “monocyclic nitrogen-containing heterocyclic group” is used herein to mean a monocyclic nitrogen-containing heterocyclic group containing only a nitrogen atom as a heteroatom that forms the ring, such as azetidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, piperidyl, tetrahydropyridyl, pyridyl, homopiperidinyl, octahydroazocinyl, imidazolidinyl, imidazolinyl, imidazolyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, piperazinyl, pyrazinyl, pyridazinyl, pyrimidinyl, homopiperazinyl, triazolyl and tetrazolyl groups.

The term “monocyclic oxygen-containing heterocyclic group” is used herein to mean a tetrahydrofuranyl, furanyl, tetrahydropyranyl or pyranyl group.

The term “monocyclic sulfur-containing heterocyclic group” is used herein to mean a thienyl group.

The term “monocyclic nitrogen/oxygen-containing heterocyclic group” is used herein to mean a monocyclic nitrogen/oxygen-containing heterocyclic group containing only a nitrogen atom and an oxygen atom as heteroatoms forming the ring, such as oxazolyl, isoxazolyl, oxadiazolyl and morpholinyl groups.

The term “monocyclic nitrogen/sulfur-containing heterocyclic group” is used herein to mean a monocyclic nitrogen/sulfur-containing heterocyclic group containing only a nitrogen atom and a sulfur atom as heteroatoms forming the ring, such as thiazolyl, isothiazolyl, thiadiazolyl, thiomorpholinyl, 1-oxide-thiomorpholinyl and 1,1-dioxide-thiomorpholinyl groups.

The term “monocyclic heterocyclic group” is used herein to mean a monocyclic nitrogen-containing heterocyclic group, a monocyclic oxygen-containing heterocyclic group, a monocyclic sulfur-containing heterocyclic group, a monocyclic nitrogen/oxygen-containing heterocyclic group or a monocyclic nitrogen/sulfur-containing heterocyclic group.

The term “bicyclic nitrogen-containing heterocyclic group” is used herein to mean a bicyclic nitrogen-containing heterocyclic group containing only a nitrogen atom as a heteroatom forming the ring, such as indolinyl, indolyl, isoindolinyl, isoindolyl, benzimidazolyl, indazolyl, benzotriazolyl, quinolyl, tetrahydroquinolinyl, quinolyl, tetrahydroisoquinolinyl, isoquinolinyl, quinolizinyl, cinnolinyl, phthalazinyl, quinazolinyl, dihydroquinoxalinyl, quinoxalinyl, naphthyridinyl, pyrrolopyridyl, imidazopyridyl, indolidinyl, dihydrocyclopentapyridyl, triazolopyridyl, pyrazolopyridyl, pyridopyrazyl, purinyl, pteridinyl and quinuclidinyl groups.

The term “bicyclic oxygen-containing heterocyclic group” is used herein to mean a bicyclic oxygen-containing heterocyclic group containing only an oxygen atom as a heteroatom forming the ring, such as 2,3-dihydrobenzofuranyl, benzofuranyl, isobenzofuranyl, chromanyl, chromenyl, isochromanyl, 1,3-benzodioxolyl, 1,3-benzodioxanyl and 1,4-benzodioxanyl groups.

The term “bicyclic sulfur-containing heterocyclic group” is used herein to mean a bicyclic sulfur-containing heterocyclic group containing only a sulfur atom as a heteroatom forming the ring, such as 2,3-dihydrobenzothienyl and benzothienyl groups.

The term “bicyclic nitrogen/oxygen-containing heterocyclic group” is used herein to mean a bicyclic nitrogen/oxygen-containing heterocyclic group containing only a nitrogen atom and an oxygen atom as heteroatoms forming the ring, such as benzoxazolyl, benzoisoxazolyl, benzoxadiazolyl, benzomorpholinyl, dihydropyranopyridyl, dihydrodioxinopyridyl, 1,3-dioxolopyridyl and dihydropyridooxazinyl groups.

The term “bicyclic nitrogen/sulfur-containing heterocyclic group” is used herein to mean a bicyclic nitrogen/sulfur-containing heterocyclic group containing a nitrogen atom and a sulfur atom as heteroatoms forming the ring, such as benzothiazolyl, benzoisothiazolyl, benzothiadiazolyl and thiazolopyridyl groups.

The term “bicyclic heterocyclic group” is used herein to mean a bicyclic nitrogen-containing heterocyclic group, a bicyclic oxygen-containing heterocyclic group, a bicyclic sulfur-containing heterocyclic group, a bicyclic nitrogen/oxygen-containing heterocyclic group, or a bicyclic nitrogen/sulfur-containing heterocyclic group.

The term “heterocyclic group” is used herein to mean a monocyclic heterocyclic group or a bicyclic heterocyclic group.

The term “cyclic amino group” is used herein to mean a 4-, 5-, 6- or 7-membered ring, condensed ring, or bridged ring cyclic amino group, which contains one or more nitrogen atoms as heteroatoms forming the ring and which may further optionally contain one or more oxygen atoms or sulfur atoms, such as azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, imidazolidinyl, piperazinyl, homopiperazinyl, morpholinyl, thiomorpholinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzomorpholinyl, dihydropyridooxazinyl and quinuclidinyl groups.

The amino-protecting group includes all groups that can be used as ordinary protecting groups for amino groups. Examples of such an amino-protecting group include groups described in W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pp. 696 to 926, 2007, John Wiley & Sons, INC. Specific examples include an ar-C₁₋₆ alkyl group, a C₁₋₆ alkoxy C₁₋₆ alkyl group, an acyl group, a C₁₋₆ alkoxycarbonyl group, an ar-C₁₋₆ alkoxycarbonyl group, an aryloxycarbonyl group, a C₁₋₆ alkylsulfonyl group, an arylsulfonyl group, and a silyl group.

The hydroxyl-protecting group includes all groups that can be used as ordinary protecting groups for hydroxyl groups. Examples of such a hydroxyl-protecting group include groups described in W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pp. 16 to 299, 2007, John Wiley & Sons, INC. Specific examples include a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, an ar-C₁₋₆ alkyl group, a C₁₋₆ alkoxy C₁₋₆ alkyl group, an ar-C₁₋₆ alkoxy C₁₋₆ alkyl group, acyl group, a C₁₋₆ alkoxycarbonyl group, an ar-C₁₋₆ alkoxycarbonyl group, a C₁₋₆ alkylsulfonyl group, an arylsulfonyl group, a silyl group, a tetrahydrofuranyl group, and a tetrahydropyranyl group.

The carboxyl-protecting group includes all groups that can be used as ordinary protecting groups for carboxyl groups. Examples of such a carboxyl-protecting group include groups described in W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pp. 533 to 643, 2007, John Wiley & Sons, INC. Specific examples include a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, an aryl group, an ar-C₁₋₆ alkyl group, a C₁₋₆ alkoxy C₁₋₆ alkyl group, an ar-C₁₋₆ alkoxy C₁₋₆ alkyl group, an acyl C₁₋₆ alkyl group, an acyloxy C₁₋₆ alkyl group, and a silyl group.

Examples of a leaving group include a halogen atom, a C₁₋₆ alkylsulfonyloxy group, and an arylsulfonyloxy group.

Aliphatic hydrocarbons include pentane, hexane, and cyclohexane.

Halogenated hydrocarbons include methylene chloride, chloroform, and dichloroethane.

Alcohols include methanol, ethanol, propanol, 2-propanol, butanol, and 2-methyl-2-propanol.

Glycols include ethylene glycol, propylene glycol, and diethylene glycol.

Ethers include diethyl ether, diisopropyl ether, dioxane, tetrahydrofuran, anisole, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, and diethylene glycol diethyl ether.

Ketones include acetone, 2-butanone, and 4-methyl-2-pentanone.

Esters include methyl acetate, ethyl acetate, propyl acetate, and butyl acetate.

Amides include N,N-dimethylformamide, N,N-dimethylacetamide, and 1-methyl-2-pyrrolidone.

Nitriles include acetonitrile and propionitrile.

Sulfoxides include dimethyl sulfoxide.

Aromatic hydrocarbons include benzene, toluene, and xylene.

Salts of the compound represented by the formula [1] include generally known salts, namely, the salts of basic groups such as amino groups, and the salts of acidic groups such as hydroxyl or carboxyl groups.

Examples of the salts of basic groups include: salts with mineral acids such as hydrochloric acid, hydrobromic acid, nitric acid, and sulfuric acid; salts with organic carboxylic acids such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid, tartaric acid, aspartic acid, trichloroacetic acid, and trifluoroacetic acid; and salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid, and naphthalenesulfonic acid.

Examples of the salts of acidic groups include: salts with alkaline metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts; and salts with nitrogen-containing organic bases such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethyl aniline, N-methyl piperidine, N-methyl morpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-ephenamine, and N,N′-dibenzylethylenediamine.

Among the above-described salts, pharmaceutically acceptable salts are preferable.

The nicotinamide derivative of the present invention is characterized in that it is represented by the following formula (I):

R¹ is a halogen atom. R¹ is preferably a fluorine atom, a chlorine atom, or a bromine atom, more preferably a fluorine atom or a chlorine atom, and most preferably a fluorine atom.

R² is a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl, aryl, ar-C₁₋₆ alkyl or heterocyclic group, each optionally having at least one substituent.

R² is preferably a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl, aryl, ar-C₁₋₆ alkyl or heterocyclic group, each optionally having at least one substituent selected from the following substituent group α₁₋₁.

The substituent group α₁₋₁ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent; and a group represented by the formula -Q¹-Q²-NR⁶-R⁷ (wherein R⁶ and R⁷ each independently represent a hydrogen atom; an amino-protecting group; a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, aryl or heterocyclic group, each optionally having at least one substituent; or R⁶ and R⁷ may form a cyclic amino group optionally having at least one substituent, together with the nitrogen atom to which they bind; Q¹ represents —NH—; a C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene group, each optionally having at least one substituent; or a bond; Q² represents a group represented by —C(═X⁷)— (wherein X⁷ represents an oxygen atom, a sulfur atom, or a group represented by ═NR²⁹ (wherein R²⁹ represents a hydrogen atom, or a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl or C₁₋₆ alkoxy group, each optionally having at least one substituent)), a C₁₋₆ alkylene group, or a bond).

With regard to R⁶ and R⁷, the substituent optionally possessed by the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, aryl or heterocyclic group is not particularly limited. A preferred example is a halogen atom, and among others, a fluorine atom is preferable.

When R⁶ and R⁷ may form a cyclic amino group together with the nitrogen atom to which they bind, the substituent optionally possessed by the cyclic amino group is not particularly limited. A preferred example is a halogen atom, and among others, a fluorine atom is preferable.

With regard to Q¹, the substituent that binds to the C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene group is not particularly limited. A preferred example is a halogen atom, and among others, a fluorine atom is preferable.

With regard to R²⁹, the substituent optionally possessed by the C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl or C₁₋₆ alkoxy group is not particularly limited. A preferred example is a halogen atom, and among others, a fluorine atom is preferable.

Moreover, R² is more preferably a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl, aryl, ar-C₁₋₆ alkyl or heterocyclic group, each optionally having at least one substituent selected from a substituent group α₁₋₂.

The substituent group α₁₋₂ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from a substituent group β₁₋₁; and the formula -Q¹-Q²-NR⁶R⁷ (wherein Q¹, Q², R⁶ and R⁷ have the same definitions as those described above)

The substituent group β₁₋₁ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, aryl or heterocyclic group, each optionally having at least one halogen atom.

Furthermore, R² is further preferably a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl, aryl, ar-C₁₋₆ alkyl or heterocyclic group, each optionally having at least one substituent selected from a substituent group α₁₋₃.

The substituent group α₁₋₃ consists of a cyano group; an oxo group; an optionally protected hydroxyl group; an optionally protected amino group; an aryl, C₁₋₆ alkoxy or heterocyclic group, each optionally having at least one substituent selected from a substituent group β₁₋₂; and the formula -Q¹-Q²-NR⁶R⁷ (wherein Q¹, Q², R⁶ and R⁷ have the same definitions as those described above), wherein the substituent group β₁₋₂ consists of a halogen atom and an optionally protected amino group.

Still further, R² is further preferably a C₁₋₁₂ alkyl or C₃₋₈ cycloalkyl group, each optionally having, as a substituent, an optionally protected amino group or a heterocyclic group having at least one substituent, and is still further preferably a C₁₋₁₂ alkyl or C₃₋₈ cycloalkyl group having an amino group as a substituent.

A preferred example of R² is a substituent represented by any one of the following formulae (II) to (V) and (VII). R² is preferably a substituent represented by the formula (II), (III) or (VII), and is more preferably a substituent represented by the formula (II) or (III):

wherein R¹⁰, R¹¹, R¹², R¹³, R¹⁶, R¹⁷, R¹⁸, R²⁰ and R²¹ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent, R¹⁴, R¹⁵, R¹⁹ and R³⁰ each independently represent a hydrogen atom, or a C₁₋₁₂ alkyl or acyl group, each optionally having at least one substituent, X⁸ represents an oxygen atom, a sulfur atom or ═NR²³ (wherein R²³ represents a hydrogen atom, or a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl or C₁₋₆ alkoxy group, each optionally having at least one substituent), R²² represents a heterocyclic group optionally having at least one substituent, X⁹ and X¹⁰ each independently represent an oxygen atom, —NR³¹— (wherein R³¹ represents a hydrogen atom, or a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, acyl, C₁₋₆ alkoxycarbonyl, aryloxycarbonyl or heterocyclic oxycarbonyl group, each optionally having at least one substituent), or a methylene group (wherein either one of X⁹ and X¹⁰ represents a methylene group, and when m3 is 0, X¹⁰ represents a methylene group), m1 and m3 each independently represents an integer from 0 to 2, m2 represents an integer of 1 or 2, wherein R²⁰ and R²¹ may be different from each other when m2 is 2, n represents an integer from 0 to 4, R¹⁶s may be different from one another when n is 2 to 4, and wherein R¹⁰ and R¹¹, R¹² and R¹³, R¹⁷ and R¹⁸, and R²⁰ and R²¹ may each together form a C₃₋₈ cycloalkyl or heterocyclic group, each optionally having at least one substituent.

It is preferable that R¹⁰, R¹¹, R¹², R¹³, R¹⁶, R¹⁷, R¹⁸, R²⁰ and R²¹ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from the following substituent group γ₁₋₁.

The substituent group γ₁₋₁ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl, C₃₋₈ cycloalkyl or heterocyclic group optionally having at least one substituent; and the formula -Q⁵-Q⁶-NR²⁷R²⁸ (wherein R²⁷ and R²⁸ each independently represent a hydrogen atom; an amino-protecting group; or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, aryl or heterocyclic group, each optionally having at least one substituent; Q⁵ represents —NH—; a C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene group, each optionally having at least one substituent; or a bond; and Q⁶ represents —C(═O)—, a C₁₋₆ alkylene group or a bond).

With regard to R²⁷ and R²⁸, the substituent optionally possessed by the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, aryl or heterocyclic group is not particularly limited. A preferred example is a halogen atom, and among others, a fluorine atom is preferable.

With regard to Q⁵, the substituent optionally possessed by the C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene group is not particularly limited. A preferred example is a halogen atom, and among others, a fluorine atom is preferable.

With regard to the substituent represented by the above-described formula (II), it is preferable that R¹⁰, R¹² and R¹³ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl or heterocyclic group, each optionally having at least one substituent selected from the above-described substituent γ₁₋₁.

R¹⁰ and R¹¹, and R¹² and R¹³ may each together form a C₃₋₈ cycloalkyl or heterocyclic group optionally having a substituent. Preferably, they may form a C₅₋₇ cycloalkyl, monocyclic oxygen-containing heterocyclic group, or bicyclic oxygen-containing heterocyclic group optionally having a substituent.

It is preferable that R¹⁰ and R¹¹ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from the above-described substituent γ₁₋₁. It is more preferable that R¹⁰ and R¹¹ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from the following substituent group γ₁₋₂. It is further preferable that R¹⁰ and R¹¹ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl or heterocyclic group, each optionally having at least one substituent selected from the following substituent group γ₁₋₂

Preferred examples of the heterocyclic group used herein include imidazolyl, pyridyl, thienyl, triazolyl, furanyl and pyrazolyl groups. Of these, an imidazolyl, pyridyl or thienyl group is preferable. Moreover, as an aryl group, a phenyl group is preferable.

The substituent group γ₁₋₂ consists of a halogen atom, and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl or heterocyclic group, optionally having at least one substituent.

Preferred examples of the heterocyclic group used herein include imidazolyl, pyridyl, thienyl, triazolyl, furanyl and pyrazolyl groups. Moreover, as an aryl group, a phenyl group is preferable. The substituent optionally possessed by the C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl or heterocyclic group is not particularly limited. A preferred example is a halogen atom, and among others, a fluorine atom is preferable.

With regard to R¹⁰ and R¹¹, either one of R¹⁰ and R¹¹, and preferably R¹¹ is a hydrogen atom, and the other one, and preferably R¹⁰ is preferably a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, optionally having at least one substituent selected from the above-described substituent group γ₁₋₁, and is more preferably a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, optionally having at least one substituent selected from the above-described substituent group 71-2. Preferred examples of the heterocyclic group used herein include imidazolyl, pyridyl, thienyl, triazolyl, furanyl and pyrazolyl groups.

R¹² and R¹³ each independently represent, preferably a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from the above-described substituent group γ₁₋₁, more preferably a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from the above-described substituent group γ₁₋₂, and further preferably a hydrogen atom, or a C₁₋₆ alkyl or C₃₋₈ cycloalkyl group, each optionally having at least one substituent selected from the above-described substituent group γ₁₋₂.

R¹⁴ represents a hydrogen atom, or a C₁₋₁₂ alkyl or acyl group, each optionally having at least one substituent, preferably a hydrogen atom, or a C₁₋₆ alkyl or acyl group, and more preferably a hydrogen atom.

The substituent represented by the above-described formula (II) is preferably a substituent represented by the following formula (II-1), more preferably a substituent represented by the following formula (II-2), and further preferably a substituent represented by the following formula (II-3):

wherein R³², R³³, R⁹⁶, R⁹⁷, R³⁴ and R³⁵ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from the above-described substituent group γ_(1-2.)

R³², R⁹⁶ and R³⁴ each independently represent, preferably a hydrogen atom, or a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl or heterocyclic group, each optionally having at least one substituent selected from the substituent group γ₁₋₂, and more preferably an alkyl group; an alkyl group substituted with a cycloalkyl group; a cycloalkyl group; or a cycloalkyl group substituted with an alkyl group, each containing 3 to 5 carbon atoms in total, or an alkoxyalkyl group containing 2 to 4 carbon atoms in total. By applying the present substituent, toxicity can be reduced.

Preferred examples of the alkyl group, the alkyl group substituted with a cycloalkyl group, the cycloalkyl group, or the cycloalkyl group substituted with an alkyl group, each containing 3 to 5 carbon atoms in total, include linear or branched pentyl, n-butyl, i-butyl, t-butyl, n-propyl, i-propyl, cyclopropyl, cyclopropylmethyl and cyclopropylethyl groups. Of these, n-butyl, i-butyl, n-propyl and cyclopropyl groups are preferable.

Preferred examples of the alkoxyalkyl group containing 2 to 4 carbon atoms in total include methoxymethyl, methoxyethyl, ethoxymethyl and ethoxyethyl groups.

R³², R⁹⁶ and R³⁴ are preferably a methyl group or ethyl group substituted with a heterocyclic group, and more preferably a methyl group substituted with a heterocyclic group. Preferred examples of the heterocyclic group used herein include imidazolyl, pyridyl, thienyl, triazolyl, furanyl and pyrazolyl groups. By applying the present substituent, toxicity can be further reduced.

R³³, R⁹⁷ and R³⁵ each independently represent, preferably a hydrogen atom, or a C₁₋₆ alkyl or C₃₋₈ cycloalkyl group, more preferably a hydrogen atom, or a C₁₋₆ alkyl group, and further preferably a C₁₋₃ alkyl group. Preferred examples include a methyl group and an ethyl group.

The total number of carbon atoms contained in R³² and R³³, the total number of carbon atoms contained in R⁹⁶ and R⁹⁷, and the total number of carbon atoms contained in R³⁴ and R³⁵ are each preferably from 4 to 6. By applying the present substituent, toxicity can be further reduced.

The substituent represented by the above-described formula (III) is preferably a substituent represented by any one of the following formulae (III-1) to (III-3):

wherein R¹⁵, R¹⁶, m1 and n have the same definitions as those described above.

Preferred formulae are (III-1) and (III-2), and a more preferred formula is (III-1).

In the above-described formula (III) and the above-described formulae (III-1) to (III-3), R¹⁶ represents, preferably a hydrogen atom, or a C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl or heterocyclic group, each optionally having at least one substituent selected from the above-described substituent group γ₁₋₁, more preferably a hydrogen atom, or a C₁₋₆ alkyl, C₁₋₆ alkoxy or aryl group, each optionally having at least one substituent selected from the above-described substituent group γ₁₋₁, and further preferably a hydrogen atom, or a C₁₋₆ alkyl, C₁₋₆ alkoxy or aryl group.

m1 is an integer from 0 to 2, and is preferably 1.

n is an integer from 0 to 4, and R¹⁶s may be different from one another when n is 2 to 4. n is preferably an integer from 0 to 2, and more preferably 0.

R¹⁵ represents a hydrogen atom, or a C₁₋₁₂ alkyl or acyl group, each optionally having at least one substituent, preferably a hydrogen atom, or a C₁₋₆ alkyl or acyl group, and more preferably a hydrogen atom.

When R² is a substituent represented by the above-described formula (III), it is preferably the following formula (III-4), more preferably the following formula (III-5), and further preferably the following formula (III-6).

With regard to the substituent represented by the above-described formula (IV), R¹⁷ and R¹⁸ each independently represent, preferably a hydrogen atom, or a C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl or heterocyclic group, each optionally having at least one substituent selected from the above-described substituent group γ₁₋₁, more preferably a hydrogen atom, or a C₁₋₆ alkyl, C₁₋₆ alkoxy or aryl group, each optionally having at least one substituent selected from the above-described substituent group γ₁₋₁, and further preferably a hydrogen atom, or a C₁₋₆ alkyl, C₁₋₆ alkoxy or aryl group.

R¹⁷ and R¹⁸ may together form a C₃₋₈ cycloalkyl or heterocyclic group optionally having a substituent. Among others, a C₅₋₇ cycloalkyl or oxygen-containing heterocyclic group optionally having a substituent is preferable.

R¹⁷ is preferably a hydrogen atom. In addition, R¹⁸ is preferably a C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl or heterocyclic group, each optionally having at least one substituent selected from the above-described substituent group γ₁₋₁, more preferably a C₁₋₆ alkyl, C₁₋₆ alkoxy or aryl group, each optionally having at least one substituent selected from the above-described substituent group γ₁₋₁, and further preferably a C₁₋₆ alkyl, C₁₋₆ alkoxy or aryl group.

R¹⁹ is a hydrogen atom, or a C₁₋₁₂ alkyl or acyl group each optionally having at least one substituent, preferably a hydrogen atom, a C₁₋₁₂ alkyl or acyl group, and more preferably a hydrogen atom.

With regard to the substituent represented by the above-described formula (V), R²⁰ and R²¹ each independently represent, preferably a hydrogen atom, or a C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl or heterocyclic group, each optionally having at least one substituent selected from the above-described substituent group γ₁₋₁, more preferably a hydrogen atom, or a C₁₋₆ alkyl, C₁₋₆ alkoxy or aryl group, each optionally having at least one substituent selected from the above-described substituent group γ₁₋₁, and further preferably a hydrogen atom, or a C₁₋₆ alkyl group, C₁₋₆ alkoxy group or aryl group.

R²⁰ and R²¹ may together form a C₃₋₈ cycloalkyl or heterocyclic group optionally having a substituent. Among others, a C₅₋₇ cycloalkyl or oxygen-containing heterocyclic group optionally having a substituent is preferable.

R²² is a heterocyclic group optionally having a substituent.

m2 is an integer of 1 or 2. R²⁰ and R²¹ may be different from each other when m2 is 2. m2 is preferably 1.

R⁴ and R⁵ each independently represent a hydrogen atom, or a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl or C₂₋₁₂ alkynyl group, each optionally having at least one substituent. R⁴ and R⁵ represent, preferably a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl or C₂₋₆ alkynyl group, more preferably a hydrogen atom, or a C₁₋₆ alkyl group, and further preferably a hydrogen atom.

With regard to the substituent represented by the above-described formula (VII), m3 is an integer from 0 to 2, and is preferably 1.

R³⁰ represents a hydrogen atom, or a C₁₋₁₂ alkyl or acyl group each optionally having at least one substituent, preferably a hydrogen atom, a C₁₋₆ alkyl or acyl group, and more preferably a hydrogen atom.

X⁹ and X¹⁰ each independently represent an oxygen atom, —NR³¹— (wherein R³¹ represents a hydrogen atom, or a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, acyl or C₁₋₆ alkoxycarbonyl group, each optionally having at least one substituent), or a methylene group (wherein either one of X⁹ and X¹⁰ represents a methylene group, and when m3 is 0, X¹⁰ represents a methylene group).

R³¹ represents a hydrogen atom, or a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, acyl, C₁₋₆ alkoxycarbonyl, aryloxycarbonyl or heterocyclic oxycarbonyl group, each optionally having at least one substituent, preferably a hydrogen atom, or a C₁₋₁₂ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, acyl, C₁₋₆ alkoxycarbonyl, aryloxycarbonyl or heterocyclic oxycarbonyl group, each optionally having at least one substituent, more preferably a hydrogen atom, or a C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, acyl, C₁₋₆ alkoxycarbonyl, aryloxycarbonyl or heterocyclic oxycarbonyl group, each optionally having at least one substituent, and further preferably a hydrogen atom, or a C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, acyl, C₁₋₆ alkoxycarbonyl, aryloxycarbonyl or heterocyclic oxycarbonyl group.

The nicotinamide derivative of the present invention is preferably represented by the following formula (I-1).

wherein R³ represents the same substituent as that described above, and its preferred range is also the same as that described above. R²⁶ represents a substituent represented by any one of the above-described formulae (II) to (V) and (VII), and its preferred range is also the same as that described above.

In the above-described formula (I) and (I-1), R³ represents an aryl or heterocyclic group each optionally having at least one substituent.

R³ preferably represents an aryl or heterocyclic group each optionally having at least one substituent selected from the substituent group α₂₋₁.

The substituent group α₂₋₁ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent; and the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein R²⁴ and R²⁵ each independently represent a hydrogen atom; an amino-protecting group; a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, ar-C₁₋₆ alkyl, aryl or heterocyclic group, each optionally having at least one substituent; or R²⁴ and R²⁵ may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind; Q³ represents —NH—; a C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene group, each optionally having at least one substituent; or a bond; and Q⁴ represents —C(═O)—, a C₁₋₆ alkylene group, or a bond).

With regard to R²⁴ and R²⁵, the substituent optionally possessed by the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, ar-C₁₋₆ alkyl, aryl or heterocyclic group is not particularly limited. A preferred example is a halogen atom, and among others, a fluorine atom is preferable.

The substituent optionally possessed by the cyclic amino group that is formed by R²⁴ and R²⁵, together with the nitrogen atom to which they bind, is not particularly limited. A preferred example is a halogen atom, and among others, a fluorine atom is preferable.

With regard to Q³, the substituent optionally possessed by the C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene group is not particularly limited. A preferred example is a halogen atom, and among others, a fluorine atom is preferable.

Moreover, R³ is more preferably an aryl or heterocyclic group, each optionally having at least one substituent selected from a substituent group α₂₋₂.

The substituent group α₂₋₂ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from a substituent group β₂₋₁; and the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein Q³, Q⁴, R²⁴ and R²⁵ have the same definitions as those described above).

The substituent group β₂₋₁ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group, and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, ar-C₁₋₆ alkyl, aryl or heterocyclic group, each optionally having at least one halogen atom.

Furthermore, R³ is further preferably an aryl or heterocyclic group, each optionally having at least one substituent selected from a substituent group α₂₋₃.

The substituent group α₂₋₃ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected amino group; a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from a substituent group β₂₋₂; and the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein Q³, Q⁴, R²⁴ and R²⁵ have the same definitions as those described above).

The substituent group β₂₋₂ consists of a halogen atom; an optionally protected hydroxyl group; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, aryl or heterocyclic group, each optionally having at least one halogen atom.

R³ represents an aryl or heterocyclic group optionally having at least one substituent. Preferred examples of the aryl or heterocyclic group include monocyclic and bicyclic groups.

Preferred examples of the aryl group include phenyl, naphthyl and indanyl groups. Among such aryl groups, a phenyl group is preferable.

Preferred examples of a monocyclic heterocyclic group include pyridyl, pyrimidinyl, pyridazinyl, thiazolyl and thienyl groups. As such monocyclic heterocyclic groups, pyridyl and pyridazinyl groups are preferable, and a pyridyl group is more preferable.

Preferred examples of a bicyclic heterocyclic group include quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, indolyl, indazolyl, imidazopyridyl, benzothiazolyl, benzoxazolyl, benzothiadiazolyl, benzimidazolyl, pyrrolopyridyl, pyrazolopyridyl, pyridopyrazyl, thiazolopyridyl, naphthyridinyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, isoindolinyl, tetrahydroisoquinolinyl, and dihydropyrido oxazinyl groups. As such bicyclic heterocyclic groups, quinolyl, isoquinolyl, quinoxalinyl, indolyl, pyrrolopyridyl, indazolyl and imidazopyridyl groups are preferable, quinoxalinyl and indazolyl group are more preferable, and an indazolyl group is further preferable.

R³ represents an aryl or heterocyclic group optionally having at least one substituent. As such an aryl or heterocyclic group, phenyl, pyridyl, pyridazinyl, quinoxalinyl and indazolyl groups are preferable, pyridyl. As such an aryl or heterocyclic group, pyridyl, quinoxalinyl and indazolyl groups are more preferable, and pyridyl and indazolyl group are further preferable. By applying the present substituent, toxicity can be further reduced.

The monocyclic heterocyclic group is preferably a 5-membered ring or 6-membered ring group.

A preferred 6-membered ring is a pyridyl or pyrimidinyl group. Preferred examples of the pyridyl and pyrimidinyl group include a pyridin-5-yl group optionally having a substituent(s) at positions 2 and/or 3, a pyridin-4-yl group optionally having a substituent(s) at positions 2 and/or 6, a pyrimidin-4-yl group optionally having a substituent(s) at positions 2 and/or 6, and a pyrimidin-5-yl group optionally having a substituent at position 2.

R³ is preferably a phenyl, pyridyl, pyridazinyl, quinoxalinyl or indazolyl group, each optionally having at least one substituent, is more preferably a phenyl, pyridyl, pyridazinyl, quinoxalinyl or indazolyl group, each optionally having at least one substituent selected from the substituent group α₂₋₁, is further preferably a phenyl, pyridyl, pyridazinyl, quinoxalinyl or indazolyl group, each optionally having at least one substituent selected from the substituent group α₂₋₂, and is still further preferably a phenyl, pyridyl, pyridazinyl, quinoxalinyl or indazolyl group, each optionally having at least one substituent selected from the substituent group α₂₋₃.

When R³ is a pyridyl group optionally having at least one substituent, the substituent optionally possessed by the pyridyl group is preferably selected from the substituent group α₂₋₁, is more preferably selected from a substituent group α₂₋₄, is further preferably selected from a substituent group α₂₋₅, and is still further preferably selected from a substituent group α₂₋₆.

The substituent group α₂₋₄ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from a substituent group β₂₋₃; and the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein Q³, Q⁴, R²⁴ and R²⁵ have the same definitions as those described above).

The substituent group β₂₋₃ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -Q⁵m4-R³⁶ (wherein Q⁵ represents a C₁₋₆ alkyleneoxy group (wherein the R³⁶ side is an alkylene group), R³⁶ represents a hydrogen atom, or a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl or heterocyclic group, and m4 represents an integer from 1 to 3, and Q⁵s may be different from one another when m4 is 2 or 3), aryl or heterocyclic group, each optionally having at least one halogen atom.

The substituent group α₂₋₅ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected amino group; a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from a substituent group β₂₋₄; and the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein Q³, Q⁴, R²⁴ and R²⁵ have the same definitions as those described above).

The substituent group β₂₋₄ consists of a halogen atom; an optionally protected hydroxyl group; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above), aryl or heterocyclic group, each optionally having at least one halogen atom.

The substituent group α₂₋₆ consists of a halogen atom; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy or heterocyclic group, each optionally having at least one substituent selected from a substituent group β₂₋₅.

The substituent group β₂₋₅ consists of a halogen atom; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above), aryl or heterocyclic group, each optionally having at least one halogen atom.

When R³ is a pyridyl group optionally having at least one substituent, the pyridyl group is preferably represented by the following formula (VIII-1) or (VIII-2), and is more preferably represented by the following formula (VIII-1):

wherein R³⁷, R³⁸, R³⁹, R⁴⁰, R⁴¹, R⁴², R⁴³ and R⁴⁴ each independently represent a hydrogen atom, or a substituent selected from the above-described substituent group α₂₋₆.

R³⁷ and R³⁸ each independently represent, preferably a hydrogen atom or a halogen atom, more preferably a hydrogen atom or a fluorine atom, and further preferably a hydrogen atom.

R³⁹ is more preferably a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy or heterocyclic group, optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl and C₃₋₈ cycloalkyl groups, and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above), and is further preferably a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy or 5-membered ring heterocyclic group, optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above).

Herein, preferred examples of the 5-membered ring heterocyclic group include pyrrolyl, pyrrolidinyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl and furanyl groups. Among these groups, triazolyl and furanyl groups are more preferable. This 5-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a methyl group and an ethyl group, and is further preferably unsubstituted or substituted with a fluorine atom or a methyl group.

The aryl group is preferably a phenyl group.

The C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl group is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl group, and more preferably a hydrogen atom, or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

R⁴⁰ is more preferably a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy or heterocyclic group, optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³², m3, Q⁶ have the same definitions as those described above), and is further preferably a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy, or 5-membered ring or 6-membered ring heterocyclic group, optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4, Q⁶ have the same definitions as those described above).

Herein, preferred examples of the 5-membered ring heterocyclic group include pyrrolyl, pyrrolidinyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl and furanyl groups. Among these groups, triazolyl and furanyl groups are more preferable. This 5-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, and is further preferably unsubstituted or substituted with a fluorine atom or a methyl group.

A preferred example of the 6-membered ring heterocyclic group is a morpholinyl group. This 6-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, is further preferably unsubstituted or substituted with a fluorine atom or a methyl group, and is still further preferably unsubstituted.

The aryl group is preferably a phenyl group.

The C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂, alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, a C₁₋₃ alkyl or cyclopropyl group, and more preferably a hydrogen atom or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

When R³⁹ is a 5-membered ring heterocyclic group optionally having at least one substituent selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above), R⁴⁰ is preferably a halogen atom, or a C₁₋₆ alkyl or C₁₋₆ alkoxy group.

Herein, preferred examples of the 5-membered ring heterocyclic group include pyrrolyl, pyrrolidinyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl and furanyl groups. Among these groups, triazolyl and furanyl groups are more preferable. This 5-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, and is further preferably unsubstituted or substituted with a fluorine atom or a methyl group.

The C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl group is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, a C₁₋₃ alkyl or cyclopropyl group, and more preferably a hydrogen atom or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

When R³⁹ is a halogen atom; or a C₁₋₆ alkyl or C₁₋₆ alkoxy group optionally having at least one halogen atom, R⁴⁰ is preferably a 5-membered ring or 6-membered ring heterocyclic group optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above).

Herein, preferred examples of the 5-membered ring heterocyclic group include pyrrolyl, pyrrolidinyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl and furanyl groups. Among these groups, triazolyl and furanyl groups are more preferable. This 5-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, and is further preferably unsubstituted or substituted with a fluorine atom or a methyl group.

A preferred example of the 6-membered ring heterocyclic group is a morpholinyl group. This 6-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, is further preferably unsubstituted or substituted with a fluorine atom or a methyl group, and is still further preferably unsubstituted.

The aryl group is preferably a phenyl group.

The C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl group is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl group, and more preferably a hydrogen atom or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

Further, a compound in which R³⁹ represents a fluorine atom or a methyl or ethyl group and R⁴⁰ represents a morpholinyl group, is preferable.

R⁴¹ and R⁴² each independently represent, preferably a hydrogen atom or a halogen atom, more preferably a hydrogen atom or a fluorine atom, and further preferably a hydrogen atom.

R⁴³ and R⁴⁴ each represent, more preferably a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy or heterocyclic group, optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above), further preferably a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl or C₁₋₆ alkoxy group optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above), and still further preferably a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl or C₁₋₆ alkoxy group.

Herein, preferred examples of the heterocyclic group include pyrrolyl, pyrrolidinyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl and furanyl groups. Among these groups, triazolyl and furanyl groups are more preferable. This heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, and is further preferably unsubstituted or substituted with a fluorine atom or a methyl group.

The aryl group is preferably a phenyl group.

The C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl groups, and more preferably a hydrogen atom or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

Among pyridyl groups represented by the above-described formula (VIII-1), a pyridyl group represented by the following formula (VIII-3) is more preferable. Among pyridyl groups represented by the above-described formula (VIII-2), a pyridyl group represented by the following formula (VIII-4) is more preferable. Among others, the pyridyl group represented by the following formula (VIII-3) is further preferable.

wherein R⁴⁵, R⁴⁶, R⁴⁷ and R⁴⁸ independently represent a hydrogen atom, or a substituent selected from the above-described substituent group α₂₋₆.

R⁴⁵ is more preferably a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy or heterocyclic group optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above), and is further preferably a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy or 5-membered ring heterocyclic group optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above).

Herein, preferred examples of the 5-membered ring heterocyclic group include pyrrolyl, pyrrolidinyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl and furanyl groups. Among these groups, triazolyl and furanyl groups are more preferable. This 5-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, and is further preferably unsubstituted or substituted with a fluorine atom or a methyl group.

The C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl groups, and more preferably a hydrogen atom, or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

R⁴⁶ is more preferably a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy or heterocyclic group optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³², m3, Q⁶ have the same definitions as those described above), and is further preferably a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy, or 5-membered ring or 6-membered ring heterocyclic group optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4, Q⁶ have the same definitions as those described above).

Herein, preferred examples of the 5-membered ring heterocyclic group include pyrrolyl, pyrrolidinyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl and furanyl groups. Among these groups, triazolyl and furanyl groups are preferable. This 5-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, and is further preferably unsubstituted or substituted with a fluorine atom or a methyl group.

A preferred example of the 6-membered ring heterocyclic group is a morpholinyl group. This 6-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, is further preferably unsubstituted or substituted with a fluorine atom or a methyl group, and is still further preferably unsubstituted.

The aryl group is preferably a phenyl group.

The C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl groups, and more preferably a hydrogen atom or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

When R⁴⁵ is a 5-membered ring heterocyclic group optionally having at least one substituent selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above), R⁴⁶ is preferably a halogen atom, a C₁₋₆ alkyl or C₁₋₆ alkoxy group.

Herein, preferred examples of the 5-membered ring heterocyclic group include pyrrolyl, pyrrolidinyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl and furanyl groups. Among these groups, triazolyl and furanyl groups are more preferable. This 5-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, and is further preferably unsubstituted or substituted with a fluorine atom or a methyl group.

The C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl groups, and more preferably a hydrogen atom, or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

When R⁴⁵ is a halogen atom; or a C₁₋₆ alkyl or C₁₋₆ alkoxy group optionally having at least one halogen atom, R⁴⁶ is preferably a 5-membered ring or 6-membered ring heterocyclic group optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above).

Herein, preferred examples of the 5-membered ring heterocyclic group include pyrrolyl, pyrrolidinyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl and furanyl groups. Among these groups, triazolyl and furanyl group are more preferable. This 5-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, and is further preferably unsubstituted or substituted with a fluorine atom or a methyl group.

A preferred example of the 6-membered ring heterocyclic group is a morpholinyl group. This 6-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, is further preferably unsubstituted or substituted with a fluorine atom or a methyl group, and is still further preferably unsubstituted.

The aryl group is preferably a phenyl group.

The C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl groups, and more preferably a hydrogen atom or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

Further, a compound in which R⁴⁵ represents a fluorine atom or a methyl or ethyl group and R⁴⁶ represents a morpholinyl group, is preferable.

R⁴⁷ and R⁴⁸ each represent, more preferably a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy or heterocyclic group optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above), further preferably a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl or C₁₋₆ alkoxy group optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above), and still further preferably a hydrogen atom, a halogen atom, or a C₁₋₆ alkyl or C₁₋₆ alkoxy group.

Herein, preferred examples of the heterocyclic group include pyrrolyl, pyrrolidinyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl and furanyl groups. Among these groups, triazolyl and furanyl groups are more preferable. This heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, and is further preferably unsubstituted or substituted with a fluorine atom or a methyl group.

The aryl group is preferably a phenyl group.

The C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl groups, and more preferably a hydrogen atom, or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

When R³ is an indazolyl group optionally having at least one substituent, it is preferably an indazolyl group represented by any one of the following formulae (IX-1) to (IX-6), is more preferably an indazolyl group represented by the formula (IX-1) or (IX-2), and is further preferably an indazolyl group represented by the formula (IX-1):

wherein R⁴⁹, R⁵⁰, R⁵¹, R⁵², R⁵³, R⁵⁴, R⁵⁵, R⁵⁶, R⁵⁷, R⁵⁸, R⁵⁹, R⁶⁰, R⁶¹, R⁶², R⁶³, R⁶⁴, R⁶⁵, R⁶⁶, R⁶⁷, R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷ and R⁷⁸ each independently represent a hydrogen atom, or a substituent selected from the above-described substituent group α₂₋₆.

R⁴⁹, R⁵⁰, R⁵⁴, R⁵⁵, R⁵⁹, R⁶⁰, R⁶⁴, R⁶⁵, R⁶⁹, R⁷⁰, R⁷⁴ and R⁷⁵ each independently represent, preferably a hydrogen atom or a halogen atom, more preferably a hydrogen atom or a fluorine atom, and further preferably a hydrogen atom.

R⁵³, R⁵⁸, R⁶¹, R⁶⁸, R⁷³ and R⁷⁶ each independently represent, preferably a halogen atom, or a C₁₋₆ alkyl, aryl or C₁₋₆ alkoxy group, more preferably a hydrogen atom or a halogen atom, further preferably a hydrogen atom or a fluorine atom, and still further preferably a hydrogen atom.

R⁵¹, R⁵⁷, R⁶³, R⁶⁶, R⁷² and R⁷⁸ each independently represent, preferably a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy or aryl group optionally having at least one substituent each independently selected from among C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and -Q⁵m4-R³⁶ (wherein Q⁵, R³², m4 have the same definitions as those described above), optionally having at least one halogen atom.

Herein, the C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl groups, and more preferably a hydrogen atom or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

R⁵², R⁵⁶, R⁶², R⁶⁷, R⁷¹ and R⁷⁷ each independently represent, preferably a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy or aryl group optionally having at least one substituent each independently selected from among C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above), optionally having at least one halogen atom.

Herein, the C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The aryl is preferably a phenyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl groups, and more preferably a hydrogen atom or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

With regard to the combinations such as R⁵¹ and R⁵², R⁵⁶ and R⁵⁷, R⁶² and R⁶³, R⁶⁶ and R⁶⁷, R⁷¹ and R⁷², and R⁷⁷ and R⁷⁸, at least either one preferably represents a halogen atom; or a C₁₋₆ alkyl, C₃₋₈ cycloalkyl or C₁₋₆ alkoxy group optionally having at least one substituent each independently selected from among C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4 have the same definitions as those described above) optionally having at least one halogen atom.

Herein, the C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl groups, and more preferably a hydrogen atom, or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

Among the indazolyl groups represented by the above-described formula (IX-1), an indazolyl group represented by the following formula (IX-7) is more preferable. Among the indazolyl groups represented by the above-described formula (IX-2), an indazolyl group represented by the following formula (IX-8) is more preferable. Among others, the indazolyl group represented by the formula (IX-7) is further preferable:

wherein R⁷⁹, R⁸⁰, R⁸¹ and R⁸² each independently represent a hydrogen atom, or a substituent selected from the above-described substituent group α₂₋₆, wherein R⁷⁹ is the same substituent as R⁵¹, and the preferred range of R⁷⁹ is also the same as that of R⁵¹, R⁸⁰ is the same substituent as R⁵², and the preferred range of R⁸⁰ is also the same as that of R⁵², R⁸¹ is the same substituent as R⁵⁶, and the preferred range of R⁸¹ is also the same as that of R⁵⁶, and R⁸² is the same substituent as R⁵⁷, and the preferred range of R⁸² is also the same as that of R⁵⁷.

When R³ is a phenyl group optionally having at least one substituent, the substituent optionally possessed by the phenyl group is more preferably a halogen atom; or C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy or heterocyclic group optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³², m3, Q⁶ have the same definitions as those described above), and is further preferably a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy, or 5-membered ring or 6-membered ring heterocyclic group, optionally having at least one substituent each independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, m4, Q⁶ have the same definitions as those described above).

Herein, preferred examples of the 5-membered ring heterocyclic group include pyrrolyl, pyrrolidinyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl and furanyl groups. Among these groups, triazolyl and furanyl groups are more preferable. This 5-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, and is further preferably unsubstituted or substituted with a fluorine atom or a methyl group.

A preferred example of the 6-membered ring heterocyclic group is a morpholinyl group. This 6-membered ring heterocyclic group is preferably unsubstituted or substituted with a substituent selected from the group consisting of a fluorine atom, a chlorine atom, a methyl group, an ethyl group and a propyl group, is more preferably unsubstituted or substituted with a substituent selected from among a fluorine atom, a methyl group and an ethyl group, is further preferably unsubstituted or substituted with a fluorine atom or a methyl group, and is still further preferably unsubstituted.

The aryl group is preferably a phenyl group.

The C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl groups, and more preferably a hydrogen atom, or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

When R³ is a quinoxalinyl group optionally having at least one substituent, the substituent optionally possessed by the quinoxalinyl group is preferably a halogen atom; or a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy or aryl group optionally having at least one substituent each independently selected from among C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and -Q⁵m4-R³⁶ (wherein Q⁵, R³², m4 have the same definitions as those described above), optionally having at least one halogen atom.

Herein, the C₁₋₆ alkyl group is preferably a C₁₋₃ alkyl group, and more preferably a C₁₋₂ alkyl group.

The C₁₋₆ alkoxy group is preferably a C₁₋₃ alkoxy group, and more preferably a C₁₋₂ alkoxy group.

The halogen atom is preferably a fluorine atom or a chlorine atom, and more preferably a fluorine atom.

The C₃₋₈ cycloalkyl is preferably a cyclopropyl group.

The aryl group is preferably a phenyl group.

The Q⁵ is preferably a C₁₋₃ alkyleneoxy group, and more preferably a C₁₋₂ alkyleneoxy group.

The R³⁶ is preferably a hydrogen atom, C₁₋₃ alkyl or cyclopropyl groups, and more preferably a hydrogen atom or a C₁₋₂ alkyl group.

The m4 is preferably an integer of 1 or 2.

The nicotinamide derivative of the present invention or a pharmaceutically acceptable salt thereof is preferably represented by the following formula (I-2), is more preferably represented by the following formula (I-3), is further preferably represented by the following formula (I-4), and is still further preferably represented by the following formula (I-5):

wherein R⁸³ is the same substituent as R¹⁰, and the preferred range of R⁸³ is also the same as that of R¹⁰, R⁸⁴ is the same substituent as R¹¹, and the preferred range of R⁸⁴ is also the same as that of R¹¹, R⁸⁵ is the same substituent as R¹², and the preferred range of R⁸⁵ is also the same as that of R¹², R⁸⁶ is the same substituent as R¹³, and the preferred range of R⁸⁶ is also the same as that of R¹³, R⁸⁸ is the same substituent as R³², and the preferred range of R⁸⁸ is also the same as that of R³², R⁸⁹ is the same substituent as R³³, and the preferred range of R⁸⁹ is also the same as that of R³³, R⁹¹ is the same substituent as R⁹⁶, and the preferred range of R⁹¹ is also the same as that of R⁹⁶, R⁹² is the same substituent as R⁹⁷, and the preferred range of R⁹² is also the same as that of R⁹⁷, R⁹⁸ is the same substituent as R³⁴, and the preferred range of R⁹⁸ is also the same as that of R³⁴, R⁹⁹ is the same substituent as R³⁵, and the preferred range of R⁹⁹ is also the same as that of R³⁵, R⁸⁷ is the same substituent as R³, and the preferred range of R⁸⁷ is also the same as that of R³, R⁹⁰ is the same substituent as R³, and the preferred range of R⁹⁰ is also the same as that of R³, R⁹³ is the same substituent as R³, and the preferred range of R⁹³ is also the same as that of R³, and R¹⁰⁰ is the same substituent as R³, and the preferred range of R¹⁰⁰ is also the same as that of R³.

In the above formulae, each of R⁸⁷, R⁹⁰, R⁹³ and R¹⁰⁰ preferably represents an indazolyl group or pyridyl group optionally having at least one substituent. When each of R⁸⁷, R⁹⁰, R⁹³ and R¹⁰⁰ is a pyridyl group optionally having at least one substituent, it is preferably the pyridyl group represented by the above-described formula (VIII-1) or (VIII-2), and more preferably the pyridyl group represented by the following formula (VIII-1). The preferred ranges of the pyridyl groups represented by the above-described formulae (VIII-1) and (VIII-2) are the same as those described above. When each of R⁸⁷, R⁹⁰, R⁹³ and R¹⁰⁰ is an indazolyl group optionally having at least one substituent, it is preferably the indazolyl group represented by any one of the above-described formulae (IX-1) to (IX-6), more preferably the indazolyl group represented by the formula (IX-1) or (IX-2), and further preferably the indazolyl group represented by the formula (IX-1). The preferred ranges of the indazolyl groups represented by the above-described formulae (IX-1) to (IX-6) are the same as those described above.

The nicotinamide derivative of the present invention or a pharmaceutically acceptable salt thereof is preferably represented by the following formula (I-6), is more preferably represented by the following formula (I-7), and is further preferably represented by the following formula (I-8):

wherein R⁹⁴ is the same substituent as R³, and the preferred range of R⁹⁴ is also the same as that of R³, R⁹⁵ is the same substituent as R³, and the preferred range of R⁹⁵ is also the same as that of R³, and R¹⁰¹ is the same substituent as R³, and the preferred range of R¹⁰¹ is also the same as that of R³.

In the above formulae, each of R⁹⁴, R⁹⁵ and R¹⁰¹ is more preferably a pyridyl group optionally having at least one substituent, further preferably the pyridyl group represented by the above-described formula (VIII-1) or (VIII-2), and still further preferably the pyridyl group represented by the following formula (VIII-1). The preferred ranges of the pyridyl groups represented by the above-described formulae (VIII-1) and (VIII-2) are the same as those described above.

The nicotinamide derivative of the present invention or a pharmaceutically acceptable salt thereof is preferably represented by the following formula (I-9), is more preferably represented by the following formula (I-10), and is further preferably represented by the following formula (I-11):

wherein R⁹⁶ is the same substituent as R³, and the preferred range of R⁹⁶ is also the same as that of R³, R⁹⁷ is the same substituent as R³, and the preferred range of R⁹⁷ is also the same as that of R³, R¹⁰² is the same substituent as R³, and the preferred range of R¹⁰² is also the same as that of R³, X¹¹ is the same substituent as X⁹, and the preferred range of X¹¹ is also the same as that of X⁹, X¹² is the same substituent as X¹⁰, and the preferred range of X¹² is also the same as that of X¹⁰, X¹³ is the same substituent as X⁹, and the preferred range of X¹³ is also the same as that of X⁹, X¹⁴ is the same substituent as X¹⁰, and the preferred range of X¹⁴ is also the same as that of X¹⁰, X¹⁵ is the same substituent as X⁹, and the preferred range of X¹⁵ is also the same as that of X⁹, and X¹⁶ is the same substituent as X¹⁹, and the preferred range of X¹⁶ is also the same as that of X¹⁰.

It is to be noted that, in the above formulae, R⁹⁶, R⁹⁷ and R¹⁰² each represent, more preferably a pyridyl group optionally having at least one substituent, further preferably the pyridyl group represented by the above-described formula (VIII-1) or (VIII-2), and still further preferably the pyridyl group represented by the following formula (VIII-1). Preferred ranges of the pyridyl groups represented by the formula (VIII-1) and (VIII-2) are the same as those described above.

Preferred examples of the compound represented by the formula [1] of the present invention include the following compounds:

-   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(5-phenylpyridin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(3-methylphenylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(4-(morpholin-4-yl)phenylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(3,4,5-trimethoxyphenylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(2-methoxypyridin-4-ylamino)nicotinamide; -   6-(cis-2;     aminocyclohexylamino)-2-(2,6-dimethoxypyridin-4-ylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(2-(morpholin-4-yl)pyridin-4-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(6-(morpholin-4-yl)pyridin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(pyrimidin-5-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1,5-naphthyridin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1,6-naphthyridin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1,6-naphthyridin-8-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(8-nitroquinolin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-methyl-1H-pyrrolo[2,3-c]pyridin-4-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrrolo[2,3-c]pyridin-4-ylamino)nicotinamide; -   2-(8-acetylaminoquinolin-3-ylamino)-6-(cis-2-aminocyclohexylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(5-(anilinocarbonyl)pyridin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-4-ylamino)nicotinamide; -   methyl5-(3-aminocarbonyl-6-(cis-2-aminocyclohexylamino)-5-fluoropyridin-2-ylamino)nicotinate; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(6-methylpyridin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(2-methylpyridin-4-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrrolo[2,3-b]pyridin-5-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-(2-(morpholin-4-yl)ethyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-[1,3]thiazolo[4,5-b]pyridin-6-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(1-(2-(diethylamino)ethyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-isobutyl-1H-pyrrolo[2,3-b]pyridin-4-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(1-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-ylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(5-(2H-1,2,3-triazol-2-yl)pyridin-3-ylamino)-nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(5-(1H-pyrrol-2-yl)pyridin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(5-(2-thienyl)pyridin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(5-cyclopropylpyridin-3-ylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(5-(2-furyl)pyridin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(8-aminoquinolin-3-ylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1H-pyrrolo[2,3-b]pyridin-4-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1H-pyrrolo[2,3-b]pyridin-5-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1H-pyrrolo[2,3-c]pyridin-4-ylamino)nicotinamide; -   2-(8-(aminocarbonyl)aminoquinolin-3-ylamino)-6-(cis-2-aminocyclohexylamino)-5-fluoronicotinamide; -   6-(2-aminoethylamino)-5-fluoro-2-(pyridin-4-ylamino)nicotinamide; -   6-(2-aminoethylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(2,1,3-benzothiadiazol-5-ylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(1,3-benzothiazol-6-ylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-methyl-1H-indazol-6-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(2-methyl-1,3-benzoxazol-6-ylamino)nicotinamide; -   6-(2-aminoethylamino)-2-(1,3-benzothiazol-6-ylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(2-methyl-1,3-benzoxazol-5-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(5-methylpyridin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-ylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(3-(2H-1,2,3-triazol-2-yl)phenylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(6-methoxyquinolin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(quinolin-5-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(quinoxalin-6-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(1,3-benzothiazol-5-ylamino)-5-fluoronicotinamide; -   6-(2-aminoethylamino)-5-fluoro-2-(isoquinolin-4-ylamino)nicotinamide; -   6-(2-aminoethylamino)-5-fluoro-2-(quinolin-5-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-methyl-1H-indazol-5-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-methyl-1H-benzoimidazol-6-ylamino)     nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(quinazolin-6-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(quinazolin-7-ylamino)nicotinamide; -   cis-6-(2-aminocyclohexylamino)-5-fluoro-2-(1-methyl-1H-benzoimidazol-5-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(2-methylquinolin-6-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(quinolin-7-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-methyl-1H-indazol-4-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(2-methylquinoxalin-6-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(2-(2-(pyrrolidin-1-yl)ethyl)-2H-indazol-5-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1H-indazol-5-ylamino)nicotinamide; -   6-(2-aminoethylamino)-2-(3,5-dimethoxyphenylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(quinolin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(3-chlorophenylamino)-5-fluoronicotinamide; -   6-(2-aminoethylamino)-5-fluoro-2-(quinolin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(isoquinolin-4-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(1,8-naphthyridin-3-ylamino)nicotinamide; -   5-fluoro-6-(2-(1H-imidazol-5-yl)ethylamino)-2-(quinolin-3-ylamino)nicotinamide; -   6-((1R)-2-amino-2-oxo-1-phenylethylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide; -   6-((2R)-1-amino-4-methyl-1-oxopentan-2-ylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide; -   6-((2R)-1-amino-1-oxobutan-2-ylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide; -   6-((2S)-2-aminobutylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide; -   6-((2S)-2-amino-3-methylbutylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide -   6-((2S)-2-amino-2-phenylethylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide; -   6-((2R)-2-amino-3-methoxypropylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide; -   6-((2S)-2-aminopropylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide; -   6-((2S)-2-amino-4-methylpentylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide; -   6-(3-aminopropylamino)-2-(3,5-dimethoxyphenylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-2-(3,5-dimethoxyphenylamino)-5-fluoronicotinamide; -   6-((1R,2S)-2-aminocyclohexylamino)-2-(3,5-dimethoxyphenylamino)-5-fluoronicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-chloro-2-(quinolin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-bromo-2-(quinolin-3-ylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-chloro-2-(3-methoxyphenylamino)nicotinamide; -   6-(cis-2-aminocyclohexylamino)-5-chloro-2-(5-methylpyridin-3-ylamino)nicotinamide;     and -   6-(cis-2-aminocyclohexylamino)-5-bromo-2-(5-methylpyridin-3-ylamino)nicotinamide.

The compound represented by the formula [1] of the present invention is preferably a compound having a Syk-inhibitory activity 1050, which is 50 nM or less and also having 1050 in a TNFα generation assay, which is 130 nM or less. More specific examples of such a compound include compounds wherein, in Table 21 that shows the results of a test performed according to a test method described in a “Syk enzyme assay” in Test Example 1 below, the Syk-inhibitory activity IC₅₀ is 50 nM or less (that is, evaluation standards are A and B), and in Table 22 that shows the results of a test performed according to a test method described in a “TNFα generation assay” in Test Example 2 below, the IC₅₀ is 130 nM or less (that is, evaluation standards are A and B).

Preferred examples of the compound represented by the formula [1] of the present invention include the following compounds.

Example 4-17

-   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(6-methylpyridin-3-ylamino)nicotinamide;

Example 4-228

-   6-((cis-2-aminocyclohexyl)amino)-2-((5-cyano-6-morpholinopyridin-3-yl)amino)-5-fluoronicotinamide;

Example 6-49

-   6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(5-methylpyridin-3-ylamino)nicotinamide;

Example 6-117

-   (R)-6-((1-amino-4-methylpentan-2-yl)amino)-5-fluoro-2-((quinolin-6-yl)amino)nicotinamide;

Example 6-157

-   (R)-6-(1-amino-4-methylpentan-2-yl)amino)-5-fluoro-2-((2-(2-methoxyethoxy)pyridin-4-yl)amino)nicotinamide;

Example 6-165

-   64-(1R,2S)-2-aminocyclohexylamino)-5-fluoro-2-((6-morpholinopyridin-3-yl)amino)nicotinamide;

Example 6-168

-   2-((5-(1H-pyrazol-1-yl)pyridin-3-yl)amino)-6-((1R,2S)-2-aminocyclohexylamino)-5-fluoronicotinamide;

Example 6-177

-   (R)-6-((1-amino-4-methylpentan-2-yl)amino)-2-((5,6-dimethylpyridin-3-yl)amino)-5-fluoronicotinamide;

Example 6-211

-   6-(((2S,3R)-2-aminopentane3-yl)amino)-2-((1-ethyl-1H-indazol-5-yl)amino)-5-fluoronicotinamide;

Example 6-249

-   6-(((2S,3R)-2-aminohexane-3-yl)amino)-5-fluoro-2-((2-methoxypyridin-4-yl)amino)nicotinamide;

Example 6-257

-   6-(((2S,3R)-2-aminopentane3-yl)amino)-5-fluoro-2-((5-(2-fluorophenyl)pyridin-3-yl)amino)nicotinamide;

Example 6-263

-   6-(((2S,3R)-2-aminopentane3-yl)amino)-5-fluoro-2-((1-methoxyisoquinolin-6-yl)amino)nicotinamide;

Example 6-268

-   6-(((2S,3R)-2-aminopentane3-yl)amino)-5-fluoro-2-((1-methyl-1H-indazol-4-yl)amino)nicotinamide;

Example 6-296

-   6-(((2S,3R)-2-aminohexane3-yl)amino)-2-((5,6-dimethylpyridin-3-yl)amino)-5-fluoronicotinamide;

Example 6-301

-   6-(((2S,3R)-2-aminohexane3-yl)amino)-5-fluoro-2-((5-fluoropyridin-3-yl)amino)nicotinamide;

Example 6-311

-   6-(((2S,3R)-2-aminohexane3-yl)amino)-5-fluoro-2-((2-propoxypyridin-4-yl)amino)nicotinamide;

Example 6-322

-   (R)-6-((1-amino-4-methylpentan-2-yl)amino)-2-((1-ethyl-1H-indazol-5-yl)amino)-5-fluoronicotinamide;

Example 6-342

-   6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl)amino)-2-((1-ethyl-1H-indazol-5-yl)amino)-5-fluoronicotinamide;

Example 6-368

-   6-(((1R,2S)-2-amino-1-cyclopropylpropyl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide;

Example 6-375

-   6-(((1R,2S)-2-aminocyclohexyl)amino)-5-fluoro-2-((6-methyl-5-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)amino)nicotinamide;

Example 6-377

-   6-(((1R,2S)-2-aminocyclohexyl)amino)-5-fluoro-2-((6-methoxy-5-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)amino)nicotinamide;

Example 6-383

-   6-(((2S,3R)-2-amino-5-methylhexane3-yl)amino)-5-fluoro-2-((1-methyl-1H-indazol-5-yl)amino)nicotinamide;

Example 6-384

-   6-(((2S,3R)-2-amino-5-methylhexane3-yl)amino)-2-((1-ethyl-1H-indazol-5-yl)amino)-5-fluoronicotinamide;

Example 6-395

-   6-(((1R,2S)-2-aminocyclohexyl)amino)-5-fluoro-2-((5-fluoro-6-morpholinopyridin-3-yl)amino)nicotinamide;

Example 6-433

-   6-(((1R,2S)-2-aminocyclohexyl)amino)-2-(2-ethoxy-3-fluoropyridin-4-yl)amino)-5-fluoronicotinamide;

Example 6-435

-   6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl)amino)-2-((5,6-dimethylpyridin-3-yl)amino)-5-fluoronicotinamide;

Example 6-468

-   6-(((2S,3S)-3-amino-1-methoxybutan-2-yl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide;     and

Example 8-1

-   6-(2-aminoethylamino)-2-(3,5-dimethoxyphenylamino)-5-fluoronicotinamide.

The pharmaceutical composition of the present invention is characterized in that it comprises the above-described nicotinamide derivative of the present invention or a salt thereof. The pharmaceutical composition of the present invention can be preferably used as a pharmaceutical composition for the treatment of a Syk-related disease.

An example of the Syk-related disease is a disease selected from the group consisting of rheumatism and idiopathic thrombocytopenic purpura. The pharmaceutical composition of the present invention can be preferably used as a pharmaceutical composition for the treatment of these diseases.

When isomers (for example, optical isomers, geometric isomers, tautomers, etc.) are present in the compound represented by the formula [1] or a salt thereof, the present invention includes these isomers. In addition, the present invention also includes solvates, hydrates, and various forms of crystals.

Next, a method for producing the compound of the present invention will be described.

The compound of the present invention can be produced by combining well-known methods. For example, the present compound can be produced according to production methods as described below.

[Production Method 1]

wherein R^(2a) represents a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl, aryl, ar-C₁₋₆ alkyl or heterocyclic group, having at least one amino group protected by an amino-protecting group; R^(a) represents an amino-protecting group; and R¹, R², R³, R⁴ and R⁵ have the same meanings as those described above.

The compound of the formula [1] can be produced by deprotecting the compound of the formula [2] in the presence of an acid. This reaction can be carried out, for example, by the method described in W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pp. 696 to 926, 2007, John Wiley & Sons, INC.

Examples of the acid used in this reaction include: inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrogen chloride, and hydrogen bromide; organic carboxylic acids such as acetic acid, trichloroacetic acid, and trifluoroacetic acid; and organic sulfonic acids such as methanesulfonic acid and p-toluenesulfonic acid.

The acid may be used in a molar concentration 1 time or more, and preferably 1 to 5 times, as compared with that of the compound of the formula [2]. In addition, the acid may be used as a solvent.

This reaction may be carried out in the coexistence of a solvent, as necessary. The solvent used is not particularly limited, as long as it does not affect the reaction. Examples of such a solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

It is preferable to use an acid or an aqueous solution of an acid as a solvent.

This reaction may be carried out at a temperature from 0° C. to the boiling point of a solvent, and preferably from 10° C. to 40° C., for 1 minute to 24 hours.

[Production Method 2]

wherein R¹, R², R³, R⁴ and R⁵ have the same meanings as those described above.

The compound of the formula [1] can be produced by allowing the compound of the formula [3] to react with ammonia or ammonium salts in the presence of a condensation agent and in the presence of a base.

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of such a solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are amides.

Examples of the condensation agent used in this reaction include: carbodiimides such as N,N′-dicyclohexylcarbodiimide and N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide; carbonyls such as carbonyldiimidazole; acid azides such as diphenylphosphoryl azide; acid cyanides such as diethylphosphoryl cyanide; 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline; O-benzotriazol-1-yl-1,1,3,3-tetramethyluronium hexafluorophosphate; and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate.

Examples of the base used in this reaction include: metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, and sodium tert-butoxide; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium hydrogencarbonate, sodium carbonate, potassium carbonate, sodium hydride, and potassium hydride; and organic bases such as triethylamine, diisopropylethylamine, and pyridine.

Examples of the ammonium salts include ammonium chloride, ammonium bromide, and ammonium acetate.

Ammonia or ammonium salts may be used in a molar concentration 1 to 100 times, and preferably 1 to 10 times, as compared with than that of the compound of the formula [3].

The condensation agent and the base may each be used in a molar concentration 1 time or more, and preferably 1 to 5 times, as compared with that of the compound of the formula [3].

This reaction may be carried out in the presence of a reaction promoter.

Examples of such a reaction promoter include 1-hydroxybenzotriazole and N-hydroxysuccinimide.

The reaction promoter may be used in a molar concentration 1 time or more, and preferably 1 to 5 times, as compared with than that of the compound of the formula [3].

This reaction may be carried out at a temperature from −20° C. to 150° C., and preferably from 0° C. to 100° C., for 1 minute to 24 hours.

[Production Method 3]

wherein R¹, R², R³, R⁴ and R⁵ have the same meanings as those described above.

The compound of the formula [1] can be produced by hydrolyzing the compound of the formula [4] in the presence of a base and in the presence of a hydrogen peroxide solution.

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of such a solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are alcohols and water.

Examples of the base used in this reaction include: metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, and sodium tert-butoxide; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium hydrogencarbonate, sodium carbonate, potassium carbonate, sodium hydride, and potassium hydride; and organic bases such as triethylamine, diisopropylethylamine, and pyridine.

The base may be used in a molar concentration 1 time or more, and preferably 1 to 5 times, as compared with than that of the compound of the formula [4].

The hydrogen peroxide may be used in a molar concentration 1 time or more, and preferably 1 to 10 times, as compared with that of the compound of the formula [4].

This reaction may be carried out at a temperature from 0° C. to the boiling point of a solvent, and preferably from 10° C. to 40° C., for 1 minute to 24 hours.

[Production Method 4]

wherein L¹ represents a benzotriazol-1-yloxy group or a succinimido-1-yloxy group; and R¹, R², R³, R⁴ and R⁵ have the same meanings as those described above.

The compound of the formula [1] can be produced by allowing the compound of the formula [5] to react with the compound of the formula [6] in the presence of a base.

For example, tryptophan is known as a compound of the formula [6].

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. N-methylmorpholine is preferable.

Examples of the base used in this reaction include: inorganic bases such as sodium hydrogencarbonate, sodium carbonate, potassium carbonate, cesium carbonate, and tripotassium phosphate; and organic bases such as pyridine, 4-(dimethylamino)pyridine, triethylamine, and diisopropylethylamine.

The base may be used in a molar concentration 1 to 50 times, and preferably 1 to 5 times, as compared with that of the compound of the formula [5].

The compound of the formula [6] may be used in a molar concentration 1 to 50 times, and preferably 1 to 2 times, as compared with that of the compound of the formula [5].

This reaction may be carried out at a temperature from 0° C. to the boiling point of a solvent, and preferably from 0° C. to 150° C., for 1 minute to 24 hours.

Next, a method for producing the compounds represented by the formulae [2], [3], [4] and [5], which are used as raw materials in the production of the compound of the present invention, will be described.

[Production Method A1]

wherein L^(a) represents a leaving group; and R¹, R^(2a), R³, R⁴, R⁵ and R^(a) have the same meanings as those described above.

The compound of the formula [2] can be produced by allowing the compound of the formula [Aa] to react with the compound of the formula [Ab] in the presence or absence of a base, in the presence of a palladium catalyst, and in the presence or absence of a ligand.

The compound of the formula [Aa] can be produced, for example, by a Production Method A2 as described later.

For example, 6-aminoquinoline is known as a compound of the formula [Ab].

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are ethers.

Examples of the base used in this reaction as desired include: inorganic bases such as sodium hydrogencarbonate, sodium carbonate, potassium carbonate, cesium carbonate, and tripotassium phosphate; and organic bases such as pyridine, 4-(dimethylamino)pyridine, triethylamine, and diisopropylethylamine.

The base may be used in a molar concentration 1 to 50 times, and preferably 1 to 5 times, as compared with that of the compound of the formula [Aa].

Examples of the palladium catalyst used in this reaction include: metallic palladium such as palladium carbon and palladium black; inorganic palladium salts such as palladium chloride; organic palladium salts such as palladium acetate; organic palladium complexes such as tetrakis(triphenylphosphine)palladium(0), bis(triphenylphosphine)palladium(II) chloride, 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) chloride, and tris(dibenzylideneacetone)dipalladium(0); and polymer-bound organic palladium complexes such as polymer-supported bis(acetate)triphenylphosphine palladium(II) and polymer-supported di(acetate)dicyclohexylphenylphosphine palladium (II). These compounds may be used in combination.

The palladium catalyst may be used in a molar concentration 0.00001 to 1 time, and preferably 0.001 to 0.1 time, as compared with that of the compound of the formula [Aa].

Examples of the ligand used in this reaction as desired include: trialkylphosphines such as trimethylphosphine and tri-tert-butylphosphine; tricycloalkylphosphines such as tricyclohexylphosphine; triarylphosphines such as triphenylphosphine and tritolylphosphine; trialkylphosphites such as trimethylphosphite, triethylphosphite, and tributylphosphite; tricycloalkylphosphites such as tricyclohexylphosphite; triarylphosphites such as triphenylphosphite; imidazolium salts such as 1,3-bis(2,4,6-trimethylphenyl)imidazolium chloride; diketones such as acetylacetone and octafluoroacetylacetone; amines such as trimethylamine, triethylamine, tripropylamine, and triisopropylamine; and 4,5-bis(diphenylphosphino)-9,9-dimethyl-xanthene, 1,1′-bis(diphenylphosphino)ferrocene, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl, 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl, 2-(di-tert-butylphosphino)-2′,4′,6′-triisopropylbiphenyl, and 2-(di-tert-butylphosphino)biphenyl. These compounds may be used in combination.

The ligand may be used in a molar concentration 0.00001 to 1 time, and preferably 0.001 to 0.5 time, as compared with that of the compound of the formula [Aa].

The compound of the formula [Ab] may be used in a molar concentration 1 to 50 times, and preferably 1 to 2 times, as compared with that of the compound of the formula [Aa].

This reaction may be preferably carried out in an inert gas (e.g. nitrogen, argon) atmosphere at a temperature from 40° C. to 170° C. for 1 minute to 96 hours.

[Production Method A2]

wherein R^(b) represents a carboxyl-protecting group; L^(b) represents a leaving group; and R¹, R^(2a), R⁴, R^(a) and L^(a) have the same meanings as those described above.

(A2-1)

The compound of the formula [A2c] can be produced by allowing the compound of the formula [A2a] to react with the compound of the formula [A2b] in the presence of a base.

For example, methyl 2,6-dichloro-5-fluoronicotinate is known as a compound of the formula [A2a].

For example, tert-butyl (2-aminoethyl)carbamate and tert-butyl(2-aminocyclohexyl)carbamate are known as compounds of the formula [A2b].

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are amides and ethers.

Examples of the base used in this reaction include: inorganic bases such as sodium hydrogencarbonate, sodium carbonate, potassium carbonate, cesium carbonate, and tripotassium phosphate; and organic bases such as pyridine, 4-(dimethylamino)pyridine, triethylamine, and diisopropylethylamine.

The base may be used in a molar concentration 1 to 50 times, and preferably 1 to 5 times, as compared with that of the compound of the formula [A2a].

The compound of the formula [A2b] may be used in a molar concentration 1 to 50 times, and preferably 1 to 2 times, as compared with that of the compound of the formula [A2a].

This reaction may be carried out at a temperature from 0° C. to the boiling point of a solvent, and preferably from 10° C. to 40° C., for 1 minute to 24 hours.

The compound of the formula [A2c] can also be produced by allowing the compound of the formula [A2a] to react with ethylenediamine, cyclohexanediamine or the like in the presence of a base in accordance with the above-described production method, and then protecting an amino group.

Protection of an amino group can be carried out, for example, by the method described in W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pp. 696 to 926, 2007, John Wiley & Sons, INC.

(A2-2)

The compound of the formula [A2d] can be produced by hydrolyzing the compound of the formula [A2c] in the presence of an acid or a base.

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are alcohols and water.

Examples of the acid used in this reaction include mineral acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid.

The acid may be used in a molar concentration 1 to 1000 times, and preferably 1 to 100 times, as compared with that of the compound of the formula [A2c].

Examples of the base used in this reaction include inorganic bases such as sodium hydroxide, potassium hydroxide, sodium hydrogencarbonate, sodium carbonate, potassium carbonate, sodium hydride, and potassium hydride.

The base may be used in a molar concentration 1 to 1000 times, and preferably 1 to 10 times, as compared with that of the compound of the formula [A2c].

This reaction may be carried out at a temperature from 0° C. to the boiling point of a solvent, and preferably from 0° C. to 100° C., for 1 minute to 24 hours.

(A2-3)

The compound of the formula [Aa] can be produced by allowing the compound of the formula [A2d] to react with the compound of the formula [A2d] in accordance with the Production Method 2.

For example, 2-phenyl-2-propanamine is known as a compound of the formula [A2e].

[Production Method B1]

wherein R^(c) represents an amino-protecting group; L^(c) represents a leaving group; and R¹, R^(2a), R³, R⁴, R⁵, R^(a) and L^(a) have the same meanings as those described above.

(B1-1)

The compound of the formula [Bb] can be produced by allowing the compound of the formula [Aa] to react with the compound of the formula [Ba] in accordance with the Production Method A1.

For example, benzylamine is known as a compound of the formula [Ba].

(B1-2)

The compound of the formula [Bc] can be produced by deprotecting the compound of the formula [Bb]. This reaction can be carried out, for example, by the method described in W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pp. 696 to 926, 2007, John Wiley & Sons, INC.

When R^(c) is, for example, a benzyl group, a 4-methoxybenzyl group or a 2,4-dimethoxybenzyl group, the compound of the formula [Bc] can be produced by reducing the compound of the formula [Bb] in the presence of a metal catalyst.

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are alcohols and ethers.

Examples of the metal catalyst used in this reaction include: metallic palladium such as palladium carbon and palladium black; palladium salts such as palladium oxide and palladium hydroxide; nickel metals such as Raney nickel; and platinum salts such as platinum oxide.

The metal catalyst may be used in an amount 0.001 to 5 times (W/W), and preferably 0.01 to 1 time (W/W), as compared with the amount of the compound of the formula [Bb].

Examples of the reducing agent include: hydrogen; formic acid; formates such as sodium formate, ammonium formate, and triethyl ammonium formate; and cyclohexene and cyclohexadiene.

The reducing agent may be used in a molar concentration 2 to 100 times, and preferably 2 to 10 times, as compared with that of the compound of the formula [Bb].

This reaction may be carried out at a temperature from 0° C. to the boiling point of a solvent, and preferably from 10° C. to 40° C., for 1 minute to 24 hours.

(B1-3)

The compound of the formula [2] can be produced by allowing the compound of the formula [Bc] to react with the compound of the formula [Bd] in accordance with the Production Method A1.

For example, 2-methyl-5-chloropyridine is known as a compound of the formula [Bd].

[Production Method B2]

wherein R^(1a) represents a chlorine atom or a bromine atom; and R^(2a), R⁴, R⁵, R^(a), R^(b), R^(c), L^(a) and L^(b) have the same meanings as those described above.

(B2-1)

The compound of the formula [B2c] can be produced by allowing the compound of the formula [B2a] to react with the compound of the formula [B2b] in accordance with the Production Method A2-1.

For example, ethyl 2,6-dichloronicotinate is known as a compound of the formula [B2a].

For example, benzylamine is known as a compound of the formula [B2b].

(B2-2)

The compound of the formula [B2e] can be produced by allowing the compound of the formula [B2c] to react with the compound of the formula [B2d] in the presence of a base.

For example, tert-butyl (2-aminoethyl)carbamate and tert-butyl (2-aminocyclohexyl)carbamate are known as compounds of the formula [B2d].

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. N-methylmorpholine is preferable.

Examples of the base used in this reaction include: inorganic bases such as sodium hydrogencarbonate, sodium carbonate, potassium carbonate, cesium carbonate, and tripotassium phosphate; and organic bases such as pyridine, 4-(dimethylamino)pyridine, triethylamine, and diisopropylethylamine.

The base may be used in a molar concentration 1 to 50 times, and preferably 1 to 5 times, as compared with that of the compound of the formula [B2c].

The compound of the formula [B2d] may be used in a molar concentration 1 to 50 times, and preferably 1 to 2 times, as compared with that of the compound of the formula [B2c].

This reaction may be preferably carried out at a temperature from 100° C. to 200° C. for 1 minute to 48 hours.

The compound of the formula [B2e] can also be produced by allowing the compound of the formula [B2c] to react with ethylenediamine, cyclohexanediamine or the like in the presence of a base in accordance with the above-described production method, and then protecting an amino group.

Protection of an amino group can be carried out, for example, by the method described in W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pp. 696 to 926, 2007, John Wiley & Sons, INC.

(B2-3)

The compound of the formula [B2f] can be produced from the compound of the formula [B2e] in accordance with the Production Methods A2-2 and A2-3.

(B2-4)

The compound of the formula [B2g] can be produced by deprotecting the compound of the formula [B2f] in accordance with the Production Method B1-2.

(B2-5)

The compound of the formula [B2h] can be produced by halogenating the compound of the formula [B2g] in the presence of a halogenating agent.

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are amides.

Examples of the halogenating agent used in this reaction include: halogens such as chlorine and bromine; imides such as N-chlorosuccinimide, N-bromosuccinimide, N-chlorophthalimide, and N-bromophthalimide; hydantoins such as 1,3-dibromo-5,5-dimethylhydantoin, and 1,3-dichloro-5,5-dimethylhydantoin; and sulfuryl chloride.

Preferred halogenating agents include imides.

The halogenating agent may be used in a molar concentration 1 time or more, and preferably 1 to 3 times, as compared with that of the compound of the formula [B2g].

This reaction is preferably carried out in the presence of a radical generator.

The radical generator is not particularly limited, as long as it is a commonly used radical generator. Examples of such a radical generator include: dialkyl peroxides such as di-tert-butyl peroxide, di-tert-amyl peroxide, and di(2-methyl-2-pentyl)peroxide; diacyl peroxides such as dibenzoyl peroxide, dicumyl peroxide and diphthaloyl peroxide; alkyl hydroperoxides such as tert-butyl hydroperoxide and cumyl hydroperoxide; percarboxylic acids such as perbenzoic acid, monoperoxyphthalic acid, performic acid, and peracetic acid; peroxo compounds of inorganic acids, such as persulfuric acid; and organic azo compounds such as 2,2′-azobisisobutyronitrile, 2,2′-azobis(2,4-dimethylvaleronitrile), 2,2′-azobis(2-methylbutyronitrile), 2,2′-azobisisovaleronitrile, 1,1′-azobis(cyclohexanecarbonitrile), 2,2′-azobis(4-methoxy-2,4-dimethylvaleronitrile), 2,2′-azobis(2-amidinopropane)dihydrochloride, and dimethyl 2,2′-azobisisobutyrate.

Preferred radical generators include organic azo compounds. Among such organic azo compounds, 2,2′-azobisisobutyronitrile, 2,2′-azobis(2,4-dimethylvaleronitrile) and 2,2′-azobis(4-methoxy-2,4-dimethylvaleronitrile) are more preferable.

The amount of the radical generator used is not particularly limited. The radical generator is used in a molar concentration 0.01 time or more, and preferably 0.05 to 1 time, as compared with that of the compound of the formula [B2g].

This reaction may be carried out at a temperature from 0° C. to 200° C., and preferably from 20° C. to 100° C., for 1 minute to 24 hours.

[Production Method C1]

wherein R¹, R^(2a), R³, R⁴, R⁵, R^(b) and L^(a) have the same meanings as those described above.

(C1-1)

The compound of the formula [Cc] can be produced by allowing the compound of the formula [Ca] to react with the compound of the formula [Cb] in accordance with the Production Method A2-1.

The compound of the formula [Ca] can be produced by a Production Method C4 as described later.

For example, 6-aminoquinoline is known as a compound of the formula [Cb].

(C1-2)

The compound of the formula [3] can be produced by hydrolyzing the compound of the formula [Cc] in the presence of an acid or a base in accordance with the Production Method A2-2.

[Production Method C2]

wherein R^(d) represents a C₁₋₆ alkyl group; L^(d) represents a chlorine atom or a bromine atom; M represents a potassium atom or a sodium atom; and R¹, R^(2a), R³, R⁴, R⁵ and R^(b) have the same meanings as those described above.

[C2-1]

The compound of the formula [C2c] can be produced by allowing the compound of the formula [C2a] to react with the compound of the formula [C2b].

For example, methyl 3-amino-3-ethoxyacrylate is known as a compound of the formula [C2a].

For example, 6-aminoquinoline is known as a compound of the formula

[C2b].

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are amides.

The compound of the formula [C2b] may be used in a molar concentration 1 time or more, and preferably 1 to 2 times, as compared with that of the compound of the formula [C2a].

This reaction may be carried out at a temperature from 0° C. to the boiling point of a solvent, and preferably from 10° C. to 40° C., for 1 minute to 24 hours.

(C2-2)

The compound of the formula [C2e] can be produced by allowing the compound of the formula [C2c] to react with the compound of the formula [C2d].

For example, a potassium salt of methyl 2-fluoro-3-hydroxyacrylate is known as a compound of the formula [C2d].

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are alcohols.

The compound of the formula [C2d] may be used in a molar concentration 1 time or more, and preferably 1 to 2 times, as compared with that of the compound of the formula [C2c].

This reaction may be carried out at a temperature from 0° C. to the boiling point of a solvent, and preferably from 40° C. to 100° C., for 1 minute to 24 hours.

(C2-3)

The compound of the formula [C2f] can be produced by halogenating the compound of the formula [C2e] in the presence of a phosphine and in the presence of a halogenating agent.

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are ethers.

Examples of the phosphine used in this reaction include: trialkylphosphines such as trimethylphosphine and tri-tert-butylphosphine; tricycloalkylphosphines such as tricyclohexylphosphine; and triarylphosphines such as triphenylphosphine and tritolylphosphine.

Preferred phosphines include triarylphosphines. Among others, triphenylphosphine is more preferable.

The phosphine is used in a molar concentration 1 time or more, and preferably 1 to 3 times, as compared with that of the compound of the formula [C2e].

Examples of the halogenating agent used in this reaction include: halogens such as chlorine and bromine; imides such as N-chlorosuccinimide, N-bromosuccinimide, N-chlorophthalimide, and N-bromophthalimide; hydantoins such as 1,3-dibromo-5,5-dimethylhydantoin, and 1,3-dichloro-5,5-dimethylhydantoin; and sulfuryl chloride.

Preferred halogenating agents include imides. Among such imides, N-chloro succinimide or N-bromosuccinimide is more preferable.

The halogenating agent may be used in a molar concentration 1 time or more, and preferably 1 to 5 times, as compared with that of the compound of the formula

[C2e].

This reaction may be carried out at a temperature from 0° C. to the boiling point of a solvent, and preferably from 60° C. to 100° C., for 1 minute to 24 hours.

(C2-4)

The compound of the formula [Cc] can be produced by allowing the compound of the formula [C2f] to react with the compound of the formula [C2g] in accordance with the Production Method A2-1.

[Production Method C3]

wherein R¹, R^(2a), R³, R⁴, R⁵, R⁵, R^(c), L^(a) and L^(c) have the same meanings as those described above.

(C3-1)

The compound of the formula [C3c] can be produced by allowing the compound of the formula [C3a] to react with the compound of the formula [C3b] in accordance with the Production Method A2-1.

The compound of the formula [C3a] can be produced by a Production Method C4 as described later.

For example, benzylamine is known as a compound of the formula [C3b].

(C₃₋₂)

The compound of the formula [C3d] can be produced by deprotecting the compound of the formula [C3c] in accordance with the Production Method B1-2.

(C3-3)

The compound of the formula [Cc] can be produced by allowing the compound of the formula [C3d] to react with the compound of the formula [C3e] in accordance with the Production Method A1.

For example, 2-methyl-5-chloropyridine is known as a compound of the formula [C3e].

[Production Method C4]

wherein R¹, R^(2a), R⁴, R^(b), L^(a) and L^(b) have the same meanings as those described above.

The compound of the formula [Ca] can be produced by allowing the compound of the formula [C4a] to react with the compound of the formula [C4b] in accordance with the Production Method A2-1.

For example, methyl 2,6-dichloro-5-fluoronicotinate is known as a compound of the formula [C4a].

For example, tert-butyl (2-aminoethyl)carbamate and tert-butyl(2-aminocyclohexyl)carbamate are known as compounds of the formula [C4b].

[Production Method D1]

wherein R¹, R², R³, R⁴, R⁵, R^(b) and L^(a) have the same meanings as those described above.

(D1-1)

The compound of the formula [Db] can be produced by hydrolyzing the compound of the formula [Da] in the presence of an acid or a base in accordance with the Production Method A2-2.

The compound of the formula [Da] can be produced, for example, in accordance with the Production Method C4.

(D1-2)

The compound of the formula [Dc] can be produced from the compound of the formula [Db] in accordance with the Production Method 2.

(D1-3)

The compound of the formula [Dd] can be produced by allowing the compound of the formula [Dc] to react with a dehydrating agent in the presence of a base.

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are halogenated hydrocarbons.

Examples of the base used in this reaction include: metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, and sodium tert-butoxide; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium hydrogencarbonate, sodium carbonate, potassium carbonate, sodium hydride, and potassium hydride; and organic bases such as triethylamine, diisopropylethylamine, and pyridine.

Examples of the dehydrating agent used in this reaction include: acid anhydrides such as acetylformyloxide, acetic anhydride, trichloroacetic anhydride, and trifluoroacetic anhydride; mixed acid anhydrides of organic carboxylic acids such as acetic acid with carbonic acid monoalkyl esters such as ethyl chlorocarbonate and isobutyl chlorocarbonate; mixed acid anhydrides of organic carboxylic acids such as acetic acid with organic acids such as pivalic acid; acid chlorides such as acetyl chloride, trichloroacetyl chloride, and trifluoroacetyl chloride; and acid bromides such as acetyl bromide.

The base and the dehydrating agent may each be used in a molar concentration 1 time or more, and preferably 1 to 5 times, as compared with that of the compound of the formula [Dc].

This reaction may be carried out at a temperature from −20° C. to 100° C., and preferably from 0° C. to 50° C., for 1 minute to 24 hours.

(D1-4)

The compound of the formula [4] can be produced by allowing the compound of the formula [Dd] to react with the compound of the formula [De] in accordance with the Production Method A2-1.

[Production Method D2]

wherein R¹, R², R³, R⁴, R⁵, R^(b), R^(d), M and L^(d) have the same meanings as those described above.

(D2-1)

The compound of the formula [D2c] can be produced by allowing the compound of the formula [D2a] to react with the compound of the formula [D2b] in accordance with the Production Method C₂₋₁.

For example, methyl 2-cyano-acetimidate is known as a compound of the formula [D2a].

For example, 6-aminoquinoline is known as a compound of the formula [D2b].

-   -   [D2-2]

The compound of the formula [D2e] can be produced by allowing the compound of the formula [D2c] to react with the compound of the formula [D2d] in accordance with the Production Method C_(2-2.)

For example, a potassium salt of methyl 2-fluoro-3-hydroxyacrylate is known as a compound of the formula [D2d].

(D2-3)

The compound of the formula [D2f] can be produced by halogenating the compound of the formula [D2e] in accordance with the Production Method C_(2-3.)

(D2-4)

The compound of the formula [4] can be produced by allowing the compound of the formula [D2f] to react with the compound of the formula [D2g] in accordance with the Production Method A2-1.

For example, ethylenediamine and cyclohexanediamine are known as compounds of the formula [D2g].

[Production Method D3]

wherein R^(e) represents an amino-protecting group; L^(e) represents a C₁₋₆ alkylsulfonyloxy group or an arylsulfonyloxy group; and R¹, R³, R⁵, R¹⁰, R¹¹, R¹², R¹³ and L^(d) have the same meanings as those described above.

(D3-1)

The compound of the formula [D3b] can be produced by allowing the compound of the formula [D3a] to react with sulfonyl chloride.

For example, tert-butyl (1-hydroxypropan-2-yl)carbamate is known as a compound of the formula [D3a].

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are ethers.

Examples of the sulfonyl chloride used in this reaction include methylsulfonyl chloride, ethylsulfonyl chloride, propylsulfonyl chloride, benzenesulfonyl chloride, p-toluenesulfonyl chloride, and naphthalenesulfonyl chloride.

Preferred sulfonyl chlorides include methylsulfonyl chloride and p-toluenesulfonyl chloride. Further, methylsulfonyl chloride is more preferable.

The sulfonyl chloride is used in a molar concentration of 1 time or more, and preferably 1 to 3 times, as compared with that of the compound of the formula [D3a].

Examples of the base used in this reaction as desired include: inorganic bases such as sodium hydrogencarbonate, sodium carbonate, potassium carbonate, cesium carbonate, and tripotassium phosphate; and organic bases such as pyridine, 4-(dimethylamino)pyridine, triethylamine, and diisopropylethylamine.

The base is used in a molar concentration of 1 time or more, and preferably 1 to 3 times, as compared with that of the compound of the formula [D3a].

This reaction may be carried out at a temperature from −78° C. to the boiling point of a solvent, and preferably from 0° C. to 80° C., for 1 minute to 24 hours.

(D3-2)

The compound of the formula [D3c] can be produced by allowing the compound of the formula [D3b] to react with a phthalimide compound.

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are amides.

Examples of the phthalimide compound used in this reaction include phthalimide sodium and phthalimide potassium.

The phthalimide compound can also be produced in a reaction system, using a phthalimide as a raw material.

A preferred phthalimide compound is phthalimide potassium.

The phthalimide compound is used in a molar concentration 1 time or more, and preferably 1 to 3 times, as compared with that of the compound of the formula [D3b].

This reaction may be carried out at a temperature from 0° C. to the boiling point of a solvent, and preferably from 0° C. to 100° C., for 1 minute to 24 hours.

(D3-3)

The compound of the formula [D3d] can be produced by deprotecting the compound of the formula [D3c]. This reaction can be carried out, for example, by the method described in W. Greene et al., Protective Groups in Organic Synthesis, 4th edition, pp. 696 to 926, 2007, John Wiley & Sons, INC.

In this reaction, deprotection is preferably carried out using hydrazine.

(D3-4)

The compound of the formula [4a] can be produced by allowing the compound of the formula [D3d] to react with the compound of the formula [D3e] in accordance with the Production Method A2-1.

[Production Method D4]

wherein R¹, R³, R⁵, R¹⁰, R¹¹, R¹², R¹³, R^(e) and L^(d) have the same meanings as those described above.

(D4-1)

The compound of the formula [D4a] can be produced by deprotecting the compound of the formula [D3c] in accordance with the Production Method B1-2.

(D4-2)

The compound of the formula [4b] can be produced by allowing the compound of the formula [D4a] to react with the compound of the formula [D3e] in accordance with the Production Method A2-1.

[Production Method D5]

wherein R¹,

R^(2a), R³, R⁴, R⁵, L^(a) and L^(b) have the same meanings as those described above.

(D5-1)

The compound of the formula [D5c] can be produced by allowing the compound of the formula [D5a] to react with the compound of the formula [D5b] in accordance with the Production Method A2-1.

For example, 2,6-dichloro-3-cyano-5-fluoropyridine is known as a compound of the formula [D5a].

For example, tert-butyl((1R,2S)-1-cyclopropyl-1-hydroxypropan-2-yl)carbamate is known as a compound of the formula [D5b].

(D5-2)

The compound of the formula [4c] can be produced by allowing the compound of the formula [D5c] to react with the compound of the formula [D5d] in accordance with the Production Method A2-1.

[Production Method E]

wherein R¹, R³, R⁵, R^(b) and L¹ have the same meanings as those described above.

(E-1)

The compound of the formula [Ea] can be produced, for example, in accordance with the Production Method C_(2-2.)

(E-2)

The compound of the formula [Eb] can be produced by hydrolyzing the compound of the formula [Ea] in the presence of an acid or a base in accordance with the Production Method A2-2.

(E-3)

The compound of the formula [5] can be produced by allowing the compound of the formula [Eb] to react with ammonia or ammonium salts in the presence of a reaction promoter and in the presence of a condensation agent.

The solvent used in this reaction is not particularly limited, as long as it does not affect the reaction. Examples of the solvent include aliphatic hydrocarbons, halogenated hydrocarbons, alcohols, glycols, ethers, ketones, esters, amides, nitriles, sulfoxides, aromatic hydrocarbons, and water. These solvents may be used in combination.

Preferred solvents are amides.

Examples of the condensation agent used in this reaction include: carbodiimides such as N,N′-dicyclohexylcarbodiimide and N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide; carbonyls such as carbonyldiimidazole; acid azides such as diphenylphosphoryl azide; acid cyanides such as diethylphosphoryl cyanide; 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline; O-benzotriazol-1-yl-1,1,3,3-tetramethyluronium hexafluorophosphate; and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate.

Examples of the base used in this reaction include: metal alkoxides such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, and sodium tert-butoxide; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium hydrogencarbonate, sodium carbonate, potassium carbonate, sodium hydride, and potassium hydride; and organic bases such as triethylamine, diisopropylethylamine, and pyridine.

Examples of the ammonium salts include ammonium chloride, ammonium bromide, and ammonium acetate.

The ammonia or the ammonia or ammonium salts may be used in a molar concentration 1 to 100 times, and preferably 1 to 10 times, as compared with that of the compound of the formula [Eb].

Examples of the reaction promoter used in this reaction include 1-hydroxybenzotriazole and N-hydroxysuccinimide.

The condensation agent, the base and the reaction promoter may each be used in a molar concentration 1 time or more, and preferably 1 to 5 times, as compared with that of the compound of the formula [Eb].

This reaction may be carried out at a temperature from −20° C. to 150° C., and preferably from 0° C. to 100° C., for 1 minute to 24 hours.

The compounds obtained by the above-described production methods can be converted to other compounds by subjecting them to well-known reactions such as condensation, addition, oxidation, reduction, dislocation, substitution, halogenation, dehydration or hydrolysis, or by combining these reactions, as appropriate.

When amino, hydroxyl and/or carboxyl groups are present in the compounds obtained by the above-described production methods and the intermediates thereof, reactions can be carried out by replacing their protecting groups with other groups, as appropriate. In addition, when two or more protecting groups are present, such protecting groups can be selectively deprotected by subjecting them to well-known reactions.

Among compounds used in the above-described production methods, those that can be in the form of salts can be used as salts. Examples of such salts are the same as the examples of the salt of the compound represented by the formula [1].

When isomers (for example, optical isomers, geometric isomers, tautomers, etc.) are present in the compounds used in the above-described production methods, these isomers can also be used. In addition, when solvates, hydrates, and various forms of crystals are present, these solvates, hydrates, and various forms of crystals can also be used.

When the compound represented by the formula [1] of the present invention is used as a medicament, pharmaceutical additives commonly used in formulation of such a medicament, such as an excipient, a carrier and a diluent, may be mixed into the compound of the present invention, as appropriate. The thus formulated medicament can be orally or parenterally administered in the form of a tablet, a capsule, a powdered medicine, a syrup, a granule, a pill, a suspending agent, an emulsion, a liquid agent, a powdery agent, a suppository, an eye drop, a nasal drop, an ear drop, a patch, an ointment or an injection, according to ordinary methods. An administration method, a dosage, and a number of doses can be selected, as appropriate, depending on the age, body weight and symptoms of a patient. In general, the present medicament may be administered orally or parenterally (e.g. via injection, drip infusion, or administration into a rectal site) at a dosage from 0.01 to 1000 mg/kg to an adult per day, once or dividedly several times.

Next, the usefulness of representative compounds of the present invention will be described in the following Test Examples.

Test Example 1 Syk Enzyme Assay

A glutathione S-transferase (GST)-fused full-length human Syk protein (Carna Biosciences), which had been generated using a Baculovirus expression system, was used in the Syk enzyme assay.

15 μl of a reaction solution (1.2 ng Syk, 20 mM HEPES, 10 mM MgCl₂, 50 mM NaCl, 2 mM DTT, 0.05% BSA, pH 7.0) containing a Syk protein and a predetermined concentration of a test compound was shaken for 2 minutes, and it was then left at rest at room temperature for 13 minutes. Thereafter, 5 μl of Biotin-EDPDYEWPSA-NH2 (final concentration: 0.4 μM) serving as a substrate peptide and 5 μl of ATP (final concentration: 27 μM) were added to the reaction solution, and the obtained mixture was then shaken for 2 minutes. The reaction solution was further left at rest at room temperature for 40 minutes, so as to carry out an enzyme reaction.

Thereafter, 50 μl of a reaction termination solution [5 μg/ml Streptavidin, 0.18 μg/ml PT66-K, 30 mM HEPES (pH 7.0), 150 mM KF, 75 mM EDTA, 0.15% BSA, 0.075% Tween20], which contained Streptavidin-Xlent (Cisbio) and Mab PT66-K (Cisbio), was added to the reaction solution to terminate the enzyme reaction. At the same time, the reaction solution was left at rest at room temperature for 1 hour, so as to carry out an antigen-antibody reaction. Thereafter, using EnVision (PerkinElmer), the time-resolved fluorescence was measured at 615 nm and 665 nm, so that the phosphorylation of the substrate peptide was measured.

As a result, the Syk-inhibitory activity (IC₅₀) of each compound in the following compound group was found to be 1 μM or less. The compounds in the compound group exhibited excellent Syk-inhibitory activity.

Compound Group: Example 1, Examples 2-1 to 2-7, Example 2-9, Example 2-10, Examples 2-13 to 2-21, Example 3, Examples 4-1 to 4-42, Examples 4-44 to 4-64, Example 5, Example 6-2, Examples 6-6 to 6-11, Example 6-18, Example 6-20, Example 6-21, Example 6-23, Example 6-24, Example 6-26, Example 6-27, Examples 6-29 to 6-65, Example 6-67, Example 6-68, Examples 6-70 to 6-88, Example 7, Example 8-1, Example 8-2, Examples 8-4 to 8-11, Example 9, Example 10-1, Example 10-2, Example 11, Examples 12-1 to 12-6, Example 12-8, Example 12-9, Examples 12-12 to 12-21, Example 12-25, Example 12-27, Example 12-28, Examples 12-31 to 12-34, Example 13, Examples 14-1 to 14-10, Example 15, Example 16-8, Example 16-9, Example 16-17, Example 16-18, Example 17, Example 19, Example 21, Example 22-3, Examples 22-5 to 22-7, Example 23, Example 24, Example 26, Examples 27-1 to 27-6, Example 28, Example 29-1, Examples 29-3 to 29-8, Example 29-12, Example 29-13, Example 30, Example 31-3, Example 31-4, Example 32, Example 33-1, Examples 33-4 to 33-6, Example 34, and Examples 35-1 to 35-9.

Test Example 2 TNFα Generation Assay

THP-1 cells (2×10⁵ cells/ml), which were human monocytoid cells, were cultured in the presence of 10 ng/ml IFN-γ (Roche) for 2 days, so that the cells were induced to differentiate into macrophage-like cells. The differentiation-induced THP-1 cells were recovered, and the cells (1×10⁶ cell/ml) were then allowed to react with a predetermined concentration of test compound at room temperature for 30 minutes. On the other hand, 100 μl of human IgG (10 μg/ml, SIGMA-ALDRICH) diluted with PBS was added to a 96-well plate, and it was then incubated at room temperature overnight. Thereafter, the resultant was washed with PBS twice to produce a human IgG-coated plate. Subsequently, a cell solution that contained a compound was inoculated on the human IgG-coated plate (5×10⁴ cells/well), and it was then cultured for 7 hours. Thereafter, the cultured solution was recovered, and the amount of TNFα secreted into the culture solution was then measured by the ELISA method (Roche/R & D Systems) or the AlphaLISA method (PerkinElmer).

As a result, the TNFα generation inhibitory activity (IC₅₀) of each compound in the following compound group was found to be 200 nM or less. The compounds in the compound group exhibited excellent TNFα generation inhibitory activity.

Compound Group: Example 1, Example 2-1, Example 2-3, Example 2-5, Example 2-7, Examples 2-13 to 2-15, Example 2-20, Example 3, Examples 4-2 to 4-8, Examples 4-11 to 4-13, Examples 4-16 to 4-18, Example 4-22, Example 4-23, Example 4-25, Example 4-26, Example 4-28, Examples 4-35 to 4-37, Example 4-40, Example 4-42, Examples 4-53 to 4-55, Examples 4-58 to 4-62, Example 4-64, Example 5, Example 6-26, Example 6-34, Example 6-35, Example 6-40, Example 6-43, Example 6-44, Example 6-46, Examples 6-49 to 6-58, Examples 6-60 to 6-63, Example 6-65, Example 6-70, Example 6-72, Example 6-75, Example 6-76, Example 6-82, Example 6-83, Example 6-87, Example 7, Example 8-4, Example 8-6, Example 8-8, Example 8-11, Example 9, Example 10⁻¹, Example 10⁻², Example 11, Example 12-8, Example 12-9, Example 12-31, Example 13, Example 14-1, Example 14-2, Example 14-5, Example 14-6, Example 14-9, Example 14-10, Example 21, Example 22-3, Example 22-5, Example 34, Examples 35-1 to 35-4, and Example 35-7.

The compound of the present invention exhibited excellent Syk-inhibitory activity and TNFα generation inhibitory activity.

EXAMPLES

The present invention is hereafter described with reference to the Reference Examples and the Examples, although the scope of the present invention is not limited thereto.

LC/MS analysis was conducted under the following conditions. LC/MS analyzer: Waters SQD

Column: Waters BEHC18 1.73 3 μm, 2.1×30 mm

Solvent: Liquid A: 0.1% formic acid-water

Liquid B: 0.1% formic acid-acetonitrile

Gradient cycle: 0.00 min (Liquid A/Liquid B=95/5), 2.00 min (Liquid A/Liquid B=5/95), 3.00 min (Liquid A/Liquid B=5/95), 3.01 min (Liquid A/Liquid B=100/0), 3.80 min (Liquid A/Liquid B=100/0) Flow rate: 0.5 mL/min (The column temperature was room temperature, and no temperature control was carried out.) Ionization method: Electron Spray Ionization method (ESI positive and negative ion peaks were detected.) UV detection: UV 220 nm MS analysis was conducted under the following conditions. MS analyzer: Hitachi M-8000

Solvent: Methanol

Ionization method: Electron Spray Ionization method (ESI positive and negative ion peaks were detected.) NMR spectra are proton NMR spectra. NMR spectra were measured using a JEOL JNM-AL 400 (400 MHz spectrometer) or a BRUKER AVANCE 300 (300 MHz spectrometer), and the δ value was expressed in ppm.

The carrier used for silica gel column chromatography is PSQ100B (spherical shape) (Fuji Silysia Chemical Ltd.), and the PLC glass plate is a PLC glass plate silica gel 60 F₂₅₄ (Merck), unless otherwise specified.

The compound of the formula [1a] is a mixture of a compound of the formula [1b] and a compound of the formula [1c].

Abbreviations used in the Reference Examples and the Examples stand for the terms given below.

Ac: acetyl Bn: benzyl Boc: tert-butoxycarbonyl Bu: butyl Cbz: benzyloxycarbonyl dba: 1,3-dibenzylideneacetone

DMF: N,N-dimethylformamide

DMSO-d₆: hexadeuterodimethyl sulfoxide DPPA: diphenylphosphoryl azide Et: ethyl HOBt.H₂O: 1-hydroxybenzotriazole.monohydrate Me: methyl Ms: methanesulfonyl Ph: phenyl RT, rt: retention time SEM: (2-trimethylsilylethoxy)methyl TBDMS: tert-butyldimethylsilyl Tf: trifluoromethanesulfonyl TFA: trifluoroacetic acid TIPS: triisopropylsilyl TMS: trimethylsilyl Ts: p-toluenesulfonyl WSC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-hydrochloride Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

Reference Example 1

Concentrated sulfuric acid (5 ml) was added to a methanol (50 ml) solution containing 2,6-dichloro-5-fluoronicotinic acid (25.0 g), followed by stirring at 50° C. to 60° C. for 6 hours and 30 minutes. The resulting solution was left at rest at room temperature for 15 hours. Concentrated sulfuric acid (5 ml) was added, followed by stirring at 50° C. to 60° C. for 3 hours. The reaction mixture was cooled to room temperature, neutralized with a 2N sodium hydroxide aqueous solution under ice cooling, and basified with sodium hydrogen carbonate, following which ethyl acetate was added. The organic layer was collected, washed with water and then with saturated saline, and dried over anhydrous magnesium sulfate. The solvent was distilled away under reduced pressure, and colorless oily matter of methyl 2,6-dichloro-5-fluoronicotinate (22.2 g) was thus obtained.

¹H-NMR (CDCl₃, 400 MHz) δ: 8.02 (d, 1H, J=7.3 Hz), 3.98 (s, 3H)

Reference Example 2

1st Step

Potassium carbonate (14.8 g), cis-cyclohexane-1,2-diamine (12.2 g), and DMF (20 ml) were added to a DMF (180 ml) solution containing methyl 2,6-dichloro-5-fluoronicotinate (20.0 g), followed by stirring at room temperature for 30 minutes. Water, a saturated aqueous ammonium chloride solution, and ethyl acetate were added to the reaction mixture. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate. The solvent was distilled away under reduced pressure, and yellow oily matter (28.3 g) was thus obtained.

2nd Step

Di-tert-butyl dicarbonate (19.5 g) and N,N-dimethylaminopyridine (1.10 g) were added to a tetrahydrofuran (200 ml) solution containing the yellow oily matter (28.3 g) obtained in the 1st step, followed by stirring at room temperature for 30 minutes. The solvent was distilled away under reduced pressure, and a saturated aqueous ammonium chloride solution and ethyl acetate were added. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate. The solvent was distilled away under reduced pressure. Hexane/ethyl acetate (4/1) was added to the obtained residue, solid matter was collected by filtration, and a white solid of methyl 6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-2-chloro-5-fluoronicotinate (15.7 g) was thus obtained.

¹H-NMR (CDCl₃, 400 MHz) δ: 7.72 (d, 1H, J=10.9 Hz), 5.84 (brs, 1H), 4.89 (brs, 1H), 4.27-4.18 (m, 1H), 4.06-3.99 (m, 1H), 3.87 (s, 3H), 2.03-1.31 (m, 17H)

Reference Example 3

1st Step

A 1N sodium hydroxide aqueous solution (25 ml) was added a solution of tetrahydrofuran (50 ml) and methanol (50 ml) containing methyl-6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-2-chloro-5-fluoronicotinate (5.00 g), followed by stirring at 70° C. for 1 hour. The reaction mixture was cooled to room temperature, the solvent was distilled away under reduced pressure, and a saturated aqueous ammonium chloride solution and ethyl acetate were added. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, the solvent was distilled away under reduced pressure, and 6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-2-chloro-5-fluoronicotinic acid was thus obtained.

MS (ESI, m/z): 388 (M+H), 410 (M+Na), 386 (M−H)

2nd Step

Cumylamine (1.97 ml), WSC.HCl (2.62 g), and HOBt.H₂O (2.10 g) were added to a DMF (60 ml) solution containing 6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-2-chloro-5-fluoronicotinic acid obtained in the 1st step, followed by stirring at room temperature for 4 hours. A saturated aqueous ammonium chloride solution and ethyl acetate were added to the reaction mixture. The organic layer was collected, washed with a saturated aqueous sodium hydrogen carbonate solution and then with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. Diisopropylether and hexane were added to the obtained residue, solid matter was collected by filtration, and a white solid of tert-butyl cis-2-(6-chloro-3-fluoro-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate (4.41 g) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.46 (s, 1H), 7.53 (d, 1H, J=10.4 Hz), 7.45-7.39 (m, 2H), 7.33-7.26 (m, 2H), 7.21-7.15 (m, 1H), 6.71-6.54 (m, 2H), 4.09-3.98 (m, 1H), 3.87-3.77 (m, 1H), 1.84-1.17 (m, 23H)

MS (ESI, m/z): 406 (M-Boc+H)

Reference Example 4

The following compound was obtained with reference to US2009/270405 A1.

5-phenylpyridin-3-amine Reference Example 5

The following compound was obtained with reference to US2003/220345 A1 or Helv. Chim. Acta, 1964, 47, 36.

2,6-dimethoxypyridin-4-amine Reference Example 6

The following compound was obtained with reference to WO2006/118256 A1.

2-(pyrrolidin-1-yl)pyridin-4-amine Reference Example 7

1st Step

1-(2-aminoethyl)pyrrolidine (237 μl) was added to a methanol (1 ml) suspension containing 2-chloro-5-nitropyridine (100 mg), followed by stirring at room temperature for 3 hours and 30 minutes. 1-(2-aminoethyl)pyrrolidine (158 μl) was added, followed by stirring for 2 hours. Water and ethyl acetate were added to the reaction mixture. The organic layer was collected, washed with 10% saline and then with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. Diisopropylether was added to the obtained residue, solid matter was collected by filtration and washed with diisopropylether and hexane, and a yellow solid of 5-nitro-N-(2-(pyrrolidin-1-yl)ethyl)pyridin-2-amine (27 mg) was thus obtained.

MS (ESI, m/z): 237 (M+H), 235 (M−H)

2nd Step

5% Pd/C (8 mg) was added to a methanol (2 ml) solution containing 5-nitro-N-(2-(pyrrolidin-1-yl)ethyl)pyridin-2-amine (27 mg), followed by stirring at room temperature for 2 hours in a hydrogen atmosphere. Insoluble matter was removed by filtration, and filter cake was washed with ethyl acetate. The filtrate was mixed with the washing solution, the solvent was distilled away under reduced pressure, and red oily matter of N²-(2-(pyrrolidin-1-yl)ethyl)pyridin-2,5-diamine (24 mg) was thus obtained.

¹H-NMR (CDCl₃, 400 MHz) δ: 7.72-7.66 (m, 1H), 6.99-6.92 (m, 1H), 6.38-6.32 (m, 1H), 4.66 (brs, 1H), 3.36-3.28 (m, 2H), 2.73-2.68 (m, 2H), 2.59-2.50 (m, 4H), 2.03 (brs, 2H), 1.83-1.73 (m, 4H) MS (ESI, m/z): 207 (M+H)

Reference Example 8

The following compound was obtained as described in the 1st step of Example 1.

tert-Butyl cis-2-(6-benzylamino-3-fluoro-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate

MS (ESI, m/z): 576 (M+H), 574 (M−H)

Reference Example 9

Palladium hydroxide (0.29 g) was added to a solution of tetrahydrofuran (7.2 ml) and methanol (14.3 ml) containing tert-butyl cis-2-(6-benzylamino-3-fluoro-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate (1.43 g), followed by stirring at room temperature for 1 hour in a hydrogen atmosphere. Insoluble matter was removed by filtration, and filter cake was washed with ethyl acetate. The filtrate was mixed with the washing solution, and the solvent was distilled away under reduced pressure. Diisopropylether and hexane were added to the obtained residue, solid matter was collected by filtration, and a white solid of tert-butyl cis-2-(6-amino-3-fluoro-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate (870 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 7.90 (d, 1H, J=12.7 Hz), 7.74 (s, 1H), 7.35-7.30 (m, 2H), 7.29-7.22 (m, 2H), 7.17-7.11 (m, 1H), 6.81 (s, 2H), 6.69 (d, 1H, J=7.7 Hz), 6.11 (d, 1H, J=7.8 Hz), 4.13-4.03 (m, 1H), 3.80-3.72 (m, 1H), 1.84-1.20 (m, 23H) MS (ESI, m/z): 486 (M+H), 484 (M−H)

Reference Example 10

The following compound was obtained with reference to EP1375486.

3-bromoquinolin-8-amine Reference Example 11

The following compound was obtained with reference to WO2007/5668.

4-bromoisoindolin-1-one Reference Example 12

Aniline (99 μl), WSC.HCl (209 mg), and HOBt.H₂O (167 mg) were added to a DMF (5 ml) solution containing 5-bromonicotinic acid (200 mg), followed by stirring at room temperature for 3 hours. A saturated aqueous ammonium chloride solution and ethyl acetate were added to the reaction mixture. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. Diisopropylether and hexane were added to the obtained residue, solid matter was collected by filtration, and a white solid of 5-bromo-N-phenylnicotinamide (268 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 10.50 (s, 1H), 9.07 (d, 1H, J=2.2 Hz), 8.92 (d, 1H, J=2.0 Hz), 8.55 (dd, 1H, J=2.0, 2.0 Hz), 7.76 (d, 2H, J=7.6 Hz), 7.42-7.35 (m, 2H), 7.14 (t, 1H, J=7.2 Hz)

MS (ESI, m/z): 277, 279 (M+H), 275, 277 (M−H)

Reference Example 13

Sodium hydride (60% in oil) (28 mg) was added to a DMF (2.4 ml) solution containing 5-bromo-N-methylnicotinamide (100 mg), followed by stirring at 45° C. for 1 hour. Methyl iodide (43 μl) was added under ice cooling, followed by stirring at room temperature for 1 hour. A saturated aqueous ammonium chloride solution and ethyl acetate were added to the reaction mixture. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate. The solvent was distilled away under reduced pressure. Hexane was added to the obtained residue, solid matter was collected by filtration, and a white solid of 5-bromo-N,N-dimethylnicotinamide (42 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.78 (d, 1H, J=2.2 Hz), 8.61 (d, 1H, J=1.8 Hz), 8.14 (dd, 1H, J=1.9, 2.2 Hz), 3.00 (s, 3H), 2.92 (s, 3H)

MS (ESI, m/z): 229, 231 (M+H)

Reference Example 14

The following compound was obtained with reference to J. Chem. Soc., 1948, 17, 1389.

7-bromopyrido[2,3-b]pyrazine Reference Example 15

1st Step

Diisopropylethylamine (286 μA), (2-ethylhexyl) 3-mercaptopropionate (167 Pd₂(dba)₃ (31 mg), and Xantphos (39 mg) were added to a 1,4-dioxane (3.4 ml) solution containing 2-amino-5-bromo-3-iodopyridine (200 mg), followed by stirring at 95° C. for 30 minutes in a nitrogen atmosphere. Water and ethyl acetate were added to the reaction mixture, and insoluble matter was removed by filtration. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=100:0 to 65:35), and yellow oily matter (167 mg) was thus obtained.

2nd Step

A 20% sodium ethoxide/ethanol solution (0.5 ml) was added to a tetrahydrofuran (1 ml) solution containing the yellow oily matter (167 mg) obtained in the 1st step, followed by stirring at room temperature for 15 minutes. Formic acid (1 ml) and ethyl orthoformate (2 ml) were added to the reaction mixture, followed by stirring for 30 minutes and then at 100° C. for 1 hour. The reaction mixture was cooled to room temperature, and a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate were added. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=10:0 to 2:1), and a yellow solid of 6-bromo[1,3]thiazolo[4,5-b]pyridine (56 mg) was thus obtained.

¹H-NMR (CDCl₃, 400 MHz) δ: 9.28 (s, 1H), 8.84 (d, 1H, J=2.2 Hz), 8.48 (d, 1H, J=2.2 Hz)

MS (ESI, m/z): 215, 217 (M+H),

Reference Example 16

The following compound was obtained with reference to J. Heterocycl. Chem., 1948, 32, 467.

6-bromo-3-methyl-3H-imidazo[4,5-b]pyridine Reference Example 17

The following compound was obtained with reference to J. Heterocycl. Chem., 1948, 32, 467.

6-bromo-3-methyl-3H-imidazo[4,5-b]pyridine Reference Example 18

3,5-dibromopyridine (400 mg) and cesium carbonate (550 mg) were added to an N-methylpyrrolidone (4 ml) solution containing 1H-1,2,3-triazole (117 mg), followed by stirring at 100° C. for 21 hours. The reaction mixture was cooled to room temperature, and water and ethyl acetate were added. The organic layer was collected, washed with water and then with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=10:0 to 2:3), and a white solid of 3-bromo-5-(2H-1,2,3-triazol-2-yl)pyridine (55 mg) and a white solid of 3-bromo-5-(1H-1,2,3-triazol-1-yl)pyridine (48 mg) were thus obtained.

3-bromo-5-(2H-1,2,3-triazol-2-yl)pyridine

¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.24 (d, 1H, J=2.2 Hz), 8.81-8.78 (m, 1H), 8.60 (dd, 1H, J=2.1 Hz, 2.2 Hz), 8.27 (s, 2H)

MS (ESI, m/z): 225, 227 (M+H)

3-bromo-5-(1H-1,2,3-triazol-1-yl)pyridine

¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.21-9.19 (m, 1H), 8.97 (d, 1H, J=1.2 Hz), 8.86-8.84 (m, 1H), 8.69 (dd, 111, J=2.1 Hz, 2.2 Hz), 8.06 (d, 1H, J=1.2 Hz)

MS (ESI, m/z): 225, 227 (M+H)

Reference Example 19

The following compound was obtained with reference to US2008/15191.

N-(4-chloropyridin-2-yl)acetamide Reference Example 20

Cesium carbonate (275 mg) and piperidine (83 μl) were added to an N-methylpyrrolidone (2 ml) solution containing 3,5-dibromopyridine (200 mg), followed by stirring at 80° C. for 2 hours. Piperidine (83 μl) was added, followed by stirring at 80° C. for 2 hours. The reaction mixture was cooled to room temperature, and a saturated aqueous ammonium chloride solution and chloroform were added. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=20:0 to 17:3), and yellow oily matter of 3-bromo-5-(piperidin-1-yl)pyridine (18 mg) was thus obtained.

¹H-NMR (CDCl₃, 400 MHz) δ: 8.20 (d, 1H, J=2.6 Hz), 8.06 (d, 1H, J=1.8 Hz), 7.28 (dd, 1H, J=2.0 Hz, 2.5 Hz), 3.23-3.18 (m, 4H), 1.74-1.57 (m, 6H)

Reference Example 21

The following compound was obtained with reference to US2009/69305 A1 and US2009/181941 A1.

1-(5-bromopyridin-3-yl)-4-methylpiperazine Reference Example 22

Cesium carbonate (165 mg), 1-(tert-butoxycarbonyl)-1H-pyrrol-2-ylboronic acid (136 mg) and Pd(PPh₃)₄ (24 mg) were added to a 1,4-dioxane (4 ml) solution containing 3,5-dibromopyridine (100 mg), followed by reflux for 4 hours in a nitrogen atmosphere. The reaction mixture was cooled to room temperature, and water and ethyl acetate were added. The organic layer was collected, washed with saturated saline, and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (silica gel: silica gel 60 (spherical shape) (Kanto Chemical Co., Inc.); hexane:ethyl acetate=4:1), and a white solid of tert-butyl2-(5-bromopyridin-3-yl)-1H-pyrrol-1-carboxylate (73 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.64 (d, 1H, J=2.4 Hz), 8.57 (d, 1H, J=1.9 Hz), 8.14-8.12 (m, 1H), 7.47-7.44 (m, 1H), 6.48-6.45 (m, 1H), 6.36-6.33 (m, 1H), 1.35 (s, 9H)

MS (ESI, m/z): 323 (M+H), 325 (M+H)

Reference Example 23

The following compound was obtained as described in Reference Example 22.

3-bromo-5-(2-thienyl)pyridine

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.88 (d, 1H, J=2.0 Hz), 8.62 (d, 1H, 2.2 Hz), 8.36 (dd, 1H, J=2.0, 2.2 Hz), 7.76 (dd, 1H, J=1.2, 3.8 Hz), 7.72 (dd, 1H, J=1.2, 5.1 Hz), 7.21 (dd, 1H, J=3.8, 5.1 Hz)

MS (ESI, m/z): 240 (M+H), 242 (M+H)

Reference Example 24

The following compound was obtained as described in Reference Example 22.

3-bromo-5-cyclopropylpyridine

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.45 (d, 1H, J=2.2 Hz), 8.39 (d, 1H, J=2.0 Hz), 7.70 (dd, 1H, J=2.0, 2.2 Hz), 2.01-1.93 (m, 1H), 1.05-0.99 (m, 2H), 0.84-0.78 (m, 2H)

Reference Example 25

The following compound was obtained as described in Reference Example 22.

3-bromo-5-(2,3-dihydro-1,4-benzodioxin-6-yl)pyridine

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.83 (d, 1H, J=2.0 Hz), 8.63 (d, 1H, J=2.2 Hz), 8.28 (dd, 1H, J=2.0, 2.1 Hz), 7.32 (d, 1H, J=2.2 Hz), 7.26 (dd, 1H, J=2.2, 8.5 Hz), 6.97 (d, 1H, J=8.5 Hz), 4.19 (s, 4H)

MS (ESI, m/z): 292 (M+H), 294 (M+H)

Reference Example 26

The following compound was obtained as described in Reference Example 22.

3-bromo-5-(2-furyl)pyridine

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.93 (d, 1H, J=2.0 Hz), 8.61 (d, 1H, J=2.2 Hz), 8.34 (dd, 1H, J=2.0, 2.1 Hz), 7.88 (dd, 1H, J=0.7, 1.8 Hz), 7.26 (dd, 1H, J=0.7, 3.4 Hz), 6.68 (dd, 1H, J=1.8, 3.4 Hz)

MS (ESI, m/z): 224 (M+H), 226 (M+H)

Reference Example 27

1st Step

A 1N sodium hydroxide aqueous solution (15 ml) was added to a solution of tetrahydrofuran (30 ml) and methanol (30 ml) containing methyl 6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-2-chloro-5-fluoronicotinate (3.00 g), followed by stirring at 65° C. for 2 hours. The reaction mixture was cooled to room temperature, the solvent was distilled away under reduced pressure, and a saturated aqueous ammonium chloride solution, tetrahydrofuran, and ethyl acetate were added. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. Colorless oily matter of 6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-2-chloro-5-fluoronicotinic acid (3.00 g) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 7.80-7.63 (m, 1H), 6.68 (d, 1H, J=7.7 Hz), 6.44 (brs, 1H), 4.09-3.97 (m, 1H), 3.87-3.75 (m, 1H), 1.87-1.08 (m, 17H)

MS (ESI, m/z): 410, 412 (M+Na), 386, 388 (M−H)

2nd Step

Ammonium chloride (1.10 g), WSC.HCl (2.97 g), HOBt.H₂O (2.37 g), and diisopropylethylamine (7.06 ml) were added to a DMF solution (40 ml) containing 6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-2-chloro-5-fluoronicotinic acid (2.00 g), followed by stirring at room temperature for 7 hours. A saturated aqueous ammonium chloride solution, water, and ethyl acetate were added to the reaction mixture. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. Diisopropylether was added to the obtained residue, solid matter was collected by filtration, and a white solid of tert-butyl cis-2-(5-aminocarbonyl-6-chloro-3-fluoropyridin-2-ylamino)cyclohexylcarbamate (1.75 g) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 7.72-7.61 (m, 1H), 7.56 (d, 1H, J=10.8 Hz), 7.52-7.46 (m, 1H), 6.71-6.59 (m, 2H), 4.08-3.98 (m, 1H), 3.85-3.77 (m, 1H), 1.82-1.14 (m, 17H)

MS (ESI, m/z): 409 (M+Na)

3rd Step

Trichloroacetyl chloride (0.55 ml) was added dropwise to a dichloromethane (17 ml) suspension containing tert-butyl cis-2-(5-aminocarbonyl-6-chloro-3-fluoropyridin-2-ylamino)cyclohexylcarbamate (1.74 g) and triethylamine (1.38 ml) under ice cooling, followed by stirring at room temperature for 1 hour. The solvent was distilled away under reduced pressure, and a saturated aqueous ammonium chloride solution and ethyl acetate were added. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and then the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane:ethyl acetate=10:0 to 3:1), diisopropylether was added, solid matter was collected by filtration, and a white solid of tert-butyl cis-2-(6-chloro-5-cyano-3-fluoropyridin-2-ylamino)cyclohexylcarbamate (1.26 g) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 7.96 (d, 1H, J=10.5 Hz), 7.50 (d, 1H, J=5.8 Hz), 6.68 (d, 111, J=8.0 Hz), 4.10-4.00 (m, 1H), 3.89-3.81 (m, 1H), 1.80-1.08 (m, 17H)

MS (ESI, m/z): 367 (M−H)

Reference Example 28

The following compounds were obtained as described in Reference Example 2.

Methyl 6-(2-(tert-butoxycarbonylamino)ethylamino)-2-chloro-5-fluoronicotinate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 7.98-7.88 (m, 2H), 7.10-7.00 (m, 1H), 3.91 (s, 3H), 3.56-3.48 (m, 2H), 3.32-3.24 (m, 2H), 1.50 (s, 9H)

Methyl 6-((tert-butoxycarbonyl)(2-(tert-butoxycarbonylamino)ethyl)amino)-2-chloro-5-fluoronicotinate

¹H-NMR (CDCl₃, 400 MHz) δ: 7.96 (d, 1H, J=9.3 Hz), 5.39-5.29 (br, 1H), 3.97-3.90 (m, 5H), 3.41-3.31 (m, 2H), 1.46 (s, 9H), 1.40 (s, 9H)

Methyl 6-((2-bis(tert-butoxycarbonyl)aminoethyl)(tert-butoxycarbonyl)amino)-2-chloro-5-fluoronicotinate

¹H-NMR (CDCl₃, 400 MHz) δ: 7.93 (d, 1H, J=9.3 Hz), 4.06 (t, 2H, J=6.0 Hz), 3.95 (s, 3H), 3.88 (t, 2H, J=6.0 Hz), 1.47-1.44 (m, 27H)

Reference Example 29

The following compound was obtained as described in Reference Example 27.

tert-Butyl 2-(6-chloro-5-cyano-3-fluoropyridin-2-ylamino)ethylcarbamate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.16 (brs, 1H), 7.96 (d, 1H, J=10.6 Hz), 6.91 (t, 1H, J=5.6 Hz), 3.39 (t, 2H, J=6.2 Hz), 3.13 (dt, 2H, J=5.6, 6.2 Hz), 1.36 (s, 9H)

MS (ESI, m/z): 313 (M−H)

Reference Example 30

The following compounds were obtained as described in Reference Example 27.

6-((tert-butoxycarbonyl)(2-(tert-butoxycarbonylamino)ethyl)amino)-2-chloro-5-fluoronicotinic acid

¹H-NMR (DMSO-d₆, 400 MHz) δ: 7.73 (d, 1H, J=8.5 Hz), 6.80-6.73 (m, 1H), 3.65 (t, 2H, J=6.6 Hz), 3.13-3.03 (m, 2H), 1.37 (s, 9H), 1.32 (s, 9H)

tert-Butyl 2-((5-aminocarbonyl-6-chloro-3-fluoropyridin-2-yl)(tert-butoxycarbonyl)amino)ethylcarbamate

¹H-NMR (CDCl₃, 400 MHz) δ: 8.02 (d, 1H, J=9.3 Hz), 6.96 (brs, 1H), 6.69 (brs, 1H), 5.33 (brs, 1H), 3.92 (t, 2H, J=5.7 Hz), 3.40-3.32 (m, 2H), 1.45 (s, 9H), 1.40 (s, 9H)

tert-Butyl 2-((tert-butoxycarbonyl)(5-cyano-6-chloro-3-fluoropyridin-2-yl)amino)ethylcarbamate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.65 (d, 1H, J=9.2 Hz), 6.82-6.72 (br, 1H), 3.81 (t, 2H, J=5.9 Hz), 3.19-3.10 (m, 2H), 1.41 (s, 9H), 1.30 (s, 9H)

Reference Example 31

The following compound was obtained as described in the 2nd step of Reference Example 2.

Di-tert-butyl 2-((tert-butoxycarbonyl)(5-cyano-6-chloro-3-fluoropyridin-2-yl)amino)ethylimidedicarbamate

¹H-NMR (CDCl₃, 400 MHz) δ: 7.64 (d, 1H, J=8.8 Hz), 4.06-4.03 (m, 2H), 3.87-3.83 (m, 2H), 1.45-1.42 (m, 27H)

Reference Example 32

The following compound was obtained as described in Reference Example 27.

2-chloro-6-ethylamino-5-fluoronicotinonitrile

¹H-NMR (CDCl₃, 300 MHz) δ: 7.66 (d, 1H, J=8.4 Hz), 3.87 (q, 1H, J=7.2 Hz), 1.47 (s, 9H), 1.26 (t, 3H, J=7.2 Hz)

Reference Example 33

The following compound was obtained with reference to J. Org. Chem., 2006, 71, 5392.

1-(2-(trimethylsilyl)ethoxymethyl)-1H-indazol-6-amine Reference Example 34

The following compound was obtained with reference to WO2009/136995 A2.

6-amino-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one Reference Example 35

The following compound was obtained with reference to J. Org. Chem., 2006, 71, 5392.

2-(2-(trimethylsilyl)ethoxymethyl)-2H-indazol-6-amine Reference Example 36

Ammonium chloride (893 mg), water (3 ml), and iron powder (939 mg) were added to an ethanol solution containing 2-methyl-5-nitro-1,3-benzoxazole (500 mg), followed by stirring at 85° C. for 2 hours and 30 minutes. Insoluble matter was removed by filtration and filter cake was washed with water and ethyl acetate. The filtrate was mixed with the washing solution, and ethyl acetate was added. The organic layer was collected, washed with saturated saline, and dried over anhydrous sodium sulfate, and then the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel column chromatography, and light brown oily matter of 2-methyl-1,3-benzoxazol-5-amine (402 mg) was thus obtained.

¹H-NMR (CDCl₃, 300 MHz) δ: 7.23 (d, 1H, J=9.0 Hz), 6.93 (d, 1H, J=2.4 Hz), 6.64 (dd, 1H, J=2.4, 9.0 Hz), 2.57 (s, 3H)

Reference Example 37

Triethylamine (765 μl), tert-butylalcohol (10 ml), and DPPA (1.18 ml) were added to a 1,4-dioxane (20 ml) solution containing 2-methyl-1,3-benzoxazol-6-carboxylic acid (885 mg), followed by stirring at 100° C. for 1 hour and 30 minutes. The solvent was distilled away under reduced pressure, and a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate were added. The organic layer was collected, washed with saturated saline, and dried over anhydrous sodium sulfate, and then the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel column chromatography, and a white solid of tert-butyl(2-methyl-1,3-benzoxazol-6-yl)carbamate (1.00 g) was thus obtained.

¹H-NMR (CDCl₃, 300 MHz) δ: 7.85 (brs, 1H), 7.50 (d, 1H, J=8.7 Hz), 7.00 (d, 1H, J=8.7 Hz), 6.60 (brs, 1H), 2.60 (s, 3H)

Reference Example 38

TFA (0.5 ml) was added to a chloroform solution (1 ml) containing tert-butyl(2-methyl-1,3-benzoxazol-6-yl) carbamate (50 mg) at 0° C., followed by stirring at room temperature for 3 hours. The solvent was distilled away under reduced pressure. Chloroform was added to the obtained residue, and the solvent was distilled away under reduced pressure. A saturated aqueous sodium hydrogen carbonate solution and chloroform were added to the obtained residue. The organic layer was collected and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and a light brown solid of 2-methyl-1,3-benzoxazol-6-amine (24 mg) was thus obtained.

¹H-NMR (CDCl₃, 300 MHz) δ: 7.40 (d, 1H, J=8.7 Hz), 6.79 (d, 1H, J=1.8 Hz), 6.65 (dd, 1H, J=1.8, 8.7 Hz), 3.75 (brs, 2H), 2.58 (s, 3H)

Reference Example 39

The following compound was obtained with reference to J. Heterocyclic. Chem., 1979, 16, 1599.

1-methyl-1H-indazol-6-amine Reference Example 40

The following compound was obtained with reference to J. Heterocyclic. Chem., 1979, 16, 1599.

1-methyl-2H-indazol-6-amine Reference Example 41

The following compound was obtained with reference to J. Med. Chem., 2006, 49, 4551.

4-(2-(pyrrolidin-1-yl)ethoxy)aniline Reference Example 42

The following compound was obtained with reference to J. Med. Chem., 2006, 49, 4551.

3-(2-(pyrrolidin-1-yl)ethoxy)aniline Reference Example 43

The following compound was obtained with reference to WO2009/090548.

3-(2H-1,2,3-triazol-2-yl)aniline Reference Example 44

The following compound was obtained with reference to Tetrahedron, 2006, 62, 12351.

Quinazolin-6-amine

Quinoxalin-6-amine Reference Example 45

The following compound was obtained with reference to Tetrahedron, 2005, 61, 8218.

1-methyl-1H-indazol-7-amine Reference Example 46

The following compound was obtained with reference to J. Med. Chem., 2005, 48, 3417.

1-methyl-1H-indol-5-amine Reference Example 47

The following compound was obtained as described in the 1st step of Example 1.

Methyl 2-benzylamino-6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-5-fluoronicotinate Reference Example 48

The following compound was obtained as described in Reference Example 9.

Methyl 2-amino-6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-5-fluoronicotinate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 7.45 (d, 1H, J=12.0 Hz), 7.10-6.80 (br, 2H), 6.69 (d, 1H, J=7.2 Hz), 6.51 (d, 1H, J=7.2 Hz), 4.18-4.09 (m, 1H), 3.82-3.75 (m, 1H), 3.70 (s, 3H), 1.84-1.69 (m, 2H), 1.63-1.18 (m, 15H)

MS (ESI, m/z): 383 (M+H), 381 (M−H)

Reference Example 49

1st Step

4N hydrogen chloride/1,4-dioxane (104 ml) was added dropwise to a solution of diisopropylether (200 ml), tetrahydrofuran (50 ml) and methanol (19.1 ml) containing malononitrile (25.0 g) under ice cooling, followed by stirring for 3 hours. Solid matter was collected by filtration and washed with diisopropylether, and white solid (12.8 g) was thus obtained.

2nd Step

Sodium acetate (4.95 g) was added to a DMF (60 ml) solution containing the white solid (4.49 g) obtained in the 1st step and 6-aminoquinoline (4.35 g), followed by stirring at room temperature for 6 hours. A saturated aqueous sodium hydrogen carbonate solution, sodium chloride, and ethyl acetate were added to the reaction mixture. The organic layer was collected and dried over anhydrous magnesium sulfate, and then the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 20:1), and yellow oily matter of 2-cyano-N-(quinolin-6-yl)acetamidine (4.30 g) was thus obtained.

3rd Step

Ethyl formate (16.1 ml) was added to a hexane (40 ml) suspension containing sodium hydride (60% in oil, 2.4 g) at room temperature, and then fluoroethyl acetate (3.86 ml) was added dropwise under ice cooling, followed by stirring at room temperature for 15 minutes. Ethanol (50 ml) was added to the reaction mixture, and then an ethanol (50 ml) solution containing 2-cyano-N-(quinolin-6-yl)acetamidine (4.20 g) was added dropwise, followed by stirring at 80° C. for 2 hours. The reaction mixture was cooled to room temperature. Then, solid matter was collected by filtration and washed with ethyl acetate, and a yellow solid of 5-fluoro-6-oxo-2-(quinolin-6-ylamino)-1,6-dihydropyridin-3-carbonitrile (3.71 g) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.64 (dd, 1H, J=1.6, 4.3 Hz), 8.51 (s, 1H), 8.19 (s, 1H), 8.16 (d, 1H, J=2.4 Hz), 8.13-8.06 (m, 1H), 7.91 (dd, 1H, J=2.4, 9.2 Hz), 7.80 (d, 1H, J=9.2 Hz), 7.38 (dd, 1H, J=4.2, 8.3 Hz), 7.02 (d, 1H, J=11.0 Hz)

MS (ESI, m/z): 279 (M−H)

Reference Example 50

A 1,4-dioxane (100 ml) solution containing N-chlorosuccinimide (4.15 g) was added dropwise to a 1,4-dioxane (50 ml) solution containing triphenylphosphine (8.58 g) at 50° C., followed by stirring for 30 minutes. 5-fluoro-6-oxo-2-(quinolin-6-ylamino)-1,6-dihydropyridin-3-carbonitrile (2.61 g) was added to the reaction mixture, followed by stirring at 70° C. for 3 hours. The reaction mixture was cooled to room temperature. Then solid matter was collected by filtration and was washed with tetrahydrofuran, and a gray solid of 6-chloro-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile (2.34 g) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.85 (s, 1H), 8.80 (dd, 1H, J=1.5, 4.2 Hz), 8.50 (d, 1H, J=8.0 Hz), 8.29-8.23 (m, 1H), 8.02 (d, 1H, J=2.4 Hz), 7.98 (d, 1H, J=9.0 Hz), 7.90 (dd, 1H, J=2.4, 9.0 Hz), 7.49 (dd, 1H, J=4.2, 8.3 Hz)

MS (ESI, m/z): 299 (M+H), 297 (M−H)

Reference Example 51

The following compound was obtained as described in Reference Examples 49 and 50.

2-(1,3-benzothiazol-6-ylamino)-6-chloro-5-fluoronicotinonitrile

¹H-NMR (CDCl₃, 400 MHz) δ: 8.95 (s, 1H), 8.43 (d, 1H, J=2.3 Hz), 8.12 (d, 1H, J=8.8 Hz), 7.64 (d, 1H, J=6.8 Hz), 7.50 (dd, 1H, J=2.3, 8.8 Hz), 7.18 (brs, 1H)

MS (ESI, m/z): 305 (M+H), 303 (M−H)

Reference Example 52

The following compound was obtained as described in Reference Examples 49 and 50.

6-chloro-5-fluoro-2-(quinolin-3-ylamino)nicotinonitrile

¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.94 (s, 1H), 9.04 (d, 1H, J=2.7 Hz), 8.52 (d, 1H, J=8.1 Hz), 8.37 (d, 1H, J=2.7 Hz), 8.02-7.86 (m, 2H), 7.73-7.54 (m, 2H)

MS (ESI, m/z): 299 (M+H), 297 (M−H)

Reference Example 53

1st Step

Isobutyl chloroformate (811 μl) was added dropwise to a mixture of N-benzyloxycarbonyl-D-leucine.dicyclohexylamine salt (2.23 g), 1,2-dimethoxyethane (25 ml), and N-methylmorpholine (687 μl) under ice cooling, followed by stirring at the same temperature for 1 hour. 25% aqueous ammonia solution (3.4 ml) was added to the reaction mixture under ice cooling, followed by stirring at the same temperature for 1 hour. A saturated aqueous sodium hydrogen carbonate solution and ethyl acetate were added to the reaction mixture. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and then the solvent was distilled away under reduced pressure. Hexane was added to the obtained residue and solid matter was collected by filtration, and a white solid of N²-benzyloxycarbonyl-D-leucinamide (1.47 g) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 7.45-7.25 (m, 7H), 6.95 (brs, 1H), 5.02 (s, 2H), 4.05-3.90 (m, 1H), 1.70-1.53 (m, 1H), 1.53-1.30 (m, 2H), 0.96-0.76 (m, 6H)

2nd Step

Pd/C (106 mg) was added to an ethanol (20 ml) solution containing N²-benzyloxycarbonyl-D-leucinamide (529 mg), followed by stirring at room temperature for 3 hours in a hydrogen atmosphere. Insoluble matter was removed by filtration, and 1,4-dioxane (2 ml) and 4N hydrogen chloride/1,4-dioxane were added. Solid matter was collected by filtration, and a white solid of D-leucinamide.hydrochloride (308 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.24 (brs, 3H), 8.00 (brs, 1H), 7.52 (brs, 1H), 3.75-3.61 (m, 1H), 1.76-1.61 (m, 1H), 1.61-1.50 (m, 2H), 0.97-0.84 (m, 6H)

Reference Example 54

The following compound was obtained as described in Reference Example 53.

D-phenylalaninamide-hydrochloride

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.13 (brs, 3H), 7.88 (brs, 1H), 7.56 (brs, 1H), 7.40-7.22 (m, 5H), 4.00-3.88 (m, 1H), 3.09 (dd, 1H, J=6.0, 13.9 Hz), 2.98 (dd, 1H, J=7.8, 13.9 Hz)

Reference Example 55

The following compound was obtained with reference to J. Org. Chem., 2002, 67, 3687.

Reference Example 56

1st Step

Dess-Martin periodinane (849 mg) was added to a dichloromethane (20 ml) solution containing benzyl((2R)-1-hydroxy-3-phenylpropan-2-yl)carbamate (571 mg), followed by stirring at room temperature for 3 hours and 30 minutes. Insoluble matter was removed by filtration, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=10:1 to 2:1), and a white solid of benzyl((2R)-1-oxo-3-phenylpropan-2-yl)carbamate (501 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.56 (s, 1H), 7.75 (d, 1H, J=7.8 Hz), 7.50-7.00 (m, 10H), 5.05-4.80 (m, 3H), 3.14 (dd, 1H, J=4.3, 14.2 Hz), 2.70 (dd, 1H, 10.4, 14.2 Hz)

2nd Step

A mixture of benzyl((2R)-1-oxo-3-phenylpropan-2-yl)carbamate (484 mg), glyoxal (359 mg), 2M ammonia/methanol solution (8.55 ml), and methanol (1.71 ml) was stirred at room temperature for 7 hours. Water, sodium chloride, and ethyl acetate were added to the reaction mixture. The organic layer was collected and dried over anhydrous magnesium sulfate, and then the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform:methanol=20:0 to 20:1), a liquid mixture of ethyl acetate and isopropanol was added, and solid matter was collected by filtration, and a white solid of benzyl((1R)-1-(1H-imidazol-2-yl)-2-phenylethyl)carbamate (111 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.76 (brs, 1H), 7.69 (d, 1H, J=8.8 Hz), 7.38-7.12 (m, 10H), 6.98 (s, 1H), 6.81 (s, 1H), 5.03-4.80 (m, 3H), 3.23 (dd, 1H, J=5.6, 13.6 Hz), 2.97 (dd, 1H, J=9.3, 13.6 Hz)

3rd Step

The following compound was obtained as described in the 2nd step of Reference Example 53.

(1R)-1-(1H-imidazol-2-yl)-2-phenylethylamine Reference Example 57

1st Step

The following compound was obtained as described in the 3rd step of Reference Example 27.

Benzyl((1R)-1-cyano-3-methylbutyl)carbamate

¹H′-NMR (CDCl₃, 400 MHz) δ: 7.42-7.30 (m, 5H), 5.14 (s, 2H), 5.07-4.96 (m, 1H), 4.72-4.57 (m, 1H), 1.90-1.57 (m, 3H), 0.97 (d, 6H, J=6.8 Hz)

MS (ESI, m/z): 269 (M+Na)

2nd Step

Triethylamine.hydrochloride (508 mg) and sodium azide (241 mg) were added to a toluene (12 ml) solution containing benzyl((1R)-1-cyano-3-methylbutyl)carbamate (303 mg), followed by stirring at 100° C. for 5 hours. The reaction mixture was cooled to room temperature, and water and ethyl acetate were added. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate. The solvent was distilled away under reduced pressure, and colorless oily matter of benzyl((1R)-3-methyl-1-(1H-tetrazol-5-yl)butyl)carbamate (310 mg) was thus obtained.

3rd Step

The following compound was obtained as described in the 2nd step of Reference Example 53.

(1R)-3-methyl-1-(1H-tetrazol-5-yl)butyl amine

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.26 (brs, 1H), 4.49-4.38 (m, 1H), 1.90-1.77 (m, 1H), 1.72-1.59 (m, 1H), 1.56-1.41 (m, 1H), 0.88 (d, 3H, J=6.5 Hz), 0.83 (d, 3H, J=6.5 Hz)

Reference Example 58

The following compound was obtained as described in Reference Example 56.

Benzyl((1R)-1-(1H-imidazol-2-yl)-3-methylbutyl)carbamate

MS (ESI, m/z): 288 (M+H)

Reference Example 59

The following compound was obtained as described in Reference Example 53.

(2R)-2-aminobutanamide.hydrochloride

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.22 (brs, 3H), 7.95 (brs, 1H), 7.51 (brs, 1H), 3.68-3.62 (m, 1H), 1.82-1.68 (m, 2H), 0.88 (t, 3H, J=7.4 Hz)

Reference Example 60

The following compound was obtained as described in Reference Example 53.

D-valinamide.hydrochloride

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.09 (brs, 3H), 7.86 (brs, 1H), 7.58 (brs, 1H), 3.53 (d, 1H, J=5.4 Hz), 2.16-2.02 (m, 1H), 0.94 (dd, 6H, J=7.0, 10.1 Hz)

Reference Example 61

The following compound was obtained as described in Reference Example 53.

4-fluoro-D-phenylalaninamide.hydrochloride

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.18 (brs, 3H), 7.95 (brs, 1H), 7.55 (brs, 1H), 7.34-7.26 (m, 2H), 7.20-7.10 (m, 2H), 3.96-3.88 (m, 1H), 3.09 (dd, 1H, J=6.0, 14.0 Hz), 2.98 (dd, 1H, J=7.6, 14.0 Hz)

Reference Example 62

The following compound was obtained as described in Reference Example 53.

O-methyl-D-tyrosineamide.hydrochloride

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.16 (brs, 3H), 7.93 (brs, 1H), 7.51 (brs, 1H), 7.18 (d, 2H, J=8.5 Hz), 6.88 (d, 2H, J=8.5 Hz), 3.94-3.83 (m, 1H), 3.72 (s, 3H), 3.02 (dd, 1H, J=6.2, 14.0 Hz), 2.93 (dd, 1H, J=7.3, 14.0 Hz)

Reference Example 63

The following compound was obtained with reference to WO2009/136995.

(2S)-tert-butyl 2-aminobutylcarbamate Reference Example 64

1st Step

Hydrogen chloride was introduced into a mixture of ethyl cyanoacetate (56.6 g) and phenol (47.1 g) at −15° C., followed by stirring under ice cooling for 3 hours. The reaction mixture was left at rest at 4° C. for 40 hours. Diethyl ether was added to the reaction mixture. Solid matter was collected by filtration and washed with diethyl ether, and a white solid (60.1 g) was thus obtained.

2nd Step

An ethyl acetate (300 ml) solution containing the white solid (60.1 g) obtained in the 1st step and 3,5-dimethoxyaniline (37.8 g) was refluxed for 2 hours and 30 minutes. The reaction mixture was cooled to room temperature, and ethyl acetate (100 ml) was added, followed by stirring under ice cooling for 1 hour. Solid matter was collected by filtration and washed with ethyl acetate, and a white solid of ethyl 3-(3,5-dimethoxyphenyl)amino-3-iminopropionato.hydrochloride (60.8 g) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.79 (brs, 1H), 9.81 (brs, 1H), 8.97 (brs, 1H), 6.58 (t, 1H, J=2.2 Hz), 6.42 (d, 2H, J=2.2 Hz), 4.20 (q, 2H, J=7.1 Hz), 3.85 (s, 2H), 3.79 (s, 6H), 1.25 (t, 3H, J=7.1 Hz)

3rd Step

[1]

Sodium hydride (60% in oil, 11.3 g) was added to a hexane (250 ml) solution containing fluoroethyl acetate (27.2 ml) and ethyl formate (22.7 ml) under ice cooling, followed by stirring at the same temperature for 1 hour and then at room temperature for 1 hour. Solid matter was collected by filtration and washed with hexane, and solid matter was thus obtained.

[2]

A 1N sodium hydroxide aqueous solution was added to a mixture of ethyl 3-(3,5-dimethoxyphenyl)amino-3-iminopropionato.hydrochloride (28.4 g), water (150 ml), and ethyl acetate (150 ml) so as to alkalify the mixture (pH>10). The organic layer was collected and dried over anhydrous magnesium sulfate, the solvent was distilled away under reduced pressure, and a residue was thus obtained.

[3]

An ethanol (600 ml) solution containing the substances obtained in [1] and [2] was refluxed for 4 hours. The reaction mixture was cooled to room temperature, and the solvent was distilled away under reduced pressure. Ethanol was added to the obtained residue. Solid matter was collected by filtration, dissolved in ethyl acetate, and washed with 1N hydrochloric acid. Then, the solvent was distilled away under reduced pressure, and a gray solid of ethyl 2-(3,5-dimethoxyphenyl)amino-5-fluoro-6-oxo-1,6-dihydropyridin-3-carboxylate (24.6 g) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 10.11 (s, 1H), 7.84 (d, 1H, J=11.7 Hz), 6.81-6.72 (m, 2H), 6.26-6.22 (m, 1H), 4.28 (q, 2H, J=7.1 Hz), 3.75 (s, 6H), 1.31 (t, 3H, J=7.1 Hz)

Reference Example 65

The following compound was obtained as described in Reference Example 50.

Ethyl 6-chloro-2-(3,5-dimethoxyphenylamino)-5-fluoronicotinate

¹H-NMR (CDCl₃, 400 MHz) δ: 10.19 (s, 1H), 8.03 (d, 1H, J=8.2 Hz), 6.96 (d, 2H, J=2.2 Hz), 6.22 (t, 1H, J=2.2 Hz), 4.41 (q, 2H, J=7.1 Hz), 3.82 (s, 6H), 1.42 (t, 3H, J=7.1 Hz)

Reference Example 66

The following compound was obtained with reference to WO2009/18344 A1.

(E)-tert-butyl 3-(4-(aminomethyl)phenyl)acrylate Reference Example 67

The following compound was obtained as described in Reference Example 2.

Methyl 2-chloro-6-(benzyl(tert-butoxycarbonyl)amino)-5-fluoronicotinate

¹H-NMR (CDCl₃, 400 MHz) δ: 7.89 (d, 1H, J=9.1 Hz), 7.32-7.18 (m, 5H), 5.07 (s, 2H), 3.93 (s, 3H), 1.43 (s, 9H)

Reference Example 68

The following compound was obtained as described in Example 1 and Reference Example 9.

Methyl 6-amino-5-fluoro-2-(quinolin-3-ylamino)nicotinate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 10.56 (s, 1H), 9.14 (d, 1H, J=2.6 Hz), 8.90 (d, 1H, J=2.6 Hz), 7.96-7.90 (m, 2H), 7.74 (d, 1H, J=11.6 Hz), 7.61-7.54 (m, 2H), 7.45 (brs, 2H), 3.83 (s, 3H)

MS (ESI, m/z): 313 (M+H), 311 (M−H)

Reference Example 69

The following compound was obtained as described in Reference Example 67.

Methyl 6-amino-5-fluoro-2-(3-(trifluoromethyl)phenylamino)nicotinate

¹H-NMR (CDCl₃, 400 MHz) δ: 10.42 (s, 1H), 8.07 (s, 1H), 7.78 (d, 1H, J=11.1 Hz), 7.76-7.71 (m, 1H), 7.39 (dd, 1H, J=7.9, 7.9 Hz), 7.29-7.23 (m, 1H), 4.99 (brs, 2H), 3.87 (s, 3H)

Reference Example 70

The following compound was obtained with reference to WO2008/49855.

Reference Example 71

The following compound was obtained with reference to EP2119706.

Reference Example 72

The following compound was obtained as described in Reference Example 1.

Methyl 2,6-dichloronicotinate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.33 (d, 1H, J=8.0 Hz), 7.73 (d, 1H, J=8.0 Hz), 3.89 (s, 3H)

Reference Example 73

The following compound was obtained as described in the 1st step of Reference Example 2.

Methyl 2-benzylamino-6-chloronicotinate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.57-8.49 (m, 1H), 8.10 (d, 1H, J=8.0 Hz), 7.37-7.30 (m, 4H), 7.30-7.22 (m, 1H), 6.69 (d, 1H, J=8.0 Hz), 4.64 (d, 2H, J=5.9 Hz), 3.82 (S, 3H)

MS (ESI, m/z): 277 (M+H), 279 (M+H)

Reference Example 74

Diisopropylethylamine (7.5 ml) and cis-cyclohexane-1,2-diamine (5.0 g) were added to an N-methylpyrrolidone (50 ml) solution containing methyl 2-benzylamino-6-chloronicotinate (6.0 g), followed by stirring at 120° C. for 11 hours. The reaction mixture was cooled to room temperature, and water and ethyl acetate were added. The organic layer was collected, washed with saturated saline, and dried over anhydrous sodium sulfate, and then the solvent was distilled away under reduced pressure. Di-tert-butyl dicarbonate (4.7 g) was added to a tetrahydrofuran (50 ml) solution containing the obtained residue and the resulting mixture was left at rest at room temperature for 3 days. The solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel column chromatography (silica gel:silica gel 60 (spherical shape) (Kanto Chemical Co., Inc.); hexane:ethyl acetate=3:1), and a light yellow solid of methyl 2-benzylamino-6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)nicotinate (7.7 g) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.50-8.40 (br, 1H), 7.70-7.57 (m, 1H), 7.37-7.18 (m, 5H), 6.80-6.65 (br, 1H), 6.55-6.42 (br, 1H), 5.87-5.77 (m, 1H), 4.71-4.48 (m, 2H), 4.20-4.09 (m, 1H), 3.73-3.64 (m, 4H), 1.70-1.10 (m, 17H)

MS (ESI, m/z): 455 (M+H), 477 (M+Na)

Reference Example 75

The following compound was obtained as described in Reference Example 3. 2-benzylamino-6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)nicotinic acid ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.86-11.65 (br, 1H), 8.64-8.53 (br, 1H), 7.63 (d, 1H, J=8.6 Hz), 7.36-7.26 (m, 4H), 7.26-7.18 (m, 1H), 6.70-6.40 (m, 2H), 5.80 (d, 1H, J=8.6 Hz), 4.72-4.50 (m, 2H), 4.15-3.99 (m, 1H), 3.74-3.62 (m, 1H), 1.70-1.13 (m, 17H)

MS (ESI, m/z): 441 (M+H), 463 (M+Na), 439 (M−H)

tert-Butyl cis-2-(6-benzylamino-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.96-8.88 (br, 1H), 7.85 (d, 1H, J=8.7 Hz), 7.73-7.66 (br, 1H), 7.34-7.10 (m, 10H), 6.50-6.42 (m, 1H), 6.37-6.26 (m, 1H), 5.78 (d, 1H, J=8.7 Hz), 4.57-4.38 (m, 2H), 4.06-3.95 (m, 1H), 3.70-3.58 (m, 1H), 1.70-1.14 (m, 23H)

MS (ESI, m/z): 558 (M+H)

Reference Example 76

The following compound was obtained as described in Reference Example 9. tert-Butyl cis-2-(6-amino-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 7.81 (d, 1H, J=8.7 Hz), 7.70-7.63 (br, 1H), 7.35-7.30 (m, 2H), 7.28-7.22 (m, 2H), 7.16-7.10 (m, 1H), 6.82-6.74 (br, 2H), 6.54-6.47 (m, 1H), 6.21-6.13 (m, 1H), 5.80 (d, 1H, J=8.7 Hz), 4.05-3.94 (m, 1H), 3.70-3.62 (m, 1H), 1.80-1.20 (m, 23H)

MS (ESI, m/z): 468 (M+H)

Reference Example 77

N-chlorosuccinimide (17 mg) was added to a DMF (5 ml) solution containing tert-butyl

cis-2-(6-amino-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate (60 mg) at 0° C., followed by stirring for 1 hour. Water and ethyl acetate were added to the reaction mixture. The organic layer was collected, washed with saturated saline, and dried over anhydrous sodium sulfate, and then the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (silica gel: silica gel 60 (spherical shape) (Kanto Chemical Co., Inc.); hexane:ethyl acetate=3:1), and a white solid of tert-butyl cis-2-(6-amino-3-chloro-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate (50 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.06 (s, 1H), 7.93 (s, 1H), 7.35-7.30 (m, 2H), 7.28-7.22 (m, 2H), 7.17-7.11 (m, 1H), 7.03-6.95 (br, 2H), 6.95-6.89 (m, 1H), 5.85-5.77 (m, 1H), 4.11-4.02 (m, 1H), 3.85-3.77 (m, 1H), 1.80-1.22 (m, 23H)

MS (ESI, m/z): 502 (M+H), 504 (M+H)

Reference Example 78

N-bromosuccinimide (22 mg) was added to a DMF (5 ml) solution containing tert-butyl cis-2-(6-amino-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate (60 mg) at 0° C., followed by stirring for 1 hour. Water and ethyl acetate were added to the reaction mixture. The organic layer was collected, washed with saturated saline, and dried over anhydrous sodium sulfate, and then the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (silica gel:silica gel 60 (spherical shape) (Kanto Chemical Co., Inc.); hexane:ethyl acetate=4:1 to 3:1), and a white solid of tert-butyl cis-2-(6-amino-3-bromo-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate (68 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.17 (s, 1H), 7.96 (s, 1H), 7.36-7.30 (m, 2H), 7.30-7.22 (m, 2H), 7.17-7.11 (m, 1H), 7.10-6.94 (m, 3H), 5.70-5.60 (m, 1H), 4.11-4.00 (m, 1H), 3.87-3.78 (m, 1H), 1.80-1.21 (m, 23H)

MS (ESI, m/z): 546 (M+H), 548 (M+H)

Reference Example 79

The following compound was obtained as described in Reference Example 18.

2-(3-bromophenyl)-2H-1,2,3-triazole

¹H-NMR (CDCl₃, 400 MHz) δ: 8.32-8.28 (m, 1H), 8.08-8.02 (m, 1H), 7.83 (s, 2H), 7.52-7.46 (m, 1H), 7.40-7.32 (m, 1H)

Reference Example 80

The following compound was obtained as described in Reference Example 22.

2-(5-bromopyridin-3-yl)thiazole

MS (ESI m/z): 241, 243 (M+H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.13 (d, 1H, J=2.0 Hz), 8.81 (d, 1H, J=2.2 Hz), 8.55-8.53 (m, 1H), 8.04 (d, 1H, J=3.2 Hz), 8.00-7.92 (m, 1H)

Reference Example 81

The following compound was obtained as described in Reference Example 22.

5-(5-bromopyridin-3-yl)thiazole

MS (ESI m/z): 241, 243 (M+H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.23-9.21 (m, 1H), 8.93-8.89 (m, 1H), 8.71-8.68 (m, 1H), 8.54 (s, 1H), 8.48-8.45 (m, 1H)

Reference Example 82

The following compound was obtained as described in Reference Example 22.

3-(1-benzyl-1H-pyrazol-4-yl)-5-bromopyridine

MS (ESI m/z): 312, 314 (M+H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.85 (d, 1H, J=2.0 Hz), 8.51-8.49 (m, 2H), 8.32-8.29 (m, 1H), 8.11 (s, 1H), 7.39-7.25 (m, 5H), 5.36 (s, 2H)

Reference Example 83

The following compound was obtained as described in Reference Example 22.

5-(5-bromopyridin-3-yl)-1H-indole

MS (ESI m/z): 273, 275 (M+H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.27 (s, 1H), 8.90 (d, 1H, J=1.9 Hz), 8.62 (d, 1H, J=2.2 Hz), 8.34-8.31 (m, 1H), 7.96 (s, 1H), 7.54-7.46 (m, 2H), 7.44-7.41 (m, 1H), 6.53-6.50 (m, 1H)

Reference Example 84

The following compound was obtained as described in Reference Example 22.

3-bromo-5-(thiophene-3-yl)pyridine

MS (ESI m/z): 240, 242 (M+H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.99 (d, 1H, J=1.9 Hz), 8.61 (d, 1H, J=2.2 Hz), 8.45-8.43 (m, 1H), 8.20-8.18 (m, 1H), 7.73-7.71 (m, 2H)

Reference Example 85

The following compound was obtained as described in Reference Example 22.

3-bromo-5-(furan-3-yl)pyridine

MS (ESI m/z): 224, 226 (M+H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.89 (d, 1H, J=2.0 Hz), 8.58 (d, 1H, J=2.2 Hz), 8.43-8.40 (m, 1H), 8.37-8.34 (m, 1H), 7.15-7.13 (m, 1H)

Reference Example 86

The following compound was obtained as described in Reference Example 22.

5-bromo-3-(m-toluoyl)pyridine

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.88 (d, 1H, J=2.1 Hz), 8.67 (d, 1H, J=2.1 Hz), 8.35-8.32 (m, 1H), 7.71-7.66 (m, 2H), 7.35-7.30 (m, 2H), 2.37 (s, 3H)

Reference Example 87

The following compound was obtained as described in Reference Example 22.

tert-Butyl 2-(4-aminopyridin-2-yl)-1H-pyrrol-1-carboxylate

MS (ESI m/z): 260 (M+H)

RT (min): 0.83

Reference Example 88

The following compound was obtained as described in Reference Example 22.

2-(furan-2-yl)pyridin-4-amine

MS (ESI m/z): 161 (M+H)

RT (min): 0.46

Reference Example 89

The following compound was obtained as described in Reference Example 22.

3-bromo-5-(3-fluorophenyl)pyridine

MS (ESI m/z): 252, 254 (M+H)

RT (min): 1.56

Reference Example 90

The following compound was obtained as described in Reference Example 22.

3-bromo-5-(3-chlorophenyl)pyridine

MS (ESI m/z): 268, 270, 272 (M+H)

RT (min): 1.70

Reference Example 91

The following compound was obtained as described in Reference Example 22.

3-bromo-5-(2-methoxyphenyl)pyridine

MS (ESI m/z): 264, 266 (M+H)

RT (min): 1.55

Reference Example 92

The following compound was obtained as described in Reference Example 22.

2-(2,4-dimethoxyphenyl)pyridin-4-amine

MS (ESI m/z): 231 (M+H)

RT (min): 0.74

Reference Example 93

1st Step

m-Chlorobenzoic acid (1.0 g) was added to a chloroform (19 ml) solution containing 4-bromo-7-azaindole (760 mg) under ice cooling, followed by stirring for 30 minutes. Then, chloroform (10 ml) was distilled away under reduced pressure, diisopropylether was added, an insoluble precipitate was collected by filtration, and a white solid of 4-bromo-1H-pyrrolo[2,3-b]pyridine 7-oxide (1.085 g) was thus obtained.

MS (ESI m/z): 213, 215 (M+H)

RT (min): 0.75

2nd Step

Dimethyl sulfate (410 mg) was added to an acetonitrile (7.6 ml) solution containing the white solid of 4-bromo-1H-pyrrolo[2,3-b]pyridine 7-oxide (1.085 g) obtained in the 1st step, followed by stirring at 60° C. for 25.5 hours in a nitrogen atmosphere. Then, the reaction solution was cooled to room temperature and diluted by addition of acetonitrile (7.6 ml).

MS (ESI m/z): 227, 229 (M+H)

RT (min): 0.45

3rd Step

Morpholine (0.22 ml) was added to a portion (1.2 ml) of the acetonitrile solution obtained in the 2nd step in a nitrogen atmosphere, followed by stirring at 60° C. for 30 minutes. The reaction solution was cooled to room temperature, and a saturated aqueous ammonium chloride solution was added. Then, an insoluble precipitate was washed with water, and 4-(4-bromo-1H-pyrrolo[2,3-b]pyridin-6-yl)morpholine (36 mg) was thus obtained.

MS (ESI m/z): 282, 284 (M+H)

RT (min): 1.30

4th Step

Sodium hydride (60% in oil) (6 mg) was added to a DMF (1.3 ml) solution containing 4-(4-bromo-1H-pyrrolo[2,3-b]pyridin-6-yl)morpholine (36 mg) obtained in the 3rd step in a nitrogen atmosphere under ice cooling, followed by stirring for 30 minutes. Then, di-tert-butyl dicarbonate (50 mg) was added, followed by stirring at room temperature for 1 hour. Further, a saturated aqueous ammonium chloride solution was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated saline and dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:1 to 0:1), and colorless oily matter of tert-butyl 4-bromo-6-morpholino-1H-pyrrolo[2,3-b]pyridin-1-carboxylate (34 mg) was thus obtained.

MS (ESI m/z): 382, 384 (M+H)

RT (min): 1.98

Reference Example 94

The following compound was obtained as described in Reference Example 93.

4-bromo-6-methoxy-1H-pyrrolo[2,3-b]pyridine

MS (ESI m/z): 227, 229 (M+H)

RT (min): 1.42

tert-Butyl4-bromo-6-methoxy-1H-pyrrolo[2,3-b]pyridin-1-carboxylate

MS (ESI m/z): 327, 329 (M+H)

RT (min): 2.12

Reference Example 95

The following compounds were obtained as described in Reference Example 93.

4-bromo-6-(2H-1,2,3-triazol-2-yl)-1H-pyrrolo[2,3-b]pyridine

MS (ESI m/z): 264, 266 (M+H)

RT (min): 1.22

4-bromo-6-(1H-1,2,3-triazol-1-yl)-1H-pyrrolo[2,3-b]pyridine

MS (ESI m/z): 264, 266 (M+H)

RT (min): 1.30

tert-Butyl4-bromo-6-(2H-1,2,3-triazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-1-carboxylate

MS (ESI m/z): 264, 266 (M+H)

RT (min): 1.79

tert-Butyl4-bromo-6-(1H-1,2,3-triazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-1-carboxylate

MS (ESI m/z): 364, 366 (M+H)

RT (min): 1.79

Reference Example 96

The following compounds were obtained as described in Reference Example 93.

4-bromo-6-(1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-b]pyridine

MS (ESI m/z): 264, 266 (M+H)

RT (min): 1.22

tert-Butyl4-bromo-6-(1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-b]pyridin-1-carboxylate

MS (ESI m/z): 364, 366 (M+H)

RT (min): 1.79

Reference Example 97

1st Step

The following compound was obtained as described in Reference Example 22.

tert-Butyl(5-(1-methyl-1H-pyrrol-2-yl)pyridin-3-yl)carbamate

MS (ESI m/z): 274 (M+H), 272 (M−H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.62 (s, 1H), 8.56 (d, 1H, J=2.4 Hz), 8.28 (d, 1H, J=2.0 Hz), 7.91 (s, 1H), 6.92-6.89 (m, 1H), 6.26-6.23 (m, 1H), 6.11-6.08 (m, 1H), 3.65 (s, 3H), 1.49 (s, 9H)

2nd Step

4M hydrogen chloride/1,4-dioxane (1 ml) was added to an ethyl acetate (2 ml) solution containing tert-butyl(5-(1-methyl-1H-pyrrol-2-yl)pyridin-3-yl)carbamate (80 mg) obtained in the 1st step, followed by stirring at room temperature for 15 hours. An insoluble precipitate was collected by filtration, and a light brown solid of 5-(1-methyl-1H-pyrrol-2-yl)pyridin-3-amine.hydrochloride (42 mg) was thus obtained.

MS (ESI m/z): 174 (M+H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.13 (d, 1H, J=1.2 Hz), 7.91 (d, 1H, J=2.0 Hz), 7.71-7.68 (m, 1H), 7.02-7.69 (m, 1H), 6.47-6.43 (m, 1H), 6.16-6.13 (m, 1H), 3.73 (s, 3H)

Reference Example 98

The following compounds were obtained as described in Reference Example 97.

tert-Butyl(5-(1-methyl-1H-indole-5-yl)pyridin-3-yl)carbamate

MS (ESI m/z): 324 (M+H), 322 (M−H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.64 (s, 1H), 8.56-8.48 (m, 2H), 8.19 (s, 1H), 7.82 (d, 1H, J=1.2 Hz), 7.56 (d, 1H, J=8.8 Hz), 7.45-7.41 (m, 1H), 7.42-7.38 (m, 1H), 6.53-6.50 (m, 1H), 3.82 (s, 3H), 1.51 (s, 9H)

5-(1-methyl-1H-indole-5-yl)pyridin-3-amine.hydrochloride

MS (ESI m/z): 224 (M+H)

¹H-NMR (CDCl₃, 400 MHz) δ: 8.33 (d, 1H, J=2.0 Hz), 8.05 (d, 1H, J=2.7 Hz), 7.82-7.80 (m, 1H), 7.45-7.38 (m, 1H), 7.25-7.21 (m, 1H), 7.10 (d, 1H, J=3.0 Hz), 6.54 (d, 1H, J=3.0 Hz), 3.83 (s, 3H), 3.80-3.70 (m, 2H)

Reference Example 99

The following compound was obtained with reference to US2006/79522 A1.

3-bromo-2-methyl-5-nitropyridine Reference Example 100

1st Step

The following compound was obtained as described in Reference Example 22.

2-methyl-5-nitro-3-phenylpyridine

¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.28 (d, 1H, J=2.6 Hz), 8.32 (d, 1H, J=2.7 Hz), 7.57-7.47 (m, 5H), 2.58 (s, 3H)

2nd Step

10% Pd/C (30 mg) was added to a methanol/ethyl acetate (1 ml/1 ml) solution containing 2-methyl-5-nitro-3-phenylpyridine (40 mg) obtained in the 1st step, followed by stirring at room temperature for 2.5 hours in a hydrogen atmosphere. Insoluble matter was removed, the solvent was distilled away under reduced pressure, and light yellow oily matter of 2-methyl-5-phenylpyridin-3-amine (32 mg) was thus obtained.

MS (ESI m/z): 185 (M+H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 7.84 (d, 1H, J=2.7 Hz), 7.47-7.30 (m, 5H), 6.76 (d, 1H, J=2.4 Hz), 5.15 (br, 2H), 2.22 (s, 3H), 1.97 (s, 2H)

Reference Example 101

1st Step

Triethylamine (4 ml), bis(triphenylphosphine)palladium dichloride (70 mg), copper iodide (38 mg), and trimethylsilylacetylene (1.4 ml) were added to a tetrahydrofuran (4 ml) solution containing 4-chloro-2-fluoro-6-iodoaniline (542 mg) in a nitrogen atmosphere, followed by stirring at room temperature for 30 minutes. Then, ethyl acetate was added to the reaction solution and an insoluble precipitate was removed. The organic layers were combined and the solvent was distilled away under reduced pressure. The residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:1), and 4-chloro-2-fluoro-6-((trimethylsilyl)ethynyl)aniline was thus obtained.

MS (ESI m/z): 242, 244 (M+H)

RT (min): 2.11

2nd Step

Potassium carbonate (550 mg) was added to a methanol solution (5 ml) containing the 4-chloro-2-fluoro-6-((trimethylsilyl)ethynyl)aniline obtained in the 1st step, followed by stirring at room temperature for 30 minutes. An insoluble precipitate was removed, and then the solvent was distilled away under reduced pressure. The residue was purified by silica gel chromatography, and colorless oily matter of 4-chloro-2-ethynyl-6-fluoroaniline (214 mg) was thus obtained.

MS (ESI m/z): 170, 172 (M+H)

RT (min): 1.48

3rd Step

Cyclooctadiene chloride dimer (6 mg) was added to a DMF (6 ml) solution containing 4-chloro-2-ethynyl-6-fluoroaniline (214 mg) obtained in the 2nd step, followed by stirring at 85° C. for 16 hours in a nitrogen atmosphere. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction solution, an insoluble precipitate was collected by filtration and washed with water. Then, the obtained solid was dissolved in ethyl acetate, and the organic layer was washed with water and saturated saline and dried over anhydrous sodium sulfate. Thereafter, the solvent was distilled away under reduced pressure, and green oily matter of 5-chloro-7-fluoro-1H-indole (124 mg) was thus obtained.

MS (ESI m/z): 170, 172 (M+H)

RT (min): 1.56

Reference Example 102

The following compound was obtained as described in Reference Example 101.

3-bromo-2-ethynyl-5-(trifluoromethyl)aniline

MS (ESI m/z): 264, 266 (M+H)

RT (min): 1.65

4-bromo-6-(trifluoromethyl)-1H-indole

MS (ESI m/z): 264, 266 (M+H)

RT (min): 1.75

Reference Example 103

5-chloro-7-fluoro-1H-indole (124 mg) and 2-methoxyethyl chloride (17 mg) were added to a DMF (2 ml) suspension containing sodium hydride (61% in oil) (6 mg) in a nitrogen atmosphere under ice cooling, followed by stirring at room temperature for 1 hour. Further, sodium hydride (61% in oil) (6 mg) was added, followed by stirring at 110° C. for 30 minutes. Then, a saturated aqueous ammonium chloride solution and ethyl acetate were added to the reaction solution, the organic layer was collected, washed with saturated saline, and dried over anhydrous sodium sulfate, and then the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel column chromatography, and 5-chloro-7-fluoro-1-(2-methoxyethyl)-1H-indole (27 mg) was thus obtained.

MS (ESI m/z): 228, 230 (M+H)

RT (min): 1.71

Reference Example 104

The following compound was obtained as described in Reference Example 103.

4-(2-(5-chloro-7-fluoro-1H-indole-1-yl)ethyl)morpholine

MS (ESI m/z): 283, 285 (M+H)

RT (min): 0.92

Reference Example 105

The following compound was obtained as described in Reference Example 103.

4-(2-(5-bromo-6-fluoro-1H-indole-1-yl)ethyl)morpholine

MS (ESI m/z): 327, 329 (M+H)

RT (min): 1.01

Reference Example 106

The following compound was obtained as described in Reference Example 103.

4-bromo-6-fluoro-1-(2-methoxyethyl)-1H-indole

MS (ESI m/z): 272, 274 (M+H)

RT (min): 1.70

Reference Example 107

The following compound was obtained as described in Reference Example 103.

4-(2-(4-bromo-6-(trifluoromethyl)-1H-indole-1-yl)ethyl)morpholine

MS (ESI m/z): 377, 379 (M+H)

RT (min): 1.20

Reference Example 108

The following compound was obtained as described in Reference Example 103.

4-bromo-(2-methoxyethyl)-6-(trifluoromethyl)-1H-indole

MS (ESI m/z): 322, 324 (M+H)

RT (min): 1.90

Reference Example 110

1st Step

Concentrated sulfuric acid (2.5 ml) and N-bromosuccinimide (3.44 g) were added to a TFA solution (8 ml) containing 4-fluoro-2-nitrotoluene (2 g), followed by stirring at room temperature for 15 hours. Then, the reaction solution was poured into ice water, followed by extraction with ethyl acetate. The obtained organic layer was washed with water, a saturated aqueous sodium hydrogen carbonate solution, and saturated saline and dried over anhydrous sodium sulfate. Thereafter, the solvent was distilled away under reduced pressure. The residue was purified by silica gel chromatography, and light yellow oily matter was thus obtained.

2nd Step

N,N-dimethylformamide dimethylacetal (7.7 g) was added to a DMF (20 ml) solution containing the light yellow oily matter obtained in the 1st step in a nitrogen atmosphere, followed by reflux for 30 minutes. The reaction solution was adjusted to room temperature. Water, ethyl acetate, and 1M hydrochloric acid were added, and then the organic layer was separated. The obtained organic layer was washed with 1M hydrochloric acid (×3) and saturated saline and dried over anhydrous sodium sulfate. Thereafter, the solvent was distilled away under reduced pressure, and deep brown oily matter was thus obtained.

3rd Step

An acetic acid (20 ml) solution containing the deep brown oily matter obtained in the 2nd step was added to a mixture of iron powder (3.61 g) and acetic acid (20 ml) at 110° C. for 30 minutes. The resulting mixture was stirred for 1 hour and then diluted with ethyl acetate. Insoluble matter was removed by filtration with Celite, the filtrate was washed with water and 1M hydrochloric acid (×3). The obtained organic layer was poured into a saturated aqueous sodium hydrogen carbonate solution to separate the organic layer, and the organic layer was washed with water and saturated saline and dried over anhydrous sodium sulfate. Thereafter, activated carbon was added and insoluble matter was removed by filtration with Celite. The solvent was distilled away under reduced pressure, and light brown oily matter of 4-bromo-6-fluoro-1H-indole (880 mg) was thus obtained.

MS (ESI m/z): 214, 216 (M+H)

RT (min): 1.56

¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.53 (br, 1H), 7.46 (t, 1H, J=3.0 Hz), 7.24 (dd, 1H, J=5.6, 3.0 Hz), 7.19 (dd, 1H, J=9.2, 2.0 Hz), 6.39 (d, 1H, J=2.0 Hz)

4th Step

The following compound was obtained as described in the 2nd step of Reference Example 2.

tert-Butyl-4-bromo-6-fluoro-1H-indole-carboxylate Reference Example 111

Sodium hydride (61% in oil) (40 mg) was added to a DMF (1 ml) solution containing 2-(ethoxycarbonyl)-5-bromoindole (134 mg) under ice cooling, followed by stirring for 10 minutes. Then, a DMF (1 ml) solution containing di-tert-butyldicarbonate (108 mg) was added, followed by stirring at room temperature for 5 minutes. Water was added to the reaction solution and a solid precipitate was collected by filtration, the obtained solid was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:1), and colorless oily matter of tert-butyl 2-ethyl 5-bromo-1H-indole-1,2-dicarboxylate (100 mg) was thus obtained. ¹H-NMR (DMSO-d₆, 300 MHz) δ: 7.96 (t, 1H, J=2.6 Hz), 7.92 (d, 1H, J=9.2 Hz), 7.62 (dd, 1H, J=8.6, 2.0 Hz), 7.24 (s, 1H), 4.33 (q, 2H, J=7.0 Hz), 1.57 (s, 9H), 1.32 (t, 3H, J=7.0 Hz)

Reference Example 112

1st Step

Potassium carbonate (200 mg) and 2-chloroethylmethylether (0.1 ml) were added to a DMF (1.5 ml) solution containing 4-nitro-1H-indazole (80 mg), followed by stirring at 60° C. for 4 hours. Subsequently, an insoluble precipitate was collected by filtration and washed with ethyl acetate, and a mixture of 1-(2-methoxyethyl)-4-nitro-1H-indazole and 2-(2-methoxyethyl)-4-nitro-2H-indazole was thus obtained.

1-(2-methoxyethyl)-4-nitro-1H-indazole

MS (ESI m/z): 222 (M+H)

RT (min): 1.19

2-(2-methoxyethyl)-4-nitro-2H-indazole

MS (ESI m/z): 222 (M+H)

RT (min): 1.12

2nd Step

Iron powder (170 mg), ammonium chloride (160 mg), and water (3 ml) were added to an ethanol solution (10 ml) containing the mixture obtained in the 1st step, followed by stirring at 80° C. for 2 hours. Ethyl acetate was added to the reaction solution, insoluble matter was removed, the filtrates were combined, and the solvent was distilled away under reduced pressure. The obtained residue was purified by alumina silica gel column chromatography, and 1-(2-methoxyethyl)-1H-indole-4-amine (49 mg) and 2-(2-methoxyethyl)-2H-indole-4-amine (40 mg) were thus obtained.

1-(2-methoxyethyl)-1H-indazol-4-amine

MS (ESI m/z): 192 (M+H)

RT (min): 0.72

2-(2-methoxyethyl)-2H-indazol-4-amine

MS (ESI m/z): 192 (M+H)

RT (min): 0.53

Reference Example 113

The following compounds were obtained as described in Reference Example 112.

1-(cyclopropylmethyl)-1H-indazol-4-amine

MS (ESI m/z): 188 (M+H)

RT (min): 1.03

2-(cyclopropylmethyl)-2H-indazol-4-amine

MS (ESI m/z): 188 (M+H)

RT (min): 0.69

Reference Example 114

The following compounds were obtained as described in Reference Example 112.

1-(2-(2-ethoxyethoxy)ethyl)-1H-indazol-4-amine

MS (ESI m/z): 250 (M+H)

RT (min): 0.89

2-(2-(2-ethoxyethoxy)ethyl)-2H-indazol-4-amine

MS (ESI m/z): 250 (M+H)

RT (min): 0.71

Reference Example 115

The following compounds were obtained as described in Reference Example 112.

1-(cyclopropylmethyl)-1H-indazol-6-amine

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.81 (s, 1H), 8.32 (s, 1H), 8.02 (d, 1H, J=8.6 Hz), 7.95 (dd, 1H, J=8.6, 1.7 Hz), 4.49 (d, 2H, J=7.3 Hz), 1.32 (dd, 1H, J=12.2, 7.3 Hz), 0.47 (m, 4H)

2-(cyclopropylmethyl)-2H-indazol-6-amine

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.69 (s, 1H), 8.64 (s, 1H), 7.99 (d, 1H, J=9.2 Hz), 7.82 (dd, 1H, J=9.2, 2.0 Hz), 4.40 (d, 2H, J=7.3 Hz), 1.49-1.37 (m, 1H), 0.63-0.54 (m, 2H), 0.51-0.46 (m, 2H)

Reference Example 116

The following compounds were obtained as described in Reference Example 112.

6-amino-1-(methoxyethyl)-1H-indazole

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.74 (d, 1H, J=2.0 Hz), 8.33 (s, 1H), 8.01 (d, 1H, J=8.6 Hz), 7.95 (dd, 1H, J=8.6, 2.0 Hz), 4.75 (t, 2H, J=5.0 Hz), 3.77 (t, 2H, J=5.0 Hz), 3.18 (s, 3H)

6-amino-2-(methoxyethyl)-2H-indazole

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.63 (s, 1H), 7.98 (d, 1H, J=9.2 Hz), 7.81 (dd, 1H, J=9.2, 2.0 Hz), 4.70 (t, 2H, J=5.0 Hz), 3.86 (t, 2H, J=5.0 Hz), 3.23 (s, 3H)

Reference Example 117

The following compounds were obtained as described in Reference Example 112.

6-amino-1-(2-(2-ethoxyethoxy)ethyl)-1H-indazole

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.75 (s, 1H), 8.33 (s, 1H), 8.00 (d, 1H, J=9.2 Hz), 7.94 (dd, 1H, J=9.2, 1.7 Hz), 4.75 (t, 2H, J=5.0 Hz), 3.84 (t, 2H, J=5.0 Hz), 3.45 (t, 2H, J=4.9 Hz), 3.32 (t, 2H, J=4.9 Hz), 3.24 (q, 2H, J=7.0 Hz), 0.94 (t, 3H, J=7.0 Hz)

6-amino-2-(2-(2-ethoxyethoxy)ethyl)-2H-indazole

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.64 (s, 1H), 7.98 (d, 1H, J=9.2 Hz), 7.82 (dd, 1H, J=9.2, 2.0 Hz), 4.70 (t, 2H, J=5.3 Hz), 3.95 (t, 2H, J=5.3 Hz), 3.51 (t, 2H, J=5.0 Hz), 3.40 (t, 2H, J=5.0 Hz), 3.28 (q, 2H, J=6.9 Hz), 1.02 (t, 3H, J=6.9 Hz)

Reference Example 118

Potassium carbonate (200 mg) and 1-(bromomethyl)cyclopropane (0.1 ml) were added to a DMF (1.5 ml) solution containing 5-bromo-1H-indazole (100 mg), followed by stirring at 60° C. for 4 hours. Ethyl acetate was added to the reaction solution, an insoluble precipitate was removed, and the organic layer was washed with 1M hydrochloric acid (×2) and saturated saline and dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, the obtained solid was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:1), and 5-bromo-1-(cyclopropylmethyl)-1H-indazole (63 mg) and 5-bromo-2-(cyclopropylmethyl)-2H-indazole (42 mg) were thus obtained.

5-bromo-1-(cyclopropylmethyl)-1H-indazole

MS (ESI m/z): 251, 253 (M+H)

RT (min): 1.65

5-bromo-2-(cyclopropylmethyl)-2H-indazole

MS (ESI m/z): 251, 253 (M+H)

RT (min): 1.50

Reference Example 119

The following compounds were obtained as described in Reference Example 118

5-bromo-1-(2-(2-ethoxyethoxy)ethyl)-1H-indazole

MS (ESI m/z): 313, 315 (M+H)

RT (min): 1.49

5-bromo-2-(2-(2-ethoxyethoxy)ethyl)-2H-indazole

MS (ESI m/z): 313, 315 (M+H)

RT (min): 1.39

Reference Example 120

The following compounds were obtained as described in Reference Example 118.

5-bromo-1-(methoxyethyl)-1H-indazole

MS (ESI m/z): 255, 257 (M+H)

RT (min): 1.37

5-bromo-2-(methoxyethyl)-2H-indazole

MS (ESI m/z): 255, 257 (M+H)

RT (min): 1.25

Reference Example 121

The following compound was obtained with reference to Bioorganic and Medicinal Chemistry Letters, 2001, vol. 11, #11, pp. 1401-1406.

2-benzyl-2H-indazol-5-amine Reference Example 122

1st Step

Triethylamine (8.3 ml), DPPA (12.8 ml), and tert-butanol (7.6 ml) were added to a toluene (100 ml) solution containing 5-bromo-nicotinic acid (10 g), followed by stirring at 100° C. for 2.5 hours. The reaction solution was poured into water, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, n-hexane:ethyl acetate (=10:1) was added, and an insoluble precipitate was collected by filtration, and a white solid of benzyl(5-bromopyridin-3-yl)carbamate (10.8 g) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 10.25 (s, 1H), 8.59 (d, 1H, J=2.2 Hz), 8.34 (d, 1H, J=2.2 Hz), 8.20-8.15 (m, 1H), 7.46-7.33 (m, 5H), 5.19 (s, 2H)

2nd step

The following compound was obtained as described in Reference Example 22.

Benzyl(5-(prop-1-ene-2-yl)pyridin-3-yl)carbamate

MS (ESI m/z): 269 (M+H), 267 (M−H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 10.02 (s, 1H), 8.57-8.54 (m, 1H), 8.39 (d, 1H, J=2.0 Hz), 8.00 (s, 1H), 7.46-7.32 (m, 5H), 5.46 (s, 1H), 5.22-5.20 (m, 1H), 5.18 (s, 2H), 2.10 (s, 3H)

3rd Step

10% Pd/C (106 mg) was added to a methanol/ethyl acetate (2 ml/2 ml) solution containing benzyl(5-(prop-1-ene-2-yl)pyridin-3-yl)carbamate (64 mg) obtained in the 2nd step, followed by stirring at room temperature for 2 hours in a hydrogen atmosphere. Insoluble matter was removed with Celite, the solvent was distilled away under reduced pressure, and colorless oily matter of isopropylpyridin-3-amine (30 mg) was thus obtained.

MS (ESI m/z): 137 (M+H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 7.74 (d, 1H, J=2.7 Hz), 7.65-7.63 (m, 1H), 6.78-6.75 (m, 1H), 5.17 (br, 2H), 2.80-2.71 (m, 1H), 1.17 (s, 3H), 1.15 (s, 3H)

Reference Example 123

The following compound was obtained with reference to US2003/125267 A1.

[2,2′-bipyridine]-4-amine Reference Example 124

Cesium carbonate (213 mg), pyrrolidin-2-one (45 mg), Xantphos (76 mg), and Pd₂(dba)₃ (60 mg) were added to a 1,4-dioxane (4 ml) solution containing 3,5-dibromopyridine (100 mg) in a nitrogen atmosphere, followed by reflux for 4 hours. The reaction mixture was adjusted to room temperature and water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=3:1 to 1:1), and a white solid of 1-(5-bromopyridin-3-yl)pyrrolidin-2-one (45 mg) was thus obtained.

MS (ESI m/z): 241, 243 (M+H)

RT (min): 0.91

Reference Example 125

1st Step

The following compound was obtained as described in Reference Example 124.

2-methyl-5-nitro-3-(pyrrolidin-1-yl)pyridine

MS (ESI m/z): 208 (M+H)

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.79 (d, 1H, J=2.3 Hz), 7.70 (d, 1H, J=2.3 Hz), 3.38-3.32 (m, 4H), 2.67 (s, 3H), 2.05-2.00 (m, 4H)

2nd Step

10% Pd/C (15 mg) was added to a methanol/ethyl acetate (2 ml/2 ml) solution containing 2-methyl-5-nitro-3-(pyrrolidin-1-yl)pyridine (16 mg), followed by stirring at room temperature for 2.5 hours in a hydrogen atmosphere. Insoluble matter was removed with Celite, the solvent was distilled away under reduced pressure, and colorless oily matter of 6-methyl-5-(pyrrolidin-1-yl)pyridin-3-amine (15 mg) was thus obtained.

¹H-NMR (CDCl₃, 400 MHz) δ: 7.58 (d, 1H, J=2.4 Hz), 6.47 (d, 1H, J=2.4 Hz), 3.47 (br, 2H), 3.21-3.15 (m, 4H), 2.45 (s, 3H), 1.96-1.91 (m, 4H)

Reference Example 126

The following compound was obtained as described in Reference Example 124.

1-(5-bromopyridin-3-yl)piperidine-2-one

MS (ESI m/z): 255, 257 (M+H)

RT (min): 0.88

Reference Example 127

The following compounds were obtained as described in Reference Example 124 and the 2nd step of Reference Example 97.

tert-Butyl(2-(2-oxopyrrolidin-1-yl)pyridin-4-yl)carbamate

MS (ESI m/z): 278 (M+H)

RT (min): 0.89

1-(4-aminopyridin-2-yl)pyrrolidin-2-one

MS (ESI m/z): 178 (M+H)

RT (min): 0.21, 0.30

Reference Example 128

1st Step

The following compound was obtained as described in Reference Example 22.

3-(5-bromopyridin-3-yl)phenol

MS (ESI m/z): 250, 252 (M+H)

RT (min): 1.23

2nd Step

Potassium carbonate (17 mg) and 2-chloroethylmethylether (9 mg) were added to an N,N-dimethylacetamide (2 ml) solution containing 3-(5-bromopyridin-3-yl)phenol (20 mg) obtained in the 1st step, followed by stirring at 80° C. for 6 hours. Water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=7:1 to 3:1), and colorless oily matter of 3-bromo-5-(3-(2-methoxyethoxy)phenyl)pyridine (18 mg) was thus obtained.

MS (ESI m/z): 308, 310 (M+H)

RT (min): 1.62

Reference Example 129

The following compound was obtained as described in Reference Example 128.

4-(5-bromopyridin-3-yl)phenol

MS (ESI m/z): 250, 252 (M+H)

RT: 1.20 min

3-bromo-5-(4-(2-methoxyethoxy)phenyl)pyridine

MS (ESI m/z): 308, 310 (M+H)

RT: 1.50 min

Reference Example 130

The following compound was obtained as described in Reference Example 128.

4-(5-bromopyridin-3-yl)phenol

MS (ESI m/z): 250, 252 (M+H)

RT (min): 1.20

4-(2-(4-(5-bromopyridin-3-yl)phenoxy)ethyl)morpholine

MS (ESI m/z): 363, 365 (M+H)

RT (min): 0.90

Reference Example 131

The following compound was obtained as described in the 2nd step of Reference Example 128.

4-(2-(3-(5-bromopyridin-3-yl)phenoxy)ethyl)morpholine

MS (ESI m/z): 363, 365 (M+H)

RT (min): 0.95

Reference Example 132

An isopropanol (2 ml) solution containing 2-chloropyridin-4-amine (300 mg), and sodium hydroxide (467 mg) were added to a tube and the tube was sealed, followed by stirring at 170° C. for 3 hours. The reaction solution was cooled to room temperature. Saturated saline was added, followed by extraction with ethyl acetate. Subsequently, the resultant was washed with saturated saline and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=4:1 to 1:1), and light yellow oily matter of 2-isopropoxypyridin-4-amine (168 mg) was thus obtained.

MS (ESI m/z): 153 (M+H)

RT (min): 0.46

Reference Example 133

The following compound was obtained as described in Reference Example 132.

2-(2-(pyrrolidin-1-yl)ethoxy)pyridin-4-amine

MS (ESI m/z): 208 (M+H)

RT (min): 0.21

Reference Example 134

The following compound was obtained as described in Reference Example 132.

2-(2-methoxyethoxy)-6-phenylpyridin-4-amine

MS (ESI m/z): 245 (M+H)

RT (min): 0.69

Reference Example 135

The following compounds were obtained with reference to Tetrahedron, 2004, vol. 60, p. 5487.

Ethyl 8-bromo-2-fluoroindolizine-3-carboxylate Ethyl 6-bromo-2-fluoroindolizine-3-carboxylate Reference Example 136

The following compound was obtained with reference to US2009/270405 A1.

5-phenylpyridin-3-amine Reference Example 137

The following compound was obtained with reference to Journal of the American Chemical Society, 1946, vol. 68, p. 1544.

3-bromoquinolin-8-amine Reference Example 138

A DMF (2 ml) solution containing 3-bromoquinolin-8-amine (223 mg), dimethyl sulfate (189 mg), potassium carbonate (415 mg), and sodium iodide (20 mg) were added to a tube and the tube was sealed, followed by stirring at 95° C. for 17 hours. The reaction solution was cooled to room temperature, ethyl acetate was added, an insoluble precipitate was removed, and the organic layer was washed with 1M hydrochloric acid, water, and saturated saline. Subsequently, the organic layer was dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=0:1 to 1:1), and a yellow solid of 3-bromo-N-methylquinolin-8-amine (52 mg) was thus obtained.

MS (ESI m/z): 237, 239 (M+H)

RT (min): 1.76

Reference Example 139

1st step

p-Toluenesulfonyl chloride (2 g) and tetrabutyl ammonium hydrogen sulfate (250 mg) were added to a toluene (20 ml) solution containing 5-chloroindole (1.52 g), followed by stirring at room temperature for 11 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with water (×3) and saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=0:1 to 1:1), and a colorless solid of 5-chloro-1-tosyl-1H-indole (3.18 g) was thus obtained.

2nd Step

Lithium diisopropylamide (2M tetrahydrofuran solution) (3.41 ml) was slowly added to a tetrahydrofuran (65 ml) solution containing 5-chloro-1-tosyl-1H-indole (1.98 g) obtained in the 1st step at −78° C. in a nitrogen atmosphere. The reaction solution was adjusted to room temperature. Further, trimethyl tin chloride (1.36 g) was added, followed by stirring for 17 hours. A saturated aqueous potassium fluoride solution was added to the reaction solution and tetrahydrofuran was distilled away under reduced pressure. Ethyl acetate was added, the resultant was washed with saturated saline and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=0:1 to 1:1), and colorless viscous oily matter of 5-chloro-1-tosyl-2-(trimethylstannyl)-1H-indole (2.05 g) was thus obtained.

3rd Step

N-fluoro-N′-(chloromethyl)triethylenediamine bis(tetrafluoroborate) (2.33 g) was added to an acetonitrile solution (88 ml) containing 5-chloro-1-tosyl-2-(trimethylstannyl)-1H-indole (2.05 g) obtained in the 2nd step in a nitrogen atmosphere, followed by stirring at room temperature for 16 hours. Chloroform was added to the reaction solution, an insoluble precipitate was removed, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=0:1 to 1:100), and a light yellow solid of 5-chloro-2-fluoro-1-tosyl-1H-indole (520 mg) was thus obtained.

4th Step

Potassium hydroxide (246 mg) was added to a tetrahydrofuran/ethanol (3 ml/6 ml) solution containing 5-chloro-2-fluoro-1-tosyl-1H-indole (520 mg) obtained in the 3rd step, followed by stirring at 50° C. for 17 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate (×2). The organic layers were combined and washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=0:1 to 1:1), and light yellow oily matter of 5-chloro-2-fluoro-1H-indole (69 mg) was thus obtained.

5th step

Sodium hydride (60% in oil) (16 mg) was added to a DMF (1 ml) solution containing 5-chloro-2-fluoro-1H-indole (45 mg) obtained in the 4th step at room temperature, followed by stirring for 10 minutes. Then, dimethyl sulfate (50 mg) was added, followed by stirring at room temperature for 30 minutes. Water was added to the reaction solution, followed by extraction with ethyl acetate, the resultant was washed with water (×3) and saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by PLC (n-hexane:ethyl acetate=10:1), and 5-chloro-2-fluoro-1-methyl-1H-indole (18 mg) was thus obtained.

Reference Example 140

Toluenesulfonylmethylisocyanide (126 mg) and 1,8-diazabicyclo[5.4.0]undec-7-ene (122 mg) were added to a dichloromethane (4 ml) solution containing 5-bromo-3-pyridinecarboxaldehyde (100 mg) at room temperature, followed by stirring for 5 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=4:1 to 5:2), and a white solid of 5-(5-bromopyridin-3-yl)oxazole (96 mg) was thus obtained.

MS (ESI m/z): 225, 227 (M+H)

RT (min): 1.00

Reference Example 141

1st Step

The following compound was obtained as described in Reference Example 22.

tert-butyl (5-(5-methylfuran-2-yl)pyridin-3-yl)carbamate

MS (ESI m/z): 275 (M+H)

RT (min): 1.46

2nd Step

TFA (1 ml) was added to a chloroform solution (2 ml) containing tert-butyl(5-(5-methylfuran-2-yl)pyridin-3-yl)carbamate (61 mg) obtained in the 1st step, stirring at room temperature for 2 hours. The solvent was distilled away under reduced pressure, the obtained residue was dissolved in chloroform, and the resultant was washed with water and a saturated aqueous sodium hydrogen carbonate solution. Subsequently, the aqueous layers were combined, followed by extraction with chloroform (×2). The organic layers was combined and dried over anhydrous sodium sulfate. The solvent was distilled away from the obtained organic layers under reduced pressure, and a white solid of 5-(5-methylfuran-2-yl)pyridin-3-amine (46 mg) was thus obtained.

MS (ESI m/z): 175 (M+H)

RT (min): 0.63

Reference Example 142

The following compounds were obtained as described in Reference Example 141.

tert-Butyl(2-(5-methylfuran-2-yl)pyridin-4-yl)carbamate

MS (ESI m/z): 275 (M+H)

RT (min): 1.10

2-(5-methylfuran-2-yl)pyridin-4-amine

MS (ESI m/z): 175 (M+H)

RT (min): 0.59

Reference Example 143

1st Step

Triethylamine (200 mg), bis(pinacolato)diboron (127 mg), 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (100 mg), and bis(acetonitrile)palladium dichloride (17 mg) were added to a 1,4-dioxane (4 ml) solution containing 3-bromo-1-(triisopropylsilyl)pyrrole (200 mg) in a nitrogen atmosphere, followed by stirring for 10 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=100:1 to 10:1), and light yellow oily matter of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(triisopropylsilyl)-1H-pyrrole (58 mg) was thus obtained.

MS (ESI m/z): 350 (M+H)

RT (min): 2.56

2nd Step

The following compound was obtained as described in Reference Example 22.

5-(1-(triisopropylsilyl)-1H-pyrrol-3-yl)pyridin-3-amine

MS (ESI m/z): 316 (M+H)

RT (min): 1.43

Reference Example 144

1st Step

The following compound was obtained as described in Reference Example 22.

3-bromo-5-(1-(triisopropylsilyl)-1H-pyrrol-3-yl)pyridine

MS (ESI m/z): 379, 381 (M+H)

RT (min): 2.38

2nd Step

Tetrabutylammonium fluoride (1M tetrahydrofuran solution: 1 ml) was added to a tetrahydrofuran (2 ml) solution containing 3-bromo-5-(1-(triisopropylsilyl)-1H-pyrrol-3-yl)pyridine (71 mg), followed by stirring at room temperature for 2 hours. The reaction solution was poured into water, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Then the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=5:1 to 2:1), and a white solid of 3-bromo-5-(1H-pyrrol-3-yl)pyridine (28 mg) was thus obtained.

MS (ESI m/z): 223, 225 (M+H)

RT (min): 1.06

3rd Step

Sodium hydride (60% in oil) (6 mg) was added to a DMF (1 ml) solution containing 3-bromo-5-(1H-pyrrol-3-yl)pyridine (28 mg), followed by stirring. Methyl iodide (9 μl) was added, followed by stirring at room temperature for 3 hours. The reaction solution was poured into water, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=30:1 to 3:1), and a white solid of 3-bromo-5-(1-methyl-1H-pyrrol-3-yl)pyridine (18 mg) was thus obtained.

MS (ESI m/z): 237, 239 (M+H)

RT (min): 1.29

Reference Example 145

1st Step

Cesium carbonate (300 mg), phenylboronic acid (82 mg), and bis(triphenylphosphine)palladium dichloride (43 mg) were added to a tetrahydrofuran (2 ml) solution containing 4-amino-2,6-dichloropyridine (100 mg) in a nitrogen atmosphere, followed by stirring for 8.5 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous magnesium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=9:1 to 6:1), and colorless oily matter of 2-chloro-6-phenylpyridin-4-amine (26 mg) was thus obtained.

MS (ESI m/z): 205, 207 (M+H)

RT (min): 1.02

2nd Step

Sodium methoxide (28% methanol solution) (1 ml) was added to a methanol (2 ml) solution containing 2-chloro-6-phenylpyridin-4-amine (26 mg) obtained in the 1st step at room temperature, followed by stirring at 150° C. for 6.5 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous magnesium sulfate, and then the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=50:1 to 6:1), and 2-methoxy-6-phenylpyridin-4-amine (6 mg) was thus obtained.

MS (ESI m/z): 201 (M+H)

RT (min): 0.64

Reference Example 146

1st Step

N-bromosuccinimide (360 mg) was added to an acetic acid (6 ml) solution containing 7-nitroquinoline (700 mg), followed by stirring at 110° C. for 3 hours. N-bromosuccinimide (360 mg) was added again, followed by stirring at 110° C. for 10 minutes. The reaction solution was poured into ice water, an insoluble precipitate was collected by filtration, and light brown 3-bromo-7-nitroquinoline (660 mg) was thus obtained.

MS (ESI m/z): 253, 255 (M+H)

RT (min): 1.44

2nd Step

12M hydrochloric acid (2 ml) and 3-bromo-7-nitroquinoline (660 mg) obtained in the 1st step were added to a suspension of iron powder (3.61 g), ethanol (33 ml) and water (2 ml), followed by reflux for 4 hours. Subsequently, 6M hydrochloric acid (4 ml) was added, followed by reflux for 2.5 hours. Then, the solvent was distilled away under reduced pressure, and an insoluble precipitate was filtered and washed with ethyl acetate. Subsequently, the filtrate was collected, the solvent was again distilled away under reduced pressure, a 28% aqueous ammonia solution was added to the obtained oily matter, and a solid precipitate was filtered and washed with water. Then, the obtained solid was dissolved in ethyl acetate, an insoluble precipitate was removed, and the solvent was distilled away under reduced pressure. Further, diisopropylether was added to the obtained solid, an insoluble precipitate was collected by filtration, and a mixture of a light brown solid of 3-bromo-7-nitroquinoline and 3-bromoquinolin-7-amine (170 mg) was thus obtained.

MS (ESI m/z): 223, 225 (M+H)

RT (min): 0.65

3rd Step

Potassium carbonate (92 mg), sodium iodide (10 mg), and bis(2-chloroethoxy)ethane (64 mg) were added to a tube containing a DMF solution (0.5 ml) containing a portion (50 mg) of the mixture obtained in the 2nd step and the tube was sealed, followed by stirring at 130° C. for 14 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with water (×3) and saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:1), and a yellow solid of 4-(3-bromoquinolin-7-yl)morpholine (15 mg) was thus obtained.

MS (ESI m/z): 278, 280 (M+H)

RT (min): 1.45

Reference Example 147

1st Step

A 55% sulfuric acid solution (420 ml) containing a portion (33 mg) of the mixture obtained in the 2nd step of Reference Example 146 was irradiated with microwaves (Initiator™, 220° C., 1 hour, 2.45 GHz, 0-240 W). Ice water was added to the reaction solution and neutralized with 28% ammonia water, followed by extraction with ethyl acetate (×2). The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, and a light brown solid of 3-bromoquinolin-7-ol (21 mg) was thus obtained.

2nd Step

Sodium hydride (61% in oil) and 2-chloroethylmethylether (6 mg) were added to a DMF solution (0.5 ml) containing 3-bromoquinolin-7-ol (21 mg) obtained in the 1st step in a nitrogen atmosphere, followed by stirring at 120° C. for 30 minutes. Water was added to the reaction solution, an insoluble precipitate was collected by filtration, and light brown 3-bromo-7-(2-methoxyethoxy)quinoline (17 mg) was thus obtained.

MS (ESI m/z): 282, 284 (M+H)

RT (min): 1.33

Reference Example 148-1

The following compound was obtained with reference to Monatshefte fuer Chemie, 1991, vol. 122, #11, pp. 935-942.

3-bromoquinolin-8-ol Reference Example 148-2

The following compound was obtained as described in the 2nd step of Reference Example 147.

3-bromo-8-(2-methoxyethoxy)quinoline

MS (ESI m/z): 282, 284 (M+H)

RT (min): 1.25

Reference Example 149

Potassium carbonate (92 mg) and 2-chloroethylmethylether (32 mg) were added to a tube containing a DMF (0.5 ml) solution containing 3-bromoquinolin-8-amine (50 mg) and the tube was sealed, followed by stirring at 110° C.-130° C. for 22 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with water (×3) and saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:1), and light yellow oily matter of 3-bromo-N-(2-methoxyethyl)quinolin-8-amine (15 mg) was thus obtained.

MS (ESI m/z): 281, 283 (M+H)

RT (min): 1.86

Reference Example 150

Potassium carbonate (92 mg) and dimethyl sulfate (100 mg) were added to a DMF (0.5 ml) solution containing a portion (50 mg) of the mixture obtained in the 2nd step of Reference Example 146, followed by stirring at 60° C. for 5 hours and at 80° C. for 3 hours. The reaction solution was diluted with ethyl acetate, insoluble matter was removed, the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 9:1), and a light yellow solid of 3-bromo-N,N-dimethylquinolin-7-amine (25 mg) was thus obtained.

MS (ESI m/z): 251, 253 (M+H)

RT (min): 1.42

Reference Example 151

Morpholine (1 ml) was added to 2-chloro-6-phenylpyridin-4-amine (30 mg), followed by stirring at 130° C. for 2 hours and 170° C. for 4 hours. The reaction solution was adjusted to room temperature, and 10% saline was added, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=2:1 to 1:2), and colorless oily matter of 2-morpholino-6-phenylpyridin-4-amine (24 mg) was thus obtained.

MS (ESI m/z): 256 (M+H)

RT (min): 0.71

Reference Example 152

Water (0.5 ml), sodium carbonate (92 mg), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-carboxylate (203 mg), and bis(tri-tert-butylphosphine)palladium (30 mg) were added to a tetrahydrofuran (4.5 ml) solution containing 5-bromopyridin-3-amine (100 mg) in a nitrogen atmosphere, followed by stirring for 2.75 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (chloroform:methanol=1:0 to 30:1), and a white solid of tert-butyl-4-(5-aminopyridin-3-yl)-1H-pyrazol-1-carboxylate (52 mg) was thus obtained.

MS (ESI m/z): 261 (M+H)

RT (min): 0.75

Reference Example 153

The following compound was obtained as described in Reference Example 152.

MS (ESI m/z): 261 (M+H)

RT (min): 0.74

Reference Example 154

Potassium carbonate (69 mg), sodium iodide (20 mg), and 2-(2-ethoxyethoxy)ethyl-4-methylbenzenesulfonate (Tetrahedron Letters, 2009, vol. 50, #37, pp. 5231-5234) were added to a tube containing a DMF (2 ml) solution containing 3-bromoquinolin-8-amine (223 mg) and the tube was sealed, followed by stirring at 130° C. for 7 hours. The reaction solution was adjusted to room temperature, and water was added, followed by extraction with ethyl acetate. The resultant was washed with water (×3) and saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:7), and light yellow oily matter of 3-bromo-N-(2-(2-ethoxyethoxy)ethyl)quinolin-8-amine (40 mg) was thus obtained.

MS (ESI m/z): 339, 341 (M+H)

RT (min): 1.82

Reference Example 155

The following compound was obtained as described in Reference Example 154.

3-bromo-N-(cyclopropylmethyl)quinolin-8-amine

MS (ESI m/z): 277, 279 (M+H)

RT (min): 2.05

Reference Example 156

A mixture of 3-bromoquinolin-8-amine (38 mg), 48% aqueous fluoroboric acid solution (0.5 ml), and sodium nitrite (16 mg) was stirred at room temperature for 1 hour. Water was poured into the reaction solution and an insoluble precipitate was collected by filtration. Further, the solid collected by filtration was dissolved in 1,2-dichlorobenzene (1 ml) and stirred at 130° C. for 1 hour and at 190° C. for 0.5 hour. 1M hydrochloric acid was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with water (×2) and saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:1), and 3-bromo-8-fluoroquinolin-8-amine (32 mg) was thus obtained.

MS (ESI m/z): 226, 228 (M+H)

RT (min): 1.34

Reference Example 157-1

The following compound was obtained with reference to Monatshefte fuer Chemie, 1994, vol. 125, #6/7, pp. 723-730.

6-bromoquinolin-8-amine Reference Example 157-2

Potassium carbonate (69 mg), sodium iodide (5 mg), and dimethyl sulfate (31 mg) were added to a DMF (1 ml) solution containing 6-bromoquinolin-8-amine (37 mg), followed by stirring at 100° C. for 14 hours. The reaction solution was adjusted to room temperature, and water was added, followed by extraction with ethyl acetate. The organic layer was washed with water (×3) and saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:1), and 6-bromo-N-methylquinolin-8-amine (17 mg) was thus obtained.

MS (ESI m/z): 237, 239 (M+H)

RT (min): 1.68

Reference Example 158

Potassium carbonate (69 mg), sodium iodide (5 mg), and 2-methoxyethyl chloride (24 mg) were added to a DMF (1 ml) solution containing 6-bromoquinolin-8-amine (37 mg), followed by stirring at 140° C. for 12 hours. Further, cesium carbonate (160 mg), sodium iodide (20 mg), N,N-dimethyl-4-aminopyridine (100 mg), and 2-methoxyethyl chloride (120 mg) were added, followed by stirring at 160° C. for 4.5 hours. The reaction solution was adjusted to room temperature, and water was added, followed by extraction with ethyl acetate. The resultant was washed with water (×3) and saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 4:1), and 6-bromo-N-(2-methoxyethyl)quinolin-8-amine (10 mg) was thus obtained.

MS (ESI m/z): 281, 283 (M+H)

RT (min): 1.68

Reference Example 159

1st Step

Cesium carbonate (214 mg), pyrrole (30 mg), Xantphos (63 mg), and Pd₂(dba)₃ (50 mg) were added to a 1,4-dioxane solution (5 mL) containing tert-butyl(5-bromopyridin-3-yl)carbamate (100 mg) in a nitrogen atmosphere, followed by stirring at 100° C. for 8 hours. The reaction solution was adjusted to room temperature, and water was added, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=5:1 to 1:1), and a light yellow solid of tert-butyl(5-(1H-pyrrol-1-yl)pyridin-3-yl)carbamate (36 mg) was thus obtained.

MS (ESI m/z): 260 (M+H)

RT (min): 1.38

2nd Step

TFA (1 ml) was added to a chloroform (1 ml) solution containing tert-butyl(5-(1H-pyrrol-1-yl)pyridin-3-yl)carbamate (36 mg) obtained in the 1st step, followed by stirring at room temperature for 1 hour. Then, the solvent was distilled away under reduced pressure and the residue was added to a mixture of chloroform, water, and a 1M sodium hydroxide aqueous solution, followed by extraction with chloroform. The resultant was dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and a light brown solid of 5-(1H-pyrrol-1-yl)pyridin-3-amine (23 mg) was thus obtained.

MS (ESI m/z): 160 (M+H)

RT (min): 0.52

Reference Example 160

The following compounds were obtained as described in Reference Example 159.

tert-Butyl(2-(1H-pyrrol-1-yl)pyridin-4-yl)carbamate

MS (ESI m/z): 260 (M+H)

RT (min): 1.55

2-(1H-pyrrol-1-yl)pyridin-4-amine

MS (ESI m/z): 160 (M+H)

RT (min): 0.48

Reference Example 161

1st Step

Triethylamine (191 mg) and morpholine (120 mg) were added to a tetrahydrofuran (4 ml) solution containing 3-bromo-2-chloro-5-nitropyridine (300 mg), followed by stirring for 40 minutes. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (chloroform:methanol=1:0 to 3:1), and a yellow solid of 4-(3-bromo-5-nitropyridin-2-yl)morpholine (346 mg) was thus obtained.

MS (ESI m/z): 288, 290 (M+H)

RT (min): 1.37

2nd Step

The following compound was obtained as described in Reference Example 22.

4-(3-methyl-5-nitropyridin-2-yl)morpholine

MS (ESI m/z): 224 (M+H)

RT (min): 1.20

3rd Step

A methanol (20 ml) solution containing 4-(3-methyl-5-nitropyridin-2-yl)morpholine (67 mg) was prepared and subjected to a hydrogenation reaction (room temperature; 1 bar; flow rate: 1 ml/min; 10% Pd/C) using H-cube™. Then, the solvent was distilled away under reduced pressure, and a purple solid of 5-methyl-6-morpholinopyridin-3-amine (52.4 mg) was thus obtained.

MS (ESI m/z): 194 (M+H)

RT (min): 0.46

Reference Example 162

The following compounds were obtained as described in Reference Example 161.

4-(3-(furan-3-yl)-5-nitropyridin-2-yl)morpholine

MS (ESI m/z): 276 (M+H)

RT (min): 1.42

5-(furan-3-yl)-6-morpholinopyridin-3-amine

MS (ESI m/z): 246 (M+H)

RT (min): 0.68

Reference Example 163

The following compound was obtained as described in the 3rd step of Reference Example 161.

6-(1H-pyrazol-1-yl)pyridin-3-amine

MS (ESI m/z): 161 (M+H)

RT (min): 0.67

Reference Example 164

The following compounds were obtained as described in the 2nd and 3rd steps of Reference Example 161.

3-methyl-5-nitro-2-vinylpyridine

MS (ESI m/z): 165 (M+H)

RT (min): 1.36

6-ethyl-5-methylpyridin-3-amine

MS (ESI m/z): 137 (M+H)

RT (min): 0.47

Reference Example 165

The following compounds were obtained as described in the 2nd and 3rd steps of Reference Example 161.

2-cyclopropyl-3-methyl-5-nitropyridine

MS (ESI m/z): 179 (M+H)

RT (min): 1.56

6-cyclopropyl-5-methylpyridin-3-amine

MS (ESI m/z): 149 (M+H)

RT (min): 0.52

Reference Example 166

1st Step

Potassium carbonate (262 mg) and bis(2-methoxyethyl)amine (840 mg) were added to a DMF (2 ml) solution containing 2-chloro-5-nitropyridine (100 mg), followed by stirring at room temperature for 5 hours. Water (15 ml) was added to the reaction solution, followed by stirring at room temperature for 1 hour. Insoluble matter was collected by filtration, and a white solid of N,N-bis(2-methoxyethyl)-5-nitropyridin-2-amine (117 mg) was thus obtained.

MS (ESI m/z): 256 (M+H)

RT (min): 1.26

2nd Step

An ethyl acetate/methanol (10 ml/5 ml) solution containing N,N-bis(2-methoxyethyl)-5-nitropyridin-2-amine (20 mg) obtained in the 1st step was prepared and subjected to a hydrogenation reaction (room temperature; 1 bar; flow rate: 1 ml/min; 10% Pd/C) using H-cube™. Then, the solvent was distilled away under reduced pressure, and light peach oily matter of N²,N²-bis(2-methoxyethyl)pyridin-2,5-diamine (18 mg) was thus obtained.

MS (ESI m/z): 226 (M+H)

RT (min): 0.47

Reference Example 167

1st Step

An N,N-dimethylformamide dimethylacetal (2 ml) solution containing 1-(5-bromopyridin-3-yl)ethanone (100 mg) (WO2009/87224 A1) was stirred at 100° C. for 5 hours. The solvent was distilled away under reduced pressure, and a yellow solid of 1-(5-bromopyridin-3-yl)-3-(dimethylamino)prop-2-ene-1-one was thus obtained.

MS (ESI m/z): 255, 257 (M+H)

RT (min): 0.89

2nd Step

Hydroxyamine.hydrochloride (42 mg) was added to a methanol (2 ml) solution containing 1-(5-bromopyridin-3-yl)-3-(dimethylamino)prop-2-ene-1-one obtained in the 1st step, followed by reflux for 2 hours. The solvent was distilled away under reduced pressure, and water was added to the obtained residue, followed by extraction with ethyl acetate. Then, the organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:3), and a white solid of 5-(5-bromopyridin-3-yl)isoxazole (59.5 mg) was thus obtained.

MS (ESI m/z): 225, 227 (M+H)

RT (min): 1.10

Reference Example 168

Cesium carbonate (1.9 g) and 1H-1,2,3-triazole (540 mg) were added to a tube containing a DMF (2 ml) solution containing 2-chloropyridin-4-amine (500 mg) and the tube was sealed, followed by stirring at 180° C. for 6 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:3 to 0:1), and a white solid of 2-(2H-1,2,3-triazol-2-yl)pyridin-4-amine (75.7 mg) and brown oily matter of 2-(1H-1,2,3-triazol-1-yl)pyridin-4-amine (25.1 mg) was thus obtained.

2-(2H-1,2,3-triazol-2-yl)pyridin-4-amine

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.06 (s, 2H), 7.95 (d, 1H, 5.4 Hz), 7.12 (d, 1H, J=1.8 Hz), 6.54 (dd, 1H, J=1.8, 5.4 Hz), 6.49 (br, 2H)

2-(1H-1,2,3-triazol-1-yl)pyridin-4-amine

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.70 (s, 1H), 7.97 (d, 1H, J=5.4 Hz), 7.91 (s, 1H), 7.23 (d, 1H, J=2.1 Hz), 6.60 (br, 2H), 6.57 (dd, 1H, J=2.1, 5.4 Hz)

Reference Example 169

Imidazole (42 mg), cesium carbonate (340 mg), trans-N,N′-dimethylcyclohexane-1,2-diamine (74 mg), and copper iodide (50 mg) were added to a tube containing a N,N-dimethylacetamide (2 ml) solution containing 5-bromopyridin-3-amine (90 mg) in a nitrogen atmosphere and the tube was sealed, followed by stirring at 150° C. for 14.5 hours. The reaction solution was adjusted to room temperature, and water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (chloroform:methanol=1:0 to 10:1), and a brown solid of 5-(1H-imidazol-1-yl)pyridin-3-amine (25.8 mg) was thus obtained.

MS (ESI m/z): 161 (M+H)

RT (min): 0.19

Reference Example 170

The following compound was obtained as described in Reference Example 169.

5-(1H-pyrazol-1-yl)pyridin-3-amine

MS (ESI m/z): 161 (M+H)

RT (min): 0.38

Reference Example 171

The following compound was obtained with reference to U.S. Pat. No. 6,133,253 A1.

5-bromo-6-methylpyridin-3-amine Reference Example 172

The following compound was obtained as described in Reference Example 169.

6-methyl-5-(2H-1,2,3-triazol-2-yl)pyridin-3-amine

MS (ESI m/z): 176 (M+H)

RT (min): 0.44

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.11 (s, 2H), 7.96 (d, 1H, J=2.7 Hz), 7.25 (d, 1H, J=2.7 Hz), 5.52 (br, 2H), 2.32 (s, 3H) 6-methyl-5-(1H-1,2,3-triazol-1-yl)pyridin-3-amine

MS (ESI m/z): 176 (M+H)

RT (min): 0.20, 0.27

Reference Example 173

The following compound was obtained as described in Reference Example 169.

2-(1H-pyrazol-1-yl)pyridin-4-amine

MS (ESI m/z): 161 (M+H)

RT (min): 0.36

Reference Example 174

The following compound was obtained as described in Reference Example 169.

6-methyl-5-(1H-pyrazol-1-yl)pyridin-3-amine

MS (ESI m/z): 175 (M+H)

RT (min): 0.42

Reference Example 175

The following compound was obtained as described in Reference Example 169.

5-(1H-1,2,4-triazol-1-yl)pyridin-3-amine

MS (ESI m/z): 162 (M+H)

RT (min): 0.27

Reference Example 176

The following compound was obtained as described in Reference Example 169.

6-methyl-5-(1H-1,2,4-triazol-1-yl)pyridin-3-amine

MS (ESI m/z): 176 (M+H)

RT (min): 0.27

Reference Example 178

Sodium hydroxide (311 mg) was added to a tube containing an n-propanol (2 ml) solution containing 2-chloropyridin-4-amine (200 mg) and the tube was sealed, followed by stirring at 150° C. for 5 hours. The reaction solution was adjusted to room temperature, and water was added, followed by extraction with toluene. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=7:3 to 2:3), and yellow oily matter of 2-propoxypyridin-4-amine (200 mg) was thus obtained.

MS (ESI m/z): 153 (M+H)

RT (min): 0.48

Reference Example 179

The following compound was obtained as described in Reference Example 178.

2-butoxypyridin-4-amine

MS (ESI m/z): 167 (M+H)

RT (min): 0.59

Reference Example 180

The following compound was obtained as described in Reference Example 178.

2-isobutoxypyridin-4-amine

MS (ESI m/z): 167 (M+H)

RT (min): 0.58

Reference Example 181

The following compound was obtained as described in Reference Example 178.

2-(3-methoxybutyl)pyridin-4-amine

MS (ESI m/z): 197 (M+H)

RT (min): 0.51

Reference Example 182

The following compound was obtained as described in Reference Example 178.

2-(benzyloxy)pyridin-4-amine

MS (ESI m/z): 201 (M+H)

RT (min): 0.65

Reference Example 183

1st Step

The following compound was obtained as described in Reference Example 22.

4-nitro-2-(1-(triisopropylsilyl)-1H-pyrrol-3-yl)pyridine

MS (ESI m/z): 346 (M+H)

RT (min): 2.26

2nd Step

The following compound was obtained as described in the 3rd step of Reference Example 161.

2-(1-(triisopropylsilyl)-1H-pyrrol-3-yl)pyridin-4-amine

MS (ESI m/z): 316 (M+H)

RT (min): 1.42

Reference Example 184

1st Step

N-chlorosuccinimide (45 mg) was added to an acetic acid (0.5 ml) solution containing 7-nitroquinoline (39 mg), followed by stirring at 160° C. for 0.5 hours. Water was added to the reaction solution, an insoluble precipitate was purified by silica gel chromatography (n-hexane:ethyl acetate=1:1), and 3-chloro-7-nitroquinoline (12 mg) was thus obtained.

MS (ESI m/z): 209, 211 (M+H)

RT (min): 1.37

2nd Step

Ammonium chloride (19 mg) and iron powder (19 mg) were added to an ethanol solution containing 3-chloro-7-nitroquinoline (12 mg), followed by stirring at 80° C. for 2 hours. The solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=1:0 to 0:1), and 3-chloroquinolin-7-amine (7 mg) was thus obtained.

MS (ESI m/z): 179, 181 (M+H)

RT (min): 0.61

Reference Example 185

The following compound was obtained with reference to Journal of Medicinal Chemistry, 1988, vol. 31, #7, pp. 1347-1351.

2-chloro-7-nitroquinoline Reference Example 186

1st Step

Sodium methoxide (28% methanol solution) (50 mg) was added to a DMF (1 ml) solution containing 2-chloro-7-nitroquinoline (42 mg), followed by stirring at 0° C. for 5 minutes. A saturated aqueous ammonium chloride solution was added to the reaction solution, an insoluble precipitate was washed with water, and 2-methoxy-7-nitroquinoline (33 mg) was thus obtained.

2nd Step

A methanol (10 ml) solution containing 2-methoxy-7-nitroquinoline (33 mg) obtained in the 1st step was prepared and subjected to a hydrogenation reaction (60° C.; 50 bar; flow rate: 1 ml/min; 10% Pd/C) using H-cube™. Then, the solvent was distilled away under reduced pressure, and a purple solid of 2-methoxyquinolin-7-amine (28 mg) was thus obtained.

MS (ESI m/z): 175 (M+H)

RT (min): 0.55

Reference Example 187

The following compound was obtained as described in Reference Example 186.

4-methoxyquinolin-7-amine

MS (ESI m/z): 175 (M+H)

RT (min): 0.54

Reference Example 188

The following compound was obtained as described in the 1st step of Reference Example 186.

4-bromo-1-methoxyisoquinoline

MS (ESI m/z): 238, 240 (M+H)

RT (min): 1.82

Reference Example 189

The following compound was obtained as described in the 1st step of Reference Example 186.

5-bromo-1-methoxyisoquinoline

MS (ESI m/z): 238, 240 (M+H)

RT (min): 1.76

Reference Example 190

1st Step

Sodium hydride (61% in oil) (4 mg) and methoxyethanol (30 μl) were added to a DMF (1.3 ml) solution containing 2-chloro-7-nitroquinoline (30 mg) under ice cooling, followed by stirring for 0.5 hours. A saturated aqueous ammonium chloride solution was added to the reaction solution and a solid precipitate was collected by filtration.

2nd Step

A methanol (10 ml) solution containing the solid obtained in the 1st step was prepared and subjected to a hydrogenation reaction (60° C.; 50 bar; flow rate: 2 ml/min; 10% Pd/C) using H-cube™. Then, the solvent was distilled away under reduced pressure, and 2-(2-methoxyethoxy)quinolin-7-amine (24 mg) was thus obtained.

MS (ESI m/z): 219 (M+H)

RT (min): 0.64

Reference Example 191

The following compound was obtained as described in Reference Example 190.

2-((1-methoxypropan-2-yl)oxy)quinolin-7-amine

MS (ESI m/z): 233 (M+H)

RT (min): 0.72

Reference Example 192

The following compound was obtained as described in Reference Example 190.

2-(3-methoxybutoxy)-quinolin-7-amine

MS (ESI m/z): 247 (M+H)

RT (min): 0.81

Reference Example 193

The following compound was obtained as described in Reference Example 190.

2-(2-(2-ethoxyethoxy)ethoxy)-quinolin-7-amine

MS (ESI m/z): 277 (M+H)

RT (min): 0.79

Reference Example 194

The following compound was obtained as described in Reference Example 190.

2-(2-methoxyethoxy)quinolin-6-amine

MS (ESI m/z): 219 (M+H)

RT (min): 0.67

Reference Example 195

The following compound was obtained as described in Reference Example 190.

2-((1-methoxypropan-2-yl)oxy)quinolin-6-amine

MS (ESI m/z): 233 (M+H)

RT (min): 0.82

Reference Example 196

The following compound was obtained as described in Reference Example 190.

2-(3-methoxybutoxy)quinolin-6-amine

MS (ESI m/z): 247 (M+H)

RT (min): 1.68

Reference Example 197

The following compound was obtained as described in Reference Example 190.

2-(2-(2-ethoxyethoxy)ethoxy)quinolin-6-amine

MS (ESI m/z): 277 (M+H)

RT (min): 0.82

Reference Example 198

The following compound was obtained as described in the 1st step of Reference Example 190.

4-bromo-1-(2-methoxyethoxy)isoquinoline

MS (ESI m/z): 282, 284 (M+H)

RT (min): 2.25

Reference Example 199

The following compound was obtained as described in the 1st step of Reference Example 190.

4-bromo-1-(3-methoxybutoxy)isoquinoline

MS (ESI m/z): 310 (M+H)

RT (min): 2.00

Reference Example 200

The following compound was obtained as described in the 1st step of Reference Example 190.

4-bromo-1-(2-(2-ethoxyethoxy)ethoxy)isoquinoline

MS (ESI m/z): 340, 342 (M+H)

RT (min): 1.82

Reference Example 201

The following compound was obtained as described in the 1st step of Reference Example 190.

5-bromo-1-(2-methoxyethoxy)isoquinoline

MS (ESI m/z): 282, 284 (M+H)

RT (min): 1.67

Reference Example 202

The following compound was obtained as described in the 1st step of Reference Example 190.

5-bromo-1-(2-methoxypropan-2-yl)oxy)isoquinoline

MS (ESI m/z): 296, 298 (M+H)

RT (min): 1.87

Reference Example 203

The following compound was obtained as described in the 1st step of Reference Example 190.

5-bromo-1-(2-methoxypropoxy)isoquinoline

MS (ESI m/z): 209, 210 (M+H)

RT (min): 1.37

Reference Example 204

The following compound was obtained as described in the 1st step of Reference Example 190.

5-bromo-1-(2-(2-ethoxyethoxy)ethoxy)isoquinoline

MS (ESI m/z): 340, 342 (M+H)

Reference Example 205

The following compound was obtained as described in the 1st step of Reference Example 190.

4-bromo-1-((1-methoxypropan-2-yl)oxy)isoquinoline

MS (ESI m/z): 296, 298 (M+H)

RT (min): 1.93

Reference Example 206

The following compound was obtained as described in the 1st step of Reference Example 190.

6-bromo-1-isopropoxyisoquinoline

MS (ESI m/z): 266, 268 (M+H)

RT (min): 2.07

Reference Example 207

The following compound was obtained as described in the 1st step of Reference Example 190.

6-bromo-1-isobutoxyisoquinoline

MS (ESI m/z): 280, 282 (M+H)

RT (min): 2.18

Reference Example 208

The following compound was obtained as described in the 1st step of Reference Example 190.

6-bromo-1-(2-methoxyethoxy)isoquinoline

MS (ESI m/z): 282, 284 (M+H)

RT (min): 1.64

Reference Example 209

The following compound was obtained as described in the 1st step of Reference Example 190.

6-bromo-1-(2-(2-ethoxyethoxy)ethoxy)isoquinoline

MS (ESI m/z): 340, 342 (M+H)

RT (min): 1.73

Reference Example 210

The following compound was obtained as described in the 1st step of Reference Example 190.

6-bromo-1-(2-isobutoxyethoxy)isoquinoline

MS (ESI m/z): 324, 326 (M+H)

RT (min): 2.11

Reference Example 211

The following compound was obtained as described in the 1st step of Reference Example 190.

6-bromo-1-((tetrahydrofuran-2-yl)methoxy)isoquinoline

MS (ESI m/z): 308, 310 (M+H)

RT (min): 1.73

Reference Example 212

The following compound was obtained as described in Reference Example 190.

2-ethoxyquinolin-6-amine

MS (ESI m/z): 189 (M+H)

RT (min): 0.77

Reference Example 213

The following compound was obtained as described in Reference Example 190.

2-isopropoxyquinolin-6-amine

MS (ESI m/z): 203 (M+H)

RT (min): 0.92

Reference Example 214

The following compound was obtained as described in Reference Example 190.

(S)-2-(2-methylbutoxy)quinolin-6-amine

MS (ESI m/z): 231 (M+H)

RT (min): 1.34

Reference Example 215

The following compound was obtained as described in Reference Example 190.

2-(2-ethoxyethoxy)quinolin-6-amine

MS (ESI m/z): 233 (M+H)

RT (min): 0.80

Reference Example 216

The following compound was obtained as described in Reference Example 190.

2-(2-butoxyethoxy)quinolin-6-amine

MS (ESI m/z): 261 (M+H)

RT (min): 1.19

Reference Example 217

The following compound was obtained as described in Reference Example

2-(2-isobutoxyethoxy)quinolin-6-amine

MS (ESI m/z): 261 (M+H)

RT (min): 1.21

Reference Example 218

The following compound was obtained as described in Reference Example 190.

2-(2-(2-methoxyethoxy)ethoxy)quinolin-6-amine

MS (ESI m/z): 263 (M+H)

RT (min): 0.70

Reference Example 219

The following compound was obtained as described in Reference Example 190.

2-(2-(2-butoxyethoxy)ethoxy)quinolin-6-amine

MS (ESI m/z): 305 (M+H)

RT (min): 1.17

Reference Example 220

The following compound was obtained as described in Reference Example 190.

2-((tetrahydrofuran-2-yl)methoxy)quinolin-6-amine

MS (ESI m/z): 245 (M+H)

RT (min): 0.78

Reference Example 221

The following compound was obtained as described in Reference Example 190.

1-(2-((6-aminoquinolin-2-yl)oxy)ethyl)pyrrolidin-2-one

MS (ESI m/z): 272 (M+H)

RT (min): 0.64

Reference Example 222

The following compound was obtained as described in Reference Example 190.

1-(2-((6-chloroquinoxalin-2-yl)oxy)ethyl)pyrrolidin-2-one

MS (ESI m/z): 292, 294 (M+H)

RT (min): 1.25

Reference Example 223

Dibromomethane (91 mg) and cesium carbonate (380 mg) were added to a tube containing a DMF (4 ml) solution containing 5-bromopyridin-2,3-diol (100 mg) and the tube was sealed, followed by stirring at 100° C.-110° C. for 8 hours. The reaction solution was adjusted to room temperature, and water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=50:1 to 4:1), and a brown solid of 5-bromo-[1,3]dioxolo[4,5-b]pyridine (13.8 mg) was thus obtained.

MS (ESI m/z): 202, 204 (M+H)

RT (min): 1.09

Reference Example 224

The following compound was obtained as described in Reference Example 223.

7-bromo-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine

MS (ESI m/z): 216, 218 (M+H)

RT (min): 1.08

Reference Example 225

Sodium ethoxide (20% ethanol solution, 112 mg) was added to a DMF (0.5 ml) solution containing 6-bromo-1-chloroisoquinoline (40 mg), followed by stirring at room temperature for 2 hours. A saturated aqueous ammonium chloride solution was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with water and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography, and 6-bromo-1-ethoxyisoquinoline (31 mg) was thus obtained.

MS (ESI m/z): 252, 254 (M+H)

RT (min): 1.91

Reference Example 226

The following compound was obtained with reference to Chem. Abstr. 1960, p. 17397.

2-propoxyquinolin-6-amine Reference Example 227

1H-1,2,4-triazole (540 mg), cesium carbonate (1.9 g), trans-N,N′-dimethylcyclohexane-1,2-diamine (74 mg), and copper iodide (50 mg) were added to a tube containing a DMF (5 ml) solution containing 2-chloropyridin-4-amine (500 mg) and the tube was sealed, followed by stirring at 150° C. for 14.5 hours. The reaction solution was adjusted to room temperature, and water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (chloroform:methanol=1:0 to 10:1), and a brown solid of 2-(1H-1,2,4-triazol-1-yl)pyridin-4-amine (25.8 mg) was thus obtained.

MS (ESI m/z): 162 (M+H)

RT (min): 0.30

¹H-NMR (DMSO-d₆, 300 MHz) δ: 9.20 (s, 1H), 8.21 (s, 1H), 7.92 (d, 1H, J=5.1 Hz), 7.00 (d, 1H, J=1.8 Hz), 6.55 (br, 2H), 6.51 (dd, 1H, J=1.8, 5.1 Hz)

Reference Example 228

The following compound was obtained as described in Reference Example 227.

6-methoxy-5-(2H-1,2,3-triazol-2-yl)pyridin-3-amine

MS (ESI m/z): 192 (M+H)

RT (min): 0.58

¹H-NMR (CDCl₃, 300 MHz) δ: 7.87 (s, 2H), 7.77 (d, 1H, J=2.4 Hz), 7.39 (d, 1H, J=2.4 Hz), 3.98 (s, 3H), 3.53 (br, 2H)

6-methoxy-5-(1H-1,2,3-triazol-2-yl)pyridin-3-amine

MS (ESI m/z): 192 (M+H)

RT (min): 0.56

¹H-NMR (CDCl₃, 300 MHz) δ: 8.36-8.33 (m, 1H), 7.82 (s, 1H), 7.77-7.72 (m, 2H), 3.98 (s, 3H), 3.60 (br, 2H)

Reference Example 229

1st Step

Triethylamine (32 μl), n-butyl acrylate (33 μl), tri(o-toluoyl)phosphine (24 mg), and palladium acetate (5 mg) were added to a tube containing a DMF (3 ml) solution containing 3-bromo-N-methyl-5-nitropyridin-2-amine (45 mg) and the tube was sealed, followed by stirring at 100° C. for 8 hours. The reaction solution was adjusted to room temperature, and n-butyl acrylate (33 μl), tri(o-toluoyl)phosphine (24 mg), and palladium acetate (5 mg) were added again to the tube and the tube was sealed, followed by stirring at 100° C. for 9 hours. Further, the reaction solution was adjusted to room temperature, and water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=16:1 to 3:1), and a yellow solid of n-butyl 3-(2-(methylamino)-5-nitropyridin-3-yl)acrylate (44 mg) was thus obtained.

MS (ESI m/z): 280 (M+H), 278 (M−H)

RT (min): 1.62

2nd Step

5M sodium methoxide (methanol solution) (0.5 ml) was added to a methanol solution (2 ml) containing n-butyl 3-(2-(methylamino)-5-nitropyridin-3-yl)acrylate (43 mg) obtained in the 1st step, followed by reflux for 3.5 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=4:1 to 2:1), and a white solid of 1-methyl-6-nitro-1,8-naphthyridin-2(1H)-one (24 mg) was thus obtained.

MS (ESI m/z): 206 (M+H)

RT (min): 0.94

3rd Step

The following compound was obtained as described in the 3rd step of Reference Example 161.

MS (ESI m/z): 176 (M+H)

RT (min): 0.49

Reference Example 230

1st Step

Triethylamine (53 μl) and 2-methoxyethylamine (23 mg) were added to a tetrahydrofuran (2 ml) solution containing 3-bromo-2-chloro-5-nitropyridine (60 mg), followed by stirring at room temperature for 1 hour. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=6:1 to 3:1), and a light yellow solid of 3-bromo-N-(2-methoxyethyl)-5-nitropyridin-2-amine (93.5 mg) was thus obtained.

MS (ESI m/z): 276, 278 (M+H)

RT (min): 1.30

2nd, 3rd, and 4th steps

The following compounds were obtained as described in the 1st, 2nd, and 3rd steps of Reference Example 229.

Butyl 3-(2-((2-methoxyethyl)amino)-5-nitropyridin-3-yl)acrylate

MS (ESI m/z): 324 (M+H)

RT (min): 1.67

1-(2-methoxyethyl)-6-nitro-1,8-naphthyridin-2(1H)-one

MS (ESI m/z): 250 (M+H)

RT (min): 1.01

6-amino-1-(2-methoxyethyl)-1,8-naphthyridin-2(1H)-one

MS (ESI m/z): 220 (M+H)

RT (min): 0.57

Reference Example 231

Sodium hydride (61% in oil) (11 mg) was added to a DMF (0.9 ml) solution containing (5-bromopyridin-3-yl)methanol (34 mg) under ice cooling, followed by stirring for 1 hour. Then, methyl iodide (17 μl) was added, followed by stirring at room temperature for 13 hours. Thereafter, water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=4:1 to 1:1), and a light yellow solid of 3-bromo-5-(methoxymethyl)pyridine (26.5 mg) was thus obtained.

MS (ESI, m/z): 202, 204 (M+H)

RT (min): 0.97

Reference Example 232

The following compound was obtained with reference to Journal of the American Chemical Society, 2005, vol. 127, #1, pp. 74-75.

6-bromoquinolin-8-ol Reference Example 233

The following compound was obtained as described in Reference Example 231.

6-bromo-8-methoxyquinoline

MS (ESI m/z): 238, 240 (M+H)

RT (min): 1.68

Reference Example 234

The following compound was obtained as described in Reference Example 231.

6-bromo-8-(2-methoxyethoxy)quinoline

MS (ESI m/z): 281, 283 (M+H)

RT (min): 0.98

Reference Example 235

The following compound was obtained as described in Reference Example 231.

8-(benzyloxy)-6-bromoquinoline

MS (ESI m/z): 314, 316 (M+H)

RT (min): 1.49

Reference Example 236

The following compound was obtained as described in Reference Example 231.

3-((benzyloxy)methyl)-5-bromopyridine

MS (ESI, m/z): 278, 280 (M+H)

RT (min): 1.55

Reference Example 237

The following compound was obtained as described in Reference Example 231.

4-chloro-2-(methoxymethyl)pyridine

MS (ESI, m/z): 158, 160 (M+H)

RT (min): 0.84

Reference Example 238

Triethylamine (70 μl) and bis(2-bromoethyl)ether (28 μl) were added to a DMF (2 ml) solution containing 3-(5-bromopyridin-3-yl)aniline (50 mg), followed by stirring at 80° C. for 3.5 hours. Bis(2-bromoethyl)ether (30 μl) was added, followed by stirring at 80° C. for 3 hours. Bis(2-bromoethyl)ether (30 μl) was added again, followed by stirring at 80° C. for 4.5 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=10:1 to 3:1), and colorless oily matter of 4-(3-(5-bromopyridin-3-yl)phenyl)morpholine (12.3 mg) was thus obtained.

MS (ESI m/z): 319, 321 (M+H)

RT (min): 1.47

Reference Example 239

The following compound was obtained as described in Reference Example 238.

4-(4-(5-bromopyridin-3-yl)phenyl)morpholine

MS (ESI m/z): 319, 321 (M+H)

RT (min): 1.45

Reference Example 240

The following compound was obtained as described in Reference Example 231.

tert-Butyl(4-(5-bromopyridin-3-yl)phenyl)methylcarbamate

MS (ESI m/z): 363, 365 (M+H)

RT (min): 1.78

Reference Example 241

Sodium hydride (61% in oil, 14 mg) and 6-bromo-2-chloroquinoline (80 mg) were added to a DMF (0.5 ml) solution containing 1-(3-hydroxypropyl)-2-pyrrolidone (52 mg) in a nitrogen atmosphere, followed by stirring at room temperature for 6 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 0:1), and 1-(3-((6-bromoquinolin-2-yl)oxy)propyl)pyrrolidin-2-one (46 mg) was thus obtained.

MS (ESI m/z): 349, 351 (M+H)

RT (min): 1.48

Reference Example 242

The following compound was obtained as described in Reference Example 241.

3-(2-(6-bromoquinolin-2-yl)oxy)ethyl)oxazolidin-2-one

MS (ESI m/z): 337, 339 (M+H)

RT (min): 1.42

Reference Example 243

1st Step

An acetic acid (1 ml) solution containing 7-nitroquinoline (93 mg) was prepared, and N-iodosuccinimide (132 mg) was added thereto, followed by stirring at 110° C. for 1.5 hours. N-iodosuccinimide (400 mg) and acetic acid (1 ml) were added again, followed by stirring at 110° C. for 1 hour. Water and a 25% aqueous ammonia solution were added to the reaction solution, an insoluble precipitate was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 4:1), and 3-iodo-7-nitroquinoline (90 mg) was thus obtained.

MS (ESI m/z): 301 (M+H)

RT (min): 1.48

2nd Step

Pyrazole (20 mg), trans-N,N′-dimethylcyclohexane-1,2-diamine (24 μl), copper iodide (14 mg), and cesium carbonate (73 mg) were added to an N,N-dimethylpropyleneurea (2 ml) solution containing 3-iodo-7-nitroquinoline (45 mg), followed by stirring at 70° C. for 2.5 hours in a nitrogen atmosphere. Water was added to the reaction solution, an insoluble precipitate was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 0:1), and a light yellow solid of 7-nitro-3-(1H-pyrazol-1-yl)quinoline (36 mg) was thus obtained.

MS (ESI m/z): 241 (M+H)

RT (min): 1.26

3rd Step

A methanol (10 ml) solution containing 7-nitro-3-(1H-pyrazol-1-yl)quinoline (36 mg) was prepared and subjected to a hydrogenation reaction (80° C.; 50 bar; flow rate: 1 ml/min; 10% Pd/C) using H-cube™. Thereafter, the solvent was distilled away under reduced pressure, and a purple solid of 3-(1H-pyrazol-1-yl)quinolin-7-amine (20 mg) was thus obtained.

MS (ESI m/z): 211 (M+H)

RT (min): 0.61

Reference Example 244

The following compound was obtained as described in the 2nd step of Reference Example 243.

3-bromo-7-(1H-pyrazol-1-yl)quinoline

MS (ESI m/z): 274, 276 (M+H)

RT (min): 1.39

Reference Example 245

The following compound was obtained as described in the 3rd step of Reference Example 243.

1-ethyl-1H-indazol-4-amine

MS (ESI m/z): 162 (M+H)

RT (min): 0.92

Reference Example 246

1st Step

The following compound was obtained as described in Reference Example 22.

3-(2-fluorophenyl)-2-methoxy-5-nitropyridine

MS (ESI m/z): 249 (M+H)

RT (min): 1.62

2nd Step

The following compound was obtained as described in the 2nd step of Reference Example 161.

5-(2-fluorophenyl)-6-methoxypyridin-3-amine

MS (ESI m/z): 219 (M+H)

RT (min): 0.96

Reference Example 247

The following compounds were obtained as described in Reference Example 246.

3-(furan-2-yl)-2-methoxy-5-nitropyridine

MS (ESI m/z): 221 (M+H)

RT (min): 1.60

5-(furan-2-yl)-6-methoxypyridin-3-amine

MS (ESI m/z): 191 (M+H)

RT (min): 0.85

Reference Example 248

The following compounds were obtained as described in Reference Example 246.

3-(furan-3-yl)-2-methoxy-5-nitropyridine

MS (ESI m/z): 221 (M+H)

RT (min): 1.53

5-(furan-3-yl)-6-methoxypyridin-3-amine

MS (ESI m/z): 191 (M+H)

RT (min): 0.85

Reference Example 249

The following compounds were obtained as described in Reference Example 246.

3-cyclopropyl-2-methoxy-5-nitropyridine

MS (ESI m/z): 195 (M+H)

RT (min): 1.53

5-cyclopropyl-6-methoxypyridin-3-amine

MS (ESI m/z): 165 (M+H)

RT (min): 0.67

Reference Example 250

Sodium hydride (61% in oil, 30 mg) and pyrazole (68 mg) were added to a DMF (1 ml) solution containing 2,6-dichloroquinoxaline (100 mg) in a nitrogen atmosphere, followed by stirring at 100° C. for 30 minutes. Water was added to the reaction solution and an insoluble precipitate was collected by filtration, and 6-chloro-2-(1H-pyrazol-1-yl)quinoxaline (109 mg) was thus obtained.

MS (ESI m/z): 230, 232 (M+H)

RT (min): 1.62

Reference Example 251

The following compound was obtained as described in Reference Example 250.

6-bromo-2-(2H-1,2,3-triazol-2-yl)quinoline

MS (ESI m/z): 275, 277 (M+H)

RT (min): 1.49

Reference Example 252

The following compound was obtained as described in Reference Example 250.

6-bromo-2-(1H-pyrazol-1-yl)quinoline

MS (ESI m/z): 274, 276 (M+H)

RT (min): 1.79

Reference Example 253

1st and 2nd steps

The following compounds were obtained as described in the 1st and 2nd steps of Reference Example 146.

3-bromo-7-nitroquinoline

MS (ESI m/z): 253, 255 (M+H)

RT (min): 1.42

3-bromoquinolin-7-amine

MS (ESI m/z): 223, 225 (M+H)

RT (min): 0.65

3rd Step

Cesium iodide (564 mg), copper iodide (94 mg), iodine (250 mg), and isoamyl nitrate (1.23 ml) were added to a 1,2-dimethoxyethane (5.6 ml) solution containing 3-bromoquinolin-7-amine (440 mg), followed by stirring at 65° C. for 1 hour. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction solution, followed by extraction with ethyl acetate (×2). The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. The solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 10:1), and 3-bromo-7-iodoquinoline (440 mg) was thus obtained.

MS (ESI m/z): 334, 336 (M+H)

RT (min): 1.75

4th Step

The following compound was obtained as described in the 2nd step of Reference Example 243.

3-bromo-7-(2H-1,2,3-triazol-2-yl)quinoline

MS (ESI m/z): 275, 277 (M+H)

RT (min): 1.50

Reference Example 254

1st step

Pyrrolidin-2-one (129 mg), cesium carbonate (412 mg), Pd₂(dba)₃ (116 mg), and Xantphos (146 mg) were added to a 1,4-dioxane (10 ml) solution containing 2-chloro-5-nitropyridine (200 mg) in a nitrogen atmosphere, followed by stirring at 100° C. for 5 hour. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=4:1 to 2:1), and a light red solid of 1-(5-nitropyridin-2-yl)pyrrolidin-2-one (261 mg) was thus obtained.

¹H-NMR (CDCl₃, 300 MHz) δ: 9.23-9.20 (m, 1H), 8.67-8.62 (m, 1H), 8.46 (dd, 1H, J=2.8, 9.4 Hz), 4.17 (t, 2H, J=7.3 Hz), 2.73 (t, 2H, J=8.3 Hz), 2.26-2.13 (m, 2H)

2nd Step

A methanol (20 ml) solution containing 1-(5-nitropyridin-2-yl)pyrrolidin-2-one (31 mg) was prepared and subjected to a hydrogenation reaction (30° C.; 1 bar; flow rate: 1 ml/min; 10% Pd/C) using H-cube™. Then, the solvent was distilled away under reduced pressure, and a purple solid of 1-(5-aminopyridin-2-yl)pyrrolidin-2-one (29 mg) was thus obtained.

MS (ESI m/z): 178 (M+H)

RT (min): 0.38

Reference Example 255

The following compounds were obtained as described in Reference Example 254.

4-(5-nitropyridin-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one

¹H-NMR (CDCl₃, 300 MHz) δ: 9.46-9.43 (m, 1H), 8.68 (dd, 1H, J=2.8, 8.8 Hz), 7.79-7.74 (m, 1H), 7.15-7.07 (m, 2H), 6.99-6.91 (m, 1H), 6.64-6.58 (m, 1H), 4.77 (s, 2H)

4-(5-aminopyridin-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one

MS (ESI m/z): 242 (M+H)

RT (min): 0.88

Reference Example 256

The following compounds were obtained as described in Reference Example 254.

2,2-dimethyl-4-(5-nitropyridin-2-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one

¹H-NMR (CDCl₃, 300 MHz) δ: 9.49 (d, 1H, J=2.6 Hz), 8.67 (dd, 1H, J=3.0, 8.6 Hz), 7.96 (dd, 1H, J=1.7, 5.0 Hz), 7.57 (d, 1H, J=8.6 Hz), 7.02 (dd, 1H, J=5.0, 7.9 Hz), 1.66 (s, 6H)

4-(5-aminopyridin-2-yl)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one

MS (ESI m/z): 271 (M+H)

RT (min): 0.85

Reference Example 257

The following compounds were obtained as described in Reference Example 254.

4-(5-nitropyridin-2-yl)morpholin-3-one

¹H-NMR (CDCl₃, 300 MHz) δ: 9.27-9.24 (m, 1H), 8.60-8.54 (m, 1H), 8.48 (dd, 1H, J=2.6, 9.2 Hz), 4.41 (s, 2H), 4.23-4.15 (m, 2H), 4.12-4.04 (m, 2H)

4-(5-aminopyridin-2-yl)morpholin-3-one

MS (ESI, m/z): 194 (M+H)

RT (min): 0.38

Reference Example 258

Pyridin-1-ol (96 mg), cesium carbonate (412 mg), and copper iodide (50 mg) were added to a tube containing a DMF (4 ml) solution containing 3,5-dibromopyridine (200 mg) and the tube was sealed in a nitrogen atmosphere, followed by stirring at 120° C. for 11 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:5 to 1:1), and a brown solid of 5′-bromo-2H-[1,3′-bipyridine]-2-one (25.8 mg) was thus obtained.

MS (ESI m/z): 251, 253 (M+H)

RT (min): 0.76

Reference Example 259

The following compound was obtained with reference to Roczniki Chemii, 1967, vol. 41, #2, p. 279.

3-fluoro-2-methylpyridin-4-amine Reference Example 260

1st Step

A tetrahydrofuran (5 ml) solution containing 2-chloro-5-fluoropyridine (500 mg) was added to a tetrahydrofuran (20 ml) solution containing lithium-N,N-diisopropylamide (2M tetrahydrofuran/ethylbenzene/heptane solution) (2.9 ml) at −75° C. in a nitrogen atmosphere, followed by stirring at −75° C. for 3 hours. Subsequently, a tetrahydrofuran (5 ml) solution containing iodine (1.16 g) was added, followed by stirring at −75° C. for 1 hour. Then, water/tetrahydrofuran (2 ml/8 ml), water (10 ml), and 3M aqueous sodium thiosulfate were slowly added at −75° C., −50° C., and −35° C., respectively, to the reaction solution. The reaction solution was adjusted to room temperature, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Thereafter, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=20:1 to 10:1), and a white solid of 2-chloro-5-fluoro-4-iodopyridine (457 mg) was thus obtained.

¹H-NMR (CDCl₃, 300 MHz) δ: 8.14 (s, 1H), 7.77 (d, 1H, J=4.3 Hz)

2nd Step

The following compound was obtained as described in Reference Example 124.

tert-Butyl(2-chloro-5-fluoropyridin-4-yl)carbamate

MS (ESI m/z): 247, 249 (M+H)

RT (min): 1.51

3rd Step

The following compound was obtained as described in Reference Example 22.

tert-Butyl(5-fluoro-2-methylpyridin-4-yl)carbamate

MS (ESI m/z): 227 (M+H)

RT (min): 0.79

4th Step

TFA (2 ml) was added to tert-butyl(5-fluoro-2-methylpyridin-4-yl)carbamate (20 mg) obtained in the 3rd step, followed by stirring at room temperature for 1 hour. The solvent was distilled away under reduced pressure, toluene was added for azeotropic boiling (×2), and 5-fluoro-2-methylpyridin-4-amine (32 mg) was thus obtained.

MS (ESI m/z): 127 (M+H)

RT (min): 0.23

Reference Example 261

The following compounds were obtained as described in Reference Example 124 and the 4th step of Reference Example 260.

tert-Butyl(5-fluoro-2-morpholinopyridin-4-yl)carbamate

MS (ESI m/z): 298 (M+H)

RT (min): 1.08

5-fluoro-2-morpholinopyridin-4-amine

MS (ESI m/z): 198 (M+H)

RT (min): 0.40

Reference Example 262

1st and 2nd steps

The following compounds were obtained as described in the 1st and 2nd steps of Reference Example 260

2-chloro-3-fluoro-4-iodopyridine

¹H-NMR (CDCl₃, 300 MHz) δ: 7.87 (d, 1H, J=5.3 Hz), 7.66 (dd, 1H, J=4.0, 5.0 Hz) tert-Butyl(2-chloro-3-fluoropyridin-4-yl)carbamate

MS (ESI m/z): 247, 249 (M+H)

RT (min): 1.46

3rd Step

The following compound was obtained as described in Reference Example 124.

tert-Butyl(3-fluoro-2-morpholinopyridin-4-yl)carbamate

MS (ESI m/z): 298 (M+H)

RT (min): 1.21

4th Step

The following compound was obtained as described in the 4th step of Reference Example 260.

3-fluoro-2-morpholinopyridin-4-amine

MS (ESI m/z): 198 (M+H)

RT (min): 0.43

Reference Example 263

1st Step

The following compound was obtained as described in the 4th step of Reference Example 260.

2-chloro-3-fluoropyridin-4-amine

MS (ESI m/z): 147, 149 (M+H)

RT (min): 0.60

2nd Step

The following compound was obtained as described in Reference Example 22.

3-fluoro-2-phenylpyridin-4-amine

MS (ESI m/z): 189 (M+H)

RT (min): 0.61

Reference Example 264

The following compounds were obtained as described in Reference Example 263.

2-chloro-5-fluoropyridin-4-amine

MS (ESI m/z): 147, 149 (M+H)

RT (min): 0.56

5-fluoro-2-phenylpyridin-4-amine

MS (ESI m/z): 189 (M+H)

RT (min): 0.55

Reference Example 265

1st Step

The following compound was obtained as described in Reference Example 22.

4-(5-bromopyridin-3-yl)-aniline

MS (ESI m/z): 249, 251 (M+H)

RT (min): 1.02

2nd Step

The following compound was obtained as described in the 2nd step of Reference Example 2.

tert-Butyl (4-(5-bromopyridin-3-yl)phenyl)carbamate

MS (ESI m/z): 349, 351 (M+H)

RT (min): 1.71

Reference Example 266

1st Step

The following compound was obtained as described in Reference Example 22.

3-(5-bromopyridin-3-yl)aniline

MS (ESI m/z): 249, 251 (M+H)

RT (min): 1.00

2nd Step

The following compound was obtained as described in the 2nd step of Reference Example 2.

tert-Butyl(3-(5-bromopyridin-3-yl)phenyl)carbamate

MS (ESI m/z): 349, 351 (M+H)

RT (min): 1.72

3rd Step

The following compound was obtained as described in Reference Example 231.

tert-Butyl(3-(5-bromopyridin-3-yl)phenyl)(methyl)carbamate

MS (ESI m/z): 363, 365 (M+H)

RT (min): 1.77

Reference Example 268

Acetic anhydride (18 μl) was added to a tetrahydrofuran (2 ml) solution containing 3-(5-bromopyridin-3-yl)aniline (50 mg), followed by stirring at room temperature for 5.5 hours. Water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, and a white solid of N-(4-(5-bromopyridin-3-yl)phenyl)acetamide (56.6 mg) was thus obtained.

MS (ESI m/z): 291, 293 (M+H)

RT (min): 1.14

Reference Example 269

Triethylamine (70 μl) and 4-chlorobutyryl chloride (25 μl) were added to a tetrahydrofuran (2 ml) solution containing 3-(5-bromopyridin-3-yl)aniline (50 mg), followed by stirring at room temperature for 3.5 hours. Subsequently, sodium hydride (61% in oil, 12 mg) was added, followed by stirring for 3 hours. Sodium hydride (61% in oil, 12 mg) was again added, followed by stirring for 2 hours. Water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=10:1 to 3:1), and colorless oily matter of 1-(3-(5-bromopyridin-3-yl)phenyl)pyrrolidin-2-one (12.3 mg) was thus obtained.

MS (ESI m/z): 317, 319 (M+H)

RT (min): 1.28

Reference Example 270

The following compound was obtained as described in Reference Example 269.

1-(4-(5-bromopyridin-3-yl)phenyl)pyrrolidin-2-one

MS (ESI m/z): 317, 319 (M+H)

RT (min): 1.28

Reference Example 271

Potassium carbonate (83 mg) and methyl iodide (62 W) were added to an N,N-dimethylacetamide (1 ml) solution containing 3-(5-bromopyridin-3-yl)aniline (50 mg), followed by stirring at 80° C. for 4 hours. Water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=10:1 to 3:1), and a white solid of 3-(5-bromopyridin-3-yl)-N,N-dimethylaniline (7.1 mg) was thus obtained.

MS (ESI m/z): 277, 279 (M+H)

RT (min): 1.45

Reference Example 272

N-bromosuccinimide (141 mg) was added to a DMF (3 ml) solution containing 2-morpholinonicotinonitrile (100 mg), followed by stirring at 80° C. for 5 hours. The reaction solution was adjusted to room temperature. Then, aqueous saturated sodium thiosulfate solution was added, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, and then the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=10:1 to 7:3), and a light yellow solid of 5-bromo-2-morpholinonicotinonitrile (120 mg) was thus obtained.

MS (ESI m/z): 268, 270 (M+H)

RT (min): 1.37

Reference Example 273

1st Step

Potassium carbonate (87 mg) and phenol (47 mg) were added to an N,N-dimethylacetamide (1 ml) solution containing 3-bromo-2-chloro-5-nitropyridine (100 mg), followed by stirring at 70° C. for 3 hours. Acetic acid palladium (20 mg) was added in a nitrogen atmosphere, followed by stirring at 100° C. for 3.5 hours. Water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, hexane and ethyl acetate were added to the obtained residue, an insoluble precipitate was collected by filtration, and a light yellow solid of 3-nitrobenzofuro[2,3-b]pyridine (47.1 mg) was thus obtained.

MS (ESI m/z): 215 (M+H)

RT (min): 1.48

2nd Step

The following compound was obtained as described in the 2nd step of Reference Example 166.

Benzofuro[2,3-b]pyridin-3-amine

MS (ESI m/z): 185 (M+H)

RT (min): 0.94

Reference Example 274

1st Step

A dichloromethane (10 ml) solution containing 2,2-difluoroethanol (5.0 g) and triethylamine (8.44 ml) was slowly added to a dichloromethane (10 ml) solution containing trifluoromethanesulfonic anhydride (10.2 ml) at −78° C. in a nitrogen atmosphere, followed by stirring for 45 minutes. The solvent was distilled away under reduced pressure, and colorless oily matter of 2,2-difluoroethyl trifluoromethane sulfonate (9.04 g) was thus obtained.

2nd Step

Calcium carbonate (517 mg) was added to a 1,4-dioxane (2.5 ml) solution containing 2,2-difluoroethyl trifluoromethane sulfonate (642 mg) obtained in the 1st step and 5-nitroindazole (407 mg) at room temperature in a nitrogen atmosphere, followed by stirring at 100° C. for 3 hours. Ethyl acetate was added, insoluble matter was removed, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=5:1 to 1:1). Further, hexane and ethyl acetate were added and an insoluble precipitate was collected by filtration, and 1-(2,2-difluoroethyl)-5-nitro-1H-indazole (173 mg) was thus obtained.

MS (ESI m/z): 228 (M+H)

RT (min): 1.18

3rd Step

The following compound was obtained as described in the 3rd step of Reference Example 243.

1-(2,2-difluoro ethyl)-1H-indazol-5-amine Reference Example 275

1st Step

Select flour (173 mg) and acetic acid (2.5 ml) were added to an acetonitrile (2.5 ml) solution containing 5-nitroindazole (615 mg) and irradiated with microwaves (Initiator™, 150° C., 0.5 hours, 2.45 GHz, 0-240 W). The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:1), and 3-fluoro-5-nitro-1H-indazole (404 mg) was thus obtained.

2nd Step

Methyl iodide (41 μl) and potassium carbonate (114 mg) were added to a 1,4-dioxane (2.5 ml) solution containing 3-fluoro-5-nitro-1H-indazole (100 mg), followed by stirring at 100° C. for 2 hours. Ethyl acetate was added, an insoluble precipitate was collected by filtration, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:1), and 3-fluoro-1-methyl-5-nitro-1H-indazole was thus obtained.

3rd Step

The following compound was obtained as described in the 3rd step of Reference Example 243.

3-fluoro-1-methyl-1H-indazol-5-amine

MS (ESI m/z): 166 (M+H)

RT (min): 1.32

Reference Example 276

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-ethyl-3-fluoro-1H-indazol-5-amine

MS (ESI m/z): 180 (M+H)

RT (min): 0.57

Reference Example 277

The following compounds were obtained as described in the 2nd and 3rd steps of Reference Example 275.

3-fluoro-1-methyl-6-nitro-1H-indazole

MS (ESI m/z): 196 (M+H)

RT (min): 1.38

3-fluoro-1-methyl-1H-indazol-6-amine Reference Example 278

The following compounds were obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-ethyl-3-fluoro-6-nitro-1H-indazole

MS (ESI m/z): 210 (M+H)

RT (min): 1.54

1-ethyl-3-fluoro-1H-indazol-6-amine Reference Example 279

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2-fluoroethyl)-1H-indazol-5-amine

MS (ESI m/z): 180 (M+H)

RT (min): 0.28

Reference Example 280

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2-fluoroethyl)-1H-indazol-6-amine

MS (ESI m/z): 180 (M+H)

RT (min): 0.38

Reference Example 281

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

3-fluoro-1-(2-fluoroethyl)-1H-indazol-5-amine

MS (ESI m/z): 198 (M+H)

RT (min): 0.89

Reference Example 282

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

3-fluoro-1-(2-fluoroethyl)-1H-indazol-6-amine

MS (ESI m/z): 198 (M+H)

RT (min): 0.50

Reference Example 283

The following compound was obtained with reference to Journal of Organic Chemistry, 1966, vol. 31, pp. 677-681.

1,3-dimethyl-1H-indazol-5-amine Reference Example 284-1

The following compound was obtained with reference to US2009/312314 A1.

1-ethyl-3-methyl-5-nitro-1H-indazole Reference Example 284-2

The following compound was obtained as described in the 3rd step of Reference Example 275.

The following compound was obtained with reference to US2009/312314 A1.

1-ethyl-3-methyl-1H-indazol-5-amine

MS (ESI m/z): 176 (M+H)

RT (min): 0.51

Reference Example 285

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2-methoxyethyl)-3-methyl-1H-indazol-5-amine

MS (ESI m/z): 206 (M+H)

RT (min): 0.79

Reference Example 286

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2-fluoroethyl)-3-methyl-1H-indazol-5-amine

MS (ESI m/z): 194 (M+H)

RT (min): 0.45

Reference Example 287

The following compound was obtained with reference to Organic Letters, 2008, vol. 10, #5, pp. 1021-1023.

3-methyl-5-nitro-1H-indazole Reference Example 288

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2,2-difluoroethyl)-3-methyl-1H-indazol-5-amine

MS (ESI m/z): 212 (M+H)

RT (min): 0.49

Reference Example 289

The following compound was obtained with reference to Organic Letters, 2008, vol. 10, #5, pp. 1021-1023.

3-ethyl-1H-indazole Reference Example 290

1st Step

Sodium nitrate (430 mg) was added to a 50% sulfuric acid aqueous solution (2.5 ml) containing 3-ethyl-1H-indazole (730 mg) under ice cooling, followed by stirring at 80° C. for 2 hours. Water and ethyl acetate were added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 4:1), and 3-ethyl-5-nitro-1H-indazole (197 mg) was thus obtained.

2nd and 3rd Steps

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

3-ethyl-1-methyl-1H-indazol-5-amine

MS (ESI m/z): 176 (M+H)

RT (min): 0.53

Reference Example 291

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1,3-diethyl-1H-indazol-5-amine

MS (ESI m/z): 190 (M+H)

RT (min): 0.62

Reference Example 292

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

3-ethyl-1-(2-methoxyethyl)-1H-indazol-5-amine

MS (ESI m/z): 220 (M+H)

RT (min): 0.58

Reference Example 293

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

3-ethyl-1-(2-fluoroethyl)-1H-indazol-5-amine

MS (ESI m/z): 208 (M+H)

RT (min): 0.57

Reference Example 294

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2,2-difluoroethyl)-3-ethyl-1H-indazol-5-amine

MS (ESI m/z): 226 (M+H)

RT (min): 0.65

Reference Example 295

The following compound was obtained with reference to European Journal of Organic Chemistry, 2009, #19, pp. 3184-3188.

3-propyl-1H-indazole Reference Example 296

The following compound was obtained as described in Reference Example 290.

1-methyl-3-propyl-1H-indazol-5-amine

MS (ESI m/z): 190 (M+H)

RT (min): 0.62

Reference Example 297

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-ethyl-3-propyl-1H-indazol-5-amine

MS (ESI m/z): 204 (M+H)

RT (min): 0.74

Reference Example 298

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2-methoxyethyl)-3-propyl-1H-indazol-5-amine

MS (ESI m/z): 234 (M+H)

RT (min): 0.70

Reference Example 299

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2-fluoroethyl)-3-propyl-1H-indazol-5-amine

MS (ESI m/z): 222 (M+H)

RT (min): 0.69

Reference Example 300 1st Step

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2,2-difluoroethyl)-3-propyl-1H-indazol-5-amine

MS (ESI m/z): 240 (M+H)

RT (min): 0.76

Reference Example 301-1

The following compound was obtained with reference to US2008/139558 A1.

3-isopropyl-5-nitro-1H-indazole Reference Example 301-2

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

3-isopropyl-1-methyl-1H-indazol-5-amine

MS (ESI m/z): 190 (M+H)

RT (min): 0.63

Reference Example 302

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-ethyl-3-isopropyl-1H-indazol-5-amine

MS (ESI m/z): 204 (M+H)

RT (min): 0.74

Reference Example 303

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

3-isopropyl-1-(2-methoxyethyl)-1H-indazol-5-amine

MS (ESI m/z): 234 (M+H)

RT (min): 0.70

Reference Example 304

The following compound was obtained with reference to Journal of Organic Chemistry, 2008, vol. 73, #16, pp. 6441-6444.

1-cyclopropyl-5-nitro-1H-indazole Reference Example 305

A methanol (15 ml) solution containing 1-cyclopropyl-5-nitro-1H-imidazole (60 mg) was prepared and subjected to hydrogenation reaction (80° C.; 50 bar; flow rate: 2 ml/min; 10% Pd/C) using H-cube™. Thereafter, the solvent was distilled away under reduced pressure, and a purple solid of 1-cyclopropyl-1H-imidazol-5-amine (20 mg) was thus obtained.

Reference Example 306

The following compound was obtained with reference to 2009/122180 A1, 2009.

1-cyclopropyl-1H-indazol-6-amine Reference Example 307

1st Step

Cyclopropylboronic acid monohydrate (52 mg), copper acetate (55 mg), sodium carbonate (64 mg), and pyridine (24 μl) were added to a dichloroethane (1 ml) solution containing 4-nitroindazole (50 mg) in a nitrogen atmosphere, followed by stirring at 70° C. for 3 hours. Ethyl acetate was added to the reaction solution, an insoluble precipitate was removed, and the solvent was distilled away under reduced pressure. Subsequently, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:1), and 1-cyclopropyl-4-nitro-1H-indazole (30 mg) was thus obtained.

MS (ESI m/z): 204 (M+H)

RT (min): 1.37

2nd step

The following compound was obtained as described in Reference Example 305.

1-cyclopropyl-1H-indazol-4-amine

MS (ESI m/z): 174 (M+H)

RT (min): 0.87

Reference Example 308

The following compounds were obtained as described in Reference Example 307.

1-cyclopropyl-3-fluoro-5-nitro-1H-indazole

MS (ESI m/z): 222 (M+H)

RT (min): 1.46

1-cyclopropyl-3-fluoro-1H-indazol-5-amine

MS (ESI m/z): 192 (M+H)

RT (min): 0.63

Reference Example 309

The following compounds were obtained as described in Reference Example 307.

1-cyclopropyl-3-fluoro-6-nitro-1H-indazole

MS (ESI m/z): 222 (M+H)

RT (min): 1.50

1-cyclopropyl-3-fluoro-1H-indazol-6-amine

MS (ESI m/z): 192 (M+H)

RT (min): 0.97

Reference Example 311

The following compounds were obtained as described in Reference Example

1-cyclopropyl-3-methyl-5-nitro-1H-indazole

MS (ESI m/z): 218 (M+H)

RT (min): 1.36

1-cyclopropyl-3-methyl-1H-indazol-5-amine

MS (ESI m/z): 188 (M+H)

RT (min): 0.54

Reference Example 312

The following compounds were obtained as described in Reference Example 307.

1-cyclopropyl-3-ethyl-5-nitro-1H-indazole

MS (ESI m/z): 232 (M+H)

RT (min): 1.59

1-cyclopropyl-3-ethyl-1H-indazol-5-amine

MS (ESI m/z): 202 (M+H)

RT (min): 0.64

Reference Example 313

The following compounds were obtained as described in Reference Example 307.

1-cyclopropyl-5-nitro-3-propyl-1H-indazole

MS (ESI m/z): 246 (M+H)

RT (min): 1.72

1-cyclopropyl-3-propyl-1H-indazol-5-amine

MS (ESI m/z): 216 (M+H)

RT (min): 0.73

Reference Example 314

The following compounds were obtained as described in the 2nd and 3rd steps of Reference Example 275.

1,3-dimethyl-6-nitro-1H-indazole

MS (ESI m/z): 192 (M+H)

RT (min): 1.37

1,3-dimethyl-1H-indazol-6-amine

MS (ESI m/z): 162 (M+H)

RT (min): 0.52

Reference Example 315

The following compounds were obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-ethyl-3-methyl-6-nitro-1H-indazole

MS (ESI m/z): 206 (M+H)

RT (min): 1.34

1-ethyl-3-methyl-1H-indazol-6-amine

MS (ESI m/z): 176 (M+H)

RT (min): 0.60

Reference Example 316

The following compounds were obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2-methoxyethyl)-3-methyl-6-nitro-1H-indazole

MS (ESI m/z): 236 (M+H)

RT (min): 1.40

1-(2-methoxyethyl)-3-methyl-1H-indazol-6-amine

MS (ESI m/z): 206 (M+H)

RT (min): 0.58

Reference Example 317

The following compounds were obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2-fluoroethyl)-3-methyl-6-nitro-1H-indazole

MS (ESI m/z): 224 (M+H)

RT (min): 1.30

1-(2-fluoroethyl)-3-methyl-1H-indazol-6-amine

MS (ESI m/z): 194 (M+H)

RT (min): 0.59

Reference Example 318

The following compound was obtained as described in the 2nd and 3rd steps of Reference Example 275.

1-(2,2-difluoroethyl)-3-methyl-1H-indazol-6-amine

MS (ESI m/z): 212 (M+H)

RT (min): 0.75

Reference Example 319

The following compounds were obtained as described in Reference Example 275.

3-fluoro-1-(2-methoxyethyl)-4-nitro-1H-indazole

MS (ESI m/z): 240 (M+H)

RT (min): 1.39

3-fluoro-1-(2-methoxyethyl)-1H-indazol-4-amine

MS (ESI m/z): 210 (M+H)

RT (min): 0.93

Reference Example 320

The following compounds were obtained as described in Reference Example 319.

3-fluoro-5-nitro-1H-indazole

MS (ESI m/z): 182 (M+H)

RT (min): 1.30

1-(2,2-difluoroethyl)-3-fluoro-5-nitro-1H-indazole

MS (ESI m/z): 246 (M+H)

RT (min): 1.58

1-(2,2-difluoroethyl)-3-fluoro-1H-indazol-5-amine

MS (ESI m/z): 216 (M+H)

RT (min): 0.57

Reference Example 321

1st Step

2-fluoroethyltrifluoromethane sulfonate (30 μl) and potassium carbonate (31 mg) were added to a 1,4-dioxane (0.4 ml) solution containing 3-fluoro-4-nitro-1H-indazole (20 mg) in a nitrogen atmosphere, followed by stirring at 70° C. for 5 hours. Ethyl acetate was added to the reaction solution, an insoluble precipitate was removed, and the solvent was distilled away under reduced pressure. Subsequently, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 1:1), and 3-fluoro-1-(2-fluoroethyl)-4-nitro-1H-indazole (13 mg) was thus obtained.

MS (ESI m/z): 228 (M+H)

RT (min): 1.40

2nd Step

The following compound was obtained as described in Reference Example 305.

3-fluoro-1-(2-fluoroethyl)-1H-indazol-4-amine

MS (ESI m/z): 198 (M+H)

RT (min): 0.95

Reference Example 322

The following compounds were obtained as described in Reference Example 321.

1-(2,2-difluoroethyl)-3-fluoro-4-nitro-1H-indazole

MS (ESI m/z): 246 (M+H)

RT (min): 1.45

1-(2,2-difluoroethyl)-3-fluoro-1H-indazol-4-amine

MS (ESI m/z): 216 (M+H)

RT (min): 1.06

Reference Example 323

The following compounds were obtained as described in Reference Example 22 and the 1st step of Reference Example 190.

1st step

5-bromo-2′-chloro-3,4′-bipyridine

MS (ESI m/z): 269, 271, 273 (M+H)

RT (min): 1.33

2nd Step 5-bromo-2′-methoxy-3,4′-bipyridine

MS (ESI m/z): 265, 267 (M+H)

RT (min): 1.35

Reference Example 324

1st Step

Cesium carbonate (550 mg), L-proline (65 mg), and 1H-1,2,3-triazole (92 mg) were added to a dimethyl sulfoxide (3 ml) solution containing 2-hydroxy-3-iodo-5-nitropyridine (300 mg), and copper iodide (106 mg) was further added in a nitrogen atmosphere, followed by stirring at 100° C. for 3 hours. The reaction solution was adjusted to room temperature. Water and ethyl acetate were added. The pH was adjusted to pH 7 with 1M hydrochloric acid. Insoluble matter was filtered, followed by extraction with ethyl acetate (×3). The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (chloroform:methanol=1:0 to 10:1), and an orange solid of a mixture (184 mg) of 5-nitro-3-(2H-1,2,3-triazol-2-yl)pyridin-2-ol and 5-nitro-3-(1H-1,2,3-triazol-1-yl)pyridin-2-ol was thus obtained.

2nd Step

Silver carbonate (377 mg) and methyl iodide (366 W) were added to a chloroform (10 ml) solution containing the mixture of 5-nitro-3-(2H-1,2,3-triazol-2-yl)pyridin-2-ol and 5-nitro-3-(1H-1,2,3-triazol-1-yl)pyridin-2-ol (184 mg) obtained in the 1st step while shielding light, followed by reflux for 2 hours. Water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=2:5 to 2:3), and a white solid of 1-methyl-5-nitro-3-(2H-1,2,3-triazol-2-yl)pyridin-2(1H)-one (28.1 mg) and a white solid of 1-methyl-5-nitro-3-(1H-1,2,3-triazol-1-yl)pyridin-2(1H)-one (23.3 mg) were thus obtained.

3rd Step

The following compounds were obtained as described in the 3rd step of Reference Example 161.

5-Amino-1-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2(1H)-one

MS (ESI m/z): 129 (M+H)

RT (min): 0.21, 0.26

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.00 (s, 2H), 7.41 (d, 1H, J=2.4 Hz), 7.13 (d, 1H, J=2.4 Hz), 4.53 (br, 2H), 3.51 (s, 3H)

5-Amino-1-methyl-3-(1H-1,2,3-triazol-1-yl)pyridin-2(1H)-one

MS (ESI m/z): 192 (M+H)

RT (min): 0.29

¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.85-8.83 (m, 1H), 7.89-7.87 (m, 1H), 7.85 (d, 1H, J=2.7 Hz), 7.12 (d, 1H, J=2.7 Hz), 1.82 (br, 2H), 3.51 (s, 3H)

Reference Example 325

1st Step

TFA (1 ml) was added to tert-butyl(2-chloro-5-fluoropyridin-4-yl)carbamate (100 mg), followed by stirring at room temperature for 0.5 hours. The solvent was distilled away under reduced pressure. The residue was used in the next step.

2nd Step

The residue obtained in the 1st step and a sodium methoxide solution (5M methanol solution) (5 ml) were added to a tube and the tube was sealed, followed by stirring at 170° C. for 3 hours. The reaction solution was adjusted to room temperature. Sodium hydroxide (49 mg) was added, followed by stirring at 170° C. for 1 hour. The reaction solution was adjusted to room temperature, the solvent was distilled away under reduced pressure, and a saturated aqueous ammonium chloride solution was added, followed by extraction with ethyl acetate. Subsequently, the resultant was washed with saturated saline and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=4:1 to 1:1), and yellow oily matter of 3-fluoro-2-methoxypyridin-4-amine (27 mg) was thus obtained.

MS (ESI m/z): 143 (M+H)

RT (min): 0.41

Reference Example 326

The following compound was obtained as described in Reference Example 325.

2-Ethoxy-3-fluoropyridin-4-amine

MS (ESI m/z): 157 (M+H)

RT (min): 0.53

Reference Example 327

The following compound was obtained with reference to Journal of Medicinal Chemistry, 2007, vol. 50, #15, pp. 3730-3742.

4-(5-Bromo-3-methoxypyridin-2-yl)morpholine Reference Example 328

1st Step

Sodium methoxide (5M methanol solution) (0.5 ml) was added to a methanol (1 ml) solution of 2,3-dichloro-5-nitropyridine (50 mg), followed by stirring at room temperature for 1.5 hours. Water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and colorless oily matter of 3-chloro-2-methoxy-5-nitropyridine (45.8 mg) was thus obtained.

2nd Step

The following compound was obtained as described in the 2nd step of Reference Example 112.

5-Chloro-6-methoxypyridin-3-amine

MS (ESI m/z): 159, 161 (M+H)

RT (min): 0.74

Reference Example 329

1st Step

The following compound was obtained as described in Reference Example 18.

3-Chloro-5-nitro-2-(1H-pyrazol-1-yl)pyridine

MS (ESI m/z): 225, 227 (M+H)

RT (min): 1.15

2nd Step

The following compound was obtained as described in the 2nd step of Reference Example 112.

5-Chloro-6-(1H-pyrazol-1-yl)pyridin-3-amine

MS (ESI m/z): 195, 197 (M+H)

RT (min): 0.80

Reference Example 330

1st Step

The following compound was obtained as described in Reference Example 18.

Methyl 2-chloro-5-fluoro-6-(1H-pyrazol-1-yl)nicotinate

MS (ESI m/z): 256, 258 (M+H)

RT (min): 1.26

2nd Step

10% Pd/C (40 mg) and ammonium formate (210 mg) were added to a methanol (10 ml) solution containing methyl 2-chloro-5-fluoro-6-(1H-pyrazol-1-yl)nicotinate (42 mg) obtained in the 1st step, followed by stirring at 70° C. for 1.5 hours. Insoluble matter was removed and the solvent was distilled away under reduced pressure.

Methyl 5-fluoro-6-(1H-pyrazol-1-yl)nicotinate

MS (ESI m/z): 222 (M+H)

RT (min): 1.08

3rd Step

A 1M sodium hydroxide aqueous solution (1 ml) was added to a methanol/tetrahydrofuran (1 ml/1 ml) solution containing the residue obtained in the 2nd step, followed by reflux for 1.5 hours. Further, a 2M sodium hydroxide aqueous solution (1 ml) was added, followed by reflux for 0.5 hours. Insoluble matter was removed and the solvent was distilled away under reduced pressure. Water was added to the reaction solution, and the reaction solution was acidified with 1M hydrochloric acid, followed by extraction with ethyl acetate (×3). The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and colorless oily matter of 5-fluoro-6-(1H-pyrazol-1-yl)nicotinic acid (45.8 mg) was thus obtained.

MS (ESI m/z): 208 (M+H)

RT (min): 1.08

4th Step

Triethylamine (193 μl), tert-butanol (227 μl), and DPPA (525 μl) were added to a toluene (5 ml) solution containing 5-fluoro-6-(1H-pyrazol-1-yl)nicotinic acid (330 mg), followed by reflux for 3 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=10:1 to 3:1), and a white solid of tert-butyl(5-fluoro-6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamate (210 mg) was thus obtained.

MS (ESI m/z): 279 (M+H)

RT (min): 1.37

¹H-NMR (DMSO-d₆, 300 MHz) δ: 10.03 (s, 1H), 8.37 (d, 1H, J=2.1 Hz), 8.30 (d, 1H, J=2.7 Hz), 8.05 (dd, 1H, J=2.1, 12.3 Hz), 7.79 (d, 1H, J=1.2 Hz), 6.57-6.53 (m, 1H), 1.50 (s, 3H)

5th step

The following compound was obtained as described in the 2nd step of Reference Example 141.

5-Fluoro-6-(1H-pyrazol-1-yl)pyridin-3-amine

MS (ESI m/z): 179 (M+H)

RT (min): 0.71

Reference Example 331

1st Step

The following compound was obtained as described in the 1st step of Reference Example 18.

3-Iodo-5-nitro-2-(1H-pyrazol-1-yl)pyridine

MS (ESI m/z): 317 (M+H)

RT (min): 1.30

2nd Step

Iron powder (160 mg) and ammonium chloride (50 mg) were added to an ethanol solution (4 ml) containing the residue obtained in the 1st step, followed by reflux for 5 hours. Insoluble matter was removed, and water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, and a yellow solid of 5-Iodo-6-(1H-pyrazol-1-yl)pyridin-3-amine (210 mg) was thus obtained.

MS (ESI m/z): 287 (M+H)

RT (min): 0.86

3rd Step

L-proline (7 mg), cesium carbonate (60 mg), and copper iodide (12 mg) were added to a dimethyl sulfoxide (1 ml) solution containing 5-iodo-6-(1H-pyrazol-1-yl)pyridin-3-amine (35 mg) in a nitrogen atmosphere, followed by stirring at 100° C. for 5 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=5:1 to 1:1), and a yellow solid of 5,6-di(1H-pyrazol-1-yl)pyridin-3-amine (4 mg) was obtained.

MS (ESI m/z): 227 (M+H)

RT (min): 0.75

Reference Example 332

The following compounds were obtained as described in the 3rd step of Reference Example 331.

6-(1H-pyrazol-1-yl)-5-(2H-1,2,3-triazol-2-yl)pyridin-3-amine

MS (ESI m/z): 228 (M+H)

RT (min): 0.70

¹H-NMR (CDCl₃, 300 MHz) δ: 8.10-8.00 (m, 1H), 7.90-7.80 (m, 1H), 7.76 (s, 2H), 7.55-7.47 (m, 1H), 7.44-7.36 (m, 1H), 6.41-6.33 (m, 1H), 4.06 (br, 2H)

6-(1H-pyrazol-1-yl)-5-(1H-1,2,3-triazol-1-yl)pyridin-3-amine

MS (ESI m/z): 228 (M+H)

RT (min): 0.59

¹H-NMR (CDCl₃, 300 MHz) δ: 8.08 (d, 1H, J=2.7 Hz), 7.67 (d, 1H, J=1.5 Hz), 7.64-7.62 (m, 2H), 7.49 (d, 1H, J=2.7 Hz), 7.27-7.25 (m, 1H), 6.39-6.36

Reference Example 333

The following compound was obtained with reference to WO2006/95159 A1.

5-chloro-6-morpholinopyridin-3-amine

MS (ESI m/z): 214, 216 (M+H)

RT (min): 0.77

Reference Example 334

1st Step

Potassium carbonate (78 mg) and 2-oxa-6-azaspiro[3.3]heptane (30 mg) were added to a methanol/DMF (1 ml/2 ml) solution containing 2-chloro-5-nitropyridine (30 mg), followed by stirring at 80° C. for 3 hours. The reaction solution was adjusted to room temperature, and water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:1 to 1:4), and a white solid of 6-(5-nitropyridin-2-yl)-2-oxa-6-azaspiro[3.3]heptane (23 mg) was thus obtained.

MS (ESI m/z): 222 (M+H)

RT (min): 0.88

2nd Step

The following compound was obtained as described in the 1st step of Reference Example 263.

6-(2-oxa-6-azaspiro[3.3] heptane-6-yl)pyridin-3-amine

MS (ESI m/z): 192 (M+H)

RT (min): 0.30

Reference Example 335

The following compound was obtained as described in the 3rd step of Reference Example 347.

4-(4-bromo-1H-pyrrolo[2,3-c]pyridin-7-yl)morpholine

MS (ESI m/z): 282, 284 (M+H)

RT (min): 0.74

Reference Example 336

The following compound was obtained with reference to WO2007/120729 A2, 2007.

5-fluoro-6-methoxynicotinic acid Reference Example 337

1st Step

Triethylamine (267 μl), tert-butanol (230 μl), and DPPA (413 μl) were added to a toluene (5 ml) solution containing 5-fluoro-6-methoxynicotinic acid (275 mg), followed by reflux for 3 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=10:1 to 3:1), and colorless oily matter of tert-butyl(5-fluoro-6-methoxypyridin-3-yl)carbamate (279 mg) was thus obtained.

MS (ESI m/z): 243 (M+H)

RT (min): 1.46

2nd Step

The following compound was obtained as described in the 2nd step of Reference Example 141.

5-fluoro-6-methoxypyridin-3-amine

MS (ESI m/z): 143 (M+H)

RT (min): 0.56

Reference Example 338

N,N-dimethylglycine (1.27 g), copper iodide (1.88 g), potassium tert-butoxide (4.1 g), and 1H-1,2,3,-triazole (1.7 g) were added to a dimethyl sulfoxide (25 ml) solution containing 5-bromo-6-methoxypyridin-3-amine (25 g), followed by stirring at 130° C. for 2 hours. Water was added to the reaction solution, and the pH was adjusted to pH 4 with 4M hydrochloric acid, followed by extraction with ethyl acetate (×5). The resultant was dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:1), and yellow oily matter of 6-methoxy-5-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (1 g) and a light yellow solid of 6-methoxy-5-(1H-1,2,3-triazol-1-yl)pyridin-3-amine (525 mg) were thus obtained.

(Chemical data: See Reference Example 280)

Reference Example 339

1st Step

The following compound was obtained as described in the 1st step of Reference Example 190.

2-Ethoxy-3-iodo-5-nitropyridine

MS (ESI m/z): 295 (M+H)

RT (min): 1.68

2nd Step

The following compound was obtained as described in the 2nd step of Reference Example 331.

6-Ethoxy-5-iodopyridin-3-amine

MS (ESI m/z): 265 (M+H)

RT (min): 1.09

3rd Step

The following compound was obtained as described in Reference Example 337.

6-Ethoxy-5-(1H-pyrazol-1-yl)pyridin-3-amine

MS (ESI m/z): 205 (M+H)

RT (min): 0.91

Reference Example 340

The following compounds were obtained as described in Reference Example 338.

6-Ethoxy-5-(2H-1,2,3-triazol-2-yl)pyridin-3-amine

MS (ESI m/z): 206 (M+H)

RT (min): 0.75

¹H-NMR (CDCl₃, 300 MHz) δ: 7.85 (s, 2H), 7.76 (d, 1H, J=3.3 Hz), 7.34 (d, 1H, J=3.3 Hz), 4.41 (q, 2H, J=7.2 Hz), 3.51 (br, 2H), 1.36 (t, 3H, J=7.2 Hz)

6-Ethoxy-5-(1H-1,2,3-triazol-1-yl)pyridin-3-amine

MS (ESI m/z): 206 (M+H)

RT (min): 0.78

¹H-NMR (CDCl₃, 300 MHz) δ: 8.39 (s, 1H), 7.83-7.80 (m, 1H), 7.77 (d, 1H, J=2.7 Hz), 7.72 (d, 1H, J=2.7 Hz), 4.43 (q, 2H, J=7.2 Hz), 3.60 (br, 2H), 1.40 (t, 3H, J=7.2 Hz)

Reference Example 341

1st Step

The following compound was obtained as described in the 1st step of Reference Example 190.

2-Ethoxy-3-methyl-5-nitropyridine

MS (ESI m/z): 183 (M+H)

RT (min): 1.64

2nd Step

The following compound was obtained as described in the 3rd step of Reference Example 161.

6-Ethoxy-5-methylpyridin-3-amine

MS (ESI m/z): 153 (M+H)

RT (min): 0.67

Reference Example 342

The following compound was obtained as described in Reference Example 341.

1st Step 2-(Methoxyethoxy)-3-methyl-5-nitropyridine

MS (ESI m/z): 213 (M+H)

RT (min): 1.38

2nd Step 6-(Methoxyethoxy)-5-methylpyridin-3-amine

MS (ESI m/z): 183 (M+H)

RT (min): 0.58

Reference Example 343

1st Step

Cesium carbonate (75 mg) and pyrazole (12 mg) were added to an N,N-dimethylacetamide (5 ml) solution containing 6-chloro-5-methylpyridin-3-amine (12 mg), followed by reflux for 3.5 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=1:0 to 10:1), and a light yellow solid of 3-methyl-5-nitro-2-(1H-pyrazol-1-yl)pyridine (12 mg) was obtained.

MS (ESI m/z): 205 (M+H)

RT (min): 1.39

2nd Step

The following compound was obtained as described in the 3rd step of Reference Example 161.

5-Methyl-6-(1H-pyrazol-1-yl)pyridin-3-amine

MS (ESI m/z): 175 (M+H)

RT (min): 0.71

Reference Example 344

The following compounds were obtained as described in Reference Example 343.

1st Step 3-Methyl-5-nitro-2-(2H-1,2,3-triazol-2-yl)pyridine

MS (ESI m/z): 206 (M+H)

RT (min): 1.08

¹H-NMR (CDCl₃, 300 MHz) δ: 9.28 (d, 1H, J=2.7 Hz), 8.56 (d, 1H, J=2.7 Hz), 7.99 (s, 2H), 2.74 (s, 3H)

3-Methyl-5-nitro-2-(1H-1,2,3-triazol-1-yl)pyridine

MS (ESI m/z): 206 (M+H)

RT (min): 1.01

¹H-NMR (CDCl₃, 300 MHz) δ: 9.21 (d, 1H, J=2.7 Hz), 8.59 (d, 1H, J=2.7 Hz), 8.57-8.54 (m, 1H), 7.89-7.86 (m, 1H), 2.87 (s, 3H)

2nd Step 5-Methyl-6-(2H-1,2,3-triazol-1-yl)pyridin-3-amine

MS (ESI m/z): 176 (M+H)

RT (min): 0.67

5-Methyl-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine

MS (ESI m/z): 176 (M+H)

RT (min): 0.58

Reference Example 345

1st Step

Cesium carbonate (2.45 g), 1H-1,2,3-triazole (0.52 g), 2,2,6,6-tetramethylheptane-3,5-dione (0.39 ml), and copper iodide (I) (0.72 g) were added to an N-methylpyrrolidone (10 ml) solution containing 2-hydroxy-3-iodo-5-nitropyridine (1.00 g), followed by stirring at 170° C. for 30 minutes. The reaction solution was adjusted to room temperature, water was added, an insoluble precipitate was removed, and 6M hydrochloric acid (1.5 ml) and sodium chloride (10.0 g) were added, followed by extraction with ethyl acetate. Then, the resultant was washed with saturated saline and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was subjected to silica gel chromatography (n-hexane:ethyl acetate=1:1 to 1:4) to remove initial point components, and a mixture of a yellow solid of 2-hydroxy-5-nitro-3-(2H-1,2,3-triazol-2-yl)pyridine and 2-hydroxy-5-nitro-3-(1H-1,2,3-triazol-1-yl)pyridine (385 mg) was thus obtained.

2nd Step

Thionyl chloride (3.9 ml) and DMF (0.39 ml) were added to a mixture of 2-hydroxy-5-nitro-3-(2H-1,2,3-triazol-2-yl)pyridine and 2-hydroxy-5-nitro-3-(1H-1,2,3-triazol-1-yl)pyridine (385 mg), followed by stirring at 90° C. for 2 hours. The reaction solution was adjusted to room temperature, slowly added to ice water, and stirred under ice cooling for 30 minutes, followed by extraction with ethyl acetate. Then, the resultant was washed with saturated saline and dried over anhydrous sodium sulfate. The solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=9:1 to 2:1), and a yellow solid of 2-chloro-5-nitro-3-(2H-1,2,3-triazol-2-yl)pyridine (177 mg) and a yellow solid of 2-chloro-5-nitro-3-(1H-1,2,3-triazol-1-yl)pyridine (83 mg) were thus obtained.

2-Chloro-5-nitro-3-(2H-1,2,3-triazol-2-yl)pyridine

MS (ESI m/z): 226, 228 (M+H)

RT (min): 1.10

¹H-NMR (DMSO-d₆, 300 MHz) δ: 9.32 (d, 1H, J=2.5 Hz), 8.85 (d, 1H, J=2.5 Hz), 8.01 (s, 2H)

2-Chloro-5-nitro-3-(1H-1,2,3-triazol-1-yl)pyridine

MS (ESI m/z): 226, 228 (M+H)

RT (min): 0.84

¹H-NMR (DMSO-d₆, 300 MHz) δ: 9.38 (d, 1H, J=2.3 Hz), 8.90 (d, 1H, J=2.3 Hz), 8.26 (d, 1H, J=1.0 Hz), 7.97 (d, 1H, J=1.0 Hz).

Reference Example 346

The following compound was obtained as described in Reference Example 341.

2-(2-Methoxyethoxy)-5-nitro-3-(1H-1,2,3-triazol-1-yl)pyridine

MS (ESI m/z): 266 (M+H)

RT (min): 1.26

6-(2-Methoxyethoxy)-5-(1H-1,2,3-triazol-1-yl)pyridin-3-amine

MS (ESI m/z): 236 (M+H)

RT (min): 0.69

Reference Example 347

1st Step

Pyrazole (0.60 g), cesium carbonate (3.6 g), N,N-dimethylglycine (0.76 g), and copper iodide (I) (0.76 g) were added to an N,N-dimethylacetamide (20 ml) solution containing 2-hydroxy-3-iodo-5-nitropyridine (2.00 g) in a nitrogen atmosphere, followed by stirring at 90° C. for 2.5 hours. The reaction solution was adjusted to room temperature, water and ethyl acetate were added, and an insoluble precipitate was removed. The pH was adjusted to pH 2 with the addition of 6M hydrochloric acid. Then, organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure. Ethyl acetate was added to the obtained residue, a solid precipitate was collected by filtration, and a green solid of 2-hydroxy-5-nitro-3-(1H-pyrazol-1-yl)pyridine (0.35 g) was thus obtained. Thereafter, the filtrate was collected, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=3:1 to 0:1), and a light green solid of 2-hydroxy-5-nitro-3-(1H-pyrazol-1-yl)pyridine (1.02 g) was thus obtained.

MS (ESI m/z): 207 (M+H)

RT (min): 0.94

2nd Step

Thionyl chloride (6 ml) and DMF (0.1 ml) were added to 2-hydroxy-5-nitro-3-(1H-pyrazol-1-yl)pyridine (1.37 g), followed by stirring at 80° C. for 2.5 hours. The reaction solution was adjusted to room temperature and slowly added to ice water, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=5:1 to 3:1), and a yellow solid of 2-chloro-5-nitro-3-(1H-pyrazol-1-yl)pyridine (0.12 g) was thus obtained.

MS (ESI m/z): 225, 227 (M+H)

RT (min): 1.14

3rd Step

Morpholine (50 μl) was added to a tetrahydrofuran solution (1 ml) containing 2-chloro-5-nitro-3-(1H-pyrazol-1-yl)pyridine (30 mg), followed by stirring at room temperature for 2 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and a yellow solid of 2-morpholino-5-nitro-3-(1H-pyrazol-1-yl)pyridine (37 mg) was thus obtained.

MS (ESI m/z): 276 (M+H)

RT (min): 1.13

4th Step

A methanol (5 ml) solution containing 2-morpholino-5-nitro-3-(1H-pyrazol-1-yl)pyridine (37 mg) was prepared and was subjected to a hydrogenation reaction (room temperature; 1 bar; flow rate: 1 ml/min; 10% Pd/C) using H-cube™. Then, the solvent was distilled away under reduced pressure, and a white solid of 6-morpholino-5-(1H-pyrazol-1-yl)pyridin-3-amine (31 mg) was thus obtained.

MS (ESI m/z): 246 (M+H)

RT (min): 0.70

Reference Example 348

1st Step

Cesium carbonate (3.6 g), cyclopropylboronic acid.monohydrate (1.0 g), tetrakis(triphenylphosphine)palladium (0.87 g), and water (0.2 ml) were added to a 1,4-dioxane (20 ml) solution containing 2-hydroxy-3-iodo-5-nitropyridine (2.00 g) in a nitrogen atmosphere, followed by stirring for 10 hours. Then, N,N-dimethylacetamide (10 ml) was added to the reaction solution, followed by stirring at 120° C. for 7.5 hours. The reaction solution was adjusted to room temperature and the pH was adjusted to pH 2 with the addition of water and 6M hydrochloric acid, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=3:1 to 0:1), and a white solid of 2-hydroxy-5-nitro-3-cyclopropylpyridine (0.41 g) was thus obtained.

MS (ESI m/z): 181 (M+H)

RT (min): 1.04

2nd, 3rd, and 4th steps

The following compounds were obtained as described in the 2nd, 3rd, and 4th steps of Reference Example 347.

2-Chloro-5-nitro-3-(1H-pyrazol-1-yl)pyridine

MS (ESI m/z): 199, 201 (M+H)

RT (min): 1.44

2-Morpholino-5-nitro-3-cyclopropylpyridine

MS (ESI m/z): 250 (M+H)

RT (min): 1.44

6-Morpholino-5-cyclopropylpyridin-3-amine

MS (ESI m/z): 220 (M+H)

RT (min): 0.63

Reference Example 349

1st Step

Morpholine (0.5 ml) was added to a 1,4-dioxane solution (1 ml) containing 2-chloro-5-nitro-3-(2H-1,2,3-triazol-2-yl)pyridine (30 mg), followed by stirring at room temperature for 30 minutes. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and a yellow solid of 5-nitro-2-morpholino-3-(2H-1,2,3-triazol-2-yl)pyridine (33 mg) was thus obtained.

MS (ESI m/z): 277 (M+H)

RT (min): 1.15

2nd Step

A methanol (15 ml) solution containing 5-nitro-2-morpholino-3-(2H-1,2,3-triazol-2-yl)pyridine (33 mg) was prepared and was subjected to a hydrogenation reaction (room temperature; 1 bar; flow rate: 1 ml/min; 10% Pd/C) using H-cube™. Then, the solvent was distilled away under reduced pressure, and colorless oily matter of 6-morpholino-3-(2H-1,2,3-triazol-2-yl)pyridin-4-amine (30 mg) was thus obtained.

MS (ESI m/z): 247 (M+H)

RT (min): 0.60

Reference Example 350

The following compounds were obtained as described in Reference Example 349.

5-Nitro-2-morpholino-3-(1H-1,2,3-triazol-1-yl)pyridine

MS (ESI m/z): 277 (M+H)

RT (min): 0.97

6-Morpholino-3-(1H-1,2,3-triazol-1-yl)pyridin-4-amine

MS (ESI m/z): 247 (M+H)

RT (min): 0.61

Reference Example 351

The following compounds were obtained as described in Reference Example 254.

2-(Imidazol-1-yl)-5-nitropyridine

MS (ESI m/z): 191 (M+H)

RT (min): 0.48

6-(Imidazol-1-yl)-pyridin-3-amine

MS (ESI m/z): 161 (M+H)

RT (min): 0.28

Reference Example 352

The following compounds were obtained as described in Reference Example 254.

2-(2-Methylimidazol-1-yl)-5-nitropyridine

MS (ESI m/z): 205 (M+H)

RT (min): 0.44

6-(2-Methylimidazol-1-yl)-pyridin-3-amine

MS (ESI m/z): 175 (M+H)

RT (min): 0.28

Reference Example 353

The following compounds were obtained as described in Reference Example 254.

2-((Oxazolidine-2-one)-3-yl)-5-nitropyridine

MS (ESI m/z): 210 (M+H)

RT (min): 0.95

6-((Oxazolidine-2-one)-1-yl)-pyridin-3-amine

MS (ESI m/z): 180 (M+H)

RT (min): 0.36

Reference Example 354

The following compound was obtained as described in Reference Example 22.

5-(Nitrobenzene-3-yl)-pyridin-3-amine

MS (ESI m/z): 216 (M+H)

RT (min): 0.68

Reference Example 355

The following compound was obtained with reference to Synthesis, 1990, #6, pp. 499-501.

3-Bromo-2-chloro-5-nitropyridine Reference Example 356

1st Step

Sodium methoxide (28% methanol solution) (2 ml) was added to a methanol (2 ml) solution containing 3-bromo-2-chloro-5-nitropyridine (100 mg), followed by stirring at room temperature for 1 hour. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and a yellow solid of 3-bromo-2-methoxy-5-nitropyridine (96 mg) was thus obtained.

MS (ESI m/z): 233, 235 (M+H)

RT (min): 1.43

2nd Step

Morpholine (54 μl), cesium carbonate (336 mg), Pd₂(dba)₃ (57 mg), and Xantphos (72 mg) were added to a 1,4-dioxane (3 ml) solution containing 3-bromo-2-methoxy-5-nitropyridine (96 mg) in a nitrogen atmosphere, followed by stirring at 100° C. for 10 hours. The reaction solution was adjusted to room temperature, and water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=4:1 to 2:1), and a yellow solid of 2-methoxy-3-morpholino-5-nitropyridine (54 mg) was thus obtained.

MS (ESI m/z): 240 (M+H)

RT (min): 1.21

3rd Step

A methanol (15 ml) solution containing 2-methoxy-3-morpholino-5-nitropyridine (27 mg) was prepared and was subjected to a hydrogenation reaction (room temperature; 1 bar; flow rate: 1 ml/min; 10% Pd/C) using H-cube™. Then, the solvent was distilled away under reduced pressure, and colorless oily matter of 6-methoxy-5-morpholinopyridin-3-amine (28 mg) was thus obtained.

MS (ESI m/z): 210 (M+H)

RT (min): 0.53

Reference Example 357

The following compounds were obtained as described in Reference Example 356.

3-Bromo-2-ethoxy-5-nitropyridine

MS (ESI m/z): 247, 249 (M+H)

RT (min): 1.62

2-Ethoxy-3-morpholino-5-nitropyridine

MS (ESI m/z): 254 (M+H)

RT (min): 1.39

6-Ethoxy-5-morpholinopyridin-3-amine

MS (ESI m/z): 224 (M+H)

RT (min): 0.65

Reference Example 358

1st Step

2-methoxyethanol (133 μl) was added to a tetrahydrofuran solution (50 ml) containing sodium hydride (60% in oil, 51 mg) under ice cooling, followed by stirring at room temperature for 30 minutes. The reaction solution was ice-cooled again, and 3-bromo-2-chloro-5-nitropyridine (200 mg) was added, followed by stirring at room temperature for 1 hour. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=4:1 to 1:1), and a yellow solid of 2-(2-methoxyethoxy)-3-morpholino-5-nitropyridine (97 mg) was obtained.

MS (ESI, m/z): 277, 279 (M+H)

RT (min): 1.40

2nd and 3rd steps

The following compounds were obtained as described in the 2nd and 3rd steps of Reference Example 356.

2-(2-Methoxyethoxy)-3-morpholino-5-nitropyridine

MS (ESI m/z): 284 (M+H)

RT (min): 1.23

6-(2-Methoxyethoxy)-5-morpholinopyridin-3-amine

MS (ESI m/z): 254 (M+H)

RT (min): 0.58

Reference Example 359

1st Step

The following compound was obtained as described in the 1st step of Reference Example 358.

Methyl 2-chloro-5-fluoro-6-(2-methoxyethoxy)-fluoronicotinate

MS (ESI m/z): 264, 266 (M+H)

RT (min): 1.38

2nd, 3rd, 4th, and 5th steps

The following compounds were obtained as described in the 2nd, 3rd, 4th, and 5th steps of Reference Example 330.

Methyl 6-(2-methoxyethoxy)-fluoronicotinate

MS (ESI m/z): 230 (M+H)

RT (min): 1.23

6-(2-Methoxyethoxy)-5-fluoronicotinate

MS (ESI m/z): 216 (M+H)

RT (min): 0.93

tert-Butyl(5-fluoro-6-(2-methoxyethoxy)pyridin-3-yl)carbamate

MS (ESI m/z): 287 (M+H)

RT (min): 1.45

6-(2-Methoxyethoxy)-5-fluoropyridin-3-amine

MS (ESI m/z): 187 (M+H)

RT (min): 0.64

Reference Example 360

1st Step

The following compound was obtained as described in Reference Example 22.

Methyl 2-chloro-6-cyclopropyl-5-fluoronicotinate

MS (ESI m/z): 230, 232 (M+H)

RT (min): 1.62

2nd, 3rd, 4th, and 5th steps

The following compounds were obtained as described in the 2nd, 3rd, 4th, and 5th steps of Reference Example 330.

Methyl 6-cyclopropyl-5-fluoronicotinate

MS (ESI m/z): 196 (M+H)

RT (min): 1.46

6-Cyclopropyl-5-fluoronicotinic acid

MS (ESI m/z): 182 (M+H)

RT (min): 1.10

tert-Butyl(6-cyclopropyl-5-fluoropyridin-3-yl)carbamate

MS (ESI m/z): 253 (M+H)

RT (min): 1.64

6-Cyclopropyl-5-fluoropyridin-3-amine

MS (ESI m/z): 153 (M+H)

RT (min): 0.57

Reference Example 361

1st Step

The following compound was obtained as described in Reference Example 22.

Methyl 2-chloro-5-fluoro-6-vinylnicotinate

MS (ESI m/z): 216, 218 (M+H)

RT (min): 1.49

2nd, 3rd, 4th, and 5th steps

The following compounds were obtained as described in the 2nd, 3rd, 4th, and 5th steps of Reference Example 330.

Methyl 6-ethyl-5-fluoronicotinate

MS (ESI m/z): 184 (M+H)

RT (min): 1.27

6-Ethyl-5-fluoronicotinic acid

MS (ESI m/z): 170 (M+H)

RT (min): 0.93

tert-Butyl(6-ethyl-5-fluoropyridin-3-yl)carbamate

MS (ESI m/z): 241 (M+H)

RT (min): 1.48

6-Ethyl-5-fluoropyridin-3-amine

MS (ESI m/z): 141 (M+H)

RT (min): 0.46

Reference Example 362

1st Step

Cesium carbonate (338 mg), methylboronic acid (47 mg), and tetrakis(triphenylphosphine)palladium (60 mg) were added to a 1,4-dioxane (3 ml) solution containing 2,3-dichloro-5-nitropyridine (100 mg), followed by stirring at 100° C. for 6 hours. The reaction solution was adjusted to room temperature, and water was added, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and 3-chloro-2-methyl-5-nitropyridine (344 mg) was thus obtained.

2nd Step

Water (1 ml), iron powder (344 mg), and ammonium chloride (172 mg) were added to an ethanol solution (5 mL) containing the crude product (344 mg) obtained in the 1st step, followed by stirring at 90° C. for 1 hour. The reaction solution was adjusted to room temperature, water and ethyl acetate were added, and insoluble matter was removed by filtration. The obtained organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=4:1 to 1:1), and yellow oily matter of 5-chloro-6-methylpyridin-3-amine (53 mg) was thus obtained.

MS (ESI m/z): 143, 145 (M+H)

RT (min): 0.42

Reference Example 363

The following compound was obtained as described in Reference Example 362.

5-Chloro-6-ethylpyridin-3-amine

MS (ESI m/z): 157, 159 (M+H)

RT (min): 0.59

Reference Example 364

The following compound was obtained as described in Reference Example 362.

5-Chloro-6-cyclopropylpyridin-3-amine

MS (ESI m/z): 169, 171 (M+H)

RT (min): 0.75

Reference Example 365

The following compound was obtained as described in the 1st step of Reference Example 356 and the 2nd step of Reference Example 362.

5-Chloro-6-ethoxypyridin-3-amine

MS (ESI m/z): 173, 175 (M+H)

RT (min): 1.08

Reference Example 366

The following compound was obtained as described in the 1st step of Reference Example 358 and the 2nd step of Reference Example 362.

5-Chloro-6-(2-methoxyethoxy)pyridin-3-amine

MS (ESI m/z): 203, 205 (M+H)

RT (min): 0.83

Reference Example 367

1st Step

The following compound was obtained as described in the 1st step of Reference Example 358.

Methyl 2-chloro-6-ethoxy-5-fluoronicotinate

MS (ESI, m/z): 234, 236 (M+H)

RT (min): 1.58

2nd, 3rd, 4th, and 5th steps

The following compounds were obtained as described in the 2nd, 3rd, 4th, and 5th steps of Reference Example 330.

Methyl 6-ethoxy-5-fluoronicotinate

MS (ESI m/z): 200 (M+H)

RT (min): 1.44

6-Ethoxy-5-fluoronicotinic acid

MS (ESI m/z): 1.10 (M+H)

RT (min): 186

tert-Butyl(6-ethoxy-5-fluoropyridin-3-yl)carbamate

MS (ESI m/z): 257 (M+H)

RT (min): 1.59

6-Ethoxy-5-fluoropyridin-3-amine

MS (ESI m/z): 157 (M+H)

RT (min): 0.76

Reference Example 368

1st Step

The following compound was obtained as described in the 1st step of Reference Example 358.

3-Cyclopropyl-2-ethoxy-5-nitropyridine

MS (ESI m/z): 209 (M+H)

RT (min): 1.72

2nd Step

The following compound was obtained as described in the 2nd step of Reference Example 330.

6-Ethoxy-3-cyclopropylpyridin-3-amine

MS (ESI m/z): 179 (M+H)

RT (min): 0.83

Reference Example 369

The following compound was obtained as described in Reference Example 368.

1st Step 3-Cyclopropyl-2-(2-methoxyethoxy)-5-nitropyridine

MS (ESI m/z): 239 (M+H)

RT (min): 1.50

2nd Step 6-(2-Methoxyethoxy)-3-cyclopropylpyridin-3-amine

MS (ESI m/z): 209 (M+H)

RT (min): 0.73

Reference Example 370

The following compounds were obtained as described in Reference Example 368.

1st Step 2-(2-Methoxyethoxy)-5-nitro-3-(1H-pyrazol-1-yl)pyridine

MS (ESI m/z): 265 (M+H)

RT (min): 1.34

2nd Step 6-(2-Methoxyethoxy)-5-(1H-pyrazol-1-yl)pyridin-3-amine

MS (ESI m/z): 235 (M+H)

RT (min): 0.80

Reference Example 371

1st Step

Potassium hydroxide (6.45 g) and iodine (15.6 g) were added to a DMF (60 ml) solution containing 5-nitroindazole (5.0 g), followed by stirring at 65° C. for 1 hour. The reaction solution was adjusted to room temperature and poured into a saturated aqueous sodium hydrogen carbonate solution, a solid precipitate was collected by filtration, and a yellow solid of 3-iodo-5-nitro-1H-indazole (6.83 g) was thus obtained.

MS (ESI m/z): 290 (M+H)

RT (min): 1.28

2nd Step

The following compound was obtained as described in Reference Example 103.

3-Iodo-1-methyl-5-nitro-1H-indazole

MS (ESI m/z): 304 (M+H)

RT (min): 1.41

3rd Step

The following compound was obtained as described in Reference Example 338.

1-Methyl-5-nitro-3-(1H-pyrazol-1-yl)-1H-indazole

MS (ESI m/z): 244 (M+H)

RT (min): 1.41

4th Step

The following compound was obtained as described in the 2nd step of Reference Example 190.

1-Methyl-3-(1H-pyrazol-1-yl)-1H-indazol-5-amine

MS (ESI m/z): 214 (M+H)

RT (min): 1.61

Reference Example 372

1st Step

Hydrazine.monohydrate (6.38 ml) was added to an ethanol (5 ml) solution containing methyl 2-bromo-5-nitrobenzoate (3.41 g), followed by reflux for 1 hour. The reaction solution was adjusted to room temperature, water and 1M hydrochloric acid were added, and an insoluble precipitate was collected by filtration. Thus, a light brown solid of 5-nitro-1H-indazol-3-ol (1.15 g) was obtained.

MS (ESI m/z): 180 (M+H)

RT (min): 0.73

2nd Step

The following compound was obtained as described in Reference Example 103.

3-Methoxy-1-methyl-5-nitro-1H-indazole

MS (ESI m/z): 208 (M+H)

RT (min): 1.33

3rd Step

The following compound was obtained as described in the 2nd step of Reference Example 190.

3-Methoxy-1-methyl-1H-indazol-5-amine

MS (ESI m/z): 178 (M+H)

RT (min): 0.44

Reference Example 373

The following compounds were obtained as described in the 2nd and 3rd steps of Reference Example 372.

1st Step 3-Ethoxy-1-ethyl-5-nitro-1H-indazole

MS (ESI m/z): 236 (M+H)

RT (min): 1.66

2nd Step 3-Ethoxy-1-ethyl-1H-indazol-5-amine

MS (ESI m/z): 206 (M+H)

RT (min): 0.64

Reference Example 374-1

The following compound was synthesized with reference to WO2010/097248.

tert-Butyl((3R,4R)-4-aminotetrahydro-2H-pyran-3-yl)carbamate Reference Example 374-2

The following compound was synthesized with reference to WO2010/097248.

tert-Butyl((3R,4R)-4-azidotetrahydro-2H-pyran-3-yl)carbamate Reference Example 375

1st Step

TFA (1 ml) was added to a chloroform solution (1 ml) containing tert-butyl((3R,4R)-4-azidotetrahydro-2H-pyran-3-yl)carbamate (60 mg), followed by stirring at room temperature for 1 hour. The pH of the reaction solution was adjusted to pH 12 with the addition of water, chloroform, and a 5M sodium hydroxide aqueous solution. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and colorless oily matter of (3R,4R)-4-azidotetrahydro-2H-pyran-3-amine (22 mg) was thus obtained.

Reference Example 376

The following compound was synthesized with reference to WO2005/066176.

(trans)-Benzyl4-((tert-butoxycarbonyl)amino)-3-hydroxypiperidin-1-carboxylate Reference Example 377

1st Step

Triethylamine (209 μl) and methanesulfonyl chloride (93 μl) were added to a dichloromethane (5 ml) solution containing (trans)-benzyl 4-((tert-butoxycarbonyl)amino)-3-hydroxypiperidin-1-carboxylate (350 mg) under ice cooling, followed by stirring at room temperature for 5 hours. The reaction solution was ice-cooled again, and water was added, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=4:1 to 3:2), and colorless oily matter of (trans)-benzyl 4-((tert-butoxycarbonyl)amino)-3-((methylsulfonyl)oxy)piperidin-1-carboxylate (535 mg) was thus obtained.

2nd Step

Sodium acetate (204 mg) and sodium azide (161 mg) were added to a DMF (5 mL) solution containing (trans)-benzyl 4-((tert-butoxycarbonyl)amino)-3-((methylsulfonyl)oxy)piperidin-1-carboxylate (532 mg), followed by stirring at 80° C. for 4 hours. The pH of the reaction solution was adjusted to pH 12 with the addition of water and a 2M sodium hydroxide aqueous solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=4:1 to 2:1), and a white solid of (cis)-benzyl 3-azido-4-((tert-butoxycarbonyl)amino)piperidin-1-carboxylate (124 mg) was thus obtained.

3rd Step

Triphenylphosphine (172 mg) was added to a tetrahydrofuran/water (4.95/0.05 ml) solution containing (cis)-benzyl 3-azido-4-((tert-butoxycarbonyl)amino)piperidin-1-carboxylate (123 mg), followed by stirring at 100° C. for 6 hours. The pH of the reaction solution was adjusted to pH 1 with the addition of water and 2M hydrochloric acid. The reaction solution was washed with ethyl acetate. The pH of the aqueous layer was adjusted to pH 13 with the addition of a 5M sodium hydroxide aqueous solution, followed by extraction with ethyl acetate. The obtained organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and colorless oily matter of (cis)-benzyl 3-amino-4-((tert-butoxycarbonyl)amino)piperidin-1-carboxylate (61 mg) was thus obtained.

Reference Example 378

The following compounds were synthesized with reference to Reference Example 377.

(trans)-Benzyl3-((tert-butoxycarbonyl)amino)-4-((methylsulfonyl)oxy)piperidin-1-carboxylate (cis)-Benzyl4-azido-3-((tert-butoxycarbonyl)amino)piperidin-1-carboxylate (cis)-Benzyl4-amino-3-((tert-butoxycarbonyl)amino)piperidin-1-carboxylate Reference Example 379

1st Step

Triethylamine (640 mg) and methanesulfonyl chloride (470 mg) were added to a tetrahydrofuran solution (10 ml) containing (S)-tert-butyl(1-hydroxybutan-2-yl)carbamate (600 mg) in an ice bath, followed by stirring at room temperature for 1.5 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and (S)-2-((tert-butoxycarbonyl)amino)butyl methanesulfonate was thus obtained.

2nd Step

Potassium phthalimide (650 mg) was added to a DMF (10 ml) solution containing (S)-2-((tert-butoxycarbonyl)amino)butyl methanesulfonate obtained in the 1st step, followed by stirring at 70° C. for 1 hour. The reaction solution was adjusted to room temperature and added dropwise to a saturated aqueous sodium hydrogen carbonate solution (300 ml), and a solid precipitate was collected by filtration. Subsequently, the obtained solid was purified by silica gel chromatography (n-hexane:ethyl acetate=3:1), and a white solid of (S)-tert-butyl(2-((1,3-dioxoisoindolin-2-yl)butan-2-yl)carbamate (560 mg) was thus obtained.

MS (ESI m/z): 319 (M+H)

RT (min): 1.46

3rd Step

Hydrazine.monohydrate (0.076 ml) was added to an ethanol (6 ml) solution containing (S)-tert-butyl(24-(1,3-dioxoisoindolin-2-yl)butan-2-yl)carbamate (250 mg), followed by stirring at room temperature for 2 hours. The solvent was distilled away under reduced pressure, and diisopropylether was added, followed by stirring. Insoluble matter was removed. 4M hydrogen chloride/1,4-dioxane (1 ml) was added to the obtained solution, the solid precipitate was collected by filtration, and a white solid of (S)-tert-butyl(1-aminobutan-2-yl)carbamate (160 mg) was thus obtained.

MS (ESI m/z): 190 (M+H)

Reference Example 380

The following compounds were obtained as described in Reference Example 379.

(S)-tert-butyl(1-(1,3-dioxoisoindolin-2-yl)propan-2-yl)carbamate

MS (ESI m/z): 306 (M+H)

RT (min): 1.35

(S)-tert-butyl(1-aminopropan-2-yl)carbamate

MS (ESI m/z): 175 (M+H)

Reference Example 381

The following compounds were obtained as described in Reference Example 379.

(R)-tert-butyl(2-((1,3-dioxoisoindolin-2-yl)butan-2-yl)carbamate

MS (ESI m/z): 319 (M+H)

RT (min): 1.46

(R)-tert-butyl(1-aminobutan-2-yl)carbamate

MS (ESI m/z): 190 (M+H)

Reference Example 382

The following compounds were obtained as described in Reference Example 379.

(S)-tert-butyl(1-(1,3-dioxoisoindolin-2-yl)-3-methylbutan-2-yl)carbamate

MS (ESI m/z): 333 (M+H)

RT (min): 1.56

(S)-tert-butyl(1-amino-3-methylbutan-2-yl)carbamate

MS (ESI m/z): 203 (M+H)

Reference Example 383

The following compounds were obtained as described in Reference Example 379.

(S)-tert-butyl(1-(1,3-dioxoisoindolin-2-yl)-3,3-dimethylbutan-2-yl)carbamate

MS (ESI m/z): 347 (M+H)

RT (min): 1.65

(S)-tert-butyl(1-amino-3,3-dimethylbutan-2-yl)carbamate

MS (ESI m/z): 217 (M+H)

RT (min): 0.82

Reference Example 384

The following compounds were obtained as described in Reference Example 379.

(R)-tert-butyl(1-(1,3-dioxoisoindolin-2-yl)-3-methoxypropan-2-yl)carbamate

MS (ESI m/z): 335 (M+H)

RT (min): 1.35

(R)-tert-butyl(1-amino-3-methoxypropan-2-yl)carbamate

MS (ESI m/z): 205 (M+H)

Reference Example 385

The following compound was obtained as described in Reference Example 379.

(S)-tert-butyl(1-(1,3-dioxoisoindolin-2-yl)-4-methylpentan-2-yl)carbamate

MS (ESI m/z): 347 (M+H)

RT (min): 1.67

Reference Example 386

Potassium carbonate (139 mg) and 6-chloro-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile (60 mg) were added to a tube containing a 1,4-dioxane (2 ml) solution containing (S)-tert-butyl(1-amino-4-methylpentan-2-yl)carbamate (76 mg) and the tube was sealed, followed by stirring with heating at 140° C. for 13.5 hours. The reaction solution was adjusted to room temperature and an insoluble precipitate was removed. Subsequently, the solvent was distilled away under reduced pressure. The residue was purified by silica gel chromatography (hexane:ethyl acetate=1:1), and a white solid of (S)-tert-butyl(1-((5-cyano-3-fluoro-6-(quinolin-6-ylamino)pyridin-2-yl)amino)-4-methylpentan-2-yl)carbamate (50 mg) was thus obtained.

MS (ESI m/z): 479 (M+H)

RT (min): 1.39

Reference Example 387

The following compounds were obtained as described in Reference Example 379.

(S)-tert-butyl(2-(1,3-dioxoisoindolin-2-yl)-1-phenylethyl)carbamate

MS (ESI m/z): 367 (M+H)

RT (min): 1.62

(S)-tert-butyl(2-amino-1-phenylethyl)carbamate

MS (ESI m/z): 237 (M+H)

RT (min): 0.79

Reference Example 388

The following compounds were obtained as described in Reference Example 379.

(R)-tert-butyl(2-(1,3-dioxoisoindolin-2-yl)-1-(pyridin-2-yl)ethyl)carbamate

MS (ESI m/z): 368 (M+H)

RT (min): 1.35

(R)-tert-butyl(2-amino-1-(pyridin-2-yl)ethyl)carbamate

MS (ESI m/z): 238 (M+H)

RT (min): 0.67

Reference Example 389

The following compounds were obtained as described in Reference Example 379.

(S)-tert-butyl(2-(1,3-dioxoisoindolin-2-yl)-1-(pyridin-3-yl)ethyl)carbamate

MS (ESI m/z): 368 (M+H)

RT (min): 1.00

(S)-tert-butyl(2-amino-1-(pyridin-3-yl)ethyl)carbamate

MS (ESI m/z): 238 (M+H)

RT (min): 0.47

Reference Example 390

The following compounds were obtained as described in Reference Example 379.

(S)-tert-butyl (2-(1,3-dioxoisoindolin-2-yl)-1-(thiophen-3-yl)ethyl)carbamate

MS (ESI m/z): 373 (M+H)

RT (min): 1.56

(S)-tert-butyl (2-amino-1-(thiophen-3-yl)ethyl)carbamate

MS (ESI m/z): 243 (M+H)

RT (min): 0.77

Reference Example 391

The following compounds were obtained as described in Reference Example 379.

(S)-tert-butyl(1-(1,3-dioxoisoindolin-2-yl)-3-phenylpropan-2-yl)carbamate

MS (ESI m/z): 381 (M+H)

RT (min): 1.64

(S)-tert-butyl(1-amino-3-phenylpropan-2-yl)carbamate

MS (ESI m/z): 251 (M+H)

Reference Example 392

1st Step

HOBt.H₂O (353 mg), WSC.HCl (460 mg), diisopropylethylamine (986 mg), and ammonium chloride (500 mg) were added to a DMF (5 ml) solution containing 2-((tert-butoxycarbonyl)amino)-2-cyclopropyl acetic acid (500 mg) at room temperature, followed by stirring at room temperature for 3 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The resultant was dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, and a white solid of tert-butyl(2-amino-1-cyclopropyl-2-oxoethyl)carbamate (500 mg) was thus obtained.

MS (ESI m/z): 215 (M+H)

2nd Step

A borane-tetrahydrofuran complex (1.1 M tetrahydrofuran, 1.69 ml) was slowly added to a tetrahydrofuran (5 ml) solution containing tert-butyl(2-amino-1-cyclopropyl-2-oxoethyl)carbamate (200 mg), followed by reflux for 2 hours. The reaction solution was adjusted to room temperature, and methanol was slowly added to the reaction solution until foaming stopped. Further, chloroform was added, the resultant was washed with a 1M sodium hydroxide aqueous solution and saturated saline and dried over sodium sulfate, the solvent was distilled away under reduced pressure, and the residue was directly used in the subsequent reaction.

MS (ESI m/z): 201 (M+H)

Reference Example 393

The following compounds were obtained as described in Reference Example 392.

(R)-tert-butyl(3-amino-1,1,1-trifluoro-3-oxopropan-2-yl)carbamate

MS (ESI m/z): 241 (M−H)

(R)-tert-butyl (3-amino-1,1,1-trifluoropropan-2-yl)carbamate

MS (ESI m/z): 229 (M+H)

Reference Example 394

The following compound was obtained as described in Reference Example 392.

tert-butyl(1-carbamoylcyclopropyl)carbamate

MS (ESI m/z): 201 (M+H) tert-butyl(1-(aminomethyl)cyclopropyl)carbamate

MS (ESI m/z): 187 (M+H)

Reference Example 395

The following compound was obtained as described in the 1st step of Reference Example 2.

(S)-tert-butyl(2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-1-phenylethyl)carbamate

MS (ESI m/z): 391 (M+H)

RT (min): 1.71

Reference Example 396

The following compounds were obtained as described in the 1st and 2nd steps of Reference Example 379 and the 2nd step of Reference Example 97.

(R)-tert-butyl(1-(1,3-dioxoisoindolin-2-yl)propan-2-yl)carbamate

MS (ESI m/z): 306 (M+H)

RT (min): 1.35

(R)-2-(2-aminopropyl)isoindoline-1,3-dione

MS (ESI m/z): 206 (M+H)

RT (min): 0.49

Reference Example 397

The following compounds were obtained as described in Reference Example 396.

(R)-tert-butyl(1-(1,3-dioxoisoindolin-2-yl)butan-2-yl)carbamate

MS (ESI m/z): 319 (M+H)

RT (min): 1.46

(R)-2-(2-aminobutyl)isoindoline-1,3-dione

MS (ESI m/z): 219 (M+H)

RT (min): 0.59

Reference Example 398

1st Step

Potassium carbonate (146 mg) and 6-chloro-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile (63 mg) were added to a tube containing a 1,4-dioxane (2 ml) solution containing (R)-2-(2-aminobutyl)isoindoline-1,3-dione (60 mg) and the tube was sealed, followed by stirring with heating at 140° C. for 13 hours. The reaction solution was cooled, and a saturated aqueous sodium hydrogen carbonate solution was added, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure. The residue was purified by silica gel chromatography (n-hexane:ethyl acetate=3:2), and a yellow solid of (R)-6-((1-(1,3-dioxoisoindolin-2-yl)butan-2-yl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile (20 mg) was thus obtained.

MS (ESI m/z): 481 (M+H)

RT (min): 1.13

2nd Step

The following compound was obtained as described in the 3rd step of Example 379.

(R)-6-((1-aminobutan-2-yl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile

MS (ESI m/z): 351 (M+H)

RT (min): 0.68

3rd Step

The following compound was obtained as described in the 2nd step of Reference Example 2.

(R)-tert-butyl(2-((5-cyano-3-fluoro-6-(quinolin-6-ylamino)pyridin-2-yl)amino)butyl)carbamate

MS (ESI m/z): 451 (M+H)

RT (min): 1.21

Reference Example 399

The following compounds were obtained as described in Reference Example 396.

(R)-tert-butyl(1-(1,3-dioxoisoindolin-2-yl)-4-methylpentan-2-yl)carbamate

MS (ESI m/z): 347 (M+H)

RT (min): 1.65

(R)-2-(2-amino-4-methylpentyl)isoindoline-1,3-dione

MS (ESI m/z): 247 (M+H)

RT (min): 0.75

Reference Example 400

The following compounds were obtained as described in Reference Example 398.

(R)-6-((1-(1,3-dioxoisoindolin-2-yl)-4-methylpentan-2-yl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile

MS (ESI m/z): 509 (M+H)

RT (min): 1.28

(R)-6-((1-amino-4-methylpentan-2-yl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile

MS (ESI m/z): 379 (M+H)

RT (min): 0.83

(R)-tert-butyl(2-((5-cyano-3-fluoro-6-(quinolin-6-ylamino)pyridin-2-yl)amino)-4-m ethylpentyl)carbamate

MS (ESI m/z): 479 (M+H)

RT (min): 1.34

Reference Example 401

The following compounds were obtained as described in Reference Example 396.

(R)-tert-butyl(2-(1,3-dioxoisoindolin-2-yl)-1-phenylethyl)carbamate

MS (ESI m/z): 367 (M+H)

RT (min): 1.61

(R)-2-(2-amino-2-phenylethyl)isoindoline-1,3-dione

MS (ESI m/z): 267 (M+H)

RT (min): 0.73

Reference Example 402

The following compounds were obtained as described in Reference Example 398.

(R)-6-(2-(1,3-dioxoisoindolin-2-yl)-1-phenylethyl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile

MS (ESI m/z): 529 (M+H)

RT (min): 1.29

(R)-6-((2-amino-1-phenylethyl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile

MS (ESI m/z): 399 (M+H)

RT (min): 0.76

(R)-tert-butyl(2-((5-cyano-3-fluoro-6-(quinolin-6-ylamino)pyridin-2-yl)amino)-2-phenylethyl)carbamate

MS (ESI m/z): 499 (M+H)

RT (min): 1.34

Reference Example 403

The following compounds were obtained as described in Reference Example 396.

(S)-tert-butyl(2-(1,3-dioxoisoindolin-2-yl)-1-(pyridin-2-yl)ethyl)carbamate

MS (ESI m/z): 368 (M+H)

RT (min): 1.35

(S)-2-(2-amino-2-(pyridin-2-yl)ethyl)isoindoline-1,3-dione

MS (ESI m/z): 268 (M+H)

RT (min): 0.62

Reference Example 404

The following compounds were obtained as described in Reference Example 398.

(S)-6-(2-(1,3-dioxoisoindolin-2-yl)-1-(pyridin-2-yl)ethyl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile

MS (ESI m/z): 530 (M+H)

RT (min): 1.14

(S)-6-(2-amino-1-(pyridin-2-yl)ethyl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile

MS (ESI m/z): 400 (M+H)

RT (min): 0.66

(S)-tert-butyl(2-((5-cyano-3-fluoro-6-(quinolin-6-ylamino)pyridin-2-yl)amino)-2-(pyridin-2-yl)ethyl)carbamate

MS (ESI m/z): 500 (M+H)

RT (min): 1.15

Reference Example 405

1st Step

2,6-dichloro-5-fluoro-3-pyridinecarbonitrile (3.3 g) and potassium carbonate (1.1 g) were added to a DMF (5 ml) solution containing (R)-2-(2-aminopropyl)isoindoline-1,3-dione.hydrochloride (690 mg), followed by stirring with heating at 60° C. for 5.5 hours. The reaction solution was adjusted to room temperature, and a saturated aqueous sodium hydrogen carbonate solution was added, followed by extraction with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the residue was purified by silica gel chromatography (n-hexane:ethyl acetate=7:3, and a yellow solid of (R)-2-chloro-6-((1-(1,3-dioxoisoindolin-2-yl)propan-2-yl)amino)-5-fluoronicotinonitrile (300 mg) was thus obtained.

MS (ESI m/z): 359 (M+H)

RT (min.): 1.46

2nd Step

Hydrazine.monohydrate (0.124 ml) was added to an ethanol/tetrahydrofuran (5 ml/1 ml) solution containing (R)-2-chloro-6-((1-(1,3-dioxoisoindolin-2-yl)propan-2-yl)amino)-5-fluoronicotinonitrile (300 mg), followed by stirring at room temperature for 14 hours. Further, hydrazine.monohydrate (0.062 ml) was added, followed by stirring at room temperature for 8.5 hours. The solvent was distilled away under reduced pressure, chloroform was added, and insoluble matter was removed. Then, the solvent was distilled away under reduced pressure, and a yellow solid of (R)-6-((1-aminopropan-2-yl)amino)-2-chloro-5-fluoronicotinonitrile (38 mg) was thus obtained.

MS (ESI m/z): 229 (M+H)

RT (min): 0.65

3rd Step

Potassium carbonate (127 mg) and di-tert-butyl dicarbonate (220 mg) were added to a tetrahydrofuran/water (8 ml/1.5 ml) solution containing (R)-6-(1-aminopropan-2-yl)amino)-2-chloro-5-fluoronicotinonitrile (190 mg), followed by stirring at room temperature for 30 minutes. The solvent was distilled away under reduced pressure, the residue was purified by silica gel chromatography (n-hexane:ethyl acetate=2:1), and yellow oily matter of (R)-tert-butyl(2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)propyl)carbamate (160 mg) was thus obtained.

MS (ESI m/z): 329 (M+H)

RT (min): 1.54

Reference Example 406

The following compounds were obtained as described in Reference Examples 396 and 405.

(R)-tert-butyl(1-(1,3-dioxoisoindolin-2-yl)-3-methylbutan-2-yl)carbamate

MS (ESI m/z): 333 (M+H)

RT (min): 1.54

(R)-2-(2-amino-3-methylbutyl)isoindoline-1,3-dione

MS (ESI m/z): 233 (M+H)

RT (min): 0.67

(R)-2-chloro-6-((1-(1,3-dioxoisoindolin-2-yl)-3-methylbutan-2-yl)amino)-5-fluoronicotinonitrile

MS (ESI m/z): 387 (M+H)

RT (min): 1.63

(R)-6-((1-amino-3-methylbutan-2-yl)amino)-2-chloro-5-fluoronicotinonitrile

MS (ESI m/z): 257 (M+H)

RT (min): 0.88

(R)-tert-butyl(2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-3-methylbutyl)carbamate

MS (ESI m/z): 357 (M+H)

RT (min): 1.71

Reference Example 407

The following compounds were obtained as described in Reference Examples 396 and 405.

(R)-tert-butyl(1-cyclopropyl-2-(1,3-dioxoindolin-2-yl)ethyl)carbamate

MS (ESI m/z): 331 (M+H)

RT (min): 1.48

(R)-2-(2-amino-2-cyclopropylethyl)isoindoline-1,3-dione

MS (ESI m/z): 231 (M+H)

RT (min): 0.62

(R)-2-chloro-6-((1-cyclopropyl-2-(1,3-dioxoindolin-2-yl)ethyl)amino)-5-fluoronicotinonitrile

MS (ESI m/z): 385 (M+H)

RT (min): 1.57

(R)-tert-butyl(2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-2-cyclopropylethyl) carbamate

MS (ESI m/z): 355 (M+H)

RT (min): 1.64

Reference Example 408

The following compounds were obtained as described in Reference Examples 396 and 405.

(R)-2-(2-amino-3,3-dimethylbutyl)isoindoline-1,3-dione

MS (ESI m/z): 347 (M+H)

RT (min): 1.63

(R)-tert-butyl(1-(1,3-dioxoindolin-2-yl)-3,3-dimethylbutan-2-yl)carbamate

MS (ESI m/z): 247 (M+H)

RT (min): 0.73

(R)-2-chloro-6-((1-(1,3-dioxoindolin-2-yl)-3,3-dimethylbutan-2-yl)amino)-5-fluoro nicotinonitrile

MS (ESI m/z): 401 (M+H)

RT (min): 1.70

(R)-6-((1-amino-3,3-dimethylbutan-2-yl)amino)-2-chloro-5-fluoronicotinonitrile

MS (ESI m/z): 271 (M+H)

RT (min): 0.97

(R)-tert-butyl(24-(6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-3,3-dimethylbutyl) carbamate

MS (ESI m/z): 371 (M+H)

RT (min): 1.78

Reference Example 409

The following compounds were obtained as described in Reference Examples 396 and 405.

(R)-tert-butyl(1-hydroxypentan-2-yl)carbamate

MS (ESI m/z): 333 (M+H)

RT (min): 1.56

(R)-2-(2-aminopentyl)isoindoline-1,3-dione

MS (ESI m/z): 233 (M+H)

RT (min): 0.64

(R)-2-chloro-6-((1-(1,3-dioxoindolin-2-yl)pentan-2-yl)amino)-5-fluoronicotinonitrile

MS (ESI m/z): 387 (M+H)

RT (min): 1.65

(R)-6-((1-aminopentan-2-yl)amino)-2-chloro-5-fluoronicotinonitrile

MS (ESI m/z): 257 (M+H)

RT (min): 0.86

(R)-tert-butyl(2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)pentyl)carbamate

MS (ESI m/z): 357 (M+H)

RT (min): 1.73

Reference Example 410

The following compounds were obtained as described in Reference Examples 396 and 405.

(R)-2-chloro-6-((1-(1,3-dioxoindolin-2-yl)hexan-2-yl)amino)-5-fluoronicotinonitrile

MS (ESI m/z): 401 (M+H)

RT (min): 1.79

(R)-6-((1-aminohexan-2-yl)amino)-2-chloro-5-fluoronicotinonitrile

MS (ESI m/z): 271 (M+H)

RT (min): 1.02

(R)-tert-butyl(24-(6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)hexyl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.27 (d, 1H, J=9.3 Hz), 5.90 (d, 1H, J=7.3 Hz), 4.79 (br, 1H), 4.30-4.13 (m, 1H), 3.45-3.26 (m, 2H), 1.51-1.28 (m, 15H), 0.99-0.80 (m, 3H)

MS (ESI m/z): 371 (M+H)

RT (min): 1.83

Reference Example 411

The following compounds were obtained as described in Reference Examples 396 and 405.

(R)-tert-butyl(1-(1,3-dioxoisoindolin-2-yl)-5,5,5-trifluoropentan-2-yl)carbamate

MS (ESI m/z): 387 (M+H)

RT (min): 1.58

(R)-2-chloro-6-((1-(1,3-dioxoindolin-2-yl)-5,5,5-trifluoropentan-2-yl)amino)-5-fluoronicotinonitrile

MS (ESI m/z): 441 (M+H)

RT (min): 1.64

(R)-tert-butyl(2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-5,5,5-trifluoropentyl)carbamate

MS (ESI m/z): 412 (M+H)

RT (min): 1.72

Reference Example 412

The following compounds were obtained as described in Reference Examples 396 and 405.

(R)-tert-butyl(1-(1,3-dioxoindolin-2-yl)-4-methylpentan-2-yl)carbamate

MS (ESI m/z): 347 (M+H)

RT (min): 1.65

(R)-2-(2-amino-4-methylpentyl)isoindoline-1,3-dione

MS (ESI m/z): 247 (M+H)

RT (min): 0.75

(R)-2-chloro-6-((1-(1,3-dioxoindolin-2-yl)-4-methylpentan-2-yl)amino)-5-fluoronicotinonitrile

MS (ESI m/z): 401 (M+H)

RT (min): 1.73

(R)-6-(1-amino-4-methylpentan-2-yl)amino)-2-chloro-5-fluoronicotinonitrile

MS (ESI m/z): 271 (M+H)

RT (min): 0.96

(R)-tert-butyl(2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-4-methylpentyl)carbarnate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.27 (d, 1H, J=9.3 Hz), 5.74 (d, 1H, J=5.9 Hz), 4.79 (br, 1H), 4.42-4.24 (m, 1H), 3.42-3.22 (m, 2H), 1.72-1.30 (m, 12H), 1.00-0.92 (m, 6H)

MS (ESI m/z): 371 (M+H)

RT (min): 1.81

Reference Example 413

The following compounds were obtained as described in Reference Examples 396 and 405.

(S)-tert-butyl(1-(1,3-dioxoindolin-2-yl)-4-methylpentan-2-yl)carbamate

MS (ESI m/z): 347 (M+H)

RT (min): 1.67

(S)-2-(2-amino-4-methylpentyl)isoindoline-1,3-dione

MS (ESI m/z): 247 (M+H)

RT (min): 0.76

(S)-2-chloro-6-((1-(1,3-dioxoindolin-2-yl)-4-methylpentan-2-yl)amino)-5-fluoronicotinonitrile

MS (ESI m/z): 401 (M+H)

RT (min): 1.73

(S)-6-((1-amino-4-methylpentan-2-yl)amino)-2-chloro-5-fluoronicotinonitrile

MS (ESI m/z): 271 (M+H)

RT (min): 0.98

(S)-tert-butyl(2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-4-methylpentyl)carbamate

MS (ESI m/z): 371 (M+H)

RT (min): 1.81

Reference Example 414

The following compounds were obtained as described in Reference Examples 396 and 405.

(R)-tert-butyl(1-cyclopropyl-3-(1,3-dioxoindolin-2-yl)propan-2-yl)carbamate

MS (ESI m/z): 345 (M+H)

RT (min): 1.57

(R)-2-(2-amino-3-cyclopropylpropyl)isoindolin-1,3-dione

MS (ESI m/z): 245 (M+H)

RT (min): 0.68

(R)-2-chloro-6-((1-cyclopropyl-3-(1,3-dioxoindolin-2-yl)propan-2-yl)amino)-5-fluoronicotinonitrile

MS (ESI m/z): 399 (M+H)

RT (min): 1.66

(R)-tert-butyl(2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-3-cyclopropylprop yl)carbamate

MS (ESI m/z): 369 (M+H)

RT (min): 1.73

Reference Example 415

The following compounds were obtained as described in Reference Examples 396 and 405.

(R)-tert-butyl(2-(1,3-dioxoindolin-2-yl)-1-phenylethyl)carbamate

MS (ESI m/z): 367 (M+H)

RT (min): 1.61

(R)-2-(2-amino-2-phenylethyl)isoindolin-1,3-dione

MS (ESI m/z): 267 (M+H)

RT (min): 0.73

(R)-2-chloro-6-((2-(1,3-dioxoindolin-2-yl)-1-phenylethyl)amino)-5-fluoronicotinonitrile

MS (ESI m/z): 421 (M+H)

RT (min): 1.68

(R)-6-((2-amino-1-phenylethyl)amino)-2-chloro-5-fluoronicotinonitrile

MS (ESI m/z): 291 (M+H)

RT (min): 0.93

(R)-tert-butyl(2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-2-phenylethyl)carbamate

MS (ESI m/z): 391 (M+H)

RT (min): 1.72

Reference Example 416

The following compounds were obtained as described in Reference Examples 396 and 405.

tert-Butyl(1-((1,3-dioxoindolin-2-yl)methyl)cyclopropyl)carbamate

MS (ESI m/z): 317 (M+H)

RT (min): 1.39

2-((1-aminocyclopropyl)methyl)isoindoline-1,3-dione

MS (ESI m/z): 217 (M+H)

RT (min): 0.58

2-chloro-6-((1-((1,3-dioxoindolin-2-yl)methyl)cyclopropyl)amino)-5-fluoronicotinonitrile

MS (ESI m/z): 371 (M+H)

RT (min): 1.52

tert-Butyl((1-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)cyclopropyl)methyl)carbamate

MS (ESI m/z): 341 (M+H)

RT (min): 1.53

Reference Example 417

1st Step

n-Propylmagnesium bromide (2M tetrahydrofuran solution) (100 ml) was added dropwise to a tetrahydrofuran solution (50 ml) containing (S)-tert-butyl(1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate (5 g) for 30 minutes under water cooling, followed by stirring at room temperature for 5 hours. The reaction solution was ice-cooled and added dropwise to 1M hydrochloric acid, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, the obtained solid was purified by silica gel chromatography (n-hexane:ethyl acetate=4:1), and yellow oily matter of (S)-tert-butyl(3-oxohexan-2-yl)carbamate (3.7 g) was thus obtained.

MS (ESI m/z): 216 (M+H)

RT (min): 1.37

2nd Step

Sodium borohydride (3.7 g) was added in divided portions to a methanol/isopropanol (30 ml/30 ml) solution containing (S)-tert-butyl(3-oxohexan-2-yl)carbamate (17.5 g) at room temperature, followed by stirring for 1 hour. The solvent was distilled away under reduced pressure, and water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and a white solid of tert-butyl((2S)-3-hydroxyhexan-2-yl)carbamate (17 g) was obtained.

MS (ESI m/z): 218 (M+H)

RT (min): 1.27

3rd Step

4-nitrobenzoate (16.3 g), triphenylphosphine (32 g), and diisopropyl azodicarboxylate (40% toluene solution) (64 ml) were added dropwise to a tetrahydrofuran (50 ml) solution containing tert-butyl((2S)-3-hydroxyhexan-2-yl)carbamate (17 g) for 30 minutes, followed by stirring at room temperature for 14 hours. The solvent was distilled away from the reaction solution under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=5.5:1), and a yellow solid of (2S)-2-((tert-butoxycarbonyl)amino)hexane-3-yl 4-nitrobenzoate (17 g) was thus obtained.

MS (ESI m/z): 367 (M+H)

RT (min): 1.86

4th Step

A 1M lithium hydroxide aqueous solution (60 ml) was added to a tetrahydrofuran/methanol (50 ml/100 ml) solution containing (2S)-2-((tert-butoxycarbonyl)amino)hexane-3-yl 4-nitrobenzoate (17 g) at room temperature, followed by stirring for 30 minutes. The solvent was distilled away under reduced pressure, and water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with a saturated aqueous sodium hydrogen carbonate solution and saturated saline and dried over anhydrous sodium sulfate. The solvent was distilled away under reduced pressure, and colorless oily matter of tert-butyl((2S)-3-hydroxyhexan-2-yl)carbamate (9 g) was thus obtained.

MS (ESI m/z): 218 (M+H)

RT (min): 1.27

5th step

Phthalimide (8.2 g), triphenylphosphine (18 g), and diisopropyl azodicarboxylate (40% toluene solution) (37 ml) were added dropwise to a tetrahydrofuran (50 ml) solution containing tert-butyl((2S)-3-hydroxyhexan-2-yl)carbamate (17 g) for 30 minutes, followed by stirring at room temperature for 13.5 hours. The solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=5.5:1 and hexane:acetone=9:1), and yellow oily matter of tert-butyl((2S,3R)-3-(1,3-dioxoindoline-2-yl)hexan-2-yl)carbamate (6 g) was thus obtained.

¹H-NMR (CDCl₃, 300 MHz) δ: 7.88-7.79 (m, 2H), 7.76-7.65 (m, 2H), 4.62-4.42 (m, 1H), 4.33-4.00 (m, 2H), 2.40-2.20 (m, 1H), 1.81-1.62 (m, 1H), 1.44 (s, 9H), 1.35-1.20 (m, 2H), 1.11 (d, 3H, J=6.6 Hz), 0.89 (t, 3H, J=7.3 Hz)

MS (ESI m/z): 347 (M+H)

RT (min): 1.70

6th step

Hydrazine.monohydrate (2.6 g) was added to an ethanol (20 ml) solution containing tert-butyl((2S,3R)-3-(1,3-dioxoindolin-2-yl)hexan-2-yl)carbamate (6 g), followed by stirring at 80° C. for 6 hours. Then, the solvent was distilled away under reduced pressure, chloroform was added, and insoluble matter was removed. Further, the solvent was distilled away under reduced pressure, and tert-butyl((2S,3R)-3-aminohexan-2-yl)carbamate (6 g) was thus obtained.

MS (ESI m/z): 217 (M+H)

RT (min): 0.79

7th step

Potassium carbonate (4.8 g) and 2,6-dichloro-5-fluoro-3-pyridinecarbonitrile (3.3 g) were added to a DMF (10 ml) solution containing tert-butyl((2S,3R)-3-aminohexan-2-yl)carbamate (6 g), followed by stirring at 60° C. for 1 hour. Water was added, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate. The solvent was distilled away under reduced pressure, the residue was purified by silica gel chromatography (n-hexane:ethyl acetate=9:1→4.5:1), and orange oily matter of tert-butyl((2S,3R)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)hexan-2-yl)carbamate (3.8 g) was thus obtained.

¹H-NMR (CDCl₃, 300 MHz) δ: 7.29 (d, 1H, J=9.3 Hz), 5.76 (d, 1H, J=7.3 Hz), 4.67 (d, 1H, J=6.6 Hz), 4.36-4.20 (m, 1H), 3.96-3.80 (m, 1H), 1.70-1.29 (m, 13H), 1.17 (d, 3H, J=6.6 Hz), 0.94 (t, 3H, J=7.3 Hz)

MS (ESI m/z): 371 (M+H)

RT (min): 1.78

Reference Example 418

The following compounds were obtained with reference to Tetrahedron: Asymmetry, Vol. 8, No, 14, pp. 2381-2401, 1997.

tert-Butyl((2S,3R)-3-aminobutan-2-yl)carbamate

MS (ESI m/z): 189 (M+H)

tert-Butyl((2S,3S)-3-aminobutan-2-yl)carbamate

MS (ESI m/z): 189 (M+H)

RT (min): 0.62

Reference Example 419

The following compound was obtained as described in the 7th step of Reference Example 417.

tert-Butyl((2S,3R)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)butan-2-yl)carbamate

MS (ESI m/z): 343 (M+H)

Reference Example 420

The following compound was obtained as described in the 7th step of Reference Example 417.

tert-Butyl((2S,3S)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)butan-2-yl)carbamate

MS (ESI m/z): 343 (M+H)

RT (min): 1.63

Reference Example 421

The following compound was obtained as described in Reference Example 417.

tert-Butyl((2S)-3-hydroxypentan-2-yl)carbamate

MS (ESI m/z): 204 (M+H)

RT (min): 1.12

(2S)-2-((tert-butoxycarbonyl)amino)pentan-3-yl 4-nitrobenzoate

MS (ESI m/z): 353 (M+H)

RT (min): 1.75

tert-Butyl((2S)-3-hydroxypentan-2-yl)carbamate

MS (ESI m/z): 204 (M+H)

RT (min): 1.13

tert-Butyl((2S,3R)-3-(1,3-dioxoindoline-2-yl)pentan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.84 (dd, 2H, J=3.3, 5.4 Hz), 7.72 (dd, 2H, J=3.3, 5.4 Hz), 4.60-4.50 (m, 1H), 4.35-4.20 (m, 1H), 4.10-3.95 (m, 1H), 2.38-2.17 (m, 1H), 1.93-1.80 (m, 1H), 1.43 (s, 9H), 1.11 (d, 3H, J=6.6 Hz), 0.86 (d, 3H, J=7.3 Hz)

MS (ESI m/z): 333 (M+H)

RT (min): 1.56

tert-Butyl((2S,3R)-3-aminopentan-2-yl)carbamate

MS (ESI m/z): 203 (M+H)

RT (min): 0.69

tert-Butyl((2S,3R)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)pentan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.29 (d, 1H, J=9.9 Hz), 5.76 (d, 1H, J=6.6 Hz), 4.68 (d, 1H, J=6.6 Hz), 4.26-4.14 (m, 1H), 3.98-3.84 (m, 1H), 1.80-1.62 (m, 1H), 1.49-1.36 (m, 10H), 1.17 (d, 3H, J=7.2 Hz), 0.97 (t, 3H, J=7.7 Hz)

MS (ESI m/z): 357 (M+H)

RT (min): 1.67

Reference Example 422

The following compounds were obtained as described in Reference Example 417.

tert-Butyl((2S,3S)-3-(1,3-dioxoindolin-2-yl)pentan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.85 (dd, 211, J=3.3, 5.4 Hz), 7.73 (dd, 2H, J=3.3, 5.4 Hz), 5.50 (d, 1H, J=9.3 Hz), 4.12-4.09 (m, 2H), 2.19-2.03 (m, 1H), 1.87-1.73 (m, 1H), 1.31 (s, 9H), 1.12 (d, 3H, J=6.6 Hz), 0.87 (d, 3H, J=7.3 Hz)

MS (ESI m/z): 333 (M+H)

RT (min): 1.56

tert-Butyl((2S,3S)-3-aminopentan-2-yl)carbamate

MS (ESI m/z): 203 (M+H)

RT (min): 0.67

tert-Butyl((2S,3S)-3-(6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)pentan-2-yl)carbamate

MS (ESI m/z): 357 (M+H)

RT (min): 1.72

Reference Example 423

The following compound was obtained as described in Reference Example 417.

tert-Butyl((2S)-1-cyclopropyl-1-hydroxypropan-2-yl)carbamate

MS (ESI m/z): 216 (M+H)

RT (min): 1.14

(2S)-2-((tert-butoxycarbonyl)amino)-1-cyclopropylpropyl 4-nitrobenzoate

MS (ESI m/z): 365 (M+H)

RT (min): 1.76

tert-Butyl((2S)-1-cyclopropyl-1-hydroxypropan-2-yl)carbamate

MS (ESI m/z): 216 (M+H)

RT (min): 1.14

tert-Butyl((1R,2S)-1-cyclopropyl-1-(1,3-dioxoindolin-2-yl)propan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.87-7.68 (m, 4H), 4.62 (br, 1H), 4.45-4.28 (m, 1H), 3.31 (dd, 1H, J=10.7, 6.8 Hz), 2.25-1.75 (m, 1H), 1.40 (s, 9H), 1.18 (t, 3H, J=6.9 Hz), 0.85-0.72 (m, 1H), 0.52-0.38 (m, 2H), 0.16-0.04 (m, 1H)

MS (ESI m/z): 345 (M+H)

RT (min): 1.60

tert-Butyl((1R,2S)-1-(6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-1-cyclopropyl propan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.32-7.28 (m, 1H), 6.20 (br, 1H), 4.90-4.74 (m, 1H), 4.12-3.98 (m, 1H), 3.68-3.50 (m, 1H), 1.44 (s, 9H), 1.27 (t, 3H, J=3.3 Hz), 0.98-0.85 (m, 1H), 0.73-0.40 (m, 4H)

MS (ESI m/z): 369 (M+H)

RT (min): 1.72

Reference Example 424

The following compounds were obtained as described in Reference Example 417.

(2S)-2-((tert-butoxycarbonyl)amino)-1-cyclobutylpropyl 4-nitrobenzoate

MS (ESI m/z): 379 (M+H)

RT (min): 1.91

tert-Butyl((1R,2S)-1-cyclobutyl-1-(1,3-dioxoisoindoline-2-yl)propan-2-yl)carbamate

MS (ESI m/z): 359 (M+H)

RT (min): 1.71

tert-Butyl((1R,2S)-1-amino-1-cyclobutylpropan-2-yl)carbamate

MS (ESI m/z): 229 (M+H)

RT (min): 0.85

tert-Butyl((1R,2S)-1-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-1-cyclobutylpropan-2-yl)carbamate

MS (ESI m/z): 384 (M+H)

RT (min): 1.83

Reference Example 425

The following compounds were obtained as described in Reference Example 417.

tert-Butyl((2S)-4-cyclopropyl-3-hydroxybutan-2-yl)carbamate

MS (ESI m/z): 230 (M+H)

RT (min): 1.32

(3S)-3-((tert-butoxycarbonyl)amino)-1-cyclopropylbutan-2-yl) 4-nitrobenzoate

MS (ESI m/z): 379 (M+H)

RT (min): 1.89

tert-Butyl((2S)-4-cyclopropyl-3-hydroxybutan-2-yl)carbamate

MS (ESI m/z): 230 (M+H)

RT (min): 1.32

tert-Butyl((2S,3R)-4-cyclopropyl-3-(1,3-dioxoindolin-2-yl)butan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.87-7.69 (m, 4H), 5.81-5.66 (m, 1H), 5.00-4.82 (m, 2H), 4.58-4.46 (br, 1H), 4.33-4.06 (m, 2H), 2.55-1.80 (m, 2H), 1.44 (s, 9H), 1.34-1.26 (m, 2H), 1.11 (d, 3H, J=6.6 Hz)

MS (ESI m/z): 359 (M+H)

RT (min): 1.70

tert-Butyl((2S,3R)-3-amino-4-cyclopropylbutan-2-yl)carbamate

MS (ESI m/z): 229 (M+H)

RT (min): 0.89

tert-Butyl((2S,3R)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-4-cyclopropyl butan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.29 (d, 1H, J=9.9 Hz), 5.94-5.74 (m, 1H), 5.06-4.95 (m, 2H), 4.62 (br, 1H), 4.34-4.25 (m, 1H), 3.96-3.87 (m, 1H), 2.17-2.08 (m, 2H), 1.78-1.67 (m, 1H), 1.55-1.46 (m, 2H), 1.44 (s, 9H), 1.18 (d, 3H, J=7.3 Hz)

MS (ESI m/z): 383 (M+H)

RT (min): 1.77

Reference Example 426

The following compounds were obtained as described in Reference Example 417.

(S)-tert-butyl(3-oxoheptan-2-yl)carbamate

MS (ESI m/z): 230 (M+H)

RT (min): 1.53

tert-Butyl((2S)-3-hydroxyheptane-2-yl)carbamate

MS (ESI m/z): 232 (M+H)

RT (min): 1.40

(2S)-2-((tert-butoxycarbonyl)amino)heptan-3-yl 4-nitrobenzoate

MS (ESI m/z): 381 (M+H)

RT (min): 1.96

tert-Butyl((2S)-3-hydroxyheptan-2-yl)carbamate

MS (ESI m/z): 232 (M+H)

RT (min): 1.43

tert-Butyl((2S,3R)-3-(1,3-dioxoindolin-2-yl)heptan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.87-7.79 (m, 2H), 7.76-7.68 (m, 2H), 4.53 (br, 1H), 4.32-3.99 (m, 2H), 2.40-2.17 (m, 1H), 1.86-1.69 (m, 1H), 1.44 (s, 9H), 1.36-1.04 (m, 7H), 0.83 (t, 3H, J=7.2 Hz)

MS (ESI m/z): 361 (M+H)

RT (min): 1.81

tert-Butyl((2S,3R)-3-aminoheptan-2-yl)carbamate

MS (ESI m/z): 231 (M+H)

RT (min): 0.89

tert-Butyl((2S,3R)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)heptan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.29 (d, 1H, J=9.9 Hz), 5.74 (d, 1H, J=7.3 Hz), 4.68 (d, 1H, J=6.6 Hz), 4.34-4.18 (m, 1H), 3.97-3.80 (m, 1H), 1.71-1.22 (m, 15H), 1.17 (t, 3H, J=6.6 Hz), 0.89 (t, 3H, J=6.3 Hz)

MS (ESI m/z): 385 (M+H)

RT (min): 1.87

Reference Example 427

The following compounds were obtained as described in Reference Example 417.

(S)-tert-butyl(5-methyl-3-oxohexan-2-yl)carbamate MS (ESI m/z): 230 (M+H)

RT (min): 1.53

tert-Butyl((2S)-3-hydroxy-5-methylhexan-2-yl)carbamate

MS (ESI m/z): 232 (M+H)

RT (min): 1.42

(2S)-2-((tert-butoxycarbonyl)amino)-5-methylhexan-3-yl 4-nitrobenzoate

MS (ESI m/z): 381 (M+H)

RT (min): 1.95

tert-Butyl((2S)-3-hydroxy-5-methylhexan-2-yl)carbamate

MS (ESI m/z): 232 (M+H)

RT (min): 1.42

tert-Butyl((2S,3R)-3-(1,3-dioxoindolin-2-yl)-5-methylhexan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.86-7.77 (m, 2H), 7.75-7.66 (m, 2H), 4.55 (br, 1H), 4.32-4.12 (m, 2H), 2.48-2.30 (m, 1H), 1.51-1.36 (s, 10H), 1.32-1.22 (m, 1H), 1.11 (d, 3H, J=6.6 Hz), 0.92-0.84 (m, 6H)

MS (ESI m/z): 361 (M+H)

RT (min): 1.80

tert-Butyl((2S,3R)-3-amino-5-methylhexan-2-yl)carbamate

MS (ESI m/z): 231 (M+H)

RT (min): 0.89

tert-Butyl((2S,3R)-3-(6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-5-methylhexan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.29 (d, 1H, J=9.9 Hz), 5.69 (d, 1H, J=7.9 Hz), 4.67 (d, 1H, J=6.6 Hz), 4.46-4.28 (m, 1H), 3.96-3.80 (m, 1H), 1.70-1.32 (m, 12H), 1.16 (d, 3H, J=6.6 Hz), 0.94 (dd, 6H, J=6.6, 2.0 Hz)

MS (ESI m/z): 385 (M+H)

RT (min): 1.86

Reference Example 428

The following compounds were obtained as described in Reference Example 417.

(S)-tert-butyl (5-methyl-3-oxohexa-5-en-2-yl)carbamate

MS (ESI, m/z): 228 (M+H)

RT (min): 1.40

tert-Butyl((2S)-3-hydroxy-5-methylhexa-5-en-2-yl)carbamate

MS (ESI m/z): 230 (M+H)

RT (min): 1.30

(2S)-2-((tert-butoxycarbonyl)amino)-5-methylhexane-3-yl 4-nitrobenzoate

MS (ESI m/z): 379 (M+H)

RT (min): 1.85

tert-Butyl((2S)-3-hydroxy-5-methylhexan-2-yl)carbamate

MS (ESI m/z): 230 (M+H)

RT (min): 1.30

tert-Butyl((2S,3R)-3-(1,3-dioxoindolin-2-yl)-5-methylhexa-5-en-2-yl)carbamate

MS (ESI m/z): 359 (M+H)

RT (min): 1.71

tert-Butyl((2S,3R)-3-amino-5-methylhexa-5-en-2-yl)carbamate

MS (ESI m/z): 229 (M+H)

RT (min): 0.90

tert-Butyl((2S,3R)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-5-methylhexa-5-en-2-yl)carbamate

MS (ESI m/z): 383 (M+H)

RT (min): 1.77

Reference Example 429

The following compounds were obtained as described in the 1st, 2nd, 5th, 6th, and 7th steps of Reference Example 417.

tert-Butyl((2S)-1-hydroxy-1-phenylpropan-2-yl)carbamate

MS (ESI m/z): 252 (M+H)

RT (min): 1.34

tert-Butyl((1R,2S)-1-(1,3-dioxoindolin-2-yl)-1-phenylpropan-2-yl)carbamate

MS (ESI m/z): 381 (M+H)

RT (min): 1.67

tert-Butyl((1R,2S)-1-amino-1-phenylpropan-2-yl)carbamate

MS (ESI m/z): 251

RT (min): 0.86

tert-Butyl((1R,2S)-1-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-1-phenylpropan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.95 (br, 1H), 7.42-7.19 (m, 6H), 5.04 (d, 1H, J=6.3 Hz), 4.37-4.20 (m, 2H), 1.49 (s, 9H), 1.13 (d, 3H, J=6.3 Hz)

MS (ESI m/z): 405 (M+H)

RT (min): 1.96

Reference Example 430

The following compounds were obtained as described in Reference Example 417.

tert-Butyl((2S)-1-(4-fluorophenyl)-1-hydroxypropan-2-yl)carbamate

MS (ESI m/z): 270 (M+H)

RT (min): 1.57

(2S)-2-((tert-butoxycarbonyl)amino)-1-(4-fluorophenyl)propyl 4-nitrobenzoate

MS (ESI m/z): 419 (M+H)

RT (min): 1.85

tert-Butyl((2S)-1-(4-fluorophenyl)-1-hydroxypropan-2-yl)carbamate

MS (ESI m/z): 270 (M+H)

RT (min): 1.57

tert-Butyl((1R,2S)-1-(1,3-dioxoindolin-2-yl)-1-(4-fluorophenyl)propan-2-yl)carbamate

MS (ESI m/z): 399 (M+H)

RT (min): 1.74

tert-Butyl((1R,2S)-1-amino-1-(4-fluorophenyl)propan-2-yl)carbamate

MS (ESI m/z): 269(M+H)

RT (min): 0.89

tert-Butyl((1R,2S)-1-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-1-(4-fluorophenyl)propan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 8.07 (br, 1H), 7.25-7.16 (m, 3H), 7.09-6.98 (m, 2H), 4.99 (d, 1H, J=5.9 Hz), 4.36-4.16 (m, 2H), 1.50 (s, 9H), 1.12 (d, 3H, J=6.6 Hz)

MS (ESI m/z): 423 (M+H)

RT (min): 1.81

Reference Example 431

The following compounds were obtained as described in Reference Example 417.

(S)-tert-butyl(2-oxopentan-3-yl)carbamate

MS (ESI m/z): 202 (M+H)

RT (min): 1.19

tert-Butyl((3S)-2-hydroxypentan-3-yl)carbamate

MS (ESI m/z): 204 (M+H)

RT (min): 1.09

(3S)-3-((tert-butoxycarbonyl)amino)pentan-2-yl 4-nitrobenzoate

MS (ESI m/z): 353 (M+H)

RT (min): 1.75

tert-Butyl((3S)-2-hydroxypentan-3-yl)carbamate

MS (ESI m/z): 204 (M+H)

RT (min): 1.09

tert-Butyl((2R,3S)-2-(1,3-dioxoindolin-2-yl)pentan-3-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.89-7.75 (m, 2H), 7.76-7.66 (m, 2H), 4.46 (d, 1H, J=8.6 Hz), 4.36-4.02 (m, 2H), 1.41 (s, 9H), 1.37-1.22 (m, 5H), 0.92 (t, 3H, J=7.2)

MS (ESI m/z): 333 (M+H)

RT (min): 1.58

tert-Butyl((2R,3S)-2-aminopentan-3-yl)carbamate

MS (ESI m/z): 203 (M+H)

RT (min): 0.69

tert-Butyl((2R,3S)-2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)pentan-3-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.25 (d, 1H, J=9.9 Hz), 6.79 (d, 1H, J=5.4 Hz), 4.46 (d, 1H, J=7.9 Hz), 4.30-4.15 (m, 1H), 3.80-3.68 (m, 1H), 1.71-1.30 (m, 11H), 1.17 (d, 3H, J=6.6 Hz), 1.02 (t, 3H, J=7.6 Hz)

MS (ESI m/z): 357 (M+H)

RT (min): 1.72

Reference Example 432

The following compounds were obtained as described in Reference Example 417.

(S)-tert-butyl(4-oxohexan-3-yl)carbamate

MS (ESI m/z): 216 (M+H)

RT (min): 1.36

tert-Butyl((3S)-4-hydroxyhexan-3-yl)carbamate

MS (ESI m/z): 218 (M+H)

RT (min): 1.26

(4S)-4-((tert-butoxycarbonyl)amino)hexan-3-yl 4-nitrobenzoate

MS (ESI m/z): 367 (M+H)

RT (min): 1.85

tert-Butyl((3S)-4-hydroxyhexan-3-yl)carbamate

MS (ESI m/z): 218 (M+H)

RT (min): 1.26

tert-Butyl((3S,4R)-4-(1,3-dioxoindolin-2-yl)hexan-3-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.89-7.78 (m, 2H), 7.76-7.66 (m, 2H), 4.46 (d, 1H, J=8.6 Hz), 4.36-3.90 (m, 2H), 2.39-2.15 (m, 1H), 1.96-1.76 (m, 1H), 1.67-1.40 (m, 10H), 1.34-1.16 (m, 1H), 0.96-0.80 (m, 6H)

MS (ESI m/z): 347 (M+H)

RT (min): 1.68

tert-Butyl((3S,4R)-4-aminohexan-3-yl)carbamate

MS (ESI m/z): 217 (M+H)

RT (min): 0.75

tert-Butyl((3S,4R)-4-(6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)hexan-3-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.28 (d, 1H, J=9.9 Hz), 5.80 (d, 1H, J=7.9 Hz), 4.43 (d, 1H, J=8.6 Hz), 4.29-4.05 (m, 1H), 3.74-3.60 (m, 1H), 1.78-1.27 (m, 13H), 1.00 (t, 3H, J=7.7 Hz), 0.96 (t, 3H, J=7.5 Hz)

MS (ESI m/z): 371 (M+H)

RT (min.): 1.77

Reference Example 433

The following compounds were obtained as described in Reference Example 417.

(S)-tert-butyl(4-oxoheptan-3-yl)carbamate

MS (ESI m/z): 230 (M+H)

RT (min): 1.53

tert-Butyl((3S)-4-hydroxyheptan-3-yl)carbamate

MS (ESI m/z): 232 (M+H)

RT (min): 1.39

(3S)-3-((tert-butoxycarbonyl)amino)heptan-4-yl 4-nitrobenzoate

MS (ESI m/z): 381 (M+H)

RT (min): 1.95

tert-Butyl((3S)-4-hydroxyheptan-3-yl)carbamate

MS (ESI m/z): 232 (M+H)

RT (min): 1.42

tert-Butyl((3S,4R)-4-(1,3-dioxoindolin-2-yl)heptan-3-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.86-7.78 (m, 2H), 7.77-7.65 (m, 2H), 4.42 (d, 1H, J=9.3 Hz), 4.20-4.00 (m, 2H), 2.42-2.12 (m, 1H), 1.80-1.58 (m, 1H), 1.43 (s, 9H), 1.38-1.08 (m, 4H), 0.96-0.84 (m, 6H)

MS (ESI m/z): 361 (M+H)

RT (min): 1.79

tert-Butyl((3S,4R)-4-aminoheptan-3-yl)carbamate

MS (ESI m/z): 231 (M+H)

RT (min): 0.89

tert-Butyl((3S,4R)-4-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)heptan-3-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.27 (d, 1H, J=9.9 Hz), 5.80 (d, 1H, J=7.9 Hz), 4.43 (d, 1H, J=8.6 Hz), 4.37-4.21 (m, 1H), 3.75-3.61 (m, 1H), 1.70-1.19 (m, 15H), 1.05-0.87 (m, 6H)

MS (ESI m/z): 385 (M+H)

RT (min): 1.88

Reference Example 434

The following compounds were obtained as described in Reference Example 417.

1st step

1,1′-carbonyldiimidazole (1.9 g) was added to a dichloromethane solution (10 ml) containing (R)-2-((tert-butoxycarbonyl)amino)-3-methoxypropionic acid (2 g) in an ice bath, followed by stirring for 30 minutes. Subsequently, triethylamine (1.2 g) and N,O-dimethylhydroxylamine (1.2 g) were added, followed by stirring at room temperature for 2.5 hours. The reaction solution was added dropwise to 4M hydrochloric acid, followed by extraction with ethyl acetate. The organic layer was washed with a saturated aqueous sodium hydrogen carbonate solution and water and dried over anhydrous sodium sulfate. Then, the solvent was distilled away under reduced pressure, and yellow oily matter of (R)-tert-butyl(1-(methoxy(methyl)amino)-1-oxobutan-2-yl)carbamate (1.8 g) was thus obtained.

MS (ESI m/z): 263 (M+H)

RT (min): 1.03

2nd, 3rd, 4th, 5th, 6th, and 7th steps

The following compounds were obtained as described in the 1st, 2nd, 3rd, 4th, and 5th steps of Reference Example 417 and the 2nd step of Reference Example 97.

(R)-tert-butyl(1-methoxy-3-oxobutan-2-yl)carbamate

MS (ESI m/z): 218 (M+H)

RT (min): 1.07

tert-Butyl((2R)-3-hydroxy-1-methoxybutan-2-yl)carbamate

MS (ESI, m/z): 220 (M+H)

RT (min): 0.92

(3R)-3-((tert-butoxycarbonyl)amino)-4-methoxybutan-2-yl 4-nitrobenzoate

MS (ESI m/z): 369 (M+H)

RT (min): 1.67

tert-Butyl((2R)-3-hydroxy-1-methoxybutan-2-yl)carbamate

MS (ESI m/z): 220(M+H)

RT (min): 0.92

tert-Butyl((2S,3S)-3-(1,3-dioxoisoindolin-2-yl)-1-methoxybutan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.85-7.78 (m, 2H), 7.74-7.66 (m, 2H), 5.08-4.92 (m, 1H), 4.54-4.34 (m, 2H), 3.44-3.26 (m, 2H), 3.22 (s, 3H), 1.52 (d, 3H, J=6.6 Hz), 1.45 (s, 9H)

MS (ESI m/z): 349 (M+H)

RT (min): 1.50

2-((2S,3S)-3-amino-4-methoxybutan-2-yl)isoindolin-1,3-dione

MS (ESI m/z): 249 (M+H),

RT (min): 0.64

Reference Example 435

1st Step

The following compound was obtained as described in the 1st step of Reference Example 405.

2-chloro-6-(((2S,3S)-3-(1,3-dioxoindolin-2-yl)-1-methoxybutan-2-yl)amino)-5-fluoronicotinonitrile

MS (ESI m/z): 403 (M+H),

RT (min): 1.59

2nd Step

The following compound was obtained as described in the 3rd step of Reference Example 379.

6-(((2S,3S)-3-amino-1-methoxybutan-2-yl)amino)-2-chloro-5-fluoronicotinonitrile

MS (ESI m/z): 273 (M+H),

RT (min): 0.72

3rd Step

The following compound was obtained as described in Reference Example 395.

tert-Butyl((2S,3S)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-4-methoxybutan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.31 (d, 1H, J=9.6 Hz), 6.10 (d, 1H, J=7.6 Hz), 5.17 (d 1H, J=8.9 Hz), 4.36-4.19 (m, 1H), 4.12-3.94 (m, 1H), 3.89 (s, 3H), 3.84-3.75 (m, 1H), 3.58-3.48 (m, 1H), 1.44 (s, 9H), 1.24 (d, 3H, J=7.2 Hz)

MS (ESI m/z): 373 (M+H)

RT (min): 1.60

Reference Example 436

1st Step

2,6-dichloro-5-fluoro-3-pyridinecarbonitrile (300 mg) and potassium carbonate (1.1 g) were added to a DMF (6 ml) solution containing meso-2,3-diaminobutane (690 mg) at room temperature, followed by stirring for 3.5 hours. After cooling of the reaction solution, a saturated aqueous sodium hydrogen carbonate solution was added, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate. The solvent was distilled away under reduced pressure and the residue was purified by NH silica gel chromatography (n-hexane:ethyl acetate=4:1 to 3:2), and a yellow solid of 6-(((cis)-3-aminobutan-2-yl)amino)-2-chloro-5-fluoronicotinonitrile (150 mg) was thus obtained.

MS (ESI m/z): 243 (M+H) 2nd step

The following compound was obtained as described in Reference Example 395.

tert-Butyl((cis)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)butan-2-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.26 (d, 1H, J=9.9 Hz), 6.88 (br, 1H), 4.59 (d, 1H, J=6.6 Hz), 4.26-4.10 (m, 1H), 4.06-3.90 (m, 1H), 1.46 (s, 9H), 1.24-1.14 (m, 6H)

MS (ESI m/z): 343 (M+H)

RT (min): 1.62

Reference Example 437

The following compounds were obtained as described in Reference Example 436.

6-(((cis)-2-amino-1,2-diphenylethyl)amino)-2-chloro-5-fluoronicotinonitrile

MS (ESI m/z): 367 (M+H)

RT (min): 1.05.

tert-Butyl((cis)-2-(6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-1,2-diphenylethyl)carbamate

MS (ESI m/z): 467 (M+H)

RT (min): 1.87

Reference Example 438

The following compounds were obtained as described in the 1st step of Reference Example 386 and the 3rd step of Reference Example 396.

1st Step

The following compound was obtained as described in Reference Example 386.

6-(((cis)-3-aminobutan-2-yl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile

MS (ESI m/z): 351 (M+H)

RT (min): 0.59

2nd Step

The following compound was obtained as described in Reference Example 395.

tert-Butyl((cis)-3-((5-cyano-3-fluoro-6-(quinolin-6-ylamino)pyridin-2-yl)amino)butan-2-yl)carbamate

MS (ESI m/z): 451 (M+H)

RT (min): 1.21

Reference Example 439-1

The following compounds were obtained with reference to Tetrahedron: Asymmetry, Vol. 8, No, 14, pp. 2381-2401, 1997.

tert-Butyl((2R,3S)-3-aminobutan-2-yl)carbamate

MS (ESI m/z): 343 (M+H), 341 (M−H)

tert-Butyl((2R,3R)-3-aminobutan-2-yl)carbamate

MS (ESI m/z): 343 (M+H), 341 (M−H)

Reference Example 439-2

The following compound was obtained as described in the 7th step of Reference Example 417.

tert-Butyl((2R,3S)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)butan-2-yl)carbamate

MS (ESI m/z): 343 (M+H), 341 (M−H)

tert-Butyl((2R,3R)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)butan-2-yl)carbamate

MS (ESI m/z): 343 (M+H), 341 (M−H)

Reference Example 440

The following compound was obtained with reference to Archiv der Pharmazie (Weinheim, Germany), 2004, vol. 337, #12, pp. 654-667.

(S,Z)—N-(2-((tert-butoxycarbonyl)amino)butylidyne)-1-phenylmethaneamineoxide Reference Example 441

1st Step

Methylmagnesium bromide (3M diethylether solution, 0.86 ml) was added dropwise to a tetrahydrofuran (5 ml) solution containing (S,Z)—N-(2-((tert-butoxycarbonyl)amino)butylidyne)-1-phenylmethaneamineoxide (250 mg) at −50° C., followed by stirring at −50° C. to −35° C. for 2 hours. Further, methylmagnesium bromide (3M diethylether solution, 0.86 ml) was added dropwise to the reaction solution, followed by stirring at −45° C. to −40° C. for 1 hour. A saturated aqueous ammonium chloride solution was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=19:1 to 4:1), and tert-butyl((3S,4R)-4-(benzyl(hydroxy)amino)pentan-3-yl)carbamate (39 mg) was thus obtained.

¹H-NMR (CDCl₃, 300 MHz) δ: 7.39-7.18 (m, 5H), 6.70 (s, 1H), 4.43 (d, 1H, J=10.2 Hz), 4.11 (d, 1H, J=13.9 Hz), 4.10-3.97 (m, 1H), 3.64 (d, 1H, J=13.9 Hz), 2.78-2.68 (m, 1H), 1.47 (s, 9H), 1.44-1.26 (m, 2H), 1.03-0.94 (m, 9H)

2nd Step

A methanol (20 ml) solution containing tert-butyl((3S,4R)-4-(benzyl(hydroxy)amino)pentan-3-yl)carbamate (39 mg) was prepared and was subjected to a hydrogenation reaction (45° C.; 100 bar; flow rate: 1 ml/min; 20% Pd(OH)₂/C) using H-cube™. Then, the solvent was distilled away under reduced pressure, and colorless oily matter of tert-butyl((3S,4R)-4-aminopentan-3-yl)carbamate (27 mg) was thus obtained.

3rd Step

The following compound was obtained as described in the 7th step of Reference Example 417.

tert-Butyl((2R,3S)-2-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)pentan-3-yl)carbamate

MS (ESI m/z): 357 (M+H), 355 (M−H)

Reference Example 442

The following compounds were obtained as described in Reference Example 441.

tert-Butyl((3S,4R)-4-(benzyl(hydroxy)amino)hexan-3-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.40-7.20 (m, 5H), 5.88 (s, 1H), 4.62 (d, 1H, J=9.6 Hz), 4.07 (d, 1H, J=13.9 Hz), 4.01-3.88 (m, 1H), 3.73 (d, 1H, J=13.9 Hz), 2.59-2.50 (m, 1H), 1.69-1.32 (m, 4H), 1.45 (s, 9H), 1.05 (t, 3H, J=7.6 Hz), 0.98 (t, 3H, J=7.3 Hz) tert-Butyl((3S,4R)-4-(6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)hexan-3-yl)carbamate

MS (ESI m/z): 371 (M+H), 369 (M−H)

Reference Example 443

The following compounds were obtained as described in Reference Example 441.

tert-Butyl((3S,4R)-4-(benzyl(hydroxy)amino)heptan-3-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.39-7.20 (m, 5H), 5.96 (s, 1H), 4.60 (d, 1H, J=9.9 Hz), 4.05 (d, 1H, J=13.9 Hz), 4.01-3.88 (m, 1H), 3.72 (d, 1H, J=13.9 Hz), 2.63-2.55 (m, 1H), 1.69-1.20 (m, 1H), 1.46 (s, 9H), 0.97 (t, 3H, J=7.6 Hz), 0.93 (t, 3H, J=6.9 Hz)

tert-Butyl((3S,4R)-4-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)heptan-3-yl)carbamate

MS (ESI m/z): 385 (M+H), 383 (M−H)

Reference Example 444

The following compounds were obtained as described in Reference Example 441.

tert-Butyl((3S,4R)-4-(benzyl(hydroxy)amino)-6-methylheptan-3-yl)carbamate

¹H-NMR (CDCl₃, 300 MHz) δ: 7.39-7.23 (m, 5H), 5.85 (s, 1H), 4.59 (d, 1H, J=9.9 Hz), 4.04 (d, 1H, J=13.5 Hz), 4.01-3.88 (m, 1H), 3.73 (d, 1H, J=13.5 Hz), 2.72-2.63 (m, 1H), 1.81-1.69 (m, 1H), 1.50-1.13 (m, 4H), 1.46 (s, 9H), 1.02-0.89 (m, 9H)

tert-Butyl((3S,4R)-4-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)-6-methylheptan-3-yl)carbamate

MS (ESI m/z): 399 (M+H), 397 (M−H)

Reference Example 445

1st Step

A tetrahydrofuran solution (50 ml) containing (S)-tert-butyl(3-oxohexa-5-en-2-yl)carbamate (8 g) was added dropwise to 9-borabicyclo[3,3,1]nonane (0.5 M tetrahydrofuran solution) (225 ml) in an ice bath, followed by stirring at room temperature for 4 hours. A 6M sodium hydroxide aqueous solution (50 ml) and then a 30% hydrogen peroxide solution (50 ml) were added to the reaction solution in an ice bath. An insoluble precipitate was removed, followed by extraction with ethyl acetate. The obtained organic layer was washed with water and saturated saline and dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, and colorless oily matter of tert-butyl((2S)-3,6-dihydroxyhexan-2-yl)carbamate (4.4 g) was thus obtained.

MS (ESI m/z): 232 (M+H)

RT (min): 0.85

2nd Step

A DMF solution (5 ml) containing imidazole (1.4 g) and tert-butyldimethylsilyl chloride (3 g) was added to a DMF (10 ml) solution containing tert-butyl((2S)-3,6-dihydroxyhexan-2-yl)carbamate (4.4 g), followed by stirring at room temperature for 40 minutes. Water was added to the reaction solution, followed by extraction with ethyl acetate. The obtained organic layer was washed with a 1M citric acid aqueous solution and dried over anhydrous sodium sulfate. The solvent was distilled away under reduced pressure. The residue was purified by silica gel chromatography (n-hexane:ethyl acetate=7:3), and colorless oily matter of tert-butyl((2S)-6-((tert-butyldimethylsilyl)oxy)-3-hydroxyhexan-2-yl)carbamate (4.9 g) was thus obtained.

MS (ESI m/z): 348 (M+H)

RT (min): 1.94

3rd, 4th, 5th, 6th, and 7th steps

The following compounds were obtained as described in the 3rd, 4th, 5th, 6th, and 7th steps of Reference Example 417.

tert-Butyl((2S)-6-((tert-butyldimethylsilyl)oxy)-3-(4-nitrobenzoyl)oxyhexan-2-yl)carbamate

MS (ESI m/z): 497 (M+H)

RT (min): 2.29

tert-Butyl((2S,3R)-6-((tert-butyldimethylsilyl)oxo)-3-(1,3-dioxoisoindolin-2-yl)hexan-2-yl)carbamate

MS (ESI m/z): 477 (M+H)

RT (min): 2.22

tert-Butyl((2S,3R)-6-((tert-butyldimethylsilyl)oxo)-3-((6-chloro-5-cyano-3-fluoropyridin-2-yl)amino)hexan-2-yl)carbamate

MS (ESI m/z): 502 (M+H)

RT (min): 2.26

Reference Example 446

1st Step

The following compound was obtained as described in the 1st step of Example 5.

tert-Butyl((2S,3R)-6-((tert-butyldimethylsilyl)oxo)-3-((5-cyano-6-((5,6-dimethylpyridin-3-yl)amino)-3-fluoropyridin-2-yl)amino)hexan-2-yl)carbamate

MS (ESI m/z): 588 (M+H)

RT (min): 1.58

2nd Step

The following compound was obtained as described in the 2nd step of Example 5.

tert-Butyl((2S,3R)-6-((tert-butyldimethylsilyl)oxy)-3-((5-carbamoyl-6-((5,6-dimethylpyridin-3-yl)amino)-3-fluoropyridin-2-yl)amino)hexan-2-yl)carbamate

MS (ESI m/z): 606 (M+H)

RT (min): 1.57

Reference Example 447

1st Step

Tetrabutylammonium fluoride (1M tetrahydrofuran solution, 150 μl) was added to a tetrahydrofuran solution (2 ml) containing tert-butyl((2S,3R)-6-((tert-butyldimethylsilyl)oxy)-3-((5-carbamoyl-6-((5,6-dimethylpyridin-3-yl)amino)-3-fluoropyridin-2-yl)amino)hexan-2-yl)carbamate (60 mg), followed by stirring for 30 minutes. Further, tetrabutylammonium fluoride (1M in tetrahydrofuran, 300 μl) was added, followed by stirring for 1 hour. Water was added to the reaction solution, followed by extraction with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate. The solvent was distilled away under reduced pressure. The residue was purified by silica gel chromatography (ethyl acetate:methanol=1:0 to 97:3) and used in the subsequent reaction.

2nd and 3rd Steps

The following compounds were obtained as described in the 5th and 6th steps of Reference Example 417.

tert-Butyl((2S,3R)-3-(5-carbamoyl-6-((5,6-dimethylpyridin-3-yl)amino)-3-fluoropyridin-2-yl)amino)-6-(1,3-dioxoisoindolin-2-yl)hexan-2-yl)carbamate

MS (ESI m/z): 621 (M+H)

RT (min): 1.16

tert-Butyl((2S,3R)-6-amino-3-((5-carbamoyl-6-((5,6-dimethylpyridin-3-yl)amino)-3-fluoropyridin-2-yl)amino)hexan-2-yl)carbamate

MS (ESI m/z): 491 (M+H)

RT (min): 0.80

Reference Example 447

The following compound was obtained as described in Reference Example 386.

tert-Butyl(2-((5-cyano-6-(quinolin-6-ylamino)pyridin-2-yl)amino)-2-methylpropyl)carbamate

MS (ESI m/z): 451 (M+H)

RT (min): 1.27

Reference Example 448

The following compound was obtained as described in Reference Example 386.

tert-Butyl(1-((5-cyano-3-fluoro-6-(quinolin-6-ylamino)pyridin-2-yl)amino)-2-methylpropan-2-yl)carbamate

MS (ESI m/z): 451 (M+H)

RT (min): 1.26

Example 1

1st Step

5-phenylpyridin-3-amine (10 mg), cesium carbonate (32 mg), Pd₂(dba)₃ (5 mg), and Xantphos (7 mg) were added to a 1,4-dioxane (0.8 ml) solution containing tert-butyl cis-2-(6-chloro-3-fluoro-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate (20 mg), followed by stirring at 100° C. for 2 hours in a nitrogen atmosphere. The reaction mixture was cooled to room temperature. Then, water and ethyl acetate were added. Insoluble matter was removed by filtration, and the filter cake was washed with ethyl acetate and water. The filtrate was mixed with the washing solution. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified using a PLC glass plate (hexane:ethyl acetate=1:1), diisopropylether and hexane were added, solid matter was collected by filtration, and light yellow oily matter of tert-butyl cis-2-(3-fluoro-5-(2-phenylpropan-2-ylaminocarbonyl)-6-(5-phenylpyridin-3-ylamino)pyridin-2-ylamino)cyclohexylcarbamate (11 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.30 (s, 1H), 8.59 (d, 1H, J=2.3 Hz), 8.38 (d, 1H, J=2.0 Hz), 8.35 (s, 1H), 8.19 (d, 1H, J=13.3 Hz), 8.14 (s, 1H), 7.72-7.66 (m, 2H), 7.52-7.45 (m, 2H), 7.44-7.36 (m, 3H), 7.32-7.26 (m, 2H), 7.20-7.14 (m, 1H), 6.67-6.60 (m, 2H), 4.03-3.94 (m, 1H), 3.84-3.76 (m, 1H), 1.74-1.10 (m, 23H)

MS (ESI, m/z): 639 (M+H), 637 (M−H)

2nd Step

A mixture of tert-butyl cis-2-(3-fluoro-5-(2-phenylpropan-2-ylaminocarbonyl)-6-(5-phenylpyridin-3-ylamino)pyridin-2-ylamino)cyclohexylcarbamate (10 mg) and TFA (0.2 ml) was stirred at room temperature for 30 minutes. The solvent was distilled away under reduced pressure (at 40° C. or less), and ethyl acetate and 4N hydrogen chloride/1,4-dioxane (20 μl) were added, followed by stirring at room temperature for 30 minutes. Solid matter was collected by filtration and washed with ethyl acetate, and a yellow solid of

6-(cis-2-amino cyclohexylamino)-5-fluoro-2-(5-phenylpyridin-3-ylamino)nicotinamide.hydrochloride (8 mg) was thus obtained.

(¹H-NMR data and MS data are shown in table 1.)

Example 2

The compounds listed in table 1 were obtained as described in Example 1.

TABLE 1 Number Structure Number Structure Example 2-1 (Example 1) HCl salt

Example 2-2 HCl salt

Example 2-3 HCl salt

Example 2-4 HCl salt

Example 2-5 HCl salt

Example 2-6 HCl salt

Example 2-7 HCl salt

Example 2-8 HCl salt

Example 2-9 HCl salt

Example 2-10 HCl salt

Example 2-11 HCl salt

Example 2-12 HCl salt

Example 2-13 HCl salt

Example 2-14 HCl salt

Example 2-15 HCl salt

Example 2-16 2HCl salt

Example 2-17 HCl salt

Example 2-18 HCl salt

Example 2-19 HCl salt

Example 2-20 HCl salt

Example 2-21 2HCl salt

Example 2-22

6-((cis-2-aminocyclohexyl)amino)-2-((2,6- dimethylpyridin-4-yl)amino)-5- fluoronicotinamide Example 2-23

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- methyl-5-phenylpyridin-3-yl)amino)nicotinamide Example 2-24

6-(cis-2-aminocyclohexylamino)-2-((5,6- dimethylpyridin-3-yl)amino)-5- fluoronicotinamide Example 2-25

2-(1H-indazol-4-yl)amino)-6-(cis-2- aminocyclohexylamino)-5-fluoronicotinamide Example 2-26

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((1- (2-(pyrrolidin-1-yl)ethyl)-1H-indazol-4-yl) amino)nicotinamide Example 2-27

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((1- (2-morpholinoethyl)-1H-indazol-4-yl) amino)nicotinamide Example 2-28

6-(cis-2-aminocyclohexylamino)-2-((1- (cyclopropylmethyl)-1H-indazol-4-yl)amino)-5- fluoronicotinamide Example 2-29

6-(cis-2-aminocyclohexylamino)-2-((1-benzyl- 1H-indazol-4-yl)amino)-5-fluoronicotinamide Example 2-30

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((1- (2-methoxyethyl)-1H-indazol-4-yl) amino)nicotinamide Example 2-31

6-(cis-2-aminocyclohexylamino)-2-((1-(2-(2- ethoxyethoxy)ethyl)-1H-indazol-4-yl)amino)-5- fluoronicotinamide Example 2-32

6-(cis-2-aminocyclohexylamino)-2-((2- (cyclopropylmethyl)-2H-indazol-4-yl)amino)-5- fluoronicotinamide Example 2-33

6-(cis-2-aminocyclohexylamino)-2-((2-benzyl- 2H-indazol-4-yl)amino)-5-fluoronicotinamide Example 2-34

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-methoxyethyl)-2H-indazol-4-yl) amino)nicotinamide Example 2-35

6-(cis-2-aminocyclohexylamino)-2-((2-(2-(2- ethoxyethoxy)ethyl)-2H-indazol-4-yl)amino)-5- fluoronicotinamide Example 2-36

6-(cis-2-aminocyclohexylamino)-2-((1-benzyl- 1H-indazol-5-yl)amino)-5-fluoronicotinamide Example 2-37

6-(cis-2-aminocyclohexylamino)-2-((2-benzyl- 2H-indazol-5-yl)amino)-5-fluoronicotinamide Example 2-38

6-(cis-2-aminocyclohexylamino)-2-((5- ethylpyridin-3-yl)amino)-5-fluoronicotinamide Example 2-39

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- isopropylpyridin-3-yl)amino)nicotinamide Example 2-40

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- methyl-5-(pyrrolidin-1-yl)pyridin-3-yl) amino)nicotinamide Example 2-41

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- methyl-2H-indazol-5-yl)amino)nicotinamide Example 2-42

6-(cis-2-aminocyclohexylamino)-2-((2- (cyclopropylmethyl)-2H-indazol-6-yl)amino)-5- fluoronicotinamide Example 2-43

6-(cis-2-aminocyclohexylamino)-2-((2-benzyl- 2H-indazol-6-yl)amino)-5-fluoronicotinamide Example 2-44

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-methoxyethyl)-2H-indazol-6-yl) amino)nicotinamide Example 2-45

6-(cis-2-aminocyclohexylamino)-2-((2-(2-(2- ethoxyethoxy)ethyl)-2H-indazol-6-yl)amino)-5- fluoronicotinamide Example 2-46

6-(cis-2-aminocyclohexylamino)-2-((1- (cyclopropylmethyl)-1H-indazol-6-yl)amino)-5- fluoronicotinamide Example 2-47

6-(cis-2-aminocyclohexylamino)-2-((1-benzyl- 1H-indazol-6-yl)amino)-5-fluoronicotinamide Example 2-48

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((1- (2-methoxyethyl)-1H-indazol-6-yl) amino)nicotinamide Example 2-49

6-(cis-2-aminocyclohexylamino)-2-((1-(2-(2- ethoxyethoxy)ethyl)-1H-indazol-6-yl)amino)-5- fluoronicotinamide Example 2-50

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (trifluoromethyl)pyridin-4-yl)amino)nicotinamide Example 2-51

2-(2-(1H-pyrrol-2-yl)pyridin-4-yl)amino)-6- (cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 2-52

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- phenylpyridin-4-yl)amino)nicotinamide Example 2-53

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (furan-2-yl)pyridin-4-yl)amino)nicotinamide Example 2-54

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-oxopyrrolidin-1-yl)pyridin-4-yl) amino)nicotinamide Example 2-55

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- isopropoxypyridin-4-yl)amino)nicotinamide Example 2-56

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-(pyrrolidin-1-yl)ethoxy)pyridin-4-yl) amino)nicotinamide Example 2-57

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (furan-3-yl)pyridin-4-yl)amino)nicotinamide Example 2-58

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (methylamino)pyridin-4-yl)amino)nicotinamide Example 2-59

6-(cis-2-aminocyclohexylamino)-2-(2- (ethylamino)pyridin-4-yl)amino)-5- fluoronicotinamide Example 2-60

6-(cis-2-aminocyclohexylamino)-2-(2- ethoxypyridin-4-yl)amino)-5-fluoronicotinamide Example 2-61

6-(cis-2-aminocyclohexylamino)-2-(2,6- diethoxypyridin-4-yl)amino)-5- fluoronicotinamide Example 2-62

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (5-methylfuran-2-yl)pyridin-3-yl) amino)nicotinamide Example 2-63

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- ((5-methylfuran-2-yl)pyridin-4-yl) amino)nicotinamide Example 2-64

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((imidazo[1,2-a]pyridin-8-yl)amino)nicotinamide Example 2-65

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- methoxy-6-phenylpyridin-4-yl) amino)nicotinamide Example 2-66

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-methoxyethoxy)pyridin-4-yl) amino)nicotinamide Example 2-67

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-methoxyethoxy)-6-phenylpyridin-4-yl) amino)nicotinamide Example 2-68

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- morpholino-6-phenylpyridin-4-yl) amino)nicotinamide Example 2-69

2-((5-(1H-pyrazol-4-yl)pyridin-3-yl)amino)-6- (cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 2-70

2-(2-(1H-pyrazol-4-yl)pyridin-4-yl)amino)-6- (cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 2-71

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- methyl-6-morpholinopyridin-3-yl) amino)nicotinamide Example 2-72

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (furan-3-yl)-6-morpholinopyridin-3-yl) amino)nicotinamide Example 2-73

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- methylaminopyridin-3-yl)amino)nicotinamide Example 2-74

6-(cis-2-aminocyclohexylamino)-2-(6- dimethylaminopyridin-3-yl)amino)-5- fluoronicotinamide Example 2-75

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- (2-hydroxyethylamino)pyridin-3-yl) amino)nicotinamide Example 2-76

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- (2-methoxyethylamino)pyridin-3-yl) amino)nicotinamide Example 2-77

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- (piperidin-1-yl)pyridin-3-yl)amino)nicotinamide Example 2-78

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- (pyrrolidin-1-yl)pyridin-3-yl)amino)nicotinamide Example 2-79

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- (2-hydroxyethoxy)pyridin-3-yl) amino)nicotinamide Example 2-80

6-(cis-2-aminocyclohexylamino)-2-(6-(bis (2- methoxyethylamino)pyridin-3-yl)amino)-5- fluoronicotinamide Example 2-81

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- (3-morpholinopropylamino)pyridin-3-yl) amino)nicotinamide Example 2-82

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- propoxypyridin-4-yl)amino)nicotinamide Example 2-83

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- butoxypyridin-4-yl)amino)-5-fluoronicotinamide Example 2-84

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- isobutoxypyridin-4-yl)amino)nicotinamide Example 2-85

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (3-methoxybutoxy)pyridin-4-yl) amino)nicotinamide Example 2-86

6-(cis-2-aminocyclohexylamino)-2-((2- (benzyloxy)pyridin-4-yl)amino)-5- fluoronicotinamide Example 2-87

6-(cis-2-aminocyclohexylamino)-2-((3- chloroquinolin-7-yl)amino)-5-fluoronicotinamide Example 2-88

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- methoxyquinolin-7-yl)amino)nicotinamide Example 2-89

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((4- methoxyquinolin-7-yl)amino)nicotinamide Example 2-90

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-methoxyethoxy)quinolin-7-yl) amino)nicotinamide Example 2-91

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- ((1-methoxypropan-2-yl)oxy)quinolin-7-yl) amino)nicotinamide Example 2-92

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (3-methoxybutoxy)quinolin-7-yl) amino)nicotinamide Example 2-93

6-(cis-2-aminocyclohexylamino)-2-((2-(2-(2- ethoxyethoxy)ethoxy)quinolin-7-yl)amino)-5- fluoronicotinamide Example 2-94

6-(cis-2-aminocyclohexylamino)-2-((5- cyclopentylpyridin-3-yl)amino)-5- fluoronicotinamide Example 2-95

6-(cis-2-aminocyclohexylamino)-2-((5-(1- cyclohexen-1-yl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 2-96

6-(cis-2-aminocyclohexylamino)-2-((5- cyclohexylpyridin-3-yl)amino)-5- fluoronicotinamide Example 2-97

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-methoxyethoxy)quinolin-6-yl) amino)nicotinamide Example 2-98

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- ((1-methoxypropan-2-yl)oxy)quinolin-6-yl) amino)nicotinamide Example 2-99

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (3-methoxybutoxy)quinolin-6-yl) amino)nicotinamide Example 2-100

6-(cis-2-aminocyclohexylamino)-2-((2-(2-(2- ethoxyethoxy)ethoxy)quinolin-6-yl)amino)-5- fluoronicotinamide Example 2-101

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- methoxyquinolin-6-yl)amino)nicotinamide Example 2-102

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((1- (2-methoxyethoxy)isoquinolin-5-yl) amino)nicotinamide Example 2-103

6-(cis-2-aminocyclohexylamino)-2-((2- ethoxyquinolin-6-yl)amino)-5-fluoronicotinamide Example 2-104

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- propoxyquinolin-6-yl)amino)nicotinamide Example 2-105

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- isobutoxyquinolin-6-yl)amino)nicotinamide Example 2-106

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- ((S)-2-methylbutoxy)quinolin-6-yl) amino)nicotinamide Example 2-107

6-(cis-2-aminocyclohexylamino)-2-((2-(2- ethoxyethoxy)quinolin-6-yl)amino)-5- fluoronicotinamide Example 2-108

6-(cis-2-aminocyclohexylamino)-2-((2-(2- butoxyethoxy)quinolin-6-yl)amino)-5- fluoronicotinamide Example 2-109

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-isobutoxyethoxy)quinolin-6-yl) amino)nicotinamide Example 2-110

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-(2-methoxyethoxy)ethoxy)quinolin-6-yl) amino)nicotinamide Example 2-111

6-(cis-2-aminocyclohexylamino)-2-((2-(2-(2- butoxyethoxy)ethoxy)quinolin-6-yl)amino)-5- fluoronicotinamide Example 2-112

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- ((tetrahydrofuran-2-yl)methoxy)quinolin-6-yl) amino)nicotinamide Example 2-113

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-(2-oxopyrrolidin-1-yl)ethoxy)quinolin-6-yl) amino)nicotinamide Example 2-114

2-((2-(1H-1,2,4-triazol-1-yl)pyridin-4-yl) amino)-6-(cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 2-115

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((8- methyl-7-oxo-7,8-dihydro-1,8-naphthyridin-3- yl)amino)nicotinamide Example 2-116

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((8- (2-methoxyethyl)-7-oxo-7,8-dihydro-1,8- naphthyridin-3-yl)amino)nicotinamide Example 2-117

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (furan-3-yl)-6-methylpyridin-3-yl) amino)nicotinamide Example 2-118

6-(cis-2-aminocyclohexylamino)-2-((5- cyclopropyl-6-methylpyridin-3-yl)amino)-5- fluoronicotinamide Example 2-119

6-(cis-2-aminocyclohexylamino)-2-((2,3- dimethoxyquinoxalin-6-yl)amino)-5- fluoronicotinamide Example 2-120

6-(cis-2-aminocyclohexylamino)-2-((2,3- diethoxyquinoxalin-6-yl)amino)-5- fluoronicotinamide Example 2-121

6-(cis-2-aminocyclohexylamino)-2-((2,3-bis(2- methoxyethoxy)quinoxalin-6-yl)amino)-5- fluoronicotinamide Example 2-122

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((4- methyl-3,4-dihydro-2H-[1,4]oxazino[2,3- b]quinoxalin-7-yl)amino)nicotinamide Example 2-123

6-(cis-2-aminocyclohexylamino)-2-((2,3- dimethylquinoxalin-6-yl)amino)-5- fluoronicotinamide Example 2-124

6-(cis-2-aminocyclohexylamino)-2-((2,3- diethylquinoxalin-6-yl)amino)-5- fluoronicotinamide Example 2-125

6-(cis-2-aminocyclohexylamino)-2-((1-ethyl- 1H-indazol-5-yl)amino)-5-fluoronicotinamide Example 2-126

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((1- propyl-1H-indazol-5-yl)amino)nicotinamide Example 2-127

6-(cis-2-aminocyclohexylamino)-2-((6-((cis)- 2,6-dimethylmorpholino)pyridin-3-yl)amino)-5- fluoronicotinamide Example 2-128

6-((2-((2-aminoethyl)amino)ethyl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide Example 2-129

2-((2-(2H-1,2,3-triazol-2-yl)pyridin-4-yl) amino)-6-((2-((2-aminoethyl)amino)ethyl)amino)- 5-fluoronicotinamide Example 2-130

2-((2-(1H-1,2,4-triazol-1-yl)pyridin-4-yl) amino)-6-((2-((2-aminoethyl)amino)ethyl)amino)- 5-fluoronicotinamide Example 2-131

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-fluorophenyl)pyridin-4-yl)amino)nicotinamide Example 2-132

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-methoxyphenyl)pyridin-4-yl) amino)nicotinamide Example 2-133

6-(cis-2-aminocyclohexylamino)-2-((2-(2,4- difluorophenyl)pyridin-4-yl)amino)-5- fluoronicotinamide Example 2-134

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- methyl-5-(2H-1,2,3-triazol-2-yl)pyridin-3-yl) amino)nicotinamide Example 2-135

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- methyl-5-(1H-pyrazol-1-yl)pyridin-3-yl) amino)nicotinamide Example 2-136

6-(cis-2-aminocyclohexylamino)-2-((2-(2,4- dimethoxyphenyl)pyridin-4-yl)amino)-5- fluoronicotinamide Example 2-137

2-((5-(1H-1,2,4-triazol-1-yl)pyridin-3-yl) amino)-6-(cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 2-138

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- methyl-5-(1H-1,2,4-triazol-1-yl)pyridin-3-yl) amino)nicotinamide Example 2-139

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-fluoro-3-methoxyphenyl)pyridin-4-yl) amino)nicotinamide Example 2-140

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-fluoro-4-methoxyphenyl)pyridin-4-yl) amino)nicotinamide Example 2-141

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (2-fluoro-5-methoxyphenyl)pyridin-4-yl) amino)nicotinamide Example 2-142

6-(cis-2-aminocyclohexylamino)-2-((6- cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide Example 2-143

2-((3-(1H-pyrazol-1-yl)quinolin-7-yl)amino)-6- (cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 2-144

6-(cis-2-aminocyclohexylamino)-2-((2-(2,3- difluorophenyl)pyridin-4-yl)amino)-5- fluoronicotinamide Example 2-145

6-(cis-2-aminocyclohexylamino)-2-((2-(2,5- difluorophenyl)pyridin-4-yl)amino)-5- fluoronicotinamide Example 2-146

6-(cis-2-aminocyclohexylamino)-2-((2-(3- chloro-2-fluorophenyl)pyridin-4-yl)amino)-5- fluoronicotinamide Example 2-147

6-(cis-2-aminocyclohexylamino)-2-((2-((5- chloro-2-fluorophenyl)pyridin-4-yl)amino)-5- fluoronicotinamide Example 2-148

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- methoxy-5-phenylpyridin-3-yl) amino)nicotinamide Example 2-149

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (2-fluorophenyl)-6-methoxypyridin-3-yl) amino)nicotinamide Example 2-150

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (furan-2-yl)-6-methoxypyridin-3-yl) amino)nicotinamide Example 2-151

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (furan-3-yl)-6-methoxypyridin-3-yl) amino)nicotinamide Example 2-152

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- methoxy-5-methylpyridin-3-yl) amino)nicotinamide Example 2-153

6-(cis-2-aminocyclohexylamino)-2-((5- cyclopropyl-6-methoxypyridin-3-yl)amino)-5- fluoronicotinamide Example 2-154

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- methoxy-5-(1H-pyrazol-1-yl)pyridin-3-yl) amino)nicotinamide Example 2-155

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- methoxy-5-(2H-1,2,3-triazol-2-yl)pyridin-3-yl) amino)nicotinamide Example 2-156

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- (2-oxopyrrolidin-1-yl)pyridin-3-yl) amino)nicotinamide Example 2-157

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- (2-oxopiperidin-1-yl)pyridin-3-yl) amino)nicotinamide Example 2-158

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- (3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)pyridin- 3-yl)amino)nicotinamide Example 2-159

6-(cis-2-aminocyclohexylamino)-2-((6-(2,2- dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin- 4(3H)-yl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 2-160

2-((6-(1H-pyrazol-1-yl)pyridin-3-yl)amino)-6- (cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 2-161

2-((6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl) amino)-6-(cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 2-162

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- (3-oxomorpholino)pyridin-3-yl) amino)nicotinamide Example 2-163

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((3- fluoro-2-methylpyridin-4-yl)amino)nicotinamide Example 2-164

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- fluoro-2-methylpyridin-4-yl)amino)nicotinamide Example 2-165

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((3- fluoro-2-morpholinopyridin-4-yl) amino)nicotinamide Example 2-166

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- fluoro-2-morpholinopyridin-4-yl) amino)nicotinamide Example 2-167

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((3- fluoro-2-phenylpyridin-4-yl)amino)nicotinamide Example 2-168

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- fluoro-2-phenylpyridin-4-yl)amino)nicotinamide Example 2-169

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((6- phenylpyridazin-4-yl)amino)nicotinamide Example 2-170

6-(cis-2-aminocyclohexylamino)-2-((5-(3,4- dimethoxyphenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 2-171

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (3,4,5-trimethoxyphenyl)pyridin-3-yl) amino)nicotinamide Example 2-172

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (4-nitrophenyl)pyridin-3-yl)amino)nicotinamide Example 2-173

6-(cis-2-aminocyclohexylamino)-2-((5-(4- cyanophenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 2-174

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (4-(trifluoromethoxy)phenyl)pyridin-3-yl) amino)nicotinamide Example 2-175

6-(cis-2-aminocyclohexylamino)-2-((5- (benzo[d][1,3]dioxol-5-yl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 2-176

6-(cis-2-aminocyclohexylamino)-2-((2- (benzo[d][1,3]dioxol-5-yl)pyridin-4-yl)amino)-5- fluoronicotinamide Example 2-177

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6- yl)pyridin-3-yl)amino)nicotinamide Example 2-178

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6- yl)pyridin-4-yl)amino)nicotinamide Example 2-179

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (isoquinolin-5-yl)pyridin-3-yl)amino)nicotinamide Example 2-180

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (isoquinolin-5-yl)pyridin-4-yl)amino)nicotinamide Example 2-181

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5- (quinolin-8-yl)pyridin-3-yl)amino)nicotinamide Example 2-182

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (quinolin-8-yl)pyridin-4-yl)amino)nicotinamide Example 2-183

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (3-methoxyphenyl)pyridin-4-yl) amino)nicotinamide Example 2-184

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((2- (4-methoxyphenyl)pyridin-4-yl) amino)nicotinamide Example 2-185

6-((cis-2-aminocyclohexyl)amino)-2-((1-ethyl- 1H-indazol-6-yl)amino)-5-fluoronicotinamide Example 2-186

6-((cis-2-aminocyclohexyl)amino)-2-((1-ethyl- 1H-indazol-4-yl)amino)-5-fluoronicotinamide Example 2-187

6-((cis-2-aminocyclohexyl)amino)-2-((1-(2,2- difluoroethyl)-1H-indazol-5-yl)amino)-5- fluoronicotinamide Example 2-188

6-((cis-2-aminocyclohexyl)amino)-2-((1-(2,2- difluoroethyl)-1H-indazol-6-yl)amino)-5- fluoronicotinamide Example 2-189

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((5-(quinolin-7-yl)pyridin-3-yl) amino)nicotinamide Example 2-190

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((5-(isoquinolin-6-yl)pyridin-3-yl) amino)nicotinamide Example 2-191

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((5-(isoquinolin-7-yl)pyridin-3-yl) amino)nicotinamide Example 2-192

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((2-(quinolin-7-yl)pyridin-4-yl) amino)nicotinamide Example 2-193

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((2-(isoquinolin-6-yl)pyridin-4-yl) amino)nicotinamide Example 2-194

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((2-(isoquinolin-7-yl)pyridin-4-yl) amino)nicotinamide Example 2-195

6-(((cis)-2-aminocyclohexyl)amino)-2- ((benzofuro[2,3-b]pyridin-3-yl)amino)-5- fluoronicotinamide Example 2-196

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((3-fluoro-1-methyl-1H-indazol-5-yl) amino)nicotinamide Example 2-197

6-((cis-2-aminocyclohexyl)amino)-2-((1-ethyl- 3-fluoro-1H-indazol-5-yl)amino)-5- fluoronicotinamide Example 2-198

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((3-fluoro-1-methyl-1H-indazol-6-yl) amino)nicotinamide Example 2-199

6-((cis-2-aminocyclohexyl)amino)-2-((1-ethyl- 3-fluoro-1H-indazol-6-yl)amino)-5- fluoronicotinamide Example 2-200

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((1-(2-fluoroethyl)-1H-indazol-5-yl) amino)nicotinamide Example 2-201

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((1-(2-fluoroethyl)-1H-indazol-6-yl) amino)nicotinamide Example 2-202

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((1-methyl-6-oxo-1,6-dihydropyridin-3-yl) amino)nicotinamide Example 2-203

6-((cis-2-aminocyclohexyl)amino)-2-((5-chloro- 6-methoxypyridin-3-yl)amino)-5- fluoronicotinamide Example 2-204

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((3-fluoro-1-(2-fluoroethyl)-1H-indazol-5-yl) amino)nicotinamide Example 2-205

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((3-fluoro-1-(2-fluoroethyl)-1H-indazol-6-yl) amino)nicotinamide Example 2-206

6-((cis-2-aminocyclohexyl)amino)-2-((1,3- dimethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide Example 2-207

6-((cis-2-aminocyclohexyl)amino)-2-((1-ethyl- 3-methyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide Example 2-208

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((1-(2-methoxyethyl)-3-methyl-1H-indazol-5- yl)amino)nicotinamide Example 2-209

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((1-(2-fluoroethyl)-3-methyl-1H-indazol-5-yl) amino)nicotinamide Example 2-210

6-((cis-2-aminocyclohexyl)amino)-2-((1-(2,2- difluoroethyl)-3-methyl-1H-indazol-5-yl) amino)-5-fluoronicotinamide Number Compound name ¹H-NMR MS (ESI, m/z) Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.14 (s, 1H), 421 (M + H) 2-1 5-fluoro-2-((5-phenylpyridin-3- 9.09 (s, 1H), 8.74-8.67 (m, 2H), 8.08-7.90 HCl salt yl)amino)nicotinamide (m, 5H), 7.88-7.83 (m, 2H), 7.62-7.43 (m, 4H), 7.13-7.06 (m, 1H), 4.28-4.17 (m, 1H), 1.87-1.15 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (CD₃OD), 300 MHz) δ: 8.47 (d, 1H, J = 384 (M + H) 2-2 5-fluoro-2-((imidazo [1, 2-a]pyri- 6.8 Hz), 8.07-7.98 (m, 3H), 7.88 (d, 1H, HCl salt din-3-yl)amino)nicotinamide J = 11.7 Hz), 7.56-7.46 (m, 1H), 3.58-3.52 (m, 1H), 3.13-3.10 (m, 1H), 1.70-1.06 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.53 (s, m), 358 (M + H) 2-3 5-fluoro-2-((3-methylphenyl) 7.95-7.70 (m, 5H), 7.43-7.33 (m, 2H), HCl salt amino)nicotinamide 7.33-7.13 (m, 2H), 6.84 (d, 1H, J = 5.8 Hz), 6.77 (d, 1H, J = 7.6 Hz), 4.30-4.20 (m, 1H), 3.71-3.62 (m, 1H), 2.30 (s, 3H), 1.95-1.36 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d6, 400 MHz) δ: 11.49 (s, 1H), 372 (M + H) 2-4 2-((3,5-dimethylphenyl)amino)-5- 8.00-7.65 (m, 5H), 7.30-7.16 (m, 3H), 6.80 HCl salt fluoronicotinamide (d, 1H, J = 6.8 Hz), 6.59 (s, 1H), 4.34-4.25 (m, 1H), 3.66-3.56 (m, 1H), 2.25 (s, 6H), 1.96-1.85 (m, 2H), 1.72-1.56 (m, 2H), 1.52-1.35 (m, 2H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.60-11.40 429 (M + H) 2-5 5-fluoro-2-((4-(morpholin-4-yl) (br, 1H), 8.00-7.60 (m, 5H), 7.60-7.46 (1H, HCl salt phenyl)amino)nicotinamide 2H), 7.40-7.00 (br, 3H), 6.90-6.83 (m, 1H), 4.23-4.13 (m, 1H), 3.90-3.80 (m, 4H), 3.72-3.62 (m, 1H), 3.32-3.10 (m, 4H), 1.96-1.37 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.59 (s, 1H), 374 (M + H) 2-6 5-fluoro-2-((3-methoxyphenyl) 7.96-7.70 (m, 5H), 7.34-7.15 (m, 3H), HCl salt amino)nicotinamide 7.07-7.03 (m, 1H), 6.89 (d, 1H, J = 6.6 Hz), 6.54 (dd, 1H, J = 2.2, 7.8 Hz), 4.28-4.20 (m, 1H), 3.75 (s, 3H), 3.72-3.63 (m, 1H), 1.95-1.36 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.43 (s, 1H), 434 (M + H) 2-7 5-fluoro-2-((3,4,5-trimethoxy- 8.00-7.66 (m, 5H), 7.35-7.10 (br, 1H), 6.82 HCl salt phenyl)amino)nicotinamide (s, 2H), 6.72 (d, 1H, J = 6.8 Hz), 4.42-4.31 (m, 1H), 3.79 (s, 6H), 3.62 (s, 3H), 3.56-3.45 (m, 1H), 1.95-1.80 (m, 2H), 1.69-1.54 (, 4H), 1.47-1.28 (m, 2H). ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 7.90 (d, 1H, J = 12.4 Hz), 6.84 (s, 2H), 4.42-4.32 (m, 1H), 3.79 (s, 6H), 3.62 (s, 3H), 3.56-3.46 (m, 1H), 1.90-1.30 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.72 (s, 1H), 421 (M + H), 2-8 5-fluoro-2-((2-phenylpyridin-3- 9.08 (s, 1H), 8.42-8.37 (m, 1H), 8.03 (brs, 419 (M − H) HCl salt yl)amino)nicotinamide 3H), 7.92 (d, 1H, J = 12.3 Hz), 7.84-7.61 (m, 4H), 7.58-7.52 (m, 3H), 7.27 (brs, 1H), 7.02 (d, 1H, J = 5.9 Hz), 4.25-4.16 (m, 1H), 3.10-3.90 (1H, overlapping with H₂O), 1.97-1.78 (m, 2H), 1.72-1.57 (m, 4H), 1.51-1.38 (m, 2H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.89 (s, 1H), 421 (M + H), 2-9 5-fluoro-2-((6-phenylpyridin-3- 8.95 (s, 1H), 8.27-8.21 (m, 1H), 8.08-7.85 419 (M − H) HCl salt yl)amino)nicotinamide (m, 8H), 7.54-7.48 (m, 2H), 7.47-7.36 (m, 2H), 6.99 (d, 1H, J = 6.4 Hz), 4.36-4.27 (m, 1H), 3.71-3.64 (m, 1H), 1.96-1.40 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.21 (s, 1H), 375 (M + H), 2-10 5-fluoro-2-((6-methoxypyridin-3- 8.29-8.27 (m, 1H), 7.94-7.66 (m, 6H), 7.24 373 (M − H) HCl salt yl)amino)nicotinamide (brs, 1H), 6.84 (d, 1H, J = 5.8 Hz), 6.82-6.78 (m, 1H), 4.15-4.06 (m, 1H), 3.82 (s, 3H), 3.60-3.54 (m, 1H), 1.91-1.33 (m, 8H). Example 2-((2-acetylphenyl)amino)-6-(cis- ¹H-NMR (CD₃OD, 400 MHz) δ: 8.10-8.05 (m, 386 (M + H), 2-11 2-aminocyclohexylamino)-5- 1H), 7.89-7.84 (m, 1H), 7.71 (d, 1H, J = 384 (M − H) HCl salt fluoronicotinamide 11.7 Hz), 7.52-7.46 (m, 1H), 7.11-7.03 (m, 1H), 4.26-4.17 (m, 1H), 3.78-3.70 (m, 1H), 2.54 (s, 3H), 1.88-1.38 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.94 (s, 1H), 421 (M + H), 2-12 5-fluoro-2-((4-phenylpyridin-3- 9.80 (s, 1H), 8.50 (d, 1H, J = 5.5 Hz), 419 (M − H) HCl salt yl)amino)nicotinamide 8.08-7.96 (m, 3H), 7.95 (d, 1H, J = 12.3 Hz), 7.85-7.71 (m, 2H), 7.58-7.51 (m, 5H), 7.33 (brs, 1H), 7.05 (d, 1H, J = 6.2 Hz), 4.37-4.28 (m, 1H), 3.62-3.53 (m, 1H), 1.94-1.37 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.51 (s, m), 375 (M + H), 2-13 5-fluoro-2-((2-methoxypyridin-4- 8.16-7.99 (m, 6H), 7.58 (brs, 1H), 7.40 (s, 373 (M − H) HCl salt yl)amino)nicotinamide 1H), 7.30 (brs, 1H), 7.14 (d, 1H, J = 6.5 Hz), 4.38-4.26 (m, 1H), 3.99 (s, 3H), 3.67-3.55 (m, 1H), 2.00-1.36 (m, 8H). Example 6-(cis-2-aminocyclohoxylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.93 (s, 1H), 405 (M + H), 2-14 2-((2,6-dimethoxypyridin-4-yl) 8.01-7.85 (m, 5H), 7.38 (brs, 1H), 7.05 (d, 403 (M − H) HCl salt amino)-5-fluoronicotinamide 1H, J = 6.0 Hz), 6.59 (s, 2H), 4.25-4.16 (m, 1H), 3.80 (s, 6H), 3.72-3.64 (m, 1H), 1.98-1.35 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.52 (s, 1H), 430 (M + H), 2-15 5-fluoro-2-((2-(morpholin-4-yl) 8.16-7.99 (m, 5H), 7.91 (d, 1H, J = 7.1 Hz), 428 (M − H) HCl salt pyridin-4-yl)amino)nicotinamide 7.62 (s, 1H), 7.38-7.27 (m, 1H), 7.20 (s, 1H), 7.12-7.03 (m, 1H), 4.39-4.30 (m, 1H), 3.86-3.70 (m, 4H), 3.62-3.50 (m, 5H), 1.98-1.35 (m, 8H). Example 6-(cis-2-aminocyclohexylamirio)- ¹H-NMR (D₂O, 400 MHz) δ: 7.88 (d, 1H, J = 443 (M − H), 2-16 5-fluoro-2-((2-(4-methylpiperazin- 7.1 Hz), 7.74 (d, 1H, J = 11.5 Hz), 441 (M − H) 2HCl salt 1-yl)pyridin-4-yl)amino)nico- 7.57-7.51 (m, 1H), 6.94-6.89 (m, 1H), tinamide 4.55-4.46 (m, 1H), 4.19-3.10 (m, 9H), 2.99 (s, 3H), 1.95-1.47 (m, 8H). Example 6-(cis-2-aminocyclohexylatnino)- ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 8.00 (d, 415 (M + H) 2-17 5-fluoro-2-((2-(pyrrolidin-1-yl) 1H, J = 11.8 Hz), 7.73 (d, 1H, J = 7.2 Hz), HCl salt pyridin-4-yl)amino)nicotinamide 7.14 s, 1H), 7.02-6.97 (m, 1H), 4.47-4.41 (m, 1H), 3.56-3.42 (m, 5H), 2.09-2.01 (m, 4H), 1.92-1.40 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 8.03-7.96 428 (M + H), 2-18 5-fluoro-2-((2-(piperidin-1-yl) (m, 1H), 7.81-7.76 (m, 1H), 7.29 (s, 1H), 426 (M − H) HCl salt pyridin-4-yl)amino)nicotinamide 7.18-7.12 (m, 1H), 4.42-4.35 (m, 1H), 3.59-3.50 (m, 5H), 1.92-1.38 (m, 14H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 8.32 (d, 457 (M + H) 2-19 5-fluoro-2-((6-((2-(pyrrolidin- 1H, J = 2.3 Hz), 7.93 (dd, 1H, J = 2.3, 9.3 HCl salt 1-yl)ethyl)amino)pyridin-3-yl) Hz), 7.90 (d, 1H, J = 12.2 Hz), 6.93 (d, 1H, amino)nicotinamide J = 9.4 Hz), 4.24-4.17 (m, 1H), 3.72-3.65 (m, 2H), 3.60-3.54 (m, 1H), 3.43-3.35 (m, 2H), 2.60-2.50 (1H, overlapping with H₂O), 2.05-1.92 (m, 4H), 1.88-1.37 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 8.36 (d, 430 (M + H), 2-20 5-fluoro-2-((6-(morpholin-4-yl) 1H, J = 2.6 Hz), 7.96 (dd, 1H, J = 2.6, 9.4 428 (M − H) HCl salt pyridin-3-yl)amino)nicotinamide Hz), 7.88 (d, 1H, J = 12.2 Hz), 7.12 (d, 1H, J = 9.4 Hz), 4.21-4.14 (m, 1H), 3.78-3.72 (m, 4H), 3.60-3.54 (m, 1H), 3.49-3.43 (m, 4H), 1.88-1.38 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 8.41 (d, 443 (M + H) 2-21 5-fluoro-2-((6-(4-methylpiperazin- 1H, J = 2.7 Hz), 7.94 (dd, 1H, J = 2.7, 9.2 2HCl salt 1-yl)pyridin-3-yl)amino)nico- Hz), 7.88 (d, 1H, J = 12.2 Hz), 7.06 (d, tinamide 1H, J = 9.2 Hz), 4.36-4.12 (m, 2H), 3.63-3.48 (m, 4H), 3.22-3.06 (m, 4H), 2.86 (s, 3H), 1.89-1.38 (m, 8H). Mass Mass Number Salt Solvent NMR 1HNMR (M + H) (M − H) rt(min) Example 2-22 HCl DMSO-d6 400 MHz δ: 14.04 (s, 1H), 12.84 (s, 1H), 8.18- 373 371 8.31 8.12 (m, 1H), 8.09 (d, 1H, J = 12.2 Hz), 8.08-7.86 (m, 3H), 7.80-7.70 (m, 3H), 7.28-7.21 (m, 1H), 4.40-4.30 (m, 1H), 3.67-3.58 (m, 1H), 2.57 (s, 6H), 2.05-1.35 (m, 8H). Example 2-23 HCl DMSO-d6 400 MHz δ: 12.15 (s, 1H), 9.02-8.90 (m, 1H), 435 433 8.45 8.51 (s, 1H), 8.02 (d, 1H, J = 12.2 Hz), 8.00-7.87 (m, 4H), 7.58-7.45 (m, 6H), 7.06 (d, 1H, J = 7.1 Hz), 4.15-4.06 (m, 1H), 3.43-3.35 (m, 1H), 2.54 (s, 3H), 1.80-1.10 (m, 8H). Example 2-24 HCl DMSO-d6 400 MHz δ: 12.02 (s, 1H), 9.02 (s, 1H), 8.24(s, 373 371 10.61 1H), 8.02 (d, 1H, J = 12.2 Hz), 8.02- 7.90 (m, 4H), 7.48 (s, 1H), 7.04 (d, 1H, J = 6.3 Hz), 4.36-4.28(m, 1H), 3.60- 3.50 (m, 1H), 2.58(s, 3H), 2.38 (s, 3H), 1.95-1.35(m, 8H). Example 2-25 free 384 382 0.8 Example 2-26 free 481 479 0.68 Example 2-27 free 497 495 0.67 Example 2-28 free 438 436 1.05 Example 2-29 free 474 472 1.12 Example 2-30 free 442 440 0.9 Example 2-31 free 500 498 0.97 Example 2-32 HCl 438 436 0.95 Example 2-33 HCl 474 472 1.05 Example 2-34 HCl 442 440 0.86 Example 2-35 HCl 500 498 0.92 Example 2-36 free 474 472 1.08 Example 2-37 free 474 472 1.02 Example 2-38 HCl DMSO-d6 300 MHz δ: 12.12 (s, 1H), 9.18 (s, 1H), 8.35 (s, 1H), 8.25 (s, 1H), 8.06-7.90 (m, 5H), 7.48 (br, 1H), 7.06 (d, 1H, J = 7.2 Hz), 373 371 7.28 4.40-4.28 (m, 1H), 3.60-3.48 (m, 1H), 2.76 (q, 2H, J = 7.5 Hz), 2.00-1.35 (m, 8H), 1.25 (t, 3H, J = 7.5 Hz). Example 2-39 HCl DMSO-d6 300 MHz δ: 12.12(s, 1H), 9.24 (s , 1H), 8.39 (s, 1H), 8.22 (s, 1H), 8.26-7.88 (m, 5H), 7.49 (br, 1H), 7.0 5(d, 1H, J = 7.2 Hz), 387 385 7.87 4.40-4.29 (m, 1H), 3.60-3.46 (m, 1H), 3.15-3.06 (m, 1H), 2.00-1.35 (m, 8H), 1.29 (d, 6H, J = 6.6 Hz). Example 2-40 free DMSO-d6 300 MHz δ: 11.92(s, 1H), 8.69 (s, 1H), 8.04- 7.86 (m, 5H), 7.43 (br, 1H), 7.24 (s, 1H), 6.99 (d, 1H, J = 6.6 Hz), 4.36- 428 426 7.83 4.24 (m, 1H), 3.60-3.40 (m, 5H), 2.72 (s, 3H), 2.00-1.35 (m, 12H). Example 2-41 free 398 396 0.77 Example 2-42 free 438 436 0.98 Example 2-43 free 474 472 1.07 Example 2-44 free 442 440 0.85 Example 2-45 free 500 498 0.93 Example 2-46 free 438 436 0.98 Example 2-47 free 474 472 1.06 Example 2-48 free 442 440 0.88 Example 2-49 free 500 498 0.94 Example 2-50 HCl DMSO-d6 300 MHz δ: 12.32 (s, 1H), 8.48 (d, 1H, J = 5.6 413 411 Hz), 8.24 (d, 1H, J = 2.0 Hz), 8.03 (d, 1H, J = 12.2 Hz), 8.02-7.80 (m, 4H), 7.62 (dd, 1H, J = 2.0, 5.6 Hz), 7.59- 7.46 (m, 1H), 7.04 (d, 1H, J = 6.6 Hz), 4.40-4.29 (m, 1H), 3.63-3.54 (m, 1H), 2.01-1.82 (m, 2H), 1.80-1.32 (m, 6H). Example 2-51 HCl DMSO-d6 300 MHz δ: 14.35 (br, 1H), 12.89 (s, 1H), 410 408 0.67 12.31 (s, 1H), 8.39-8.28 (m, 1H), 8.22-8.05 (m, 6H), 7.80-7.65 (m, 1H), 7.35-7.20 (m, 3H), 6.38-6.33 (m, 1H), 4.40-4.26 (m, 1H), 3.70-3.55 (m, 1H), 2.00-1.40 (m, 8H). Example 2-52 HCl DMSO-d6 300 MHz δ: 13.02 (s, 1H), 8.54 (d, 1H, J = 6.6 421 419 0.71 Hz), 8.46-8.38 (m, 1H), 8.25-7.60 (m, 12H), 7.34-7.26 (m, 1H), 4.32-4.20 (m, 1H), 3.72-3.59 (m, 1H), 1.95-1.15 (m, 8H). Example 2-53 HCl DMSO-d6 300 MHz δ: 12.85 (br, 1H), 8.45-8.33 (m, 2H), 411 409 0.67 8.18-7.96 (m, 6H), 7.76-7.60 (m, 3H), 7.27-7.18 (m, 1H), 6.88-6.82 (m, 1H), 4.47-4.35 (m, 1H), 3.70-3.58 (m, 1H), 2.00-1.35 (m, 8H). Example 2-54 HCl DMSO-d6 300 MHz δ: 12.54(s, 1H), 8.25-7.95 (m, 7H), 428 426 0.65 7.70-7.50 (m, 2H), 7.13 (d, 1H, J = 7.4 Hz), 4.50-4.36 (m, 1H), 4.14-3.92 (m, 2H), 3.70-3.58 (m, 1H), 2.70-2.60 (m, 2H), 2.20-2.05 (m, 2H), 2.00-1.35 (m, 8H). Example 2-55 HCl DMSO-d6 300 MHz δ: 12.30 (s, 1H), 8.10-7.93 (m, 5H), 403 401 7.92-7.83 (m, 1H), 7.53-7.47 (m, 1H), 7.45-7.40 (m, 1H), 7.22 (d, 1H, J = 6.3 Hz), 7.20-7.05 (m, 1H), 5.22-5.11 (m, 1H), 4.29-4.18 (m, 1H), 3.74-3.66 (m, 1H), 2.05-1.35 (m, 8H), 1.35-1.29 (m, 6H). Example 2-56 2HCl DMSO-d6 300 MHz δ: 12.16 (s, 1H), 10.68-10.05 (m, 459 457 1H), 8.10-7.92 (m, 6H), 7.55-7.40 (m, 1H), 7.35-7.30 (m, 1H), 7.15-7.05 (m, 1H), 4.69-4.50 (m, 2H), 4.36-4.24 (m, 1H), 3.73-3.63 (m, 1H), 3.62-3.48 (m, 4H), 3.22-3.00 (m, 2H), 2.08-1.37 (m, 12H). Example 2-57 HCl DMSO-d6 300 MHz δ: 12.88 (s, 1H), 8.83 (s, 1H), 8.48 (d, 411 409 0.68 1H, J = 6.6 Hz), 8.25-7.95 (m, 8H), 7.73 (br, 1H), 7.40 (s, 1H), 7.30 (d, 1H, J = 5.7 Hz), 4.40-4.24 (m, 1H), 3.68- 3.54 (m, 1H), 2.00-1.30 (m, 8H). Example 2-58 HCl DMSO-d6 300 MHz δ: 12.62-12.52 (m, 1H), 12.43 (s, 374 372 1H), 8.35-8.23 (m, 1H), 8.13-7.96 (m, 4H), 8.05 (d, 1H, J = 12.2 Hz), 7.80-7.73 (m, 1H), 7.68-7.59 (m, 1H), 7.26-7.20 (m, 1H), 7.01 (d, 1H, J = 6.6 Hz), 6.90 (d, 1H, J = 5.9 Hz), 4.50-4.38 (m, 1H), 3.66-3.55 (m, 1H), 2.92 (d, 3H, J = 5.0 Hz), 1.98-1.32 (m, 8H). Example 2-59 HCl DMSO-d6 300 MHz δ: 12.58-12.50 (m, 1H), 12.37 (s, 388 386 1H), 8.36-8.27 (m, 1H), 8.12-7.98 (m, 4H), 8.04 (d, 1H, J = 12.2 Hz), 7.80-7.71 (m, 1H), 7.67-7.58 (m, 1H), 7.20 (s, 1H), 7.06 (d, 1H, J = 6.6 Hz), 6.96 (d, 1H, J = 5.9 Hz), 4.47- 4.35 (m, 1H), 3.63-3.56 (m, 1H), 3.39-3.26 (m, 2H), 2.02-1.36 (m, 8H), 1.21 (t, 3H, J = 7.1 Hz). Example 2-60 HCl DMSO-d6 300 MHz δ: 12.54 (s, 1H), 8.16-8.00 (m, 6H), 389 387 7.66-7.55 (m, 1H), 7.45 (s, 1H), 7.36- 7.25 (m, 1H), 7.22 (d, 1H, J = 6.6 Hz), 4.44-4.25 (m, 3H), 3.67-3.57 (m, 1H), 2.05-1.38 (m, 8H), 1.37 (t, 3H, J = 6.9 Hz). Example 2-61 HCl DMSO-d6 300 MHz δ: 11.92 (s, 1H), 8.02-7.80 (m, 4H), 433 431 7.96 (d, 1H, J = 12.6 Hz), 7.46-7.32 (m, 1H), 7.17 (d, 1H, J = 5.9 Hz), 6.57 (s, 2H), 4.28-4.17 (m, 1H), 4.23 (q, 4H, J = 6.9 Hz), 3.77-3.66 (m, 1H), 2.00-1.37 (m, 8H), 1.29 (t, 6H, J = 6.9 Hz). Example 2-62 HCl DMSO-d6 300 MHz δ: 11.98 (s, 1H), 8.93-8.88 (m, 1H), 425 423 0.88 8.64-8.6 1(m, 1H), 8.42-8.37 (m, 1H), 8.02 (d, 1H, J = 12.3 Hz), 8.00-7.88 (m, 4H), 7.45 (br, 1H), 7.20 (d, 1H, J = 3.0 Hz), 7.04(d, 1H, J = 6.6 Hz), 6.33 (d, 1H, J = 3.0 Hz), 4.32-4.25 (m, 1H), 3.63-3.43 (m, 1H), 2.40 (s, 3H), 1.95- 1.25 (m, 8H). Example 2-63 HCl DMSO-d6 300 MHz δ: 12.83 (br, 1H), 8.38 (d, 1H, J = 7.2 425 423 0.74 Hz), 8.20-7.98 (m, 6H), 7.88-7.56 (m, 3H), 7.26-7.16 (m, 1H), 6.49 (d, 1H, J = 2.7 Hz), 4.45-4.33 (m, 1H), 3.65- 3.53 (m, 1H), 2.46 (s, 3H), 2.05-1.30 (m, 8H). Example 2-64 HCl DMSO-d6-D2O 300 MHz δ: 8.50 (d, 1H, J = 6.3 Hz), 8.24 (d, 384 382 1H, J = 1.7 Hz), 8.05 (d, 1H, J = 7.3 Hz), 7.96 (d, 1H, J = 12.2 Hz), 7.96 (d, 1H, J = 1.7 Hz), 7.36-7.28 (m, 1H), 3.84-3.77 (m, 1H), 3.41-3.30 (m, 1H), 1.84-1.20 (m, 8H). Example 2-65 HCl DMSO-d6-D2O 300 MHz δ: 8.64-8.00 (m, 2H), 7.95 (d, 1H, J = 452 450 12.2 Hz), 7.57-7.42 (m, 4H), 7.24 (d, 1H, J = 1.7 Hz), 4.32-4.22 (m, 1H), 3.96 (s, 3H), 3.71-3.61 (m, 1H), 1.92-1.32 (m, 8H). Example 2-66 HCl DMSO-d6-D2O 300 MHz δ: 8.01 (d, 1H, J = 6.6 Hz), 7.98 (d, 419 417 1H, J = 11.9 Hz), 7.52-7.48 (m, 1H), 7.33-7.25 (m, 1H), 4.46-4.38 (m, 2H), 4.36-4.26 (m, 1H), 3.76-3.69 (m, 2H), 3.71-3.63 (m, 1H), 3.33 (s, 3H), 1.98-1.40 (m, 8H). Example 2-67 HCl DMSO-d6 300 MHz δ: 8.06-7.99 (m, 2H), 7.95 (d, 1H, J = 496 494 11.9 Hz), 7.56-7.44 (m, 3H), 7.44- 7.37 (m, 2H), 4.55-4.43 (m, 2H), 4.30-4.18 (m, 1H), 3.77-3.67 (m, 3H), 3.33 (s, 3H), 1.96-1.33 (m, 8H). Example 2-68 HCl DMSO-d6 300 MHz δ: 7.98 (d, 1H, J = 12.2 Hz), 7.92- 507 505 7.84 (m, 2H), 7.79 (s, 1H), 7.62-7.53 (m, 3H), 6.89 (s, 1H), 4.30-4.20 (m, 1H), 3.82-3.73 (m, 4H), 3.62-3.52 (m, 4H), 3.51-3.44 (m, 1H), 1.87-1.05 (m, 8H). Example 2-69 HCl DMSO-d6 300 MHz δ: 12.02 (s, 1H), 9.05 (s, 1H), 8.70 (s, 411 409 0.6 1H), 8.56 (s, 1H), 8.38 (s, 2H), 8.02 (d, 1H, J = 12.6 Hz), 8.01-7.94 (m, 4H), 7.48 (br, 1H), 7.08 (d, 1H, J = 6.6 Hz), 4.33-4.22 (m, 1H), 3.65-3.50 (m, 1H), 1.90-1.25 (m, 8H). Example 2-70 HCl DMSO-d6 300 MHz δ: 14.50 (br, 1H), 12.83 (s, 1H), 411 409 0.6 8.46-8.37 (m, 1H), 8.20-7.86 (m, 9H), 7.71 (s, 1H), 7.34-7.22 (m, 1H), 4.38- 4.26 (m, 1H), 3.66-3.54 (m, 1H), 1.95- 1.20 (m, 8H). Example 2-71 HCl DMSO-d6 300 MHz δ: 11.47 (s, 1H), 8.50-8.42 (m, 1H), 444 442 0.77 7.97-7.70 (m, 6H), 7.30 (br, 1H), 6.85 (d, 1H, J = 6.6 Hz), 4.32-4.21 (m, 1H), 3.78-3.70 (m, 4H), 3.70-3.50 (m, 1H), 3.14-3.06 (m, 4H), 2.30 (s, 3H), 1.95- 1.35 (m, 8H). Example 2-72 HCl DMSO-d6 300 MHz δ: 11.35 (s, 1H), 8.32(d, 1H, J = 2.7 496 494 0.96 Hz), 8.27-8.24 (m, 1H), 8.08 (d, 1H, J = 2.7 Hz), 7.92 (d, 1H, J = 12.3 Hz), 7.82-7.70 (m, 5H), 7.26 (br, 1H), 7.09 (d, 1H, J = 1.2 Hz), 6.89 (d, 1H, 5.1 Hz), 4.12-4.00 (m, 1H), 3.73-3.66 (m, 4H), 3.55-3.40 (m, 1H), 3.04-2.90 (m, 4H), 1.85-1.15 (m, 8H). Example 2-73 HCl DMSO-d6 300 MHz δ: 11.38 (s, 1H), 8.64 (br, 1H), 8.42 374 372 (d, 1H, J = 2.0 Hz), 8.10-7.75 (m, 4H), 7.96 (d, 1H, J = 12.6 Hz), 7.92 (dd, 1H, J = 2.0, 9.6 Hz), 7.32 (br, 1H), 7.04 (d, 1H, J = 9.6 Hz), 6.83 (d, 1H, J = 6.6 Hz), 4.37-4.26 (m, 1H), 3.62- 3.43 (m, 1H), 2.99 (d, 3H, J = 4.3 Hz), 1.95-1.30 (m, 8H). Example 2-74 HCl DMSO-d6 300 MHz δ: 11.38 (s, 1H), 8.52 (s, 1H), 8.05- 388 386 7.70 (m, 5H), 7.95 (d, 1H, J = 12.6 Hz), 7.45-7.05 (m, 2H), 6.79 (d, 1H, J = 6.6 Hz), 4.39-4.26 (m, 1H), 3.62- 3.51 (m, 1H), 3.20 (s, 6H), 1.92-1.31 (m, 8H). Example 2-75 HCl DMSO-d6-D2O 300 MHz δ: 8.22 (d, 1H, J = 2.3 Hz), 7.98 (dd, 404 402 1H, J = 2.3, 9.6 Hz), 7.90 (d, 1H, J = 9.6 Hz), 7.10 (d, 1H, J = 9.6 Hz), 4.24-4.15 (m, 1H), 3.65 (t, 2H, J = 5.3 Hz), 3.59-3.51 (m, 1H), 3.42 (t, 2H, J = 5.3 Hz), 1.90-1.37 (m, 8H). Example 2-76 HCl DMSO-d6-D2O 300 MHz δ: 8.22 (d, 1H, J = 2.1 Hz), 7.98 (dd, 418 416 1H, J = 2.1, 9.5 Hz), 7.90 (d, 1H, J = 12.2 Hz), 7.08 (d, 1H, J = 9.5 Hz), 4.24-4.14 (m, 1H), 3.61-3.46 (m, 5H), 3.31 (s, 3H), 1.92-1.36 (m, 8H). Example 2-77 HCl DMSO-d6-D2O 300 MHz δ: 8.32 (d, 1H, J = 2.6 Hz), 8.02 (dd, 429 427 1H, J = 2.6, 9.7 Hz), 7.90 (d, 1H, J = 12.2 Hz), 7.32 (d, 1H, J = 9.7 Hz), 4.26-4.17 (m, 1H), 3.64-3.45 (m, 5H), 1.90-1.37 (m, 14H). Example 2-78 HCl DMSO-d6 300 MHz δ: 11.37 (s, 1H), 8.46 (s, 1H), 8.03- 414 412 7.70 (m, 5H), 7.95 (d, 1H, J = 12.2 Hz), 7.43-7.23 (m, 1H), 7.13-6.95 (m, 1H), 6.80 (d, 1H, J = 7.3 Hz), 4.36- 4.25 (m, 1H), 3.60-3.48 (m, 5H), 2.10-1.97 (m, 4H), 1.93-1.32 (m, 8H). Example 2-79 HCl DMSO-d6-D2O 300 MHz δ: 8.29 (d, 1H, J = 2.6 Hz), 7.90 (dd, 405 403 1H, J = 2.6, 8.8 Hz), 7.86 (d, 1H, J = 12.2 Hz), 6.86 (d, 1H, J = 5.1 Hz), 4.24 (t, 2H, J = 5.1 Hz), 4.18-4.09 (m, 1H), 3.73 (t, 2H, J = 5.1 Hz), 3.64-3.57 (m, 1H), 1.90-1.36 (m, 8H). Example 2-80 HCl CD3OD 300 MHz δ: 8.48 (d, 1H, J = 2.6 Hz), 8.04 (dd, 477 475 1H, J = 2.6, 9.9 Hz), 7.82 (d, 1H, J = 11.9 Hz), 7.39 (d, 1H, J = 9.9 Hz), 4.57-4.47 (m, 1H), 3.89 (t, 4H, J = 5.0 Hz), 3.80-3.75 (m, 1H), 3.70 (t, 4H, J = 5.0 Hz), 3.37 (s, 6H), 1.94- 1.52 (m, 8H). Example 2-81 2HCl DMSO-d6-D2O 300 MHz δ: 8.29 (d, 1H, J = 2.5 Hz), 7.95 (dd, 487 485 1H, J = 2.5, 9.5 Hz), 7.91 (d, 1H, J = 12.2 Hz), 6.98 (d, 1H, J = 9.5 Hz), 4.28-4.18 (m, 1H), 3.95-3.80 (m, 6H), 3.62-3.52 (m, 1H), 3.45-3.37 (m, 2H), 3.35-3.51 (m, 4H), 2.08-1.94 (m, 2H), 1.92-1.34 (m, 8H). Example 2-82 HCl DMSO-d6 300 MHz δ: 12.60 (s, 1H), 8.22-8.02 (m, 6H), 403 401 0.74 7.62 (s, 1H), 7.48 (s, 1H), 7.33 (s, 1H), 7.23 (d, 1H, J = 6.9 Hz), 4.39-4.21 (m, 3H), 3.60-3.50 (m, 1H), 2.05-1.58 (m, 8H), 1.54-1.36 (m, 2H), 1.01 (t, 3H, J = 7.4 Hz). Example 2-83 HCl DMSO-d6 300 MHz δ: 12.63 (s, 1H), 8.25-8.02 (m, 6H), 417 415 0.83 7.62 (s, 1H), 7.48 (s, 1H), 7.37 (s, 1H), 7.25 (d, 1H, J = 6.6 Hz), 4.44-4.26 (m, 3H), 3.60-3.50 (m, 1H), 2.05-1.61 (m, 8H), 1.55-1.36 (m, 4H), 0.95 (t, 3H, J = 7.3 Hz). Example 2-84 HCl DMSO-d6 300 MHz δ: 12.67 (s, 1H), 8.33-8.03 (m, 6H), 417 415 0.82 7.64 (s, 1H), 7.50 (s, 1H), 7.37 (s, 1H), 7.24 (d, 1H, J = 6.6 Hz), 4.41-4.29 (m, 1H), 4.25-4.05 (m, 2H), 3.60-3.50 (m, 1H), 2.15-1.58 (m, 7H), 1.55-1.35 (m, 2H), 1.04-0.99 (m, 6H). Example 2-85 HCl DMSO-d6-D2O 300 MHz δ: 8.02 (d, 1H, J = 6.6 Hz), 8.00 (d, 447 445 0.75 1H, J = 11.9 Hz), 7.52 (s, 1H), 7.28 (d, 1H, J = 5.9 Hz), 4.43-4.27 (m, 3H), 3.69-3.59 (m, 1H), 3.59-3.47 (m, 1H), 3.24 (s, 3H), 2.02-1.35 (m, 10H), 1.16 (d, 3H, J = 6.3 Hz). Example 2-86 HCl DMSO-d6 300 MHz δ: 12.46 (s, 1H), 8.15-7.97 (m, 6H), 451 449 0.94 7.62-7.12 (m, 9H), 5.46-5.34 (m, 2H) 4.31-4.19 (m, 1H), 3.60-3.50 (m, 1H), 1.92-1.47 (m, 6H), 1.43-1.17 (m, 2H). Example 2-87 free 429 427 1.07 Example 2-88 HCl 425 423 1.06 Example 2-89 HCl 425 423 0.69 Example 2-90 HCl 469 467 1.05 Example 2-91 HCl 483 481 1.15 Example 2-92 HCl 497 495 1.19 Example 2-93 HCl 527 525 1.12 Example 2-94 HCl DMSO-d6 300 MHz δ: 12.04 (s, 1H), 9.20-9.13 (m, 1H), 413 411 0.86 8.37-8.32 (m, 1H), 8.20-8.14 (m, 1H), 8.01 (d, 1H, J = 12.6 Hz), 8.00-7.80 (m, 4H), 7.48 (br, 1H), 7.05 (d, 1H, J = 6.6 Hz), 4.36-4.26 (m, 1H), 3.60-3.45 (m, 1H), 3.20-3.02 (m, 1H), 2.16-2.02 (m, 2H), 1.95-1.35 (m, 14H). Example 2-95 HCl DMSO-d6 300 MHz δ: 11.98 (s, 1H), 9.02-8.86 (m, 1H), 425 423 0.9 8.42-8.38 (m, 1H), 8.31-8.26 (m, 1H), 8.00 (d, 1H, J = 12.0 Hz), 8.00-7.80 (m, 4H), 7.45 (br, 1H), 7.06(d, 1H, J = 7.2 Hz), 6.50-6.43 (m, 1H), 4.30-4.18 (m, 1H), 3.63-3.43 (m, 1H), 2.50-2.37 (m, 2H), 2.30-2.18 (m, 2H), 1.90-1.35 (m, 12H). Example 2-96 HCl DMSO-d6 300 MHz δ: 12.01 (s, 1H), 9.10-9.02 (m, 1H), 427 425 0.88 8.32-8.28 (m, 1H), 8.20-8.09 (m, 1H), 8.00 (d, 1H, J = 11.7 Hz), 8.00-7.78 (m, 4H), 7.46 (br, 1H), 7.04 (d, 1H, J = 7.5 Hz), 4.38-4.26 (m, 1H), 3.60-3.55 (m, 1H), 2.75-2.62 (m, 1H), 1.90-1.15 (m, 18H). Example 2-97 HCl 469 467 1 Example 2-98 HCl 483 481 1.1 Example 2-99 HCl 497 495 1.14 Example 2-100 HCl 527 525 1.07 Example 2-101 HCl 425 423 1.02 Example 2-102 HCl 469 467 1.01 Example 2-103 HCl 439 437 1.1 Example 2-104 HCl 453 451 1.21 Example 2-105 HCl 467 465 1.3 Example 2-106 HCl 481 479 1.39 Example 2-107 HCl 483 481 1.09 Example 2-108 HCl 511 509 1.29 Example 2-109 HCl 511 509 1.3 Example 2-110 HCl 513 511 1 Example 2-111 HCl 555 553 1.26 Example 2-112 HCl 495 493 1.07 Example 2-113 HCl 522 520 0.93 Example 2-114 HCl DMSO-d6 300 MHz δ: 12.36 (s, 1H), 9.35 (s, 1H), 8.57- 412 410 0.82 8.53 (m, 1H), 8.33 (s, 1H), 8.29-8.24 (m, 1H), 8.80-7.94 (m, 2H), 7.94-7.80 (m, 3H), 7.54 (br, 1H), 7.28-7.21 (m, 1H), 7.09 (d, 1H, J = 6.6 Hz), 4.59- 4.45 (m, 1H), 3.73-3.60 (m, 1H), 2.00- 1.35 (m, 8H). Example 2-115 HCl DMSO-d6 300 MHz δ: 11.57 (s, 1H), 8.78 (d, 1H, J = 1.8 426 424 0.8 Hz), 8.42 (d, 1H, J = 1.8 Hz), 7.95 (d, 1H, J = 12.6 Hz), 7.92 (d, 1H, J = 9.6 Hz), 7.86-7.64 (m, 4H), 7.34 (br, 1H), 6.86 (d, 1H, J = 7.2 Hz), 6.73 (d, 1H, J = 9.6 Hz), 4.30-4.18 (m, 1H), 3.68 (s, 3H), 3.65-3.56 (m, 1H), 1.90-1.35 (m, 8H). Example 2-116 HCl DMSO-d6 300 MHz δ: 11.58 (s, 1H), 8.79 (d, 1H, J = 1.8 470 468 0.83 Hz), 8.40 (d, 1H, J = 1.8 Hz), 8.05- 7.75 (m, 6H), 7.33 (br, 1H), 6.91 (d, 1H, J = 6.0 Hz), 6.71 (d, 1H, J = 9.3 Hz), 4.58 (t, 2H, J = 6.0 Hz), 4.32- 4.16 (m, 1H), 3.61 (t, 2H, J = 6.0 Hz), 3.55-3.40 (m, 1H), 3.27 (s, 3H), 1.95- 1.35 (m, 8H). Example 2-117 HCl DMSO-d6 300 MHz δ: 12.02 (s, 1H), 8.99 (s, 1H), 8.51 (s, 425 423 0.74 1H), 8.23 (s, 1H), 8.0 1(d, 1H, J = 12.6 Hz), 8.00-7.86 (m, 5H), 7.46 (br, 1H), 7.09-7.03 (m, 2H), 4.28-4.16 (m, 1H), 3.50-3.30 (m, 1H), 2.69 (s, 3H), 1.85- 1.25 (m, 8H), . Example 2-118 HCl DMSO-d6 300 MHz δ: 11.89 (s, 1H), 9.08-9.01 (m, 1H), 399 397 0.69 8.04-7.78 (m, 6H), 7.44 (br, 1H), 7.01 (d, 1H, J = 7.5 Hz), 4.36-4.24 (m, 1H), 3.60-3.45 (m, 1H), 2.71 (s, 3H), 2.10- 1.98 (m, 1H), 1.95-1.35 (m, 8H), 1.10- 1.00 (m, 2H), 0.92-0.80 (m, 2H). Example 2-119 HCl 456 454 1.05 Example 2-120 HCl 484 482 1.21 Example 2-121 HCl 544 542 1.36 Example 2-122 HCl 467 465 1.12 Example 2-123 HCl 424 422 0.91 Example 2-124 HCl 452 450 1.12 Example 2-125 HCl 412 410 0.91 Example 2-126 HCl 426 424 0.98 Example 2-127 HCl DMSO-d6-D2O 300 MHz δ: 8.40 (d, 1H, J = 2.6 Hz), 8.03 (dd, 458 456 0.76 1H, J = 2.6, 9.6 Hz), 7.91 (d, 1H, J = 12.2 Hz), 7.27 (d, 1H, J = 9.6 Hz), 4.29-4.18 (m, 1H), 4.06-3.95 (m, 2H), 3.76-3.62 (m, 2H), 3.60-3.50 (m, 1H), 2.74-2.62 (m, 2H), 1.92-1.36 (m, 8H), 1.19 (d, 6H, J = 5.9 Hz). Example 2-128 HCl 384 382 0.46 Example 2-129 HCl 401 399 0.55 Example 2-130 HCl 401 399 0.58 Example 2-131 HCl DMSO-d6 300 MHz δ: 12.94 (br, 1H), 8.62-8.55 (m, 1H), 439 437 0.69 8.40-8.28 (m, 1H), 8.20-8.02 (m, 2H), 8.00-7.62 (m, 7H), 7.58-7.42 (m, 2H), 7.34-7.24 (m, 1H), 4.22-4.10 (m, 1H), 3.60-3.40 (m, 1H), 1.90-1.15 (m, 8H). Example 2-132 HCl DMSO-d6 300 MHz δ: 13.08 (s, 1H), 8.52 (d, 1H, J = 5.4 451 449 0.7 Hz), 8.46-8.34 (m, 1H), 8.24-8.12 (m, 1H), 8.10 (d, 1H, J = 12.6 Hz), 8.00- 7.86 (m, 3H), 7.82-7.70 (m, 2H), 7.70- 7.60 (m, 2H), 7.40-7.25 (m, 2H), 7.25- 7.16 (m, 1H), 4.14-4.00 (m, 1H), 3.86 (s, 3H), 3.60-3.40 (m, 1H), 1.90-1.00 (m, 8H). Example 2-133 HCl DMSO-d6 300 MHz δ: 12.84 (br, 1H), 8.57 (d, 1H,J = 6.6 457 455 0.73 Hz), 8.28-8.16 (m, 1H), 8.16-8.06 (m, 1H), 8.07 (d, 1H, J = 12.6 Hz), 8.00- 7.50 (m, 7H), 7.42-7.32 (m, 1H), 7.30- 7.21 (m, 1H), 4.25-4.13 (m, 1H), 3.60- 3.48 (m, 1H), 1.90-1.15 (m, 8H). Example 2-134 HCl DMSO-d6 300 MHz δ: 11.95 (s, 1H), 8.65 (d, 1H, J = 2.4 426 424 0.85 Hz), 8.54 (d, 1H, J = 2.4 Hz), 8.22 (s, 2H), 7.98 (d, 1H, J = 12.6 Hz), 7.94- 7.64 (m, 4H), 7.40 (br, 1H), 6.96 (d, 1H, J = 6.6 Hz), 4.24-4.12 (m, 1H), 3.60-3.48 (m, 1H), 2.48 (s, 3H), 1.85- 1.15 (m, 8H). Example 2-135 HCl DMSO-d6 300 MHz δ: 12.00 (s, 1H), 8.62 (d, 1H, J = 2.7 425 423 0.81 Hz), 8.53 (d, 1H, J = 2.7 Hz), 8.26 (d, 1H, J = 1.8 Hz), 7.98 (d, 1H, J = 12.0 Hz), 7.96-7.76 (m, 5H), 7.41 (br, 1H), 7.03 (d, 1H, J = 6.6 Hz), 6.60-6.57 (m, 1H), 4.18-4.06 (m, 1H), 3.60-3.46 (m, 1H), 2.43 (s, 3H), 1.85-1.10 (m, 8H). Example 2-136 HCl DMSO-d6 300 MHz δ: 14.09 (br, 1H), 13.03 (s, 1H), 8.46 481 479 0.78 (d, 1H, J = 6.6 Hz), 8.39-8.30 (m, 1H), 8.20-8.12 (m, 1H), 8.09 (d, 1H, J = 12.0 Hz), 7.90-7.68 (m, 5H), 7.62 (d, 1H, J = 10.4 Hz), 7.33 (d, 1H, J = 7.2 Hz), 6.84-6.75 (m, 2H), 4.14-4.02 (m, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.56- 3.40 (m, 1H), 1.90-1.40 (m, 5H), 1.25- 1.00 (m, 3H). Example 2-137 HCl DMSO-d6 300 MHz δ: 12.03 (s, 1H), 9.45 (s, 1H), 8.81- 412 410 0.73 8.77 (m, 1H), 8.71 (d, 1H, J = 2.7 Hz), 8.68 (d, 1H, J = 21 Hz), 8.35 (s, 1H), 8.01 (d, 1H, J = 12.6 Hz), 8.00-7.80 (m, 4H), 7.50-7.36 (m, 1H), 7.05 (d, 1H, J = 7.2 Hz), 4.40-4.24 (m, 1H), 3.62-3.50 (m, 1H), 1.90-1.25 (m, 8H). Example 2-138 HCl DMSO-d6 300 MHz δ: 11.95 (s, 1H), 9.05 (s, 1H), 8.61 (d, 426 424 0.73 1H, J = 1.8 Hz), 8.45 (d, 1H, J = 1.8 Hz), 8.31 (s, 1H), 7.98 (d, 1H, J = 12.6 Hz), 7.87 (br, 1H), 7.82-7.66 (m, 3H), 7.41 (br, 1H), 7.00 (d, 1H, J = 6.6 Hz), 4.20-4.04 (m, 1H), 3.65-3.50 (m, 1H), 2.35 (s, 3H), 1.80-1.05 (m, 8H). Example 2-139 HCl DMSO-d6 300 MHz δ: 12.96 (s, 1H), 8.57 (d, 1H, J = 6.6 469 467 0.73 Hz), 8.36 (s, 1H), 8.14 (s, 1H), 8.08 (d, 1H, J = 12.0 Hz), 8.00-7.80 (m, 3H), 7.80-7.64 (m, 2H), 7.48-7.22 (m, 4H), 4.20-4.08 (m, 1H), 3.93 (s, 3H), 3.60- 3.46 (m, 1H), 1.90-1.10 (m, 8H). Example 2-140 HCl DMSO-d6 300 MHz δ: 12.99 (br, 1H), 8.54 (d, 1H, J = 6.6 469 467 0.76 Hz), 8.34-8.24 (m, 1H), 8.20-8.13 (m, 1H), 8.00 (d, 1H, J = 12.0 Hz), 8.05- 7.90 (m, 3H), 7.84-7.64 (m, 3H), 7.31 (d, 1H, J = 5.7 Hz), 7.20-7.10 (m, 1H), 7.10-7.02 (m, 1H), 4.23-4.10 (m, 1H), 3.88 (s, 3H), 3.60-3.46 (m, 1H), 1.90- 1.15 (m, 8H). Example 2-141 HCl DMSO-d6 300 MHz δ: 12.97 (s, 1H), 8.58 (d, 1H, J = 6.6 469 467 0.74 Hz), 8.40-8.28 (m, 1H), 8.20-8.10 (m, 1H), 8.09 (d, 1H, J = 11.7 Hz), 8.00- 7.65 (m, 5H), 7.50-7.37 (m, 2H), 7.36- 7.10 (m, 2H), 4.22-4.10 (m, 1H), 3.83 (s, 3H), 3.60-3.46 (m, 1H), 1.90-1.10 (m, 8H). Example 2-142 HCl DMSO-d6 300 MHz δ: 11.74 (s, 1H), 8.90-8.70 (m, 1H), 385 383 0.67 8.20-8.04 (m, 1H), 7.97(d, 1H, J = 12.0 Hz), 7.95-7.75 (m, 4H), 7.46- 7.30 (m, 2H), 7.00-6.92 (m, 1H), 4.30- 4.18 (m, 1H), 3.66-3.50 (m, 1H), 2.28- 2.12(m, 1H), 1.90-1.40 (m, 8H), 1.16- 0.92 (m, 4H). Example 2-143 HCl 461 459 0.93 Example 2-144 HCl DMSO-d6 300 MHz δ: 12.87 (br, 1H), 8.60 (d, 1H, J = 6.6 457 455 0.75 Hz), 8.30-8.23 (m, 1H), 8.18-8.04 (m, 1H), 8.08 (d, 1H, J = 12.0 Hz), 8.00- 7.76 (m, 4H), 7.76-7.60 (m, 3H), 7.51- 7.40 (m, 1H), 7.28 (d, 1H, J = 5.4 Hz), 4.24-4.12 (m, 1H), 3.56-3.48 (m, 1H), 1.90-1.15 (m, 8H). Example 2-145 HCl DMSO-d6 300 MHz δ: 12.90 (s, 1H), 8.60 (d, 1H, J = 6.6 457 455 0.73 Hz), 8.32-8.20 (m, 1H), 8.17-8.07(m, 1H), 8.08 (d, 1H, J = 12.0 Hz), 8.00- 7.75 (m, 5H), 7.75-7.65 (m, 1H), 7.60- 7.50 (m, 2H), 7.29 (d, 1H, J = 6.6 Hz), 4.24-4.14 (m, 1H), 3.56-3.48 (m, 1H), 1.90-1.15 (m, 8H). Example 2-146 HCl DMSO-d6 300 MHz δ: 12.84 (br, 1H), 8.59 (d, 1H, J = 6.6 475 473 0.8 Hz), 8.33-8.23 (m, 1H), 8.15-8.05 (m, 473 471 1H), 8.08 (d, 1H, J = 11.7 Hz), 8.02- 7.88 (m, 3H), 7.88-7.60 (m, 4H), 7.51- 7.43 (m, 1H), 7.30-7.20 (m, 1H), 4.25- 4.14 (m, 1H), 3.56-3.40 (m, 1H), 1.90- 1.15 (m, 8H). Example 2-147 HCl DMSO-d6 300 MHz δ: 12.82 (br, 1H), 8.58 (d, 1H, 6.6 475 473 0.79 Hz), 8.30-8.20 (m, 1H), 8.15-8.00 (m, 473 471 2H), 8.00-7.62 (m, 7H), 7.60-7.50 (m, 1H), 7.25 (d, 1H, J = 6.0 Hz), 4.28- 4.14 (m, 1H), 4.56-4.40 (m, 1H), 1.90- 1.20 (m, 8H). Example 2-148 HCl DMSO-d6 300 MHz δ: 11.45 (s, 1H), 8.20-8.15 (m, 2H), 451 449 1.13 8.02 (d, 1H, J = 12.6 Hz), 7.80-7.66 (m, 4H), 7.62-7.56 (m, 2H), 7.50-7.42 (m, 2H), 7.40-7.33 (m, 1H), 7.26 (br, 1H), 6.86 (d, 1H, J = 6.0 Hz), 4.20- 3.92 (m, 1H), 3.86 (s, 3H), 3.46-3.35 (m, 1H), 1.74-1.34 (m, 5H), 1.19-0.92 (m, 3H). Example 2-149 HCl DMSO-d6 300 MHz δ: 11.52 (s, 1H), 8.22 (d, 1H, J = 2.7 469 467 1.11 Hz), 8.16 (d, 1H, J = 2.7 Hz), 7.93 (d, 1H, J = 12.3 Hz), 7.93-7.70 (m, 4H), 7.51-7.41 (m, 2H), 7.34-7.24 (m, 3H), 6.92 (d, 1H, J = 6.6 Hz), 4.04-3.92 (m, 1H), 3.82 (s, 3H), 3.46-3.36 (m, 1H), 1.80-1.30 (m, 5H), 1.20-0.90 (m, 3H). Example 2-150 HCl DMSO-d6 300 MHz δ: 11.37 (s, 1H), 8.44 (d, 1H, J = 2.7 441 439 1.09 Hz), 8.08 (d, 1H, J = 2.7 Hz), 8.00- 7.78 (m, 6H), 7.27 (br, 1H), 7.02 (d, 1H, J = 3.3 Hz), 6.87 (d, 1H, J = 6.0 Hz), 6.65 (dd, 1H, J = 1.5, 3.3 Hz), 4.22-4.06 (m, 1H), 3.97 (s, 3H), 3.6- 0-3.44 (m, 1H), 2.00-1.20 (m, 8H). Example 2-151 HCl DMSO-d6 300 MHz δ: 11.16 (s, 1H), 8.22-8.19 (m, 1H), 441 439 1.05 8.20-8.16 (m, 2H), 7.91(d, 1H, J = 12.6 Hz), 7.82-7.64 (m, 5H), 7.23 (br, 1H), 7.16-7.12 (m, 1H), 6.84 (d, 1H, J = 6.0 Hz), 4.12-4.00 (m, 1H), 3.96 (s, 3H), 3.56-3.40 (m, 1H), 1.82-1.15 (m, 8H). Example 2-152 HCl DMSO-d6 300 MHz δ: 11.18 (s, 1H), 8.12 (d, 1H, J = 2.4 389 387 0.95 Hz), 8.00-7.84 (m, 4H), 7.78-7.60 (m, 1H), 7.25 (br, 1H), 6.83 (d, 1H, J = 6.0 Hz), 4.22-4.08 (m, 1H), 3.85 (s, 3H), 3.62-3.50 (m, 1H), 2.16 (s, 3H), 1.95- 1.78 (m, 2H), 1.70-1.50 (m, 4H), 1.50- 1.30 (m, 2H). Example 2-153 HCl DMSO-d6 300 MHz δ: 11.08 (s, 1H), 8.14 (d, 1H, J = 2.7 415 413 1.03 Hz), 7.96-7.60 (m, 4H), 7.30 (d, 1H, J = 2.7 Hz), 7.30-7.10 (m, 1H), 6.81 (d, 1H, J = 6.6 Hz), 4.22-4.04 (m, 1H), 3.87 (s, 3H), 3.58-3.44 (m, 1H), 2.05- 1.94 (m, 1H), 1.92-1.76 (m, 2H), 1.70- 1.52 (m, 4H), 1.50-1.30 (m, 2H), 0.96- 0.80 (m, 3H), 0.80-0.60 (m, 2H). Example 2-154 HCl DMSO-d6 300 MHz δ: 11.56 (s , 1H), 8.69 (d, 1H, J = 2.1 441 439 1 Hz), 8.39 (d, 1H, J = 2.7 Hz), 8.11 (d, 1H, J = 2.7 Hz), 7.93 (d, 1H, J = 12.0 Hz), 7.79 (d, 1H, J = 2.1 Hz), 7.80- 7.60 (m, 4H), 7.31 (br, 1H), 6.89 (d, 1H, J = 7.2 Hz), 6.57-6.53 (m, 1H), 4.26-4.15 (m, 1H), 3.98 (s, 3H), 3.58- 3.42 (m, 1H), 1.80-1.20 (m, 8H). Example 2-155 HCl DMSO-d6 300 MHz δ: 11.59 (s, 1H), 8.52 (d, 1H, J = 2.4 442 440 0.88 Hz), 8.28 (d, 1H, J = 2.4 Hz), 8.13 (s, 2H), 7.94 (d, 1H, J = 12.3 Hz), 7.88- 7.67 (m, 4H), 7.31 (br, 1H), 6.91 (d, 1H, J = 6.6 Hz), 4.17-4.05 (m, 1H), 3.89 (s, 3H), 3.51-3.41 (m, 1H), 1.82- 1.13 (m, 8H). Example 2-156 HCl DMSO-d6-D2O 300 MHz δ: 8.54 (d, 1H, J = 2.3 Hz), 8.19 (d, 428 426 0.83 1H, J = 9.2 Hz), 8.08 (dd, 1H, J = 2.6, 9.2 Hz), 7.88 (d, 1H, J = 12.2 Hz) 4.27-4.17 (m, 1H), 4.01-3.93 (m, 2H), 3.69-3.61 (m, 1H), 2.60-2.52 (m, 2H), 2.15-2.00 (m, 2H), 1.93-1.35 (m, 8H). Example 2-157 HCl DMSO-d6-D2O 300 MHz δ: 8.63 (d, 1H, J = 2.6 Hz), 8.07 (dd, 442 440 0.82 1H, J = 2.8, 8.8 Hz), 7.90 (d, 1H, J = 12.2 Hz), 7.50 (d, 1H, J = 8.9 Hz), 4.30-4.20 (m, 1H), 3.82-3.75 (m, 2H), 3.78-3.70 (m, 2H), 3.69-3.62 (m, 1H), 2.45 (t, 2H, J = 6.3 Hz), 1.95-1.38 (m, 10H). Example 2-158 HCl DMSO-d6-D2O 300 MHz δ: 8.88 (d, 1H, J = 2.6 Hz), 8.25 (dd, 493 491 0.99 1H, J = 2.6, 8.6 Hz), 7.93 (d, 1H, J = 12.2 Hz), 7.47 (d, 1H, J = 8.6 Hz), 7.15-7.03 (m, 2H), 6.97-6.90 (m, 1H), 6.36 (dd, 1H, J = 1.3, 8.3 Hz), 4.81 (s, 2H), 4.33-4.22 (m, 1H), 3.73-3.63 (m, 1H), 1.93-1.35 (m, 8H). Example 2-159 HCl DMSO-d6-D2O 300 MHz δ: 8.84 (d, 1H, J = 2.6 Hz), 8.24 (dd, 521 519 0.97 1H, J = 2.6, 8.6 Hz), 7.93 (d, 1H, J = 11.9 Hz), 7.84 (dd, 1H, J = 1.3, 4.6 Hz), 7.51 (dd, 1H, J = 1,5, 8.1 Hz) 7.39 (d, 1H, J = 8.9 Hz), 7.12 (dd, 1H, J = 4.6, 7.9 Hz), 4.33-4.23 (m, 1H), 3.71-3.62 (m, 1H), 1.92-1.36 (m, 8H), 1.56 (s, 6H). Example 2-160 HCl DMSO-d6 300 MHz δ: 11.70 (s, 1H), 8.60 (d, 1H, J = 2.7 411 409 0.93 Hz), 8.53 (d, 1H, J = 2.7 Hz), 8.27 (dd, 1H, J = 2.7, 5.7 Hz), 7.96 (d, 1H, J = 12.6 Hz), 7.90-7.74 (m, 6H), 7.35 (br, 1H), 6.94 (d, 1H, J = 5.7 Hz), 6.57- 6.54 (m, 1H), 4.30-4.20 (m, 1H), 3.72- 3.60 (m, 1H), 1.94-1.40 (m, 8H). Example 2-161 HCl DMSO-d6 300 MHz δ: 11.88 (s, 1H), 8.78 (d, 1H, J = 412 410 0.84 2.4 Hz), 8.28 (dd, 1H, J = 2.4, 8.7 Hz), 8.13 (s, 2H), 7.99 (d, 1H, J = 12.0 Hz), 7.94 (d, 1H, J = 8.7 Hz), 7.90-7.75 (m, 4H), 7.41 (br, 1H), 6.95 (d, 1H, J = 6.6 Hz), 4.36-4.24 (m, 1H), 3.72-3.60 (m, 1H), 1.94-1.40 (m, 8H). Example 2-162 HCl DMSO-d6-D2O 300 MHz δ: 8.64 (d, 1H, J = 2.6 Hz), 8.11 (dd, 444 442 0.76 1H, J = 2.6, 8.9 Hz), 7.90 (d, 1H, J = 12.2 Hz), 7.76 (d, 1H, J = 8 9 Hz), 4.27-4.20 (m, 1H), 4.26 (s, 2H), 4.02- 3.95 (m, 2H), 3.94-3.86 (m, 2H), 3.70- 3.62 (m, 1H), 1.94-1.39 (m, 8H). Example 2-163 HCl DMSO-d6-D2O 300 MHz δ: 8.68 (dd, 1H, J = 6.9, 6.9 Hz), 8.35 377 375 0.61 (d, 1H, J = 6.9 Hz), 8.05 (d, 1H, J = 11.9 Hz), 4.39-4.29 (m, 1H), 3.74- 3.66 (m, 1H), 2.57 (d, 3H, J = 2.6 Hz), 1.98-1.42 (m, 8H). Example 2-164 HCl DMSO-d6-D2O 300 MHz δ: 8.62 (d, 1H, J = 7.3 Hz), 8.61 (d, 377 375 0.62 1H, J = 5.0 Hz), 8.05 (d, 1H, J = 11.9 Hz), 4.46-4.36 (m, 1H), 3.72-3.63 (m, 1H), 2.59 (s, 3H), 2.03-1.40 (m, 8H). Example 2-165 HCl DMSO-d6-D2O 300 MHz δ: 8.10 (dd, 1H, J = 5.6, 5.9 Hz), 7.96 448 446 0.78 (d, 1H, J = 12.2 Hz), 7.90 (d, 1H, J = 5.9 Hz), 4.33-4.24 (m, 1H), 3.79-3.72 (m, 4H), 3.76-3.68 (m, 1H), 3.41-3.33 (m, 4H), 1.98-1.42 (m, 8H). Example 2-166 HCl DMSO-d6-D2O 300 MHz δ: 8.06 (d, 1H, J = 3.3 Hz), 8.00 (d, 448 446 0.72 1H, J = 11.9 Hz), 7.86 (d, 1H, J = 5.9 Hz), 4.51-4.43 (m, 1H), 3.80-3.72 (m, 4H), 3.54-3.45 (m, 1H), 3.44-3.36 (m, 4H), 1.96-1.33 (m, 8H). Example 2-167 HCl DMSO-d6-D2O 300 MHz δ: 8.70 (dd, 1H, J = 6.3, 6.6 Hz), 8.45 439 437 0.89 (d, 1H, J = 6.3 Hz), 8.04 (d, 1H, J = 11.9 Hz), 7.87-7.78 (m, 2H), 7.68- 7.60 (m, 3H), 4.44-4.33 (m, 1H), 3.79- 3.70 (m, 1H), 2.02-1.44 (m, 8H). Example 2-168 HCl DMSO-d6-D2O 300 MHz δ: 9.00 (d, 1H, J = 6.9 Hz), 8.65 (d, 439 437 0.85 1H, J = 4.0 Hz), 8.04 (d, 1H, J = 11.9 Hz), 7.93-7.86 (m, 2H), 7.68-7.54 (m, 3H), 4.33-4.22 (m, 1H), 3.53-3.44 (m, 1H), 1.85-0.83 (m, 8H). Example 2-169 HCl DMSO-d6 300 MHz δ: 12.74 (br, 1H), 9.34-9.30 (m, 1H), 422 420 0.73 8.64-8.56 (m, 1H), 8.14-8.02 (m, 4H), 7.90-7.80 (m, 3H), 7.74-7.58 (m, 4H), 7.18-7.10 (m, 1H), 4.32-4.24 (m, 1H), 3.60-3.4 5(m, 1H), 2.00-1.10 (m, 8H). Example 2-170 HCl DMSO-d6 300 MHz δ: 11.96 (s, 1H), 8.95 (s, 1H), 8.65- 481 479 0.78 8.55 (m, 2H), 8.00 (d, 1H, J = 12.6 Hz), 7.96-7.75 (m, 4H), 7.50-7.32 (m 3H), 7.17-7.00 (m, 2H), 4.23-4.12 (m, 1H), 3.87 (s, 3H), 3.82 (s, 3H), 3.6- 3.46 (m, 1H), 1.85-1.15 (m, 8H). Example 2-171 HCl DMSO-d6 300 MHz δ: 11.93 (s, 1H), 8.96 (s, 1H), 8.64 (s, 511 509 0.82 2H), 8.00 (d, 1H, J = 12.6 Hz), 8.00- 7.75 (m, 4H), 7.42 (br, 1H), 7.10-7.04 (m, 3H), 4.20-4.08 (m, 1H), 3.88 (s, 6H), 3.70 (s, 3H), 3.60-3.46 (m, 1H), 1.85-1.10 (m, 8H). Example 2-172 HCl DMSO-d6 300 MHz δ: 11.99 (s, 1H), 9.02-8.95 (m, 1H), 466 464 0.95 8.68-8.64 (m, 1H), 8.62-8.58 (m, 1H), 8.40-8.34 (m, 2H), 8.14-8.08 (m, 2H), 8.00 (d, 1H, J = 12.6 Hz), 7.96-7.80 (m, 4H), 7.44 (br, 1H), 7.02 (d, 1H, J = 6.6 Hz), 4.26-4.15 (m, 1H), 3.60-3.48 (m, 1H), 1.86-1.14 (m, 8H). Example 2-173 HCl DMSO-d6 300 MHz δ: 12.00 (s, 1H), 8.98 (s, 1H), 8.65 (s, 446 444 0.88 1H), 8.61 (s, 1H), 8.04-7.97 (m, 5H), 7.97-7.70 (m, 4H), 7.44 (br, 1H), 7.03 (d, 1H, J = 6.6 Hz), 4.25-4.14 (m, 1H), 3.62-3.50 (m, 1H), 1.90-1.12 (m, 8H). Example 2-174 HCl DMSO-d6 300 MHz δ: 12.09 (s, 1H), 9.04-8.96 (m, 1H), 505 503 1.08 8.74-8.66 (m, 1H), 8.66-8.62 (m, 1H), 8.05-7.85 (m, 7H), 7.56 (d, 2H, J = 5.8 Hz), 7.46 (br, 1H), 7.08 (d, 1H, J = 6.6 Hz), 4.24-4.10 (m, 1H), 3.62-3.50 (m, 1H), 1.86-1.45 (m, 5H), 1.36-1.10 (m, 3H). Example 2-175 HCl DMSO-d6-D2O 300 MHz δ: 9.00 (d, 1H, J = 2.3 Hz), 8.80 (dd, 465 463 0.93 1H, J = 2.0, 2.0 Hz), 8.60 (d, 1H, J = 2.0 Hz), 7.98 (d, 1H, J = 12.2 Hz), 7.45 (d, 1H, J = 2.0 Hz), 7.35 (dd,1H, J = 1.8, 8.1 Hz), 7.13 (d, 1H, J = 7.9 Hz), 6.11 (d, 2H, J = 2.6 Hz), 4.28- 4.17 (m, 1H), 3.55-3.46 (m, 1H), 1.90- 1.20 (m, 8H). Example 2-176 HCl DMSO-d6-D2O 300 MHz δ: 8.46 (s, 1H), 8.39 (d, 1H, J = 7.3 465 463 0.83 Hz), 8.04 (d, 1H, J = 11.9 Hz), 7.76 (s, 1H), 7.50 (d, 1H, J = 2.0 Hz), 7.44 (dd, 1H, J = 2.0, 8.3 Hz), 7.21 (d, 1H, J = 8.3 Hz), 6.17 (d, 2H, J = 5.6 Hz), 4.34-4.23 (m, 1H), 3.62-3.51 (m, 1H), 1.90-1.22 (m, 8H). Example 2-177 HCl DMSO-d6-D2O 300 MHz δ: 8.90-8.85 (m, 1H), 8.64 (s, 1H), 492 490 0.85 8.50 (d, 1H, J = 1.7 Hz), 7.95 (d, 1H, J = 11.9 Hz), 7.42-7.35 (m, 1H), 7.28 (d, 1H, J = 2.3 Hz), 7.18 (d, 1H, J = 8.3 Hz), 4.66 (s, 2H), 4.20-4.10 (m, 1H), 3.55-3.47 (m, 1H), 1.95-1.15 (m, 8H). Example 2-178 HCl DMSO-d6-D2O 300 MHz δ: 8.41 (d, 1H, J = 6.9 Hz), 8.40 (s, 492 490 0.76 1H), 8.03 (d, 1H, J = 11.9 Hz), 7.78 (s, 1H), 7.49 (dd, 1H, J = 2.3, 8.3 Hz), 7.38 (d, 1H, J = 2.0 Hz), 7.26 (d, 1H, J = 8.3 Hz), 4.72 (s, 2H), 4.26-4.13 (m, 1H), 3.63-3.53 (m, 1H), 1.90-1.16 (m, 8H). Example 2-179 HCl DMSO-d6-D2O 300 MHz δ: 9.72 (s, 1H), 8.97 (d, 1H, J = 2.3 472 470 0.69 Hz), 8.69-8.64 (m, 1H), 8.59 (d, 1H, J = 6.6 Hz), 8.52 (d, 1H, J = 7.9 Hz), 8.43 (d, 1H, J = 2.0 Hz), 8.19-8.13 (m, 1H), 8.10-8.02 (m, 2H), 7.95 (d, 1H, J = 12.2 Hz), 3.97-3.89 (m, 1H), 3.38- 3.30 (m, 1H), 1.75-0.55 (m, 8H). Example 2-180 HCl DMSO-d6-D2O 300 MHz δ: 9.61 (s, 1H), 8.64 (d, 1H, J = 6.3 472 470 0.59 Hz), 8.61-8.54 (m, 1H), 8.58 (d, 1H, J = 6.9 Hz), 8.54 (d, 1H, J = 5.9 Hz), 8.24-8.18(m, 1H), 8.05-7.98 (m, 1H), 8.04 (d, 1H, J = 11.9 Hz), 7.94 (d, 1H, J = 5.9 Hz), 7.81 (s, 1H), 3.86-3.76 (m, 1H), 3.34-3.25 (m, 1H), 1.70-0.40 (m, 8H). Example 2-181 HCl DMSO-d6-D2O 300 MHz δ: 9.11-9.00 (m, 2H), 8.99-8.93 (m, 472 470 0.8 1H), 8.71 (s, 1H), 8.60-8.52 (m, 1H), 8.21 (d, 1H, J = 8.9 Hz), 8.05 (d, 1H, J = 7.3 Hz), 7.98 (d, 1H, J = 12.2 Hz), 7.84 (dd, 1H, J = 7.6, 7.9 Hz), 7.69 (dd, 1H, J = 4.3, 8.3 Hz), 3.96-3.88 (m, 1H), 3.39-3.31 (m, 1H), 1.75-0.65 (m, 8H). Example 2-182 HCl DMSO-d6-D2O 300 MHz δ: 9.02 (dd, 1H, J = 1.7, 4.3 Hz), 8.70 472 470 0.76 (s, 1H), 8.61 (dd, 1H, J = 1.7, 8.6 Hz), 8.57 (d, 1H, J = 6.9 Hz), 8.37-8.30 (m, 1H), 8.28-8.22 (m, 1H), 8.04 (d, 1H, J = 11.9 Hz), 7.89 (dd, 1H, J = 7.6, 7.9 Hz), 7.85-7.76 (m, 1H), 7.75 (dd, 1H, J = 4.3, 8.6 Hz), 3.97-3.92 (m, 1H), 3.44-3.33 (m, 1H), 1.75-0.83 (m, 8H). Example 2-183 HCl DMSO-d6 300 MHz δ: 12.97 (s, 1H), 8.53 (d, 1H, J = 6.6 451 449 0.75 Hz), 8.48-8.36 (m, 1H), 8.25-8.10 (m, 1H), 8.10 (d, 1H, J = 12.6 Hz), 8.05- 7.80 (m, 4H), 7.80-7.70 (m, 1H), 7.61- 7.50 (m, 3H), 7.32-7.20 (m, 2H), 4.32- 4.20 (m, 1H), 3.88 (s, 3H), 3.60-3.48 (m, 1H), 1.90-1.10 (m, 8H). Example 2-184 HCl DMSO-d6 300 MHz δ: 12.96 (s, 1H), 8.48 (d, 1H, J = 6.6 451 449 0.75 Hz), 8.40-8.30 (m, 1H), 8.20-8.10 (m, 1H), 8.10 (d, 1H, J = 11.7 Hz), 8.05- 7.65 (m, 7H), 7.28 (d, 1H, J = 5.4 Hz), 7.21 (d, 2H, J = 9.0 Hz), 4.32-4.20 (m, 1H), 3.87 (s, 3H), 3.60-3.48 (m, 1H), 1.95-1.15 (m, 8H). Example 2-185 HCl 412 410 0.9 Example 2-186 HCl CD3OD 300 MHz δ: 8.09 (s, 1H), 7.90 (d, 1H, J = 7.3 412 410 0.94 Hz), 7.82 (d, 1H, J = 12.6 Hz), 7.38 (t, 1H, J = 7.9 Hz), 7.17 (d, 1H, J = 7.9 Hz), 4.45 (q, 2H, J = 7.0 Hz), 4.36 (br, 1H), 3.87 (br, 1H), 1.85-1.61 (m, 8H), 1.47 (t, 3H, J = 7.3 Hz). Example 2-187 HCl 448 446 0.87 Example 2-188 HCl 448 446 0.89 Example 2-189 HCl DMSO-d6-D2O 300 MHz δ: 9.14-9.07 (m, 2H), 8.99-8.92 (m, 472 470 0.78 1H), 8.81 (d, 1H, J = 1.7 Hz), 8.76 (d, 1H, J = 7.9 Hz), 8.50 (s, 1H), 8.34 (d, 1H, J = 8.9 Hz), 8.17 (dd, 1H, J = 1.7, 8.6 Hz), 7.98 (d, 1H, J = 11.9 Hz), 7.83 (dd, 1H, J = 4.6, 8.3 Hz), 4.33- 4.21 (m, 1H), 3.59-3.50 (m, 1H), 1.82- 0.96 (m, 8H). Example 2-190 HCl DMSO-d6-D2O 300 MHz δ: 9.72 (s, 1H), 9.05 (d, 1H, J = 2.3 472 470 0.67 Hz), 8.75 (d, 1H, J = 2.0 Hz), 8.69 (dd, 1H, J = 2.0, 2.0 Hz), 8.67-8.63 (m, 1H), 8.64 (d, 1H, J = 6.6 Hz), 8.59 (d, 1H, J = 8.6 Hz), 8.40 (d, 1H, J = 6.6 Hz), 8.37-8.31 (m, 1H), 7.96 (d, 1H, J = 12.2 Hz), 4.28-4.15 (m, 1H), 3.54- 3.46 (m, 1H), 1.82-0.97 (m, 8H). Example 2-191 HCl DMSO-d6-D2O 300 MHz δ: 9.77 (s, 1H), 9.16 (d, 1H, J = 2.3 472 470 0.68 Hz), 8.87 (s, 1H), 8.80 (d, 1H, J = 1.7 Hz), 8.75 (dd, 1H, J = 2.0, 2.3 Hz), 8.66 (d, 1H, J = 6.6 Hz), 8.54 (dd, 1H, J = 1.8, 8.8 Hz), 8.47-8.40 (m, 2H), 7.98 (d, 1H, J = 12.2 Hz), 4.27-4.16 (m, 1H), 3.56-3.46 (m, 1H), 1.85-1.02 (m, 8H). Example 2-192 HCl DMSO-d6-D2O 300 MHz δ: 9.11 (dd, 1H, J = 1.5, 4.5 Hz), 8.70 472 470 0.7 (s, 1H), 8.67-8.59 (m, 2H), 8.55 (d, 1H, J = 6.9 Hz), 8.35 (d, 1H, J = 8.6 Hz), 8.12 (dd, 1H, J = 1.8, 8.4 Hz), 8.06 (d, 1H, J = 11.9 Hz), 7.93-7.83 (m, 1H), 7.80 (dd, 1H, J = 4.3, 8.3 Hz), 4.39-4.28 (m, 1H), 3.66-3.55 (m, 1H), 1.87-0.83 (m, 8H). Example 2-193 HCl DMSO-d6-D2O 300 MHz δ: 9.59 (s, 1H), 8.70 (m, 2H), 8.58 (d, 472 470 0.63 1H, J = 6.9 Hz), 8.55-8.47 (m, 2H), 8.30-8.24 (m, 1H), 8.20 (d, 1H, J = 5.9 Hz), 8.05 (d, 1H, J = 11.9 Hz), 7.98-7.90 (m, 1H), 4.30-4.19 (m, 1H), 3.57-3.48 (m, 1H), 1.90-0.90 (m, 8H). Example 2-194 HCl DMSO-d6-D2O 300 MHz δ: 9.64 (s, 1H), 8.84 (s, 1H), 8.69 (d, 472 470 0.64 1H, J = 5.9 Hz), 8.57 (d, 1H, J = 6.6 Hz), 8.52 (s, 1H), 8.40-8.35 (m, 2H), 8.21 (d, 1H, J = 6.3 Hz), 8.05 (d, 1H, J = 11.9 Hz), 8.03-7.95 (m, 1H), 4.30- 4.19 (m, 1H), 3.59-3.50 (m, 1H), 1.90- 0.90 (m, 8H). Example 2-195 HCl DMSO-d6 300 MHz δ: 11.59 (s, 1H), 8.82 (d, 1H, J = 2.4 435 433 1.06 Hz), 8.56 (d, 1H, J = 2.4 Hz), 8.21 (d, 1H, J = 7.2 Hz), 7.97 (d, 1H, J = 12.6 Hz), 7.90-7.70 (m, 5H), 7.63-7.55 (m, 1H), 7.48-7.40 (m, 1H), 7.35 (br, 1H), 6.92 (d, 1H, J = 5.1 Hz), 4.32-4.21 (m, 1H), 3.60-3.50 (m, 1H), 1.92-1.25 (m, 8H). Example 2-196 HCl 416 414 0.94 Example 2-197 HCl 430 428 1.02 Example 2-198 HCl 416 414 0.97 Example 2-199 HCl 430 428 1.03 Example 2-200 HCl 430 428 0.81 Example 2-201 HCl no data 430 428 0.86 Example 2-202 HCl DMSO-d6 300 MHz δ: 10.73 (s, 1H), 7.90-7.70 (m, 6H), 375 373 0.66 7.55 (dd, 1H, J = 3.0, 9.6 Hz), 7.20 (br, 1H), 6.76 (d, 1H, J = 6.0 Hz), 6.38 (d, 1H, J = 12.3 Hz), 4.14-4.03 (m, 1H), 3.60-3.48 (m, 1H), 3.43 (s, 3H), 1.90-1.25 (m, 8H). Example 2-203 HCl DMSO-d6 300 MHz δ: 11.40 (s, 1H), 8.31 (d, 1H, J = 2.4 409 407 1.02 Hz), 8.13 (d, 1H, J = 2.4 Hz), 7.93 (d, 411 409 1H, J = 12.3 Hz), 7.90-7.70 (m, 4H), 7.29 (br, 1H), 6.90 (d, 1H, J = 6.0 Hz), 4.22-4.10 (m, 1H), 3.91 (s, 3H), 3.61- 3.50 (m, 1H), 1.95-1.45 (m, 8H). Example 2-204 HCl CD3OD 300 MHz δ: 8.10 (s, 1H), 7.76 (d, 1H, J = 11.9 448 446 0.97 Hz), 7.49 (d, 1H, J = 9.2 Hz), 7.38 (dd, 1H, J = 9.2, 2.0 Hz), 4.84-4.82 (m, 1H), 4.69-4.67 (m, 1H), 4.59-4.57 (m, 1H), 4.50-4.49 (m, 1H), 4.36-4.33 (m, 1H), 3.81-3.78 (m, 1H), 1.90-1.50 (m, 8H). Example 2-205 HCl no data 448 446 1.02 Example 2-206 HCl CD3OD 300 MHz δ: 7.85 (s, 1H), 7.75 (d, 1H, J = 11.9 412 410 0.98 Hz), 7.48 (s, 1H), 7.47 (t, 1H, J = 7.9 Hz), 4.35-4.32 (m, 1H), 3.99 (s, 3H), 3.65-3.61 (m, 1H), 2.55 (s, 3H), 1.99- 1.50 (m, 8H). Example 2-207 HCl no data 426 424 0.95 Example 2-208 HCl CD3OD 300 MHz δ: 7.81 (s, 1H), 7.75 (d, 1H, J = 11.9 456 454 0.91 Hz), 7.49 (s, 1H), 7.49 (s, 1H), 4.48 (t, 2H, J = 5.3 Hz), 4.30 (s, 1H), 3.78 (t, 2H, J = 5.3 Hz), 3.64 (s, 1H), 3.27 (s, 3H), 2.54 (s, 3H), 1.98-1.50 (m, 8H). Example 2-209 HCl CD3OD 300 MHz δ: 7.80 (s, 1H), 7.74 (d, 1H, J = 11.9 444 442 0.92 Hz), 7.49 (s, 1H), 7.48 (s, 1H), 4.85- 4.83 (m, 1H), 4.71-4.65 (m, 2H), 4.58- 4.56 (m, 1H), 4.29-4.26 (m, 1H), 3.65- 3.61 (m, 1H), 2.54 (s, 3H), 1.90-1.51 (m, 8H). Example 2-210 HCl no data 462 460 0.95

Example 3

1st Step

5-bromo-2-picoline (13 mg), cesium carbonate (42 mg), Pd₂(dba)₃ (7 mg) and Xantphos (9 mg) were added to a 1,4-dioxane (0.5 ml) solution containing tert-butyl

cis-2-(6-amino-3-fluoro-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate (25 mg), followed by stirring at 100° C. for 2 hours in a nitrogen atmosphere. The reaction mixture was cooled to room temperature, and water and ethyl acetate were added. Insoluble matter was removed by filtration, and the filter cake was washed with water and ethyl acetate. The filtrate was mixed with the washing solution, the organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified using a PLC glass plate (hexane:ethyl acetate=1:1), diisopropylether and hexane were added, solid matter was collected by filtration, and a light yellow solid of tert-butyl cis-2-(3-fluoro-5-(2-phenylpropan-2-ylaminocarbonyl)-6-(6-methylpyridin-3-ylamino)pyridin-2-ylamino)cyclohexylcarbamate (14 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.07 (s, 1H), 8.50 (d, 1H, J=2.5 Hz), 8.15 (d, 1H, J=12.7 Hz), 8.08 (s, 1H), 7.92 (dd, 1H, J=2.5 Hz, 8.4 Hz), 7.40-7.34 (m, 2H), 7.31-7.25 (m, 2H), 7.19-7.13 (m, 1H), 7.10 (d, 1H, J=8.4 Hz), 6.72-6.60 (m, 2H), 4.06-3.87 (m, 2H), 2.37 (s, 3H), 1.88-1.10 (m, 23H)

MS (ESI, m/z): 577 (M+H), 575 (M−H)

2nd Step

A mixture of tert-butyl cis-2-(3-fluoro-5-(2-phenylpropan-2-ylaminocarbonyl)-6-(6-methylpyridin-3-ylamino)pyridin-2-ylamino)cyclohexylcarbamate (13 mg) and TFA (0.26 ml) was stirred at room temperature for 30 minutes. The solvent was distilled away under reduced pressure (at 40° C. or less), and ethyl acetate and 4N hydrogen chloride/1,4-dioxane (28 μl) were added, followed by stirring at room temperature for 30 minutes. Solid matter was collected by filtration, washed with ethyl acetate, and a yellow solid of 6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(6-methylpyridin-3-ylamino)nicotinamide.hydrochloride (11 mg) was thus obtained.

(¹H-NMR data and MS data are shown in table 2.)

Example 4

The compounds listed in table 2 were obtained as described in Example 3.

TABLE 2 Number Structure Number Structure Example 4-1

Example 4-2

Example 4-3

Example 4-4

Example 4-5

Example 4-6

Example 4-7

Example 4-8

Example 4-9

Example 4-10 HCl salt

Example 4-11 HCl salt

Example 4-12

Example 4-13

Example 4-14

Example 4-15 HCl salt

Example 4-16 HCl salt

Example 4-17 (Example 3) HCl salt

Example 4-18 HCl salt

Example 4-19 HCl salt

Example 4-20

Example 4-21

Example 4-22

Example 4-23

Example 4-24

Example 4-25

Example 4-26 HCl salt

Example 4-27

Example 4-28

Example 4-29

Example 4-30

Example 4-31 HCl salt

Example 4-32

Example 4-33 HCl salt

Example 4-34

Example 4-35

Example 4-36

Example 4-37

Example 4-38

Example 4-39 HCl salt

Example 4-40

Example 4-41 HCl salt

Example 4-42 HCl salt

Example 4-43 HCl salt

Example 4-44

Example 4-45

Example 4-46

Example 4-47

Example 4-48

Example 4-49 HCl salt

Example 4-50 HCl salt

Example 4-51 HCl salt

Example 4-52 2HCl salt

Example 4-53 HCl salt

Example 4-54 HCl salt

Example 4-55 HCl salt

Example 4-56 HCl salt

Example 4-57 HCl salt

Example 4-58 HCl salt

Example 4-59

Example 4-60

Example 4-61

Example 4-62

Example 4-63

Example 4-64

Number Structure Compound name Example 4-65

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((6-methoxy-1H-pyrrolo[2,3-b]pyridin-4-yl) amino)nicotinamide Example 4-66

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((6-morpholino-1H-pyrrolo[2,3-b]pyridin-4-yl) amino)nicotinamide Example 4-67

2-((6-(2H-1,2,3-triazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)-6-(cis-2- aminocyclohexylamino)-5-fluoronicotinamide Example 4-68

2-((6-(1H-1,2,3-triazol-1-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)-6-(cis-2- aminocyclohexylamino)-5-fluoronicotinamide Example 4-69

2-((6-(1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)-6-(cis-2- aminocyclohexylamino)-5-fluoronicotinamide Example 4-70

2-((1H-indol-5-yl)amino)-6-(cis-2- aminocyclohexylamino)-5-fluoronicotinamide Example 4-71

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-methyl-1H-indol-5-yl)amino)nicotinamide Example 4-72

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl) amino)nicotinamide Example 4-73

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(thiazol-5-yl)pyridin-3-yl)amino) nicotinamide Example 4-74

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(thiazol-5-yl)pyridin-3-yl)amino) nicotinamide Example 4-75

6-(cis-2-aminocyclohexylamino)-2-((5-(1- benzyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)- 5-fluoronicotinamide Example 4-76

2-((5-(1H-indol-5-yl)pyridin-3-yl)amino)-6- (cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 4-77

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(thiophene-3-yl)pyridin-3-yl)amino) nicotinamide Example 4-78

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(furan-3-yl)pyridin-3-yl)amino) nicotinamide Example 4-79

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((7-fluoro-1H-indol-5-yl)amino)nicotinamide Example 4-80

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((7-fluoro-1-(2-morpholinoethyl)-1H-indol-5- yl)amino)nicotinamide Example 4-81

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((7-fluoro-1-(2-methoxyethyl)-1H-indol-5-yl) amino)nicotinamide Example 4-82

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((6-fluoro-1H-indol-4-yl)amino)nicotinamide Example 4-83

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((6-fluoro-1-(2-morpholinoethyl)-1H-indol-4- yl)amino)nicotinamide Example 4-84

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((6-fluoro-1-(2-methoxyethyl)-1H-indol-4-yl) amino)nicotinamide Example 4-85

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((6-(trifluoromethyl)-1H-indol-4-yl)amino) nicotinamide Example 4-86

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-methyl-6-trifluoromethyl)-1H-indol-4-yl) amino)nicotinamide Example 4-87

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-2-morpholinoethyl)-6-(trifluoromethyl)-1H- indol-4-yl)amino)nicotinamide Example 4-88

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-(2-methoxyethyl)-6-(trifluoromethyl)-1H- indol-4-yl)nicotinamide Example 4-89

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((7-nitro-1H-indol-5-yl)amino)nicotinamide Example 4-90

6-(cis-2-aminocyclohexylamino)-2-((1- (cyclopropylmethyl)-1H-indazol-5-yl)amino)- 5-fluoronicotinamide Example 4-91

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-(2-methoxyethyl)-1H-indazol-5-yl)amino) nicotinamide Example 4-92

6-(cis-2-aminocyclohexylamino)-2-((1-(2-(2- ethoxyethoxy)ethyl)-1H-indazol-5-yl)amino)- 5-fluoronicotinamide Example 4-93

6-(cis-2-aminocyclohexylamino)-2-((2- (cyclopropylmethyl)-2H-indazol-5-yl)amino)- 5-fluoronicotinamide Example 4-94

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-(2-methoxyethyl)-2H-indazol-5-yl)amino) nicotinamide Example 4-95

6-(cis-2-aminocyclohexylamino)-2-((2-(2-(2- ethoxyethoxy)ethyl)-2H-indazol-5-yl)amino)- 5-fluoronicotinamide Example 4-96

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((pyridin-3-yl)amino)nicotinamide Example 4-97

6-(cis-2-aminocyclohexylamino)-2-((5- chloropyridin-3-yl)amino)-5- fluoronicotinamide Example 4-98

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(trifluoromethyl)pyridin-3-yl)amino) nicotinamide Example 4-99

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(3-methylphenyl)pyridin-3-yl)amino) nicotinamide Example 4-100

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-methylphenyl)pyridin-3-yl)amino) nicotinamide Example 4-101

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-methylphenyl)pyridin-3-yl)amino) nicotinamide Example 4-102

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((6-(trifluoromethyl)pyridin-3-yl)amino) nicotinamide Example 4-103

2-([3,3′-bipyridine]-5-yl)amino)-6-(cis-2- aminocyclohexylamino)-5-fluoronicotinamide Example 4-104

2-([3,4′-bipyridine]-5-yl)amino)-6-(cis-2- aminocyclohexylamino)-5-fluoronicotinamide Example 4-105

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-fluoropyridin-3-yl)amino)nicotinamide Example 4-106

2-([2,3′-bipyridine]-5′-yl)amino)-6-(cis-2- aminocyclohexylamino)-5-fluoronicotinamide Example 4-107

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-oxopyrolidin-1-yl)pyridin-3-yl)amino) nicotinamide Example 4-108

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-oxopiperidine-1-yl)pyridin-3-yl)amino) nicotinamide Example 4-109

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(3-(2-methoxyethoxy)phenyl)pyridin-3-yl) amino)nicotinamide Example 4-110

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(3-(2-morpholinoethoxy)phenyl)pyridin-3- yl)amino)nicotinamide Example 4-111

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-(2-methoxyethoxy)phenyl)pyridin-3-yl) amino)nicotinamide Example 4-112

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-(2-morpholinoethoxy)phenyl)pyridin-3- yl)amino)nicotinamide Example 4-113

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(3-methoxyphenyl)pyridin-3-yl)amino) nicotinamide Example 4-114

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-methoxyphenyl)pyridin-3-yl)amino) nicotinamide Example 4-115

6-(cis-2-aminocyclohexylamino)-3- carbamoyl-5-fluoropyridin-2-yl)amino)-2- fluoroindolizine-3-carboxylate Example 4-116

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((8-(methylamino)quinolin-3-yl)amino) nicotinamide Example 4-117

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-fluoro-1-methyl-1H-indol-5-yl)amino) nicotinamide Example 4-118

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(oxazol-5-yl)pyridin-3-yl)amino) nicotinamide Example 4-119

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(1-methyl-1H-pyrrol-3-yl)pyridin-3-yl) amino)nicotinamide Example 4-120

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((8-methoxyquinolin-3-yl)amino)nicotinamide Example 4-121

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((8-(2-methoxyethoxy)quinolin-3-yl)amino) nicotinamide Example 4-122

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((8-(2-methoxyethyl)amino)quinolin-3-yl) amino)nicotinamide Example 4-123

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((7-morpholinoquinolin-3-yl)amino) nicotinamide Example 4-124

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((8-hydroxyquinolin-3-yl)amino)nicotinamide Example 4-125

6-(cis-2-aminocyclohexylamino)-2-((7- aminoquinolin-3-yl)amino)-5- fluoronicotinamide Example 4-126

6-(cis-2-aminocyclohexylamino)-2-(7- (dimethylamino)quinolin-3-yl)amino)-5- fluoronicotinamide Example 4-127

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((7-(2-methoxyethoxy)quinolin-3-yl)amino) nicotinamide Example 4-128

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((7-methoxyquinolin-3-yl)amino)nicotinamide Example 4-129

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- (phenylamino)nicotinamide Example 4-130

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((imidazo[1,2-a]pyridin-6-yl)amino) nicotinamide Example 4-131

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((imidazo[1,2-a]pyridin-7-yl)amino) nicotinamide Example 4-132

2-((5-acetylpyridin-3-yl)amino)-6-(cis-2- aminocyclohexylamino)-5-fluoronicotinamide Example 4-133

6-(cis-2-aminocyclohexylamino)-2-(8-(2-(2- ethoxyethoxy)ethylamino)quinolin-3-yl)amino)- 5-fluoronicotinamide Example 4-134

6-(cis-2-aminocyclohexylamino)-2-(8- (cyclopropylmethylamino)quinolin-3-yl)amino)- 5-fluoronicotinamide Example 4-135

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((8-fluoroquinolin-3-yl)amino)nicotinamide Example 4-136

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((8-(methylamino)quinolin-6-yl)amino) nicotinamide Example 4-137

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((8-(2-methoxyethylamino)quinolin-6-yl) amino)nicotinamide Example 4-138

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((8-methoxyquinolin-6-yl)amino)nicotinamide Example 4-139

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((8-(2-methoxyethoxy)quinolin-6-yl)amino) nicotinamide Example 4-140

6-(cis-2-aminocyclohexylamino)-2-((8- (benzyloxy)quinolin-6-yl)amino)-5- fluoronicotinamide Example 4-141

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(isoxazol-5-yl)pyridin-3-yl)amino) nicotinamide Example 4-142

methyl 2-amino-5-((6-(cis-2- aminocyclohexylamino)-3-carbamoyl-5- fluoropyridin-2-yl)amino)nicotinate Example 4-143

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-fluorophenyl)pyridin-3-yl)amino) nicotinamide Example 4-144

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(3-fluorophenyl)pyridin-3-yl)amino) nicotinamide Example 4-145

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-fluorophenyl)pyridin-3-yl)amino) nicotinamide Example 4-146

6-(cis-2-aminocyclohexylamino)-2-((5-(2- chlorophenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-147

6-(cis-2-aminocyclohexylamino)-2-((5-(3- chlorophenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-148

6-(cis-2-aminocyclohexylamino)-2-((5-(4- chlorophenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-149

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-methoxyphenyl)pyridin-3-yl)amino) nicotinamide Example 4-150

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-(2-methoxyethoxy)isoquinolin-4-yl)amino) nicotinamide Example 4-151

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-(3-methoxybutoxy)isoquinolin-4-yl)amino) nicotinamide Example 4-152

6-(cis-2-aminocyclohexylamino)-2-((1-(2-(2- ethoxyethoxy)ethoxy)isoquinolin-4-yl)amino)- 5-fluoronicotinamide Example 4-153

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-methoxyisoquinolin-4-yl)amino) nicotinamide Example 4-154

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-((1-methoxypropan-2-yl)oxy)isoquinolin-4- yl)amino)nicotinamide Example 4-155

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-methoxyisoquinolin-5-yl)amino) nicotinamide Example 4-156

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-((1-methoxypropan-2-yl)oxy)isoquinolin-5- yl)amino)nicotinamide Example 4-157

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-(3-methoxybutoxy)isoquinolin-5-yl)amino) nicotinamide Example 4-158

6-(cis-2-aminocyclohexylamino)-2-((1-(2-(2- ethoxyethoxy)ethoxy)isoquinolin-5-yl)amino)- 5-fluoronicotinamide Example 4-159

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((isoquinolin-5-yl)amino)nicotinamide Example 4-160

2-([1,3]dioxolo[4,5-b]pyridin-6-yl)amino)-6- (cis-6-aminocyclohexylamino)-5- fluoronicotinamide Example 4-161

6-(cis-2-aminocyclohexylamino)-2-((2,3- dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)amino)- 5-fluoronicotinamide Example 4-162

6-(cis-2-aminocyclohexylamino)-2-((6,7- dihydro-5H-cyclopenta[b]pyridin-3-yl)amino)- 5-fluoronicotinamide Example 4-163

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((isoquinolin-6-yl)amino)nicotinamide Example 4-164

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-methoxyisoquinolin-6-yl)amino) nicotinamide Example 4-165

6-(cis-2-aminocyclohexylamino)-2-((1- ethoxyisoquinolin-6-yl)amino)-5- fluoronicotinamide Example 4-166

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-isopropoxyisoquinolin-6-yl)amino) nicotinamide Example 4-167

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-isobutoxyisoquinolin-6-yl)amino) nicotinamide Example 4-168

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-(2-methoxyethoxy)isoquinolin-6-yl)amino) nicotinamide Example 4-169

6-(cis-2-aminocyclohexylamino)-2-((1-(2-(2- ethoxyethoxy)ethoxy)isoquinolin-6-yl)amino)- 5-fluoronicotinamide Example 4-170

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-(2-isobutoxyethoxy)isoquinolin-6-yl)amino) nicotinamide Example 4-171

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-((tetrahydrofuran-2-yl) methoxy)isoquinolin-6-yl)amino)nicotinamide Example 4-172

6-((1R,2S)-2-aminocyclohexylamino)-5-fluoro- 2-((1-(2-methoxyethyl)-1H-indazol-5-yl) amino)nicotinamide Example 4-173

6-(cis-2-aminocyclohexylamino)-2-((7- ethoxyquinolin-3-yl)amino)-5- fluoronicotinamide Example 4-174

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((7-propoxyquinolin-3-yl)amino)nicotinamide Example 4-175

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-methoxyquinolin-6-yl)amino) nicotinamide Example 4-176

6-(cis-2-aminocyclohexylamino)-2-((2- ethoxyquinoxalin-6-yl)amino)-5- fluoronicotinamide Example 4-177

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-propoxyquinoxalin-6-yl)amino)nicotinamide Example 4-178

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-(2-methoxyethoxy)quinoxalin-6-yl)amino) nicotinamide Example 4-179

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-(2-(2-methoxyethoxy)ethoxy)quinoxalin-6- yl)amino)nicotinamide Example 4-180

6-(cis-2-aminocyclohexylamino)-2-((5-cis-2,6- dimethylmorpholino)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-181

6-(cis-2-aminocyclohexylamino)-2-((5-(2,4- difluorophenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-182

6-(cis-2-aminocyclohexylamino)-2-((5-(2- ethoxyphenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-183

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-isobutoxyphenyl)pyridin-3-yl)amino) nicotinamide Example 4-184

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-((5-(2- (cyclopropylmethoxy)phenyl)pyridin-3-yl) amino)-5-fluoronicotinamide Example 4-185

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-(2-methoxyethoxy)phenyl)pyridin-3-yl) amino)nicotinamide Example 4-186

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-hydroxyphenyl)pyridin-3-yl)amino) nicotinamide Example 4-187

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-(2-(2-oxopyridin-1-yl)ethoxy)quinoxalin- 6-yl)amino)nicotinamide Example 4-188

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(methoxymethyl)pyridin-3-yl)amino) nicotinamide Example 4-189

6-(cis-2-aminocyclohexylamino)-2-((5- ((benzyloxy)methyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-190

6-(cis-2-aminocyclohexylamino)-2-((5-(2,4- dimethoxyphenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-191

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-(methoxymethyl)pyridin-4-yl)amino) nicotinamide Example 4-192

6-(cis-2-aminocyclohexylamino)-2-((2- ((benzyloxy)methyl)pyridin-4-yl)amino)-5- fluoronicotinamide Example 4-193

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(hydroxymethyl)pyridin-3-yl)amino) nicotinamide Example 4-194

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-(hydroxymethyl)pyridin-4-yl)amino) nicotinamide Example 4-195

(R)-2-((5-(2H-1,2,3-triazol-2-yl)pyridin-3-yl) amino)-6-((1-amino-4-methylpentan-2-yl) amino)-5-fluoronicotinamide Example 4-196

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 2-((8-aminoquinolin-3-yl)amino)-5- fluoronicotinamide Example 4-197

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-fluoro-3-methoxyphenyl)pyridin-3-yl) amino)nicotinamide Example 4-198

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-fluoro-4-methoxyphenyl)pyridin-3-yl) amino)nicotinamide Example 4-199

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-fluoro-5-methoxyphenyl)pyridin-3-yl) amino)nicotinamide Example 4-200

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-(3-(2-oxopyrrolidin-1-yl)propoxy)quinolin- 6-yl)amino)nicotinamide Example 4-201

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-(2-(2-oxooxazolidin-3-yl)ethoxy)quinolin- 6-yl)amino)nicotinamide Example 4-202

2-((2-(2H-1,2,3-triazol-2-yl)quinolin-6-yl) amino)-6-(cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 4-203

2-((2-(1H-pyrazol-1-yl)quinolin-6-yl)amino)- 6-(cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 4-204

6-(cis-2-aminocyclohexylamino)-2-((5-(2,3- difluorophenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-205

6-(cis-2-aminocyclohexylamino)-2-((5-(2,5- difluorophenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-206

6-(cis-2-aminocyclohexylamino)-2-((5-(3- chloro-2-fluorophenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-207

6-(cis-2-aminocyclohexylamino)-2-((5-(5- chloro-2-fluorophenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-208

2-((2-(1H-pyrazol-1-yl)quinoxalin-6-yl)amino)- 6-(cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 4-209

2-((7-(2H-1,2,3-triazol-2-yl)quinolin-3-yl) amino)-6-(cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 4-210

2-((7-(1H-pyrazol-1-yl)quinolin-3-yl)amino)- 6-(cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 4-211

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-oxo-2H-[1,3′-bipyridin]-5′-yl)amino) nicotinamide Example 4-212

2-([1,2,4]triazol[4,3-a]pyridin-7-yl)amino)-6- (cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 4-213

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((1-methyl-1H-pyrazole[3,4-b]pyridin-5-yl) amino)nicotinamide Example 4-214

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(pyrimidin-2-yl)pyridin-3-yl)amino) nicotinamide Example 4-215

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(3-nitrophenyl)pyridin-3-yl)amino) nicotinamide Example 4-216

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-fluoro-6-morpholinopyridin-3-yl)amino) nicotinamide Example 4-217

6-(cis-2-aminocyclohexylamino)-2-((5-(3- aminophenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-218

6-(cis-2-aminocyclohexylamino)-2-((5-(4- aminophenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-219

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(3-(methylamino)phenyl)pyridin-3-yl) amino)nicotinamide Example 4-220

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-(methylamino)phenyl)pyridin-3-yl) amino)nicotinamide Example 4-221

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(3-morpholinophenyl)pyridin-3-yl)amino) nicotinamide Example 4-222

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-morpholinophenyl)pyridin-3-yl)amino) nicotinamide Example 4-223

2-((5-(3-acetamidephenyl)pyridin-3-yl)amino)- 6-(cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 4-224

2-((5-(4-acetamidephenyl)pyridin-3-yl)amino)- 6-(cis-2-aminocyclohexylamino)-5- fluoronicotinamide Example 4-225

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(3-(2-oxopyrrolidin-1-yl)phenyl)pyridin-3- yl)amino)nicotinamide Example 4-226

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-(2-oxopyrrolidin-1-yl)phenyl)pyridin-3- yl)amino)nicotinamide Example 4-227

6-(cis-2-aminocyclohexylamino)-2-((5-(3- (dimethylamino)phenyl)pyridin-3-yl)amino)-5- fluoronicotinamide Example 4-228

6-((cis-2-aminocyclohexyl)amino)-2-((5- cyano-6-morpholinopyridin-3-yl)amino)-5- fluoronicotinamide Example 4-229

2-((5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl) amino)-6-((cis-2-aminocyclohexyl)amino)-5- fluoronicotinamide Example 4-230

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((6-methoxy-[2,3′-bipyridin]-5′-yl)amino) nicotinamide Example 4-231

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((6′-methoxy-[3,3′-bipyridin]-5-yl)amino) nicotinamide Example 4-232

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((2′-methoxy-[3,4′-bipyridine]-5-yl)amino) nicotinamide Example 4-233

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-methoxy-6-morpholinopyridin-3- yl)amino)nicotinamide Example 4-234

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((7-morpholino-1H-pyrrolo[2,3- c]pyridin-4-yl)amino)nicotinamide Example 4-235

6-(((1R,2S)-2-aminocyclohexylamino)-5- fluoro-2-((7-methoxy-1H-pyrrolo[2,3- c]pyridin-4-yl)amino)nicotinamide Number Compound name ¹H-NMR MS (ESI, m/z) Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.71 (s, 1H), 347 (M + H) 4-1 5-fluoro-2-((pyrimidin-5-yl) 9.08 (s, 2H), 8.73 (s, 1H), 7.92 (d, 1H, J = amino)nicotinamide 12.5 Hz), 7.86-7.58 (br, 1H), 7.58-7.00 (br, 1H), 6.72-6.66 (m, 1H), 3.92-3.88 (m, 1H), 3.15-3.13 (m, 1H), 1.78-1.17 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.28 (s, 1H), 396 (M + H) 4-2 5-fluoro-2-((1,5-naphthyridin-3- 8.98 (d, 1H, J = 2.4 Hz), 8.89 (dd, 1H, J = yl)amino)nicotinamide 1.7, 4.2 Hz), 8.86 (d, 1H, J = 2.6 Hz), 8.29 (d, 1H, J = 7.6 Hz), 7.98 (d, 1H, J = 12.5 Hz), 7.92-7.76 (br, 1H), 7.55 (dd, 1H, J = 4.2, 8.4 Hz), 7.48-7.25 (br, 1H), 6.85-6.62 (m, 1H), 4.20-4.16 (m, 1H), 3.20-3.16 (m, 1H), 1.94-1.30 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.23 (s, 1H), 396 (M + H) 4-3 5-fluoro-2-((1,6-naphthyridin-3- 9.21 (s, 1H), 9.07 (d, 1H, J = 2.6 Hz), 8.93 yl)amino)nicotinamide (d, 1H, J = 2.2 Hz), 8.56 (d, 1H, J = 5.8 Hz), 7.96 (d, 1H, J = 12.6 Hz), 7.92-7.74 (br, 1H), 7.82 (d, 1H, J = 5.7 Hz), 7.57-7.08 (br, 1H), 6.74-6.59 (m, 1H), 4.09-4.05 (m, 1H), 3.20-3.16 (m, 1H), 1.86-1.26 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ 12.79 (s, 1H), 396 (M + H) 4-4 5-fluoro-2-((1,6-naphthyridin-8- 10.04 (s, 1H), 9.11 (dd, 1H, J = 1.7, 4.2 yl)amino)nicotinamide Hz), 8.91 (s, 1H), 8.53 (dd, 1H, J = 1.7, 8.3 Hz), 7.93 (d, 1H, J = 12.5 Hz), 7.73 (dd, 1H, J = 4.3, 8.2 Hz), 7.86-7.47 (br, 1H), 7.40-6.80 (br, 1H), 6.66 (d, 1H, J = 7.0 Hz), 4.12-4.08 (m, 1H), 3.27-3.25 (m, 1H), 1.86-1.33 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (CD₃OD, 300 MHz) δ: 9.23 (d, 1H, J = 440 (M + H) 4-5 5-fluoro-2-((8-nitroquinolin-3- 2.5 Hz), 8.54 (d, 1H, J = 2.5 Hz), 8.07 yl)amino)nicotinamide (dd, 1H, J = 1.2, 8.4 Hz), 7.92 (dd, 1H, J = 1.3, 7.5 Hz), 7.83 (d, 1H, J = 11.9 Hz), 7.64 (t, 1H, J = 7.9 Hz), 4.49-4.45 (m, 1H), 3.74-3.70 (m, 1H), 1.95-1.47 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.03 (s, 1H), 398 (M + H) 4-6 5-fluoro-2-((1-methyl-1H-pyrrolo 9.26 (s, 1H), 8.46 (s, 1H), 8.31 (s, 1H), [2,3-c]pyridin-4-yl)amino) 7.91 (d, 1H, J = 12.7 Hz), 7.86-7.57 (br, nicotinamide 1H), 7.49 (d, 1H, J = 3.0 Hz), 7.46-7.04 (br, 1H), 6.62 (d, 1H, J = 6.9 Hz), 6.49 (d, 1H, J = 2.9 Hz), 4.06-4.02 (m, 1H), 3.89 (s, 3H), 3.21-3.17 (m, 1H), 1.77-1.27 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (CD₃OD, 300 MHz) δ: 9.22 (s, 1H), 481 (M + H) 4-7 5-fluoro-2-((1-(2-(pyrrolidin-1- 8.45 (s, 1H), 7.73 (d, 1H, J = 12.2 Hz), 7.49 yl)ethyl)-1H-pyrrolo[2,3-c] (d, 1H, J = 3.2 Hz), 6.70 (d, 1H, J = 3.2 pyridin-4-yl)amino)nicotinamide Hz), 4.42 (t, 2H, J = 7.0 Hz), 4.35-4.30 (m, 1H), 3.32-3.28 (1H, overlapping with CH₃OH peak), 2.95 (t, 2H, J = 7.0), 2.64-2.48 (m, 4H), 1.96-1.41 (m, 12H). Example 2-((8-acetylaminoquinolin-3-yl) 452 (M + H) 4-8 amino)-6-(cis-2-aminocyclohexyl- amino)-5-fluoronicotinamide Example 6-(cis-2-aminocyclohexylamino)- 399 (M + H) 4-9 5-fluoro-2-((1-oxoisoindolin-4- yl)amino)nicotinamide Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.93 (s, 1H), 400 (M − H) 4-10 5-fluoro-2-((5-(methylamino- 8.91 (d, 1H, J = 2.1 Hz), 8.80-8.73 (m, 1H), HCl salt carbonyl)pyridin-3-yl)amino) 8.67-8.63 (m, 1H), 8.62 (d, 1H, J = 1.7 Hz), nicotinamide 7.99 (d, 1H, J = 12.3 Hz), 7.96-7.82 (m, 4H), 7.49-7.37 (m, 1H), 7.08-7.02 (m, 1H), 4.36-4.27 (m, 1H), 3.60-3.53 (1H, overlapping with H₂O peak), 2.81 (d, 3H, J = 4.5 Hz), 1.90-1.37 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.95 (s, 1H), 464 (M + H) 4-11 5-fluoro-2-((5-(anilinocarbonyl) 10.51 (s, 1H), 8.88-8.84 (m, 1H), 8.80-8.76 HCl salt pyridin-3-yl)amino)nicotinamide (m, 1H), 8.74-8.69 (m, 1H), 7.99 (d, 1H, J = 12.2 Hz), 7.96-7.75 (m, 5H), 7.50-7.27 (m, 3H), 7.18-7.10 (m, 2H), 7.09-7.01 (m, 1H), 4.34-4.24 (m, 1H), 3.60-3.53 (1H, overlapping with H₂O peak), 1.88-1.16 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.48 (s, 1H), 398 (M + H) 4-12 5-fluoro-2-((1-methyl-1H-pyrrolo 8.47 (d, 1H, J = 2.4 Hz), 8.18 (d, 1H, J = [2,3-b]pyridin-5-yl)amino)nicotinamide 2.4 Hz), 7.85 (d, 1H, J = 12.7 Hz), 7.72-7.48 (br, 1H), 7.46 (d, 1H, J = 3.4 Hz), 7.36-6.92 (br, 1H), 6.55-6.45 (m, 1H), 6.32 (d, 1H, J = 3.4 Hz), 3.92-3.88 (m, 1H), 3.79 (s, 3H), 3.13-3.09 (m, 1H), 1.74-1.18 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.46 (s, 1H), 398 (M + H) 4-13 5-fluoro-2-((1-methyl-1H-pyrrolo 8.17 (d, 1H, J = 5.5 Hz), 8.07 (d, 1H, J = [2,3-b]pyridin-4-yl)amino)nicotinamide 5.5 Hz), 7.95 (d, 1H, J = 12.7 Hz), 7.90-7.70 (br, 1H), 7.54-7.19 (m, 2H), 6.76-6.64 (m, 1H), 6.46 (d, 1H, J = 3.5 Hz), 4.05-4.01 (m, 1H), 3.79 (s, 3H), 3.24-3.20 (m, 1H), 1.82-1.27 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (CDCl₃, 300 MHz) δ: 10.90 (s, 1H), 458 (M − H) 4-14 5-fluoro-2-((2-phenylimido[1, 8.96 (s, 1H), 7.94-7.89 (m, 2H), 7.77 (s, 2-a]pyridin-6-yl)amino)nicotinamide 1H), 7.55 (d, 1H, J = 9.3 Hz), 7.46-7.41 (m, 2H), 7.34-7.30 (m, 1H), 7.23-7.22 (m, 2H), 4.13-4.03 (m, 1H), 3.26-3.18 (m, 1H), 1.96-0.80 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.01 (s, 1H), 416 (M + H) 4-15 2-((5-(dimethylaminocarbonyl) 8.84 (d, 1H, J = 2.1 Hz), 8.38-8.34 (m, 1H), HCl salt pyridin-3-yl)amino)-5-fluoronicotinamide 8.28 (d, 1H, J = 1.6 Hz), 8.00 (d, 1H, J = 12.3 Hz), 7.97-7.88 (m, 4H), 7.50-7.37 (m, 1H), 7.13-7.07 (m, 1H), 4.26-4.16 (m, 1H), 3.58-3.50 (1H, overlapping with H₂O peak), 3.00 (s, 3H), 2.96 (s, 3H), 1.94-1.36 (m, 8H). Example Methyl ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.97 (s, 1H), 403 (M + H) 4-16 5-(3-carbamoyl-6-(cis-2-amino- 8.90 (d, 1H, J = 2.6 Hz), 8.74-8.71 (m, 1H), HCl salt cyclohexyl)-5-fluoropyridin- 8.68 (d, 1H, J = 1.8 Hz), 8.04-7.86 (m, 4H), 2-ylamino)nicotinamide 8.00 (d, 1H, J = 12.4 Hz), 7.50-7.36 (m, 1H), 7.05-6.98 (m, 1H), 4.37-4.27 (m, 1H), 3.91 (s, 3H), 3.52-3.46 (1H, overlapping with H₂O peak), 1.94-1.83 (m, 2H), 1.73-1.57 (m, 4H), 1.50-1.37 (m, 2H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.07 (s, 1H), 359 (M + H) 4-17 5-fluoro-2-((6-methylpyridin-3- 9.17 (s, 1H), 8.40-8.32 (m, 1H), 8.10-7.92 HCl salt yl)amino)nicotinamide (m, 5H), 7.77-7.69 (m, 1H), 7.54-7.42 (m, 1H), 7.11-7.03 (m, 1H), 4.36-4.26 (m, 1H), 3.60-3.50 (m, 1H), 2.65 (s, 3H), 1.95-1.35 (m, 8H) Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.92 (s, 1H), 359 (M + H) 4-18 5-fluoro-2-((2-methylpyridin-4- 8.48-8.41 (m, 1H), 8.26-8.14 (m, 4H), 8.11 HCl salt yl)amino)nicotinamide (d, 1H, J = 12.1 Hz), 8.00-7.91 (m, 1H), 7.83 (s, 1H), 7.74 (s, 1H), 7.35-7.28 (m, 1H), 4.38-4.28 (m, 1H), 3.68-3.58 (m, 1H), 2.60 (s, 3H), 2.05-1.38 (m, 8H) Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.35 (s, 1H), 359 (M + H) 4-19 5-fluoro-2-((4-methylpyridin-3- 9.74 (s, 1H), 8.41 (d, 1H, J = 5.6 Hz), HCl salt yl)amino)nicotinamide 8.12-7.99 (m, 4H), 7.92-7.88 (m, 1H), 7.60-7.51 (m, 1H), 7.18-7.12 (m, 1H), 4.42-4.32 (m, 1H), 3.60-3.51 (m, 1H), 2.54 (s, 3H), 1.94-1.36 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.56 (s, 1H), 461 (M + H) 4-20 5-fluoro-2-((1-phenyl-1H-pyrazolo 9.37 (s, 1H), 8.88 (s, 1H), 8.34 (s, 1H), [3,4-c]pyridin-4-yl)amino)nicotinamide 7.99 (d, 1H, J = 12.6 Hz), 7.87 (d, 2H, J = 7.6 Hz), 7.64 (t, 2H, J = 7.9 Hz), 7.47 (t, 2H, J = 7.3 Hz), 7.45-7.20 (br, 1H), 7.20-6.95 (br, 1H), 6.80-6.70 (m, 1H), 4.03-3.99 (m, 1H), 3.27-3.23 (1H, overlapping with H₂O peak), 1.79-1.20 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (CD₃OD, 300 MHz) δ: 9.13 (d, 1H, J = 397 (M + H) 4-21 5-fluoro-2-((pyrido[2,3-b] 2.8 Hz), 9.09 (d, 1H, J = 2.8 Hz), 8.92 pyrazin-7-yl)amino)nicotinamide (d, 1H, J = 1.9 Hz), 8.84 (d, 1H, J = 1.9 Hz), 7.85 (d, 1H, J = 12.0 Hz), 4.54-4.50 (m, 1H), 3.64-3.60 (m, 1H), 1.94-1.20 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.39 (s, 1H), 481 (M + H) 4-22 5-fluoro-2-((1-(2-(pyrrolidin-1- 8.33 (d, 1H, J = 2.6 Hz), 8.21 (d, 1H, J = yl)ethyl)-1H-pyrrolo[2,3-b] 2.3 Hz), 7.86 (d, 1H, J = 12.7 Hz), pyridin-5-yl)amino)nicotinamide 7.80-7.55 (br, 1H), 7.52 (d, 1H, J = 3.4 Hz), 7.35-6.92 (br, 1H), 6.66-6.50 (m, 1H), 6.33 (d, 1H, J = 3.7 Hz), 4.33 (t, 2H, J = 6.2 Hz), 3.92-3.88 (m, 1H), 3.27-3.23 (m, 1H), 2.83 (t, 2H, J = 6.6 Hz), 2.69-2.34 (4H, overlapping with DMSO peak), 1.77-1.21 (m, 12H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.44 (s, 1H), 481 (M + H) 4-23 5-fluoro-2-((1-(2-(pyrrolidin-1- 8.14 (d, 1H, J = 5.5 Hz), 8.06 (d, 1H, J = yl)ethyl)-1H-pyrrolo[2,3-b] 5.5 Hz), 7.95 (d, 1H, J = 12.7 Hz), pyridin-4-yl)amino)nicotinamide 7.90-7.69 (br, 1H), 7.44 (d, 1H, J = 3.5 Hz), 7.42-7.20 (br, 1H), 6.76-6.60 (m, 1H), 6.45 (d, 1H, J = 3.5 Hz), 4.33 (t, 2H, J = 6.7 Hz), 4.06-4.02 (m, 1H), 3.26-3.22 (m, 1H), 2.81 (t, 2H, J = 6.7 Hz), 2.6-2.43 (4H, overlapping with DMSO peak), 1.80-1.25 (m, 12H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.43 (s, 1H), 497 (M + H) 4-24 5-fluoro-2-((1-(2-(morpholin-4- 8.39 (d, 1H, J = 2.3 Hz), 8.18 (d, 1H, J = yl)ethyl)-1H-pyrrolo[2,3-b] 2.3 Hz), 7.85 (d, 1H, J = 12.7 Hz), pyridin-5-yl)amino)nicotinamide 7.8-7.52 (br, 1H), 7.53 (d, 1H, J = 3.4 Hz), 7.40-6.80 (br, 1H), 6.56-6.46 (m, 1H), 6.32 (d, 1H, J = 3.4 Hz), 4.34 (t, 2H, J = 6.7 Hz), 3.90-3.86 (m, 1H), 3.53 (t, 4H, J = 4.5 Hz), 3.12-3.08 (m, 1H), 2.70 (t, 2H, J = 6.7 Hz), 2.43 (t, 4H, J = 4.5 Hz), 1.70-1.21 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.45 (s, 1H), 497 (M + H) 4-25 5-fluoro-2-((1-(2-(morpholin-4- 8.15 (d, 1H, J = 5.5 Hz), 8.06 (d, 1H, J = yl)ethyl)-1H-pyrrolo[2,3-b] 5.5 Hz), 7.95 (d, 1H, J = 12.7 Hz), pyridin-4-yl)amino)nicotinamide 7.90-7.53 (br, 1H), 7.44 (d, 1H, J = 3.6 Hz), 7.42-7.02 (br, 1H), 6.73-6.65 (m, 1H), 6.45 (d, 1H, J = 3.6 Hz), 4.34 (t, 2H, J = 6.5 Hz), 4.04-4.00 (m, 1H), 3.53 (t, 4H, J = 4.5 Hz), 3.24-3.20 (m, 1H), 2.69 (t, 2H, J = 6.4 Hz), 2.43 (t, 4H, J = 4.4 Hz), 1.75-1.39 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.91 (s, 1H), 402 (M + H) 4-26 5-fluoro-2-(([1,3]thiazolo[4,5- 9.48 (s, 1H), 8.96 (d, 1H, J = 2.4 Hz), 8.76 HCl salt b]pyridin-6-yl)amino)nicotinamide (d, 1H, J = 2.6 Hz), 8.62-7.84 (m, 5H), 7.46-7.32 (m, 1H), 7.04-6.99 (m, 1H), 4.33-4.34 (m, 1H), 3.68-3.60 (m, 1H), 1.94-1.38 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- 477 (M + H) 4-27 5-fluoro-2-((3-methyl-3H-imidazo [4,5-b]pyridin-6-yl)amino)nicotinamide Example 6-(cis-2-aminocyclohexylamino)- 488 (M + H) 4-28 2-((1-(2-(diethylamino)ethyl)- 1H-pyrrolo[2,3-b]pyridin-4-yl) amino)-5-fluoronicotinamide Example 6-(cis-2-aminocyclohexylamino)- 496 (M + H) 4-29 5-fluoro-2-((1-(2-(piperidin-1- yl)ethyl)-1H-pyrrolo[2,3-b] pyridin-4-yl)amino)nicotinamide Example 6-(cis-2-aminocyclohexylamino)- 470 (M + H) 4-30 2-((1-(3-(dimethylamino)propyl)- 1H-pyrrolo[2,3-b]pyridin-4-yl) amino)-5-fluoronicotinamide Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.03 (s, 1H), 375 (M + H), 4-31 5-fluoro-2-((5-methoxypyridin-3- 8.77 (s, 1H), 8.14 (d, 1H, J = 2.2 Hz), 373 (M − H) HCl salt yl)amino)nicotinamide 8.03-7.92 (m, 6H), 7.45 (brs, 1H), 7.05 (d, 1H, J = 6.5 Hz), 4.33-4.24 (m, 1H), 3.93 (s, 3H), 3.60-3.52 (m, 1H), 1.95-1.37 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- 438 (M + H) 4-32 2-((8-(dimethylamino)quinolin-3- yl)amino)-5-fluoronicotinamide Example 6-(cis-2-aminocyclohexylamino)- 480 (M + H) 4-33 5-fluoro-2-((8-(morpholin-4-yl) HCl salt quinolin-3-yl)amino)nicotinamide Example 2-(8-(acetyl(methyl)amino) 466 (M + H) 4-34 quinolin-3-yl)amino-6-(cis-2-amino- cyclohexylamino)-5-fluoronicotinamide Example 6-(cis-2-aminocyclohexylamino)- 442 (M + H) 4-35 5-fluoro-2-((1-(2-methoxyethyl)- 1H-pyrrolo[2,3-b]pyridin-4-yl) amino)nicotinamide Example 6-(cis-2-aminocyclohexylamino)- 440 (M + H) 4-36 5-fluoro-2-((1-isobutyl-1H- pyrrolo[2,3-b]pyridin-4-yl)amino) nicotinamide Example 6-(cis-2-aminocyclohexylamino)- 424 (M + H) 4-37 2-((1-cyclopropyl-1H-pyrrolo[2, 3-b]pyridin-4-yl)amino)-5-fluoro- nicotinamide Example 6-(cis-2-aminocyclohexylamino)- 460 (M + H) 4-38 5-fluoro-2-((1-phenyl-1H-pyrrolo- [2,3-b]pyridin-4-yl)amino) nicotinamide Example 6-(cis-2-aminocyclohexylamino)- 424 (M + H) 4-39 5-fluoro-2-((1-(2,2,2-trifluoro- HCl salt ethyl)-1H-pyrrolo[2,3-b]pyridin- 4-yl)amino)nicotinamide Example 6-(cis-2-aminocyclohexylamino)- 466 (M + H) 4-40 2-((1-(cyclopropylmethyl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)- 5-fluoronicotinamide Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.07 (s, 1H), 437 (M + H), 4-41 5-fluoro-2-((5-phenoxypyridin-3- 8.70 (d, 1H, J = 1.6 Hz), 8.13-7.90 (m, 7H), 435 (M − H) HCl salt yl)amino)nicotinamide 7.49-7.41 (m, 3H), 7.25-7.19 (m, 1H), 7.15-7.10 (m, 2H), 7.05 (d, 1H, J = 6.7 Hz), 4.17-4.08 (m, 1H), 3.52-3.43 (m, 1H), 1.92-1.21 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.09 (s, 1H), 412 (M + H), 4-42 5-fluoro-2-((5-(2H-1,2,3-triazol- 9.07-9.04 (m, 1H), 8.80 (d, 1H, J = 2.1 Hz), 410 (M − H) HCl salt 2-yl)pyridin-3-yl)amino)nicotinamide 8.56 (d, 1H, J = 2.1 Hz), 8.24 (s, 2H), 8.01 (d, 1H, J = 12.3 Hz), 7.96-7.82 (m, 4H), 7.43 (brs, 1H), 7.02 (d, 1H, J = 6.5 Hz), 4.47-4.38 (m, 1H), 3.63-3.56 (m, 1H), 1.93-1.32 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- 412 (M + H), 4-43 5-fluoro-2-((5-(1H-1,2,3-triazol 410 (M − H) HCl salt 1-yl)pyridin-3-yl)amino)nicotinamide Example 6-(((2R)-1-amino-1-oxo-3-phenyl 448 (M + H) 4-44 propan-2-yl)amino)-5-fluoro-2-(1- methyl-1H-pyrrolo[2,3-b] pyridin-4-ylamino)nicotinamide Example 6-(((2R)-1-amino-1-oxo-3-phenyl 547 (M + H) 4-45 propan-2-yl)amino)-5-fluoro-2- (1-(2-(morpholin-4-yl)ethyl)-1H- pyrrolo[2,3-b]pyridin-4-ylamino) nicotinamide Example 6-(((2R)-1-amino-1-oxo-3-phenyl 488 (M + H) 4-46 propan-2-yl)amino)-2-((1-(cyclo propylmethyl)-1H-pyrrolo[2,3-b] pyridin-4-yl)amino)-5-fluoro- nicotinamide Example 2-((8-acetylaminoquinolin-3-yl) 502 (M + H) 4-47 amino)-6-(((2R)-1-amino-1-oxo-3- phenylpropan-2-yl)amino)-5- fluoronicotinamide Example 2-((2-acetylaminopyridin-4-yl) 402 (M + H) 4-48 amino)-6-(cis-2-aminocyclohexyl- amino)-5-fluoronicotinamide Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.98 (s, 1H), 414 (M + H) 4-49 5-fluoro-2-((5-(pyrrolidin-1-yl) 8.64 (s, 1H), 8.03-7.90 (m, 5H), 7.72 (d, HCl salt pyridin-3-yl)amino)nicotinamide 1H, J = 2.1 Hz), 7.75 (brs, 1H), 7.27 (s, 1H), 7.02 (d, 1H, J = 6.5 Hz), 4.33-4.24 (m, 1H), 3.56-3.46 (m, 1H), 3.32-3.26 (4H, overlapping with H₂O peak), 2.04-1.93 (m, 4H), 1.92-1.34 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.98 (s, 1H), 428 (M + H), 4-50 5-fluoro-2-((5-(piperidin-1-yl) 8.79 (s, 1H), 8.17-7.90 (m, 6H), 7.70 (s, 426 (M − H) HCl salt pyridin-3-yl)amino)nicotinamide 1H), 7.46 (brs, 1H), 7.11-7.02 (m, 1H), 4.34-4.25 (m, 1H), 3.56-3.36 (5H, overlapping with H₂O peak), 1.94-1.22 (m, 14H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 8.74-8.71 430 (M + H), 4-51 5-fluoro-2-((5-(morpholin-4-yl) (m, 1H), 8.04 (d, 1H, J = 2.3 Hz), 7.96 (d, 428 (M − H) HCl salt pyridin-3-yl)amino)nicotinamide 1H, J = 12.1 Hz), 7.72 (s, 1H), 4.30-4.23 (m, 1H), 3.81-3.72 (m, 4H), 3.58-3.52 (m, 1H), 3.35-3.27 (m, 4H), 1.90-1.41 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (D₂O, 400 MHz) δ: 8.90 (d, 1H, J = 443 (M + H), 4-52 5-fluoro-2-((5-(4-methylpiperazin- 1.7 Hz), 8.02 (d, 1H, J = 2.4 Hz), 7.80-7.77 441 (M − H) 2HCl salt 1-yl)pyridin-3-yl)amino) (m, 1H), 7.72 (d, 1H, J = 11.6 Hz), nicotinamide 4.47-4.40 (m, 1H), 3.81-3.75 (m, 1H), 3.42-3.24 (m, 8H), 3.00 (s, 3H), 1.90-1.51 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.10 (s, 1H), 410 (M + H) 4-53 5-fluoro-2-((5-(1H-pyrrol-2-yl) 11.85 (s, 1H), 9.04-8.98 (m, 1H), 8.73-8.69 HCl salt pyridin-3-yl)amino)nicotinamide (m, 1H), 8.57-8.52 (m, 1H), 8.07-7.90 (m, 5H), 7.55-7.45 (br, 1H), 7.11 (d, 1H, J = 6.6 Hz), 7.09-7.04 (m, 1H), 6.94-6.88 (m, 1H), 6.25-6.22 (m, 1H), 4.34-4.25 (m, 1H), 3.60-3.50 (1H, overlapping with H₂O peak), 1.90-1.25 (m, 8H). ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 8.90-8.85 (m, 1H), 8.63-8.55 (m, 2H), 7.98 (d, 1H, J = 12.2 Hz), 7.09-7.04 (m, 1H), 6.90-6.82 (m, 1H), 6.30-6.24 (m, 1H), 4.30-4.20 (m, 1H), 3.60-3.50 (m, 1H), 1.90-1.30 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.98 (s, 1H), 427 (M + H) 4-54 5-fluoro-2-((5-(2-thienyl) 8.92-8.87 (m, 1H), 8.67-8.60 (m, 1H), HCl salt pyridin-3-yl)amino)nicotinamide 8.54-8.05 (m, 1H), 8.04-7.88 (m, 5H), 7.79 (d, 1H, J = 3.6 Hz), 7.78-7.73 (m, 1H), 7.52-7.37 (br, 1H), 7.24 (dd, 1H, J = 3.6, 5.0 Hz), 7.05 (d, 1H, J = 6.8 Hz), 4.32-4.23 (m, 1H), 3.60-3.50 (1H, overlapping with H₂O peak), 1.90-1.20 (m, 8H). ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 8.81-8.78 (m, 1H), 8.60-8.56 (m, 2H), 7.95 (d, 1H, J = 12.2 Hz), 7.74-7.70 (m, 2H), 7.26 (dd, 1H, J = 4.0, 4.8 Hz), 4.32-4.24 (m, 1H), 3.60-3.50 (m, 1H), 1.85-1.25 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.01 (s, 1H), 385 (M + H) 4-55 2-((5-cyclopropylpyridin-3-yl) 9.15-9.08 (m, 1H), 8.26-8.20 (m, 1H), HCl salt amino)-5-fluoronicotinamide 8.10-7.90 (m, 6H), 7.55-7.40 (br, 1H), 7.06 (d, 1H, J = 6.6 Hz), 4.37-4.26 (m, 1H), 3.58-3.46 (m, 1H), 2.18-2.08 (m, 1H), 1.94-1.36 (m, 8H), 1.16-1.06 (m, 2H), 1.00-0.90 (m, 2H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.07 (s, 1H), 479 (M + H) 4-56 2-((5-(2,3-dihydro[1,4]benzo- 9.00-8.90 (m, 1H), 8.68-8.62 (m, 1H), HCl salt dioxin-6-yl)pyridin-3-yl)amino)-5- 8.62-8.56 (m, 1H), 8.02 (d, 1H, J = 12.2 fluoronicotinamide Hz), 8.00-7.85 (m, 4H), 7.50-7.42 (br, 1H), 7.40 (d, 1H, J = 2.0), 7.32 (dd, 1H, J = 2.0, 8.5 Hz), 7.08-7.00 (m, 2H), 4.35-4.20 (m, 5H), 3.55-3.46 (1H, overlapping with H₂O peak), 1.85-1.20 (m, 8H). ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 8.85-8.82 (m, 1H), 8.74-8.68 (m, 1H), 8.55-8.50 (m, 1H), 7.97 (d, 1H, J = 12.2 Hz), 7.34 (d, 1H, J = 2.2 Hz), 7.28 (dd, 1H, J = 2.2, 8.6 Hz), J = 7.06 (d, 1H, J = 8.3 Hz), 4.35-4.18 (m, 5H), 3.55-3.46 (m, 1H), 1.84-1.20 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.58 (s, 1H), 364 (M + H) 4-57 5-fluoro-2-((5-methyl-3-thienyl) 8.00-7.60 (m, 5H), 7.32-7.12 (m, 2H), HCl salt amino)nicotinamide 6.85-6.76 (m, 2H), 4.32-4.22 (m, 1H), 3.75-3.66 (m, 1H), 2.42-2.38 (m, 3H), 1.96-1.38 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.96 (s, 1H), 411 (M + H) 4-58 5-fluoro-2-((5-(2-furyl)pyridin- 8.82-8.77 (m, 1H), 8.68-8.64 (m, 1H), HCl salt 3-yl)amino)nicotinamide 8.60-8.55 (m, 1H), 8.04-7.88 (m, 6H), 7.50-7.38 (br, 1H), 7.29 (d, 1H, J = 3.6 Hz), 7.02 (d, 1H, J = 6.8 Hz), 6.72-6.69 (m, 1H), 4.36-4.26 (m, 1H), 3.61-3.54 (1H, overlapping with H₂O peak), 1.92-1.30 (m, 8H). ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 8.71 (d, 1H, J = 2.2 Hz), 8.65-8.60 (m, 2H), 7.97 (d, 1H, J = 12.2 Hz), 7.89 (d, 1H, J = 1.7 Hz), 7.23 (d, 1H, J = 3.4 Hz), 6.71 (dd, 1H, J = 1.7, 3.4 Hz), 4.36-4.27 (m, 1H), 3.61-3.54 (m, 1H), 1.90-1.30 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (CD₃OD, 300 MHz) δ: 8.80 (d, 1H, J = 410 (M + H) 4-59 2-((8-aminoquinolin-3-yl)amino)- 2.4 Hz), 8.40 (d, 1H, J = 2.7 Hz), 7.79 5-fluoronicotinamide (d, 1H, J = 11.8 Hz), 7.28 (t, 1H, J = 7.9 Hz), 7.07 (dd, 1H, J = 0.9, 8.1 Hz), 6.85 (dd, 1H, J = 1.17, 7.4 Hz), 4.44-4.40 (m, 1H), 3.79-3.75 (m, 1H), 1.96-1.43 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.42 (s, 1H), 384 (M + H) 4-60 5-fluoro-2-((1H-pyrrolo[2,3-b] 11.50 (br, 1H), 8.14 (d, 1H, J = 5.3 Hz), pyridin-4-yl)amino)nicotinamide 8.03 (d, 1H, J = 5.6 Hz), 7.94 (d, 1H, J = 12.8 Hz), 7.84 (br, 1H), 7.55 (dd, 1H, J = 4.22, 8.4 Hz), 7.34 (br, 1H), 7.32 (t, 1H, J = 2.9 Hz), 6.69 (br, 1H), 6.46 (dd, 1H, J = 2.0, 3.60 Hz), 4.05-4.01 (m, 1H), 3.23-3.19 (m, 1H), 1.84-1.31 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.02 (s, 1H), 384 (M + H) 4-61 5-fluoro-2-((1H-pyrrolo[2,3-b] 11.55 (br, 1H), 9.22 (s, 1H), 8.39 (s, 1H), pyridin-5-yl)amino)nicotinamide 7.91 (d, 1H, J = 12.7 Hz), 7.75 (br, 1H), 7.53 (t, 1H, J = 2.5 Hz), 7.26 (br, 1H), 6.62 (br, 1H), 6.52 (br, 1H), 4.08-4.04 (m, 1H), 3.22-3.18 (m, 1H), 1.81-1.30 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.50 (br, 384 (M + H) 4-62 5-fluoro-2-((1H-pyrrolo[2,3-c] 1H), 11.45 (s, 1H), 8.37 (d, 1H, J = 2.3 Hz), pyridin-4-yl)amino)nicotinamide 8.22 (d, 1H, J = 2.4 Hz), 7.84 (d, 1H, J = 12.7 Hz), 7.63 (br, 1H), 7.41 (t, 1H, J = 2.9 Hz), 7.16 (br, 1H), 6.51 (br, 1H), 6.52 (dd, 1H, J = 1.8, 3.4 Hz), 3.93-3.91 (m, 1H), 3.14-3.10 (m, 1H), 1.76-1.27 (m, 8H). Example 6-(((2R)-1-amino-1-oxo-3-phenyl 434 (M + H) 4-63 propan-2-yl)amino)-5-fluoro-2- ((1H-pyrrolo[2,3-b]pyridin-4-yl) amino)nicotinamide Example 2-((8-(aminocarbonyl)amino- 481 (M + H) 4-64 quinolin-3-yl)amino)-6-(cis-2-amino- cyclohexylamino)-5-fluoronicotinamide Mass Mass Number Salt Solvent NMR 1HNMR (M + H) (M − H) rt (min) Example 4-65 free 414 412 0.86 Example 4-66 free 469 467 0.74 Example 4-67 free 451 449 0.89 Example 4-68 free 451 449 0.91 Example 4-69 free 451 449 0.86 Example 4-70 free 383 381 0.89 Example 4-71 free 397 395 0.96 Example 4-72 HCl DMSO-D6 400 MHz δ: 12.05 (s, 1H), 9.08 (s, 1H), 425 423 8.17 8.67 (s, 1H), 8.55-8.48 (m, 2H), 8.16 (s, 1H), 8.03 (d, 1H, J = 12.2 Hz), 8.02-7.90 (m, 4H), 7.48 (br, 1H), 7.09 (d, 1H, J = 6.8 Hz), 4.32-4.22 (m, 1H), 3.90 (s, 3H), 3.60-3.48 (m, 1H), 1.90-1.28 (m, 8H). Example 4-73 HCl DMSO-d6 400 MHz δ: 11.95 (s, 1H), 8.87-8.84 428 426 9.83 (m, 1H), 8.73-8.69 (m, 2H), 8.03 (d, 1H, J = 5.6 Hz), 8.00 (d, 1H, J = 12.0 Hz), 7.93 (d, 1H, J = 5.6 Hz), 7.90-7.78 (m, 4H), 7.41 (br, 1H), 7.00 (d, 1H, J = 3.1 Hz), 4.42-4.31 (m, 1H), 3.63-3.52 (m, 1H), 1.90-1.25 (m, 8H). Example 4-74 HCl DMSO-d6 400 MHz δ: 11.98 (s, 1H), 9.24 (s, 1H), 428 426 8.67 8.95 (s, 1H), 8.60 (s, 1H), 8.56 (s, 2H), 8.01 (d, 1H, J = 12.4 Hz), 8.01-7.88 (m, 4H), 7.45 (br, 1H), 7.04 (d, 1H, J = 5.6 Hz), 4.32-4.22 (m, 1H), 3.60- 3.48 (m, 1H), 1.90-1.20 (m, 8H). Example 4-75 HCl DMSO-d6 400 MHz δ: 11.97 (br, 1H), 8.99 (s, 1H), 501 499 10.92 8.68-8.59 (m, 2H), 8.51 (s, 1H), 8.20 (s, 1H), 8.01 (d, 1H, J = 12.4 Hz), 8.00-7.82 (m, 4H), 7.46 (br, 1H), 7.40-7.26 (m, 5H), 7.06 (d, 1H, J = 6.1 Hz), 5.40 (s, 2H), 4.30-4.20 (m, 1H), 3.55-3.40 (m, 1H), 1.85-1.10 (m, 8H). Example 4-76 HCl 460 458 10.23  Example 4-77 HCl DMSO-d6 400 MHz δ: 12.00 (s, 1H), 9.01 (s, 1H), 427 425 9.98 8.76-8.72 (m, 1H), 8.67 (s, 1H), 8.27 (s, 1H), 8.02 (d, 1H, J = 12.4 Hz), 8.00-7.85 (m, 4H), 7.79-7.74 (m, 2H), 7.46 (br, 1H), 7.07 (d, 1H, J = 6.3 Hz), 4.28-4.18 (m, 1H), 3.60- 3.48 (m, 1H), 1.85-1.20 (m, 8H). Example 4-78 HCl DMSO-d6 400 MHz δ: 11.98 (s, 1H), 9.06 (s, 1H), 411 409 9.43 8.67 (s, 1H), 8.55-8.50 (m, 2H), 8.02 (d, 1H, J = 12.1 Hz), 8.01-7.88 (m, 4H), 7.88-7.85 (m, 1H), 7.46 (br, 1H), 7.21 (s, 1H), 7.07 (d, 1H, J = 6.1 Hz), 4.31-4.22 (m, 1H), 3.59-3.50 (m, 1H), 1.90-1.25 (m, 8H). Example 4-79 free 401 399 0.94 Example 4-80 free 514 512 0.82 Example 4-81 free 459 457 1.07 Example 4-82 free 401 399 0.98 Example 4-83 free 514 512 0.77 Example 4-84 free 459 457 1.09 Example 4-85 free 451 449 1.09 Example 4-86 free 465 463 1.21 Example 4-87 free 564 562 0.88 Example 4-88 free 509 507 1.2  Example 4-89 free 428 426 0.98 Example 4-90 free 438 436 1    Example 4-91 free CD3OD 300 MHz δ: 8.15 (d, 1H, J = 1.3 Hz), 442 440 0.86 7.90 (s, 1H), 7.65 (d, 1H, J = 11.9 Hz), 7.51 (d, 1H, J = 9.2 Hz), 7.42 (dd, 1H, J = 9.2, 2.0 Hz), 4.83-4.82 (m, 1H), 4.54 (t, 2H, J = 5.3 Hz), 4.18 (dd, 1H, J = 9.2, 4.0 Hz), 3.81 (t, 2H, J = 5.3 Hz), 3.27 (s, 3H), 1.74- 1.51 (m, 8H). Example 4-92 free CD3OD 300 MHz δ: 8.17 (d, 1H, J = 1.3 Hz), 500 498 0.93 7.91 (d, 1H, J = 2.0 Hz), 7.66 (d, 1H, J = 12.6 Hz), 7.55 (d, 1H, J = 8.6 Hz), 7.41 (dd, 1H, J = 8.6, 2.0 Hz), 4.85-4.77 (m, 1H), 4.56 (t, 2H, J = 5.3 Hz), 4.26-4.15 (m, 1H), 3.90 (t, 2H, J = 5.3 Hz), 3.47 (m, 4H), 3.37 (q, 2H, J = 6.9 Hz), 1.80-1.50 (m, 8H), 1.08 (t, 3H, J = 6.9 Hz). Example 4-93 free 438 436 0.93 Example 4-94 free 442 440 0.81 Example 4-95 HCl 500 498 0.88 Example 4-96 HCl DMSO-d6 300 MHz δ: 12.10 (s, 1H), 9.23 (s, 1H), 345 343 0.55 8.44-8.35 (m, 2H), 8.08-7.90 (m, 5H), 7.86-7.74 (m, 1H), 7.47 (br, 1H), 7.07 (d, 1H, J = 6.6 Hz), 4.36-4.24 (m, 1H), 3.66-3.54 (m, 1H), 2.00-1.35 (m, 8H). Example 4-97 HCl DMSO-d6 300 MHz δ: 11.92 (s, 1H), 8.55 (d, 1H, 381 379 0.89 J = 2.1 Hz), 8.44-8.40 (m, 1H), 379 377 8.19 (d, 1H, J = 2.1 Hz), 8.05- 7.80 (m, 5H), 7.40 (br, 1H), 7.05 (d, 1H, J = 6.6 Hz), 4.32- 4.20 (m, 1H), 3.75-3.55 (m, 1H), 2.00-1.35 (m, 8H). Example 4-98 HCl DMSO-d6 300 MHz δ: 12.03 (s, 1H), 8.91 (d, 1H, 413 411 0.97 J = 2.7 Hz), 8.60-8.54 (m, 1H), 8.54-8.49 (m, 1H), 8.10-7.80 (m, 5H), 7.43 (br, 1H), 7.01 (d, 1H, J = 6.6 Hz), 4.36-4.23 (m, 1H), 3.56-3.44 (m, 1H), 2.00- 1.30 (m, 8H). Example 4-99 HCl DMSO-d6 300 MHz δ: 12.02 (s, 1H), 8.97 (s, 1H), 435 433 0.92 8.60 (s, 2H), 8.01 (d, 1H, J = 12.0 Hz), 7.96-7.78 (m, 4H), 7.67-7.66 (m, 2H), 7.48-7.39 (m, 2H), 7.34-7.28 (m, 1H), 7.02 (d, 1H, J = 6.0 Hz), 4.26- 4.15 (m, 1H), 3.75-3.55 (m, 1H), 2.41 (s, 3H), 1.85-1.15 (m, 8H). Example 4-100 HCl DMSO-d6 300 MHz δ: 12.02 (s, 1H), 8.95 (s, 1H), 435 433 0.91 8.60 (s, 2H), 8.01 (d, 1H, J = 12.6 Hz), 8.00-7.78 (m, 4H), 7.76-7.68 (m, 2H), 7.52-7.32 (m, 3H), 7.03 (d, 1H, J = 6.6 Hz), 4.28-4.16 (m, 1H), 3.75- 3.55 (m, 1H), 2.38 (s, 3H), 1.90-1.15 (m, 8H). Example 4-101 HCl DMSO-d6 300 MHz δ: 12.15 (s, 1H), 8.87 (s, 1H), 435 433 0.89 8.47 (s, 1H), 8.33 (s, 1H), 8.00 (d, 1H, J = 12.3 Hz), 8.00-7.78 (m, 4H), 7.54-7.30 (m, 5H), 7.08 (d, 1H, J = 6.0 Hz), 4.14- 4.00 (m, 1H), 3.75-3.55 (m, 1H), 2.28 (s, 3H), 1.85-1.00 (m, 8H). Example 4-102 HCl DMSO-d6 300 MHz δ: 12.07 (s, 1H), 8.91 (d, 1H, 413 411    1 J = 2.4 Hz), 8.29 (dd, 1H, J = 2.4, 8.7 Hz), 8.00 (d, 1H, J = 11.7 Hz), 8.00-7.80 (m, 4H), 7.81 (d, 1H, J = 8.7 Hz), 7.45 (br, 1H), 7.01 (d, 1H, J = 6.0 Hz), 4.34-4.23 (m, 1H), 3.70- 3.58 (m, 1H), 2.00-1.40 (m, 8H). Example 4-103 HCl DMSO-d6 300 MHz δ: 12.09 (s, 1H), 9.18-9.12 422 420 0.66 (m, 2H), 8.81-8.76 (m, 1H), 8.76-8.71 (m, 1H), 8.69-8.64 (m, 1H), 8.50 (d, 1H, J = 8.1 Hz), 8.02 (d, 1H, J = 11.7 Hz), 8.02-7.90 (m, 4H), 7.81-7.72 (m, 1H), 7.46 (br, 1H), 7.07 (d, 1H, J = 6.6 Hz), 4.32-4.18 (m, 1H), 3.58-3.40 (m, 1H), 1.90- 1.20 (m, 8H). Example 4-104 HCl DMSO-d6 300 MHz δ: 11.96 (s, 1H), 9.15-9.14 422 420 0.62 (m, 1H), 8.92 (d, 2H, J = 6.0 Hz), 8.79-8.74 (m, 1H), 8.63- 8.58 (m, 1H), 8.25 (d, 2H, J = 6.0 Hz), 8.01 (d, 1H, J = 12.6 Hz), 8.00-7.86 (m, 4H), 7.44 (br, 1H), 7.03 (d, 1H, J = 6.6 Hz), 4.29-4.18 (m, 1H), 3.56- 3.45 (m, 1H), 1.90-1.15 (m, 8H). Example 4-105 HCl DMSO-d6 300 MHz δ: 11.95 (s, 1H), 8.48-8.45 363 361 0.82 (m, 1H), 8.24-8.16 (m, 1H), 8.15 (d, 1H, J = 2.7 Hz), 7.99 (d, 1H, J = 12.6 Hz), 7.96-7.80 (m, 4H), 7.40 (br, 1H), 7.04 (d, 1H, J = 6.6 Hz), 4.31-4.20 (m, 1H), 3.72-3.59 (m, 1H), 2.00- 1.35 (m, 8H). Example 4-106 HCl DMSO-d6 300 MHz δ: 12.23 (s, 1H), 9.24-9.20 422 420 0.75 (m, 1H), 9.13-9.08 (m, 1H), 9.05-9.02 (m, 1H), 8.82-8.78 (m, 1H), 8.27 (d, 1H, J = 7.8 Hz), 8.08-7.96 (m, 6H), 7.60- 7.45 (m, 2H), 7.10 (d, 1H, J = 7.2 Hz), 4.40-4.28 (m, 1H), 3.75-3.55 (m, 1H), 1.95-1.20 (m, 8H). Example 4-107 HCl DMSO-d6 300 MHz δ: 12.05 (s, 1H), 8.95 (s, 1H), 428 426 0.68 8.64-8.56 (m, 2H), 8.10-7.90 (m, 5H), 7.47 (br, 1H), 7.06 (d, 1H, J = 6.6 Hz), 4.40-4.26 (m, 1H), 4.20-3.86 (m, 2H), 3.72- 3.59 (m, 1H), 2.62-2.50 (m, 2H), 2.20-2.06 (m, 2H), 1.95- 1.35 (m, 8H). Example 4-108 HCl DMSO-d6 300 MHz δ: 12.03 (s, 1H), 8.91-8.84 443 441 0.74 (m, 1H), 8.35-8.31 (m, 1H), 8.31-8.24 (m, 1H), 8.04-7.86 (m, 5H), 7.44 (br, 1H), 7.04 (d, 1H, J = 6.6 Hz), 4.36-4.24 (m, 1H), 3.80-3.64 (m, 2H), 3.56- 3.45 (m, 1H), 2.48-2.41 (m, 2H), 1.95-1.35 (m, 12H). Example 4-109 HCl DMSO-d6 300 MHz δ: 12.02 (s, 1H), 8.94 (s, 1H), 495 493 0.87 8.70-8.59 (m, 2H), 8.01 (d, 1H, J = 12.0 Hz), 8.00-7.80 (m, 4H), 7.52-7.34 (m, 4H), 7.14- 6.98 (m, 2H), 4.30-4.16 (m, 3H), 3.76-3.66 (m, 2H), 3.56- 3.45 (m, 1H), 3.33 (s, 3H), 1.90-1.10 (m, 8H). Example 4-110 2HCl DMSO-d6 300 MHz δ: 11.98 (s, 1H), 11.02-10.84 550 548 0.64 (m, 1H), 8.97 (s, 1H), 8.59 (s, 1H), 8.53-8.47 (m, 1H), 8.00 (d, 1H, J = 11.7 Hz), 7.98-7.84 (m, 4H), 7.54-7.36 (m, 4H), 7.16-7.08 (m, 1H), 7.07-6.96 (m, 1H), 4.56-4.49 (m, 2H), 4.28-4.16 (m, 1H), 4.04-3.94 (m, 2H), 3.88-3.76 (m, 2H), 3.64-3.20 (m, 7H), 1.90-1.15 (m, 8H). Example 4-111 HCl DMSO-d6 300 MHz δ: 11.93 (s, 1H), 8.85-8.77 495 493 0.84 (m, 1H), 8.55-8.48 (m, 2H), 7.99 (d, 1H, J = 12.6 Hz), 7.94-7.68 (m, 6H), 7.50-7.30 (m, 1H), 7.14-7.07 (m, 2H), 7.02-6.94 (m, 1H), 4.26-4.13 (m, 3H), 3.71-3.66 (m, 2H), 3.54-3.44 (m, 1H), 3.33 (s, 3H), 1.85-1.10 (m, 8H). Example 4-112 2HCl DMSO-d6 300 MHz δ: 11.85 (s, 1H), 1.74-10.50 550 549 0.6  (m, 1H), 8.86 (s, 1H), 8.50 (s, 1H), 8.38-8.32 (m, 1H), 7.98 (d, 1H, J = 12.6 Hz), 7.92-7.72 (m, 6H), 7.46-7.33 (m, 1H), 7.21-7.12 (m, 2H), 7.03-6.95 (m, 1H), 4.52-4.41 (m, 2H), 4.30-4.14 (m, 1H), 4.06-3.94 (m, 2H), 3.86-3.72 (m, 2H), 3.65-3.48 (m, 3H), 3.48-3.20 (m, 4H), 1.90-1.15 (m, 8H). Example 4-113 HCl DMSO-d6 300 MHz δ: 12.11 (s, 1H), 9.09-9.03 451 449 0.87 (m, 1H), 8.75-8.60 (m, 2H), 8.08-7.86 (m, 5H), 7.52-7.36 (m, 4H), 7.12-7.03 (m, 2H), 4.30-4.16 (m, 1H), 3.85 (s, 3H), 3.65-3.55 (m, 1H), 1.90- 1.15 (m, 8H). Example 4-114 HCl DMSO-d6 300 MHz δ: 12.11 (s, 1H), 9.08-9.03 451 449 0.83 (m, 1H), 8.65 (s, 2H), 8.03 (d, 1H, J = 11.7 Hz), 8.02-7.88 (m, 4H), 7.85-7.78 (m, 2H), 7.46 (br, 1H), 7.15-7.03 (m, 3H), 4.30-4.17 (m, 1H), 3.83 (s, 3H), 3.66-3.54 (m, 1H), 1.90-1.15 (m, 8H). Example 4-115 HCl DMSO-d6 300 MHz δ: 12.26 (s, 1H), 8.96 (d, 1H, 473 471 1.23 J = 7.2 Hz), 8.20-7.85 (m, 6H), 7.49 (br, 1H), 7.12-7.00 (m, 2H), 6.44 (s, 1H), 4.40-4.22 (m, 3H), 3.78-3.66 (m, 1H), 2.05-1.40 (m, 8H), 1.33 (t, 3H, J = 6.9 Hz). Example 4-116 HCl 424 422 1.02 Example 4-117 free 415 413 1.03 Example 4-118 HCl DMSO-d6 300 MHz δ: 11.92 (s, 1H), 8.80 (d, 1H, 412 410 0.73 J = 1.8 Hz), 8.66-8.62 (m, 2H), 8.57-8.52 (m, 1H), 8.00 (d, 1H, J = 12.6 Hz), 8.00-7.86 (m, 5H), 7.56-7.30 (m, 1H), 7.00 (d, 1H, J = 6.6 Hz), 4.38-4.26 (m, 1H), 3.64-3.44 (m, 1H), 1.95-1.25 (m, 8H). Example 4-119 HCl 424 422 0.73 Example 4-120 HCl 425 423 0.79 Example 4-121 HCl 469 467 0.82 Example 4-122 HCl 468 466 1.07 Example 4-123 HCl 480 478 0.71 Example 4-124 HCl 411 409 0.77 Example 4-125 HCl 410 408 0.61 Example 4-126 HCl 438 436 1    Example 4-127 HCl 469 467 0.79 Example 4-128 HCl 425 423 0.78 Example 4-129 HCl DMSO-d6 300 MHz δ: 7.89 (d, 1H, J = 12.6 Hz), 344 342 7.59-7.53 (m, 2H), 7.35-7.27 (m, 2H), 7.01-6.94 (m, 1H), 4.27-4.15 (m, 1H), 3.76-3.67 (m, 1H), 1.97-1.35 (m, 8H). Example 4-130 HCl 384 382 Example 4-131 HCl DMSO-d6 300 MHz δ: 8.57 (d, 1H, J = 7.3 Hz), 384 382 8.37-8.32 (m, 1H), 7.98-7.93 (m, 1H), 7.92 (d, 1H, J = 11.9 Hz), 7.79 (d, 1H, J = 3.0 Hz), 7.44 (dd, 1H, J = 2.0, 7.6 Hz), 4.70-4.62 (m, 1H), 3.92-3.83 (m, 1H), 2.05-1.50 (m, 8H). Example 4-132 HCl DMSO-d6 300 MHz δ: 11.92 (s, 1H), 8.94 (d, 1H, 387 385 0.75 J = 2.7 Hz), 8.78 (d, 1H, J = 2.1 Hz), 8.64-8.60 (m, 1H), 7.99 (d, 1H, J = 12.6 Hz), 7.98-7.76 (m, 4H), 7.41 (br, 1H), 6.99 (d, 1H, 6.6 Hz), 4.41- 4.30 (m, 1H), 3.64-3.48 (m, 1H), 2.66 (s, 3H), 1.95-1.35 (m, 8H). Example 4-133 HCl 526 524 1.12 Example 4-134 HCl 464 462 1.21 Example 4-135 HCl 413 411 0.94 Example 4-136 HCl 424 422 0.92 Example 4-137 HCl 468 466 0.97 Example 4-138 HCl 425 423 0.66 Example 4-139 HCl 469 467 0.69 Example 4-140 HCl 501 499 0.85 Example 4-141 HCl DMSO-d6 300 MHz δ: 11.94 (s, 1H), 8.77-8.70 412 410 0.81 (m, 4H), 8.00 (d, 1H, J = 12.0 Hz), 8.00-7.80 (m, 4H), 7.42 (br, 1H), 7.25 (d, 1H, J = 2.1 Hz), 7.03 (d, 1H, J = 5.4 Hz), 4.40-4.29 (m, 1H), 3.60- 3.50 (m, 1H), 1.95-1.25 (m, 8H). Example 4-142 HCl DMSO-d6 300 MHz δ: 11.24 (s, 1H), 8.51-8.42 418 416 0.72 (m, 2H), 8.00-7.88 (m, 3H), 7.93 (d, 1H, J = 12.2 Hz), 7.88-7.68 (m, 1H), 7.40-7.20 (m, 1H), 6.87 (d, 1H, J = 6.3 Hz), 4.20-4.09 (m, 1H), 3.88 (s, 3H), 3.60-3.50 (m, 1H), 1.92-1.73 (m, 2H), 1.70-1.50 (m, 4H), 1.48-1.28 (m, 2H). Example 4-143 HCl DMSO-d6 300 MHz δ: 12.05 (s, 1H), 8.87 (d, 1H, 439 437 0.89 J = 2.1 Hz), 8.56-8.51 (m, 1H), 8.46-8.42 (m, 1H), 8.00 (d, 1H, J = 12.6 Hz), 8.00-7.76 (m, 4H), 7.74-7.65 (m, 1H), 7.59- 7.50 (m, 1H), 7.46-7.35 (m, 3H), 7.06 (d, 1H, J = 6.6 Hz), 4.20-4.08 (m, 1H), 3.60-3.50 (m, 1H), 1.85-1.05 (m, 8H). Example 4-144 HCl DMSO-d6 300 MHz δ: 12.00 (s, 1H), 8.95 (s, 1H), 439 437 0.92 8.62 (s, 2H), 8.00 (d, 1H, J = 12.3 Hz), 8.00-7.78 (m, 4H), 7.77-7.64 (m, 2H), 7.64-7.53 (m, 1H), 7.44 (br, 1H), 7.38- 7.28 (m, 1H), 7.04 (d, 1H, J = 6.6 Hz), 4.28-4.14 (m, 1H), 3.55-3.40 (m, 1H), 1.90-1.15 (m, 8H). Example 4-145 HCl DMSO-d6 300 MHz δ: 12.09 (s, 1H), 9.06 (s, 1H), 439 437 0.89 8.67-8.63 (m, 2H), 8.02 (d, 1H, J = 12.6 Hz), 8.02-7.86 (m, 6H), 7.54-7.36 (m, 3H), 7.07 (d, 1H, J = 7.5 Hz), 4.28-4.16 (m, 1H), 3.55-3.40 (m, 1H), 1.90-1.20 (m, 8H). Example 4-146 HCl DMSO-d6 300 MHz δ: 12.12 (s, 1H), 8.80-8.74 457 455 0.94 (m, 1H), 8.57-8.52 (m, 1H), 455 453 8.35-8.30 (m, 1H), 8.00 (d, 1H, J = 12.6 Hz), 8.00-7.70 (m, 4H), 7.70-7.61 (m, 1H), 7.61- 7.35 (m, 4H), 7.09 (d, 1H, J = 6.0 Hz), 4.14-4.00 (m, 1H), 3.55-3.40 (m, 1H), 1.90-0.95 (m, 8H). Example 4-147 HCl DMSO-d6 300 MHz δ: 11.98 (s, 1H), 8.91 (s, 1H), 457 455 1.03 8.62-8.57 (m, 2H), 8.00 (d, 1H, 455 453 J = 12.6 Hz), 8.00-7.74 (m, 6H), 7.62-7.36 (m, 3H), 7.01 (d, 1H, J = 6.6 Hz), 4.28-4.16 (m, 1H), 3.50-3.35 (m, 1H), 1.90-1.15 (m, 8H). Example 4-148 HCl DMSO-d6 300 MHz δ: 11.99 (s, 1H), 8.94-8.89 457 455 1.01 (m, 1H), 8.60-8.56 (m, 2H), 455 453 8.00 (d, 1H, J = 12.6 Hz), 8.00-7.75 (m, 6H), 7.64-7.58 (m, 2H), 7.43 (br, 1H), 7.03 (d, 1H, J = 6.6 Hz), 4.24-4.13 (m, 1H), 3.63-3.43 (m, 1H), 1.85- 1.15 (m, 8H). Example 4-149 HCl DMSO-d6 300 MHz δ: 12.03 (s, 1H), 8.86-8.80 451 449 0.82 (m, 1H), 8.55-8.50 (m, 1H), 8.43-8.38 (m, 1H), 8.00 (d, 1H, J = 12.6 Hz), 8.00-7.70 (m, 4H), 7.50-7.36 (m, 3H), 7.23- 7.17 (m, 1H), 7.14-7.04 (m, 2H), 4.12-4.01 (m, 1H), 3.80 (s, 3H), 3.63-3.43 (m, 1H), 1.85-1.00 (m, 8H). Example 4-150 HCl 469 467 1.01 Example 4-151 HCl 497 495 1.13 Example 4-152 HCl 527 525 1.08 Example 4-153 HCl 425 423 1.01 Example 4-154 HCl 483 481 1.1  Example 4-155 HCl 425 423 1.02 Example 4-156 HCl 483 481 1.08 Example 4-157 HCl 497 495 1.13 Example 4-158 HCl 527 525 1.07 Example 4-159 HCl 395 393 0.66 Example 4-160 HCl DMSO-d6 300 MHz δ: 11.35 (s, 1H), 7.91 (d, 1H, 389 387 0.8  J = 12.0 Hz), 7.90-7.70 (m, 4H), 7.68 (d, 1H, J = 1.8 Hz), 7.62 (d, 1H, J = 1.8 Hz), 7.26 (br, 1H), 6.89 (d, 1H, J = 6.0 Hz), 6.13 (s, 2H), 4.18-4.08 (m, 1H), 3.68-3.54 (m, 1H), 1.95-1.30 (m, 8H). Example 4-161 HCl DMSO-d6 300 MHz δ: 11.40 (s, 1H), 7.91 (d, 1H, 403 401 0.78 J = 12.6 Hz), 7.83 (d, 1H, J = 2.4 Hz), 7.80-7.68 (m, 4H), 7.67 (d, 1H, J = 2.4 Hz), 7.27 (br, 1H), 6.88 (d, 1H, J = 6.6 Hz), 4.38-4.32 (m, 2H), 4.26- 4.21 (m, 2H), 4.20-4.10 (m, 1H), 3.68-3.56 (m, 1H), 1.95- 1.30 (m, 8H). Example 4-162 HCl DMSO-d6 300 MHz δ: 12.09 (s, 1H), 9.07-9.01 385 383 0.66 (m, 1H), 8.35-8.30 (m, 1H), 8.10-7.84 (m, 5H), 7.48 (br, 1H), 7.09 (d, 1H, J = 6.6 Hz), 4.34-4.22 (m, 1H), 3.66-3.50 (m, 1H), 3.20-3.10 (m, 2H), 3.08-2.98 (m, 2H), 2.30-2.14 (m, 2H), 2.00-1.37 (m, H). Example 4-163 HCl 395 393 0.62 Example 4-164 HCl 425 423 0.95 Example 4-165 HCl 439 437 1.02 Example 4-166 HCl 453 451 1.09 Example 4-167 HCl 467 465 1.2  Example 4-168 HCl 469 467 0.97 Example 4-169 HCl 527 525 1.03 Example 4-170 HCl 511 509 1.24 Example 4-171 HCl 495 493 1.02 Example 4-172 HCl DMSO-d6 300 MHz δ: 8.08 (d, 1H, J = 1.7 Hz), 443 441 0.87 7.98 (s, 1H), 7.87 (d, 1H, J = 12.2 Hz), 7.60 (d, 1H, J = 8.9 Hz), 7.38 (dd, 1H, J = 1.8, 9.1 Hz), 4.52 (t, 2H, J = 5.1 Hz), 4.22-4.15 (m, 1H), 3.76 (t, 2H, J = 5.1 Hz), 3.75-3.66 (m, 1H), 3.19 (s, 3H), 1.91-1.38 (m, 8H). Example 4-173 HCl 439 437 0.86 Example 4-174 HCl 453 451 0.95 Example 4-175 HCl 426 424 0.99 Example 4-176 HCl 440 438 1.09 Example 4-177 HCl 454 452 1.19 Example 4-178 HCl 470 468 0.98 Example 4-179 HCl 514 512 0.98 Example 4-180 HCl DMSO-d6 300 MHz δ: 8.77 (d, 1H, J = 1.3 Hz), 458 456 0.75 8.06 (d, 1H, J = 2.0 Hz), 7.96 (d, 1H, J = 12.2 Hz), 7.73 (s, 1H), 4.33-4.23 (m, 1H), 3.91- 3.81 (m, 2H), 3.83-3.63 (m, 2H), 3.63-3.51 (m, 1H), 2.57- 2.45 (m, 2H), 1.93-1.39 (m, 8H), 1.19 (d, 6H, J = 5.9 Hz). Example 4-181 HCl DMSO-d6 300 MHz δ: 11.99 (s, 1H), 8.87-8.81 457 455 0.93 (m, 1H), 8.48-8.36 (m, 2H), 7.99 (d, 1H, J = 12.3 Hz), 8.00- 7.68 (m, 5H), 7.55-7.36 (m, 2H), 7.35-7.25 (m, 1H), 7.10- 7.00 (m, 1H), 4.20-4.08 (m, 1H), 4.60-4.45 (m, 1H), 1.85- 1.10 (m, 8H). Example 4-182 HCl DMSO-d6 300 MHz δ: 12.15 (s, 1H), 8.98-8.93 465 463 0.87 (m, 1H), 8.67-8.62 (m, 1H), 8.54-8.50 (m, 1H), 8.02 (d, 1H, J = 12.3 Hz), 8.00-7.75 (m, 4H), 7.56-7.42 (m, 3H), 7.22- 7.06 (m, 3H), 4.16-4.06 (m, 3H), 3.60-3.46 (m, 1H), 1.85- 1.40 (m, 5H), 1.32-1.10 (m, 6H). Example 4-183 HCl DMSO-d6 300 MHz δ: 12.12 (s, 1H), 8.94-8.87 493 491 0.99 (m, 1H), 8.71-8.63 (m, 1H), 8.49-8.43 (m, 1H), 8.01 (d, 1H, J = 11.7 Hz), 7.98-7.80 (m, 4H), 7.54-7.40 (m, 3H), 7.21- 7.07 (m, 3H), 4.14-4.00 (m, 1H), 3.86-3.76 (m, 2H), 3.60- 3.46 (m, 1H), 2.00-1.87 (m, 1H), 1.85-1.40 (m, 5H), 1.22- 1.04 (m, 3H), 0.89 (d, 3H, J = 2.7 Hz), 0.87 (d, 3H, J = 2.7 Hz). Example 4-184 HCl 491 489 0.95 Example 4-185 HCl DMSO-d6 300 MHz δ: 12.06 (s, 1H), 8.93-8.84 495 493 0.8  (m, 1H), 8.74-8.64 (m, 1H), 8.52-8.46 (m, 1H), 8.00 (d, 1H, J = 12.0 Hz), 8.00-7.72 (m, 4H), 7.57-7.40 (m, 3H), 7.24- 7.06 (m, 3H), 4.24-4.02 (m, 3H), 3.64-3.54 (m, 2H), 3.54- 3.40 (m, 1H), 3.18 (s, 3H), 1.85-1.35 (m, 5H), 1.25-1.05 (m, 3H). Example 4-186 HCl 437 435 0.75 Example 4-187 HCl 523 521 0.9  Example 4-188 HCl DMSO-d6- 300 MHz δ: 8.92 (d, 1H, J = 2.6 Hz), 389 387 0.63 8.33-8.30 (m, 1H), 8.27-8.23 (m, 1H), 7.96 (d, 1H, J = 12.2 Hz), 4.54 (s, 2H), 4.35-4.25 (m, 1H), 3.63-3.53 (m, 1H), 3.38 (s, 3H), 1.93-1.39 (m, 8H). Example 4-189 HCl DMSO-d6- 300 MHz δ: 9.02 (d, 1H, J = 2.3 Hz), 465 463 0.88 8.44-8.39 (m, 1H), 8.33 (d, 1H, J = 1.3 Hz), 7.97 (d, 1H, J = 12.2 Hz), 7.43-7.30 (m, 5H), 4.69 (s, 2H), 4.63 (s, 2H), 4.33-4.22 (m, 1H), 3.55-3.49 (m, 1H), 1.93-1.29 (m, 8H). Example 4-190 HCl DMSO-d6 300 MHz δ: 11.97 (s, 1H), 8.79-8.71 481 479 0.83 (m, 1H), 8.47-8.42 (m, 1H), 8.35 (s, 1H), 7.98 (d, 1H, J = 11.7 Hz), 7.90 (br, 1H), 7.82- 7.66 (m, 3H), 7.45-7.35 (m, 2H), 7.05 (d, 1H, J = 7.2 Hz), 6.75-6.65 (m, 2H), 4.11-3.98 (m, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 3.60-3.45 (m, 1H), 1.85- 1.35 (m, 5H), 1.25-1.05 (m, 3H). Example 4-191 HCl DMSO-d6- 300 MHz δ: 8.40 (d, 1H, J = 6.9 Hz), 389 387 0.59 8.06-7.98 (m, 1H), 8.02 (d, 1H, J = 11.9 Hz), 7.92-7.83 (m, 1H), 4.67 (s, 2H), 4.40-4.31 (m, 1H), 3.70-3.61 (m, 1H), 3.45 (s, 3H), 1.98-1.41 (m, 8H). Example 4-192 HCl DMSO-d6- 300 MHz δ: 8.42 (d, 1H, J = 6.9 Hz), 465 463 0.78 8.08-8.01 (m, 1H), 8.04 (d, 1H, J = 11.9 Hz), 7.93-7.82 (m, 1H), 7.43-7.33 (m, 5H), 4.76 (d, 2H, J = 3.0 Hz), 4.68 (s, 2H), 4.32-4.22 (m, 1H), 3.60- 3.51 (m, 1H), 1.96-1.29 (m, 8H). Example 4-193 HCl DMSO-d6- 300 MHz δ: 8.94 (d, 1H, J = 2.3 Hz), 375 373 0.55 8.36 (s, 1H), 8.27-8.23 (m, 1H), 7.96 (d, 1H, J = 11.9 Hz), 4.65 (s, 2H), 4.38-4.28 (m, 1H), 3.63-3.55 (m, 1H), 1.95- 1.37 (m, 8H). Example 4-194 HCl DMSO-d6- 300 MHz δ: 8.37 (d, 1H, J = 6.9 Hz), 375 373 0.55 8.10 (s, 1H), 8.03 (d, 1H, J = 11.9 Hz), 7.24 (d, 1H, J = 9.6 Hz), 7.83-7.73 (m, 1H), 4.75 (s, 2H), 4.44-4.34 (m, 1H), 3.68-3.60 (m, 1H), 1.95-1.43 (m, 8H). Example 4-195 HCl 414 412 0.95 Example 4-196 HCl 412 410 0.96 Example 4-197 HCl DMSO-d6 300 MHz δ: 12.10 (s, 1H), 8.90-8.84 469 467 0.89 (m, 1H), 8.58 (s, 1H), 8.43 (s, 1H), 8.00 (d, 1H, J = 12.0 Hz), 8.00-7.80 (m, 4H), 7.45 (br, 1H), 7.34-7.26 (m, 2H), 7.24- 7.16 (m, 1H), 7.07 (d, 1H, J = 6.6 Hz), 4.20-4.08 (m, 1H), 3.90 (s, 3H), 3.54-3.40 (m, 1H), 1.85-1.10 (m, 8H). Example 4-198 HCl DMSO-d6 300 MHz δ: 12.07 (s, 1H), 8.93-8.87 469 467 0.9  (m, 1H), 8.53-8.48 (m, 1H), 8.60-8.42 (m, 1H), 8.01 (d, 1H, J = 12.6 Hz), 8.00-7.80 (m, 4H), 7.70-7.01 (m, 1H), 7.44 (br, 1H), 7.10-7.60 (m, 2H), 6.98 (dd, 1H, J = 2.4, 8.4 Hz), 4.20-4.08 (m, 1H), 3.84 (s, 3H), 3.60-3.46 (m, 1H), 1.85- 1.10 (m, 8H). Example 4-199 HCl DMSO-d6 300 MHz δ: 12.03 (s, 1H), 8.86-8.81 469 467 0.93 (m, 1H), 8.56-8.51 (m, 1H), 8.45-8.41 (m, 1H), 8.00 (d, 1H), 8.00-7.76 (m, 4H), 7.42 (br, 1H), 7.38-7.28 (m, 1H), 7.21 (dd, 1H, J = 3.3, 6.0 Hz), 7.10-7.02 (m, 2H), 4.20-4.08 (m, 1H), 3.81 (s, 3H), 3.60- 3.46 (m, 1H), 1.85-1.10 (m, 8H). Example 4-200 HCl 536 534 0.96 Example 4-201 HCl 524 522 0.91 Example 4-202 HCl 462 460 0.96 Example 4-203 HCl 461 459 1.09 Example 4-204 HCl DMSO-d6 300 MHz δ: 12.10 (s, 1H), 8.97-8.92 457 455 0.96 (m, 1H), 8.54 (s, 1H), 8.48 (s, 1H), 8.01 (d, 1H, J = 12.6 Hz), 8.00-7.82 (m, 4H), 7.64-7.34 (m, 4H), 7.08 (d, 1H, J = 6.6 Hz), 4.22-4.10 (m, 1H), 3.54- 3.40 (m, 1H), 1.90-1.10 (m, 8H). Example 4-205 HCl DMSO-d6 300 MHz δ: 12.04 (s, 1H), 8.91-8.96 457 455 0.95 (m, 1H), 8.54-8.48 (m, 1H), 8.46-8.42 (m, 1H), 8.00 (d, 1H, J = 12.6 Hz), 7.95-7.80 (m, 4H), 7.70-7.60 (m, 1H), 7.53- 7.32 (m, 3H), 7.06 (d, 1H, J = 6.6 Hz), 4.22-4.10 (m, 1H), 3.54-3.40 (m, 1H), 1.85-1.10 (m, 8H). Example 4-206 HCl DMSO-d6 300 MHz δ: 12.07 (s, 1H), 8.92-8.86 (m, 475 473 1.02 1H), 8.54 (s, 1H), 8.45 (s, 1H), 473 471 8.00 (d, 1H, J = 12.6 Hz), 8.00-7.80 (m, 4H), 7.76-7.62 (m, 2H), 7.50-7.36 (m, 2H), 7.06 (d, 1H, J = 6.6 Hz), 4.21- 4.10 (m, 1H), 3.54-3.40 (m, 1H), 1.85-1.10 (m, 8H). Example 4-207 HCl DMSO-d6 300 MHz δ: 11.94 (s, 1H), 8.76 (d, 1H, 475 473 1.04 J = 1.8 Hz), 8.43 (s, 1H), 8.39- 473 471 8.35 (m, 1H), 7.98 (d, 1H, J = 12.6 Hz), 7.96-7.65 (m, 5H), 7.62-7.54 (m, 1H), 7.52-7.30 (m, 2H), 7.00 (d, 1H, J = 5.4 Hz), 4.22-4.10 (m, 1H), 4.54- 4.40 (m, 1H), 1.85-1.10 (m, 8H). Example 4-208 HCl 462 460 1.07 Example 4-209 HCl 462 460 0.96 Example 4-210 HCl 461 459 0.92 Example 4-211 HCl DMSO-d6 300 MHz δ: 12.08 (s, 1H), 8.64 (d, 1H, 438 436 0.73 J = 1.8 Hz), 8.48-8.44 (m, 1H), 8.22 (d, 1H, J = 2.1 Hz), 7.99 (d, 1H, J = 12.3 Hz), 7.90-7.74 (m, 5H), 7.60-7.52 (m, 1H), 7.43 (br, 1H), 7.07 (d, 1H, J = 6.6 Hz), 6.54 (d, 1H, J = 9.3 Hz), 6.42-6.34 (m, 1H), 4.22- 4.08 (m, 1H), 3.54-3.44 (m, 1H), 1.84-1.20 (m, 8H). Example 4-212 HCl 385 383 0.58 Example 4-213 HCl 399 397 0.77 Example 4-214 HCl DMSO-d6 300 MHz δ: 11.94 (s, 1H), 9.13-9.09 423 421 0.74 (m, 2H), 9.01 (s, 1H), 8.99 (s, 1H), 8.85 (d, 1H, J = 2.7 Hz), 8.00 (d, 1H, J = 12.6 Hz), 7.85-7.70 (m, 4H), 7.60-7.54 (m, 1H), 7.42 (br, 1H), 6.97 (d, 1H, J = 7.2 Hz), 4.44-4.32 (m, 1H), 3.64-3.50 (m, 1H), 1.95- 1.25 (m, 8H). Example 4-215 HCl DMSO-d6 300 MHz δ: 12.04 (s, 1H), 9.09 (s, 1H), 466 464 0.92 8.72 (s, 1H), 8.68-8.60 (m, 2H), 8.36-8.28 (m, 2H), 8.02 (d, 1H, J = 12.6 Hz), 8.00-7.80 (m, 5H), 7.45 (br, 1H), 7.04 (d, 1H, J = 6.0 Hz), 4.30-4.16 (m, 1H), 3.54-3.40 (m, 1H), 1.90- 1.15 (m, 8H). Example 4-216 HCl DMSO-d6 300 MHz δ: 11.49 (s, 1H), 8.08 (s, 1H), 448 446 0.93 8.05 (dd, 1H, J = 2.0, 12.9 Hz), 7.98-7.72 (m, 4H), 7.93 (d, 1H, J = 12.6 Hz), 7.41-7.17 (m, 1H), 6.69-6.90 (m, 1H), 4.23- 4.11 (m, 1H), 3.78-3.70 (m, 4H), 3.68-3.59 (m, 1H), 3.28- 3.20 (m, 4H), 1.97-1.32 (m, 8H). Example 4-217 HCl DMSO-d6 300 MHz δ: 12.12 (s, 1H), 9.03-8.98 436 434 0.69 (m, 1H), 8.63-8.58 (m, 1H), 8.58-8.53 (m, 1H), 8.02 (d, 1H, J = 12.6 Hz), 8.00-7.84 (m, 4H), 7.55-7.17 (m, 4H), 7.17- 7.95 (m, 2H), 4.26-4.14 (m, 1H), 3.62-3.50 (m, 1H), 1.88- 1.15 (m, 8H). Example 4-218 HCl DMSO-d6 300 MHz δ: 12.05 (s, 1H), 8.97 (s, 1H), 436 434 0.65 8.60-8.51 (m, 2H), 8.01 (d, 1H, J = 12.0 Hz), 8.00-7.76 (m, 4H), 7.64-7.57 (m, 2H), 7.47 (br, 1H), 7.06 (d, 1H, J = 6.6 Hz), 6.85-6.73 (m, 2H), 4.28- 4.18 (m, 1H), 4.63-4.52 (m, 1H), 1.90-1.20 (m, 8H). Example 4-219 HCl DMSO-d6 300 MHz δ: 12.15 (s, 1H), 9.08-9.04 450 448 0.77 (m, 1H), 8.73-8.68 (m, 1H), 8.64-8.61 (m, 1H), 8.03 (d, 1H, J = 12.6 Hz), 8.02-7.84 (m, 4H), 7.49 (br, 1H), 7.34-7.26 (m, 1H), 7.71-6.96 (m, 3H), 6.77 (d, 1H, J = 6.6 Hz), 4.25- 4.14 (m, 1H), 3.60-3.48 (m, 1H), 2.78 (s, 3H), 1.85-1.15 (m, 8H). Example 4-220 HCl DMSO-d6 300 MHz δ: 12.11 (s, 1H), 9.04-8.98 450 448 0.77 (m, 1H), 8.64-8.59 (m, 2H), 8.02 (d, 1H, J = 12.6 Hz), 8.01-7.80 (m, 4H), 7.67 (d, 2H, J = 8.4 Hz), 7.49 (br, 1H), 7.09 (d, 1H, J = 6.0 Hz), 6.70 (d, 2H, J = 8.4 Hz), 4.30-4.18 (m, 1H), 3.62-3.50 (m, 1H), 2.74 (s, 3H), 1.95-1.15 (m, 8H). Example 4-221 HCl DMSO-d6 300 MHz δ: 12.11 (s, 1H), 9.12-9.08 506 504 0.85 (m, 1H), 8.75-8.68 (m, 2H), 8.02 (d, 1H, J = 11.7 Hz), 8.02-7.80 (m, 4H), 7.48 (br, 1H), 7.44-7.32 (m, 2H), 7.28- 7.22 (m, 1H), 7.12-7.05 (m, 2H), 4.24-4.12 (m, 1H), 3.80- 3.73 (m, 4H), 3.60-3.48 (m, 1H), 3.26-3.19 (m, 4H), 1.85- 1.15 (m, 8H). Example 4-222 HCl DMSO-d6 300 MHz δ: 11.96 (s, 1H), 8.86-8.79 506 504 0.82 (m, 1H), 8.58-8.52 (m, 2H), 8.00 (d, 1H, J = 12.6 Hz), 7.89 (br, 1H), 7.82-7.60 (m, 5H), 7.43 (br, 1H), 7.09 (d, 2H, J = 8.7 Hz), 7.06-6.99 (m, 1H), 4.22-4.12 (m, 1H), 3.80-3.73 (m, 4H), 3.56-3.44 (m, 1H), 3.23-3.15 (m, 4H), 1.90-1.15 (m, 8H). Example 4-223 HCl DMSO-d6 300 MHz δ: 12.11 (s, 1H), 10.21 (s, 478 476 0.72 1H), 8.94-8.90 (m, 1H), 8.66- 8.60 (m, 1H), 8.56-8.52 (m, 1H), 8.05-7.80 (m, 6H), 7.70- 7.61 (m, 1H), 7.50-7.40 (m, 3H), 7.06 (d, 1H, J = 6.6 Hz), 4.24-4.12 (m, 1H), 3.52-3.40 (m, 1H), 2.08 (s, 3H), 1.85- 1.10 (m, 8H). Example 4-224 HCl DMSO-d6 300 MHz δ: 12.05 (s, 1H), 10.19 (s, 478 476 0.69 1H), 8.89-8.93 (m, 1H), 8.62- 8.52 (m, 2H), 8.01 (d, 1H, J = 12.6 Hz), 8.00-7.70 (m, 8H), 7.56-7.34 (m, 1H), 7.06 (d, 1H, J = 6.0 Hz), 4.28-4.16 (m, 1H), 3.60-3.48 (m, 1H), 2.09 (s, 3H), 1.90-1.15 (m, 8H). Example 4-225 HCl DMSO-d6 300 MHz δ: 11.94 (s, 1H), 8.85-8.80 504 502 0.81 (m, 1H), 8.54-8.50 (m, 2H), 8.02-7.95 (m, 2H), 7.90 (br, 1H), 7.80-7.65 (m, 3H), 7.56- 7.60 (m, 2H), 7.41 (br, 1H), 7.03-6.97 (m, 2H), 4.21-4.10 (m, 1H), 3.98-3.86 (m, 2H), 3.58-3.46 (m, 1H), 2.58-2.50 (m, 2H), 2.16-2.04 (m, 2H), 1.85-1.10 (m, 8H). Example 4-226 HCl DMSO-d6 300 MHz δ: 11.98 (s, 1H), 8.92-8.87 504 502 0.78 (m, 1H), 8.61-8.53 (m, 2H), 8.00 (d, 1H, J = 12.6 Hz), 8.00-7.70 (m, 8H), 7.42 (br, 1H), 7.05-7.69 (m, 1H), 4.28- 4.16 (m, 1H), 3.94-3.85 (m, 2H), 3.60-3.48 (m, 1H), 2.58- 2.48 (m, 2H), 2.16-2.03 (m, 2H), 1.85-1.15 (m, 8H). Example 4-227 HCl DMSO-d6 300 MHz δ: 11.98 (s, 1H), 8.92-8.86 464 462 0.87 (m, 1H), 8.65-8.55 (m, 2H), 8.00 (d, 1H, J = 12.6 Hz), 7.93 (br, 1H), 7.82-7.68 (m, 3H), 7.45 (br, 1H), 7.39-7.30 (m, 1H), 7.07-7.00 (m, 3H), 6.88- 6.82 (m, 1H), 4.20-4.08 (m, 1H), 3.60-3.48 (m, 1H), 2.98 (s, 6H), 1.85-1.10 (m, 8H). Example 4-228 HCl DMSO-d6 300 MHz δ: 8.50-8.46 (m, 2H), 7.89 (d, 455 453 0.92 1H, J = 12.2 Hz), 4.23-4.13 (m, 1H), 3.80-3.72 (m, 4H), 3.62-3.53 (m, 1H), 3.48-3.40 (m, 4H), 1.95-1.36 (m, 8H). Example 4-229 HCl DMSO-d6 300 MHz δ: 12.04 (s, 1H), 9.50 (s, 1H), 413 411 0.75 8.98-8.95 (m, 1H), 8.78 (d, 1H, J = 2.7 Hz), 8.74 (d, 1H, J = 1.8 Hz), 8.01 (d, 1H, J = 12.6 Hz), 8.00-7.76 (m, 4H), 7.44 (br, 1H), 7.02 (d, 1H, J = 6.0 Hz), 4.48-4.37 (m, 1H), 3.66- 3.50 (m, 1H), 1.95-1.30 (m, 8H). Example 4-230 HCl DMSO-d6 300 MHz δ: 11.87 (s, 1H), 9.00-8.94 452 450 0.93 (m, 1H), 8.94-8.90 (m, 1H), 8.76-8.72 (m, 1H), 7.99 (d, 1H, J = 12.3 Hz), 7.94-7.68 (m, 6H), 7.42 (br, 1H), 7.03 (d, 1H, J = 6.0 Hz), 6.91 (d, 1H, J = 7.8 Hz), 4.24-4.12 (m, 1H), 3.96 (s, 3H), 3.60-3.48 (m, 1H), 1.90-1.15 (m, 8H). Example 4-231 HCl DMSO-d6 300 MHz δ: 11.93 (s, 1H), 8.57-8.52 452 450 0.88 (m, 1H), 8.61 (d, 1H, J = 2.7 Hz), 8.52-8.48 (m, 2H), 8.15 (dd, 1H, J = 2.7, 8.7 Hz), 7.99 (d, 1H, J = 12.6 Hz), 7.98-7.64 (m, 4H), 7.42 (br, 1H), 7.05- 6.95 (m, 2H), 4.25-4.14 (m, 1H), 3.91 (s, 3H), 3.60-3.48 (m, 1H), 1.85-1.15 (m, 8H). Example 4-232 HCl DMSO-d6 300 MHz δ: 12.04 (s, 1H), 9.04-9.00 452 450 0.88 (m, 1H), 8.70-8.66 (m, 2H), 8.32 (d, 1H, J = 5.1 Hz), 8.01 (d, 1H, J = 12.6 Hz), 8.00-7.80 (m, 4H), 7.48-7.40 (m, 2H), 7.32-7.28 (m, 1H), 7.05 (d, 1H, J = 6.6 Hz), 4.34-4.20 (m, 1H), 3.92 (s, 3H), 3.62-3.50 (m, 1H), 1.90-1.20 (m, 8H). Example 4-233 HCl DMSO-d6 300 MHz δ: 8.18-8.12 (m, 1H), 7.88 (d, 460 458 0.8  1H, J = 12.2 Hz), 7.47-7.40 (m, 1H), 4.29-4.19 (m, 1H), 3.85 (s, 3H), 3.80-3.68 (m, 4H), 3.60-3.52 (m, 1H), 3.30- 3.18 (m, 4H), 1.95-1.05 (m, 8H). Example 4-234 HCl DMSO-d6- 300 MHz δ: 8.47 (s, 1H), 7.99 (d, 1H, J = 469 467 0.71 12.2 Hz), 7.93-7.89 (m, 1H), 6.82-6.78 (m, 1H), 4.42-4.33 (m, 1H), 4.00-3.90 (m, 4H), 3.71-3.65 (m, 1H), 3.63-3.53 (m, 4H), 1.93-1.38 (m, 8H). Example 4-235 HCl DMSO-d6- 300 MHz δ: 8.39 (s, 1H), 7.93 (d, 1H, J = 414 412 0.74 12.2 Hz), 7.61 (d, 1H, J = 3.0 Hz), 6.59 (d, 1H, J = 3.0 Hz), 4.33-4.21 (m,1 H), 4.10 (s, 3H), 3.66-3.57 (m, 1H), 1.95- 1.37 (m, 8H).

Example 5

1st Step

5-methyl-3-pyridineamine (191 mg), cesium carbonate (1.10 g), Pd₂(dba)₃ (186 mg), and Xantphos (235 mg) were added to a 1,4-dioxane (14 ml) solution containing tert-butyl

cis-2-(6-chloro-5-cyano-3-fluoropyridin-2-ylamino)cyclohexylcarbamate (500 mg), followed by stirring at 100° C. for 2 hours in a nitrogen atmosphere. The reaction mixture was cooled to room temperature, and water and ethyl acetate were added. Insoluble matter was removed by filtration, the filter cake was washed with water and ethyl acetate, the organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane:ethyl acetate=10:0 to 1:4), diisopropylether was added, solid matter was collected by filtration, and a light yellow solid of tert-butyl cis-2-(6-(5-methylpyridin-3-ylamino)-5-cyano-3-fluoropyridin-2-ylamino)cyclohexylcarbamate (523 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 8.90 (s, 1H), 8.55-8.51 (m, 1H), 8.05-8.02 (m, 1H), 7.78 (s, 1H), 7.67 (d, 1H, J=11.1 Hz), 7.00-6.94 (m, 1H), 6.67-6.62 (m, 1H), 3.95-3.80 (m, 2H), 2.28 (s, 3H), 1.82-1.10 (m, 17H)

MS (ESI, m/z): 441 (M+H), 439 (M−H)

2nd step

A 5N sodium hydroxide aqueous solution (1.18 ml) and 30% hydrogen peroxide solution (0.70 ml) were added to a solution of dimethyl sulfoxide (10 ml) and ethanol (10 ml) containing tert-butyl cis-2-(6-(5-methylpyridin-3-ylamino)-5-cyano-3-fluoropyridin-2-ylamino)cyclohexylcarbamate (520 mg), followed by stirring at 34° C. for 30 minutes. The reaction mixture was cooled to room temperature, and water was added. Solid matter was collected by filtration, dissolved in ethyl acetate and tetrahydrofuran, washed with water and then with saturated saline, and dried over anhydrous magnesium sulfate. The solvent was distilled away under reduced pressure. The obtained residue was added to diisopropylether, solid matter was collected by filtration and washed with diisopropylether and hexane, and a light yellow solid of tert-butyl cis-2-(5-aminocarbonyl-3-fluoro-6-(5-methylpyridin-3-ylamino)pyridin-2-ylamino)cyclohexylcarbamate (506 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.72 (s, 1H), 8.59 (d, 1H, J=2.2 Hz), 8.01 (s, 1H), 7.97 (s, 1H), 7.89 (d, 1H, J=12.6 Hz), 7.76 (brs, 1H), 7.26 (brs, 1H), 6.74-6.64 (m, 2H), 4.14-4.04 (m, 1H), 3.95-3.86 (m, 1H), 2.31 (s, 3H), 1.87-1.10 (m, 17H)

MS (ESI, m/z): 459 (M+H), 457 (M−H)

3rd Step

A mixture of tert-butyl cis-2-(5-aminocarbonyl-3-fluoro-6-(5-methylpyridin-3-ylamino)-pyridin-2-ylamino)cyclohexylcarbamate (500 mg) and TFA (5 ml) was stirred at room temperature for 30 minutes. The solvent was distilled away under reduced pressure (at 40° C. or less). 4N hydrogen chloride/1,4-dioxane (1.36 ml) was added to a tetrahydrofuran/methanol (10/1) (50 ml) suspension containing the obtained residue, followed by stirring at room temperature for 30 minutes. Solid matter was collected by filtration, washed with tetrahydrofuran/methanol (10/1), and a light yellow solid of 6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(5-methylpyridin-3-ylamino)nicotinamide.hydrochloride (498 mg) was obtained.

(¹H-NMR data and MS data are shown in table 3.)

Example 6

The compounds listed in table 3 were obtained as described in Example 5.

TABLE 3 3-1 3-2 Number Structure Compound Name ¹H-NMR MS (ESI, m/z) Example 6-1 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-(pyridin-4-ylamino)nico- tinamide ¹H-NMR (DMSO-d₆, 400 MHz) δ: 13.04 (s, 1H), 8.59 (d, 2H, J = 7.1 Hz), 8.23 (brs, 3H), 8.16 (brs, 1H), 8.12-8.02 (m, 3H), 7.81-7.75 (m, 1H), 7.70 (brs, 1H), 3.78-3.70 (m, 2H), 3.13-3.04 (m, 2H). 291 (M + H), 289 (M − H) Example 6-2 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-(3-methylphenylamino)nico- tinamide ¹H-NMR (CD₃OD, 400 MHz) δ: 7.72 (d, 1H, J = 12.0 Hz), 7.39 (d, 1H, J = 8.0 Hz), 7.35 (s, 1H), 7.18 (t, 1H, J = 8.0 Hz), 6.82 (d, 1H, J = 8.0 Hz), 3.73 (t, 2 H, J = 5.2 Hz), 3.22 (t, 2 H, J = 5.2 Hz), 2.32 (s, 3H). 304 (M + H) Example 6-3 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-(pyridin-3-ylamino)nico- tinamide ¹H-NMR (CD₃OD, 400 MHz) δ: 9.51 (d, 1H, J = 2.7 Hz), 8.59 (ddd, 1H, J = 1.2, 2.7, 8.7 Hz), 8.40-8.37 (m, 1H), 7.97 (dd, 1H, J = 5.3, 8.7 Hz), 7.89 (d, 1H, J = 11.7 Hz), 3.88 (t, 2H, J = 5.9 Hz), 3.48-3.21 (2H, overlapping with CH₃OH peak). 291 (M + H) Example 6-4 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-(quinolin-2-ylamino)nico- tinamide ¹H-NMR (CD₃OD, 400 MHz) δ: 9.96 (d, 1H, J = 2.3 Hz), 9.03 (d, 1H, J = 2.3 Hz), 8.23-8.15 (m, 2H), 7.97-7.93 (m, 1H), 7.90-7.80 (m, 2H), 3.92 (t, 2H, J = 6.1 Hz), 3.35 (t, 2H, J = 6.1 Hz). 341 (M + H) Example 6-5 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-(4-methylphenylamino)nico- tinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 7.71 (d, 1H, J = 12.0 Hz), 7.41 (d, 2H, J = 8.4 Hz), 7.12 (d, 2H, J = 8.4 Hz), 3.70 (t, 2H, J = 5.2 Hz), 3.19 (t, 2H, J = 5.2 Hz), 2.30 (s, 3 H). 304 (M + H) Example 6-6

6-((2-aminoethyl)amino)-2-(3- chlorophenylamino)-5-fluoronico- tinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.00 (s, 1H), 7.75 (d, 1H, J = 12.0 Hz), 7.26-7.24 (m, 2H), 6.97-6.94 (m, 1H), 3.79 (t, 2H, J = 5.2 Hz), 3.33 (t, 2H, J = 5.2 Hz). 324 (M + H) Example 6-7

6-((2-aminoethyl)amino)-2-((3,5- dichlorophenyl)amino)-5-fluoro- nicotinamide ¹H NMR (CD₃OD, 300 MHz) δ: 7.77 (d, 1H, J = 12.0 Hz), 7.68-7.67 (m, 2H), 6.98-6.97 (m, 1H), 3.79 (t, 2H, J = 5.2 Hz), 3.33 (t, 2H, J = 5.2 Hz). 358 (M + H) Example 6-8 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-((3-trifluoromethyl)phenyl) amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.32 (s, 1H), 7.77 (d, 1H, J = 12.0 Hz), 7.54 (d, 1H, J = 8.4 Hz), 7.45 (t, 1H, J = 8.4 Hz), 7.22 (d, 1H, J = 8.4 Hz), 3.80 (t, 2H, J= 5.7 Hz), 3.24 (t, 2H, J = 5.7 Hz). 358 (M + H) Example 6-9 HCl salt

6-((2-aminoethyl)amino)-2-((3,5- bis(trifluoromethyl)phenyl) amino)-5-fluoronicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.27 (s, 2H), 7.82 (d, 1H, J = 12.0 Hz), 7.46 (s, 1H), 3.82 (t, 2H, J = 5.7 Hz), 3.24 (t, 2H, J = 5.7 Hz). 426 (M + H) Example 6-10 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-((1H-indazol-6-yl)amino) nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.51 (s, 1H), 8.46-8.45 (m, 1H), 7.83 (d, 1H, J = 9.0 Hz), 7.82 (d, 1H, J = 12.0 Hz), 7.23 (dd, 1H, J = 1.8, 9.0 Hz), 3.93 (t, 2H, J = 5.7 Hz), 3.37 (t, 2H, J = 5.7 Hz). 330 (M + H) Example 6-11 HCl salt

6-((2-aminoethyl)amino)-2-((3,4- dichlorophenyl)amino)-5-fluoro- nicotinamide ¹H-NMR (CD₃OD, 400 MHz) δ: 8.15 (d, 1H, J = 2.4 Hz), 7.76 (d, 1H, J = 12 Hz), 7.39 (d, 1H, J = 8.8 Hz), 7.29 (dd, 1H, J = 2.4, 8.8 Hz), 3.78 (t, 2H, J = 6.0 Hz), 3.28 (t, 2H, J = 6.0 Hz). 358 (M + H) Example 6-12 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-((1,3-thiazol-2-yl)amino) nicotinamide 297 (M + H) Example 6-13 HCl salt

6-(2-aminoethylamino)-5-fluoro- 2-((1-methyl-1H-pyrazolo[3,4-b] pyridin-3-yl)amino)nicotinamide 345 (M + H) Example 6-14 HCl salt

6-((2-aminoethyl)amino)-2-((4,6- dimethylpyridin-2-yl)amino)-5- fluoronicotinamide ¹H-NMR (CD₃OD, 400 MHz) δ: 8.02 (d, 1H, J = 11.7 Hz), 7.50-7.44 (m, 2H), 3.72 (t, 2H, J = 5.7 Hz), 3.23 (t, 2H, J = 5.7 Hz), 2.67 (s, 6H). 319 (M + H) Example 6-15 HCl salt

6-((2-aminoethyl)amino)-2-((4,6- dimethylpyrimidin-2-yl)amino)- 5-fluoronicotinamide ¹H-NMR (CD₃OD, 400 MHz) δ: 8.06 (d, 1H, J = 11.7 Hz), 7.22 (s, 1H), 3.94 (t, 2H, J = 5.7 Hz), 3.39 (t, 2H, J = 5.7 Hz), 2.67 (s, 6H). 320 (M + H) Example 6-16 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-((5-methyl-1,3-thiazol-2-yl) amino)nicotinamide ¹H-NMR (CD₃OD, 400 MHz) δ: 8.00 (d, 1H, J = 11.5 Hz), 7.35 (d, 1H, J = 1.3 Hz), 3.99 (t, 2H, J = 5.8 Hz), 3.37 (t, 2H, J = 5.8 Hz), 2.47 (d, 3H, J = 1.3 Hz). 311 (M + H), 309 (M − H) Example 6-17 HCl salt

6-((2-aminoethyl)amino)-2-((2,2- dimethyl-3-oxo-3,4-dihydro-2H- pyrido[3,2-b][1,4]oxazin-6-yl) amino)-5-fluoronicotinamide ¹H-NMR (CD₃OD, 400 MHz) δ: 7.82 (d, 1H, J = 11.7 Hz), 7.77-7.68 (m, 1H), 7.32 (d, 1H, J = 8.8 Hz), 3.83 (t, 2H, J = 6.0 Hz), 3.38-3.15 (2H, overlapping with CH₃OH peak), 1.48 (s, 6H). 390 (M + H), 388 (M − H) Example 6-18

6-(ethylamino)-5-fluoro-2-((1H- indazol-6-yl)amino)nicotinamide ¹H-NMR (CD₃OD, 400 MHz) δ: 8.46 (s, 1H), 7.92 (s, 1H), 7.65 (d, 1H, J = 12 Hz), 7.61 (d, 1H, J = 9.2 Hz), 7.04 (dd, 1H, J = 9.2 Hz), 3.65 (q, 2H, J = 7.2 Hz), 1.34 (t, 3H, J = 7.2 Hz). 313 (M − H) Example 6-19

6-(ethylamino)-5-fluoro-2-((3- (trifluoromethyl)phenyl)amino) nicotinamide ¹H-NMR (CDCl₃, 300 MHz) δ: 11.2 (s, 1H), 8.56 (s, 1H), 7.48 (s, 1H, J = 8.7 Hz), 7.36 (t, 1H, J = 8.7 Hz), 7.23-7.19 (m, 2H), 5.41 (brs, 2H), 5.01 (brs, 1H), 3.60 (dq, 2H, J = 5.4, 9.6 Hz), 1.31 (t, 3H, J = 5.4 Hz). 343 (M + H) Example 6-20

6-(ethylamino)-5-fluoro-2- (quinolin-3-ylamino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.96 (d, 1H, J = 2.4 Hz), 8.89 (d, 1H, J = 2.4 Hz), 7.95-7.88 (m, 1H), 7.80-7.75 (m, 1H), 7.69 (d, 1H, J = 12.0 Hz), 7.61-7.49 (m, 2H), 3.63 (q, 2H, J = 7.2 Hz), 1.36 (t, 3H, J = 7.2 Hz). 326 (M + H) Example 6-21 HCl salt

6-((2-aminoethyl)amino)-5- fluoro-2-((2-methylbenzo[d]thiazol-6- yl)amino)nicotinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.82 (s, 1H), 8.38 (d, 1H, J = 2.1 Hz), 8.00-7.85 (m, 6H), 7.45-7.35 (m, 3H), 3.76-3.65 (m, 2H), 3.20-3.08 (2H, m), 2.80 (s, 3H). 361 (M + H) Example 6-22 HCl salt

6-(2-aminoethylamino)-5-fluoro- 2-((2-methylbenzo[d]oxazol-5-yl) amino)nicotinamide ¹H-NMR (CD₃OD, 400 MHz) δ: 8.31 (d, 1H, J = 2.0 Hz), 7.75 (d, 1H, J = 12.0 Hz), 7.48 (d, 1H, J = 8.8 Hz), 7.19 (dd, 1H, J = 2.0, 8.8 Hz), 3.79 (t, 2H, J = 6.0 Hz), 3.25 (t, 2H, J = 6.0 Hz), 2.64 (s, 3H). 345 (M + H) Example 6-23 HCl salt

6-((2-aminoethyl)amino)-5- fluoro-2-((2-methylbenzo[d]oxazol-6- yl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.12 (d, 1H, J = 2.0 Hz), 7.76 (d, 1H, J = 12.0 Hz), 7.51 (d, 1H, J = 8.4 Hz), 7.34 (dd, 1H, J = 2.0, 8.4 Hz), 3.79 (t, 2H, J = 6.0 Hz), 3.25 (t, 2H, J = 6.0 Hz), 2.64 (s, 3H). 345 (M + H) Example 6-24 HCl salt

2-((3-acetylaminophenyl)amino)- 6-((2-aminoethyl)amino)-5- fluoronicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.56 (s, 1H), 7.73 (d, 1H, J = 12.0 Hz), 7.24-7.17 (m, 1H), 6.99-6.88 (m, 1H), 6.80-6.74 (m, 1H), 3.91 (t, 2H, J = 6.0 Hz), 3.18 (t, 2H, J = 6.0 Hz), 2.15 (s, 3H). 347 (M + H) Example 6-25 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-((3-(methylsulfonyl)phenyl) amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 9.07-9.05 (m, 1H), 7.77 (d, 1H, J = 12.0 Hz), 7.53-7.51 (m, 2H), 7.37-7.33 (m, 1H), 3.89 (t, 2H, J = 6.0 Hz), 3.26 (t, 2H, J = 6.0 Hz), 3.15 (s, 3H). 368 (M + H) Example 6-26 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-(quinolin-6-ylamino)nico- tinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.30 (s, 1H), 8.99-8.98 (m, 1H), 8.94 (d, 1H, J = 8.7 Hz), 8.66 (d, 1H, J = 2.1 Hz), 8.26 (d, 1H, J = 9.0 Hz), 8.21-8.08 (m, 4H), 8.02 (d, 1H, J = 12.0 Hz), 7.99-7.90 (m, 1H), 7.87 (dd, 1H, J = 5.1, 8.4 Hz), 7.55-7.35 (m, 2H), 3.79 (q, 2H, J = 5.4 Hz), 3.21 (q, 2H, J = 6.0 Hz). 341 (M + H) Example 6-27 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-((1- methyl-1H-indazol-6-yl) amino)nicotinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.90 (s, 1H), 8.21 (s, 1H), 8.08-7.88 (m, 5H), 7.63 (d, 1H, J = 8.7 Hz), 7.38-7.32 (m, 2H), 6.99 (dd, 1H, J = 1.8, 8.7 Hz), 3.97 (s, 3H), 3.83-3.75 (m, 2H), 3.19-3.10 (m, 2H). 344 (M + H) Example 6-28 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-((2-methyl-2H-indazol-6-yl) amino)nicotinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.83 (s, 1H), 8.31 (s, 1H), 8.25 (s, 1H), 8.00-7.93 (m, 4H), 7.64 (d, 1H, J = 9.0 Hz), 7.38-7.32 (m, 2H), 6.91 (dd, 1H, J = 1.8, 9.0 Hz), 4.13 (s, 3H), 3.73-3.71 (m, 2H), 3.21-3.18 (m, 2H). 344 (M + H) Example 6-29 HCl salt

6-((2-aminoethyl)amino)-2-((3- chloro-4-fluorophenyl)amino)-5- fluoronicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.01 (dd, 1H, J = 2.7, 6.9 Hz), 7.75 (d, 1H, J = 12.0 Hz), 7.33-7.27 (m, 1H), 7.18-7.13 (m, 1H), 3.77-3.73 (m, 2H), 3.28-3.23 (m, 2H). 342 (M + H) Example 6-30 HCl salt

6-((2-aminoethyl)amino)-2-(bi- phenyl-3-yl)amino)-5-fluoronico- tinamide ¹H-NMR (CD3OD, 300 MHz) δ: 7.96 (t, 1H, J = 1.8 Hz), 7.75 (d, 1H, J = 12.0 Hz), 7.64-7.58 (m, 2H), 7.57-7.52 (m, 1H), 7.48-7.31 (m, 4H), 7.256-7.22 (m, 1H), 3.73-3.72 (m, 2H), 3.11-3.07 (m, 2H). 366 (M + H) Example 6-31 HCl salt

6-((2-aminoethyl)amino)-2-((3- cyanophenyl)amino)-5-fluoronico- tinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.38-8.36 (m, 1H), 7.78 (d, 1H, J = 12.0 Hz), 7.64-7.58 (m, 1H), 7.44 (t, 1H, 8.1 Hz), 7.30-7.28 (m, 1H), 3.83-3.78 (m, 2H), 3.35-3.22 (m, 2H). 315 (M + H) Example 6-32 HCl salt

2-((3-aminocarbonyl)phenyl)amino)- 6-((2-aminoethyl)amino)-5- fluoronicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.99-8.98 (m, 1H), 7.75 (d, 1H, J = 12.0 Hz), 7.45-7.33 (m, 2H), 7.35-7.32 (m, 1H), 3.90 (t, 2H, J = 6.9 Hz), 3.23 (t, 2H, J = 6.9 Hz). 333 (M + H) Example 6-33 HCl salt

2-((3-acetylphenyl)amino)-6-((2- aminoethyl)amino)-5-fluoronico- tinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.85-8.40 (m, 1H), 7.75 (d, 1H, J = 12.0 Hz), 7.65-7.63 (m, 1H), 7.45-7.38 (m, 2H), 3.90 (t, 2H, J = 6.3 Hz), 3.35 (t, 2H, J = 6.3 Hz), 2.63 (s, 3H). 332 (M + H) Example 6-34 HCl salt

6-(cis-2-aminocyclohexylamino)- 2-((benzo[c][1,2,5]thiadiazol- 5-yl)amino)-5-fluoronico- tinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.79 (d, 1H, J = 2.0 Hz), 7.88 (d, 1H, J = 9.3 Hz), 7.84 (d, 1H, J = 11.9 Hz), 7.47 (dd, 1H, J = 2.0, 9.3 Hz), 4.56-4.53 (m, 1H), 4.04-4.00 (m, 1H), 1.95-1.56 (m, 8H). 402 (M + H) Example 6-35 HCl salt

6-(cis-2-aminocyclohexylamino)- 2-((benzo[d]thiazol-6-yl)amino)- 5-fluoronicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 9.19 (s, 1H), 8.52 (d, 1H, J = 2.1 Hz), 7.98 (d, 1H, J = 8.9 Hz), 7.79 (d, 1H, J = 12.0 Hz), 7.60 (dd, 1H, J = 2.1, 8.9 Hz), 4.46-4.33 (m, 1H), 3.92-3.79 (m, 1H), 1.86-1.62 (m, 8H). 401 (M + H), 399 (M − H) Example 6-36 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-((3-(methylaminocarbonyl) phenyl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.97-8.95 (m, 1H), 7.75 (d, 1H, J = 12.0 Hz), 7.35-7.33 (m, 2H), 7.24-7.17 (m, 1H), 3.90 (t, 2H, J = 6.3 Hz), 3.25 (t, 2H, J = 6.3 Hz), 2.94 (s, 3H). 347 (M + H) Example 6-37 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-(1-naphthylamino)nicotinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 8.46 (dd, 1H, J = 2.7, 6.0 Hz), 8.22 (d, 1H, J = 7.8 Hz), 8.02-7.89 (m, 6H), 7.61-7.49 (m, 4H), 7.42-7.32 (m, 2H), 3.67-3.59 (m, 2H), 3.12-3.05 (m, 2H). 340 (M + H) Example 6-38 HCl salt

6-(cis-2-aminocyclohexylamino)- 2-((benzo[d][1,3]dioxol-5-yl)amino)- 5-fluoronicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 7.72 (d, 1H, J = 12.1 Hz), 7.33-7.29 (m, 1H), 6.79-6.75 (m, 2H), 5.95-5.90 (m, 2H), 4.30-4.20 (m, 1H), 3.90-3.80 (m, 1H), 1.90-1.50 (m, 8H). 388 (M + H) Example 6-39 HCl salt

6-(cis-2-aminoyclohexylamino)- 2-((2,3-dihydro-1H-inden-5-yl) amino)-5-fluoronicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 7.72 (d, 1H, J = 12.0 Hz), 7.39 (brs, 1H), 7.24 (dd, 1H, J = 1.9, 8.0 Hz), 7.14 (d, 1H, J = 8.0 Hz), 4.38-4.25 (m, 1H), 3.88-3.75 (m, 1H), 3.00-2.71 (m, 4H), 2.18-2.00 (m, 2H), 1.92-1.50 (m, 8H). 384 (M + H) Example 6-40 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-methyl-1H-indazol- 6-yl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.47 (s, 1H), 8.24 (s, 1H), 7.84 (d, 1H, J = 11.9 Hz), 7.77 (d, 1H, J = 9.0 Hz), 7.25 (dd, 1H, J = 1.7, 9.0 Hz), 4.68-4.54 (m, 1H), 4.28 (s, 3H), 3.96-3.84 (m, 1H), 2.00-1.50 (m, 8H). 398 (M + H), 396 (M − H) Example 6-41 HCl salt

6-(cis-2-aminocyclohexylamino)- 2-(biphenyl-3-ylamino)-5-fluoro- nicotinamide ¹H-NMR (CD₃OD , 300 MHz) δ: 8.13-8.07 (m, 1H), 7.76 (d, 1H, J = 12.0 Hz), 7.70-7.20 (m, 8H), 4.30-4.17 (m, 1H), 3.76-3.65 (m, 1H), 1.88-1.11 (m, 8H). 420 (M + H), 418 (M − H) Example 6-42

2-((benzo[d]thiazol-6-yl)amino)- 6-(ethylamino)-5-fluoronico- tinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.9 (s, 1H), 9.17 (s, 1H), 8.75 (d, 1H, J = 2.1 Hz), 7.95 (d, 1H, J = 9.0 Hz), 7.88 (d, 1H, J = 12.0 Hz), 7.54 (dd, 1H, J = 2.1, 9.0 Hz), 3.46 (q, 2H, J = 7.2 Hz), 1.22 (t, 3H, J = 7.2 Hz). 361 (M + H) Example 6-43

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((2-methylbenzo[d] oxazol-6-yl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.34 (d, 1H, J = 2.0 Hz), 7.69 (d, 1H, J = 12.2 Hz), 7.46 (d, 1H, J = 8.6 Hz), 7.23 (dd, 1H, J = 2.0, 8.6 Hz), 4.31-4.19 (m, 1H), 3.44-3.37 (m, 1H), 2.61 (s, 3H), 1.87-1.44 (m, 8H). 399 (M + H), 397 (M − H) Example 6-44 TFA salt

6-(2-aminoethylamino)-2-((benzo [d]thiazol-6-yl)amino)-5-fluoro- nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 9.07 (s, 1H), 8.40 (d, 1H, J = 2.1 Hz), 7.97 (d, 1H, J = 8.9 Hz), 7.77 (d, 1H, J = 12.0 Hz), 7.69 (dd, 1H, J = 2.1, 8.9 Hz), 3.79 (t, 2H, J = 5.7 Hz), 3.25 (t, 2H, J = 5.7 Hz). 347 (M + H), 345 (M − H) Example 6-45 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((4-(2-(pyrrolidin-1- yl)ethoxy)phenyl)amino)nico- tinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 7.73 (d, 1H, J = 12.0 Hz), 7.48 (d, 2H, J = 8.3 Hz), 7.02 (d, 2H, J = 8.3 Hz), 4.50-4.20 (m, 3H), 3.93-3.50 (m, 5H), 3.39-3.15 (2H, overlapping with CH₃OH peak), 2.30-2.00 (m, 4H), 2.00-1.45 (m, 8H). 455 (M − H) Example 6-46 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((2-methylbenzo[d] oxazol-5-yl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.10 (d, 1H, J = 2.1 Hz), 7.77 (d, 1H, J = 12.0 Hz), 7.49 (d, 1H, J = 8.7 Hz), 7.25 (dd, 1H, J = 2.1, 8.7 Hz), 4.46-4.30 (m, 1H), 3.89-3.76 (m, 1H), 2.64 (s, 3H), 1.94-1.50 (m, 8H). 399 (M + H), 397 (M − H) Example 6-47 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((3-(2-(pyrrolidin-1- yl)ethoxy)phenyl)amino)nico- tinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 7.76 (d, 1H, J = 12.0 Hz), 7.60-7.51 (m, 1H), 7.27 (t, 1H, J = 8.2 Hz), 7.00-6.94 (m, 1H), 6.68 (dd, 1H, J = 2.2, 8.0 Hz), 4.43-4.30 (m, 3H), 3.94-3.84 (m, 1H), 3.80-3.60 (m, 4H), 3.30-3.17 (m, 2H), 2.25-1.97 (m, 4H), 1.95-1.40 (m, 8H). 457 (M + H), 455 (M − H) Example 6-48 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-((3-(hydroxymethyl)phenyl) amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.04 (brs, 1H), 7.74 (d, 1H, J = 12.0 Hz), 7.28-7.16 (m, 2H), 6.92 (d, 1H, J = 7.5 Hz), 4.63 (s, 2H), 3.79 (t, 2H, J = 6.3 Hz), 3.21 (t, 2H, J = 6.3 Hz). 319 (M + H) Example 6-49 (Example 5) HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((5-methylpyridin-3- yl)amino)nicotinamide ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.09 (s, 1H), 9.10 (s, 1H), 8.29 (s, 1H), 8.25 (s, 1H), 8.02 (d, 1H, J = 12.3 Hz), 8.02-7.92 (m, 3H), 7.54-7.44 (m, 1H), 7.10-7.04 (m, 1H), 4.36-4.27 (m, 1H), 3.60-3.53 (m, 1H), 2.42 (s, 3H), 1.95-1.38 (m, 8H) 359 (M + H), 357 (M − H) Example 6-50 HCl salt

6-(cis-2-aminocyclohexylamino)- 2-((1,3-dimethyl-1H-pyrazolo[3, 4-b]pyridin-5-yl)amino)-5-fluoro- nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.77 (d, 1H, J = 2.3 Hz), 8.36 (d, 1H, J = 2.3 Hz), 7.79 (d, 1H, J = 11.9 Hz), 4.35-4.23 (m, 1H), 4.05 (s, 3H), 3.65-3.54 (m, 1H), 2.57 (s, 3H), 1.92-1.42 (m, 8H). 413 (M + H), 411 (M − H) Example 6-51 HCl salt

6-(cis-2-aminocyclohexylamino)- 2-((2,3-dihydrobenzo[b][1,4]di- oxin-6-yl)amino)-5-fluoronico- tinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 7.71 (d, 1H, J = 12.0 Hz), 7.32-7.27 (m, 1H), 6.77-6.74 (m, 2H), 4.32-4.14 (m, 5H), 3.94-3.85 (m, 1H), 1.88-1.52 (m, 8H). 402 (M + H) Example 6-52 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((3-(2H-1,2,3-triazol- 2-yl)phenyl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.86 (t, 1H, J = 2.1 Hz), 7.96 (s, 2H), 7.79 (d, 1H, J = 12.0 Hz), 7.72-7.64 (m, 1H), 7.42 (t, 1H, J = 8.1 Hz), 7.22-7.13 (m, 1H), 4.77-4.61 (m, 1H), 3.88-3.73 (m, 1H), 2.00-1.42 (m, 8H). 411 (M + H) Example 6-53 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((6-methoxyquinolin- 3-yl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 9.49 (d, 1H, J = 2.3 Hz), 9.00 (d, 1H, J = 2.3 Hz), 8.06 (d, 1H, J = 9.3 Hz), 7.90 (d, 1H, J = 11.8 Hz), 7.59 (dd, 1H, J = 2.6, 9.3 Hz), 7.51 (d, 1H, J = 2.6 Hz), 4.67-4.50 (m, 1H), 4.02 (s, 3H), 3.83-3.69 (m, 1H), 2.00-1.50 (m, 8H). 425 (M + H), 423 (M − H) Example 6-54 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-(quinolin-5-ylamino)- nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 9.41 (d, 1H, J = 8.7 Hz), 9.19 (dd, 1H, J = 1.4, 5.4 Hz), 8.82 (d, 1H, J = 8.3 Hz), 8.17 (t, 1H, J = 8.3 Hz), 8.09 (dd, 1H, J = 5.4, 8.7 Hz), 7.93 (d, 1H, J = 11.9 Hz), 7.81 (d, 1H, J = 8.3 Hz), 4.46-4.35 (m, 1H), 3.88-3.75 (m, 1H), 2.00-1.50 (m, 8H). 395 (M + H), 393 (M − H) Example 6-55 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-(quinoxalin-6-ylamino) nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.87 (d, 1H, J = 2.1 Hz), 8.79-8.78 (m, 2H), 8.05 (d, 1H, J = 9.3 Hz), 7.87 (d, 1H, J = 12.0 Hz), 7.85-7.82 (m, 1H), 4.73-4.60 (m, 1H), 4.02-3.95 (m, 1H), 2.20-1.60 (m, 8H). 396 (M + H) Example 6-56 HCl salt

6-(cis-2-aminocyclohexylamino)- 2-((benzo[d]thiazol-5-yl)amino)- 5-fluoronicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 9.36 (brs, 1H), 8.67 (brs, 1H), 8.05-7.92 (m, 1H), 7.86-7.73 (m, 1H), 7.51-7.40 (m, 1H), 4.63-4.38 (m, 1H), 4.40-3.79 (m, 1H), 1.87-1.61 (m, 8H). 401 (M + H), 399 (M − H) Example 6-57 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-(isoquinolin-4-ylamino) nicotinamide ¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.71 (s, 1H), 9.43-9.35 (m, 1H), 8.50-8.35 (m, 2H), 8.28-8.18 (m, 1H), 8.11(d, 1H, J = 12.1 Hz), 8.07-7.95 (m, 4H), 7.73-7.57 (m, 2H), 3.83-3.74 (m, 2H), 3.21-3.10 (m, 2H) 341 (M + H), 339 (M − H) Example 6-58 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-(quinolin-5-ylamino)nico- tinamide ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.79 (s, 1H), 9.14-9.09 (m, 1H), 8.93-8.85 (m, 1H), 8.65 (d, 1H, J = 7.8 Hz), 8.04 (d, 1H, J = 12.4 Hz), 8.00-7.83 (m, 6H), 7.53-7.43 (m, 2H), 3.78-3.61 (m, 2H), 3.12-3.03 (m, 2H) 341 (M + H), 339 (M − H) Example 6-59

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-methyl-1H-indol- 4-yl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.08 (d, 1H, J = 7.6 Hz), 7.68 (d, 1H, J = 12.3 Hz), 7.15-7.06 (m, 2H), 7.01 (d, 1H, J = 8.2 Hz), 6.61 (dd, 1H, J = 0.6, 3.2 Hz), 4.33-4.21 (m, 1H), 3.78 (s, 3H), 3.42-3.33 (m, 1H), 1.85-1.42 (m, 8H). 397 (M + H), 395 (M − H) Example 6-60 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-methyl-1H-indazol- 5-yl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.03-7.98 (m, 1H), 7.97-7.94 (m, 1H), 7.75 (d, 1H, J = 12.0 Hz), 7.53 (d, 1H, J = 9.0 Hz), 7.45 (dd, 1H, J = 1.9, 9.0 Hz), 4.33-4.22 (m, 1H), 4.06 (s, 3H), 3.81-3.70 (m, 1H), 1.91-1.46 (m, 8H). 398 (M + H), 396 (M − H) Example 6-61 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-methyl-1H-benzo [d]imidazol-6-yl)amino)nico- tinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 9.25 (s, 1H), 8.15 (d, 1H, J = 1.7 Hz), 7.86 (dd, 1H, J = 1.7, 9.0 Hz), 7.84 (d, 1H, J = 11.9 Hz), 7.75 (d, 1H, J = 9.0 Hz), 4.66-4.50 (m, 1H), 4.12 (s, 3H), 3.77-3.68 (m, 1H), 1.92-1.45 (m, 8H). 398 (M + H), 396 (M − H) Example 6-62

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-(quinazolin-6-ylamino) nicotinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.10 (s, 1H), 9.36 (s, 1H), 9.12 (s, 1H), 8.56 (d, 1H, J = 2.4 Hz), 8.02 (dd, 1H, J = 2.4, 9.0 Hz), 7.94 (d, 1H, J = 12.0 Hz), 7.91 (d, 1H, J = 9.0 Hz), 7.88-7.75 (m, 1H), 7.40-7.25 (m, 1H), 6.64 (d, 1H, 6.9 Hz), 4.13-4.03 (m, 1H), 3.22-3.15 (m, 1H), 1.87-1.30 (m, 8H). 396 (M + H) Example 6-63 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-(quinazolin-7-ylamino) nicotinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.60 (s, 1H), 9.46 (s, 1H), 9.18 (s, 1H), 8.69 (d, 1H, J = 2.4 Hz), 8.13-8.00 (m, 6H), 7.63 (dd, 1H, J = 2.4, 9.0 Hz), 7.60-7.53 (m, 1H), 7.22 (d, 1H, J = 6.3 Hz), 4.50-4.40 (m, 1H), 3.83-3.73 (m, 1H), 2.12-1.46 (m, 8H). 396 (M + H) Example 6-64, HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-(quinolin-8-ylamino)- nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 9.24 (d, 1H, J = 7.5 Hz), 9.16-9.08 (m, 1H), 8.24-8.08 (m, 3H), 7.98 (dd, 1H, J = 7.9, 8.0 Hz), 7.85 (d, 1H, J = 11.7 Hz), 3.40-3.26 (2H, overlapping with CH₃OH peak), 3.13-2.96 (m, 1H), 1.68-1.39 (m, 8H). 395 (M + H) Example 6-65 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-methyl-1H-benzo [d]imidazol-5-yl)amino)nico- tinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 9.28 (s, 1H), 8.21 (d, 1H, J = 1.6 Hz), 7.88-7.73 (m, 3H), 4.58-4.46 (m, 1H), 4.13 (s, 3H), 3.92-3.77 (m, 1H), 2.00-1.50 (m, 8H). 398 (M + H) Example 6-66 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-methyl-1H-indazol- 7-yl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.04 (s, 1H), 7.78 (d, 1H, J = 11.9 Hz), 7.64 (dd, 1H, J = 1.0, 8.0 Hz), 7.24 (dd, 1H, J = 1.0, 7.3 Hz), 7.18-7.11 (m, 1H), 4.01 (s, 3H), 3.34-3.26 (m, 1H), 2.96-2.86 (m, 1H), 1.70-1.28 (m, 8H). 398 (M + H), 396 (M − H) Example 6-67 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((8-methoxyquinolin- 5-yl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 9.29 (d, 1H, J = 8.7 Hz), 9.12 (d, 1H, J = 4.9 Hz), 8.36 (d, 1H, J = 8.7 Hz), 8.17-8.09 (m, 1H), 7.86 (d, 1H, J = 11.9 Hz), 7.73 (d, 1H, J = 8.7 Hz), 4.24 (s, 3H), 4.08-3.92 (m, 1H), 3.56-3.44 (m, 1H), 1.88-1.33 (m, 8H). 425 (M + H), 423 (M − H) Example 6-68 HCl salt

6-(cis-2-aminocyclohexylamino)- 2-(benzo[c][1,2,5]thiadiazol-4- ylamino)-5-fluoronicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.45 (dd, 1H, J = 0.8, 7.5 Hz), 7.82 (d, 1H, J = 12.0 Hz), 7.57-7.48 (m, 1H), 7.43 (dd, 1H, J = 0.8, 8.7 Hz), 4.56-4.46 (m, 1H), 4.16-4.04 (m, 1H), 2.12-1.54 (m, 8H). 402 (M + H), 400 (M − H) Example 6-69

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-methyl-1H-indol- 5-yl)amino)nicotinamide 397 (M + H) Example 6-70 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((2-methylquinolin-6- yl)amino)nicotinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.10 (s, 1H), 8.83-8.73 (m, 1H), 8.55 (s, 1H), 8.22 (d, 1H, J = 9.3 Hz), 8.15-7.90 (m, 6H), 7.81 (d, 1H, J = 8.1 Hz), 7.49-7.38 (m, 1H), 6.99 (d, 1H, J = 6.3 Hz), 4.50-4.43 (m, 1H), 3.76-3.66 (m, 1H), 2.88 (s, 3H), 2.00-1.38 (m, 8H) 409 (M + H) Example 6-71 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-(isoquinolin-7-yl- amino)nicotinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.20 (s, 1H), 9.65 (s, 1H), 8.71 (s, 1H), 8.48 (d, 1H, J = 6.3 Hz), 8.32 (d, 1H, J = 6.3 Hz), 8.27-8.19 (m, 2H), 8.18-8.08 (m, 3H), 8.03 (d, 1H, J = 12.6 Hz), 8.02-7.93 (m, 1H), 7.53-7.43 (m, 1H), 7.01 (d, 1H, J = 6.6 Hz), 4.54-4.46 (m, 1H), 3.76-3.66 (m, 1H), 2.02-1.38 (m, 8H). 395 (M + H) Example 6-72 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-(quinolin-7-ylamino) nicotinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.40 (s, 1H), 9.01 (d, 1H, J = 5.1 Hz), 8.96-8.83 (m, 1H), 8.70 (s, 1H), 8.19 (d, 1H, J = 8.7 Hz), 8.06 (d, 1H, J = 12.3 Hz), 8.05-7.97 (m, 4H), 7.82 (d, 1H, J = 9.6 Hz), 7.78-7.68 (m, 1H), 7.60-7.53 (m, 1H), 6.94 (d, 1H, J = 6.9 Hz), 4.73-4.62 (m, 1H), 3.86-3.77 (m, 1H), 1.97-1.35 (m, 8H). 395 (M + H) Example 6-73 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-(quinazolin-6-ylamino) nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 7.80-7.72 (m, 2H), 7.25-7.14 (m, 2H), 4.46-4.31 (m, 3H), 3.87-3.80 (m, 1H), 3.51 (t, 2H, J = 6.3 Hz), 3.14-3.09 (m, 2H), 2.00-1.50 (m, 8H). 399 (M + H) Example 6-74

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((2-methyl-2H-indazol- 7-yl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.21 (d, 1H, J = 7.3 Hz), 8.07 (s, 1H), 7.71 (d, 1H, J = 12.2 Hz), 7.22 (d, 1H, J = 8.3 Hz), 7.01-6.94 (m, 1H), 4.37-4.25 (m, 1H), 4.21 (s, 3H), 3.48-3.40 (m, 1H), 1.93-1.47 (m, 8H). 398 (M + H) Example 6-75 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-methyl-1H-indazol- 4-yl)amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.07 (d, 1H, J = 0.8 Hz), 7.90 (d, 1H, J = 7.5 Hz), 7.82 (d, 1H, J = 12.0 Hz), 7.39 (t, 1H, J = 8.2 Hz), 7.16 (d, 1H, J = 8.5 Hz), 4.42-4.33 (m, 1H), 4.05 (s, 3H), 3.93-3.85 (m, 1H), 1.93-1.51 (m, 8H). 398 (M + H) Example 6-76 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((2-methylquinoxalin- 6-yl)amino)nicotinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.10 (s, 1H), 8.76 (s, 1H), 8.62 (d, 1H, J = 2.4 Hz), 8.00 (d, 1H, J = 12.6 hz), 7.97-7.90 (m, 4H), 7.87 (d, 1H, J = 9.0 Hz), 7.65 (dd, 1H, J = 2.4, 9.0 Hz), 7.50-7.34 (m, 1H), 7.07 (d, 1H, J = 6.3 Hz), 4.44-4.35 (m, 1H), 3.80-3.60 (m, 1H), 2.65 (s, 3H), 2.10-1.45 (m, 8H). 410 (M + H) Example 6-77

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((2-methyl-1,2,3,4- tetrahydroisoquinolin-7-yl)amino) nicotinamide ¹H-NMR (CDCl₃, 300 MHz) δ: 10.80 (s, 1H), 7.49-7.43 (m, 1H), 7.35-7.34 (m, 1H), 7.17 (d, 1H, J = 11.7 Hz), 7.01 (d, 1H, J = 8.4 Hz), 5.65 (brd, 1H, J = 9.0 Hz), 5.38 (brs, 2H), 4.14-4.03 (m, 1H), 3.60-3.54 (m, 2H), 3.18 (q, 1H, J = 3.9 Hz), 2.93-2.85 (m, 2H), 2.72-2.65 (m, 2H), 2.46 (s, 3H), 1.90-1.35 (m, 8H). 413 (M + H) Example 6-78 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-(2-(morpholin-4- yl)ethyl)-1H-indazol-5-yl)amino) nicotinamide 497 (M + H) Example 6-79 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-(2-(morpholin-4- yl)ethyl)-1H-indazol-6-yl)amino) nicotinamide 497 (M + H) Example 6-80 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((2-(2-(morpholin-4- yl)ethyl)-2H-indazol-5-yl)amino) nicotinamide 497 (M + H) Example 6-81 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((2-(2-(morpholin-4- yl)ethyl)-2H-indazol-6-yl)amino) nicotinamide 497 (M + H) Example 6-82 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-(2-(pyrrolidin-1- yl)ethyl)-1H-indazol-5-yl)amino) nicotinamide 481 (M + H) Example 6-83 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((2-(2-(pyrrolidin-1- yl)ethyl)-2H-indazol-5-yl)amino) nicotinamide 481 (M + H) Example 6-84 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1-(2-(pyrrolidin-1- yl)ethyl)-1H-indazol-6-yl) amino)nicotinamide 481 (M + H) Example 6-85 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((2-(2-(pyrrolidin-1- yl)ethyl)-2H-indazol-6-yl) amino)nicotinamide 481 (M + H) Example 6-86

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1H-indazol-6-yl) amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.04 (s, 1H), 7.92 (d, 1H, J = 1.0 Hz), 7.68 (d, 1H, J = 12.2 Hz), 7.63 (d, 1H, J = 8.7 Hz), 7.17 (dd, 1H, J = 1.7, 8.7 Hz), 4.38-4.23 (m, 1H), 3.36-3.24 (2H, overlapping with CH₃OH peak), 1.86-1.47 (m, 8H). 384 (M + H), 382 (M − H) Example 6-87 HCl salt

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((1H-indazol-5-yl) amino)nicotinamide ¹H-NMR (CD₃OD, 300 MHz) δ: 8.08 (d, 1H, J = 0.8 Hz), 8.04 (d, 1H, J = 1.1 Hz), 7.76 (d, 1H, J = 12.0 Hz), 7.54 (d, 1H, J = 8.9 Hz), 7.45 (dd, 1H, J = 1.9, 8.9 Hz), 4.32-4.27 (m, 1H), 3.80-3.76 (m, 1H), 1.83-1.56 (m, 8H). 384 (M + H) Example 6-88 HCl salt

6-((2-aminoethyl)amino)-5-fluoro- 2-((4′-methylbipenyl-3-yl) amino)nicotinamide ¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.70 (s, 1H), 7.92 (d, 1H, J = 12.0 Hz), 7.89-7.82 (m, 5H) , 7.63-7.52 (m, 3H), 7.41-7.26 (m, 5H), 7.21-7.18 (m, 1H), 3.70-3.64 (m, 2H), 3.07-3.00 (m, 2H), 2.35 (s, 3H). 380 (M + H) 3-1 3-2 Mass Mass (M + (M − rt Example Structure Compound name Salt Solvent NMR 1HNMR H) H) (min) Example 6-89

6-((2-aminoethyl)amino)-5-fluoro-2-((5- phenylpyridin-3-yl)amino)nicotinamide HCl DMSO- d6 400 MHz δ: 12.20 (s, 1H), 9.35-9.25 (m, 1H), 8.74 (s, 1H), 8.57 (s, 1H), 8.02 (d, 1H, J = 12.4 Hz), 8.02-7.90 (m, 4H), 7.88- 7.83 (m, 2H), 7.60-7.83 (m, 5H), 3.75- 3.68 (m, 2H), 3.12-3.03 (m, 2H). 367 365 8.61 Example 6-90

6-((2-aminoethyl)amino)-5-fluoro-2-((5-(1- methyl-1H-pyrrol-2-yl)pyridin-3-yl)amino) nicotinamide HCl DMSO- d6 400 MHz δ: 12.18 (s, 1H), 9.33 (s, 1H), 8.55 (s, 1H), 8.24 (s, 1H), 8.10-7.90 (m, 5H), 7.60-7.54 (m, 1H), 7.46 (br, 1H), 7.03- 7.00 (m, 1H), 6.55-6.50 (m, 1H), 6.18- 6.15 (m, 1H), 3.77 (s, 3H), 3.75-3.67 (m, 2H), 3.12-3.04 (m, 2H). 370 368 8.17 Example 6-91

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((5-(1-methyl-1H-indol-5-yl)pyridin-3-yl) amino)nicotinamide HCl 474 472 11.39 Example 6-92

(S)-6-((2-aminopropyl)amino)-5-fluoro-2- ((quinolin-3-yl)amino)nicotinamide HCl DMSO- d6-D2O 400 MHz δ: 9.31 (d, 1H, J = 2.4 Hz), 8.96-8.89 (m, 1H), 8.12-8.03 (m, 2H), 7.96 (d, 1H, J = 12.2 Hz), 7.87-7.70 (m, 2H), 3.77-3.66 (m, 1H), 3.58-3.45 (m, 2H), 1.21 (d, 3H, J = 5.9 Hz) 355 353 ND Example 6-93

(S)-6-((2-aminopropyl)amino)-2-(3,5- dimethoxyphenylamino)-5-fluoronicotinamide HCl DMSO- d6 400 MHz δ: 11.64 (s, 1H), 7.97-7.70 (m, 5H), 7.43-7.17 (m, 2H), 6.79 (d, 2H, J = 2.2 Hz), 6.13 (t, 1H, J = 2.2 Hz), 3.73 (s, 6H), 3.68-3.49 (m, 2H), 3.50-3.30 (m, 1H), 1.24 (d, 3H, J = 6.6 Hz) 364 362 ND Example 6-94

(S)-6-((2-aminopropyl)amino)-5-fluoro-2-((5- methylpyridin-3-yl)amino)nicotinamide HCl CD3OD 400 MHz δ: 9.39 (d, 1H, J = 2.2 Hz), 8.34-8.29 (m, 1H), 8.28-8.23 (m, 1H), 7.87 (d, 1H, J = 11.7 Hz), 3.85-3.60 (m, 3H), 2.53 (s, 3H), 1.39 (d, 3H, J = 6.3 Hz) 319 317 ND Example 6-95

(S)-6-((2-aminopropyl)amino)-5-fluoro-2-((6- methylpyridin-3-yl)amino)nicotinamide HCl CD3OD 400 MHz δ: 9.32 (d, 1H, J = 2.3 Hz), 8.43 (dd, 1H, J = 2.3, 8.9 Hz), 7.86 (d, 1H, J = 12.0 Hz), 7.78 (d, 1H, J = 8.9 Hz), 3.84-3.59 (m, 3H), 2.72 (s, 3H), 1.39 (d, 3H, J = 6.6 Hz) 319 317 ND Example 6-96

(S)-6-((2-aminopropyl)amino)-5-fluoro-2-((2- methoxypyridin-4-yl)amino)nicotinamide HCl DMSO- d6-D2O 400 MHz δ: 8.10-7.98 (m, 2H), 7.58-7.50 (m, 1H), 7.46-7.36 (m, 1H), 4.04 (s, 3H), 3.72-3.50 (m, 3H), 1.27 (d, 3H, J = 6.1 Hz) 335 333 ND Example 6-97

(S)-2-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)- 6-((2-aminopropyl)amino)-5- fluoronicotinamide HCl DMSO- d6 400 MHz δ: 11.94 (s, 1H), 8.76-8.70 (m, 1H), 8.12 (s, 2H), 8.04-7.77 (m, 5H), 7.64- 7.56 (m, 1H), 7.52-7.27 (m, 4H), 3.79- 3.68 (m, 1H), 3.67-3.47 (m, 2H), 1.13 (d, 3H, J = 6.6 Hz) 371 369 ND Example 6-98

(S)-6-((2-aminopropyl)amino)-2-((2,6- dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl DMSO- d6-D2O 400 MHz δ: 7.92 (d, 1H, J = 12.0 Hz), 6.64 (s, 2H), 3.82 (s, 6H), 3.73-3.51 (m, 2H), 3.45-3.34 (m, 1H), 1.30 (d, 3H, J = 6.6 Hz) 365 363 ND Example 6-99

(S)-6-((2-aminopropyl)amino)-5-fluoro-2-((3- methylphenylamino)nicotinamide HCl DMSO- d6 400 MHz δ: 11.55 (s, 1H), 8.00-7.66 (m, 5H), 7.50-7.42 (m, 1H), 7.41-7.12 (m, 4H), 6.77 (d, 1H, J = 7.3 Hz), 3.67-3.35 (m, 3H), 2.29 (s, 3H), 1.22 (d, 3H, J = 6.3 Hz) 318 316 ND Example 6-100

(R)-6-((1-aminopopan-2-yl)amino)-2-((3,5- dimethoxyphenyl)amino)-5-fluoronicotinamide HCl 364 362 0.84 Example 6-101

(R)-6-((1-aminopropan-2-yl)amino)-5-fluoro- 2-((5-methylpyridin-3-yl)amino)nicotinamide HCl 319 317 0.5 Example 6-102

(R)-6-((1-aminopropan-2-yl)amino)-5-fluoro- 2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 358 356 0.73 Example 6-103

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-methylpyridin-3-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 12.08 (s, 1H), 9.11-9.05 (m, 1H), 8.29 (s, 1H), 8.25 (s, 1H), 8.02 (d, 1H, J = 12.2 Hz), 8.01-7.88 (m, 4H), 7.60- 7.38 (m, 1H), 7.06 (d, 1H, J = 6.6 Hz), 4.37-4.26 (m, 1H), 3.64-3.50 (m, 1H), 2.42 (s, 3H), 1.97-1.35 (m, 8H). 359 357 Example 6-104

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-methylpyridin-3-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 12.02 (s, 1H), 9.12 (s, 1H), 8.34 (d, 1H, J = 8.6 Hz), 8.02 (d, 1H, J = 11.9 Hz), 8.02-7.88 (m, 4H), 7.70 (d, 1H, J = 8.3 Hz), 7.55-7.37 (m, 1H), 7.04 (d, 1H, J = 6.6 Hz), 4.35-4.24 (m, 1H), 3.60-3.52 (m, 1H), 2.63 (s, 3H), 1.97- 1.33 (m, 8H). 359 357 Example 6-105

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-methylpyridin-3-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 12.11 (s, 1H), 9.11 (s, 1H), 8.30 (s, 1H), 8.26 (s, 1H), 8.08-7.87 (m, 4H), 8.02 (d, 1H, J = 12.2 Hz), 7.55- 7.43 (m, 1H), 7.07 (d, 1H, J = 6.9 Hz), 4.38-4.26 (m, 1H), 3.62-3.52 (m, 1H), 2.43 (s, 3H), 1.98-1.35 (m, 8H). 359 357 Example 6-106

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-methylpyridin-3-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 12.03 (s, 1H), 9.12 (s, 1H), 8.41- 8.31 (m, 1H), 8.02-7.85 (m, 4H), 8.02 (d, 1H, J = 12.2 Hz), 7.71 (d, 1H, J = 8.6 Hz), 7.53-7.40 (m, 1H), 7.08-7.00 (m, 1H), 4.35-4.24 (m, 1H), 3.60-3.51 (m, 1H), 2.63 (s, 3H), 1.95-1.36 (m, 8H). 359 357 Example 6-107

6-(((2R,3S)-3-aminobutan-2-yl)amino)-2- (3,5-dimethoxyphenyl)amino)-5- fluoronicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-2- (3,5-dimethoxyphenyl)amino)-5- fluoronicotinamide HCl 378 376 0.88 Example 6-108

6-((2R,3S)-3-aminobutan-2-yl)amino)-2-((5- methylpyridin-3-yl)amino)-5- fluoronicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-2-((5- methylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 333 331 0.51 Example 6-109

6-(((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 372 370 0.76 Example 6-110

6-((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-(quinolin-5-ylamino)nicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoro-2-(quinolin-5-ylamino)nicotinamide HCl 369 367 0.59 Example 6-111

2-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-6- (((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoronicotinamide 2-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-6- (((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoronicotinamide HCl 385 383 0.95 Example 6-112

6-(((2R,3S)-3-aminobutan-2-yl)amino)-2- ((2,6-dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-2- ((2,6-dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl 379 377 0.9 Example 6-113

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-phenylpyridin-3-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 12.13 (s, 1H), 9.08 (s, 1H), 8.73- 8.65 (m, 2H), 8.03 (d, 1H, J = 12.6 Hz), 8.02-7.90 (m, 4H), 7.88-7.82 (m, 2H), 7.61-7.48 (m, 4H), 7.08 (d, 1H, J = 7.2 Hz), 4.28-4.16 (m, 1H), 3.54- 3.34 (m, 1H), 1.90-1.15 (m, 8H). 421 419 0.86 Example 6-114

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((2,6- dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.94 (s, 1H), 7.96 (d, 1H, J = 12.6 Hz), 7.94-7.80 (m, 4H), 7.48- 7.30 (m, 1H), 7.03 (d, 1H, J = 6.3 Hz), 6.60 (s, 2H), 4.29-4.17 (m, 1H), 3.82 (s, 6H), 3.74-3.65 (m, 1H), 2.02-1.36 (m, 8H). 405 403 Example 6-115

6-((1S,2R)-2-aminocyclohexylamino)-2-((2,6- dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.94 (s, 1H), 8.02-7.85 (m, 4H), 7.96 (d, 1H, J = 12.2 Hz), 7.48-7.28 (m, 1H), 7.05 (d, 1H, J = 6.3 Hz), 6.60 (s, 2H), 4.28-4.17 (m, 1H), 3.82 (s, 6H), 3.75-3.64 (m, 1H), 2.02-1.35 (m, 8H). 405 403 Example 6-116

2-((5-(1H-pyrrol-3-yl)pyridin-3-yl)amino)-6- ((cis-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.98 (s, 1H), 11.34 (s, 1H), 8.96 (s, 1H), 8.62 (s, 1H), 8.48 (s, 1H), 8.02 (d, 1H, J = 12.3 Hz), 8.00-7.80 (m, 4H), 7.64-7.69 (m, 1H), 7.47 (br, 1H), 7.06 (d, 1H, J = 6.6 Hz), 6.94-6.89 (m, 1H), 6.72-6.68 (m, 1H), 4.34-4.20 (m, 1H), 3.60-3.46 (m, 1H), 1.90-1.20 (m, 8H). 410 408 0.65 Example 6-117

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl CD3OD 300 MHz δ: 9.07 (d, 1H, J = 7.9 Hz), 8.94 (dd, 1H, J = 5.3, 1.3 Hz), 8.71 (d, 1H, J = 2.6 Hz), 8.30 (dd, 1H, J = 9.2, 2.0 Hz), 8.17 (d, 1H, J = 9.2 Hz), 8.03-7.95 (m, 1H), 7.86 (d, 1H, J = 11.9 Hz), 4.82- 4.67 (m, 1H), 3.41-3.33 (m, 1H), 3.17- 3.05 (m, 1H), 1.81-1.45 (m, 3H), 0.96- 0.86 (m, 6H). 397 395 0.77 Example 6-118

(S)-6-((2-amino-2-phenylethyl)amino)-5- fluoro-2-((5-methylpyridin-3-yl)amino) nicotinamide HCl 381 379 0.58 Example 6-119

(S)-6-((2-amino-2-phenylethyl)amino)-5- fluoro-2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 420 418 0.86 Example 6-120

(S)-2-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)- 6-((2-amino-2-phenylethyl)amino)-5- fluoronicotinamide HCl 433 431 1 Example 6-121

2-((3-(1H-1,2,3-triazol-1-yl)phenyl)amino)-6- (((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoronicotinamide 2-((3-(1H-1,2,3-triazol-1-yl)phenyl)amino)-6- (((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoronicotinamide HCl 385 383 0.79 Example 6-122

2-(3-(1H-1,2,3-triazol-1-yl)phenylamino)-6- ((cis-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl 411 409 0.87 Example 6-123

2-((5-(1H-pyrrol-1-yl)pyridin-3-yl)amino)-6- (cis-2-aminocyclohexylamino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.95 (s, 1H), 9.75-8.70 (m, 1H), 8.57-8.53 (m, 1H), 8.53-8.49 (m, 1H), 8.00 (d, 1H, J = 12.6 Hz), 8.00-7.80 (m, 4H), 7.55-7.51 (m, 2H), 7.43 (br, 1H), 7.06 (d, 1H, J = 6.0 Hz), 6.36- 6.32 (m, 2H), 4.27-4.15 (m, 1H), 3.70- 3.50 (m, 1H), 1.90-1.15 (m, 8H). 410 408 0.9 Example 6-124

2-((2-(1H-pyrrol-1-yl)pyridin-4-yl)amino)-6- ((cis-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.13 (s, 1H), 8.21 (d, 1H, J = 5.7 Hz), 8.01 (d, 1H, J = 12.6 Hz), 8.00- 7.80 (m, 5H), 7.66-7.62 (m, 2H), 7.56- 7.38 (m, 2H), 7.07 (d, 1H, J = 6.6 Hz), 6.30-6.27 (m, 2H), 4.37-4.25 (m, 1H), 3.65-3.50 (m, 1H), 1.95-1.25 (m, 8H). 410 408 0.92 Example 6-125

2-((2-(2H-1,2,3-triazol-2-yl)pyridin-4-yl) amino)-6-((cis-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.37 (s, 1H), 8.70-8.60 (m, 1H), 8.36-8.24 (m, 1H), 8.19 (s, 2H), 8.03 (d, 1H, J = 12.0 Hz), 8.02-7.84 (m, 4H), 7.60-7.44 (m, 1H), 7.34-7.24 (m, 1H), 7.10 (d, 1H, J = 7.2 Hz), 4.52- 4.40 (m, 1H), 3.70-3.55 (m, 1H), 2.00- 1.35 (m, 8H). 412 410 0.79 Example 6-126

2-((2-(1H-1,2,3-triazol-1-yl)pyridin-4-yl) amino)-6-((cis-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.41 (s, 1H), 8.90 (d, 1H, J = 1.8 Hz), 8.84 (d, 1H, J = 1.5 Hz), 8.32 (d, 1H, J = 6.0 Hz), 8.10-7.86 (m, 6H), 7.54 (br, 1H), 7.25 (dd, 1H, J = 1.8, 6.0 Hz), 7.14 (d, 1H, J = 7.2 Hz), 4.58- 4.46 (m, 1H), 3.69-3.57 (m, 1H), 1.95- 1.25 (m, 8H). 412 410 0.86 Example 6-127

2-((5-(1H-imidazol-1-yl)pyridin-3-yl)amino)- 6-((cis-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.03 (s, 1H), 9.75-9.70 (m, 1H), 9.07 (d, 1H, J = 2.1 Hz), 8.59 (d, 1H, J = 2.1 Hz), 8.48-8.44 (m, 1H), 8.39- 8.36 (m, 1H), 8.19-7.85 (m, 6H), 7.45 (br, 1H), 7.11 (d, 1H, J = 6.0 Hz), 4.28-4.16 (m, 1H), 3.60-3.40 (m, 1H), 1.90-1.50 (m, 8H). 411 409 0.57 Example 6-128

2-((2-(1-imidazol-1-yl)pyridin-4-yl)amino)- 6-((cis-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.35 (s, 1H), 9.85 (s, 1H), 8.47 (s, 1H), 8.40 (d, 1H, J = 6.0 Hz), 8.08- 7.94 (m, 7H), 7.87 (s, 1H), 7.55 (br, 1H), 7.16 (d, 1H, J = 6.0 Hz), 4.36- 4.24 (m, 1H), 3.70-3.58 (m, 1H), 2.00-1.30 (m, 8H). 411 409 0.63 Example 6-129

2-((5-(1H-pyrazol-1-yl)pyridin-3-yl)amino)- 6-((cis-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.97 (s, 1H), 8.84-8.80 (m, 1H), 8.74-8.66 (m, 1H), 8.67 (d, 1H, J = 2.4 Hz), 8.62-8.54 (m, 1H), 8.00 (d, 1H, J = 11.7 Hz), 8.00-7.77 (m, 5H), 7.42 (br, 1H), 7.03 (d, 1H, J = 6.6 Hz), 6.64- 6.61 (m, 1H), 4.40-4.28 (m, 1H), 3.62- 3.48 (m, 1H), 1.90-1.25 (m, 8H). 411 409 0.82 Example 6-130

2-((2-(1H-pyrazol-1-yl)pyridin-4-yl)amino)- 6-((cis-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.26 (s, 1H), 8.62-8.58 (m, 2H), 8.21 (d, 1H, J = 6.0 Hz), 8.01 (d, 1H, J = 12.6 Hz), 8.01-7.92 (m, 1H), 7.86- 7.74 (m, 4H), 7.60-7.44 (m, 1H), 7.13 (dd, 1H, J = 1.4, 6.0 Hz), 7.06 (d, 1H, J = 7.2 Hz), 6.59-6.55 (m, 1H), 4.60- 4.46 (m, 1H), 3.73-3.60 (m, 1H), 1.95- 1.35 (m, 8H). 411 409 0.93 Example 6-131

2-((2-(1H-pyrrol-3-yl)pyridin-4-yl)amino)-6- ((cis-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 13.99 (br, 1H), 12.76 (s, 1H), 11.78-11.68 (m, 1H), 8.29 (d, 1H, J = 6.6 Hz), 8.20-8.04 (m, 3H), 8.00-7.86 (m, 4H), 7.82-7.64 (m, 2H), 7.25 (d, 1H, J = 6.0 Hz), 7.04-7.00 (m, 1H), 6.88-6.84 (m, 1H), 4.40-4.28 (m, 1H), 3.68-3.52 (m, 1H), 1.95-1.25 (m, 8H). 410 408 0.65 Example 6-132

(R)-2-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)- 6-((2-amino-1-phenylethyl)amino)-5- fluoronicotinamide HCl 433 431 1.03 Example 6-133

(R)-6-((2-amino-1-phenylethyl)amino)-5- fluoro-2-((2-methoxypyridin-4-yl)amino) nicotinamide HCl 397 395 0.66 Example 6-134

(R)-6-((2-amino-1-phenylethyl)amino)-5- fluoro-2-(quinolin-7-ylamino)nicotinamide HCl CD3OD 300 MHz δ: 8.92 (d, 2H, J = 5.9 Hz), 8.69 (s, 1H), 8.10 (d, 1H, J = 9.2 Hz), 7.92- 7.73 (m, 3H), 7.48 (d, 2H, J = 6.6 Hz), 7.34-7.16 (m, 3H), 5.94 (d, 1H, J = 8.1 Hz), 3.59-3.40 (2H, m). 417 415 0.77 Example 6-135

6-(((1R,2S)-2-amino-1,2-diphenylethyl)amino)- 5-fluoro-2-(quinolin-6-ylamino)nicotinamide 6-(((1S,2R)-2-amino-1,2-diphenylethyl)amino)- 5-fluoro-2-(quinolin-6-ylamino)nicotinamide HCl 493 491 0.81 Example 6-136

6-(((1R,2S)-2-amino-1,2-diphenylethyl)amino)- 5-fluoro-2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide 6-(((1S,2R)-2-amino-1,2-diphenylethyl)amino)- 5-fluoro-2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 496 494 0.97 Example 6-137

6-(((1R,2S)-2-amino-1,2-diphenylethyl)amino)- 2-((3,5-dimethoxyphenyl)amino)-5- fluoronicotinamide 6-(((1S,2R)-2-amino-1,2-diphenylethyl)amino)- 2-((3,5-dimethoxyphenyl)amino)-5- fluoronicotinamide HCl 502 501 1.08 Example 6-138

2-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-6- (((1R,2S)-2-amino-1,2-diphenylethyl)amino)-5- fluoronicotinamide 2-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-6- (((1S,2R)-2-amino-1,2-diphenylethyl)amino)-5- fluoronicotinamide HCl 509 507 1.13 Example 6-139

6-((1R,2S)-2-amino-1,2-diphenylethyl)amino)- 5-fluoro-2-((2-methoxypyridin-4-yl)amino) nicotinamide 6-(((1S,2R)-2-amino-1,2-diphenylethyl)amino)- 5-fluoro-2-((2-methoxypyridin-4-yl)amino) nicotinamide HCl 473 471 0.77 Example 6-140

6-(((1R,2S)-2-amino-1,2-diphenylethyl)amino)- 5-fluoro-2-((5-methylpyridin-3-yl)amino) nicotinamide 6-(((1S,2R)-2-amino-1,2-diphenylethyl)amino)- 5-fluoro-2-((5-methylpyridin-3-yl)amino) nicotinamide HCl 458 456 0.79 Example 6-141

6-(((1R,2S)-2-amino-1,2-dipenylethyl)amino)- 5-fluoro-2-(quinolin-7-ylamino)nicotinamide 6-(((1S,2R)-2-amino-1,2-diphenylethyl)amino)- 5-fluoro-2-(quinolin-7-ylamino)nicotinamide HCl CD3OD 300 MHz δ: 9.02-8.95 (m, 2H), 8.52 (s, 1H), 8.24 (d, 1H, J = 8.9 Hz), 8.02 (dd, 1H, J = 9.1, 1.8 Hz), 7.85-7.60 (m, 6H), 7.46-7.30 (m, 6H), 6.11 (d, 1H, J = 9.2 Hz), 4.85-4.83 (m, 1H). 493 491 0.88 Example 6-142

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((1-methyl-1H-indazol-5-yl) amino)nicotinamide HCl 400 398 0.95 Example 6-143

(R)-2-((2-(1H-1,2,3-triazol-1-yl)pyridin-4-yl) amino)-6-((1-amino-4-methylpentan-2-yl) amino)-5-fluoronicotinamide HCl 414 412 0.97 Example 6-144

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 2-((5-cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 387 385 0.84 Example 6-145

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 2-((2-ethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl 391 389 0.79 Example 6-146

2-((2-(2H-1,2,3-triazol-2-yl)pyridin-4-yl) amino)-6-(((1R,2S)-2-aminocyclohexyl)amino)- 5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.37 (s, 1H), 8.70-8.60 (m, 1H), 8.36-8.24 (m, 1H), 8.19 (s, 2H), 8.03 (d, 1H, J = 12.0 Hz), 8.02-7.84 (m, 4H), 7.60-7.44 (m, 1H), 7.34-7.24 (m, 1H), 7.10 (d, 1H, J = 7.2 Hz), 4.52-4.40 (m, 1H), 3.70-3.55 (m, 1H), 2.00-1.35 (m, 8H). 412 410 0.79 Example 6-147

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 2-(benzo[d]thiazol-5-ylamino)-5- fluoronicotinamide HCl 403 401 1.01 Example 6-148

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((2-methylquinoxalin-6-yl)amino) nicotinamide HCl 412 410 0.98 Example 6-149

6-(((3S)-4-aminopentan-2-yl)amino)-5- fluoro-2-(quinolin-6-ylamino)nicotinamide HCl 383 381 0.61 Example 6-150

6-(((4S)-4-aminohexan-3-yl)amino)-5-fluoro- 2-(quinolin-6-ylamino)nicotinamide HCl 397 395 0.66 Example 6-151

6-(((5S)-5-amino-2-methylheptan-4-yl)amino)- 5-fluoro-2-(quinolin-6-ylamino)nicotinamide HCl 425 423 0.79 Example 6-152

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((6-methyl-5-(1H-1,2,3-triazol-1-yl)pyridin-3- yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 12.00 (s, 1H), 8.68-8.66 (m, 1H), 8.63 (d, 1H, J = 2.7 Hz), 8.50 (d, 1H, J = 2.7 Hz), 8.03 (s, 1H), 7.98 (d, 1H, J = 12.6 Hz), 7.94-7.70 (m, 4H), 7.41 (br, 1H), 7.01 (d, 1H, J = 6.6 Hz), 4.16-4.04 (m, 1H), 3.50-3.36 (m, 1H), 2.31 (s, 3H), 1.80-1.00 (m, 8H). 426 424 0.75 Example 6-153

(R)-2-((2-(1H-1,2,4-triazol-1-yl)pyridin-4-yl) amino)-6-((1-amino-4-methylpentan-2-yl) amino)-5-fluoronicotinamide HCl 414 412 0.96 Example 6-154

(R)-2-((2-(2H-1,2,3-triazol-2-yl)pyridin-4-yl) amino)-6-((1-amino-4-methylpentan-2-yl) amino)-5-fluoronicotinamide HCl 414 412 0.93 Example 6-155

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((2-(furan-3-yl)pyridin-4-yl) amino)nicotinamide HCl 413 411 0.87 Example 6-156

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 2-((2,6-dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl 407 405 1.09 Example 6-157

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((2-(2-methoxyethoxy)pyridin-4- yl)amino)nicotinamide HCl 421 419 0.82 Example 6-158

6-(((2S)-2-amino-4-methylpentan-3-yl)amino)- 5-fluoro-2-(quinolin-6-ylamino)nicotinamide HCl 397 395 0.72 Example 6-159

6-(((2S)-2-amino-5-methylhexan-3-yl)amino)- 5-fluoro-2-(quinolin-6-ylamino)nicotinamide HCl 411 409 0.8 Example 6-160

(R)-6-((1-amino-3-methylbutan-2-yl)amino)- 5-fluoro-2-(quinolin-6-ylamino)nicotinamide HCl 383 381 0.69 Example 6-161

(R)-6-((1-aminopentan-2-yl)amino)-5-fluoro- 2-(quinolin-6-ylamino)nicotinamide HCl 383 381 0.71 Example 6-162

(R)-6-((1-amino-3,3-dimethylbutan-2-yl) amino)-5-fluoro-2-(quinolin-6-ylamino) nicotinamide HCl 397 395 0.75 Example 6-163

6-((cis-2-aminocyclohexyl)amino)-2-((2- chloropyridin-4-yl)amino)-5- fluoronicotinamide HCl 379 381 377 379 0.84 Example 6-164

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((6-(phenylamino)pyridin-3-yl)amino) nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.37 (d, 1H, J = 2.6 Hz), 7.92 (dd, 1H, J = 2.5, 8.8 Hz), 7.88 (d, 1H, J = 11.9 Hz), 7.54-7.46 (m, 2H), 7.41-7.32 (m, 2H), 7.11-6.99 (m, 2H), 4.22-4.10 (m, 1H), 3.66-3.58 (m, 1H), 1.93-1.36 (m, 8H). 436 434 0.83 Example 6-165

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-mopholinopyridin-3-yl)amino) nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.43 (d, 1H, J = 2.6 Hz), 8.03 (dd, 1H, J = 2.5 Hz, 9.4 Hz), 7.91 (d, 1H, J = 12.2 Hz), 7.24 (d, 1H, J = 9.6 Hz), 4.29-4.17 (m, 1H), 3.81-3.73 (m, 4H), 3.61-3.51 (m, 1H), 3.59-3.47 (m, 4H), 1.93-1.36 (m, 8H). 430 428 0.67 Example 6-166

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-(2-fluorophenyl)pyridin-3-yl) amino)fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.05 (s, 1H), 8.87 (d, 1H, J = 2.1 Hz), 8.56-8.51 (m, 1H), 8.46-8.42 (m, 1H), 8.00 (d, 1H, J = 12.6 Hz), 8.00- 7.76 (m, 4H), 7.74-7.65 (m, 1H), 7.59- 7.50 (m, 1H), 7.46-7.35 (m, 3H), 7.06 (d, 1H, J = 6.6 Hz), 4.20-4.08 (m, 1H), 3.60-3.50 (m, 1H), 1.85-105 (m, 8H). 439 437 0.88 Example 6-167

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5- cycylopropylpyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.01 (s, 1H), 9.15-9.08 (m, 1H), 8.26-8.20 (m, 1H), 7.10-7.90 (m, 6H), 7.55-7.40 (br, 1H), 7.06 (d, 1H, J = 6.6 Hz), 4.37-4.26 (m, 1H), 3.58-3.46 (m, 1H), 2.18-2.08 (m, 1H), 1.94-1.36 (m, 8H), 1.16-1.06 (m, 2H), 1.00-0.90 (m, 2H). 385 383 0.65 Example 6-168

2-((5-(1H-pyrazol-1-yl)pyridin-3-yl)amino)- 6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.97 (s, 1H), 8.84-8.80 (m, 1H), 8.74-7.66 (m, 1H), 8.67 (d, 1H, J = 2.4 Hz), 8.62-8.54 (m, 1H), 8.00 (d, 1H, J = 11.7 Hz), 8.00-7.77 (m, 5H), 7.42 (br, 1H), 7.03 (d, 1H, J = 6.6 Hz), 6.64-6.61 (m, 1H), 4.40-4.28 (m, 1H), 3.62-3.48 (m, 1H), 1.90-1.25 (m, 8H). 411 409 0.82 Example 6-169

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((2-propoxypyridin-4-yl)amino) nicotinamide HCl 403 401 0.72 Example 6-170

(R)-2-((5-(1H-pyrazol-1-yl)pyridin-3-yl) amino)-6-((1-amino-4-methylpentan-2-yl) amino)-5-fluoronicotinamide HCl 413 411 0.94 Example 6-171

6-((1-(aminomethyl)cyclopropyl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl 367 365 0.61 Example 6-172

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((7-methoxyquinolin-3-yl)amino) nicotinamide HCl 425 423 0.78 Example 6-173

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((7-(2-methoxyethoxy)quinolin-3-yl) amino)nicotinamide HCl 469 467 0.79 Example 6-174

6-(((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-((7-methoxyquinolin-3-yl)amino) nicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoro-2-((7-methoxyquinolin-3-yl)amino) nicotinamide HCl 399 397 0.7 Example 6-175

6-((cis-2-aminocyclopentyl)amino)-5-fluoro- 2-(quinolin-6-yl)amino)nicotinamide HCl 381 379 0.62 Example 6-176

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((7-methoxyquinolin-3-yl)amino) nicotinamide HCl 427 425 0.94 Example 6-177

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 2-((5,6-dimethylpyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.06 (s, 1H), 9.21 (s, 1H), 8.19 (s, 1H), 8.06-7.88 (m, 4H), 7.44 (s, 1H), 7.29-7.20 (m, 2H), 4.45-4.36 (m, 1H), 3.02 (s, 2H), 2.59 (s, 3H), 2.38 (s, 3H), 1.68-1.50 (m, 2H), 1.45-1.35 (m, 1H), 0.80 (dd, 6H, J = 12.9, 6.3 Hz). 375 373 0.72 Example 6-178

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl 383 381 0.65 Example 6-179

6-(((2S,3S)-2-aminopentan-3-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl 383 381 0.65 Example 6-180

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 2-((5-chloropyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.92 (br, 1H), 8.67 (d, 1H, J = 2.0 Hz), 8.29 (t, 1H, J = 2.0 Hz), 8.18 (1H, d, J = 2.0 Hz), 7.95 (d, 1H, J = 12.6 Hz), 7.90-7.80 (m, 3H), 7.37 (s, 1H), 7.19-7.10 (m, 1H), 4.37 (s, 2H), 3.04 (s, 2H), 1.68-1.50 (m, 2H), 1.45-1.35 (m, 1H), 0.85 (6H, dd, J = 12.9, 6.3 Hz). 382 380 1 Example 6-181

6-(((2S,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl 369 367 0.59 Example 6-182

6-(((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-((quinolin-7-yl)amino)nicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoro-2-((quinolin-7-yl)amino)nicotinamide HCl 369 367 0.56 Example 6-183

6-(((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-((7-(2-methoxyethoxy)quinolin-3-yl) amino)nicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoro-2-((7-(2-methoxyethoxy)quinolin-3-yl) amino)nicotinamide HCl 443 441 0.71 Example 6-184

6-(((2R,3S)-3-aminobutan-2-yl)amino)-2-((1- ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-2-((1- ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 386 384 0.82 Example 6-185

6-(((2R,3S)-3-aminobutan-2-yl)amino)-2- ((2,3-dimethylquinoxalin-6-yl)amino)-5- fluoronicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-2- ((2,3-dimethylquinoxalin-6-yl)amino)-5- fluoronicotinamide HCl 398 396 0.81 Example 6-186

(R)-6-((2-amino-1-cyclopropylethyl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl 381 379 0.65 Example 6-187

6-(((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-((2-propoxypyridin-4-yl)amino) nicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoro-2-((2-propoxypyridin-4-yl)amino) nicotinamide HCl 377 375 0.65 Example 6-188

6-(((2R,3S)-3-aminobutan-2-yl)amino)-2- (benzo[d]thiazol-5-ylamino)-5- fluoronicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-2- (benzo[d]thiazol-5-ylamino)-5- fluoronicotinamide HCl 375 373 0.82 Example 6-189

2-((2-(2H-1,2,3-triazol-2-yl)pyridin-4-yl) amino)-6-(((2R,3S)-3-aminobutan-2-yl)amino)- 5-fluoronicotinamide 2-((2-(2H-1,2,3-triazol-2-yl)pyridin-4-yl) amino)-6-(((2S,3R)-3-aminobutan-2-yl)amino)- 5-fluoronicotinamide HCl 386 384 0.7 Example 6-190

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((7-methoxyquinolin-3-yl)amino) nicotinamide HCl 413 411 0.76 Example 6-191

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((6-morpholinopyridin-3-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 11.63 (br, 1H), 8.87 (br, 1H), 8.09 (br, 3H), 7.98-7.75 (m, 4H), 7.38-7.23 (m, 2H), 7.16-7.08 (m, 1H), 4.60-4.45 (m, 1H), 3.79-3.73 (m, 4H), 3.65-3.58 (m, 4H), 2.98 (s, 2H), 1.53-1.18 (m, 4H), 0.88-0.75 (m, 6H). 433 431 0.76 Example 6-192

2-((5-(1H-pyrazol-1-yl)pyridin-3-yl)amino)- 6-(((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoronicotinamide 2-((5-(1H-pyrazol-1-yl)pyridin-3-yl)amino)- 6-(((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.19 (br, 1H), 8.87 (s, 2H), 8.84 (s, 1H), 8.72 (d, 1H, J = 2.6 Hz), 8.12- 8.00 (m, 5H), 7.89 (d, 1H, J = 1.3 Hz), 7.54-7.40 (m, 1H), 7.33 (d, 1H, J = 7.9 Hz), 6.66 (t, 1H, J = 2.3 Hz), 4.54- 4.42 (m, 1H), 3.47-3.36 (m, 1H), 1.29- 1.16 (m, 6H). 385 383 0.73 Example 6-193

6-(((2R,3S)-3-aminobutan-2-yl)amino)-2-((5- cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-2-((5- cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.21 (br, 1H), 9.42 (d, 1H, J = 2.0 Hz), 8.35 (d, 1H, J = 1.3 Hz), 8.22 (br, 3H), 8.06-7.95 (m, 3H), 7.52-7.44 (m, 1H), 7.41 (d, 2H, J = 9.2 Hz), 4.46- 4.35 (m, 1H), 3.65-3.56 (m, 1H), 2.21- 2.12 (m, 2H), 1.32-1.26 (m, 3H), 1.20- 1.05 (m, 3H), 1.00-0.95 (m, 2H). 359 357 0.57 Example 6-194

6-(((2R,3S)-3-aminobutan-2-yl)amino)-2- ((5,6-dimethylpyridin-3-yl)amino)-5- fluoronicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-2- (5,6-dimethylpyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.15 (br, 1H), 9.30 (s, 1H), 8.16 (br, 3H), 8.06-7.90 (m, 2H), 7.54-7.42 (m, 3H), 4.44-4.30 (m, 1H), 3.64-3.54 (m, 1H), 2.59 (s, 3H), 2.38 (s, 3H), 1.35-1.22 (m, 6H). 347 345 0.52 Example 6-195

6-(((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-((5-phenylpyridin-3-yl)amino) nicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoro-2-((5-phenylpyridin-3-yl)amino)- nicotinamide HCl DMSO- d6 300 MHz δ: 12.14 (br, 1H), 9.23 (s, 1H), 8.72 (s, 1H), 8.55 (s, 1H), 8.05-7.97 (m, 6H), 7.87-7.82 (m, 1H), 7.58-7.50 (m, 4H), 7.28 (d, 1H, J = 8.6 Hz), 4.36 (s, 1H), 3.62-3.54 (m, 1H), 1.21 (t, 3H, J = 9.9 Hz), 1.14 (dd, 3H, J = 11.6, 6.9 Hz). 395 393 0.75 Example 6-196

6-(((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-((2-methylquinoxalin-6-yl)amino) nicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoro-2-((2-methylquinoxalin-6-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 12.14 (br, 1H), 8.74 (s, 1H), 8.52 (t, 1H, J = 4.3 Hz), 8.03-7.87 (m, 7H), 7.74-7.68 (m, 1H), 7.46-7.30 (m, 1H), 7.19 (d, 1H, J = 8.6 Hz), 4.41 (t, 1H, J = 5.6 Hz), 3.60 (s, 1H), 2.65 (s, 3H), 1.37-1.30 (m, 6H). 384 382 0.78 Example 6-197

6-(((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-((1-(2-methoxyethyl)-1H-indazol-5- yl)amino)nicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoro-2-((1-(2-methoxyethyl)-1H-indazol-5- yl)amino)nicotinamide HCl 416 414 0.79 Example 6-198

6-(((2R,3S)-3-aminopentan-2-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.90-8.83 (m, 1H), 8.65 (d, 1H, J = 8.3 Hz), 8.42-8.36 (m, 1H), 8.13-8.02 (m, 2H), 7.95 (d, 1H, J = 12.2 Hz), 7.77 (dd, 1H, J = 4.8, 8.4 Hz), 4.53- 4.42 (m, 1H), 3.38-3.28 (m, 1H), 1.72- 1.50 (m, 2H), 1.30 (d, 3H, J = 6.9 Hz), 0.75 (t, 3H, J = 6.9 Hz). 383 381 0.62 Example 6-199

6-(((3R,4S)-4-aminohexan-3-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.89 (dd, 1H, J = 1.3, 5.0 Hz), 8.67 (d, 1H, J = 7.6 Hz), 8.41 (s, 1H), 8.11- 8.08 (m, 2H), 7.96 (d, 1H, J = 12.6 Hz), 7.80 (dd, 1H, J = 4.8, 8.4 Hz), 4.40-4.28 (m, 1H), 3.34-3.22 (m, 1H), 1.90-1.45 (m, 4H), 0.98 (t, 3H, J = 7.3 Hz), 0.81 (t, 3H, J = 7.4 Hz). 397 395 0.68 Example 6-200

6-(((3S,4R)-3-aminoheptan-4-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.88-8.83 (m, 1H), 8.58-8.51 (m, 1H), 8.32 (s, 1H), 8.08-8.03 (m, 2H), 7.95 (d, 1H, J = 12.2 Hz), 7.73 (dd, 1H, J = 5.0, 8.3 Hz), 4.47-4.37 (m, 1H), 3.30-3.20 (m, 1H), 1.75-1.21 (m, 6H), 0.90 (t, 3H, J = 7.3 Hz), 0.79 (t, 3H, J = 7.4 Hz). 411 409 0.74 Example 6-201

6-(((4R,5S)-5-amino-2-methylheptan-4-yl) amino)-5-fluoro-2-((quinolin-6-yl)amino) nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.85-8.79 (m, 1H), 8.48-8.40 (m, 1H), 8.24 (s, 1H), 8.05-8.00 (m, 2H), 7.94 (d, 1H, J = 12.2 Hz), 7.3-7.63 (m, 1H), 4.52-4.38 (m, 1H), 3.29-3.13 (m, 1H), 1.74-1.20 (m, 5H), 1.02-0.83 (m, 6H), 0.74 (t, 3H, J = 7.4 Hz). 425 423 0.85 Example 6-202

6-(((2S,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.91 (dd, 1H, J = 1.3, 5.0 Hz), 8.70-8.61 (m, 2H), 8.15-8.10 (m, 1H), 8.02 (dd, 1H, J = 2.5, 9.1 Hz), 7.97 (d, 1H, J = 12.2 Hz), 7.85 (dd, 1H, J = 5.1, 8.4 Hz), 4.43-4.30 (m, 1H), 3.56- 3.42 (m, 1H), 1.32 (d, 6H, J = 6.6 Hz). 369 367 0.61 Example 6-203

(S)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl 397 395 0.78 Example 6-204

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((7-methoxyquinolin-3-yl)amino) nicotinamide HCl 427 425 0.84 Example 6-205

6-(((2S,3R)-2-aminoheptan-3-yl)amino)-5- fluoro-2-((7-methoxyquinolin-3-yl)amino) nicotinamide HCl 441 439 0.92 Example 6-206

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((7-methoxyquinolin-3-yl) amino)nicotinamide HCl 441 439 0.92 Example 6-207

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl CD3OD 300 MHz δ: 9.03-8.93 (m, 2H), 8.62 (d, J = 2.0 Hz), 8.30 (dd, 1H, J = 9.2, 2.3 Hz), 8.18 (d, 1H, J = 9.6 Hz), 7.99 (dd, 1H, J = 8.4, 5.4 Hz), 7.88 (d, 1H, J = 12.3 Hz), 4.66-4.57 (m, 1H), 3.71-3.60 (m, 1H), 1.84-1.41 (m, 4H), 1.37 (d, 3H, J = 6.9 Hz), 1.00 (t, 3H, J = 7.3 Hz). 397 395 0.71 Example 6-208

6-(((2S,3R)-2-aminoheptan-3-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl CD3OD 300 MHz δ: 9.01 (d, 1H, J = 8.3 Hz), 8.95 (dd, 1H, J = 5.3, 1.0 Hz), 8.61 (d, 1H, J = 2.3 Hz), 8.30 (dd, 1H, J = 9.4, 2.1 Hz), 8.18 (d, 1H, J = 9.2 Hz), 8.00 (dd, 1H, J = 8.4, 5.4 Hz), 7.88 (d, 1H, J = 12.0 Hz), 4.67-4.55 (m, 1H), 3.7-3.60 (m, 1H), 1.90-1.32 (m, 9H), 0.88 (t, 3H, J = 6.9 Hz). 411 409 0.8 Example 6-209

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((quinolin-6-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 9.03-8.93 (m, 2H), 8.58 (d, 1H, J = 2.3 Hz), 8.33 (dd, 1H, J = 9.2, 2.3 Hz), 8.19 (d, 1H, J = 9.2 Hz), 8.00 (dd, 1H, J = 8.4, 5.4 Hz), 7.88 (d, 1H, J = 12.0 Hz), 4.73-4.63 (m, 1H), 3.69-3.57 (m, 1H), 1.84-1.31 (m, 6H), 0.99 (dd, 6H, J = 13.5, 6.6 Hz). 411 409 0.79 Example 6-210

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 386 384 0.81 Example 6-211

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((1-ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl CD3OD 300 MHz δ: 7.97 (s, 1H), 7.93 (d, 1H, J = 2.0 Hz), 7.76 (d, 1H, J = 11.9 Hz), 7.57 (d, 1H, J = 8.6 Hz), 7.43 (dd, 1H, J = 8.6, 2.0 Hz), 4.85-4.75 (m, 1H), 4.46 (q, 2H, J = 7.3 Hz), 4.18-4.12 (m, 1H), 1.75-1.56 (m, 2H), 1.47 (dd, 3H, J = 13.2, 6.6 Hz), 1.20 (d, 3H, J = 6.6 Hz), 1.05 (t, 3H, J = 7.3 Hz). 400 398 0.88 Example 6-212

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((quinoxalin-6-yl)amino) nicotinamide HCl 398 396 0.91 Example 6-213

6-(((2R,3S)-3-aminobutan-2-yl)amino)-2-((2- ethoxypyridin-4-yl)amino)-5- fluoronicotinamide 6-(((2S,3R)-3-aminobutan-2-yl)amino)-2-((2- ethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl 363 361 0.56 Example 6-214

(R)-6-((1-amino-3-cyclopropylpropan-2-yl) amino)-5-fluoro-2-((quinolin-6-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 12.24 (br, 1H), 8.93 (d, 1H, J = 4.0 Hz), 8.76 (s, 1H), 8.63 (s, 1H), 8.16- 7.96 (m, 9H), 7.82-7.76 (m, 1H), 7.45- 7.35 (m, 1H), 7.26 (d, 1H, J = 8.6 Hz), 4.65-4.55 (m, 1H), 3.40-3.35 (m, 2H), 1.59-1.50 (m, 2H), 0.74-0.64 (m, 1H), 0.28 (d, 2H, J = 7.9 Hz). 395 393 0.69 Example 6-215

(R)-6-((1-amino-3-cyclopropylpropan-2-yl) amino)-5-fluoro-2-((7-methoxyquinolin-3-yl) amino)nicotinamide HCl 425 423 0.83 Example 6-216

6-(((2R,3S)-3-aminobutan-2-yl)amino)-2-((5- chloropyridin-3-yl)amino)-5- fluoronicotinamide HCl 354 352 0.78 Example 6-217

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((quinolin-6-yl)amino) nicotinamide HCl 409 407 0.79 Example 6-218

2-((5-(1H-pyrazol-1-yl)pyridin-3-yl)amino)- 6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoronicotinamide HCl 399 397 0.82 Example 6-219

2-((5-(1H-pyrazol-1-yl)pyridin-3-yl)amino)- 6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.03 (br, 1H), 8.92 (s, 1H), 8.73 (d, 1H, J = 2.0 Hz), 8.68-8.62 (m, 2H), 7.99 (d, 1H, J = 12.6 Hz), 7.87-7.75 (m, 5H), 7.48-7.35 (m, 1H), 7.15 (d, 1H, J = 8.6 Hz), 6.64 (t, 1H, J = 2.3 Hz), 4.56-4.45 (m, 1H), 3.55-3.48 (m, 1H), 1.64-1.56 (m, 2H), 1.44-1.36 (m, 2H), 1.21-1.12 (m, 3H), 0.83 (t, 3H, J = 7.3 Hz). 413 411 0.9 Example 6-220

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-(furan-2-yl)pyridin-4-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 12.94 (br, 1H), 8.47 (d, 1H, J = 7.3 Hz), 8.31 (s, 1H), 8.16-8.04 (m, 3H), 8.00-7.94 (m, 3H), 7.84-7.78 (m, 1H), 7.72-7.60 (m, 2H), 7.45-7.38 (m, 1H), 6.87-6.85 (m, 1H), 4.56-4.46 (m, 1H), 3.55-3.49 (m, 1H), 1.78-1.60 (m, 2H), 1.42-1.36 (m, 2H), 1.22-1.18 (m, 3H), 0.87 (t, 3H, J = 7.3 Hz). 413 411 0.72 Example 6-221

2-((2-(2H-1,2,3-triazol-2-yl)pyridin-4-yl) amino)-6-(((2S,3R)-2-aminohexan-3-yl) amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.33 (br, 1H), 8.77 (d, 1H, J = 1.3 Hz), 8.30 (d, 1H, J = 1.3 Hz), 8.27 (s, 1H), 8.02-7.97 (m, 3H), 7.77 (3H, br), 7.56-7.46 (m, 1H), 7.30-7.20 (m, 2H), 4.68-4.58 (m, 1H), 3.65-3.59 (m, 1H), 1.72-1.58 (m, 2H), 1.46-1.30 (m, 2H), 1.19 (d, 3H, J = 6.6 Hz), 0.86 (t, 3H, J = 7.3 Hz). 414 412 0.84 Example 6-222

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((5-(2-fluorophenyl)pyridin-3-yl) amino)nicotinamide HCl 441 439 0.94 Example 6-223

6-(((2S,3R)-2-aminohexan-3-yl)amino)-2-((5- cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 387 385 0.73 Example 6-224

6-(((2R,3R)-3-aminobutan-2-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.88 (d, 1H, J = 5.0 Hz), 8.68-8.62 (m, 2H), 8.12 (d, 1H, J = 9.2 Hz), 8.02 (dd, 1H, J = 2.1, 9.1 Hz), 7.94 (d, 1H, J = 12.2 Hz), 7.84 (dd, 1H, J = 5.1, 8.4 Hz), 4.42-4.30 (m, 1H), 3.56-3.42 (m, 1H), 1.32 (d, 6H, J = 6.6 Hz). 369 367 0.6 Example 6-225

6-(((2S,3R)-3-aminobutan-2-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.91 (dd, 1H, J = 1.4, 5.1 Hz), 8.77 (d, 1H, J = 7.9 Hz), 8.54 (d, 1H, J = 2.0 Hz), 8.17-8.06 (m, 2H), 7.95 (d, 1H, J = 11.9 Hz), 7.86 (dd, 1H, J = 5.1, 8.4 Hz), 4.48-4.36 (m, 1H), 3.61- 3.50 (m, 1H), 1.34 (d, 3H, J = 6.9 Hz), 1.26 (d, 3H, J = 6.9 Hz). 369 367 0.6 Example 6-226

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((1-methyl-1H-indazol-6-yl) amino)nicotinamide HCl 400 398 0.93 Example 6-227

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((1-methyl-1H-indazol-4-yl) amino)nicotinamide HCl 400 398 0.97 Example 6-228

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((quinolin-7-yl)amino)nicotinamide HCl 397 395 0.76 Example 6-229

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((quinolin-5-yl)amino)nicotinamide HCl 397 395 0.75 Example 6-230

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((quinolin-8-yl)amino)nicotinamide HCl 397 395 1.02 Example 6-231

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-(isoquinolin-4-yl)amino) nicotinamide HCl 397 395 0.78 Example 6-232

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((6-methoxyquinolin-3-yl)amino) nicotinamide HCl 427 425 0.93 Example 6-233

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((6-methylpyridin-3-yl)amino) nicotinamide HCl 361 359 0.65 Example 6-234

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((2-methoxypyridin-4-yl)amino) nicotinamide HCl 377 375 0.94 Example 6-235

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((5-phenylpyridin-3-yl)amino) nicotinamide HCl 423 421 0.69 Example 6-236

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 400 398 0.91 Example 6-237

6-(((2S,3R)-2-aminohexan-3-yl)amino)-2-((1- ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.54 (br, 1H), 8.09 (s, 1H), 7.93- 7.87 (m, 3H), 7.79-7.70 (m, 3H), 7.59 (d, 1H, J = 9.2 Hz), 7.35-7.10 (t, 1H, J = 5.6 Hz), 6.89 (d, 1H, J = 7.3 Hz), 4.48-4.36 (m, 2H), 4.26-4.16 (m, 1H), 3.55-3.50 (m, 1H), 1.63-1.54 (m, 2H), 1.44-1.36 (m, 4H), 1.19 (t, 4H, J = 5.0 Hz), 0.87 (t, 3H, J = 6.9 Hz). 414 412 0.98 Example 6-238

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((7-(2-methoxyethoxy)quinolin-3-yl) amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.87 (br, 1H), 8.96 (s, 1H), 8.55 (s,l 1H), 7.98-7.70 (m, 5H), 7.38-7.24 (m, 3H), 7.14-6.98 (m, 1H), 4.30-4.20 (m, 3H), 3.76-3.72 (m, 2H), 3.55-3.20 (m, 5H), 1.62-1.58 (m, 2H), 1.46-1.30 (m, 2H), 1.19 (d, 3H, J = 6.6 Hz), 0.85 (t, 3H, J = 7.3 Hz). 472 470 0.88 Example 6-239

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((1-methoxyisoquinolin-6-yl)amino) nicotinamide HCl 427 425 1.02 Example 6-240

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((quinoxalin-6-yl)amino)nicotinamide HCl 398 396 0.89 Example 6-241

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((isoquinolin-4-yl)amino)nicotinamide HCl 397 395 0.76 Example 6-242

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((6-methoxyquinolin-3-yl)amino) nicotinamide HCl 427 425 0.91 Example 6-243

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((quinolin-8-yl)amino)nicotinamide HCl 397 395 0.99 Example 6-244

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((quinolin-7-yl)amino)nicotinamide HCl 397 395 0.74 Example 6-245

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-methylquinoxalin-6-yl)amino) nicotinamide HCl 412 410 0.92 Example 6-246

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((6-mopholinopyridin-3-yl)amino) nicotinamide HCl 433 431 0.71 Example 6-247

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((5-phenylpyridin-3-yl)amino) nicotinamide HCl 424 422 0.91 Example 6-248

6-(((2S,3R)-2-aminohexan-3-yl)amino)-2- ((2,6-dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.92 (br, 1H), 7.99-7.80 (m, 5H), 7.44-7.30 (m, 1H), 7.13 (d, 1H, J = 8.6 Hz), 6.57 (s, 2H), 4.26-4.16 (m, 1H), 3.81 (s, 6H), 3.52-3.41 (m, 1H), 1.68-1.56 (m, 2H), 1.55-1.40 (m, 2H), 1.30 (d, 3H, J = 6.6 Hz), 0.89 (t, 3H, J = 7.3 Hz). 407 405 1.02 Example 6-249

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-methoxypyridin-4-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 12.32 (br, 2H), 8.10-7.78 (m, 6H), 7.63-7.43 (m, 1H), 7.30-7.08 (m, 2H), 4.33-4.22 (m, 1H), 3.84 (s, 3H), 3.53- 3.45 (m, 1H), 1.67-1.55 (m, 2H), 1.51- 1.18 (m, 5H), 0.95-0.78 (m, 3H). 377 375 0.65 Example 6-250

6-(((2S,3R)-2-aminohexan-3-yl)amino)-2-((5- cyclopropyl-6-methylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 401 399 0.76 Example 6-251

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-4-yl)amino) nicotinamide HCl 400 398 0.94 Example 6-252

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((6-methyl-5-(2H-1,2,3-triazol-2-yl) pyridin-3-yl)amino)nicotinamide HCl 428 426 0.92 Example 6-253

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((6-methoxy-5-(2H-1,2,3-triazol-2- yl)pyridin-3-yl)amino)nicotinamide HCl 444 442 0.94 Example 6-254

2-((2-(2H-1,2,3-triazol-2-yl)pyridin-4-yl) amino)-6-(((2S,3R)-2-aminopentan-3-yl) amino)-5-fluoronicotinamide HCl 400 398 0.77 Example 6-255

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((5-cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 373 371 0.65 Example 6-256

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((2-(furan-2-yl)pyridin-4-yl)amino) nicotinamide HCl 399 397 0.66 Example 6-257

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((5-(2-fluorophenyl)pyridin-3-yl) amino)nicotinamide HCl CD3OD 300 MHz δ: 9.46 (d, 1H, J = 2.3 Hz), 8.73 (s, 1H), 8.62 (s, 1H), 7.91 (d, 1H, J = 11.9 Hz), 7.72 (td, 1H, J = 7.8, 1.7 Hz), 7.64-7.55 (m, 1H), 7.47-7.32 (m, 2H), 4.53-4.43 (m, 1H), 3.62-3.51 (m, 1H), 1.86-1.54 (m, 2H), 1.30 (d, 3H, J = 6.9 Hz), 0.99 (t, 3H, J = 7.1 Hz). 427 425 0.88 Example 6-258

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((quinolin-8-yl)amino)nicotinamide HCl 383 381 0.9 Example 6-259

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((7-(2-methoxyethoxy)quinolin-3-yl) amino)nicotinamide HCl 458 456 0.8 Example 6-260

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((quinoxalin-6-yl)amino)nicotinamide HCl 384 382 0.81 Example 6-261

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((quinolin-7-yl)amino)nicotinamide HCl 383 381 0.64 Example 6-262

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((isoquinolin-4-yl)amino)nicotinamide HCl 383 381 0.67 Example 6-263

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((1-methoxyisoquinolin-6-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 8.38 (d, 1H, J = 9.3 Hz), 8.31 (d, 1H, J = 2.1 Hz), 8.01 (dd, 1H, J = 9.1, 2.1 Hz), 7.88 (d, 1H, J = 12.0 Hz), 7.78 (d, 1H, J = 6.9 Hz), 7.57 (d, 1H, J = 6.9 Hz), 4.56-4.47 (m, 1H), 4.45 (s, 1H), 3.73-3.59 (m, 1H), 1.96-1.62 (m, 2H), 1.36 (d, 3H, J = 6.6 Hz), 1.11 (t, 3H, J = 7.4 Hz). 413 411 0.93 Example 6-264

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((6-methoxyquinolin-3-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 9.66 (d, 1H, J = 2.3 Hz), 8.78 (d, 1H, J = 2.0 Hz), 8.06 (d, 1H, J = 9.2 Hz), 7.89 (d, 1H, J = 12.0 Hz), 7.58 (dd, 1H, J = 9.2, 2.6 Hz), 7.49 (d, 1H, J = 2.6 Hz), 4.52-4.44 (m, 1H), 4.02 (s, 3H), 3.64-3.54 (m, 1H), 1.92-1.58 (m, 2H), 1.32 (d, 3H, J = 6.9 Hz), 1.07 (t, 3H, J = 7.4 Hz). 413 411 0.84 Example 6-265

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((6-morpholinopyridin-3-yl)amino) nicotinamide HCl 418 416 0.64 Example 6-266

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((2-methoxypyridin-4-yl)amino) nicotinamide HCl 363 361 0.58 Example 6-267

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((2,6-dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl 393 391 0.94 Example 6-268

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-4-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 8.08 (s, 1H), 7.87 (d, 1H, J = 7.6 Hz), 7.83 (d, 1H, J = 11.9 Hz), 7.45- 7.38 (m, 1H), 7.17 (d, 1H, J = 8.3 Hz), 4.37-4.27 (m, 1H), 4.06 (s, 1H), 3.36- 3.35 (m, 1H), 1.84-1.57 (m, 2H), 1.30 (d, 3H, J = 6.9 Hz), 1.07 (t, 3H, J = 7.3 Hz). 386 384 0.87 Example 6-269

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((5-fluoropyridin-3-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 9.14 (d, 1H, J = 2.0 Hz), 8.55 (dt, 1H, J = 10.8, 2.1 Hz), 8.43 (s, 1H), 7.89 (d, 1H, J = 11.9 Hz), 4.48-4.38 (m, 1H), 3.68-3.56 (m, 1H), 1.92-1.57 (m, 2H), 1.37 (d, 3H, J = 6.9 Hz), 1.05 (t, 3H, J = 7.4 Hz). 351 349 0.78 Example 6-270

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((5-phenylpyridin-3-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 9.29 (d, 1H, J = 2.3 Hz), 8.80 (s, 1H), 8.65 (d, 1H, J = 1.3 Hz), 7.90 (d, 1H, J = 11.9 Hz), 7.82-7.76 (m, 2H), 7.63-7.56 (m, 3H), 4.47-4.38 (m, 1H), 3.60-3.48 (m, 1H), 1.84-1.56 (m, 2H), 1.25 (d, 3H, J = 6.9 Hz), 1.00 (t, 3H, J = 7.4 Hz). 409 407 0.83 Example 6-271

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((2-(2-methoxyethoxy)quinolin-6-yl) amino)nicotinamide HCl 458 456 1 Example 6-272

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((5-cyclopropyl-6-methylpyridin-3-yl)amino)- 5-fluoronicotinamide HCl 387 385 0.68 Example 6-273

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((6-methoxy-5-(2H-1,2,3-triazol-2- yl)pyridin-3-yl)amino)nicotinamide HCl 430 428 0.86 Example 6-274

(R)-6-((1-aminohexan-2-yl)amino)-5-fluoro- 2-(quinolin-6-ylamino)nicotinamide HCl 397 395 0.78 Example 6-275

6-(((2R,3S)-3-aminobutan-2-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.90 (dd, 1H, J = 1.5, 5.1 Hz), 8.74 (d, 1H, J = 8.3 Hz), 8.53 (d, 1H, J = 2.0 Hz), 8.16-8.05 (m, 2H), 7.95 (d, 1H, J = 12.2 Hz), 7.84 (dd, 1H, J = 5.0, 8.3 Hz), 4.49-4.35 (m, 1H), 3.62- 3.48 (m, 1H), 1.34 (d, 3H, J = 6.6 Hz), 1.26 (d, 3H, J = 6.9 Hz). 369 367 0.59 Example 6-276

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((5-(3-methoxyphenyl)pyridin-3-yl) amino)nicotinamide HCl 439 437 0.83 Example 6-277

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((5-(4-methoxyphenyl)pyridin-3-yl) amino)nicotinamide HCl 439 437 0.8 Example 6-278

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((5-(2-fluoro-3- methoxyphenyl)pyridin-3-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 9.26 (d, 1H, J = 2.0 Hz), 8.93 (s, 1H), 8.58 (s, 1H), 7.91 (t, 1H, J = 5.9 Hz), 7.33 (dd, 2H, J = 5.3, 3.3 Hz), 7.25-7.18 (m, 1H), 4.47 (ddd, 1H, J = 21.1, 11.6, 5.3 Hz), 3.96 (s, 3H), 3.56 (ddd, 1H, J = 15.4, 8.4, 5.1 Hz), 1.80- 1.58 (m, 2H), 1.28 (d, 3H, J = 6.6 Hz), 0.96 (t, 3H, J = 7.3 Hz). 457 455 0.85 Example 6-279

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((5-(2-fluoro-4- methoxyphenyl)pyridin-3-yl)amino) nicotinamide HCl 457 455 0.86 Example 6-280

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((5-(2-fluoro-5- methoxyphenyl)pyridin-3-yl)amino) nicotinamide HCl 457 455 0.99 Example 6-281

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((2-(2-fluoro-3- methoxyphenyl)pyridin-4-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 8.47 (d, 1H, J = 7.3 Hz), 8.43 (s, 1H) , 7.96 (d, 1H, J = 11.2 Hz), 7.91 (s, 1H), 7.47-7.38 (m, 2H), 7.26 (td, 1H, J = 6.8, 2.4 Hz), 4.49-4.43 (m, 1H), 3.99 (s, 3H), 3.59-3.53 (m, 1H), 2.02-1.58 (m, 2H), 1.27 (t, 3H, J = 5.9 Hz), 0.94 (t, 3H, J = 7.6 Hz). 457 455 0.69 Example 6-282

(R)-6-((1-amino-3-cyclopropylpropan-2-yl) amino)-5-fluoro-2-((1-methyl-1H-indazol-5- yl)amino)nicotinamide HCl 398 396 0.88 Example 6-283

(R)-6-((1-amino-3-cyclopropylpropan-2-yl) amino)-5-fluoro-2-((5-phenylpyridin-3-yl) amino)nicotinamide HCl 421 419 0.88 Example 6-284

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((5-(3-methoxyphenyl)pyridin-3-yl) amino)nicotinamide HCl 453 451 0.91 Example 6-285

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((5-(4-methoxyphenyl)pyridin-3-yl) amino)nicotinamide HCl CD3OD 300 MHz δ: 9.32 (d, 1H, J = 2.0 Hz), 8.71 (t, 1H, J = 2.0 Hz), 8.63 (d, 1H, J = 1.3 Hz), 7.90 (d, 1H, J = 11.9 Hz), 7.75 (d, 2H, J = 9.2 Hz), 7.14 (d, 2H, J = 8.6 Hz), 4.51 (dd, 1H, J = 9.9, 4.6 Hz), 3.87 (d, 3H, J = 5.3 Hz), 3.56 (td, 1H, J = 8.1, 4.4 Hz), 1.66-1.38 (m, 4H), 1.27 (d, 3H, J = 6.6 Hz), 0.93 (q, 3H, J = 6.6 Hz). 453 451 0.87 Example 6-286

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((5-(2-fluoro-3- methoxyphenyl)pyridin-3-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 9.23 (s, 1H), 8.95 (s, 1H), 8.57 (s, 1H), 7.90 (d, 1H, J = 11.9 Hz), 7.34 (d, 2H, J = 5.3 Hz), 7.21 (t, 1H, J = 6.6 Hz), 4.56-4.53 (m, 1H), 3.97 (s, 3H), 3.56-3.52 (m, 1H), 1.64-1.62 (m, ,2H), 1.43-1.33 (m, 2H), 1.27 (d, 3H, J = 6.6 Hz), 0.89 (t, 3H, J = 7.3 Hz). 471 469 0.92 Example 6-287

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((5-(2-fluoro-4- methoxyphenyl)pyridin-3-yl)amino) nicotinamide HCl 471 469 0.93 Example 6-288

6-((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((5-(2-fluoro-5- methoxyphenyl)pyridin-3-yl)amino) nicotinamide HCl 471 469 1.06 Example 6-289

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-(2-fluoro-3- methoxyphenyl)pyridin-4-yl)amino) nicotinamide HCl 471 469 0.76 Example 6-290

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-(2-fluoro-5- methoxyphenyl)pyridin-4-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 8.50 (d, 1H, J = 7.3 Hz), 8.33 (s, 1H), 8.03 (br, 1H), 7.95 (d, 1H, J = 11.9 Hz), 7.37 (t, 1H, J = 9.6 Hz), 7.32-7.23 (m, 2H), 4.54-4.51 (m, 1H), 3.89 (s, 3H), 3.59-3.54 (m, 1H), 1.64 (q, 2H, J = 7.5 Hz), 1.42 (dq, 2H, J = 30.9, 7.9 Hz), 1.27 (d, 3H, J = 6.6 Hz), 0.89 (t, 3H, J = 7.3 Hz). 471 469 0.92 Example 6-291

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((5-(4-methoxyphenyl)pyridin-3- yl)amino)nicotinamide HCl 453 451 0.93 Example 6-292

(R)-6-((1-aminohexan-2-yl)amino)-5-fluoro- 2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 400 398 0.94 Example 6-293

(R)-6-((1-aminohexan-2-yl)amino)-5-fluoro- 2-((7-methoxyquinolin-3-yl)amino) nicotinamide HCl 427 425 0.89 Example 6-294

(R)-2-((5-(1H-pyrazol-1-yl)pyridin-3-yl) amino)-6-((1-aminohexan-2-yl)amino)-5- fluoronicotinamide HCl 413 411 0.93 Example 6-295

(R)-6-((1-aminohexan-2-yl)amino)-5-fluoro- 2-((5-phenylpyridin-3-yl)amino)nicotinamide HCl 423 421 0.94 Example 6-296

6-(((2S,3R)-2-aminohexan-3-yl)amino)-2- ((5,6-dimethylpyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.20 (br, 1H), 9.39 (s, 1H), 8.13 (br, 3H), 8.05-7.88 (m, 3H), 7.53-7.42 (m, 1H), 7.29 (d, 1H, J = 9.2 Hz), 4.43-4.30 (m, 1H), 3.56-3.48 (m, 1H), 2.59 (s, 3H), 2.38 (s, 3H), 1.75-1.50 (m, 2H), 1.43-1.21 (m, 5H), 0.82 (dt, 3H, J = 21.8, 7.3 Hz). 375 373 0.66 Example 6-297

6-(((2S,3R)-2-aminohexan-3-yl)amino)-2-((5- chloropyridin-3-yl)amino)-5- fluoronicotinamide HCl 382 380 0.94 Example 6-298

2-((5-(2H-1,2,3-triazol-2-yl)pyridin-3-yl) amino)-6-(((2S,3R)-2-aminohexan-3-yl) amino)-5-fluoronicotinamide HCl 414 412 0.92 Example 6-299

2-((2-(1H-1,2,3-triazol-1-yl)pyridin-4-yl) amino)-6-(((2S,3R)-2-aminohexan-3-yl) amino)-5-fluoronicotinamide HCl 414 412 0.91 Example 6-300

2-((2-(1H-1,2,4-triazol-1-yl)pyridin-4-yl) amino)-6-(((2S,3R)-2-aminohexan-3-yl) amino)-5-fluoronicotinamide HCl 414 412 0.87 Example 6-301

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((5-fluoropyridin-3-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 11.96 (br, 1H), 8.51 (s, 1H), 8.17- 8.13 (m, 2H), 7.97 (d, 1H, J = 12.6 Hz), 7.90-7.80 (m, 4H), 7.45-7.30 (m, 1H), 7.09 (d, 1H, J = 9.2 Hz), 4.30- 4.14 (m, 1H), 3.54-3.45 (m, 1H), 1.64- 1.53 (m, 2H), 1.48-1.20 (m, 5H), 0.87 (t, 3H, J = 6.9 Hz). 365 363 0.87 Example 6-302

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((6-methylpyridin-3-yl)amino) nicotinamide HCl 361 359 0.61 Example 6-303

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-(2-methoxyethoxy)quinolin-6-yl) amino)nicotinamide HCl 472 470 1.08 Example 6-304

6-((1-amino-5,5,5-trifluoropentan-2-yl)amino)- 5-fluoro-2-((quinolin-6-yl)amino)nicotinamide HCl 437 435 0.73 Example 6-305

6-((1-amino-5,5,5-trifluoropentan-2-yl)amino)- 5-fluoro-2-((5-phenylpyridin-3-yl)amino) nicotinamide HCl 463 461 0.96 Example 6-306

6-(((2S,3R)-2-aminohexan-3-yl)amino)-2- ((2,3-dimethylquinoxalin-6-yl)amino)-5- fluoronicotinamide HCl 426 424 0.97 Example 6-307

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-(quinolin-5-ylamino)nicotinamide HCl 397 395 0.73 Example 6-308

6-(((2S,3R)-2-aminohexan-3-yl)amino)-2- (benzo[d]thiazol-5-ylamino)-5- fluoronicotinamide HCl 403 401 0.98 Example 6-309

6-(((2S,3R)-2-aminohexan-3-yl)amino)-2-((2- ethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl 391 389 0.72 Example 6-310

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-(2-methoxyethoxy)pyridin-4-yl) amino)nicotinamide HCl 421 419 0.72 Example 6-311

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-propoxypyridin-4-yl)amino) nicotinamide HCl 405 403 0.78 Example 6-312

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((5-methylpyridin-3-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 9.39 (d, 1H, J = 1.7 Hz), 8.26 (s, 2H), 7.88 (d, 1H, J = 11.9 Hz), 4.59- 4.50 (m, 1H), 3.63-3.51 (m, 1H), 2.53 (s, 3H), 1.8-1.36 (m, 7H), 0.97 (t, 3H, J = 7.3 Hz). 361 359 0.64 Example 6-313

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((1-(2-methoxyethyl)-1H-indazol-5- yl)amino)nicotinamide HCl CD3OD 300 MHz δ: 8.46 (s, 1H), 8.38 (d, 1H, J = 2.0 Hz), 8.24 (d, 1H, J = 11.9 Hz), 8.07 (d, 1H, J = 9.2 Hz), 7.90 (dd, 1H, J = 9.2, 2.0 Hz), 5.05 (t, 2H, J = 5.0 Hz), 4.66- 4.60 (m, 1H), 4.31 (t, 2H, J = 5.0 Hz), 3.76 (s, 3H), 3.96-3.94 (m, 1H), 2.23- 2.04 (m, 2H), 1.68 (d, 3H, J = 7.3 Hz), 1.55 (t, 3H, J = 6.8 Hz). 430 428 0.83 Example 6-314

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((1-(2-methoxyethyl)-1H-indazol-5- yl)amino)nicotinamide HCl 444 442 0.91 Example 6-315

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((2-(2-fluoro-5- methoxyphenyl)pyridin-4-yl)amino) nicotinamide HCl 457 455 0.7 Example 6-316

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((5-(2-fluorophenyl)pyridin-3-yl) amino)nicotinamide HCl 441 439 0.99 Example 6-317

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((5-(3-methoxyphenyl)pyridin-3- yl)amino)nicotinamide HCl 453 451 0.96 Example 6-318

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((5-(2-fluoro-3- methoxyphenyl)pyridin-3-yl)amino) nicotinamide HCl 471 469 0.98 Example 6-319

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((5-(2-fluoro-4- methoxyphenyl)pyridin-3-yl)amino) nicotinamide HCl 471 469 0.99 Example 6-320

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((5-(2-fluoro-5- methoxyphenyl)pyridin-3-yl)amino) nicotinamide HCl 471 469 0.95 Example 6-321

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((2-(2-fluoro-5- methoxyphenyl)pyridin-4-yl)amino) nicotinamide HCl 471 469 0.81 Example 6-322

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 2-((1-ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl CD3OD 300 MHz δ: 8.02 (s, 1H), 7.93 (s, 1H), 7.74 (d, 1H, J = 11.9 Hz), 7.53 (d, 1H, J = 9.2 Hz), 7.43 (d, 1H, J = 9.2 Hz), 4.45 (q, 2H, J = 7.3 Hz), 3.05 (tt, 1H, J = 18.8, 6.4 Hz), 1.65 (tt, 2H, J = 16.8, 5.7 Hz), 1.47 (t, 3H, J = 7.3 Hz), 1.37 (dd, 1H, J = 13.5, 7.6 Hz), 0.91 (t, 6H, J = 7.3 Hz). 414 412 0.99 Example 6-323

(R)-6-(1-aminohexan-2-yl)amino)-2-((1- ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 414 412 1 Example 6-324

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((2-(2-fluorophenyl)pyridin-4-yl) amino)nicotinamide HCl 441 439 0.78 Example 6-325

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((2-(3-methoxyphenyl)pyridin-4- yl)amino)nicotinamide HCl 453 451 0.82 Example 6-326

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((2-(4-methoxyphenyl)pyridin-4- yl)amino)nicotinamide HCl 453 451 0.82 Example 6-327

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((2-(2-fluoro-3- methoxyphenyl)pyridin-4-yl)amino) nicotinamide HCl 471 469 0.8 Example 6-328

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((2-(2-fluoro-4- methoxyphenyl)pyridin-4-yl)amino) nicotinamide HCl 471 469 0.83 Example 6-329

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((2-(2-fluorophenyl)pyridin-4-yl) amino)nicotinamide HCl 427 425 0.66 Example 6-330

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((2-(3-methoxyphenyl)pyridin-4-yl) amino)nicotinamide HCl CD3OD 300 MHz δ: 8.94 (d, 1H, J = 6.6 Hz), 8.84 (s, 1H), 8.51 (br, 1H), 8.44 (d, 1HJ = 11.9 Hz), 8.08 (t, 1H, J = 8.3 Hz), 7.91 (s, 2H), 7.75 (d, 1H, J = 7.3 Hz), 4.97- 4.94 (m, 1H), 4.41 (s, 3H), 4.07-4.04 (m, 1H), 2.23-2.17 (m, 2H), 1.76 (d, 3H, J = 6.6 Hz), 1.46 (t, 3H, J = 7.3 Hz). 439 437 0.7 Example 6-331

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((2-(4-methoxyphenyl)pyridin-4-yl) amino)nicotinamide HCl 439 437 0.71 Example 6-332

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((2-(2-fluoro-4- methoxyphenyl)pyridin-4-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 8.45 (d, 1H, J = 7.3 Hz), 8.20 (s, 1H), 8.02 (br, 1H), 7.95 (d, 1H, J = 11.9 Hz), 7.70 (t, 1H, J = 8.9 Hz), 7.04 (dd, 2H, J = 8.9, 5.6 Hz), 4.46-4.44 (m, 1H), 3.92 (s, 3H), 3.59-3.57 (m, 1H), 1.69 (ddt, 2H, J = 31.7, 13.9, 5.7 Hz), 1.29 (d, 3H, J = 6.6 Hz), 0.97 (t, 3H, J = 7.3 Hz). 457 455 0.72 Example 6-333

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-(2-fluorophenyl)pyridin-4-yl) amino)nicotinamide HCl 441 439 0.73 Example 6-334

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-(3-methoxyphenyl)pyridin-4-yl) amino)nicotinamide HCl 453 451 0.76 Example 6-335

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-(4-methoxyphenyl)pyridin-4-yl) amino)nicotinamide HCl 453 451 0.76 Example 6-336

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((2-(2-fluoro-4- methoxyphenyl)pyridin-4-yl)amino) nicotinamide HCl 471 469 0.77 Example 6-337

(R)-6-((2-amino-1-cyclopropylethyl)amino)-5- fluoro-2-((5-phenylpyridin-3-yl)amino) nicotinamide HCl 407 405 0.82 Example 6-338

(R)-6-((21-aminohexan-2-yl)amino)-5-fluoro- 2-((1-(2-methoxyethyl)-1H-indazol-5-yl) amino)nicotinamide HCl CD3OD 300 MHz δ: 8.04 (d, 1H, J = 1.3 Hz), 7.98 (s, 1H), 7.74 (d, 1H, J = 12.6 Hz), 7.56 (d, 1H, J = 9.2 Hz), 7.43 (dd, 1H, J = 8.9, 2.3 Hz), 4.56 (t, 2H, J = 5.3 Hz), 4.40- 4.30 (m, 2H), 3.81 (t, 2H, J = 5.3 Hz), 3.57-3.53 (m, 1H), 3.27 (s, 3H), 1.65 (tt, 2H, J = 22.5, 7.6 Hz), 1.35 (dq, 4H, J = 22.1, 5.8 Hz), 0.86 (t, 3H, J = 6.9 Hz). 444 442 0.96 Example 6-339

(R)-6-((1-aminohexan-2-yl)amino)-5-fluoro- 2-((1-methyl-1H-indazol-4-yl)amino) nicotinamide HCl 400 398 0.98 Example 6-340

(R)-6-((1-aminohexan-2-yl)amino)-2-((5- cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 387 385 0.76 Example 6-341

(R)-6-((1-aminohexane-2-yl)amino)-2-((5,6- dimethylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 375 373 0.71 Example 6-342

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-ethyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl CD3OD 300 MHz δ: 7.96 (s, 1H), 7.91 (s, 1H), 7.76 (d, 1H, J = 11.9 Hz), 7.56 (d, 1H, J = 9.2 Hz), 7.42 (d, 1H, J = 8.6 Hz), 5.90- 5.75 (m, 1H), 5.02-4.99 (m, 2H), 4.46 (q, 2H, J = 7.3 Hz), 4.29-4.26 (m, 1H), 3.67-3.64 (m, 1H), 2.35-2.10 (m, 2H), 1.70 (br, 1H), 1.48 (t, 3H, J = 7.3 Hz), 1.18 (d, 3H, J = 6.6 Hz). 426 424 0.95 Example 6-343

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((1-(2-methoxyethyl)-1H- indazol-5-yl)amino)nicotinamide HCl CD3OD 300 MHz δ: 7.97 (s, 1H), 7.86 (t, 1H, J = 7.3 Hz), 7.76 (d, 1H, J = 11.9 Hz), 7.58 (d, 1H, J = 9.2 Hz), 7.42 (dd, 1H, J = 9.2, 2.0 Hz), 5.91-5.78 (m, 1H), 5.04-4.96 (m, 2H), 4.57 (t, 2H, J = 5.3 Hz), 4.30- 4.24 (m, 1H), 3.83 (t, 3H, J = 5.3 Hz), 3.45-3.43 (m, 1H), 2.31-2.08 (m, 2H), 1.72 (ddd, 2H, J = 22.5, 14.5, 7.9 Hz), 1.17 (t, 3H, J = 7.3 Hz). 456 454 0.92 Example 6-344

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((quinolin-6-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 12.11 (s, 1H), 8.85 (s, 1H), 8.55- 8.40 (m, 1H), 8.33 (s, 1H), 8.06-7.95 (m, 3H), 7.87 (br, 3H), 7.70-7.62 (m, 1H), 7.50-7.40 (m, 2H), 7.15-7.10 (m, 1H), 5.88-5.74 (m, 1H), 5.00-4.85 (m, 2H), 4.45-4.30 (m, 1H), 3.55-3.48 (m, 1H), 2.25-1.65 (m, 4H), 1.25-1.15 (m, 3H). 409 407 0.73 Example 6-345

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((1-methyl-1H-indazol-5- yl)amino)nicotinamide HCl 412 410 0.93 Example 6-346

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((7-methoxyquinolin-3-yl) amino)nicotinamide HCl 440 438 0.9 Example 6-347

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((quinoxalin-6-yl)amino) nicotinamide HCl 410 408 0.9 Example 6-348

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-(benzo[d]thiazol-5-ylamino)-5- fluoronicotinamide HCl 416 414 0.98 Example 6-349

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((2,6-dimethoxypyridin-4-yl)amino)- 5-fluoronicotinamide HCl 419 417 1.05 Example 6-350

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((5-cyclopropylpyridin-3-yl)amino)- 5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.87 (br, 1H), 8.95 (s, 1H), 8.20- 7.70 (m, 8H), 7.44-7.00 (m, 2H), 5.84- 5.70 (m, 1H), 5.00-4.85 (m, 2H), 4.32- 4.22 (m, 1H), 3.45-3.38 (m, 1H), 2.25- 1.65 (m, 4H), 1.26-1.12 (m, 5H), 0.90- 0.82 (m, 2H). 399 397 0.76 Example 6-351

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((5-phenylpyridin-3-yl) amino)nicotinamide HCl DMSO- d6 300 MHz δ: 12.07 (1H, br, 1H), 9.13 (1H, s, 1H), 8.67 (1H, s, 1H), 8.47 (1H, s, 1H), 8.05-7.77 (6H, m, 6H), 7.57-7.40 (2H, m), 7.24-7.18 (2H, m), 5.80-5.65 (1H, m), 4.94-4.81 (2H, m), 4.36-4.27 (1H, m), 3.45-3.38 (1H, m), 2.20-1.60 (5H, m), 1.20-1.04 (3H, m). 436 434 0.95 Example 6-352

2-((5-(2H-1,2,3-triazol-2-yl)pyridin-3-yl) amino)-6-(((2R,3S)-3-amino-1- cyclopropylbuan-2-yl)amino)-5- fluoronicotinamide HCl 426 424 0.93 Example 6-353

2-((2-(1H-1,2,4-triazol-1-yl)pyridin-4-yl) amino)-6-(((2R,3S)-3-amino-1- cyclopropylbutan-2-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.34 (s, 1H), 9.35 (s, 1H), 8.65 (s, 1H), 8.47 (s, 1H), 8.30 (s, 1H), 8.28 (t, 1H, J = 7.9 Hz), 8.04-7.90 (m, 2H), 7.73 (br, 3H), 7.32-7.22 (m, 2H), 5.86- 5.75 (m, 1H), 4.98-4.83 (m, 2H), 4.68- 4.57 (m, 1H), 3.35-3.28 (m, 1H), 2.20- 1.60 (m, 4H), 1.24-1.16 (m, 3H). 426 424 0.88 Example 6-354

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((isoquinolin-4-yl)amino) nicotinamide HCl 409 407 0.79 Example 6-355

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((2-methoxypyridin-4-yl) amino)nicotinamide HCl 389 387 0.68 Example 6-356

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((1-methyl-1H-indazol-4- yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 12.39 (s, 1H), 8.02-7.92 (m, 2H), 7.91-7.68 (m, 3H), 7.47-7.00 (m, 6H), 5.90-5.76 (m, 1H), 5.05-4.90 (m, 2H), 4.37-4.25 (m, 1H), 4.03 (s, 3H), 3.49- 3.34 (m, 1H), 2.20-1.60 (m, 4H), 1.30- 1.16 (m, 3H). 412 410 0.97 Example 6-357

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((5-fluoropyridin-3-yl) amino)nicotinamide HCl 379 377 0.88 Example 6-358

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-6-yl)amino) nicotinamide HCl 386 384 0.82 Example 6-359

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-6-yl)amino) nicotinamide HCl 400 398 0.89 Example 6-360

(R)-6-((1-aminohexan-2-yl)amino)-5-fluoro- 2-((1-methyl-1H-indazol-6-yl)amino) nicotinamide HCl 400 398 0.89 Example 6-361

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((1-methyl-1H-indazol-6- yl)amino)nicotinamide HCl 412 410 0.86 Example 6-362

6-(((2R,3S)-3-aminopentan-2-yl)amino)-2- ((1-ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 400 398 0.91 Example 6-363

6-(((2R,3S)-3-aminopentan-2-yl)amino)-5- fluoro-2-((1-(2-methoxyethyl)-1H-indazol-5- yl)amino)nicotinamide HCl 430 428 0.84 Example 6-364

6-(((3R,4S)-4-aminohexan-3-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 400 398 0.81 Example 6-365

6-(((3R,4S)-4-aminohexan-3-yl)amino)-2-((1- ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 414 412 0.85 Example 6-366

6-(((3R,4S)-4-aminohexan-3-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-6-yl)amino) nicotinamide HCl 400 398 0.91 Example 6-367

6-(((3R,4S)-4-aminohexan-3-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-4-yl)amino) nicotinamide HCl 400 398 0.96 Example 6-368

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-5-fluoro-2- ((quinolin-6-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 12.25 (s, 1H), 8.86 (d, 1H, J = 6.0 Hz), 8.77 (d, 1H, J = 6.0 Hz), 8.42 (s, 1H), 8.22-7.80 (m, 8H), 7.47-7.35 (m, 1H), 7.31 (d, 1H, J = 8.6 Hz), 3.91- 3.80 (m, 1H), 3.41-3.33 (m, 1H), 1.31 (d, 3H, J = 6.6 Hz), 1.20-1.11 (m, 1H), 0.78-0.33 (m, 4H). 395 393 0.64 Example 6-369

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-5-fluoro-2-((1- methyl-1H-indazol-5-yl)amino)nicotinamide HCl 398 396 0.84 Example 6-370

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-5-fluoro-2-((1- methyl-1H-indazol-6-yl)amino)nicotinamide HCl 398 396 0.85 Example 6-371

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((5- cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 385 383 0.67 Example 6-372

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-5-fluoro-2-((5- fluoropyridin-3-yl)amino)nicotinamide HCl 363 361 0.8 Example 6-373

2-((5-(1H-pyrazol-1-yl)pyridin-3-yl)amino)- 6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.98 (dd, 1H, J = 26.1, 18.2 Hz), 8.76-8.53 (m, 4H), 8.02-7.74 (m, 6H), 7.48-7.25 (m, 2H), 6.64 (dq, 1H, J = 27.1, 9.5 Hz), 3.82-3.72 (m, 1H), 3.41- 3.33 (m, 1H), 1.25-1.05 (m, 4H), 0.63- 0.24 (m, 4H). 411 409 0.84 Example 6-374

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((6-methyl-5-(2H-1,2,3- triazol-2-yl)pyridin-3-yl)amino)nicotinamide HCl 440 438 0.96 Example 6-375

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-methyl-5-(2H-1,2,3-triazol-2-yl) pyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.96 (s, 1H), 8.65 (d, 1H, J = 2.4 Hz), 8.55 (d, 1H, J = 2.4 Hz), 8.22 (s, 2H), 7.98 (d, 1H, J = 12.6 Hz), 7.94- 7.66 (m, 4H), 7.41 (br, 1H), 6.97 (d, 1H, J = 5.4 Hz), 4.24-4.12 (m, 1H), 2.50 (s, 3H), 3.58-3.45 (m, 1H), 1.90- 1.10 (m, 8H). 426 424 0.86 Example 6-376

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-(furan-2-yl)-6-methylpyridin-3- yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 12.00 (s, 1H), 8.88-8.82 (m, 1H), 8.68-8.62 (m, 1H), 8.04-7.84 (m, 6H), 7.45 (br, 1H), 7.12 (d, 1H, J = 3.9 Hz), 7.02 (d, 1H, J = 6.6 Hz), 6.78-6.74 (m, 1H), 4.34-4.22 (m, 1H), 3.60-3.56 (m, 1H), 2.76 (s, 3H), 1.90-1.25 (m, 8H). 425 423 0.76 Example 6-377

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-methoxy-5-(2H-1,2,3-triazol-2- yl)pyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.59 (s, 1H), 8.52 (d, 1H, J = 2.4 Hz), 8.28 (d, 1H, J = 2.4 Hz), 8.13 (s, 2H), 7.94 (d, 1H, J = 12.3 Hz), 7.88- 7.67 (m, 4H), 7.33 (br, 1H), 6.91 (d, 1H, J = 7.2 Hz), 4.17-4.05 (m, 1H), 3.89 (s, 3H), 3.51-3.40 (m, 1H), 1.80- 1.15 (m, 8H). 442 440 0.88 Example 6-378

6-(((3R,4S)-4-aminohexan-3-yl)amino)-2-((5- cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 387 385 0.68 Example 6-379

6-(((3R,4S)-4-aminohexan-3-yl)amino)-2- ((2,6-dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl 407 405 0.98 Example 6-380

6-(((3R,4S)-4-aminohexan-3-yl)amino)-5- fluoro-2-((6-methyl-5-(2H-1,2,3-triazol-2-yl) pyridin-3-yl)amino)nicotinamide HCl 428 426 0.85 Example 6-381

6-(((3R,4S)-4-aminohexan-3-yl)amino)-5- fluoro-2-((2-methoxypyridin-4-yl)amino) nicotinamide HCl 377 375 0.62 Example 6-382

6-(((3R,4S)-4-aminohexan-3-yl)amino)-5- fluoro-2-((5-fluoropyridin-3-yl)amino) nicotinamide HCl 365 363 0.82 Example 6-383

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((1-methyl-1H-indazol-5- yl)amino)nicotinamide HCl CD3OD 300 MHz δ: 7.93 (s, 1H), 7.90 (s, 1H), 7.75 (d, 1H, J = 11.9 Hz), 7.55 (d, 1H, J = 8.6 Hz), 7.43 (dd, 1H, J = 8.9, 1.7 Hz), 4.32-4.28 (m, 1H), 4.07 (s, 3H), 3.38- 3.35 (m, 1H), 1.72-1.57 (m, 1H), 1.35- 1.30 (m, 2H), 1.17 (d, 3H, J = 6.6 Hz), 0.99 (d, 3H, J = 5.9 Hz), 0.91 (d, 3H, J = 5.9 Hz). 414 412 0.95 Example 6-384

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((1-ethyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl CD3OD 300 MHz δ: 7.93 (s, 1H), 7.91 (d, 1H, J = 2.0 Hz), 7.76 (d, 1H, J = 11.9 Hz), 7.56 (d, 1H, J = 8.6 Hz), 7.42 (dd, 1H, J = 9.2, 2.0 Hz), 4.46 (q, 2H, J = 7.3 Hz), 4.36- 4.31 (m, 1H), 3.41-3.39 (m, 1H), 1.73- 1.56 (m, 1H), 1.47 (t, 3H, J = 7.3 Hz), 1.36-1.30 (m, 2H), 1.17 (d, 3H, J = 7.3 Hz), 0.99 (d, 3H, J = 6.6 Hz), 0.92 (d, 3H, J = 6.6 Hz). 428 426 1 Example 6-385

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((1-(2-methoxyethyl)-1H- indazol-5-yl)amino)nicotinamide HCl 458 456 0.96 Example 6-386

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((6-methyl-5-(2H-1,2,3- triazol-2-yl)pyridin-3-yl)amino)nicotinamide HCl 442 440 0.94 Example 6-387

6-(((2S,3R)-2-aminoheptane-3-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 414 412 0.95 Example 6-388

6-(((2S,3R)-2-aminoheptane-3-yl)amino)-2- ((1-ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 428 426 1 Example 6-389

6-(((2S,3R)-2-aminoheptane-3-yl)amino)-5- fluoro-2-((1-(2-methoxyethyl)-1H-indazol-5- yl)amino)nicotinamide HCl 458 456 0.97 Example 6-390

6-(((2S,3R)-2-aminoheptan-3-yl)amino)-5- fluoro-2-((6-methyl-5-(2H-1,2,3-triazol-2-yl) pyridin-3-yl)amino)nicotinamide HCl 442 440 0.95 Example 6-391

6-(((3R,4S)-4-aminohexan-3-yl)amino)-5- fluoro-2-((6-methoxy-5-(2H-1,2,3-triazol-2- yl)pyridin-3-yl)amino)nicotinamide HCl 444 442 0.88 Example 6-392

2-((5-(1H-pyrazol-1-yl)pyridin-3-yl)amino)- 6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.98 (s, 1H), 8.89-8.54 (m, 3H), 8.01-7.70 (m, 6H), 7.50-7.30 (m, 1H), 7.20-7.00 (m, 2H), 6.62 (t, 1H, J = 2.3 Hz), 5.87-5.30 (m, 1H), 4.95-4.82 (m, 2H), 4.56-4.45 (m, 1H), 3.51-3.43 (m, 1H), 2.25-1.62 (m, 4H), 1.21-1.11 (m, 3H). 425 423 0.91 Example 6-393

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((6-methoxy-5-(2H-1,2,3- triazol-2-yl)pyridin-3-yl)amino)nicotinamide HCl 456 454 0.95 Example 6-394

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((2-(2- methoxyethoxy)pyridin-4-yl)amino) nicotinamide HCl 433 431 0.74 Example 6-395

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-fluoro-6-morpholinopyridin-3-yl) amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.48 (s, 1H), 8.10-8.00 (m, 1H), 8.08 (s, 1H), 7.92 (d, 1H, J = 12.2 Hz), 7.87-7.66 (m, 4H), 7.36-7.21 (m, 1H), 6.97-6.88 (m, 1H), 4.23-4.12 (m, 1H), 3.77-3.69 (m, 4H), 3.68-3.59 (m, 1H), 3.28-3.20 (m, 4H), 1.96-1.34 (m, 8H). 448 446 0.91 Example 6-396

6-(((2S,3R)-2-amino-5-methylhex-5-en-3-yl) amino)-5-fluoro-2-(quinolin-6-ylamino) nicotinamide HCl 409 407 0.74 Example 6-397

6-(((2S,3R)-2-amino-5-methylhex-5-en-3-yl) amino)-2-((1-ethyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 427 425 Example 6-398

6-(((3S,4R)-3-aminoheptan-4-yl)amino)-5- fluoro-2-((1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 414 412 0.97 Example 6-399

6-(((3S,4R)-3-aminoheptan-4-yl)amino)-2- ((1-ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 428 426 1.01 Example 6-400

6-(((3S,4R)-3-aminoheptan-4-yl)amino)-5- fluoro-2-((1-(2-methoxyethyl)-1H-indazol-5- yl)amino)nicotinamide HCl CD3OD 300 MHz δ: 7.95 (s, 1H), 7.86 (d, 1H, J = 1.3 Hz), 7.75 (d, 1H, J = 11.9 Hz), 7.57 (d, 1H, J = 8.9 Hz), 7.40 (dd, 1H, J = 9.1, 1.8 Hz), 4.56 (t, 2H, J = 5.1 Hz), 4.31- 4.21 (m, 1H), 3.82 (t, 2H, J = 5.1 Hz), 3.28 (s, 3H), 3.26-3.18 (m, 1H), 1.68- 1.32 (m, 6H), 0.99 (t, 3H, J = 6.9 Hz), 0.75 (t, 3H, J = 7.6 Hz). 458 456 0.96 Example 6-401

6-(((3S,4R)-3-aminoheptan-4-yl)amino)-5- fluoro-2-((2-(2-methoxyethoxy)pyridin-4-yl) amino)nicotinamide HCl 435 433 0.76 Example 6-402

6-(((3S,4R)-3-aminoheptan-4-yl)amino)-2- ((5-cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 401 399 0.77 Example 6-403

6-(((3S,4R)-3-aminoheptan-4-yl)amino)-5- fluoro-2-((6-methyl-5-(2H-1,2,3-triazol-2-yl) pyridin-3-yl)amino)nicotinamide HCl 442 440 0.94 Example 6-404

6-(((3S,4R)-3-aminoheptan-4-yl)amino)-5- fluoro-2-((2-methoxypyridin-4-yl)amino) nicotinamide HCl 391 389 0.71 Example 6-405

6-(((2S,3R)-2-aminoheptan-3-yl)amino)-2- ((2,6-dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl 421 419 1.07 Example 6-406

6-(((2S,3R)-2-aminoheptan-3-yl)amino)-5- fluoro-2-((2-methoxypyridin-4-yl)amino) nicotinamide HCl 391 389 0.72 Example 6-407

6-(((2S,3R)-2-aminoheptan-3-yl)amino)-5- fluoro-2-((2-(2-methoxyethoxy)pyridin-4-yl) amino)nicotinamide HCl 435 433 0.78 Example 6-408

6-(((2S,3R)-2-aminoheptan-3-yl)amino)-2- ((5-cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 401 399 0.77 Example 6-409

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((2,6-dimethoxypyridin-4-yl)amino)- 5-fluoronicotinamide HCl 421 419 1.07 Example 6-410

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((2-methoxypyridin-4-yl) amino)nicotinamide HCl 391 389 0.71 Example 6-411

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((2-(2- methoxyethoxy)pyridin-4-yl)amino) nicotinamide HCl 435 433 0.77 Example 6-412

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((5-cyclopropylpyridin-3-yl)amino)- 5-fluoronicotinamide HCl 401 399 0.76 Example 6-413

6-(((3S,4R)-3-aminoheptan-4-yl)amino)-2- ((2,6-dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl 421 419 1.07 Example 6-414

(R)-6-((1-aminohexan-2-yul)amino)-5-fluoro- 2-((1-(2-fluoroethyl)-1H-indazol-5-yl)amino) nicotinamide HCl 432 430 0.92 Example 6-415

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 5-fluoro-2-((1-(2-fluoroethyl)-1H-indazol-5- yl)amino)nicotinamide HCl 432 430 0.91 Example 6-416

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((1-(2-fluoroethyl)-1H-indazol-5-yl) amino)nicotinamide HCl 418 416 0.79 Example 6-417

6-(((2S,3R)-2-aminohexan-3-yl)amino)-5- fluoro-2-((1-(2-fluoroethyl)-1H-indazol-5-yl) amino)nicotinamide HCl 432 430 0.87 Example 6-418

6-(((2S,3R)-2-aminoheptan-3-yl)amino)-5- fluoro-2-((1-(2-fluoroethyl)-1H-indazol-5-yl) amino)nicotinamide HCl 446 444 0.94 Example 6-419

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((1-(2-fluoroethyl)-1H- indazol-5-yl)amino)nicotinamide HCl 446 444 0.93 Example 6-420

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((1-(2-fluoroethyl)-1H- indazol-5-yl)amino)nicotinamide HCl 444 442 0.88 Example 6-421

(R)-6-((1-aminohexan-2-yl)amino)-2-((1-(2,2- difluoroethyl)-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 450 448 0.96 Example 6-422

(R)-6-((1-amino-4-methylpentan-2-yl)amino)- 2-((1-(2,2-difluoroethyl)-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 450 448 0.96 Example 6-423

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((1-(2,2-difluoroethyl)-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 436 434 0.85 Example 6-424

6-(((2S,3R)-2-aminohexan-3-yl)amino)-2-((1- (2,2-difluoroethyl)-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 450 448 0.76 Example 6-425

6-(((2S,3R)-2-aminoheptan-3-yl)amino)-2- ((1-(2,2-difluoroethyl)-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 464 462 0.99 Example 6-426

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-(2,2-difluoroethyl)-1H-indazol-5- yl)amino)-5-fluoronicotinamide HCl 462 460 0.93 Example 6-427

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((1-methyl-6-oxo-5-(2H-1,2,3-triazol-2-yl)- 1,6-dihydropyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 10.86 (s, 1H), 8.09 (d, 1H, J = 2.7 Hz), 8.04 (s, 2H), 8.01 (d, 1H, J = 2.7 Hz), 7.88 (d, 1H, J = 11.7 Hz), 7.80- 7.60 (m, 4H), 7.25 (br, 1H), 6.79 (d, 1H, J = 7.2 Hz), 4.16-4.05 (m, 1H), 3.62-3.50 (m, 1H), 3.55 (s, 3H), 1.80- 1.15 (m, 8H). 442 440 0.72 Example 6-428

6-((cis-2-aminocyclohexyl)amino)-5-fluoro-2- ((1-methyl-6-oxo-5-(1H-1,2,3-triazol-1-yl)- 1,6-dihydropyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.00 (s, 1H), 8.85 (s, 1H), 8.54 (d, 1H, J = 2.7 Hz), 8.03 (d, 1H, J = 2.7 Hz), 7.95-7.60 (m, 6H), 7.30 (br, 1H), 6.83 (d, 1H, J = 6.6 Hz), 4.28-4.14 (m, 1H), 3.61 (s, 3H), 3.54-3.40 (m, 1H), 2.00-1.15 (m, 8H). 442 440 0.74 Example 6-429

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((2,6- dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.86 (s, 1H), 7.97-7.80 (m, 5H), 7.40-7.22 (m, 3H), 7.26 (d, 1H, J = 8.6 Hz), 6.51 (s, 2H), 3.84-3.78 (s, 6H), 3.70-3.50 (m, 2H), 1.33 (d, 3H, J = 6.6 Hz), 1.24-1.08 (m, 1H), 0.74-0.30 (m, 3H). 405 403 0.98 Example 6-430

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-5-fluoro-2-((2- methoxypyridin-4-yl)amino)nicotinamide HCl 375 373 0.62 Example 6-431

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-5-fluoro-2-((2-(2- methoxyethoxy)pyridin-4-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 12.51 (s, 1H), 8.30-7.70 (m, 6H), 7.60-7.40 (m, 3H), 7.16 (s, 1H), 4.46- 4.40 (m, 2H), 3.78-3.66 (m, 3H), 3.40- 3.36 (m, 1H), 3.25 (s, 3H), 1.33 (d, 3H, J = 6.6 Hz), 1.20-1.08 (m, 1H), 0.70- 0.24 (m, 4H). 419 417 0.69 Example 6-432

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((3-fluoro-2-methoxypyridin-4-yl) amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.10 (dd, 1H, J = 5.6, 5.6 Hz), 7.93 (d, 1H, J = 12.2 Hz), 7.85 (d, 1H, J = 5.9 Hz), 4.35-4.23 (m, 1H), 3.93 (s, 3H), 3.79-3.66 (m, 1H), 1.98-1.41 (m, 8H). 393 391 0.92 Example 6-433

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((2- ethoxy-3-fluoropyridin-4-yl)amino)-5- fluoronicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.07 (dd, 1H, J = 5.3, 5.6 Hz), 7.95 (d, 1H, J = 12.2 Hz), 7.83 (d, 1H, J = 5.6 Hz), 4.38 (q, 2H, J = 6.9 Hz), 4.33- 4.23 (m, 1H), 3.76-3.67 (m, 1H), 2.00- 1.40 (m, 8H), 1.35 (t, 3H, J = 6.9 Hz). 407 405 0.98 Example 6-434

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((5,6- dimethylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 373 371 0.64 Example 6-435

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((5,6-dimethylpyridin-3-yl)amino)- 5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.20 (s, 1H), 9.40 (s, 1H), 8.22- 7.95 (m, 6H), 7.47 (s, 1H), 7.34 (d, 1H, J = 8.6 Hz), 5.85-5.70 (m, 1H), 4.97- 4.78 (m, 2H), 4.44-4.30 (m, 1H), 3.50- 3.44 (m, 1H), 2.62 (s, 3H), 2.39 (s, 3H), 2.25-1.62 (m, 4H), 1.21-1.11 (m, 3H). 387 385 0.73 Example 6-436

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-(1-ethyl-1H-indazol-6-yl)amino)- 5-fluoronicotinamide HCl 426 424 0.96 Example 6-437

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((1-(2-fluoroethyl)-1H- indazol-6-yl)amino)nicotinamide HCl 444 442 N.D Example 6-438

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-(2,2-difluoroethyl)-1H-indazol-6- yl)amino)-5-fluoronicotinamide HCl 462 460 N.D Example 6-439

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((3-fluoro-1-methyl-1H- indazol-5-yl)amino)nicotinamide HCl 430 428 0.99 Example 6-440

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((3-fluoro-1-methyl-1H- indazol-6-yl)amino)nicotinamide HCl 430 428 1.04 Example 6-441

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-ethyl-3-fluoro-1H-indazol-6-yl) amino)-5-fluoronicotinamide HCl 444 442 N.D Example 6-442

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1,3-dimethyl-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 426 424 0.95 Example 6-443

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-ethyl-3-methyl-1H-indazol-5- yl)amino)-5-fluoronicotinamide HCl 440 438 1.01 Example 6-444

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((1-(2-methoxyethyl)-3- methyl-1H-indazol-5-yl)amino)nicotinamide HCl 470 468 N.D Example 6-445

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-(2,2-difluoroethyl)-3-methyl-1H- indazol-5-yl)amino)-5-fluoronicotinamide HCl 476 474 0.95 Example 6-446

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5- chloro-6-(1H-pyrazol-1-yl)pyridin-3-yl) amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.06 (s, 1H), 8.65 (d, 1H, J = 2.7 Hz), 8.54 (d, 1H, J = 2.7 Hz), 8.15 (s, 1H, J = 2.7 Hz), 8.01 (d, 1H, J = 12.6 Hz), 8.00-7.77 (m, 4H), 7.76 (d, 1H, J = 2.1 Hz), 7.47 (br, 1H), 7.03 (d, 1H, J = 6.6 Hz), 6.54-6.50 (m, 1H), 4.35- 4.25 (m, 1H), 3.68-3.56 (m, 1H), 2.00- 1.35 (m, 8H). 445 447 443 445 0.95 Example 6-447

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-fluoro-6-(1H-pyrazol-1-yl) pyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 12.07 (s, 1H), 8.48 (dd, 1H, J = 2.1, 13.2 Hz), 8.39 (d, 1H, J = 2.1 Hz), 8.29 (d, 1H, J = 2.7 Hz), 8.01 (d, 1H, J = 12.6 Hz), 8.00-7.82 (m, 4H), 7.79 (d, 1H, J = 1.5 Hz), 7.44 (br, 1H), 7.09 (d, 1H, J = 6.6 Hz), 6.57-6.54 (m, 1H), 4.34-4.22 (m, 1H), 3.74-3.60 (m, 1H), 2.00-1.35 (m, 8H). 429 427 0.9 Example 6-448

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5,6- di(1H-pyrazol-1-yl)pyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.20 (s, 1H), 8.88 (d, 1H, J = 2.7 Hz), 8.50 (d, 1H, J = 2.7 Hz), 8.05- 7.92 (m, 2H), 7.94 (br, 1H), 7.80-7.68 (m, 4H), 7.62 (d, 1H, J = 1.8 Hz), 7.47 (br, 1H), 7.13 (d, 1H, J = 2.7 Hz), 7.03 (d, 1H, J = 5.7 Hz), 6.50-6.46 (m, 1H), 6.40-6.37 (m, 1H), 4.34-4.20 (m, 1H), 3.60-3.50 (m, 1H), 1.90-1.20 (m, 8H). 477 475 0.93 Example 6-449

2-((6-(1H-pyrazol-1-yl)-5-(2H-1,2,3-triazol- 2-yl)pyridin-3-yl)amino)-6-(((1R,2S)-2- aminocyclohexyl)amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.19 (s, 1H), 8.86 (d, 1H, J = 1.8 Hz), 8.59 d, 1H, J = 2.7 Hz), 8.16 (d, 1H, J = 2.7 Hz), 8.04-7.88 (m, 4H), 7.82-7.70 (m, 3H), 7.55-7.42 (m, 2H), 7.02 (d, 1H, J = 6.6 Hz), 6.44-6.41 (m, 1H), 4.30-4.16 (m, 1H), 3.57-3.45 (m, 1H), 1.85-1.15 (m, 8H). 478 476 0.9 Example 6-450

2-((6-(1H-pyrazol-1-yl)-5-(1H-1,2,3-triazol- 1-yl)pyridin-3-yl)amino)-6-(((1R,2S)-2- aminocyclohexyl)amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 12.24 (s, 1H), 8.88 (d, 1H, J = 2.7 Hz), 8.65 (d, 1H, J = 2.4 Hz), 8.20 (d, 1H, J = 2.1 Hz), 8.05-7.88 (m, 3H), 7.84 (d, 1H, J = 1.2 Hz), 7.83-7.68 (m, 3H), 7.53 (d, 1H, J = 1.2 Hz), 7.49 (br, 1H), 7.05 (d, 1H, J = 7.5 Hz), 6.49- 6.45 (m, 1H), 4.28-4.14 (m, 1H), 3.54- 3.40 (m, 1H), 1.85-1.15 (m, 8H). 478 476 0.85 Example 6-451

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((3- ethyl-1-methyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 426 424 0.92 Example 6-452

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1,3- diethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 440 438 0.96 Example 6-453

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((3- ethyl-1-(2-methoxyethyl)-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 470 468 0.94 Example 6-454

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((3- ethyl-1-(2-fluoroethyl)-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 458 456 0.94 Example 6-455

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- (2,2-difluoroethyl)-3-ethyl-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 476 474 0.99 Example 6-456

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((1-methyl-3-propyl-1H-indazol-5-yl) amino)nicotinamide HCl 440 438 0.98 Example 6-457

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- ethyl-3-propyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 454 452 1.04 Example 6-458

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((1-(2-methoxyethyl)-3-propyl-1H- indazol-5-yl)amino)nicotinamide HCl 484 482 1 Example 6-459

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((1-(2-fluoroethyl)-3-propyl-1H- indazol-5-yl)amino)nicotinamide HCl 472 470 1.02 Example 6-460

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- (2,2-difluoroethyl)-3-propyl-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 490 488 1.04 Example 6-461

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((3-isopropyl-1-methyl-1H-indazol-5- yl)amino)nicotinamide HCl 440 438 0.98 Example 6-462

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- ethyl-3-isopropyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 454 452 1.05 Example 6-463

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((3-isopropyl-1-(2-methoxyethyl)-1H- indazol-5-yl)amino)nicotinamide HCl 484 482 1.01 Example 6-464

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((1-methyl-3-propyl-1H- indazol-5-yl)amino)nicotinamide HCl 454 452 1.02 Example 6-465

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-ethyl-3-isopropyl-1H-indazol-5- yl)amino)-5-fluoronicotinamide HCl 468 466 1.1 Example 6-466

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5- chloro-6-morpholinopyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.31 (d, 1H, J = 2.5 Hz), 8.26 (d, 1H, J = 2.5 Hz), 7.90 (d, 1H, J = 12.2 Hz), 4.26-4.15 (m, 1H), 3.80-3.72 (m, 4H), 3.64-3.55 (m, 1H), 3.19-3.12 (m, 4H), 1.96-1.35 (m, 8H). 464 466 462 464 1 Example 6-467

2-((6-(2-oxa-6-azaspiro[3.3]heptane-6-yl) pyridin-3-yl)amino)-6-(((1R,2S)-2- aminocyclohexyl)amino)-5-fluoronicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.34 (d, 1H, J = 2.4 Hz), 8.04 (dd, 1H, J = 2.4, 9.5 Hz), 7.91 (d, 1H, J = 12.2 Hz), 6.92 (d, 1H, J = 9.5 Hz), 4.25-4.15 (m, 1H), 4.13-3.92 (m, 8H), 3.58-3.50 (m, 1H), 1.92-1.38 (m, 8H). 442 440 0.67 Example 6-468

6-(((2S,3S)-3-amino-1-methoxybutan-2-yl) amino)-5-fluoro-2-((quinolin-6-yl)amino) nicotinamide HCl CD3OD 300 MHz δ: 8.80 (d, 1H, J = 5.1 Hz), 8.73 (s, 1H), 8.73 (s, 1H), 8.10 (s, 2H), 7.92- 7.84 (m, 2H), 3.95-3.62 (m, 3H), 3.46 (s, 3H), 3.42-3.33 (m, 1H), 1.41 (d, 3H, J = 6.9 Hz). 399 397 0.58 Example 6-469

6-(((2S,3S)-3-amino-1-methoxybutan-2-yl) amino)-2-((1-ethyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl CD3OD 300 MHz δ: 8.01 (s, 1H), 7.94 (s, 1H), 7.77 (d, 1H, J = 12.2 Hz), 7.54 (d, 1H, J = 8.9 Hz), 7.40 (dd, 1H, J = 9.1, 1.8 Hz), 4.45 (q, 2H, J = 7.3 Hz), 4.38-4.31 (m, 1H), 3.86-3.78 (m, 1H), 3.74-3.55 (m, 2H), 3.42 (s, 3H), 1.47 (t, 3H, J = 7.1 Hz), 1.26 (d, 3H, J = 6.9 Hz). 416 414 0.83 Example 6-470

6-(((2S,3S)-3-amino-1-methoxybutan-2-yl) amino)-5-fluoro-2-((2-methoxypyridin-4-yl) amino)nicotinamide HCl 379 377 0.52 Example 6-471

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((1-ethyl-1H- indazol-5-yl)amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.55 (s, 1H), 8.09-7.85 (m, 5H), 7.90 (d, 1H, J = 12.6 Hz), 7.85-7.67 (m, 1H), 7.58 (d, 1H, J = 8.9 Hz), 7.30-7.08 (m, 2H), 7.29 (dd, 1H, J = 2.0, 8.1 Hz), 4.40 (q, 2H, J = 7.3 Hz), 3.72-3.54 (m, 2H), 1.39 (t, 3H, J = 7.3 Hz), 1.27 (d, 3H, J = 6.6 Hz), 1.17- 1.02 (m, 1H), 0.72-0.27 (m, 4H). 412 410 0.94 Example 6-472

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- cyclopropyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 424 422 0.95 Example 6-473

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- cyclopropyl-1H-indazol-6-yl)amino)-5- fluoronicotinamide HCl 424 422 0.93 Example 6-474

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- cyclopropyl-1H-indazol-4-yl)amino)-5- fluoronicotinamide HCl 424 422 1.03 Example 6-475

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- cyclopropyl-3-fluoro-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 442 440 1.11 Example 6-476

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- cyclopropyl-3-fluoro-1H-indazol-6-yl)amino)- 5-fluoronicotinamide HCl 42 440 1.1 Example 6-477

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- cyclopropyl-3-methyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 438 436 1 Example 6-478

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- cyclopropyl-3-ethyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 452 450 1.06 Example 6-479

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((1- cyclopropyl-3-propyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 466 464 1.13 Example 6-480

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-cyclopropyl-1H-indazol-6-yl) amino)-5-fluoronicotinamide HCl 438 436 1.02 Example 6-481

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-cyclopropyl-3-fluoro-1H- indazol-6-yl)amino)-5-fluoronicotinamide HCl 456 454 1.2 Example 6-482

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-cyclopropyl-3-propyl-1H- indazol-5-yl)amino)-5-fluoronicotinamide HCl 480 478 1.19 Example 6-483

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-5-fluoro-2-((6- methyl-5-(2H-1,2,3-triazol-2-yl)pyridin-3-yl) amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.96 (s, 1H), 8.67 (d, 1H, J = 2.0 Hz), 8.48 (d, 1H, J = 2.6 Hz), 8.22 (s, 2H), 8.01-7.80 (m, 5H), 7.46-7.24 (m, 2H), 3.75-3.65 (m, 1H), 3.40-3.36 (m, 1H), 2.53 (s, 3H), 1.22-1.00 (m, 4H), 0.60-0.16 (m, 4H). 426 424 0.86 Example 6-484

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-fluoro-6-methoxypyridin-3-yl) amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.43 (s, 1H), 8.12 (dd, 1H, J = 2.4, 12.9 Hz), 8.01 (d, 1H, J = 2.4 Hz), 7.92 (d, 1H, J = 12.6 Hz), 7.88-7.66 (m, 4H), 7.30 (br, 1H), 6.90 (d, 1H, J = 6.0 Hz), 4.20-4.10 (m, 1H), 3.91 (s, 3H), 3.68-3.52 (m, 1H), 1.95-1.30 (m, 8H). 393 391 0.95 Example 6-485

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1,3-dimethyl-1H-indazol-6-yl) amino)-5-fluoronicotinamide HCl 426 424 0.86 Example 6-486

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-ethyl-3-methyl-1H-indazol-6- yl)amino)-5-fluoronicotinamide HCl 440 438 0.93 Example 6-487

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((1-(2-methoxyethyl)-3- methyl-1H-indazol-6-yl)amino)nicotinamide HCl 470 468 0.89 Example 6-488

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((1-(2-fluoroethyl)-3- methyl-1H-indazol-6-yl)amino)nicotinamide HCl 458 456 0.92 Example 6-489

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-(2,2-difluoroethyl)-3-methyl-1H- indazol-6-yl)amino)-5-fluoronicotinamide HCl 476 474 0.97 Example 6-490

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((3-fluoro-1-(2- methoxyethyl)-1H-indazol-4-yl)amino) nicotinamide HCl 474 472 0.98 Example 6-491

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((3-fluoro-1-(2- fluoroethyl)-1H-indazol-4-yl)amino) nicotinamide HCl 462 460 1.14 Example 6-492

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-(2,2-difluoroethyl)-3-fluoro-1H- indazol-4-yl)amino)-5-fluoronicotinamide HCl 480 478 1.03 Example 6-493

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-methoxy-5-(1H-1,2,3-triazol-1- yl)pyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.67 (s, 1H), 8.78 (d, 1H, J = 1.8 Hz), 8.64 (d, 1H, J = 1.2 Hz), 8.27 (d, 1H, J = 2.7 Hz), 8.00-7.60 (m, 6H), 7.33 (br, 1H), 6.92 (d, 1H, J = 7.2 Hz), 4.30-4.18 (m, 1H), 3.95 (s, 3H), 3.52- 3.40 (m, 1H), 1.85-1.15 (m, 8H). 442 440 1.01 Example 6-494

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((6- ethoxy-5-(1H-pyrazol-1-yl)pyridin-3-yl) amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.55 (s, 1H), 8.70 (d, 1H, J = 2.4 Hz), 8.41 (d, 1H, J = 2.4 Hz), 8.08 (d, 1H, J = 2.7 Hz), 7.93 (d, 1H, J = 12.6 Hz), 7.90-7.70 (m, 5H), 7.29 (br, 1H), 6.90 (d, 1H, J = 6.0 Hz), 6.58-6.54 (m, 1H), 4.43 (q, 2H, J = 7.2 Hz), 4.14- 4.00 (m, 1H), 3.62-3.40 (m, 1H), 1.95- 1.10 (m, 8H), 1.38 (t, 3H, J = 7.2 Hz). 455 453 1.24 Example 6-495

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((6- ethoxy-5-(2H-1,2,3-triazol-2-yl)pyridin-3-yl) amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.57 (s, 1H), 8.49 (d, 1H, J = 2.7 Hz), 8.26 (d, 1H, J = 2.4 Hz), 8.13 (s, 2H), 7.93 (d, 1H, J = 12.6 Hz), 7.88- 7.64 (m, 4H), 7.26 (br, 1H), 6.90 (d, 1H, J = 6.6 Hz), 4.37 (q, 2H, J = 7.2 Hz), 4.16-4.04 (m, 1H), 3.50-3.40 (m, 1H), 1.80-1.10 (m, 8H), 1.25 (t, 3H, J = 7.2 Hz). 456 454 1.1 Example 6-496

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((6- ethoxy-5-(1H-1,2,3-triazol-1-yl)pyridin-3-yl) amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.66 (s, 1H), 8.79 (d, 1H, J = 2.7 Hz), 8.64 (s, 1H), 8.25 (d, 1H, J = 1.8 Hz), 7.99 (s, 1H), 7.95 (d, 1H, J = 12.6 Hz), 7.90-7.60 (m, 4H), 7.33 (br, 1H), 6.92 (d, 1H, J = 6.6 Hz), 4.41 (q, 2H, J = 7.2 Hz), 4.30-4.18 (m, 1H), 3.52- 3.40 (m, 1H), 1.80-1.20 (m, 8H), 1.33 (t, 3H, J = 7.2 Hz). 456 454 1.11 Example 6-497

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((6- ethoxy-5-methylpyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.15 (s, 1H), 8.10 (d, 1H, J = 2.7 Hz), 7.99 (d, 1H, J = 12.6 Hz), 7.80- 7.60 (m, 5H), 7.20 (br, 1H), 6.79 (d, 1H, J = 6.0 Hz), 4.28 (q, 2H, J = 7.2 Hz), 4.20-4.08 (m, 1H), 3.64-3.50 (m, 1H), 2.14 (s, 3H), 1.95-1.25 (m, 8H), 1.31 (t, 3H, J = 7.2 Hz). 403 401 1.18 Example 6-498

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-(2-methoxyethoxy)-5- methylpyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.18 (s, 1H), 8.11 (d, 1H, J = 2.7 Hz), 7.90 (d, 1H, J = 12.6 Hz), 7.86- 7.60 (m, 5H), 7.23 (br, 1H), 6.81 (d, 1H, J = 6.6 Hz), 4.38-4.32 (m, 2H), 4.20-4.08 (m, 1H), 3.70-3.64 (m, 2H), 3.60-3.48 (m, 1H), 3.31 (s, 3H), 2.16 (s, 3H), 1.90-1.30 (m, 8H). 433 431 1.08 Example 6-499

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-methyl-6-(1H-pyrazol-1-yl) pyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.76 (s, 1H), 8.58 (d, 1H, J = 1.8 Hz), 8.20 (d, 1H, J = 2.1 Hz), 8.07 (d, 1H, J = 2.7 Hz), 7.98 (d, 1H, J = 12.6 Hz), 7.98-7.80 (m, 4H), 7.73 (d, 1H, J = 1.2 Hz), 7.37 (br, 1H), 6.94 (d, 1H, J = 6.6 Hz), 6.52-6.48 (m, 1H), 4.36- 4.25 (m, 1H), 3.70-3.58 (m, 1H), 2.38 (s, 3H), 2.00-1.34 (m, 8H). 425 423 1.03 Example 6-500

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-methyl-6-(2H-1,2,3-triazol-2-yl) pyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.91 (s, 1H), 8.73-8.69 (m, 1H), 8.12-8.10 (m, 1H), 8.09 (s, 2H), 7.99 (d, 1H, J = 12.3 Hz), 7.94-7.70 (m, 4H), 7.43 (br, 1H), 6.94 (d, 1H, J = 6.6 Hz), 4.38-4.26 (m, 1H), 3.68-3.58 (m, 1H), 2.17 (s, 3H), 1.95-1.35 (m, 8H). 426 424 0.98 Example 6-501

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-methyl-6-(1H-1,2,3-triazol-1-yl) pyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.92 (s, 1H), 8.70 (d, 1H, J = 2.1 Hz), 8.53 (s, 1H), 8.18 (d, 1H, J = 2.1 Hz), 7.99 (d, 1H, J = 12.3 Hz), 7.95 (s, 1H), 7.95-7.70 (m, 4H), 7.42 (br, 1H), 6.97-6.90 (m, 1H), 4.38-4.28 (m, 1H), 3.70-3.58 (m, 1H), 2.29 (s, 3H), 2.00- 1.35 (m, 8H). 426 424 0.89 Example 6-502

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((6- ethyl-5-methylpyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.97 (br, 1H), 9.10-8.90 (m, 1H), 8.30-8.14 (m, 1H), 8.00 (d, 1H, J = 12.3 Hz), 8.00-7.80 (m, 4H), 7.56-7.36 (m, 1H), 7.05-6.95 (m, 1H), 4.37-4.26 (m, 1H), 3.61-3.50 (m, 1H), 2.98-2.84 (m, 2H), 2.42 (s, 3H), 1.95-1.35 (m, 8H), 1.24 (t, 3H, J = 7.5 Hz). 387 385 0.69 Example 6-503

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((6- cyclopropyl-5-methylpyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz 399 397 0.73 Example 6-504

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-hydroxy-5-(2H-1,2,3-triazol-2-yl) pyridin-3-yl)amino)nicotinamide 428 426 0.7 Example 6-505

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((3-ethyl-1-methyl-1H-indazol-5- yl)amino)-5-fluoronicotinamide HCl 440 438 1.01 Example 6-506

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1,3-diethyl-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 454 452 1.07 Example 6-507

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((3-isopropyl-1-methyl- 1H-indazol-5-yl)amino)nicotinamide HCl 454 452 1.07 Example 6-508

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-ethyl-1H-indazol-4-yl)amino)- 5-fluoronicotinamide HCl 426 424 1 Example 6-509

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-ethyl-3-fluoro-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 444 442 0.99 Example 6-510

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((1-(2,2-difluoroethyl)-3-fluoro-1H- indazol-5-yl)amino)-5-fluoronicotinamide HCl 480 478 1.03 Example 6-511

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((3-fluoro-1-methyl-1H- indazol-5-yl)amino)nicotinamide HCl 432 430 1.08 Example 6-512

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((1-ethyl-3-fluoro-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 446 444 1.13 Example 6-513

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((1-(2,2-difluoroethyl)-3-fluoro-1H- indazol-5-yl)amino)-5-fluoronicotinamide HCl 482 480 1.09 Example 6-514

2-([1,3]dioxolo[4,5-b]pyridin-6-ylamino)-6- (((1R,2S)-2-amino-1-cyclopropylpropyl)amino)- 5-fluoronicotinamide HCl 389 387 0.8 Example 6-515

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-5-fluoro-2-((6- morpholinopyridin-3-yl)amino)nicotinamide HCl 430 428 0.67 Example 6-516

6-(((1R,2S)-2-amino-1-phenylpropyl)amino)- 2-((1-ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl CD3OD 300 MHz δ: 7.95 (s, 1H), 7.84 (d, 1H, J = 2.0 Hz), 7.76 (d, 1H, J = 12.2 Hz), 7.51- 7.33 (dtd, 6H, J = 40.5, 14.5, 4.3 Hz), 7.27 (dd, 1H, J = 8.9, 2.0 Hz), 5.50 (d, 1H, J = 5.9 Hz), 4.46 (q, 2H, J = 7.3 Hz), 3.87-3.75 (s, 1H), 1.49 (t, 3H, J = 7.3 Hz), 1.30 (d, 3H, J = 6.9 Hz). 448 446 0.92 Example 6-517

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-(2-methoxyethoxy)-5-(2H-1,2,3- triazol-2-yl)pyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.59 (s, 1H), 8.51 (d, 1H, J = 2.7 Hz), 8.26 (d, 1H, J = 2.7 Hz), 8.13 (s, 2H), 7.93 (d, 1H, J = 12.6 Hz), 7.90- 7.60 (m, 4H), 7.32 (br, 1H), 6.90 (d, 1H, J = 6.6 Hz), 4.57-4.41 (m, 2H), 4.16-4.06 (m, 1H), 3.63-3.58 (m, 2H), 3.50-3.40 (m, 1H), 3.22 (s, 3H), 1.80- 1.10 (m, 8H). 486 484 0.92 Example 6-518

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-(2-methoxyethoxy)-5-(1H-1,2,3- triazol-1-yl)pyridin-3-yl)amino)nicotinamide HCl 486 484 0.94 Example 6-519

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((1-ethyl-1H-indazol-4-yl)amino)- 5-fluoronicotinamide HCl 428 426 1.05 Example 6-520

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((1,3-dimethyl-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 428 426 1 Example 6-521

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((1-ethyl-3-methyl-1H-indazol-5- yl)amino)-5-fluoronicotinamide HCl 442 440 1.03 Example 6-522

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((1-(2,2-difluoroethyl)-3-methyl-1H- indazol-5-yl)amino)-5-fluoronicotinamide HCl 478 476 1.05 Example 6-523

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((1-ethyl-1H-indazol-4-yl)amino)-5- fluoronicotinamide HCl 400 398 0.94 Example 6-524

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((1,3-dimethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 400 398 0.87 Example 6-525

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((1-ethyl-3-methyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 414 412 0.94 Example 6-526

6-(((2S,3R)-2-aminopntan-3-yl)amino)-2- ((1-(2,2-difluoroethyl)-3-methyl-1H-indazol-5- yl)amino)-5-fluoronicotinamide HCl 450 448 0.87 Example 6-527

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-morpholino-5-(1H-pyrazol-1-yl) pyridin-3-yl)amino)nicotinamide HCl DMSO- d6 300 MHz δ: 11.64 (s, 1H), 8.45 (d, 1H, J = 2.4 Hz), 8.37 (d, 1H, J = 2.7 Hz), 8.22 (d, 1H, J = 2.7 Hz), 7.93 (d, 1H, J = 12.0 Hz), 7.88-7.62 (m, 5H), 7.31 (br, 1H), 6.92 (d, 1H, J = 6.0 Hz), 6.59-6.55 (m, 1H), 4.20-4.09 (m, 1H), 3.62-3.56 (m, 4H), 3.55-3.43 (m, 1H), 2.78-2.70 (m, 4H), 1.80-1.20 (m, 8H). 496 494 0.97 Example 6-528

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5- cyclopropyl-6-morpholinopyridin-3-yl)amino)- 5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.27 (s, 1H), 8.46-8.40 (m, 1H), 7.91 (d, 1H, J = 12.6 Hz), 7.90-7.70 (m, 4H), 7.32-7.18 (m, 2H), 6.80 (d, 1H, J = 6.0 Hz), 4.28-4.32 (m, 1H), 3.80-3.73 (m, 4H), 3.60-3.48 (m, 1H), 3.22-3.13 (m, 4H), 2.12-2.00 (m, 1H), 1.90-1.30 (m, 8H), 1.10-1.05 (m, 2H), 0.86-0.70 (m, 2H). 470 468 0.89 Example 6-529

(3R,4S)-benzyl 4-amino-3-((5-carbamoyl-3- fluoro-6-((2-methoxypyridin-4-yl)amino) pyridin-2-yl)amino)piperidine-1-carboxylate) and (3S,4R)-benzyl-4-amino-3-((5-carbamoyl- 3-fluoro-6-((2-methoxypyridin-4-yl)amino) pyridin-2-yl)amino)piperidine-1- carboxylate(= 1:1) HCl CD3OD 300 MHz δ: 8.01 (d, 1H, J = 6.9 Hz), 7.95-7.75 (m, 1H), 7.58-6.90 (m, 7H), 4.57-4.40 (m, 1H), 4.37-4.15 (m, 2H), 4.11 (s, 3H), 3.92-3.80 (m, 1H), 3.46-2.99 (m, 4H), 2.14-1.88 (m, 2H). 510 508 0.78 Example 6-530

(3S,4R)-benzyl 3-amino-4-((5-carbamoyl-3- fluoro-6-((2-methoxypyridin-4-yl)amino) pyridin-2-yl)amino)piperidine-1-carboylate and (3R,4S)-benzyl 3-amino-4-((5-carbamoyl- 3-fluoro-6-((2-methoxypyridin-4-yl)amino) pyridin-2-yl)amino)piperidine-1- carboxylate(= 1:1) HCl CD3OD 300 MHz δ: 8.07 (d, 1H, J = 6.6 Hz), 7.92 (d, 1H, J = 11.6 Hz), 7.80-7.71 (m, 1H), 7.44-7.30 (m, 5H), 7.23 (s, 1H), 5.25- 5.10 (m, 2H), 4.54-4.42 (m, 1H), 4.40- 4.21 (m, 2H), 4.10 (s, 3H), 4.04-3.97 (m, 1H), 3.62-3.35 (m, 1H), 2.06-1.94 (m, 2H). 510 508 0.88 Example 6-531

6-(((3R,4R)-3-aminotrahydro-2H-pyran-4-yl) amino)-5-fluoro-2-((2-methoxypyridin-4-yl) amino)nicotinamide HCl CD3OD 300 MHz δ: 8.04 (d, 1H, J = 6.6 Hz), 7.91 (d, 1H, J = 11.6 Hz), 7.67-7.58 (m, 1H), 7.31-7.28 (m, 1H), 4.56-4.46 (m, 1H), 4.20-3.38 (m, 5H), 4.09 (s, 3H), 2.26- 1.87 (m, 2H). 377 375 0.57 Example 6-532

6-(((3S,4S)-4-aminotrahydro-2H-pyran-3-yl) amino)-5-fluoro-2-((2-methoxypyridin-4-yl) amino)nicotinamide HCl CD3OD 300 MHz δ: 8.02-7.92 (m, 1H), 7.95 (d, 1H, J = 11.6 Hz), 7.46-7.40 (m, 1H), 7.37-7.30 (m, 1H), 4.75-4.68 (m, 1H), 4.12-3.98 (m, 2H), 4.07 (s, 3H), 3.90-3.51 (m, 3H), 2.20-1.86 (m, 2H). 377 375 0.52 Example 6-533

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-morpholino-5-(2H-1,2,3-triazol-2- yl)pyridin-3-yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.41 (d, 1H, J = 2.6 Hz), 8.32 (d, 1H, J = 2.6 Hz), 8.16 (s, 2H), 7.90 (d, 1H, J = 12.2 Hz), 4.15-4.04 (m, 1H), 3.57-3.50 (m, 4H), 3.50-3.43 (m, 1H), 2.83-2.66 (m, 4H), 1.80-1.16 (m, 8H). 497 495 0.89 Example 6-534

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-morpholino-5-(1H-1,2,3-triazol-1- yl)pyridin-3-yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.71 (d, 1H, J = 1.0 Hz), 8.61 (d, 1H, J = 2.6 Hz), 8.34 (d, 1H, J = 2.6 Hz), 8.03 (d, 1H, J = 1.0 Hz), 7.91 (d, 1H, J = 12.2 Hz), 4.26-4.14 (m, 1H), 3.62-3.54 (m, 4H), 3.52-3.44 (m, 1H), 2.78-2.69 (m, 4H), 1.80-1.21 (m, 8H). 497 495 0.88 Example 6-535

2-((6-(1H-imidazole-1-yl)pyridin-3-yl)amino)- 6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoronicotinamide HCl DMSO- d6-D2O 300 MHz δ: 9.68-9.65 (m, 1H), 8.80 (d, 1H, J = 2.8 Hz), 8.39 (dd, 1H, J = 2.8, 8.8 Hz), 8.34-8.30 (m, 1H), 8.02-7.90 (m, 2H), 7.81-7.77 (m, 1H), 4.34-4.23 (m, 1H), 3.70-3.62 (m, 1H), 1.98-1.37 (m, 8H). 411 409 0.65 Example 6-536

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-(2-methyl-1H-imidazol-1-yl) pyridin-3-yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.89 (d, 1H, J = 2.7 Hz), 8.36 (dd, 1H, J = 2.7, 8.7 Hz), 7.97 (d, 1H, J = 11.9 Hz), 7.95 (d, 1H, J = 2.3 Hz), 7.75 (d, 1H, J = 8.37 Hz), 7.69 (d, 1H, J = 2.3 Hz), 4.35-4.24 (m, 1H), 3.72-3.64 (m, 1H), 2.71 (s, 3H), 2.00-1.38 (m, 8H). 425 423 0.63 Example 6-537

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-(2-oxooxazolidin-3-yl)pyridin-3- yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.51 (d, 1H, J = 2.5 Hz), 8.11 (dd, 1H, J = 2.5, 8.8 Hz), 8.01 (d, 1H, J = 8.8 Hz), 7.91 (d, 1H, J = 12.2 Hz), 4.51-4.42 (m, 2H), 4.25-4.11 (m, 3H), 3.68-3.50 (m, 1H), 1.93-1.35 (m, 8H). 430 428 0.83 Example 6-538

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((3-ethyl-1-methyl-1H-indazol-5- yl)amino)-5-fluoronicotinamide HCl 442 440 1.06 Example 6-539

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((3-ethyl-1-methyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 414 412 0.93 Example 6-540

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((1,3-diethyl-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 456 454 1.13 Example 6-541

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((1,3-diethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 428 426 0.98 Example 6-542

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((3-isopropyl-1-methyl- 1H-indazol-5-yl)amino)nicotinamide HCl 456 454 1.12 Example 6-543

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((3-isopropyl-1-methyl-1H-indazol-5- yl)amino)nicotinamide HCl 428 426 0.99 Example 6-544

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((3- cyclopropyl-1-methyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 438 436 0.95 Example 6-545

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((3-cyclopropyl-1-methyl-1H- indazol-5-yl)amino)-5-fluoronicotinamide HCl 452 450 1.05 Example 6-546

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((3-cyclopropyl-1-methyl-1H- indazol-5-yl)amino)-5-fluoronicotinamide HCl 454 452 1.05 Example 6-547

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((3-cyclopropyl-1-methyl-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 426 424 0.97 Example 6-548

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((3- cyclopropyl-1-ethyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 452 450 1.06 Example 6-549

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((3-cyclopropyl-1-ethyl-1H-indazol- 5-yl)amino)-5-fluoronicotinamide HCl 466 464 1.11 Example 6-550

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((3-cyclopropyl-1-ethyl-1H-indazol- 5-yl)amino)-5-fluoronicotinamide HCl 468 466 1.15 Example 6-551

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((3-cyclopropyl-1-ethyl-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 440 438 1.04 Example 6-552

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((5-fluoro-6-(2- methoxyethoxy)pyridin-3-yl)amino) nicotinamide HCl DMSO- d6 300 MHz δ: 11.43 (s, 1H), 8.11 (dd, 1H, J = 2.1, 12.3 Hz), 7.93 (d, 1H, J = 12.3 Hz), 7.90-7.70 (m, 4H), 7.29 (br, 1H), 6.92 (d, 1H, J = 6.6 Hz), 4.44-4.39 (m, 2H), 4.20-4.10 (m, 1H), 3.70-3.65 (m, 2H), 3.65-3.55 (m, 1H), 3.30 (s, 3H), 1.95-1.75 (m, 2H), 1.75-1.50 (m, 4H), 1.50-1.20 (m, 2H). 437 435 0.96 Example 6-553

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((6- cyclopropyl-5-fluoropyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.74 (s, 1H), 8.26-8.23 (m, 1H), 8.13 (dd, 1H, J = 2.1, 12.6 Hz), 7.96 (dd, 1H, J = 12.6 Hz), 7.95-7.80 (m, 4H), 7.34 (br, 1H), 7.00 (d, 1H, J = 6.0 Hz), 4.26-4.15 (m, 1H), 3.7-3.60 (m, 1H), 2.26-2.16 (m, 1H), 2.00-1.35 (m, 8H), 0.98-0.90 (m, 4H). 403 401 1.04 Example 6-554

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((6- ethyl-5-fluoropyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.83 (s, 1H), 8.40-8.36 (m, 1H), 8.17 (dd, 1H, J = 2.1, 12.6 Hz), 7.97 (d, 1H, J = 12.3 Hz), 7.96-7.80 (m, 4H), 7.37 (br, 1H), 7.02 (d, 1H, J = 5.7 Hz), 4.30-4.18 (m, 1H), 3.70-3.60 (m, 1H), 2.80-2.69 (m, 2H), 2.00-1.35 (m, 8H), 1.21 (t, 3H, J = 7.5 Hz). 391 389 0.95 Example 6-555

6-(((1R,2S)-2-amino-1-(4- fluorophenyl)propyl)amino)-2-((1-ethyl-1H- indazol-5-yl)amino)-5-fluoronicotinamide HCl 466 464 1.01 Example 6-556

6-(((1R,2S)-2-amino-1-(4- fluorophenyl)propyl)amino)-5-fluoro-2-((2- methoxypyridin-4-yl)amino)nicotinamide HCl 429 427 0.73 Example 6-557

6-(((1R,2S)-2-amino-1-(4- fluorophenyl)propyl)amino)-2-((2,6- dimethoxypyridin-4-yl)amino)-5- fluoronicotinamide HCl 459 457 1.05 Example 6-558

6-(((1R,2S)-2-amino-1-(4- fluorophenyl)propyl)amino)-2-((5,6- dimethylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 427 425 0.68 Example 6-559

6-(((1R,2S)-2-amino-1-(4- fluorophenyl)propyl)amino)-5-fluoro-2-((2-(2- methoxyethoxy)pyridin-4-yl)amino) nicotinamide HCl 473 471 0.81 Example 6-560

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((1-methyl-3-morpholino-1H-indazol- 5-yl)amino)nicotinamide HCl 483 481 0.9 Example 6-561

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((1-methyl-3-morpholino- 1H-indazol-5-yl)amino)nicotinamide HCl 497 495 0.94 Example 6-562

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((1-methyl-3-morpholino- 1H-indazol-5-yl)amino)nicotinamide HCl 499 497 0.99 Example 6-563

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((1-methyl-3-morpholino-1H-indazol- 5-yl)amino)nicotinamide HCl 471 469 0.87 Example 6-564

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-methoxy-5-mopholinopyridin-3- yl)amino)nicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.07 (d, 1H, J = 2.1 Hz), 7.86 (d, 1H, J = 12.2 Hz), 7.22 (d, 1H, J = 2.1 Hz), 4.26-4.17 (m, 1H), 3.86 (s, 3H), 3.79-3.70 (m, 4H), 3.59-3.50 (m, 1H), 3.06-2.98 (m, 4H), 1.90-1.33 (m, 8H). 460 458 0.88 Example 6-565

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((6- ethoxy-5-morpholinopyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.05 (d, 1H, J = 2.1 Hz), 7.86 (d, 1H, J = 12.2 Hz), 7.20 (d, 1H, J = 2.1 Hz), 4.30 (q, 2H, J = 6.9 Hz), 4.25- 4.17 (m, 1H), 3.79-3.72 (m, 4H), 3.58- 3.50 (m, 1H), 3.12-2.97 (m, 4H), 1.92- 1.34 (m, 8H), 1.33 (t, 3H, J = 6.9 Hz). 474 472 0.95 Example 6-566

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((6-(2-methoxyethoxy)-5- morpholinopyridin-3-yl)amino)nicotinamide HCl CD3OD 300 MHz δ: 8.16 (d, 1H, J = 2.1 Hz), 7.74 (d, 1H, J = 11.9 Hz), 7.18 (d, 1H, J = 2.1 Hz), 4.53-4.43 (m, 1H), 3.95-3.70 (m, 7H), 3.42 (s, 3H), 3.40-3.35 (m, 4H), 3.19-3.08 (m, 2H), 1.97-1.35 (m, 8H). 504 502 0.91 Example 6-567

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5- chloro-6-methylpyridin-3-yl)amino)-5- fluoronicotinamide HCl CD3OD 300 MHz δ: 8.98 (d, 1H, J = 2.3 Hz), 8.72 (d, 1H, J = 2.3 Hz), 7.87 (d, 1H, J = 11.9 Hz), 4.57-4.47 (m, 1H), 3.83-3.71 (m, 1H), 3.01 (s, 3H), 2.08-1.54 (m, 8H). 393 391 0.94 Example 6-568

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5- chloro-6-ethylpyridin-3-yl)amino)-5- fluoronicotinamide HCl CD3OD 300 MHz δ: 8.86 (d, 1H, J = 2.3 Hz), 8.72 (d, 1H, J = 2.3 Hz), 7.87 (d, 1H, J = 11.9 Hz), 4.53 -4.44 (m, 1H), 3.81-3.73 (m, 1H), 3.04 (q, 2H, J = 7.6 Hz), 2.05- 1.50 (m, 8H), 1.34 (t, 3H, J = 7.6 Hz). 407 405 1.06 Example 6-569

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5- chloro-6-cyclopropylpyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.37-8.33 (m, 2H), 7.91 (d, 1H, J = 12.2 Hz), 4.28-4.19 (m, 1H), 3.65-3.57 (m, 1H), 2.46-2.34 (m, 1H), 1.97-1.37 (m, 8H), 1.05-0.87 (m, 4H). 419 417 1.14 Example 6-570

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5- chloro-6-ethoxypyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6-D2O 300 MHz δ: 8.30 (d, 1H, J = 2.5 Hz), 8.11 (d, 1H, J = 2.5 Hz), 7.89 (d, 1H, J = 12.2 Hz), 4.35 (q, 2H, J = 6.9 Hz), 4.21- 4.12 (m, 1H), 3.63-3.53 (m, 1H), 1.94- 1.34 (m, 8H), 1.34 (t, 3H, J = 6.9 Hz). 423 421 1.11 Example 6-571

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5- chloro-6-(2-methoxyethoxy)pyridin-3-yl) amino)-5-fluoronicotinamide HCl CD3OD 300 MHz δ: 8.19 (d, 1H, J = 2.5 Hz), 8.10 (d, 1H, J = 2.5 Hz), 7.75 (d, 1H, J = 11.9 Hz), 4.50-4.44 (m, 2H), 4.34-4.24 (m, 1H), 3.81-3.74 (m, 3H), 3.44 (s, 3H), 1.93-1.48 (m, 8H). 453 451 1.04 Example 6-572

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((6- ethoxy-5-fluoropyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.43 (s, 1H), 8.10 (dd, 1H, J = 2.1, 12.9 Hz), 7.99 (d, 1H, J = 2.1 Hz), 7.93 (d, 1H, J = 12.6 Hz), 7.92-7.70 (m, 4H), 7.29 (br, 1H), 6.92 (d, 1H, J = 6.6 Hz), 4.35 (q, 2H, J = 7.2 Hz), 4.20- 4.10 (m, 1H), 3.66-3.54 (m, 1H), 1.95- 1.30 (m, 8H), 1.34 (t, 3H, J = 7.2 Hz). 407 405 1.04 Example 6-573

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5- cyclopropyl-6-ethoxypyridin-3-yl)amino)-5- fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.07 (s, 1H), 8.13 (d, 1H, J = 1.8 Hz), 7.96-7.84 (m, 5H), 7.27 (d, 1H, J = 2.7 Hz), 7.20 (br, 1H), 6.81 (d, 1H, J = 5.1 Hz), 4.31 (q, 2H, J = 7.2 Hz), 4.16-4.06 (m, 1H), 3.58-3.46 (m, 1H), 2.06-1.96 (m, 1H), 1.92-1.75 (m, 2H), 1.70-1.50 (m, 4H), 1.50-1.30 (m, 2H), 1.33 (t, 3H, J = 7.2 Hz), 0.96-0.80 (m, 2H), 0.80-0.64 (m, 2H). 429 427 1.15 Example 6-574

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5- cyclopropyl-6-(2-methoxyethoxy)pyridin-3-yl) amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.07 (s, 1H), 8.13 (d, 1H, J = 2.7 Hz), 7.98 (d, 1H, J = 12.6 Hz), 7.84- 7.64 (m, 4H), 7.27 (d, 1H, J = 1.8 Hz), 7.20 (br, 1H), 6.79 (d, 1H, J = 5.7 Hz), 4.40-4.34 (m, 2H), 4.16-4.04 (m, 1H), 3.70-3.65 (m, 2H), 3.60-3.50 (m, 1H), 3.32 (s, 3H), 2.07-1.96 (m, 1H), 1.90- 1.70 (m, 2H), 1.70-1.50 (m, 4H), 1.50- 1.30 (m, 2H), 0.95-0.88 (m, 2H), 0.82- 0.64 (m, 2H). 459 457 1.07 Example 6-575

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((6- (2-methoxyethoxy)-5-(1H-pyrazol-1-yl) pyridin-3-yl)amino)-5-fluoronicotinamide HCl DMSO- d6 300 MHz δ: 11.57 (s, 1H), 8.73 (d, 1H, J = 2.7 Hz), 8.45 (d, 1H, J = 1.8 Hz), 8.08 (d, 1H, J = 1.5 Hz), 7.93 (d, 1H, J = 12.0 Hz), 7.80 (d, 1H, J = 1.5 Hz), 7.80- 7.70 (m, 4H), 7.31 (br, 1H), 6.88 (d, 1H, J = 6.6 Hz), 6.59-6.56 (m, 1H), 4.53-4.47 (m, 2H), 4.28-4.16 (m, 1H), 3.75-3.70 (m, 2H), 3.55-3.45 (m, 1H), 3.31 (s, 3H), 1.85-1.15 (m, 8H). 485 483 1.03 Example 6-576

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((1-ethyl-1H- indazol-4-yl)amino)-5-fluoronicotinamide HCl 412 410 0.96 Example 6-577

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((3-fluoro-1- methyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 416 414 0.97 Example 6-578

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((3-ethyl-1- methyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 426 424 0.94 Example 6-579

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((1,3-diethyl-1H- indazol-5-yl)amino)-5-fluoronicotinamide HCl 440 438 0.99 Example 6-580

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-5-fluoro-2-((3- isopropyl-1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 440 438 1 Example 6-581

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((1-ethyl-1H- indazol-6-yl)amino)-5-fluoronicotinamide HCl 412 410 0.9 Example 6-582

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((1,3-dimethyl-1H- indazol-5-yl)amino)-5-fluoronicotinamide HCl 412 410 0.9 Example 6-583

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((1-ethyl-3- methyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 426 424 0.95 Example 6-584

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-2-((1-(2,2- difluoroethyl)-3-methyl-1H-indazol-5-yl) amino)-5-fluoronicotinamide HCl 462 460 0.97 Example 6-585

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((3-methoxy-1-methyl-1H-indazol-5- yl)amino)nicotinamide HCl 428 426 0.95 Example 6-586

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-5-fluoro-2-((3-methoxy-1-methyl-1H- indazol-5-yl)amino)nicotinamide HCl 442 440 0.96 Example 6-587

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((3-methoxy-1-methyl-1H- indazol-5-yl)amino)nicotinamide HCl 444 442 1.03 Example 6-588

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((3-methoxy-1-methyl-1H-indazol-5- yl)amino)nicotinamide HCl 416 414 0.92 Example 6-589

6-(((1R,2S)-2-amino-1- cyclopropylpropyl)amino)-5-fluoro-2-((3- methoxy-1-methyl-1H-indazol-5-yl)amino) nicotinamide HCl 428 426 0.95 Example 6-590

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((3- ethoxy-1-ethyl-1H-indazol-5-yl)amino)-5- fluoronicotinamide HCl 456 454 1.05 Example 6-591

6-(((2R,3S)-3-amino-1-cyclopropylbutan-2-yl) amino)-2-((3-ethoxy-1-ethyl-1H-indazol-5- yl)amino)-5-fluoronicotinamide HCl 470 468 1.12 Example 6-592

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-2-((3-ethoxy-1-ethyl-1H-indazol-5- yl)amino)-5-fluoronicotinamide HCl 472 470 1.18 Example 6-593

6-(((2S,3R)-2-aminopentan-3-yl)amino)-2- ((3-ethoxy-1-ethyl-1H-indazol-5-yl)amino)- 5-fluoronicotinamide HCl 444 442 1.03 Example 6-594

6-(((1R,2S)-2-aminocyclohexyl)amino)-5- fluoro-2-((1-methyl-3-(1H-pyrazol-1-yl)-1H- indazol-5-yl)amino)nicotinamide HCl 464 462 1.02 Example 6-595

6-(((2S,3R)-2-amino-5-methylhexan-3-yl) amino)-5-fluoro-2-((1-methyl-3-(1H-pyrazol- 1-yl)-1H-indazol-5-yl)amino)nicotinamide HCl 480 478 1.15 Example 6-596

6-(((2S,3R)-2-aminopentan-3-yl)amino)-5- fluoro-2-((1-methyl-3-(1H-pyrazol-1-yl)-1H- indazol-5-yl)amino)nicotinamide HCl 452 450 0.99 Example 6-597

6-(((1R,2S)-2-amino-1- cyclobutylpropyl)amino)-2-((5,6- dimethylpyridin-3-yl)amino)-5- fluoronicotinamide HCl 387 385 0.74 Example 6-598

6-(((1R,2S)-2-amino-1- cyclobutylpropyl)amino)-5-fluoro-2-((6- methyl-5-(2H-1,2,3-triazol-2-yl)pyridin-3-yl) amino)nicotinamide HCl 440 438 0.96

Example 7

1st Step

The following compound was obtained as described in Reference Example 2. Methyl6-(cis-2-(bis(tert-butoxycarbonyl)amino)cyclohexylamino)-2-chloro-5-fluoro nicotinate

¹H-NMR (CDCl₃, 400 MHz) δ: 7.69 (d, 1H, J=10.7 Hz), 7.32 (brs, 1H), 4.34 (dt, 1H, J=3.7 Hz, 13.0 Hz), 4.30-4.24 (m, 1H), 3.86 (s, 3H), 2.51-2.43 (m, 1H), 2.31-2.17 (m, 1H), 1.90-1.82 (m, 1H), 1.65-1.30 (m, 5H), 1.47 (s, 18H)

2nd Step

The following compound was obtained as described in the 1st step of Example 1.

Methyl6-(cis-2-(bis(tert-butoxycarbonyl)amino)cyclohexylamino)-5-fluoro-2-(quinolin-3-ylamino)nicotinate

MS (ESI, m/z): 610 (M+H), 608 (M−H)

3rd Step

The following compound was obtained as described in the 1st step of Reference Example 3.

6-(cis-2-(bis(tert-butoxycarbonyl)amino)cyclohexylamino)-5-fluoro-2-(quinolin-3-ylamino)nicotinic acid

MS (ESI, m/z): 596 (M+H), 594 (M−H)

4th Step

A mixture of 6-(cis-2-(bis(tert-butoxycarbonyl)amino)cyclohexylamino)-5-fluoro-2-(quinolin-3-ylamino)nicotinic acid (65 mg), HOBt.H₂O (67 mg), WSC.HCl (84 mg), and DMF (3 ml) was stirred at room temperature for 2 hours, and 25% ammonia water (1 ml) was added, followed by stirring at 40° C. for 30 minutes. Ethyl acetate was added to the reaction mixture, the reaction mixture was washed with water and then with saturated saline and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane:ethyl acetate=10:0 to 1:1), and a light yellow solid of di-tert-butyl cis-2-(5-aminocarbonyl-3-fluoro-6-(quinolin-3-ylamino)pyridin-2-ylamino)cyclohexylimidedicarbamate (41 mg) was thus obtained.

MS (ESI, m/z): 595 (M+H)

5th step

The following compound was obtained as described in the 2nd step of Example 1.

6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(quinolin-3-ylamino)nicotinamide

(¹H-NMR data and MS data are shown in table 4.)

Example 8

The compounds listed in table 4 were obtained as described in Example 7.

TABLE 4 Number Structure Number Structure Example 8-1 HCl salt

Example 8-2 HCl salt

Example 8-3 HCl salt

Example 8-4 (Example 7) HCl salt

Example 8-5 HCl salt

Example 8-6 HCl salt

Example 8-7 HCl salt

Example 8-8 HCl salt

Example 8-9 HCl salt

Example 8-10 HCl salt

Example 8-11 HCl salt

Number Compound name ¹H-NMR MS (ESI, m/z) Example 6-((2-aminoethyl)amino)-2-((3,5- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.66 (s, 1H), 350 (M + H) 8-1 dimethoxyphenyl)amino)-5-fluoro- 8.00-7.88 (m, 5H), 7.40-7.12 (m, 2H), 6.81 348 (M − H) HCl salt nicotinamide (d, 2H, J = 2.3 Hz), 6.11 (t, 1H, J = 2.3 Hz), 3.73 (s, 6H), 3.70-3.64 (m, 2H), 3.14-3.06 (m, 2H). Example 6-((2-aminoethyl)amino)-2-((3,5- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.51 (s, 1H), 318 (M + H) 8-2 dimethylphenyl)amino)-5-fluoro- 7.88 (d, 1H, J = 12.7 Hz), 7.82-7.60 (m, HCl salt nicotinamide 4H), 7.25-7.20 (m, 4H), 6.60-6.56 (m, 1H), 3.66-3.57 (m, 2H), 3.18-3.08 (m, 2H), 2.24 (s, 6H). Example 6-((2-aminoethyl)amino)-5-fluoro- ¹H-NMR (CD₃OD, 300 MHz) δ: 7.90 (d, 1H, J = 304 (M + H) 8-3 2-(2-methylphenylamino) 8.1 Hz), 7.73 (d, 1H, J = 12.0 Hz), HCl salt nicotinamide 7.25-7.16 (m, 2H), 6.99 (t, 1H, J = 8.1 Hz), 3.61 (t, 2H, J = 5.2 Hz), 3.10 (t, 2H, J = 5.2 Hz), 2.30 (s, 3H). Example 6-((cis-2-aminocyclohexyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.12 (s, 1H), 395 (M + H) 8-4 5-fluoro-2-(quinolin-3-ylamino) 9.35-9.30 (m, 1H), 8.99-8.95 (m, 1H), HCl salt nicotinamide 8.15-8.01 (m, 7H), 7.80-7.70 (m, 2H), 7.45 (brs, 1H), 7.01 (d, 1H, J = 6.8 Hz), 4.45-4.38 (m, 1H), 3.64-3.58 (m, 1H), 1.98-1.84 (m, 2H), 1.78-1.57 (m, 4H), 1.52-1.36 (m, 2H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 300 MHz) δ: 11.78 (s, 1H), 413 (M + H) 8-5 5-fluoro-2-((2-methyl-1,3-benzo 8.40 (d, 1H, J = 2.1 Hz), 7.95-8.00 (m, 6H), HCl salt thiazol-6-yl)amino)nicotinamide 7.36 (dd, 1H, J = 2.1, 8.7 Hz), 7.33-7.18 (m, 1H), 6.93 (d, 1H, J = 6.0 Hz), 4.33-4.23 (m, 1H), 3.77-3.66 (m, 1H), 2.77 (s, 3H), 1.95-1.38 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (CD₃OD, 300 MHz) δ: 9.00 (d, 1H, J = 395 (M + H) 8-6 5-fluoro-2-(quinolin-6-ylamino) 8.4 Hz), 8.95 (dd, 1H, J = 1.4, 5.4 Hz), HCl salt nicotinamide 8.72 (d, 1H, J = 2.3 Hz), 8.25 (dd, 1H, J = 2.4, 9.3 Hz), 8.16 (d, 1H, J = 9.3 Hz), 8.03-7.96 (m, 1H), 7.89 (d, 1H, J = 11.9 Hz), 4.75-4.60 (m, 1H), 3.89-3.86 (m, 1H), 2.15-1.55 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.88 (s, 1H), 412 (M + H) 8-7 5-fluoro-2-((3-(trifluoromethyl) 8.15-8.12 (m, 1H), 7.95 (d, 1H, J = 12.7 HCl salt phenyl)amino)nicotinamide Hz), 7.86-7.70 (m, 3H), 7.65-7.59 (m, 1H), 7.52-7.47 (m, 1H), 7.40-7.30 (m, 1H), 7.29-7.24 (m, 1H), 6.89-6.83 (m, 1H), 4.33-4.25 (m, 1H), 3.56-3.48 (m, 1H), 1.94-1.32 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ•: 11.77 (s, 376 (M − H) 8-8 2-((3-chlorophenyl)amino)-5-fluoro- 1H), 8.01-7.97 (m, 1H), 7.93 (d, 1H, J = HCl salt nicotinamide 12.4 Hz), 7.87-7.72 (m, 3H), 7.35-7.25 (m, 2H), 7.24-7.19 (m, 1H), 7.00-6.90 (m, 2H), 4.29-4.21 (m, 1H), 3.66-3.59 (m, 1H), 1.94-1.37 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.91 (s, 1H), 413 (M + H), 8-9 2-((3,5-dichlorophenyl)amino)-5- 7.96 (d, 1H, J = 12.4 Hz), 7.93-7.82 (m, 415 (M + H) HCl salt fluoronicotinamide 4H), 7.66 (d, 2H, J = 1.8 Hz), 7.46-7.32 (m, 1H), 7.09 (t, 1H, J = 1.8 Hz), 4.29-4.21 (m, 1H), 3.64-3.54 (m, 1H), 1.96-1.36 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.86 (s, 1H), 413 (M + H), 8-10 2-((3,4-dichlorophenyl)amino)-5- 8.18 (d, 1H, J = 2.6 Hz), 8.00-7.81 (m, 4H), 415 (M + H) HCl salt fluoronicotinamide 7.96 (d, 1H, J = 12.3 Hz), 7.49 (d, 1H, J = 8.8 Hz), 7.44-7.32 (m, 1H), 7.30 (dd, 1H, J = 2.4, 8.8 Hz), 7.01-6.94 (m, 1H), 4.31-4.22 (m, 1H), 3.66-3.57 (m, 1H), 1.98-1.38 (m, 8H). Example 6-(2-aminoethylamino)-5-fluoro- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.20 (s, 1H), 341 (M + H), 8-11 2-(quinolin-3-ylamino)nicotinamide 9.40-9.34 (m, 1H), 8.97-8.92 (m, 1H), 339 (M − H) HCl salt 8.10-7.96 (m, 7H), 7.78-7.66 (m, 2H), 7.56-7.48 (m, 1H), 7.44 (brs, 1H), 3.78-3.72 (m, 2H), 3.20-3.12 (m, 2H).

Example 9

1st Step

4-bromoisoquinoline (65 mg), cesium carbonate (170 mg), Pd₂(dba)₃ (29 mg), and Xantphos (36 mg) were added to a 1,4-dioxane (2.1 ml) solution containing methyl2-amino-6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-5-fluoronicotinate (80 mg), followed by stirring at 100° C. for 3 hours in a nitrogen atmosphere. The reaction mixture was cooled to room temperature, and water and ethyl acetate were added. Insoluble matter was removed by filtration, and the filter cake was washed with water and ethyl acetate. The organic layer was collected, washed with saturated saline, and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane:ethyl acetate=10:0 to 1:2), diisopropylether was added, solid matter was collected by filtration, and a light yellow solid of methyl6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-5-fluoro-2-(isoquinoline 4-ylamino)nicotinate (77 mg) was obtained.

MS (ESI, m/z): 510 (M+H), 508 (M−H)

2nd Step

A 1N sodium hydroxide aqueous solution (2 ml) was added to a solution of tetrahydrofuran (2 ml) and methanol (2 ml) containing methyl 6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-5-fluoro-2-(isoquinoline 4-ylamino)nicotinate (75 mg), followed by stirring at 65° C. for 2 hours. The reaction mixture was cooled to room temperature, and the solvent was distilled away under reduced pressure. A saturated aqueous ammonium chloride solution was added to the obtained residue, solid matter was collected by filtration and washed with water and ethyl acetate, and a yellow solid of 6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-5-fluoro-2-(isoquinoline 4-ylamino)nicotinic acid (67 mg) was thus obtained.

MS (ESI, m/z): 496 (M+H), 494 (M−H)

3rd Step

Ammonium chloride (28 mg), WSC.HCl (75 mg), HOBt.H₂O (60 mg), and diisopropylethylamine (180 W) were added to a DMF (1.3 ml) suspension containing 6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-5-fluoro-2-(isoquinoline 4-ylamino)nicotinic acid (65 mg), followed by stirring at room temperature for 3 hours. A saturated aqueous ammonium chloride solution and ethyl acetate were added to the reaction mixture. Solid matter was collected by filtration and washed with water and ethyl acetate, and a light yellow solid of tert-butyl cis-2-(5-aminocarbonyl-3-fluoro-6-(isoquinolin-4-ylamino)pyridin-2-ylamino)cyclohexylcarbamate (47 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.39 (s, 1H), 9.56 (s, 1H), 8.95 (s, 1H), 8.18 (d, 1H, J=8.8 Hz), 8.13 (d, 1H, J=8.2 Hz), 7.96 (d, 1H, J=12.6 Hz), 7.91-7.81 (m, 2H), 7.74-7.68 (m, 1H), 7.40-7.28 (br, 1H), 6.82-6.75 (m, 1H), 6.72-6.65 (m, 1H), 4.12-4.01 (m, 1H), 3.99-3.92 (m, 1H), 1.89-1.03 (m, 17H)

MS (ESI, m/z): 495 (M+H), 493 (M−H)

4th Step

A mixture of tert-butyl cis-2-(5-aminocarbonyl-3-fluoro-6-(isoquinoline 4-ylamino)pyridin-2-ylamino)cyclohexylcarbamate (45 mg) and TFA (0.9 ml) was stirred at room temperature for 30 minutes. The solvent was distilled away under reduced pressure (at 40° C. or less), and ethyl acetate and 4N hydrogen chloride/1,4-dioxane (34 μl) were added to the obtained residue, followed by stirring at room temperature for 30 minutes. Solid matter was collected by filtration and washed with ethyl acetate, and a yellow solid of 6-(cis-2-aminocyclohexylamino)-5-fluoro-2-(isoquinolin-4-ylamino)nicotinamidehydrochloride (47 mg) was thus obtained.

(¹H-NMR data and MS data are shown in table 5.)

Example 10

The compounds listed in table 5 were obtained as described in Example 9.

TABLE 5 Number Structure Number Structure Example 10-1 (Example 9) HCl salt

Example 10-2 HCl salt

Number Compound name ¹H-NMR MS (ESI, m/z) Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 9.56 (s, 393 (M − H) 10-1 5-fluoro-2-(isoquinolin-4- 1H), 9.39-9.33 (m, 1H), 8.48-8.41 (m, 1H), HCl salt ylamino)nicotinamide 8.39-8.33 (m, 1H), 8.24-8.09 (m, 3H), 8.04-7.91 (m, 4H), 7.67-7.58 (m, 1H), 7.23-7.16 (m, 1H), 4.41-4.31 (m, 1H), 3.65-3.57 (m, 1H), 1.95-1.40 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.15 (s, 396 (M + H) 10-2 5-fluoro-2-((1,8-naphthyridin-3- 1H), 9.17 (d, 1H, J = 2.9 Hz), 8.95 (dd, 1H, HCl salt yl)nicotinamide J = 1.6, 4.3 Hz), 8.77 (d, 1H, J = 2.9 Hz), 8.50-8.45 (m, 1H), 8.02 (d, 1H, J = 12.6 Hz), 7.98-7.84 (m, 4H), 7.69 (dd, 1H, J = 4.4, 8.2 Hz), 7.52-7.42 (m, 1H), 7.01-6.96 (m, 1H), 4.48-4.39 (m, 1H), 3.71-3.61 (m, 1H), 1.98-1.40 (m, 8H).

Example 11

1st Step

Calcium carbonate (138 mg) and D-leucinamide.hydrochloride (83 mg) were added to a 1,4-dioxane (1 ml) solution containing 6-chloro-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile (30 mg), followed by reflux for 15 hours. The reaction mixture was cooled to room temperature, and water, sodium chloride, and ethyl acetate were added. The organic layer was collected and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. Diisopropylether was added to the obtained residue, solid matter was collected by filtration, and a yellow solid of (2R)-2-(5-cyano-3-fluoro-6-(quinolin-6-ylamino)pyridin-2-ylamino)-4-methylpentanamide (33 mg) was thus obtained.

MS (ESI, m/z): 393 (M+H), 391 (M−H)

2nd Step

Potassium carbonate (35 mg) and a 30% hydrogen peroxide solution (29 μl) were added to an ethanol (1 ml) solution containing (2R)-2-(5-cyano-3-fluoro-6-(quinolin-6-ylamino)pyridin-2-ylamino)-4-methylpentanamide (20 mg), followed by stirring at room temperature for 1 hour. A 30% hydrogen peroxide solution (29 μl) was added to the reaction mixture, followed by stirring at room temperature for 1 hour. Water, sodium chloride, and ethyl acetate were added to the reaction mixture. The organic layer was collected and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was dissolved in ethyl acetate, and diisopropylether was added. Solid matter was collected by filtration and washed with diisopropylether, and a yellow solid of 6-((2R)-1-amino-4-methyl-1-oxopentan-2-ylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide (8 mg) was thus obtained.

(¹H-NMR data and MS data are shown in table 6.)

Example 12

The compounds listed in table 6 below were obtained as described in Example 11.

TABLE 6 Number Structure Number Structure Example 12-1

Example 12-2

Example 12-3

Example 12-4

Example 12-5

Example 12-6

Example 12-7

Example 12-8

Example 12-9 (Example 11)

Example 12-10

Example 12-11

Example 12-12

Example 12-13

Example 12-14

Example 12-15

Example 12-16

Example 12-17

Example 12-18

Example 12-19

Example 12-20

Example 12-21

Example 12-22

Example 12-23

Example 12-24

Example 12-25

Example 12-26

Example 12-27

Example 12-28

Example 12-29

Example 12-30

Example 12-31

Example 12-32

Example 12-33

Example 12-34

Number Structure Compound name Example 12-35

(R)-6-((1-amino-3-(1H-imidazol-5-yl)-1- oxopropan-2-yl)amino)-5-fluoro-2-((quinolin- 6-yl)amino)nicotinamide Example 12-36

(R)-6-((1-amino-1-oxopropan-2-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide Example 12-37

(R)-6-(1-amino-3,3-dimethyl-1-oxobutan-2- yl)amino)-5-fluoro-2-((quinolin-6-yl)amino) nicotinamide Example 12-38

(R)-6-(1-amino-1-oxopentan-2-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide Number Compound ¹H-NMR MS (ESI, m/z) Example 5-fluoro-6-((2-(1H-imidazol-5-yl) ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.14 (s, 1H), 392 (M + H), 12-1 ethyl)amino)-2-(quinolin-3-yl 11.86 (brs, 1H), 9.02-8.71 (m, 2H), 390 (M − H) amino)nicotinamide 8.03-7.75 (m, 3H), 7.73-7.21 (m, 6H), 7.00-6.86 (m, 1H), 3.85-3.70 (m, 2H), 2.97-2.80 (m, 2H). Example 6-((cyclopropylmethyl)amino)-5- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.01 (s, 1H), 352 (M + H), 12-2 fluoro-2-(quinolin-6-ylamino)- 8.70 (dd, 1H, J = 1.6, 4.0 Hz), 8.65 (d, 1H, 350 (M − H) nicotinamide J = 2.2 Hz), 8.16-8.07 (m, 1H), 8.00-7.64 (m, 4H), 7.61-7.52 (m, 1H), 7.46 (dd, 1H, J = 4.3, 8.2 Hz), 7.25 (brs, 1H), 3.46-3.38 (m, 2H), 1.35-1.21 (m, 1H), 0.55-0.41 (m, 2H), 0.39-0.25 (m, 2H). Example 5-fluoro-6-(((1H-pyrrol-2-yl) 377 (M + H), 12-3 methyl)amino)-2-(quinolin-6- 375 (M − H) ylamino)nicotinamide Example 6-(((1R)-2-amino-2-oxo-1-phenyl ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.92 (s, 1H), 437 (M + H), 12-4 ethyl)amino)-2-(1,3-benzothiazol- 9.19 (s, 1H), 8.39 (d, 1H, J = 2.2 Hz), 435 (M − H) 6-ylamino)-5-fluoronicotinamide 8.02-7.88 (m, 3H), 7.64-7.58 (m, 2H), 7.42-7.26 (m, 7H), 6.98-6.92 (m, 1H), 5.63 (d, 1H, J = 7.3 Hz). Example 6-(((2R)-1-amino-4-methyl-1-oxo ¹H-NMR (CD₃OD, 400 MHz) δ: 8.94 (s, 1H), 417 (M + H), 12-5 pentan-2-yl)amino-2-(1,3-benzo 8.59 (d, 1H, J = 2.3 Hz), 7.83 (d, 1H, J = 439 (M + Na), thiazol-6-ylamino)-5-fluoronicotinamide 8.9 Hz), 7.66 (d, 1H, J = 12.2 Hz), 7.39 (dd, 415 (M − H) 1H, J = 2.3, 8.9 Hz), 4.53-4.48 (m, 1H), 1.77-1.66 (m, 3H), 0.91 (d, 3H, J = 6.3 Hz), 0.82 (d, 3H, J = 6.3 Hz). Example 6-(((2R)-1-amino-1-oxo-3-phenyl ¹H-NMR (CD₃OD, 400 MHz) δ: 9.05 (s, 1H), 451 (M + H), 12-6 propan-2-yl)amino)-2-(1,3-benzo 8.54 (d, 1H, J = 1.9 Hz), 7.94 (d, 1H, J = 449 (M − H) thiazol-6-ylamino)-5-fluoronicotinamide 8.8 Hz), 7.69 (d, 1H, J = 12.0 Hz), 7.49 (dd, 1H, J = 1.9, 8.8 Hz), 7.29-7.10 (m, 5H), 5.10-4.40 (1H, overlapping with H₂O peak), 3.14-3.04 (m, 2H). Example 6-(((1S)-2-amino-2-oxo-1-phenyl ¹H-NMR (CD₃OD, 400 MHz) δ: 9.04 (s, 1H), 437 (M + H), 12-7 ethyl)amino)-2-(1,3-benzothiazol- 8.44 (d, 1H, J = 1.9 Hz), 7.90 (d, 1H, J = 435 (M − H) 6-ylamino)-5-fluoronicotinamide 8.5 Hz), 7.77 (d, 1H, J = 11.9 Hz), 7.58-7.54 (m, 2H), 7.48-7.28 (m, 4H), 5.66 (s, 1H). Example 6-(((1R)-2-amino-2-oxo-1-phenyl ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.00 (s, 1H), 431 (M + H), 12-8 ethyl)amino)-5-fluoro-2-(quino- 8.74-8.67 (m, 1H), 8.37-8.28 (m, 1H), 8.19 429 (M − H) lin-6-ylamino)nicotinamide (d, 1H, J = 2.4 Hz), 8.07-7.80 (m, 4H), 7.70 (dd, 1H, J = 2.4, 9.3 Hz), 7.58 (d, 2H, J = 7.3 Hz), 7.52-7.24 (m, 6H), 7.07-6.96 (m, 1H), 5.67 (d, 1H, J = 7.3 Hz). Example 6-(((2R)-1-amino-4-methyl-1-oxo ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.03 (s, 1H), 411 (M + H), 12-9 pentan-2-yl)amino)-5-fluoro-2- 8.68 (dd, 1H, J = 1.6, 4.3 Hz), 8.58 (d, 1H, 409 (M − H) (quinolin-6-ylamino)nicotinamide J = 2.3 Hz), 8.47-8.41 (m, 1H), 7.94 (d, 1H, J = 12.4 Hz), 7.91-7.76 (m, 2H), 7.60 (dd, 1H, J = 2.3, 9.0 Hz), 7.52-7.13 (m, 5H), 4.61-4.51 (m, 1H), 1.89-1.64 (m, 3H), 0.92 (d, 3H, J = 6.1 Hz), 0.82 (d, 3H, J = 6.1 Hz). Example ((2R)-2-(5-aminocarbonyl-6-(1,3- ¹H-NMR (CD₃OD, 400 MHz) δ: 9.02 (s, 1H), 418 (M + H), 12-10 benzothiazol-6-ylamino)-3- 8.83 (d, 1H, J = 2.0 Hz), 7.90 (d, 1H, J = 416 (M − H) fluoropyridin-2-yl)amino)-4-methyly 8.9 Hz), 7.72 (d, 1H, J = 12.0 Hz), 7.40 (dd, aleric acid 1H, J = 2.0, 8.9 Hz), 4.78-4.74 (m, 1H), 1.92-1.72 (m, 3H), 1.01 (d, 3H, J = 6.3 Hz), 0.93 (d, 3H, J = 6.3 Hz). Example (2R)-2-((5-aminocarbonyl-6-(1,3- ¹H-NMR (CD₃OD, 400 MHz) δ: 9.28 (s, 1H), 452 (M + H), 12-11 benzothiazol-6-ylamino)-3- 8.80 (d, 1H, J = 2.2 Hz), 7.93 (d, 1H, J = 450 (M − H) fluoropyridin-2-yl)amino)-3-phenyl 8.8 Hz), 7.71 (d, 1H, J = 12.0 Hz), 7.45 (dd, propionic acid 1H, J = 2.2, 8.8 Hz), 7.28-7.16 (m, 5H), 4.85-4.80 (m, 1H), 3.24-3.16 (m, 2H). Example 6-((2R)-1-amino-1-oxo-3-phenyl- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.03 (s, 1H), 445 (M + H), 12-12 propan-2-ylamino)-5-fluoro-2- 8.82-8.72 (m, 1H), 8.59-8.45 (m, 2H), 443 (M − H) (quinolin-6-ylamino)nicotinamide 8.00-7.85 (m, 3H), 7.75-7.46 (m, 3H), 7.43-7.10 (m, 8H), 4.76-4.65 (m, 1H), 3.60-3.22 (1H, overlapping with H₂O peak), 3.22-3.10 (m, 1H). Example 6-(((1R)-2-amino-2-oxo-1-phenyl ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.12 (s, 1H), 431 (M + H), 12-13 ethyl)amino)-5-fluoro-2- 8.74-8.67 (m, 2H), 8.10-7.84 (m, 5H), 429 (M − H) (quinolin-3-ylamino)nicotinamide 7.66-7.23 (m, 9H), 7.14-7.04 (m, 1H), 5.68 (d, 1H, J = 7.3 Hz). Example 5-fluoro-6-((2-(1H-imidazol-5-yl) ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.10-12.04 392 (M + H), 12-14 ethyl)amino)-2-(quinolin-6-yl (m, 1H), 11.96-11.80 (m, 1H), 8.70-8.58 (m, 390 (M − H) amino)nicotinamide 2H), 8.02-8.52 (m, 7H), 7.40-7.16 (m, 2H), 6.91 (s, 1H), 3.85-3.75 (m, 2H), 2.90 (t, 2H, J = 7.6 Hz). Example 5-fluoro-6-(((1H-imidazol-5-yl) ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.97 (s, 1H), 378 (M + H), 12-15 methyl)amino)-2-(quinolin-6- 11.82 (brs, 1H), 8.66 (dd, 1H, J = 1.5, 376 (M − H) ylamino)nicotinamide 4.1 Hz), 8.57 (d, 1H, J = 2.2 Hz), 8.09 (d, 1H, J = 7.8 Hz), 7.95-7.55 (m, 6H), 7.39 (dd, 1H, J = 4.1, 8.3 Hz), 7.35-7.15 (brs, 1H), 6.89 (s, 1H), 4.67-4.60 (m, 2H). Example 5-fluoro-6-((pyridin-2-ylmethyl) ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.97 (s, 1H), 389 (M + H), 12-16 amino)-2-(quinolin-6-ylamino) 8.69-8.63 (m, 1H), 8.61-8.56 (m, 1H), 387 (M − H) nicotinamide 8.35-8.30 (m, 1H), 8.14-7.94 (m, 3H), 7.90-7.68 (m, 3H), 7.53-7.19 (m, 5H), 4.83 (d, 2H, J = 5.9 Hz). Example 5-fluoro-6-((pyridin-3-ylmethyl) ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.95 (s, 1H), 389 (M + H), 12-17 amino)-2-(quinolin-6-ylamino) 8.66 (dd, 1H, J = 1.7, 4.2 Hz), 8.60 (d, 1H, 387 (M − H) nicotinamide J = 1.7 Hz), 8.45-8.39 (m, 1H), 8.20 (d, 1H, J = 2.4 Hz), 8.03 (t, 1H, 6.1 Hz), 7.97 (d, 1H, J = 12.7 Hz), 7.88-7.72 (m, 4H), 7.65 (dd, 1H, J = 2.4, 9.0 Hz), 7.42-7.24 (m, 3H), 4.75 (d, 2H, J = 6.1 Hz). Example 5-fluoro-6-((pyridin-4-ylmethyl) ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.93 (s, 1H), 389 (M + H), 12-18 amino)-2-(quinolin-6-ylamino) 8.65 (dd, 1H, J = 1.7, 4.1 Hz), 8.54-8.46 387 (M − H) nicotinamide (m, 2H), 8.07 (d, 1H, J = 2.4 Hz), 8.04 (t, 1H, J = 6.1 Hz), 7.99 (d, 1H, J = 12.4 Hz), 7.88-7.76 (m, 1H), 7.76-7.68 (m, 2H), 7.59 (dd, 1H, J = 2.4, 9.3 Hz), 7.42-7.24 (m, 4H), 4.74 (d, 2H, J = 6.1 Hz). Example 6-((2-amino-2-oxo-ethyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.02 (s, 1H), 355 (M + H), 12-19 5-fluoro-2-(quinolin-6-ylamino) 8.70-8.66 (m, 1H), 8.52 (d, 1H, J = 2.4 Hz), 353 (M − H) nicotinamide 8.36 (d, 1H, J = 7.8 Hz), 7.98-7.75 (m, 3H), 7.61 (dd, 1H, J = 2.4, 9.0 Hz), 7.58-7.48 (m, 2H), 7.41 (dd, 1H, J = 4.3, 8.4 Hz), 7.38-7.19 (m, 2H), 4.00 (d, 2H, J = 6.1 Hz). Example 5-fluoro-6-(((1H-imidazol-5-yl) ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.04 (s, 1H), 378 (M + H), 12-20 methyl)amino)-2-(quinolin-3- 8.84-8.77 (m, 2H), 7.96 (d, 1H, J = 12.7 376 (M − H) ylamino)nicotinamide Hz), 7.92-7.73 (m, 4H), 7.72-7.66 (m, 1H), 7.56-7.44 (m, 2H), 7.30 (brs, 1H), 6.99 (s, 1H), 4.66 (d, 2H, J = 5.6 Hz). Example 5-fluoro-6-((2-hydroxyethyl) ¹H-NMR (CD₃OD, 400 MHz) δ: 8.65 (d, 1H, J = 342 (M + H), 12-21 amino)-2-(quinolin-6-ylamino) 2.4 Hz), 8.62 (dd, 1H, J = 1.7, 4.4 Hz), 340 (M − H) nicotinamide 8.30-8.24 (m, 1H), 7.90 (d, 1H, J = 9.2 Hz), 7.75 (dd, 1H, J = 2.4, 9.2 Hz), 7.70 (d, 1H, J = 12.4 Hz), 7.44 (dd, 1H, J = 4.4, 8.3 Hz), 3.88-3.83 (m, 2H), 3.78-3.73 (m, 2H). Example 5-fluoro-6-(methylamino)-2- ¹H-NMR (CD₃OD, 400 MHz) δ: 8.57 (d, 1H, J = 312 (M + H), 12-22 (quinolin-6-ylamino)nicotinamide 2.3 Hz), 8.55-8.49 (m, 1H), 8.10-8.06 (m, 310 (M − H) 1H), 7.80 (d, 1H, J = 9.1 Hz), 7.73 (dd, 1H, J = 2.3, 9.1 Hz), 7.57 (d, 1H, J = 12.2 Hz), 7.34 (dd, 1H, J = 4.4, 8.3 Hz), 3.06 (s, 3H). Example 6-(((2R)-1-hydroxy-3-phenyl- ¹H-NMR (CD₃OD, 400 MHz) δ: 8.64 (dd, 1H, J = 430 (M − H) 12-23 propan-2-yl)amino)-5-fluoro-2- 1.7, 4.4 Hz), 8.44 (d, 1H, J = 2.4 Hz), (quinolin-6-ylamino)nicotinamide 8.17-8.13 (m, 1H), 7.91 (d, 1H, J = 9.1 Hz), 7.76 (dd, 1H, J = 2.3, 9.1 Hz), 7.67 (d, 1H, J = 12.2 Hz), 7.41 (dd, 1H, 4.4, 8.3 Hz), 7.32-7.14 (m, 4H), 7.10-7.06 (m, 1H), 4.66-4.58 (m, 1H), 3.70 (d, 2H, J = 5.4 Hz), 3.02 (dd, 1H, J = 7.1, 13.4 Hz), 2.90 (dd, 1H, J = 7.3, 13.4 Hz). Example 5-fluoro-6-(((1R)-2-hydroxy-1- ¹H-NMR (CD₃OD, 400 MHz) δ: 8.63-8.60 (m, 418 (M + H), 12-24 phenylethyl)amino)-2-(quinolin-6- 1H), 8.13-8.08 (m, 1H), 8.06 (d, 1H, J = 2.2 416 (M − H) ylamino)nicotinamide Hz), 7.81 (d, 1H, J = 9.0 Hz), 7.75-7.70 (m, 2H), 7.46-7.30 (m, 5H), 7.26-7.20 (m, 1H), 5.42-5.36 (m, 1H), 3.98-3.86 (m, 2H). Example 6-(((2R)-1-amino-1-oxo-3-phenyl ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.08 (s, 1H), 445 (M + H), 12-25 propan-2-yl)amino)-5-fluoro-2- 8.85 (d, 1H, J = 2.6 Hz), 8.70 (d, 1H, J = 443 (M − H) quinolin-3-ylamino)nicotinamide 2.6 Hz), 8.13-8.03 (m, 1H), 8.00-7.75 (m, 3H), 7.67-7.50 (m, 3H), 7.40-7.10 (m, 8H), 4.77-4.67 (m, 1H), 3.40-3.21 (1H, overlapping with H₂O peak), 3.21-3.09 (m, 1H). Example 5-fluoro-6-(((1R)-3-methyl-1-(1- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.93 (s, 1H), 436 (M + H), 12-26 (1H-tetrazol-5-yl)butyl)amino)-2- 8.67 (dd, 1H, J = 1.7, 4.2 Hz), 8.28-8.16 434 (M − H) (quinolin-6-ylamino)nicotinamide (m, 2H), 8.04-7.67 (m, 5H), 7.50 (dd, 1H, J = 2.3, 8.9 Hz), 7.43 (dd, 1H, J = 4.2, 8.3 Hz), 7.39-7.23 (m, 1H), 5.75-5.65 (m, 1H), 2.11-1.98 (m, 1H), 1.94-1.82 (m, 1H), 1.80-1.65 (m, 1H), 0.91 (d, 3H, J = 6.5 Hz), 0.84 (d, 3H, J = 6.5 Hz). Example 5-fluoro-2-(quinolin-6-ylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.97 (s, 1H), 379 (M + H), 12-27 6-(((1H-1,2,3-triazol-5-yl) 10.24-10.15 (m, 1H), 8.71-8.62 (m, 1H), 377 (M − H) methyl)amino)nicotinamide 8.48-8.40 (m, 1H), 8.10-7.53 (m, 7H), 7.44-7.18 (m, 2H), 4.78 (d, 2H, J = 5.6 Hz). Example 5-fluoro-6-(((1H-imidazol-2-yl) ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.96 (s, 1H), 378 (M + H), 12-28 methyl)amino)-2-(quinolin-6- 11.76 (brs, 1H), 8.64 (dd, 1H, J = 1.5, 4.2 376 (M − H) ylamino)nicotinamide Hz), 8.39 (d, 1H, J = 2.4 Hz), 8.22-8.14 (m, 1H), 7.94 (d, 1H, J = 12.7 Hz), 7.86-7.66 (m, 3H), 7.51 (dd, 1H, J = 2.4, 9.0 Hz), 7.38 (dd, 1H, J = 4.2, 8.3 Hz), 7.28 (brs, 1H), 7.01 (s, 1H), 6.87 (s, 1H), 4.73 (d, 2H, J = 5.9 Hz). Example 5-fluoro-6-(((1R)-1-(1H-imidazol- 468 (M + H), 12-29 2-yl)-2-phenylethyl)amino)-2- 466 (M − H) (quinolin-6-ylamino)nicotinamide Example 5-fluoro-6-(((1R)-1-(1H-imidazol- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.95 (s, 1H), 434 (M + H), 12-30 2-yl)-3-methylbutyl)amino)-2- 11.69 (brs, 1H), 8.74-8.47 (m, 2H), 8.39 432 (M − H) (quinolin-6-ylamino)nicotinamide (d, 1H, J = 8.3 Hz), 8.00-7.71 (m, 3H), 7.68-7.19 (m, 4H), 7.12-6.76 (m, 2H), 5.64-5.47 (m, 1H), 1.94-1.77 (m, 2H), 1.70-1.51 (m, 1H), 0.87 (d, 3H, J = 6.4 Hz), 0.80 (d, 3H, J = 6.4 Hz). Example 6-(((2R)-1-amino-1-oxobutan-2-yl) ¹H-NMR (CD₃OD, 400 MHz) δ: 8.56-8.50 (m, 383 (M + H), 12-31 amino)-5-fluoro-2-(quinolin-6- 1H), 8.43 (d, 1H, J = 2.2 Hz), 8.41-8.37 (m, 381 (M − H) ylamino)nicotinamide 1H), 7.81 (d, 1H, J = 9.0 Hz), 7.69 (d, 1H, J = 12.2 Hz), 7.62 (dd, 1H, J = 2.4, 9.0 Hz), 7.36 (dd, 1H, J = 4.2, 8.3 Hz), 4.44 (dd, 1H, J = 4.2, 8.3 Hz), 2.06-1.76 (m, 2H), 1.02-0.96 (m, 3H). Example 6-(((2R)-1-amino-3-methyl-1-oxo- ¹H-NMR (CD₃OD, 400 MHz) δ: 8.56-8.52 (m, 397 (M + H), 12-32 butan-2-yl)amino)-5-fluoro-2- 1H), 8.44-8.40 (m, 1H), 8.40-8.36 (m, 1H), 395 (M − H) (quinolin-6-ylamino)nicotinamide 7.85-7.80 (m, 1H), 7.70 (d, 1H, J = 12.0 Hz), 7.67-7.62 (m, 1H), 7.39-7.34 (m, 1H), 4.50-4.46 (m, 1H), 2.30-2.20 (m, 1H), 1.04-0.90 (m, 6H). Example 6-(((2R)-1-amino-3-(4-fluoro- ¹H-NMR (CD₃OD, 400 MHz) δ: 8.66-8.62 485 (M + Na), 12-33 phenyl)-1-oxopropan-2-yl)amino)-5- (m, 1H), 8.47-8.37 (m, 1H), 7.90 (d, 1H, J = 461 (M − H) fluoro-2-(quinolin-6-ylamino) 9.0 Hz), 7.76-7.66 (m, 1H), 7.50-7.40 (m, nicotinamide 1H), 7.29-7.20 (m, 3H), 7.04-6.98 (m, 2H), 6.96-6.88 (m, 1H), 3.55-3.49 (m, 1H), 2.97 (dd, 1H, J = 6.0, 13.5 Hz), 2.79 (dd, 1H, J = 7.3, 13.5 Hz). Example 6-(((2R)-1-amino-3-(4-methoxy- ¹H-NMR (CD₃OD, 400 MHz) δ: 8.64 (dd, 1H, J = 475 (M + H), 12-34 phenyl)-1-oxopropan-2-yl)amino)-5- 1.6, 4.4 Hz), 8.48 (d, 1H, J = 2.4 Hz), 473 (M − H) fluoro-2-(quinolin-6-ylamino) 8.42 (d, 1H, J = 8.5 Hz), 7.92 (d, 1H, J = nicotinamide 9.0 Hz), 7.76-7.67 (m, 2H), 7.45 (dd, 1H, J = 4.4, 8.5 Hz), 7.19-7.13 (m, 2H), 6.79-6.74 (m, 2H), 5.00-4.70 (1H, overlapping with H₂O peak), 3.71 (s, 3H), 3.34-3.20 (m, 1H), 3.30-3.20 (1H, overlapping with CH₃OH peak). Mass Mass Number salt solvent NMR 1HNMR (M + H) (M − H) rt (min) Example 12-35 free 435 433 Example 12-36 free 369 367 Example 12-37 free 411 409 Example 12-38 free 397 395

Example 13

1st Step

tert-Butyl((2S)-1-aminopropan-2-yl)carbamate (63 mg) and potassium carbonate (139 mg) were added to a 1,4-dioxane (2 ml) solution containing 6-chloro-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile (60 mg), followed by reflux for 13 hours. The reaction mixture was cooled to room temperature. Ethyl acetate and a saturated aqueous sodium hydrogen carbonate solution were added. The resultant was subjected to extraction with ethyl acetate three times. The extracts were combined and dried over anhydrous sodium sulfate. The solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography, and colorless oily matter (50 mg) was thus obtained.

2nd Step

A 1N sodium hydroxide aqueous solution (573 μl) and 30% hydrogen peroxide solution (65 μl) were added to an ethanol (1 ml) solution containing colorless oily matter (50 mg) obtained in the 1st step, followed by stirring at room temperature for 5 minutes. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, solid matter was collected by filtration, and a light yellow solid was thus obtained.

3rd Step

4N hydrogen chloride/1,4-dioxane was added to a suspension of methanol (1 ml) and chloroform (1 ml) containing the light yellow solid obtained in the 2nd step, followed by stirring at room temperature for 3 hours and 30 minutes. Methanol and ethyl acetate were added to the reaction mixture, solid matter was collected by filtration, and an orange solid of 6-((2S)-2-aminopropylamino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide (28 mg) was thus obtained.

(¹H-NMR data and MS data are shown in table 7.)

Example 14

The compounds listed in table 7 were obtained as described in Example 13.

TABLE 7 Number Structure Example 14-1 HCl salt

Example 14-2 HCl salt

Example 14-3 HCl salt

Example 14-4 HCl salt

Example 14-5 HCl salt

Example 14-6 HCl salt

Example 14-7 HCl salt

Example 14-8 HCl salt

Example 14-9 (Example 13) HCl salt

Example 14-10 HCl salt

Number Structure Compound name Example 14-11

6-((2-amino-2-methylpropyl)amino)-5-fluoro- 2-((quinolin-6-yl)amino)nicotinamide Example 14-12

6-((1-amino-2-methylpropan-2-yl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide Example 14-13

6-((2-amino-2-cyclopropylethyl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide Example 14-14

6-((1-aminocyclopropylmethyl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide Example 14-15

(S)-6-((2-amino-3,3-dimethylbutyl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide Example 14-16

6-((2-amino-3,3,3-trifluoropropyl)amino)-5- fluoro-2-((quinolin-6-yl)amino)nicotinamide Example 14-17

(R)-6-((2-amino-2-(pyridin-2-yl)ethyl)amino)- 5-fluoro-2-((quinolin-6-yl)amino)nicotinamide Example 14-18

(S)-6-((2-amino-2-(pyridin-3-yl)ethyl)amino)- 5-fluoro-2-((quinolin-6-yl)amino)nicotinamide Example 14-19

(S)-6-((2-amino-2-(thiophene-3-yl)ethyl) amino)-5-fluoro-2-((quinolin-6-yl)amino) nicotinamide Example 14-20

(R)-5-fluoro-6-((3-methyl-1-(1H-1,2,3-triazol- 5-yl)butyl)amino)-2-(quinolin-6-yl)amino) nicotinamide Example 14-21

5-fluoro-6-((2-piperidin-2-ylmethyl)amino)-2- (quinolin-6-yl)amino)nicotinamide Number Compound name ¹H-NMR MS (ESI, m/z) Example 6-(((2S)-2-aminobutyl)amino)-5- ¹H-NMR (CD₃OD, 300 MHz) δ: 9.00 (d, 1H, J = 369 (M + H) 14-1 fluoro-2-(quinolin-6-ylamino) 8.4 Hz), 8.94 (dd, 1H, J = 1.4, 5.3 Hz), HCl salt nicotinamide 8.65 (d, 1H, J = 2.3 Hz), 8.29 (dd, 1H, J = 2.3, 9.3 Hz), 8.15 (d, 1H, J = 9.3 Hz), 8.00-7.95 (s, 1H), 7.87 (d, 1H, J = 11.9 Hz), 4.01 (dd, 1H, J = 4.0, 14.6 Hz), 3.74-3.63 (m, 1H), 3.56-3.43 (m, 1H), 1.85-1.62 (m, 2H), 0.99 (t, 3H, J = 7.6 Hz). Example 6-(((2S)-2-amino-3-methylbutyl) ¹H-NMR (CD₃OD, 300 MHz) δ: 9.03 (d, 1H, J = 383 (M + H) 14-2 amino)-5-fluoro-2-(quinolin-6-yl- 8.0 Hz), 8.96 (dd, 1H, J = 1.4, 5.5 Hz), HCl salt amino)nicotinamide 8.64 (d, 1H, J = 2.2 Hz), 8.31 (dd, 1H, J = 2.4, 9.3 Hz), 8.16 (d, 1H, J = 9.1 Hz), 8.02-7.97 (m, 1H), 7.87 (d, 1H, J = 11.9 Hz), 4.02 (dd, 1H, J = 3.7, 14.4 Hz), 3.81-3.70 (m, 1H), 3.46-3.37 (m, 1H), 2.12-1.97 (m, 1H), 1.05-1.00 (m, 6H). Example 6-(((2S)-2-amino-3-phenylpropyl) ¹H-NMR (CD₃OD, 300 MHz) δ: 8.96-8.89 (m, 431 (M + H) 14-3 amino)-5-fluoro-2-(quinolin-6- 2H), 8.57 (d, 1H, J = 2.3 Hz), 8.27 (dd, 1H, HCl ylamino)nicotinamide J = 2.3, 9.3 Hz), 8.13 (d, 1H, J = 9.3 Hz), 7.98-7.93 (m, 1H), 7.87 (d, 1H, J = 11.9 Hz), 7.16-7.01 (m, 5H), 4.02-3.74 (m, 3H), 3.11-2.89 (s, 2H). Example 6-(((2R)-2-aminobutyl)amino)-5- ¹H-NMR (CD₃OD, 300 MHz) δ: 9.03 (d, 1H, J = 369 (M + H) 14-4 fluoro-2-(quinolin-6-ylamino) 8.1 Hz), 8.95 (dd ,1H, J = 1.3, 5.4 Hz), HCl salt nicotinamide 8.67 (d, 1H, J = 2.3 Hz), 8.30 (dd, 1H, J = 2.3, 9.3 Hz), 8.17 (d, 1H, J = 9.3 Hz), 8.02-7.97 (m, 1H), 7.87 (d, 1H, J = 11.9 Hz), 4.01 (dd, 1H, J = 4.0, 14.4 Hz), 3.76-3.64 (m, 1H), 3.57-3.46 (m, 1H), 1.87-1.62 (m, 2H), 0.99 (t, 3H, J = 7.6 Hz). Example 6-(((2S)-2-amino-2-phenylethyl) ¹H-NMR (CD₃OD, 300 MHz) δ: 8.89 (dd, 1H, J = 417 (M + H) 14-5 amino)-5-fluoro-2-(quinolin-6-yl- 1.4, 5.4 Hz), 8.70 (d, 1H, J = 2.1 Hz), HCl salt amino)nicotinamide 8.20-8.00 (m, 3H), 7.89 (d, 1H, J = 11.9 Hz), 7.78-7.73 (m, 1H), 7.47-7.26 (m, 5H), 4.70 (dd, 1H, J = 3.3, 10.0 Hz), 4.33 (dd, 1H, J = 3.6, 14.5 Hz), 4.09-4.00 (m, 1H). Example 6-(((2R)-2-amino-3-methoxypropyl) ¹H-NMR (CD₃OD, 300 MHz) δ: 9.03 (d, 1H, J = 385 (M + H) 14-6 amino)-5-fluoro-2-(quinolin-6- 8.4 Hz), 8.95 (dd, 1H, J = 1.4, 5.4 Hz), HCl salt ylamino)nicotinamide 8.83 (d, 1H, J = 2.2 Hz), 8.22 (dd, 1H, J = 2.3, 9.3 Hz), 8.15 (d, 1H, J = 9.2 Hz), 8.02-7.98 (m, 1H), 7.88 (d, 1H, J = 11.9 Hz), 3.92-3.59 (m, 5H), 3.38 (s, 3H). Example 5-fluoro-6-((3R)-pyrrolidin-3-yl- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.12 (s, 1H), 367 (M + H), 14-7 amino)-2-(quinolin-6-ylamino)ni- 8.92-8.84 (m, 1H), 8.72-8.56 (m, 2H), 365 (M − H) HCl salt cotinamide 8.30-8.14 (m, 3H), 8.10-8.00 (m, 3H), 7.98-7.88 (m, 1H), 7.76-7.66 (m, 1H), 7.52-7.36 (m, 1H), 4.08-3.80 (m, 5H), 2.36-2.30 (m, 1H), 2.20-2.10 (m, 1H). Example 5-fluoro-6-((3S)-pyrrolidin-3-yl- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.21 (s, 1H), 367 (M + H), 14-8 amino)-2-(quinolin-6-ylamino)ni- 9.00-8.92 (m, 1H), 8.89-8.78 (m, 1H), 365 (M − H) HCl salt cotinamide 8.78-8.72 (m, 1H), 8.40-8.23 (m, 3H), 8.20-790 (m, 4H), 7.88-7.76 (m, 1H), 7.56-7.37 (m, 1H), 4.10-3.80 (m, 5H), 2.38-2.28 (m, 1H), 2.20-2.09 (m, 1H). Example 6-(((2S)-2-aminopropyl)amino-5- ¹H-NMR (CD₃OD, 300 MHz) δ: 9.01 (d, 1H, J = 355 (M + H) 14-9 fluoro-2-(quinolin-6-ylamino)ni- 8.5 Hz), 8.94 (dd, 1H, J = 1.3, 5.4 Hz), HCl salt cotinamide 8.69 (d, 1H, J = 2.2 Hz), 8.28 (dd, 1H, J = 2.3, 9.3 Hz), 8.16 (d, 1H, J = 9.3 Hz), 8.01-7.96 (m, 1H), 7.86 (d, 1H, J = 11.9 Hz), 3.95 (dd, 1H, J = 2.8, 12.8 Hz), 3.78-3.62 (m, 2H), 1.37 (d, 3H, J = 6.3 Hz). Example 6-(((2S)-2-amino-4-methyl ¹H-NMR (CD₃OD, 300 MHz) δ: 9.04 (d, 1H, J = 397 (M + H) 14-10 pentyl)amino)-5-fluoro-2- 8.3 Hz), 8.96 (dd, 1H, J = 1.3, 5.4 Hz), HCl salt (quinolin-6-ylamino)nicotinamide 8.65 (d, 1H, J = 2.2 Hz), 8.26 (dd, 1H, J = 2.3, 9.2 Hz), 8.16 (d, 1H, J = 9.3 Hz), 8.02-7.97 (m, 1H), 7.87 (d, 1H, J = 11.9 Hz), 4.03 (dd, 1H, J = 3.0, 14 Hz), 3.68-3.53 (m, 2H), 1.72-1.41 (m, 3H), 0.70 (d, 3H, J = 6.5 Hz), 0.63 (d, 3H, J = 6.5 Hz). Mass Mass Number Salt Solvent NMR 1HNMR (M + H) (M − H) rt(min) Example 14-11 HCl 369 367 0.53 Example 14-12 HCl 369 367 0.59 Example 14-13 HCl 381 379 0.57 Example 14-14 HCl 367 365 0.54 Example 14-15 HCl 397 395 0.62 Example 14-16 free 410 408 0.82 Example 14-17 HCl 418 416 0.59 Example 14-18 HCl 418 416 0.55 Example 14-19 HCl 423 421 0.63 Example 14-20 free CD3OD 400 MHz δ: 8.62 (dd, 1H, J = 1.6, 4.4 Hz), 436 433 8.56-8.18 (m, 2H), 7.87 (d, 1H, J = 9.3 Hz), 7.80-7.58 (m, 3H), 7.44 (dd, 1H, J = 4.4, 8.3 Hz), 5.80-5.70 (m, 1H), 2.02-1.70 (m, 3H), 0.97 (d, 3H, J = 6.5 Hz), 0.92 (d, 3H, J = 6.5 Hz) Example 14-21 HCl CD3OD 400 MHz δ: 9.06 (d, 1H, J = 8.5 Hz), 8.98-8.92 395 393 (m, 1H), 8.66 (d, 1H, J = 2.2 Hz), 8.32 (dd, 1H, J = 2.2, 9.3 Hz), 8.18 (d, 1H, J = 9.3 Hz), 8.00 (dd, 1H, J = 5.4, 8.5 Hz), 7.87 (d, 1H, J = 12.0 Hz), 4.00- 3.91 (m ,1H), 3.80-3.70 (m, 1H), 3.58- 3.46 (m, 1H), 2.96-2.84 (m, 1H), 2.10- 1.30 (m, 7H)

Example 15

1st Step

The following compound was obtained as described in the 1st step of Reference Example 2.

Ethyl 2-(3,5-dimethoxyphenylamino)-6-ethylamino-5-fluoronicotinate

¹H-NMR (CDCl₃, 400 MHz) δ: 10.47 (s, 1H), 7.67 (d, 1H, J=11.7 Hz), 6.99 (d, 2H, J=2.3 Hz), 6.16 (t, 1H, J=2.3 Hz), 5.02-4.96 (m, 1H), 4.30 (q, 2H, J=7.2 Hz), 3.79 (s, 6H), 3.68-3.59 (m, 2H), 1.37 (t, 3H, J=7.2 Hz), 1.31 (d, 3H, J=7.2 Hz)

2nd and 3rd Steps

The following compound was obtained as described in the 3rd and 4th steps of Example 7.

2-(3,5-dimethoxyphenylamino)-6-(ethylamino)-5-fluoronicotinamide

(¹H-NMR and ESI-MS data are shown in table 8.)

Example 16

The compounds listed in table 8 were obtained as described in Example 15.

TABLE 8 Number Structure Example 16-1 (Example 15)

Example 16-2

Example 16-3

Example 16-4

Example 16-5

Example 16-6

Example 16-7

Example 16-8

Example 16-9

Example 16-10

Example 16-11

Example 16-12

Example 16-13

Example 16-14

Example 16-15

Example 16-16

Example 16-17

Example 16-18

Example 16-19 (*)

Example 16-20 (*)

Example 16-21 (*)

Example 16-22 (*)

Example 16-23

Example 16-24

Number Compound name ¹H-NMR MS (ESI, m/z) Example 2-((3,5-dimethoxyphenyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.70 (s, 1H), 335 (M + H) 16-1 6-(ethylamino)-5-fluoronico- 7.81 (d, 1H, J = 12.8 Hz), 7.27 (t, 1H, J = tinamide 5.4 Hz), 6.87 (t, 2H, J = 2.2 Hz), 6.07 (t, 1H, J = 2.2 Hz), 3.71 (s, 6H), 3.45 (dt, 2H, J = 7.1 Hz, 12.8 Hz), 1.17 (t, 3H, J = 7.1 Hz). Example 2-((3,5-dimethoxyphenyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.67 (s, 1H), 349 (M + H) 16-2 5-fluoro-6-(isopropylamino) 7.81 (d, 1H, J = 12.7 Hz), 7.02 (d, 1H, J = nicotinamide 7.9 Hz), 6.83 (d, 2H, J = 2.2 Hz), 6.07 (t, 1H, J = 2.2 Hz), 4.35-4.25 (m, 1H), 3.71 (s, 6H), 1.20 (d, 6H, J = 6.5 Hz). Example 2-((3,5-dimethoxyphenyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.53 (s, 1H), 349 (M + H) 16-3 6-(ethyl(methyl)amino)-5-fluoro 7.88 (d, 1H, J = 15.5 Hz), 6.80 (d, 2H, J = nicotinamide 2.2 Hz), 6.08 (t, 1H, J = 2.3 Hz), 3.71 (s, 6H), 3.61-3.54 (m, 2H), 3.15-3.12 (s, 3H), 1.15 (t, 3H, J = 7.0 Hz). Example 6-((4-(1E)-3-amino-3-oxoprop-1- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.66 (s, 1H), 466 (M + H) 16-4 en-1-yl)benzyl)amino)-2-((3,5-di- 7.93-7.85 (m, 2H), 7.54-7.27 (m, 6H), methoxyphenyl)amino)-5-fluoro- 7.10-7.02 (m, 1H), 6.78 (s, 2H), 6.60-6.50 nicotinamide (s, 1H), 6.06 (s, 1H), 4.75-4.64 (m, 2H), 3.62 (s, 6H). Example 6-((2-amino-2-oxoethyl)amino)-2- ¹H-NMR (CD₃OD, 400 MJz) δ: 7.61 (d, 1H, J = 362 (M − H) 16-5 ((3,5-dimethoxyphenyl))amino)-5- 12.0 Hz), 6.73 (d, 2H, J = 2.3 Hz), 6.01 fluoronicotinamide (t, 1H, J = 2.3 Hz), 4.09 (s, 2H), 3.67 (s, 6H). Example 6-(cyclohexylamino)-2-((3,5-di- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.61 (s, 1H), 387 (M − H) 16-6 methoxyphenyl)amino)-5-fluoroni- 7.81 (d, 1H, J = 12.8 Hz), 7.74-7.56 (m, cotinamide 1H), 7.20-7.05 (m, 1H), 7.00 (d, 1H, J = 7.7 Hz), 6.83 (d, 1H, J = 2.2 Hz), 6.11 (t, 1H, J = 2.1 Hz), 3.97-3.85 (m, 1H), 3.73 (s, 6H), 1.95-1.87 (m, 2H), 1.78-1.70 (m, 2H), 1.63-1.60 (m, 1H), 1.43-1.26 (m, 4H), 1.20-1.07 (m, 1H). Example 6-(benzylamino)-2-((3,5-dimeth- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.68 (s, 1H), MS (DART, m/z) 16-7 oxyphenyl)amino)-5-fluoronico- 7.88 (d, 1H, J = 12.7 Hz), 7.34 (d, 2H, J = 397 (M + H) tinamide 7.1 Hz), 7.28 (t, 2H, J = 7.4 Hz), 7.21 (t, 1H, J = 7.2 Hz), 6.80 (d, 2H, J = 2.2 Hz), 6.05 (t, 1H, J = 2.2 Hz), 4.68 (d, 2H, J = 6.3 Hz), 3.60 (s, 6H). Example 6-((cyclopropylmethyl)amino)-2- ¹H-NMR (CD₃OD, 400 MHz) δ: 7.52 (d, 1H, J = 359 (M − H) 16-8 ((3,5-dimethoxyphenyl)amino)-5- 12.2 Hz), 6.86 (d, 2H, J = 2.3 Hz), 6.00 fluoronicotinamide (t, 1H, J = 2.3 Hz), 3.68 (s, 6H), 3.33 (d, 2H, J = 7.1 Hz), 1.16-1.06 (m, 1H), 0.43-0.39 (m, 2H), 0.20-0.16 (m, 2H). Example 6-((2-amino-2-oxo-1-phenylethyl) ¹H-NMR (CD₃OD, 400 MHz) δ: 7.61 (d, 1H, J = 440 (M + H), 16-9 amino)-2-((3,5-dimethoxyphenyl) 11.9 Hz), 7.48-7.32 (s, 3H), 7.26-7.16 (m, 438 (M − H) amino)-5-fluoronicotinamide 2H), 6.69 (d, 2H, J = 2.2 Hz), 6.07 (t, 1H, J = 2.2 Hz), 5.70 (s, 1H), 3.68 (s, 6H). Example 2-((3,5-dimethoxyphenyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.57 (s, 1H), 335 (M + H) 16-10 6-(dimethylamino)-5-fluoronico- 7.91 (d, 1H, J = 15.4 Hz), 7.81 (brs, 1H), tinamide 7.26 (brs, 1H), 6.83 (d, 2H, J = 2.2 Hz), 6.09 (t, 1H, J = 2.2 Hz), 3.72 (s, 6H), 3.17 (s, 3H), 3.16 (s, 3H). Example 2-((3,5-dimethoxyphenyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.90 (brs, 401 (M + H), 16-11 5-fluoro-6-((2-(1H-imidazol-5-yl) 1H), 11.72 (s, 1H), 7.84 (d, 1H, J = 12.7 399 (M − H) ethyl)amino)nicotinamide Hz), 7.69 (brs, 1H), 7.57 (s, 1H), 7.39-7.31 (m, 1H), 7.15 (brs, 1H), 6.87 (d, 2H, J = 2.2 Hz), 6.83 (s, 1H), 6.06 (t, 1H, J = 2.2 Hz), 3.70-3.62 (m, 8H), 2.83 (t, 2H, J = 7.4 Hz). Example 2-((3,5-dimethoxyphenyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.73 (s, 1H), MS (DART, m/z): 16-12 5-fluoro-6-(prop-2-yn-1-ylamino) 7.90 (d, 1H, J = 12.4 Hz), 7.84-7.64 (m, 345 (M + H) nicotinamide 2H), 7.23 (brs, 1H), 6.88 (d, 1H, J = 2.2 Hz), 6.09 (t, 1H, J = 2.2 Hz), 4.20 (dd, 2H, J = 2.3, 5.9 Hz), 3.75 (s, 6H), 3.08 (t, 1H, J = 2.3 Hz). Example 6-(benzyl(methyl)amino)-2-((3,5- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.53 (s, 1H), 411 (M + H) 16-13 dimethoxyphenyl)amino)-5-fluoro- 7.92 (d, 1H, J = 15.4 Hz), 7.35-7.21 (m, nicotinamide 5H), 6.76 (d, 2H, J = 2.2 Hz), 6.06 (t, 1H, J = 2.2 Hz), 4.81 (s, 2H), 3.62 (s, 6H), 3.14-3.11 (m, 3H). Example 6-((2-amionbenzyl))amino)-2-((3, ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.71 (s, 1H), MS (DART, m/z): 16-14 5-methoxyphenyl)amino)-5- 7.87 (d, 2H, J = 12.7 Hz), 7.81-7.48 (m, 412 (M + H) fluoronicotinamide 2H), 7.32-6.76 (m, 5H), 6.64-6.54 (m, 1H), 6.50-6.39 (m, 1H), 6.08-6.01 (m, 1H), 4.99 brs, 2H), 4.50 (d, 2H, J = 5.8 Hz), 3.60 (s, 6H). Example 6-((4-aminobenzyl))amino)-2-((3, ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.71 (s, 1H), MS (DART, /z): 16-15 5-dimethoxyphenyl))amino)-5-fluoro- 7.84 (d, 1H, J = 12.4 Hz), 7.80-7.56 (s, 412 (M + H) nicotinamide 2H), 7.30-6.97 (m, 3H), 6.86 (d, 2H, J = 2.0 Hz), 6.46 (d, 2H, J = 8.3 Hz), 6.12-6.01 (m, 1H), 4.92 (brs, 2H), 4.50 (d, 2H, J = 6.1 Hz), 3.63 (s, 6H). Example 2-((3,5-dimethoxyphenyl))amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.69 (s, 1H), MS (DART, m/z) 16-16 5-fluoro-6-(((1H-indol-2-yl)meth- 10.86 (s, 1H), 7.98-7.62 (m, 3H), 7.46-7.10 436 (M + H) yl)amino)nicotinamide (m, 3H), 7.07-6.81 (m, 4H), 6.33-6.27 (m, 1H), 6.07-6.02 (m, 1H), 4.82 (d, 2H, J = 5.9 Hz), 3.59 (s, 6H). Example 6-(((1R)-2-amino-2-oxo-1-phenyl ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.60 (s, 1H), 440 (M + H) 16-17 ethyl)amino)-2-((3,5-dimethoxy- 7.92 (d, 1H, J = 12.4 Hz), 7.80-7.26 (m, phenyl)amino)-5-fluoro- 9H), 7.14 (d, 1H, J = 8.2 Hz), 6.69 (d, 2H, nicotinamide J = 2.0 Hz), 6.14-6.10 (m, 1H), 5.67 (d, 1H, J = 8.2 Hz), 3.73 (s, 6H). Example 6-(((1S)-2-amino-2-oxo-1-phenyl 440 (M + H), 16-18 ethyl)amino)-2-((3,5-dimethoxy- 438 (M − H) phenyl)amino)-5-fluoronicotinamide Example 6-anilino-2-((3,5-dimethoxy- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.42 (s, 1H), 383 (M + H) 16-19 phenyl)amino)-5-fluoronicotinamide 9.18-9.14 (m, 1H), 8.03 (d, 1H, J = 12.4 (*) Hz), 7.94-7.78 (m, 1H), 7.69 (d, 2H, J = 7.8 Hz), 7.40-7.28 (m, 1H), 7.27-7.19 (m, 2H), 7.00 (t, 1H, J = 7.2 Hz), 6.68 (d, 2H, J = 2.1 Hz), 6.11 (t, 1H, J = 2.1 Hz), 3.57 (s, 6H). Example 2-((3,5-dimethoxyphenyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.30 (s, 1H), 384 (M + H) 16-20 5-fluoro-6-(pyridin-4-ylamino) 9.62 (s, 1H), 8.29-8.24 (m, 2H), 8.12 (d, (*) nicotinamide 1H, J = 12.2 Hz), 8.06-7.94 (m, 1H), 7.76-7.72 (m, 2H), 7.54-7.45 (m, 1H), 6.68 (d, 2H, J = 2.2 Hz), 6.21 (t, 1H, J = 2.2 Hz), 3.65 (s, 6H). Example 2-((3,5-dimethoxyphenyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.35 (s, 1H), 384 (M + H) 16-21 5-fluoro-6-(pyridin-2-ylamino) 9.33 (s, 1H), 8.33-8.29 (m, 1H), 8.08 (d, (*) nicotinamide 1H, J = 12.0 Hz), 8.01-7.92 (m, 1H), 7.92-7.87 (m, 1H), 7.62-7.56 (m, 1H), 7.49-7.41 (m, 1H), 7.05-7.00 (m, 1H), 6.74 (d, 2H, J = 2.2 Hz), 6.16 (t, 1H, J = 2.2 Hz), 3.64 (s, 6H). Example 2-(3,5-dimethoxyphenylamino)-5- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.38 (s, 1H), 384 (M + H) 16-22 fluoro-6-(pyridin-3-ylamino) 9.41-9.37 (s, 1H), 8.78 (d, 1H, J = 2.6 Hz), (*) nicotinamide 8.21 (dd, 1H, J = 1.5 Hz, 4.7 Hz), 8.15 (ddd, 1H, J = 1.5 Hz, 2.6 Hz, 8.3 Hz), 8.07 (d, 1H, J = 12.3 Hz), 7.98-7.86 (s, 2H), 7.46-7.34 (m, 1H), 7.22 (dd, 1H, J = 4.7 Hz, 8.3 Hz), 6.62 (d, 2H, J = 2.3 Hz), 6.12 (t, 1H, J = 2.3 Hz), 3.57 (s, 6H). Example 6-(2-(aminocarbonyl)piperidin-1- 416 (M − H) 16-23 yl)-2-((3,5-dimethoxyphenyl) amino)-5-fluoronicotinamide Example 2-((3,5-dimethoxyphenyl)amino)- ¹H-NMR (CD₃OD, 400 MHz) δ: 7.71 (d, 1H, J = 412 (M + Na), 16-24 5-fluoro-6-(3-oxopiperazin-1-yl) 14.4 Hz), 6.72 (d, 2H, J = 2.3 Hz), 6.04 388 (M − H) nicotinamide (t, 1H, J = 2.3 Hz), 4.23 (s, 2H), 3.87-3.80 (m, 2H), 3.68 (s, 6H), 3.40-3.34 (m, 2H).

Example 17

1st, 2nd, and 3rd Steps

The following compound was obtained as described in Example 15.

tert-Butyl((3R)-1-(5-carbamoyl-6-(3,5-dimethoxyphenylamino)-3-fluoropyridin-2-yl)pyrrolidin-3-yl)carbamate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.66 (s, 1H), 7.89 (d, 1H, J=14.8 Hz), 7.76 (brs, 1H), 7.30-7.14 (m, 2H), 6.89-6.83 (m, 2H), 6.10-6.05 (m, 1H), 4.14-4.03 (m, 1H), 3.91-3.73 (m, 3H), 3.72 (s, 6H), 3.55-3.49 (m, 1H), 2.15-2.01 (m, 1H), 1.94-1.82 (m, 1H), 1.39 (s, 9H)

MS (ESI, m/z): 476 (M−H), 474 (M−H)

The following compound was obtained as described in the 2nd step of Example 1.

6-((3R)-3-aminopyrrolidin-1-yl)-2-(3,5-dimethoxyphenylamino)-5-fluoronicotinamide

(¹H-NMR and ESI-MS data are shown in table 9.)

Example 18

The compounds listed in table 9 were obtained as described in Example 17.

TABLE 9 Number Structure Example 18-1 HCl salt

Example 18-2 (Example 17) HCl salt

Number Compound name ¹H-NMR MS(ESI, m/z) Example 6-((3S)-3-aminopyrrolidin-1-yl)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.65 (s, 1H), 376 (M + H) 18-1 2-((3,5-dimethoxyphenyl)amino)- 8.20-8.12 (m, 3H), 7.95 (d, 1H, J = 14.6 HCl salt 5-fluoronicotinamide Hz), 7.82 (brs, 1H), 7.28 (brs, 1H), 6.84 (d, 2H), J = 2.2 Hz), 6.10 (t, 1H, J = 2.2 Hz), 3.96-3.76 (m, 5H), 3.73 (s, 6H), 2.35-2.22 (m, 1H), 2.12-2.02 (m, 1H). Example 6-((3R)-3-aminopyrrolidin-1-yl)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.64 (s, 1H), 376 (M + H) 18-2 2-((3,5-dimethoxyphenyl)amino)- 8.20-8.12 (m, 3H), 7.95 (d, 1H, J = 14.6 HCl salt 5-fluoronicotinamide Hz), 7.82 (brs, 1H), 7.27 (brs, 1H), 6.84 (d, 2H, J = 2.2 Hz), 6.10 (t, 1H, J = 2.2 Hz), 3.97-3.75 (m, 5H), 3.73 (s, 6H), 2.35-2.22 (m, 1H), 2.12-2.03 (m, 1H).

Example 19

1st Step

The following compound was obtained as described in the 1st step of Reference Example 3.

2-(3,5-dimethoxyphenylamino)-5-fluoro-6-oxo-1,6-dihydropyridin-3-carboxylic acid

¹H-NMR (DMSO-d₆, 400 MHz) δ: 10.37 (s, 1H), 7.81 (d, 1H, J=11.0 Hz), 6.80-6.70 (br, 2H), 6.26-6.20 (br, 1H), 3.75 (s, 6H)

MS (ESI, m/z): 309 (M+H), 331 (M+Na), 307 (M−H)

2nd Step

A mixture of 2-(3,5-dimethoxyphenylamino)-5-fluoro-6-oxo-1,6-dihydropyridin-3-carboxylic acid (200 mg), WSC.HCl (312 mg), HOBt.H₂O (249 mg), and DMF (2 ml) was stirred at room temperature for 45 minutes. 25% ammonia water (1 ml) was added, followed by stirring at the same temperature for 2 hours. Ethyl acetate was added to the reaction mixture. The resultant was washed with saturated saline and dried over anhydrous magnesium sulfate, the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=7:3 to 1:1), and a yellow solid of 6-(1H-1,2,3-benzotriazol-1-yloxy)-2-(3,5-dimethoxyphenylamino)-5-fluoronicotinamide (109 mg) was thus obtained.

¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.30 (s, 1H), 8.52 (d, 1H, J=11.0 Hz), 8.30 (brs, 1H), 8.18 (d, 1H, J=8.6 Hz), 7.90-7.76 (m, 2H), 7.66-7.58 (m, 1H), 7.56-7.48 (m, 1H), 5.96-5.91 (m, 1H), 5.88 (d, 2H, J=2.2 Hz), 3.51 (s, 6H)

MS (ESI, m/z): 425 (M+H), 423 (M−H)

3rd Step

Potassium carbonate (27 mg) and tryptamine (32 mg) were added to an N-methylpyrrolidone (1 ml) solution containing 6-(1H-1,2,3-benzotriazol-1-yloxy)-2-(3,5-dimethoxyphenylamino)-5-fluoronicotinamide (41 mg), followed by stirring at 90° C. for 7 hours. The reaction mixture was cooled to room temperature, and potassium carbonate (14 mg) and tryptamine (16 mg) were added, followed by stirring at 90° C. for 7 hours. The reaction mixture was cooled to room temperature, and then water, sodium chloride, and ethyl acetate were added. The organic layer was collected and dried over anhydrous magnesium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (chloroform:methanol=10:0 to 20:1), diisopropylether was added, solid matter was collected by filtration, and a light brown solid of 2-(3,5-dimethoxyphenylamino)-5-fluoro-6-(2-(1H-indole-3-yl)ethylamino)nicotinamide (19 mg) was thus obtained.

(¹H-NMR and ESI-MS data are shown in table 10.)

Example 20

The compounds listed in table 10 below were obtained as described in Example 19.

TABLE 10 Number Structure Example 20-1

Example 20-2 (Example 19)

MS Number Compound name ¹H-NMR (ESI, m/z) Example 20-1 6-(cyclopropyl(methyl)amino)-2- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.5 (s, 1H), 359 ((3,5-dimethoxyphenyl)amino)-5- 7.92 (d, 1H, J = 14.4 Hz), 7.84 (brs, 1H), (M − H) fluoronicotinamide 7.29 (brs, 1H), 6.88 (d, 2H, J = 2.2 Hz), 6.09 (t, 1H, J = 2.2 Hz), 3.71 (s, 6H), 3.13 (d, 3H, J = 1.0 Hz), 3.02-2.96 (m, 1H), 0.84-0.76 (m, 2H), 0.70-0.62 (m, 2H). Example 20-2 2-((3,5-dimethoxyphenyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.71 (s, 1H), MS 5-fluoro-6-((2-(1H-indol-3-yl) 10.85 (s, 1H), 7.92-7.46 (m, 3H), 7.43-7.30 (DART, ethyl)amino)nicotinamide (m, 2H), 7.28-6.91 (m, 4H), 6.87 (d, 2H, m/z) J = 2.2 Hz), 6.05 (t, 1H, J = 2.2 Hz), 450 3.80-3.55 (m, 8H), 3.03 (t, 2H, J = 7.7 Hz). (M + H)

Example 21

1st Step

The following compound was obtained as described in the 1st step of Example 15.

Ethyl6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-2-(3,5-dimethoxyphenylamino)-5-fluoronicotinate

MS (ESI, m/z): 533 (M+H), 531 (M−H)

2nd, 3rd, and 4th Steps

The following compound was obtained as described in the 2nd and 3rd steps of Example 15 and the 1st step of Example.

6-(cis-2-aminocyclohexylamino)-2-(3,5-dimethoxyphenylamino)-5-fluoronicotinamide

(¹H-NMR and ESI-MS data are shown in table 11.)

Example 22

The compounds listed in table 11 were obtained as described in Example 21.

TABLE 11 Number Structure Example 22-1 HCl salt

Example 22-2 HCl salt

Example 22-3 (Example 21) HCl salt

Example 22-4 HCl salt

Example 22-5 HCl salt

Example 22-6 HCl salt

Example 22-7 HCl salt

Example 22-8

MS Number Compound name ¹H-NMR (ESI, m/z) Example 22-1 6-((3-aminopropyl)amino)-2-(3,5- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.70 (s, 1H), 364 HCl salt dimethoxyphenylamino)-5-fluoro 7.92-7.60 (m, 3H), 7.85 (d, 1H, J = 12.8 Hz), (M + H) nicotinamide 7.45-7.37 (m, 1H), 6.85 (s, 2H), 6.10 (s, 1H), 3.72 (s, 6H), 3.51-3.44 (m, 2H), 2.89-2.80 (m, 2H), 1.93-1.82 (m, 2H). Example 22-2 6-((4-aminobutyl)amino)-2-(3,5- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.71 (s, 1H), 376 HCl salt dimethoxyphenylamino)-5-fluoro- 7.84 (d, 1H, J = 12.8 Hz), 7.80-7.64 (m, (M − H) nicotinamide 3H), 7.37-7.31 (m, 1H), 6.87 (d, 2H, J = 2.3 Hz), 6.10 (t, 1H, J = 2.2 Hz), 3.73 (s, 6H), 3.56-3.42 (m, 2H), 2.84-2.73 (m, 2H), 1.70-1.52 (m, 4H). Example 22-3 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆) 400 MHz) δ: 11.58 (s, 1H), 404 HCl salt 2-(3,5-dimethoxyphenylamino)-5- 7.90 (d, 1H, J = 12.4 Hz), 7.87-7.76 (m, (M + H) fluoronicotinamide 3H), 7.32-7.16 (m, 1H), 6.89-6.83 (m, 1H), 6.75 (d, 2H, J = 2.1 Hz), 6.13 (t, 1H, J = 2.1 Hz), 4.29-4.20 (m, 1H), 3.72 (s, 6H), 3.68-3.60 (m, 1H), 1.93-1.30 (m, 8H). Example 22-4 6-(((1S,2R)-2-aminocyclohexyl) ¹H-NMR (DMSO-d₆) 400 MHz) δ: 11.59 (s, 1H), 404 HCl salt amino)-2-(3,5-dimethoxyphenyl- 7.91 (d, 1H, J = 12.6 Hz), 7.84-7.70 (m, (M + H) amino)-5-fluoronicotinamide 3H), 7.32-7.19 (m, 1H), 6.88-6.83 (m, 1H), 6.76 (d, 2H, J = 2.2 Hz), 6.14 (t, 1H, J = 2.2 Hz), 4.30-4.20 (m, 1H), 3.73 (s, 6H), 3.68-3.60 (m, 1H), 1.92-1.33 (m, 8H). Example 22-5 6-((1R,2S)-2-aminocyclohexyl- ¹H-NMR (DMSO-d₆) 400 MHz) δ: 11.59 (s, 1H), 402 HCl salt amino)-2-(3,5-dimethoxyphenyl- 7.91 (d, 1H, J = 12.6 Hz), 7.82-7.68 (m, (M − H) amino)-5-fluoronicotinamide 3H), 7.31-7.19 (m, 1H), 6.88-6.82 (m, 1H), 6.76 (d, 2H, J = 2.2 Hz), 6.14 (t, 1H, J = 2.2 Hz), 4.30-4.21 (m, 1H), 3.73 (s, 6H), 3.68-3.62 (m, 1H), 1.92-1.34 (m, 8H). Example 22-6 6-(((1R,2R)-2-aminocyclohexyl) ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.61 (s, 1H), 404 HCl salt amino)-2-(3,5-dimethoxyphenyl- 7.95-7.85 (m, 3H), 7.89 (d, 1H, J = 12.4 Hz), (M + H) amino)-5-fluoronicotinamide 7.21-7.14 (m, 1H), 6.79 (d, 2H, J = 2.2 Hz), 6.14 (t, 1H, J = 2.1 Hz), 4.07-3.96 (m, 1H), 3.74 (s, 6H), 3.30-3.18 (m, 1H), 2.15-2.03 (m, 2H), 1.81-1.65 (m, 2H), 1.51-1.19 (m, 4H). Example 22-7 6-((4-aminocyclohexyl)amino)-2- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.65 (s, 1H), 404 HCl salt (3,5-dimethoxyphenylamino)-5- 7.87 (d, 1H, J = 12.7 Hz), 7.87-7.81 (m, (M + H) f1uoronicotinamide 3H), 6.81 (d, 2H, J = 2.3 Hz), 6.76-6.72 (m, 1H), 6.11 (t, 1H, J = 2.3 Hz), 4.07-4.00 (m, 1H), 3.72 (s, 6H), 3.26-3.16 (m, 1H), 2.00-1.89 (m, 2H), 1.80-1.68 (m, 6H). Example 22-8 2-((3,5-dimethoxyphenyl)amino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.72 (s, 1H), 321 5-fluoro-6-(methylamino) 7.82 (d, 1H, J = 12.7 Hz), 7.31-7.25 (m, (M + H) nicotinamide 1H), 6.93 (d, 2H, J = 2.2 Hz), 6.08 (t, 1H, J = 2.2 Hz), 3.72 (s, 6H), 2.95 (d, 3H, J = 4.5 Hz).

Example 23

The following compound was obtained as described in Reference Example 9.

2-(3,5-dimethoxyphenylamino)-5-fluoro-6-(methylamino)nicotinamide

¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.72 (s, 1H), 7.82 (d, 1H, J=12.7 Hz), 7.31-7.25 (m, 1H), 6.93 (t, 2H, J=2.2 Hz), 6.08 (t, 1H, J=2.2 Hz), 3.72 (s, 6H), 2.95 (d, 3H, J=4.5 Hz)

MS (ESI, m/z): 321 (M+H)

Example 24

The following compound was obtained as described in the 1st step of Example 1

Methyl 5-fluoro-6-(pyridin-3-ylamino)-2-(quinolin-3-ylamino)nicotinate

The following compound was obtained as described in the 1st and 2nd steps of Reference Example 27 or the 3rd and 4th steps of Example 7.

5-fluoro-6-(pyridin-3-ylamino)-2-(quinolin-3-ylamino)nicotinamide

(¹H-NMR and ESI-MS data are shown in table 12.)

Example 25

The compounds listed in table 12 were obtained as described in Example 24.

TABLE 12 Number Structure Example 25-1

Example 25-2 (Example 24)

MS Number Compound name ¹H-NMR (ESI, m/z) Example 25-1 5-fluoro-6-(pyridin-3-ylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.71 (s, 1H), 392 2-((3-(trifluoromethyl)phenyl) 9.43 (s, 1H), 8.71 (d, 1H, J = 2.6 Hz), (M + H) amino)nicotinamide 8.24-8.20 (m, 1H), 8.10 (d, 1H, J = 12.3 Hz), 8.04-7.90 (m, 2H), 7.79 (s, 1H), 7.65 (d, 1H, J = 7.9 Hz), 7.54-7.40 (m, 1H), 7.40 (t, 1H, J = 8.0 Hz), 7.27-7.18 (m, 2H). Example 25-2 5-fluoro-6-(pyridin-3-ylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.01 (s, 1H), 375 2-(quinolin-3-ylamino) 9.54-9.50 (m, 1H), 8.84 (d, 1H, J = 2.7 Hz), (M + H) nicotinamide 8.71 (d, 1H, J = 2.7 Hz), 8.57 (d, 1H, J = 2.3 Hz), 8.38-8.34 (m, 1H), 8.17 (d, 1H, J = 12.1 Hz), 8.05-7.98 (m, 2H), 7.93-7.88 (m, 1H), 7.58-7.47 (m, 4H), 7.28 (dd, 1H, J = 4.6 Hz, 8.2 Hz).

Example 26

1st Step

The following compound was obtained as described in the 1st step of Example 3.

Benzyl(5-(6-(cis-2-(tert-butoxycarbonylamino)cyclohexylamino)-5-fluoro-3-(2-phen ylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)pyridin-3-yl)carbamate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.18 (s, 1H), 9.88 (s, 1H), 8.39 (d, 1H, J=2.1 Hz), 8.20-8.08 (m, 4H), 7.44-7.25 (m, 9H), 7.19-7.14 (m, 1H), 6.69-6.61 (m, 2H), 5.16 (s, 2H), 4.16-4.08 (m, 1H), 3.92-3.84 (m, 1H), 1.80-1.10 (m, 23H)

MS (ESI, m/z): 712 (M+H), 710 (M−H)

2nd Step

The following compound was obtained as described in the 2nd step of Reference Example 53.

tert-Butyl cis-2-(6-(5-aminopyridin-3-ylamino)-3-fluoro-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 10.99 (s, 1H), 8.16-8.04 (m, 3H), 7.51 (d, 1H, J=2.3 Hz), 7.39-7.34 (m, 2H), 7.32-7.25 (m, 2H), 7.19-7.13 (m, 1H), 7.04 (s, 1H), 6.72-6.65 (m, 1H), 6.59-6.53 (m, 1H), 4.16-4.06 (m, 1H), 3.96-3.87 (m, 1H), 1.84-1.11 (m, 23H)

MS (ESI, m/z): 578 (M+H), 576 (M−H)

3rd and 4th Steps

The following compound was obtained as described in the 2nd step of Reference Example 3 and the 2nd step of Example 1.

6-(cis-2-aminocyclohexylamino)-2-(5-benzoylaminopyridin-3-ylamino)-5-fluoronicotinamide

(¹H-NMR data and MS data are shown in table 13.)

Example 27

The compounds listed in table 13 were obtained as described in Example 26.

TABLE 13 Number Structure Example 27-1 HCl salt

Example 27-2 HCl salt

Example 27-3 (Example 26) HCl salt

Example 27-4 HCl salt

Example 27-5 HCl salt

Example 27-6 HCl salt

Number Structure Compound name Example 27-7

6-(cis-2-aminocyclohexylamino)-2-((5-(2- chlorobenzamide)pyridin-3-yl)amino)-5- fluoronicotinamide Example 27-8

6-(cis-2-aminocyclohexylamino)-2-((5-(3- chlorobenzamide)pyridin-3-yl)amino)-5- fluoronicotinamide Example 27-9

6-(cis-2-aminocyclohexylamino)-2-((5-(4- chlorobenzamide)pyridin-3-yl)amino)-5- fluoronicotinamide Example 27-10

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-fluorobenzamide)pyridin-3-yl)amino) nicotinamide Example 27-11

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-fluorobenzamide)pyridin-3-yl)amino) nicotinamide Example 27-12

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-(trifiuoromethyl)benzamide)pyridin-3-yl) amino)nicotinamide Example 27-13

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-methylbenzamide)pyridin-3-yl)amino) nicotinamide Example 27-14

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-methoxybenzamide)pyridin-3-yl)amino) nicotinamide Example 27-15

6-(cis-2-aminocyclohexylamino)-2-((5-(4- butoxybenzamide)pyridin-3-yl)amino)-5- fluoronicotinamide Example 27-16

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(4-trifluoromethoxybenzamide)pyridin-3-yl) amino)nicotinamide Example 27-17

4-((5-(6-(cis-2-aminocyclohexylamino)-3- carbamoyl-5-fluoropyridin-2-yl)aminopyridin- 3-yl)carbamoyl)benzene-1-sulfonyl fluoride Example 27-18

6-(cis-2-aminocyclohexylamino)-2-((5-(2,4- dichlorobenzamide)pyridin-3-yl)amino)-5- fluoronicotinamide Example 27-19

6-(cis-2-aminocyclohexylamino)-2-((5-(2,4- dimethoxybenzamide)pyridin-3-yl)amino)-5- fluoronicotinamide Example 27-20

N-(5-(6-(cis-2-aminocyclohexylamino)-3- carbamoyl-5-fluoropyridin-2-yl)aminopyridin- 3-yl)picolinamide Example 27-21

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(nicotinamide)pyridin-3-yl)amino) nicotinamide Example 27-22

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(isonicotinamide)pyridin-3-yl)amino) nicotinamide Example 27-23

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-methylbenzamide)pyridin-3-yl)amino) nicotinamide Example 27-24

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-methoxybenzamide)pyridin-3-yl)amino) nicotinamide Example 27-25

6-(cis-2-aminocyclohexylamino)-2-((5-(2- ethoxybenzamide)pyridin-3-yl)amino)-5- fluoronicotinamide Example 27-26

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(2-(trifluoromethoxy)benzamide)pyridin-3- yl)amino)nicotinamide Example 27-27

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(3-fluorobenzamide)pyridin-3-yl)amino) nicotinamide Example 27-28

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(3-methoxybenzamide)pyridin-3-yl)amino) nicotinamide Example 27-29

6-(cis-2-aminocyclohexylamino)-2-((5-(2,4- difluorobenzamide)pyridin-3-yl)amino)-5- fluoronicotinamide Example 27-30

6-(cis-2-aminocyclohexylamino)-2-((5-(2,3- difluorobenzamide)pyridin-3-yl)amino)-5- fluoronicotinamide Example 27-31

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(thiophene-2-carboxamide)pyridin-3-yl) amino)nicotinamide Example 27-32

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(thiophene-3-carboxamide)pyridin-3-yl) amino)nicotinamide Example 27-33

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((5-(furan-2-carboxamide)pyridin-3-yl) amino)nicotinamide Example 27-34

6-(cis-2-aminocyclohexylamino)-2-((5-(1,3- benzodioxole-5-carboxamide)pyridin-3-yl) amino)-5-fluoronicotinamide Example 27-35

6-(cis-2-aminocyclohexylamino)-2-((5-(2,3- dihydro-1,4-benzodioxin-6- carboxamide)pyridin-3-yl)amino)-5- fluoronicotinamide Example 27-36

N-(5-(6-(cis-2-aminocyclohexylamino)-3- carbamoyl-5-fluoropyridin-2-yl)aminopyridin- 3-yl)isoxazole-5-carboxamide Example 27-37

6-(cis-2-aminocyclohexylamino)-2-((5- (benzofuran-5-carboxamide)pyridin-3-yl) amino)-5-fluoronicotinamide Example 27-38

6-(cis-2-aminocyclohexylamino)-2-((5- (benzo[b]thiophene-5-carboxamide)pyridin-3- yl)amino)-5-fluoronicotinamide Example 27-39

6-(cis-2-aminocyclohexylamino)-2-((5- (benzo[b]thiophene-3-carboxamide)pyridin-3- yl)amino)-5-fluoronicotinamide Example 27-40

6-(cis-2-aminocyclohexylamino)-2-((5- (benzo[b]thiophene-2-carboxamide)pyridin-3- yl)amino)-5-fluoronicotinamide Example 27-41

6-(cis-2-aminocyclohexylamino)-2-((5- (benzofuran-2-carboxamide)pyridin-3-yl) amino)-5-fluoronicotinamide Example 27-42

N-(5-(6-(cis-2-aminocyclohexylamino)-3- carbamoyl-5-fluoropyridin-2-yl)aminopyridin- 3-yl)-1-methyl-1H-benzo[d][1,2,3]triazol-5- carboxamide MS Number Compound name ¹H-NMR (ESI, m/z) Example 27-1 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.01 (s, 360 (M + H) HCl salt 2-((5-aminopyridin-3-yl)amino)- 1H), 8.49 (s, 1H), 8.03-7.91 (m, 5H), 7.65 (d, 5-fluoronicotinamide 1H, J = 2.1 Hz), 7.57-7.53 (m, 1H), 7.52-7.46 (m, 1H), 7.08-7.03 (m, 1H), 6.46-6.33 (m, 1H), 4.34-4.25 (m, 1H), 3.63-3.53 (m, 1H), 1.93-1.36 (m, 8H). Example 27-2 2-((5-acetylaminopyridin-3-yl) ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.98 (s, 402 (M + H), 400 (M − H) HCl salt amino)-6-(cis-2-aminocyclohexyl- 1H), 10.73 (s, 1H), 8.73 (s, 1H), 8.58 (s, 1H), amino)-5-fluoronicotinamide 8.48 (s, 1H), 7.99 (d, 1H, J = 12.2 Hz), 7.97-7.83 (m, 4H), 7.46 (brs, 1H), 7.06-7.00 (m, 1H), 4.40-4.30 (m, 1H), 3.63-3.53 (m, 1H), 2.13 (s, 3H), 1.90- 1.34 (m, 8H). Example 27-3 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.09 (s, 464 (M + H), 462 (M − H) HCl salt 2-((5-benzoylaminopyridin-3-yl) 1H), 10.86 (s, 1H), 8.84 (s, 1H), 8.78 (s, 1H), amino)-5-fluoronicotinamide 8.71 (s, 1H), 8.07-7.85 (m, 7H), 7.69-7.63 (m, 1H), 7.62-7.55 (m, 2H), 7.48 (brs, 1H), 7.07 (d, 1H, J = 5.4 Hz), 4.42-4.33 (m, 1H), 3.62-3.54 (m, 1H), 1.87-1.14 (m, 8H). Example 27-4 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.99 (s, 388 (M + H), 386 (M − H) HCl salt 5-fluoro-2-((5-formylamino- 1H), 10.95 (s, 1H), 8.79 (s, 1H), 8.54-8.48 pyridin-3-yl)amino)nicotinamide (m, 2H), 8.43 (d, 1H, J = 1.6 Hz), 8.06- 7.91 (m, 5H), 7.52-7.40 (m, 1H), 7.04- 6.98 (m, 1H), 4.41-4.32 (m, 1H), 3.62- 3.53 (m, 1H), 1.92-1.36 (m, 8H). Example 27-5 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.84 (s, 500 (M + H) HCl salt 5-fluoro-2-((5-(phenylsulfonyl- 1H), 10.76-10.67 (br, 1H), 8.60-8.55 (m, 1H), amino)pyridin-3-yl)amino) 8.03-7.75 (m, 9H), 7.68-7.62 (m, 1H), nicotinamide 7.62-7.54 (m, 2H), 7.50-7.32 (br, 1H), 7.02 (d, 1H, J = 6.1 Hz), 4.37-4.27 (m, 1H), 3.67-3.60 (m, 1H), 1.94-1.38 (m, 8H). ¹H-NMR (DMS0-d₆ + D₂O, 400 MHz) δ: 8.49 (d, 1H, J = 2.2 Hz), 8.13-8.09 (m, 1H), 7.93 (d, 1H, J = 12.2 Hz), 7.78-7.74 (m, 3H), 7.70-7.63 (m, 1H), 7.62-7.55 (m, 1H), 4.42-4.28 (m, 1H), 3.67-3.60 (m, 1H), 1.90-1.43 (m, 8H). Example 27-6 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.91 (s, 438 (M + H) HCl salt 5-fluoro-2-((5-(methylsulfonyl- 1H), 10.30-10.20 (br, 1H), 8.77-8.72 (m, 1H), amino)pyridin-3-yl)amino) 8.08 (d, 1H, J = 2.2 Hz), 8.04-8.01 (m, 1H), nicotinamide 7.98 (d, 1H, J = 12.4 Hz), 7.95-7.82 (m, 4H), 7.50-7.34 (br, 1H), 7.02 (d, 1H, J = 6.4 Hz), 4.37-4.27 (m, 1H), 3.65-3.58 (m, 1H), 3.11 (s, 3H), 1.92-1.38 (m, 8H). ¹H-NMR (DMS0-d₆ + D₂O, 400 MHz) δ: 8.65 (d, 1H, J = 2.3 Hz), 8.11 (dd, 1H, J = 2.2, 2.3 Hz), 8.06 (d, 1H, J = 2.2 Hz), 7.95 (d, 1H, J = 12.2 Hz), 4.35-4.28 (m, 1H), 3.65-3.58 (m, 1H), 3.08 (s, 3H), 1.90-142 (m, 8H). Mass Mass rt Number Salt Solvent NMR 1HNMR (M + H) (M − H) (min) Example 27-7 HCl DMSO-d6 300 MHz δ: 11.88 (s, 1H), 10.91 (s, 1H), 8.70- 499 497 0.88 8.66 (m, 1H), 8.65-8.61 (m, 1H), 8.46- 8.43 (m, 1H), 7.98 (d, 1H, J = 12.2 Hz), 7.88-7.70 (m, 4H), 7.65-7.30 (m, 5H), 7.01-6.93 (m, 1H), 4.45-4.34 (m, 1H), 3.66-3.56 (m, 1H), 1.93-1.30 (m, 8H). Example 27-8 HCl DMSO-d6 300 MHz δ: 11.90 (s, 1H), 10.69 (s, 1H), 8.72- 499 497 0.94 8.68 (m, 1H), 8.71 (s, 1H), 8.54 (s, 1H), 8.08-8.03 (m, 1H), 8.02-7.85 (m, 3H), 7.80-7.68 (m, 4H), 7.65-7.58 (m, 1H), 7.50-7.30 (m, 1H), 7.05-6.97 (m, 1H), 4.42-4.29 (m, 1H), 3.66-3.56 (m, 1H), 1.85-1.12 (m, 8H). Example 27-9 HCl DMSO-d6 300 MHz δ: 11.92 (s, 1H), 10.70 (s, 1H), 8.73 (s, 499 497 0.95 1H), 8.64-8.59 (m, 1H), 8.57-8.52 (m, 1H), 8.04 (d, 2H, J = 8.6 Hz), 8.00-7.83 (m, 1H), 7.98 (d, 1H, J = 12.6 Hz), 7.83-7.79 (m, 3H), 7.66 (d, 2H, J = 8.6 Hz), 7.48-7.39 (m, 1H), 7.05-6.98 (m, 1H), 4.40-4.29 (m, 1H), 3.65-3.55 (m, 1H), 1.87-1.12 (m, 8H). Example 27-10 HCl DMSO-d6 300 MHz δ: 11.90 (s, 1H), 10.81 (s, 1H), 8.76- 483 481 0.83 8.72 (m, 1H), 8.60 (s, 1H), 8.45 (s, 1H), 7.98 (d, 1H, J = 12.2 Hz), 7.95-7.58 (m, 6H), 7.45-7.33 (m, 3H), 7.00 (d, 1H, J = 6.3 Hz), 4.42-4.30 (m, 1H), 3.65-3.55 (m, 1H), 1.88-1.22 (m, 8H). Example 27-11 HCl DMSO-d6 300 MHz δ: 12.01 (s, 1H), 10.78 (s, 1H), 8.79- 483 481 0.87 8.76 (m, 1H), 8.71 (s, 1H), 8.62 (s, 1H), 8.16-8.07 (m, 2H), 8.00 (d, 1H, J = 12.2 Hz), 7.98-7.76 (m, 4H), 7.48-7.38 (m, 3H), 7.04 (d, 1H, J = 6.3 Hz), 4.42-4.32 (m, 1H), 3.65-3.55 (m, 1H), 1.88-1.13 (m, 8H). Example 27-12 HCl DMSO-d6 300 MHz δ: 11.93 (s, 1H), 10.88 (s, 1H), 8.75- 533 531 1.03 8.71 (m, 1H), 8.65 (s, 1H), 8.58-8.55 (m, 1H), 8.21 (d, 2H, J = 8.3 Hz), 8.02- 7.60 (m, 4H), 7.98 (d, 1H, J = 12.6 Hz), 7.97 (d, 2H, J = 8.3 Hz), 7.53-7.33 (m, 1H), 7.01 (d, 1H, J = 5.6 Hz), 4.42-4.29 (m, 1H), 3.66-3.55 (m, 1H), 1.92-1.13 (m, 8H). Example 27-13 HCl DMSO-d6 300 MHz δ: 12.04 (s, 1H), 10.70 (s, 1H), 8.81 (s, 479 477 0.92 1H), 8.72 (s, 1H), 8.67 (s, 1H), 8.00 (d, 1H, J = 12.6 Hz), 8.00-7.90 (m, 1H), 7.95 (d, 2H, J = 7.9 Hz), 7.89-7.80 (m, 3H), 7.52-7.42 (m, 1H), 7.39 (d, 2H, J = 7.9 Hz), 7.05 (d, 1H, J = 6.3 Hz), 4.43- 4.31 (m, 1H), 3.65-3.55 (m, 1H), 2.41 (s, 3H), 1.90-1.15 (m, 8H). Example 27-14 HCl DMSO-d6 300 MHz δ: 12.06 (s, 1H), 10.65 (s, 1H), 8.84- 495 493 0.84 8.79 (m, 1H), 8.73 (s, 1H), 8.68 (s, 1H), 8.04 (d, 2H, J = 8.9 Hz), 8.00 (d, 1H, J = 12.2 Hz), 8.00-7.90 (m, 1H), 7.90- 7.80 (m, 3H), 7.55-7.39 (m, 1H), 7.11 (d, 2H, J = 8.9 Hz), 7.06 (d, 1H, J = 6.6 Hz), 4.43-4.31 (m, 1H), 3.86 (s, 3H), 3.63-3.55 (m, 1H), 1.90-1.13 (m, 8H). Example 27-15 HCl DMSO-d6 300 MHz δ: 12.06 (s, 1H), 10.63 (s, 1H), 8.83- 537 535 1.11 8.79 (m, 1H), 8.74 (s, 1H), 8.68 (s, 1H), 8.02 (d, 2H, J = 8.9 Hz), 8.00 (d, 1H, J = 12.6 Hz), 8.00-7.75 (m, 4H), 7.54- 7.38 (m, 1H), 7.10 (d, 2H, J = 8.9 Hz), 7.09-7.03 (m, 1H), 4.43-4.30 (m, 1H), 4.08 (t, 2H, J = 6.6 Hz), 3.64-3.55 (m, 1H), 1.90-1.15 (m, 12H), 0.95 (t, 3H, J = 7.4 Hz). Example 27-16 HCl DMSO-d6 300 MHz δ: 11.97 (s, 1H), 10.81 (s, 1H), 8.77- 548 546 1.06 8.72 (m, 1H), 8.69 (s, 1H), 8.58 (s, 1H), 8.15 (d, 2H, J = 8.8 Hz), 7.99 (d, 1H, J = 12.2 Hz), 7.97-7.70 (m, 4H), 7.59 (d, 2H, J = 8.8 Hz), 7.55-7.35 (m, 1H), 7.03 (d, 1H, J = 6.6 Hz), 4.42-4.30 (m, 1H), 3.65-3.55 (m, 1H), 1.90-1.13 (m, 8H). Example 27-17 HCl DMSO-d6 300 MHz δ: 11.95 (s, 1H), 11.06 (s, 1H), 8.73- 546 544 0.98 8.63 (m, 2H), 8.58 (s, 1H), 8.41-8.31 (m, 4H), 8.00-7.72 (m, 4H), 7.99 (d, 1H, J = 12.2 Hz), 7.51-7.35 (m, 1H), 7.02 (d, 1H, J = 5.0 Hz), 4.42-4.31 (m, 1H), 3.65-3.55 (m, 1H), 1.88-1.15 (m, 8H). Example 27-18 HCl DMSO-d6 300 MHz δ: 11.94 (s, 1H), 11.04 (s, 1H), 8.69 (s, 532 530 0.99 1H), 8.68-8.64 (m, 1H), 8.50-8.45 (m, 1H), 8.02-7.72 (m, 4H), 7.99 (d, 1H, J = 12.6 Hz), 7.82 (d, 1H, J = 1.7 Hz), 7.69- 7.59 (m, 2H), 7.53-7.33 (m, 1H), 7.00 (d, 1H, J = 6.3 Hz), 4.46-4.34 (m, 1H), 3.65-3.55 (m, 1H), 1.92-1.30 (m, 8H). Example 27-19 HCl DMSO-d6 300 MHz δ: 11.82 (s, 1H), 10.17 (s, 1H), 8.77 (s, 524 522 0.92 1H), 8.55 (s, 1H), 8.42 (s, 1H), 7.97 (d, 1H, J = 12.6 Hz), 7.97-7.80 (m, 1H), 7.77-7.68 (m, 3H), 7.76 (d, 1H, J = 8.6 Hz), 7.46-7.30 (m, 1H), 7.01-6.93 (m, 1H), 6.75-6.66 (m, 2H), 4.41-4.30 (m, 1H), 3.96 (s, 3H), 3.86 (s, 3H), 3.67- 3.53 (m, 1H), 1.90-1.18 (m, 8H). Example 27-20 HCl DMSO-d6 300 MHz δ: 11.94 (s, 1H), 11.09 (s, 1H), 8.90 (s 465 463 0.79 1H), 8.80-8.75 (m, 1H), 8.75-8.71 (m, 1H), 8.63 (s, 1H), 8.23-8.08 (m, 2H), 7.99 (d, 1H, J = 12.2 Hz), 7.98-7.83 (m 1H), 7.83-7.70 (m, 4H), 7.53-7.35 (m, 1H), 7.06-6.99 (m( 1H), 4.46-4.32 (m, 1H), 3.65-3.56 (m, 1H), 1.90-1.10 (m, 8H). Example 27-21 HCl DMSO-d6 300 MHz δ: 12.11 (s, 1H), 11.15 (s, 1H), 9.21 (d, 465 463 0.68 1H, J = 2.3 Hz), 8.85-8.79 (m, 2H), 8.84 (dd, 1H, J = 1.7, 5.0 Hz), 8.71 (s, 1H), 8.47-8.41 (m, 1H), 8.01 (d, 1H, J = 12.2 Hz), 8.00-7.80 (m, 4H), 7.70-7.63 (m, 1H), 7.55-7.42 (m, 1H), 7.07 (d, 1H, J = 5.9 Hz), 4.44-4.33 (m, 1H), 3.65-3.55 (m, 1H), 1.90-1.15 (m, 8H). Example 27-22 HCl DMSO-d6 300 MHz δ: 12.04 (s, 1H), 11.10 (s, 1H), 8.90- 465 463 0.67 8.84 (m, 2H), 8.80-8.74 (m, 2H), 8.65 (s, 1H), 8.04-7.78 (m, 7H), 7.54-7.39 (m, 1H), 7.09-7.01 (m, 1H), 4.42-4.30 (m, 1H), 3.65-3.55 (m, 1H), 1.90-1.16 (m, 8H). Example 27-23 HCl DMSO-d6 300 MHz δ: 11.92 (s, 1H), 10.72 (s, 1H), 8.71- 478 476 0.87 8.65 (m, 2H), 8.51 (s, 1H), 7.98 (d, 1H, J = 12.2 Hz), 7.96-7.85 (m, 1H), 7.85- 7.74 (m, 3H), 7.53-7.39 (m, 3H), 7.37- 7.30 (m, 2H), 7.04-6.98 (m, 1H), 4.42- 4.31 (m, 1H), 3.64-3.55 (m, 1H), 2.41 (s, 3H), 1.90-1.27 (m, 8H). Example 27-24 HCl DMSO-d6 300 MHz δ: 11.87 (s, 1H), 10.45 (s, 1H), 8.77 (s, 494 492 0.89 1H), 8.60 (s, 1H), 8.44 (s, 1H), 7.98 (d, 1H, J = 12.6 Hz), 7.95-7.82 (m, 1H), 7.82-7.73 (m, 3H), 7.67-7.62 (m, 1H), 7.60-7.51 (m, 1H), 7.48-7.35 (m, 1H), 7.22 (d, 1H, J = 8.6 Hz), 7.09 (dd, 1H, J = 6.9, 7.9 Hz), 6.98 (d, 1H, J = 6.6 Hz), 4.44-4.31 (m, 1H), 3.91 (s, 3H), 3.65- 3.55 (m, 1H), 1.88-1.27 (m, 8H). Example 27-25 HCl DMSO-d6 300 MHz δ: 11.90 (s, 1H), 10.47 (s, 1H), 8.80 (s, 508 506 0.99 1H), 8.63 (s, 1H), 8.39 (s, 1H), 7.98 (d, 1H, J = 12.6 Hz), 7.98-7.84 (m, 1H), 7.83-7.73 (m, 3H), 7.69-7.64 (m, 1H), 7.58-7.50 (m, 1H), 7.50-7.35 (m, 1H), 7.20 (d, 1H, J = 8.3 Hz), 7.09 (dd, 1H, J = 7.6 Hz, 8.3 Hz), 7.00 (d, 1H, J = 6.3 Hz), 4.44-4.32 (m, 1H), 4.19 (q, 2H, J = 6.9 Hz), 3.65-3.55 (m, 1H), 1.89-1.22 (m, 8H), 1.39 (t, 3H, J = 6.9 Hz). Example 27-26 HCl DMSO-d6 300 MHz δ: 11.87 (s, 1H), 10.87 (s, 1H), 8.67- 548 546 0.96 8.58 (m, 2H), 8.42 (s, 1H), 7.97 (d, 1H, J = 12.6 Hz), 7.97-7.83 (m, 1H), 7.81- 7.62 (m, 5H), 7.50-7.33 (m, 1H), 7.01- 6.93 (m, 1H), 4.45-4.33 (m, 1H), 3.65- 3.55 (m, 1H), 1.92-1.25 (m, 8H). Example 27-27 HCl DMSO-d6 300 MHz δ: 11.93 (s, 1H), 10.71 (s, 1H), 8.74 (s, 482 480 0.87 1H), 8.62 (s, 1H), 8.56 (s, 1H), 7.98 (d, 1H, J = 12.2 Hz), 7.97-7.69 (m, 6H), 7.69-7.58 (m, 1H), 7.56-7.35 (m, 2H), 7.05-6.95 (m, 1H), 4.41-4.29 (m, 1H), 3.65-3.55 (m, 1H), 1.88-1.13 (m, 8H). Example 27-28 HCl DMSO-d6 300 MHz δ: 11.97 (s, 1H), 10.65 (s, 1H), 8.80- 494 492 0.86 8.76 (m, 1H), 8.65 (s, 1H), 8.60 (s, 1H), 7.99 (d, 1H, J = 12.6 Hz), 7.97-7.83 (m, 1H), 7.83-7.73 (m, 3H), 7.63-7.35 (m, 4H), 7.25-7.18 (m, 1H), 7.05-6.98 (m, 1H), 4.43-4.31 (m, 1H), 3.65-3.55 (m, 1H), 3.58 (s, 3H), 1.90-1.13 (m, 8H). Example 27-29 HCl DMSO-d6 300 MHz δ: 11.92 (s, 1H), 10.83 (s, 1H), 8.78- 500 498 0.88 8.67 (m, 1H), 8.66-8.61 (m, 1H), 8.48- 8.43 (m, 1H), 7.98 (d, 1H, J = 12.6 Hz), 7.97-7.70 (m, 5H), 7.55-7.35 (m, 2H), 7.33-7.23 (m, 1H), 7.05-6.97 (m, 1H), 4.42-4.30 (m, 1H), 3.65-3.55 (m, 1H), 1.88-1.24 (m, 8H). Example 27-30 HCl DMSO-d6 300 MHz δ: 11.92 (s, 1H), 10.97 (s, 1H), 8.72- 500 498 0.88 8.68 (m, 1H), 8.66-8.61 (m, 1H), 8.49- 8.44 (m, 1H), 7.98 (d, 1H, J = 12.6 Hz), 7.97-7.75 (m, 4H), 7.75-7.62 (m, 1H), 7.57-7.49 (m, 1H), 7.46-7.38 (m, 2H), 7.00 (d, 1H, J = 5.9 Hz), 4.43-4.30 (m, 1H), 3.65-3.55 (m, 1H), 1.99-1.25 (m, 8H). Example 27-31 HCl DMSO-d6 300 MHz δ: 11.99 (s, 1H), 10.74 (s, 1H), 8.79 (s, 470 468 0.81 1H), 8.61 (s, 1H), 8.58 (s, 1H), 8.15 (d, 1H, J = 3.3 Hz), 7.99 (d, 1H, J = 12.6 Hz), 7.98-7.86 (m, 2H), 7.86-7.75 (m, 3H), 7.50-7.37 (m, 1H), 7.27 (dd, 1H, J = 4.0, 5.0 Hz), 7.05-6.98 (m, 1H), 4.45- 4.33 (m, 1H), 3.65-3.55 (m, 1H), 1.88- 1.17 (m, 8H). Example 27-32 HCl DMSO-d6 300 MHz δ: 11.93 (s, 1H), 10.49 (s, 1H), 8.76 (s, 470 468 0.79 1H), 8.63-8.53 (m, 2H), 8.50-8.45 (m, 1H), 7.98 (d, 1H, J = 12.6 Hz), 7.96- 7.85 (m, 1H), 7.82-7.73 (m, 3H), 7.73- 7.64 (m, 2H), 7.45-7.35 (m, 1H), 7.06- 6.96 (m, 1H), 4.44-4.32 (m, 1H), 3.65- 3.55 (m, 1H), 1.85-1.13 (m, 8H). Example 27-33 HCl DMSO-d6 300 MHz δ: 11.93 (s, 1H), 10.64 (s, 1H), 8.77- 454 452 0.74 8.72 (m, 1H), 8.61 (s, 1H), 8.59-8.54 (m, 1H), 8.02-7.98 (m, 1H), 7.98 (d, 1H, J = 12.6 Hz), 7.96-7.85 (m, 1H), 7.83- 7.73 (m, 3H), 7.50-7.38 (m, 2H), 7.05- 6.97 (m, 1H), 6.78-6.73 (m, 1H), 4.42- 4.37 (m, 1H), 3.65-3.55 (m, 1H), 1.90- 1.16 (m, 8H). Example 27-34 HCl DMSO-d6 300 MHz δ: 11.95 (s, 1H), 10.49 (s, 1H), 8.75 (s, 508 506 0.83 1H), 8.64 (s, 1H), 8.58 (s, 1H), 7.99 (d, 1H, J = 12.2 Hz), 7.95-7.83 (m, 1H), 7.83-7.73 (m, 3H), 7.64 (dd, 1H, J = 2.0, 8.3 Hz), 7.56 (d, 1H, 2.0 Hz), 7.52- 7.37 (m, 1H), 7.11 (d, 1H, J = 8.3 Hz), 7.06-6.98 (m, 1H), 6.16 (s, 2H), 4.42- 4.30 (m, 1H), 3.65-3.55 (m, 1H), 1.88- 1.15 (m, 8H). Example 27-35 HCl no data 522 520 0.87 Example 27-36 HCl no data 455 453 0.73 Example 27-37 HCl DMSO-d6 300 MHz δ: 11.99 (s, 1H), 10.75 (s, 1H), 8.81 (s, 504 502 0.9  1H), 8.70-8.61 (m, 2H), 8.38 (d, 1H, J = 1.7 Hz), 8.16 (d, 1H, J = 2.3 Hz), 8.03- 7.86 (m, 3H), 7.99 (d, 1H, J = 12.2 Hz), 7.86-7.74 (m, 3H), 7.55-7.30 (m, 1H), 7.16-7.13 (m, 1H), 7.03 (d, 1H, J = 6.6 Hz), 4.43-4.31 (m, 1H), 3.65-3.55 (m, 1H), 1.87-1.08 (m, 8H). Example 27-38 HCl DMSO-d6 300 MHz δ: 11.95 (s, 1H), 10.75 (s, 1H), 8.80 (s, 520 518 0.94 1H), 8.67-8.55 (m, 3H), 8.21 (d, 1H, J = 8.6 Hz), 8.04-7.83 (m, 4H), 7.83-7.70 (m, 3H), 7.63 (d, 1H, J = 5.3 Hz), 7.50- 7.38 (m, 1H), 7.05-6.99 (m, 1H), 4.44- 4.30 (m, 1H), 3.68-3.56 (m, 1H), 1.90- 1.10 (m, 8H). Example 27-39 HCl DMSO-d6 300 MHz δ: 11.99 (s, 1H), 10.84 (s, 1H), 8.80- 520 518 0.98 8.73 (m, 2H), 8.70 (s, 1H), 8.62 (s, 1H), 8.49-8.44 (m, 1H), 8.15-8.04 (m, 1H), 8.00 (d, 1H, J = 12.6 Hz), 7.97-7.85 (m, 1H), 7.85-7.73 (m, 3H), 7.55-7.40 (m, 3H), 7.06-6.98 (m, 1H), 4.44-4.30 (m, 1H), 3.65-3.55 (m, 1H), 1.87-1.08 (m, 8H). 0.98 Example 27-40 HCl DMSO-d6 300 MHz δ: 11.98 (s, 1H), 10.99 (s, 1H), 8.83- 520 518 1   8.78 (m, 1H), 8.64-8.57 (m, 2H), 8.49 (s, 1H), 8.13-8.02 (m, 2H), 7.99 (d, 1H, J = 12.6 Hz), 7.97-7.85 (m, 1H), 7.85- 7.75 (m, 3H), 7.58-7.37 (m, 3H), 7.05- 6.98 (m, 1H), 4.47-4.35 (m, 1H), 3.66- 3.57 (m, 1H), 1.90-1.15 (m, 8H). Example 27-41 HCl DMSO-d6 300 MHz δ: 11.98 (s, 1H), 11.04 (s, 1H), 8.83- 504 502 0.93 8.78 (m, 1H), 8.70-8.63 (m, 2H), 8.00 (d, 1H, J = 12.6 Hz), 7.97-7.71 (m, 7H), 7.60-7.52 (m, 1H), 7.50-7.35 (m, 2H), 7.08-7.00 (m, 1H), 4.44-4.33 (m, 1H), 3.66-3.57 (m, 1H), 1.87-1.13 (m, 8H). Example 27-42 HCl 519 517 0.75

Example 28

1st, 2nd, and 3rd Steps

The following compound was obtained as described in the 1st step of Example 3 and the 1st and 2nd steps of Reference Example 27.

tert-Butyl cis-2-(6-(5-(aminocarbonyl)pyridin-3-ylamino)-5-(tert-butylaminocarbonyl)-3-fluoropyridin-2-ylamino)cyclohexylcarbamate

¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.59 (s, 1H), 8.89 (s, 1H), 8.60-8.52 (m, 2H), 8.13 (s, 1H), 7.98 (d, 1H, J=12.8 Hz), 7.58 (s, 1H), 7.49 (s, 1H), 6.70-6.56 (m, 2H), 4.20-4.10 (m, 1H), 3.92-3.84 (m, 1H), 1.80-1.05 (m, 26H)

MS (ESI, m/z): 544 (M+H), 542 (M−H)

4th Step

The following compound was obtained as described in the 2nd step of Example 1.

2-(5-aminocarbonylpyridin-3-ylamino)-6-(cis-2-aminocyclohexylamino)-5-fluoronicotinamide

(¹H-NMR data and MS data are shown in table 14.)

Example 29

The compounds listed in table 14 were obtained as described in Example 28.

TABLE 14 Number Structure Example 29-1 HCl salt

Example 29-2 HCl salt

Example 29-3 (Example 28) HCl salt

Example 29-4

Example 29-5

Example 29-6

Example 29-7 HCl salt

Example 29-8

Example 29-9

Example 29-10

Example 29-11

Example 29-12

Example 29-13

Example 29-14

Example 29-15 HCl salt

Number Structure Compound name Example 29-16

5-((6-(cis-2-aminocyclohexylamino)- 3-carbamoyl-5-fluoropyridin- 2-yl)amino)-N,N- dimethyl-1H-indole-2-carboxamide Example 29-17

6-(cis-2-aminocyclohexylamino)-5-fluoro-2- ((2-(morpholine-4-carbonyl)-1H-indol-5-yl) amino)nicotinamide Example 29-18

5-((6-(cis-2-aminocyclohexylamino)-3- carbamoyl-5-fluoropyridin-2-yl)amino)-N- benzyl-1H-indole-2-carboxamide Example 29-19

5-((6-(cis-2-aminocyclohexylamino)-3- carbamoyl-5-fluoropyridin- 2-yl)amino)-N-(2- morpholinoethyl)-1H- indole-2-carboxamide MS Number Compound name ¹H-NMR (ESI, m/z) Example 29-1 5-((3-aminocarbonyl-6-(cis-2-amino- ¹H-NMR (DMS0-d₆ + D₂O, 389 (M + H) HCl salt cyclohexylamino)-5-fluoropyridin- 400 MHz) δ: 8.89-8.84 2-yl)amino)nicotinic acid (m, 2H), 8.68 (d, 1H, J = 1.7 Hz), 8.00 (d, 1H, J = 12.3 Hz), 4.40-4.30 (m, 1H), 3.58-3.50 (m, 1H), 1.95-1.35 (m, 8H). Example 29-2 4-(3-aminocarbonyl-6-(cis-2-amino- 428 (M + H) HCl salt cyclohexylamino)-5-fluoropyridin- 2-ylamino)-1H-pyrrolo[2,3-b] pyridin-2-carboxylic acid Example 29-3 2-((5-aminocarbonylpyridin-3-yl) ¹H-NMR (DMSO-d₆, 388 (M + H) HCl salt amino)-6-(cis-2-aminocyclohexyl- 400 MHz) δ: 12.02 (s, amino)-5-fluoronicotinamide 1H), 9.00-8.96 (m, 1H), 8.78 (s, 1H), 8.71-8.68 (m, 1H), 8.30 (s, 1H), 8.03- 7.87 (m, 5H), 7.79 (s, 1H), 7.50-7.39 (m, 1H), 7.10-7.03 (m, 1H), 4.39- 4.30 (m, 1H), 3.59-3.51 (m, 1H), 1.92-1.36 (m, 8H). Example 29-4 6-(cis-2-aminocyclohexylamino)- 469 (M + H) 2-(1-(2-(dimethylamino)-2-oxoethyl)- 1H-pyrrolo[2,3-b]pyridin-4- ylamino)-5-fluoronicotinamide Example 29-5 6-(cis-2-aminocyclohexylamino)- 509 (M + H) 5-fluoro-2-((1-(2-oxo-2-(piperidin- 1-yl)ethyl)-1H-pyrrolo[2,3-b] pyridin-4-yl)amino)nicotinamide Example 6-(cis-2-aminocyclohexylamino)- 511 (M + H) 29-6 5-fluoro-2-((1-(2-(morpholin-4- yl)-2-oxoethyl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)nicotinamide Example 29-7 (4-((3-aminocarbonyl-6-(cis-2-amino- 442 (M + H) HCl salt cyclohexylamino)-5-fluoropyridin- 2-yl)amino)-1H-pyrrolo[2,3-b] pyridin-1-yl)acetic acid Example 29-8 4-((3-aminocarbonyl-(6-(cis-2-amino- 455 (M + H) cyclohexylamino)-5-fluoropyridin- 2-yl)amino)-N,1-dimethyl-1H- pyrrolo[2,3-b]pyridin-2-carboxamide Example 29-9 4-((3-aminocarbonyl-6-(cis-2-amino- 469 (M + H) cyclohexylamino)-5-fluoropyridin- 2-yl)amino)-N,N,1-trimethyl-1H- pyrrolo[2,3-b]pyridin-2-carboxamide Example 29-10 6-(cis-2-aminocyclohexylamino)- 511 (M + H) 5-fluoro-2-((1-methyl-2-((morpholin- 4-yl)carbonyl)-1H-pyrrolo[2,3-b] pyridin-4-yl)amino)nicotinamide Example 29-11 4-((3-aminocarbonyl-6-(cis-2-amino- 554 (M + H) cyclohexylamino)-5-fluoropyridin- 2-yl)amino)-1-methyl-N-(2- (morpholin-4-yl)ethyl)-1H-pyrrolo [2,3-b]pyridin-2-carboxamide Example 29-12 4-((3-aminocarbonyl-6-(cis-2-amino- 388 (M + H) cyclohexylamino)-5-fluoropyridin- 2-yl)amino)pyridin-2-carboxamide Example 29-13 4-((3-aminocarbonyl-6-(cis-2-amino- 402 (M + H) cyclohexylamino)-5-fluoropyridin- 2-yl)amino)-N-methylpyridin- 2-carboxamide Example 29-14 4-((3-aminocarbonyl-6-(cis-2-amino- 416 (M + H) cyclohexylamino)-5-fluoropyridin- 2-yl) amino)-N,N-dimethylpyridin- 2-carboxamide Example 29-15 4-((3-aminocarbonyl-6-(cis-2-amino- 389 (M + H) HCl salt cyclohexylamino)-5-fluoropyridin- 2-yl)amino)pyridin-2-carboxylic acid Number Salt Solvent NMR 1HNMR Mass (M + H) Mass (M − H) rt (min) Example 29-16 free 454 452 0.81 Example 29-17 free 496 494 0.83 Example 29-18 free 516 514 1.03 Example 29-19 free 539 537 0.64

Example 30

The following compound was obtained as described in the 1st and 2nd steps of Example 5, the 2nd step of Reference Example 3, the 1st step of Reference Example 3, and the 2nd step of Example 1.

6-(2-aminoethylamino)-2-(3-(anilinocarbonyl)phenylamino)-5-fluoronicotinamide

(¹H-NMR data and MS data are shown in table 15.)

Example 31

The compounds listed in table 15 were obtained as described in Example 30.

TABLE 15 Num- Num- ber Structure ber Structure Ex- am- ple 31-1 HCl salt

Ex- am- ple 31-2 HCl salt

Ex- am- ple 31-3 HCl salt

Ex- am- ple 31-4 (Ex- am- ple 30) HCl salt

Ex- am- ple 31-5 HCl salt

Ex- am- ple 31-6 HCl salt

MS (ESI, Number Compound name ¹H-⁻NMR m/z) Example 6-((2-aminoethyl)amino)-2-((3- ¹H-⁻NMR (CD₃OD, 300 MHz) δ: 8.30-8.29 (m, 1H), 7.74 (d, 1H, J = 12.0 Hz), 7.28-7.33 332 31-1 (dimethylaminocarbonyl)phenyl) (m, 1H, 7.25-7.19 (m, 1H), 7.05-7.00 (m, 1H), 3.77 (t, 2H, J = 6.6 Hz), 3.17 (t, 2H, J = (M + HCl salt amino)-5-fluoronicotinamide 6.6 Hz), 3.12 (s, 3H), 3.07 (s, 3H). H) Example 6-((2-aminoethyl)amino)-5-fluoro- ¹H-⁻NMR (CD₃OD, 300 MHz) δ: 8.24 (t, 1H, J = 1.5 Hz), 7.74 (d, 1H, J = 12.0 Hz), 7.39- 401 31-2 2-((3-(piperidin-1-ylcarbonyl) 7.33 (m, 1H), 7.26-7.22 (m, 1H), 7.01-6.97 (m, 1H), 3.79-3.69 (m, 4H), 3.50-3.43 (m, 2H), (M + HCl salt phenyl)amino)nicotinamide 3.16 (t, 2H, J = 6.6 Hz), 1.78-1.52 (m, 6H). H) Example 6-((2-aminoethyl)amino)-2-((3- ¹H-⁻NMR (CD₃OD, 300 MHz) δ: 8.89-8.88 (m, 1H), 7.74 (d, 1H, J = 12.0 Hz), 7.38-7.31 415 31-3 (cyclohexylaminocarbonyl)phenyl) (m, 2H), 7.23-7.18 (m, 1H), 3.96-3.85 (m, 3H), 3.24 (t, 2H, J = 6.6 Hz), 1.99-1.65 (m, 5H), (M + HCl salt amino)-5-fluoronicotinamide 1.48-1.20 (m, 5H). H) Example 6-((2-aminoethyl)amino)-2-((3- ¹H-⁻NMR (CD₃OD, 300 MHz) δ: 9.01(s, 1H), 7.74 (d, 1H, J = 12.0 Hz), 7.69-7.67 (m, 409 31-4 (anilinocarbonyl)phenyl)amino)-5- 2H), 7.56-7.53 (m, 1H), 7.45-7.33 (m, 3H), 7.29-7.14 (m, 1H), 7.20-7.13 (m, 1H), 3.90 (M + HCl salt fluoronicotinamide (t, 2H, J = 6.6 Hz), 3.26 (t, 2H, J = 6.6 Hz). H) Example 6-((2-aminoethyl)amino)-5-fluoro- ¹H-⁻NMR (CD₃OD, 300 MHz) δ: 8.31-8.19 (m, 1H), 7.74 (d, 1H, J = 12.0 Hz), 7.39-7.34 31-5 2-((3-(morpholin-4-ylcarbonyl) (m, 1H), 7.27-7.24 (m, 1H), 7.03-6.99 (m, 1H), 3.80-3.50 (m, 10H), 3.17 (t, 2H, J = 6.6 Hz). HCl salt phenyl)amino)nicotinamide Example 6-((2-aminoethyl)amino)-5-fluoro- ¹H-⁻NMR (CD₃OD, 300 MHz) δ: 8.25-8.20 (m, 1H), 7.74 (d, 1H, J = 12.0 Hz), 7.42-7.40 31-6 2-((3-(4-methylpiperazin-1-yl (m, 2H), 7.09-6.96 (m, 1H), 3.79 (t, 2H, J = 6.6 Hz), 3.70-3.19 (m, 10H), 2.96 (s, 3H). HCl salt carbonyl)phenyl)amino) nicotinamide

Example 32

The following compound was obtained as described in the 1st step of Reference Example 2, the 2nd step of Reference Example 27, or the 4th step of Example 7.

6-(1-aminocarbonyl-2-methylpropylamino)-2-(3,5-dimethoxyphenylamino)-5-fluoro nicotinamide

(¹H-NMR and ESI-MS data are shown in table 16.)

Example 33

The compounds listed in table 16 were obtained as described in Example 32.

TABLE 16 Number Structure Number Structure Example 33-1

Example 33-2

Example 33-3

Example 33-4 (Example 32)

Example 33-5

Example 33-6

Example 33-7

Example 33-8

Number Compound name ¹H-⁻NMR MS (ESI, m/z) Example 6-((2-amino-1-methyl-2-oxoethyl) ¹H-⁻NMR (CD₃OD, 400 MHz) δ: 7.69 (d, 1H, J = 12.0 Hz), 376 (M − H) 33-1 amino)-2-(3,5-dimethoxyphenylamino)- 6.81 (d, 2H, J = 2.4 Hz), 6.13-6.10 (m, 1H), 4.50-5.00 (1H, 5-fluoronicotinamide overlapping with CH₃OH peak), 3.77 (s, 6H), 1.50 (d, 3H, J = 7.1 Hz). Example 6-((1-amino-2-methyl-1-oxopropan- ¹H-⁻NMR (CD₃OD, 400 MHz) δ: 7.56 (d, 1H, J = 12.2 Hz), 414 (M + Na), 33-2 2-yl)amino)-2-(3,5-dimethoxy- 6.58 (d, 2H, J = 2.2 Hz), 6.06 (t, 1H, J = 2.2 Hz), 3.68 390 (M − H) phenylamino)-5-fluoronicotinamide (s, 6H), 1.57 (s, 6H). Example 6-((3-amino-3-oxopropyl)amino)- ¹H-⁻NMR (CD₃OD, 400 MHz) δ: 7.54 (d, 1H, J = 12.4 Hz), 376 (M − H) 33-3 2-(3,5-dimethoxyphenylamino)-5- 6.83 (d, 2H, J = 2.2 Hz), 6.01 (t, 1H, J = 2.2 Hz), 3.82-3.67 fluoronicotinamide (m, 8H), 2.51 (t, 2H, J = 6.8 Hz). Example 6-((1-amino-3-methyl-1-oxobutan- ¹H-⁻NMR (CD₃OD, 400 MHz) δ: 7.61 (d, 1H, J = 12.2 Hz), 428 (M + Na), 33-4 2-yl)amino)-2-(3,5-dimethoxy- 6.73 (d, 2H, J = 2.2 Hz), 6.06 (t, 1H, J = 2.2 Hz), 4.53 404 (M − H) phenylamino)-5-fluoronicotinamide (d, 1H, J = 6.4 Hz), 3.69 (s, 6H), 1.20-1.18 (m, 1H), 0.95- 0.92 (m, 6H). Example 6-((1R)-1-aminocarbonyl-2,2- 420 (M + H), 33-5 dimethylpropylamino)-2-(3,5-dimethoxy- 418 (M − H) phenylamino)-5-fluoronicotinamide Example 6-(((2S)-1-amino-3,3-dimethyl-1- ¹H-⁻NMR (CD₃OD, 400 MHz) δ: 7.62 (d, 1H, J = 12.2 Hz), 442 (M + Na), 33-6 oxobutan-2-yl)amino)-2-(3,5- 6.78 (d, 2H, J = 2.0 Hz), 6.08 (t, 1H, J = 2.0 Hz), 4.58-4.60 418 (M − H) dimethoxyphenylamino)-5- (m, 1H), 3.70 (s, 6H), 1.00 (s, 9H). fluoronicotinamide Example 6-((cis-2-aminocarbonylcyclopentyl) 416 (M − H) 33-7 amino)-2-(3,5-dimethoxyphenylamino)- 5-fluoronicotinamide Example 6-(2-aminocarbonylpyrrolidin-1- ¹H-⁻NMR (DMSO-d₆, 400 MHz) δ: 11.61 (s, 1H), 7.90-7.60 402 (M − H) 33-8 yl)-2-(3,5-dimethoxyphenylamino)- (m, 1H), 7.32-7.12 (m, 1H), 6.97 (brs, 1H), 6.85 (d, 2H, J = 5-fluoronicotinamide 2.2 Hz), 6.08 (t, 1H, J = 2.2 Hz), 4.60-4.52 (m, 1H), 3.90- 3.82 (m, 2H), 3.73 (s, 6H), 2.30-2.16 (m, 1H), 2.04-1.96 (m, 1H), 1.94-1.76 (m, 2H).

Example 34

1st Step

Xantphos (5 mg) and Pd₂(dba)₃ (4 mg) were added to a mixture of tert-butyl cis-2-(6-amino-3-chloro-5-(2-phenylpropan-2-ylaminocarbonyl)pyridin-2-ylamino)cyclohexylcarbamate (20 mg), cesium carbonate (20 mg), 3-bromo-5-methylpyridine (9 mg), and 1,4-dioxane (2 ml) in a nitrogen atmosphere, followed by reflux for 3 hours in a nitrogen atmosphere. The reaction mixture was cooled to room temperature, and water and ethyl acetate were added. The organic layer was collected, washed with saturated saline, and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. The obtained residue was purified by silica gel chromatography (silica gel: Kanto Chemical Co., Inc., silica gel 60 (spherical shape), hexane.ethyl acetate=2:1 to 3:1), and a white solid of tert-butyl cis-2-(3-chloro-5-(2-phenylpropan-2-ylaminocarbonyl)-6-(5-methylpyridin-3-ylamino)pyridin-2-ylamino)cyclohexylcarbamate (13 mg) was thus obtained.

MS (ESI, m/z): 593 (M+H), 595 (M+H)

2nd Step

A mixture of tert-butyl cis-2-(3-chloro-5-(2-phenylpropan-2-ylaminocarbonyl)-6-(5-methylpyridin-3-ylamino)pyridin-2-ylamino)cyclohexylcarbamate (12 mg) and TFA (0.5 ml) was stirred at room temperature for 1 hour. The solvent was distilled away under reduced pressure (at 40° C. or less), ethyl acetate and 4N hydrogen chloride/1,4-dioxane (25 μl) were added, and the resultant was left at rest overnight at room temperature. Solid matter was collected by filtration, and a white solid of 6-(cis-2-aminocyclohexylamino)-5-chloro-2-(5-methylpyridin-3-ylamino)nicotinamide.hydrochloride (8 mg) was thus obtained.

(¹H-NMR and ESI-MS data are shown in table 17.)

Example 35

The compounds shown in table 17 were obtained as described in Example 34.

TABLE 17 Number Structure Number Structure Example 35-1 HCl salt

Example 35-2 HCl salt

Example 35-3 HCl salt

Example 35-4 (Example 34) HCl salt

Example 35-5 HC1 salt

Example 35-6 HCl salt

Example 35-7 HCl salt

Example 35-8

Example 35-9

Example 35-10

Number Compound name ¹H-⁻NMR MS (ESI, m/z) Example 6-(cis-2-aminocyclohexylamino)- ¹H-⁻NMR (DMSO-d₆, 400 MHz) δ: 12.07 (s, 1H), 411 (M + H), 35-1 5-chloro-2-(quinolin-3-ylamino) 9.25-9.20 (m, 1H), 8.90-8.85 (m, 1H), 8.24 413 (M + H) HCl salt nicotinamide (s, 1H), 8.12-7.98 (m, 6H), 7.77-7.66 (m, 2H), 7.56-7.38 (br, 1H), 6.37 (d, 1H, J = 7.1 Hz)), 4.48-4.36 (m, 1H), 3.65-3.55 (m, 1H), 2.00-1.38 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.04 (s, 1H), 455 (M + H), 35-2 5-bromo-2-(quinolin-3-ylamino) 9.24-9.18 (m, 1H), 8.88-8.82 (m, 1H), 8.36 457 (M + H) HCl salt nicotinamide (s, 1H), 8.14-7.96 (m, 6H), 7.77-7.65 (m, 2H), 7.58-7.35 (br, 1H), 6.09 (d, 1H, J = 7.6 Hz)), 4.48-4.39 (m, 1H), 3.65-3.57 (1H, overlapping with H₂O peak), 2.00-1.37 (m, 8H). ¹H-NMR (DMSO-d₆ + D₂O, 400 MHz) δ: 9.18-9.14 (m, 1H), 8.78-8.84 (m, 1H), 8.33 (s, 1H), 8.10-7.95 (m, 2H), 7.80-7.68 (m, 2H), 4.46-4.37 (m, 1H), 3.65-3.57 (m, 1H), 1.86-1.40 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.11 (s, 1H), 375 (M + H), 35-3 5-chloro-2-((3-methoxyphenyl) 9.17-9.06 (br, 1H), 8.40-8.21 (m, 3H), 377 (M + H) HCl salt amino)nicotinamide 8.15-7.96 (m, 4H), 7.60-7.45 (m, 1H), 6.43 (d, 1H, J = 7.1 Hz), 4.40-4.28 (m, 1H), 3.60-3.51 (m, 1H), 2.44 (s, 3H), 1.95-1.39 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.63 (s, 1H), 390 (M + H), 35-4 5-chloro-2-((5-methylpyridin-3- 8.12 (s, 1H), 8.00-7.83 (m, 4H), 7.40-7.17 392 (M + H) HCl salt yl)amino)nicotinamide (m, 3H), 7.10-7.04 (m, 1H), 6.63-6.56 (m, 1H), 6.30 (d, 1H, J = 7.1 Hz), 4.32-4.22 (m, 1H), 3.76 (s, 3H), 3.70-3.60 (m, 1H), 1.95-1.36 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.56 (s, 1H), 374 (M + H), 35-5 5-chloro-2-(3-methylphenylamino) 8.11 (s, 1H), 8.00-7.75 (m, 4H), 7.43-7.15 376 (M + H) HCl salt nicotinamide (m, 4H), 6.81 (d, 1H, J = 7.1 Hz), 6.24 (d, 1H, J = 7.0 Hz), 4.32-4.22 (m, 1H), 3.70-3.60 (m, 1H), 2.30 (s, 3H), 1.94-1.36 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 11.93 (s, 1H), 427 (M + H), 35-6 5-chloro-2-((3-(2H-1,2,3-triazol- 8.64-8.60 (m, 1H), 8.18 (s, 1H), 8.15 (s, 429 (M + H) HCl salt 2-yl)phenyl)amino)nicotinamide 2H), 8.05-7.77 (m, 4H), 7.66-7.61 (m, 1H), 7.51-7.30 (m, 3H), 6.28 (d, 1H, J = 6.8 Hz), 4.48-4.38 (m, 1H), 3.66-3.57 (m, 1H), 1.93-1.30 (m, 8H). Example 6-(cis-2-aminocyclohexylamino)- ¹H-NMR (DMSO-d₆, 400 MHz) δ: 12.06 (s, 1H), 419 (M + H), 35-7 5-bromo-2-((5-methylpyridin-3-yl) 9.12-9.05 (m, 1H), 8.48-8.30 (m, 2H), 421 (M + H) HCl salt amino)nicotinamide 8.30-8.22 (m, 1H), 8.15-7.96 (m, 4H), 7.60-7.44 (br, 1H), 6.13 (d, 1H, J = 7.8 Hz), 4.40-4.29 (m, 1H), 3.60-3.50 (m, 1H), 2.43 (s, 1H), 1.93-1.39 (m, 8H). Example 6-((2-aminoethyl)amino)-5-chloro- ¹H-NMR (CD₃OD, 400 MHz) δ: 7.96-7.86 (br, 334 (M + H), 35-8 2-((3,5-dimethylphenyl)amino) 1H), 7.36-7.24 (br, 2H), 6.56-6.68 (br, 336 (M + H) nicotinamide 1H), 3.68-3.56 (m, 2H), 3.00-2.80 (m, 2H), 2.36-2.24 (brs, 6H). Example 6-((2-aminoethyl)amino)-5-bromo- 1¹H-NMR (CD₃OD, 400 MHz) δ: 8.15-7.98 (m, 35-9 2-((3,5-dimethylphenyl)amino) 1H), 7.35-7.20 (br, 2H), 6.74-6.59 (br, nicotinamide 1H), 3.74-3.50 (m, 2H), 3.00-2.82 (m, 2H), 2.36-2.24 (brs, 6H). Mass Mass Number Salt Solvent NMR 1HNMR (M + H) (M − H) rt(min) Example HCl DMSO-d6 300 MHz δ: 12.05 (s, 1H), 9.14 (s, 1H), 8.38 (d, 373 371 0.61 35-10 1H, J = 8.4 Hz), 8.23 (s, 1H), 8.14-7.90 375 373 (m, 4H), 7.74 (d, 1H, J = 8.4 Hz), 7.51 (br, 1H), 6.40 (d, 1H, J = 7.8 Hz), 4.40- 4.28 (m, 1H), 3.64-3.48 (m, 1H), 2.65 (s, 3H), 1.95-1.35 (m, 8H).

Example 36

1st Step

Sodium carbonate (32 mg), 5-aminoquinoline (30 mg), Xantphos (11 mg), and Pd₂(dba)₃ (9 mg) were added to a 1,4-dioxane (0.4 ml) solution containing 2-chloro-6-(((1R,2S)-2-(1,3-dioxoisoindolin-2-yl)cyclohexyl)amino)-5-fluoronicotinonitrile (40 mg) in a nitrogen atmosphere, followed by stirring at 100° C. for 12 hours. The reaction mixture was adjusted to room temperature, and ethyl acetate was added, followed by filtration. The solvent was distilled away under reduced pressure, and the obtained residue was purified by silica gel chromatography (n-hexane ethyl acetate=9:1 to 1:1), and 6-(((1R,2S)-2-(1,3-dioxoisoindolin-2-yl)cyclohexyl)amino)-5-fluoro-2-(quinolin-5-ylamino)nicotinonitrile (30 mg) was thus obtained.

MS (ESI m/z): 508 (M+H)

RT (min): 1.37

2nd Step

Hydrazine.monohydrate (50 μl) was added to an ethanol/tetrahydrofuran (1 ml/0.2 ml) solution containing 6-(((1R,2S)-2-(1,3-dioxoisoindolin-2-yl)cyclohexyl)amino)-5-fluoro-2-(quinolin-5-ylamino)nicotinonitrile (30 mg), followed by stirring at room temperature for 2.5 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The resultant was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and 6-(((1R,2S)-2-aminocyclohexyl)amino)-5-fluoro-2-(quinolin-5-ylamino)nicotinonitrile (20 mg) was thus obtained.

MS (ESI m/z): 377 (M+H)

RT (min): 0.73

3rd Step

A 5M sodium hydroxide aqueous solution (0.1 ml) and a 30% hydrogen peroxide solution (0.1 ml) were added to a solution of dimethyl sulfoxide (1 ml) and ethanol (0.5 ml) containing 6-(((1R,2S)-2-aminocyclohexyl)amino)-5-fluoro-2-(quinolin-5-ylamino)nicotinonitrile (20 mg), followed by stirring at room temperature for 1 hour. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated saline and dried over anhydrous sodium sulfate, and the solvent was distilled away under reduced pressure. 4M hydrogen chloride/1,4-dioxane (0.5 ml) was added to the obtained residue, the resulting precipitate was collected by filtration, and a red solid of 6-(((1R,2S)-2-aminocyclohexyl)amino)-5-fluoro-2-(quinolin-5-ylamino)nicotinamide (12 mg) was thus obtained.

MS (ESI m/z): 395 (M+H)

RT (min): 0.70

Example 37

The compounds shown in table 18 were obtained as described in Example 36.

TABLE 18 Number Structure Compound name Example 37-1 (Example 36)

6-((1R,2S)-2- aminocyclohexylamino)- 5-fluoro-2-((quinolin-5- yl)amino)nicotinamide Example 37-2

6-((1R,2S)-2- aminocyclohexylamino)-5-fluoro-2-((isoquinolin-4-yl)amino)nicotinamide Example 37-3

6-((1R,2S)-2- aminocyclohexylamino)-5-fluoro-2-((quinolin-6-yl)amino)nicotinamide Example 37-4

6-((1R,2S)-2- aminocyclohexylamino)- 5-fluoro-2-((quinolin-3- yl)amino)nicotinamide Example 37-5

6-((1R,2S)-2- aminocyclohexylamino)- 5-fluoro-2-((1-methyl-1H- indazol-5-yl)amino) nicotinamide Mass Mass Number Salt Solvent NMR 1HNMR (M + H) (M − H) rt(min) Example 37-1 (Example 36) HCl 395 393 0.65 Example 37-2 HCl 395 393 0.67 Example 37-3 HCl 395 393 0.64 Example 37-4 HCl 395 393 0.81 Example 37-5 HCl 398 396 0.84

Example 38

1st Step

Potassium carbonate (115 mg) and 6-chloro-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile (50 mg) were added to a tube containing a 1,4-dioxane (2 ml) solution containing (R)-2-(2-aminopropyl)isoindoline-1,3-dione (52 mg) and the tube was sealed, followed by stirring with heating at 140° C. for 13 hours. The reaction solution was adjusted to room temperature, and a saturated aqueous sodium hydrogen carbonate solution was added, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate. Subsequently, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=3:2), and a yellow solid of (R)-6-((1-(1,3-dioxoisoindolin-2-yl)propan-2-yl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile (57 mg) was thus obtained.

MS (ESI m/z): 467 (M+H)

RT (min): 1.03

2nd Step

The following compound was obtained as described in the 3rd step of Reference Example 379.

(R)-6-((1-aminopropan-2-yl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinonitrile

MS (ESI m/z): 337 (M+H)

RT (min): 0.60

3rd Step

The following compound was obtained as described in the 2nd step of Reference Example 2.

(R)-tert-butyl(2-((5-cyano-3-fluoro-6-(quinolin-6-ylamino)pyridin-2-yl)amino)propyl)carbamate

MS (ESI m/z): 437 (M+H)

RT (min): 1.14

4th and 5th Steps

The following compound was obtained as described in the 2nd and 3rd steps of Example 5.

(R)-tert-butyl(2-((5-carbamoyl-3-fluoro-6-(quinolin-6-ylamino)pyridin-2-yl)amino)propyl)carbamate

MS (ESI m/z): 455 (M+H)

RT (min): 1.02

(R)-6-(1-aminopropan-2-yl)amino)-5-fluoro-2-(quinolin-6-ylamino)nicotinamide

MS (ESI m/z): 355 (M+H)

RT (min): 0.56

Example 39

The compounds listed in table 19 were obtained as described in Example 38.

TABLE 19 Number Structure Compound name Example 39-1

6-(((2R,3S)-3-aminobutan-2- yl)amino)-5-fluoro-2- ((quinolin- 6-yl)amino)nicotinamide 6-(((2S,3R)-3-aminobutan-2- yl)amino)-5-fluoro-2- ((quinolin- 6-yl)amino)nicotinamide Example 39-2

(R)-6-((1-aminobutan-2- yl)amino)-5-fluoro-2- ((quinolin-6- yl)amino)nicotinamide Example 39-3 (Example 38)

(R)-6-((1-aminopropan-2- yl)amino)-5-fluoro-2- ((quinolin-6- yl)amino)nicotinamide Example 39-4

(R)-6-((2-amino-1- phenylethyl)amino)-5-fluoro- 2-((quinolin-6- yl)amino)nicotinamide Example 39-5

(R)-6-((2-amino-1-(pyridin-2- yl)ethyl)amino)-5-fluoro-2- ((quinolin-6- yl)amino)nicotinamide Mass Mass Number Salt Solvent NMR 1HNMR (M + H) (M − H) rt(min) Example 39-1 HCl 369 367 0.57 Example 39-2 HCl 369 367 0.62 Example 39-3 (Example 38) HCl 355 353 0.56 Example 39-4 HCl 417 415 0.71 Example 39-5 HCl 418 416 0.62

Example 40

1st Step

Cesium carbonate (238 mg), 3-bromo-8-nitroquinoline (92 mg), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (23 mg), and Pd₂(dba)₃ (22 mg) were added to a 1,4-dioxane solution (2 ml) containing tert-butyl((cis)-2-(6-amino-3-fluoro-5-((2-phenylpropan-2-yl)carbamoyl)pyridin-2-yl)amino)cyclohexyl)carbamate (118 mg) in a nitrogen atmosphere, followed by stirring at 100° C. for 45 minutes. The reaction solution was adjusted to room temperature, ethyl acetate was added, and insoluble matter was filtered. Then, the solvent was distilled away under reduced pressure, the obtained residue was purified by silica gel chromatography (n-hexane ethyl acetate=9:1 to 3:7), and tert-butyl((cis)-2-((3-fluoro-6-((8-nitroquinolin-3-yl)amino)-5-((2-phenylpropan-2-yl)carbamoyl)pyridin-2-yl)amino)cyclohexyl)carbamate (98 mg) was thus obtained.

MS (ESI m/z): 658 (M+H)

RT (min): 2.08

2nd Step

The following compound was obtained as described in the 2nd step of Reference Example 186.

tert-Butyl((cis)-2-((6-((8-aminoquinolin-3-yl)amino)-3-fluoro-5-((2-phenylpropan-2-yl)carbamoyl)pyridin-2-yl)amino)cyclohexyl)carbamate

MS (ESI m/z): 629 (M+H), 627 (M−H)

RT (min): 1.98

3rd Step

Triethylamine (4 μl) and methanesulfonyl chloride (1.4 μl) were added to a dichloromethane (1 ml) solution containing tert-butyl((cis)-2-(6-((8-aminoquinolin-3-yl)amino)-3-fluoro-5-((2-phenylpropan-2-yl)carbamoyl)pyridin-2-yl)amino)cyclohexyl)carbamate (10 mg) obtained in the 2nd step, followed by stirring at room temperature for 1 hour. Triethylamine (12 μl) and methanesulfonyl chloride (5 μl) were added again to the reaction mixture, followed by stirring at room temperature for 1 hour. Saturated sodium bicarbonate water was added, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate, the solvent was distilled away under reduced pressure, and tert-butyl((cis)-2-(3-fluoro-6-((8-(methylsulfonamide)quinolin-3-yl)amino)-5-((2-phenylpropan-2-yl)carbamoyl)pyridin-2-yl)amino)cyclohexyl)carbamate (12 mg) was thus obtained.

MS (ESI m/z): 707 (M+H)

RT (min): 2.06

4th Step

The following compound was obtained as described in the 2nd step of Example 1.

6-(((cis)-2-aminocyclohexyl)amino)-5-fluoro-2-((8-(methylsulfonamide)quinolin-3-yl)amino)nicotinamide

MS (ESI m/z): 488 (M+H), 486 (M−H)

RT (min): 0.97

Example 41

The compounds listed in table 20 were obtained as described in Example 40.

TABLE 20 Number Structure Compound name Example 41-1

6-(cis-2-aminocyclohexylamino)- 2-((8-aminoquinolin-6- yl)amino)-5-fluoronicotinamide Example 41-2 (Example 40)

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((8- (methylsulphonamide)quinolin- 3-yl)amino)nicotinamide Example 41-3

6-(cis-2-aminocyclohexylamino)- 2-((8-(2- chloromethylsulphonamide)quinolin- 3-yl)amino)-5-fluoronicotinamide Example 41-4

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((8-(4- methylphenylsulphonamide)quinolin- 3-yl)amino)nicotinamide Example 41-5

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((8-(4- methoxyphenylsulphonamide)quinolin- 3-yl)amino)nicotinamide Example 41-6

6-(cis-2-aminocyclohexylamino)- 2-((8-(4- chlorophenylsulphonamide)quinolin- 3-yl)amino)-5-fluoronicotinamide Example 41-7

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((8-(4- (trifluoromethyl)phenylsulphonamide) quinolin-3-yl)amino)nicotinamide Example 41-8

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((8- (pyridin-3-sulphonamide)quinolin- 3-yl)amino)nicotinamide Example 41-9

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((8- (phenylmethylsulphonamide)quinolin- 3-yl)amino)nicotinamide Example 41-10

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((8-picolinamidequinolin- 3-yl)amino)nicotinamide Example 41-11

6-(cis-2-aminocyclohexylamino)- 5-fluoro-2-((8- pivalamidequinolin-3- yl)amino)nicotinamide Example 41-12

6-(cis-2-aminocyclohexylamino)- 2-((8- (ethylsulphonamide)quinolin- 3-yl)amino)-5- fluoronicotinamide Mass Mass Number Salt Solvent NMR 1HNMR (M + H) (M − H) rt(min) Example 41-1 HCl 410 408 0.77 Example 41-2 (Example 40) HCl 488 486 0.95 Example 41-3 HCl 522 520 1.05 Example 41-4 HCl 564 562 1.21 Example 41-5 HCl 580 578 1.16 Example 41-6 HCl 584 582 1.25 Example 41-7 HCl 618 616 1.29 Example 41-8 HCl 551 549 1.02 Example 41-9 HCl 564 562 1.17 Example 41-10 HCl 515 513 1.15 Example 41-11 HCl 494 492 1.18 Example 41-12 HCl 502 500 1.01

Example 42

1st Step

The following compound was obtained as described in the 1st step of Example 40.

tert-Butyl((cis)-2-(6-((8-(benzyloxy)quinolin-6-yl)amino)-3-fluoro-5-((2-phenylpro pan-2-yl)carbamoyl)pyridin-2-yl)amino)cyclohexyl)carbamate

MS (ESI m/z): 720 (M+H), 718 (M−H)

RT (min): 1.75

2nd Step

The following compound was obtained as described in the 2nd step of Example 1.

6-(((cis)-2-aminocyclohexyl)amino)-2-((8-(benzyloxy)quinolin-6-yl)amino)-5-fluoronicotinamide

MS (ESI m/z): 502 (M+H)

RT (min): 0.87

3rd Step

A methanol (5 ml) solution containing 6-(((cis)-2-aminocyclohexyl)amino)-2-((8-(benzyloxy)quinolin-6-yl)amino)-5-fluoronicotinamide (20 mg) was prepared and was subjected to a hydrogenation reaction (room temperature; 1 bar; flow rate: 1 ml/min; 20% Pd(OH)₂/C) using H-cube™. Then, the solvent was distilled away under reduced pressure. The residue was dissolved in ethyl acetate, 4M hydrogen chloride/1,4-dioxane (50 μl) was added, the resulting precipitate was collected by filtration, and a yellow solid of 6-(((cis)-2-aminocyclohexyl)amino)-5-fluoro-2-((8-hydroxyquinolin-6-yl)amino)nicotinamide (12 mg) was thus obtained.

6-(((cis)-2-aminocyclohexyl)amino)-5-fluoro-2-((8-hydroxyquinolin-6-yl)amino)nicotinamide

MS (ESI m/z): 411 (M+H)

RT (min): 0.66

Example 43

1st Step

The following compound was obtained as described in the 1st step of Example 5.

tert-Butyl((1S,2R)-2-((5-cyano-3-fluoro-6-((5-(3-nitrophenyl)pyridin-3-yl)amino)pyridin-2-yl)amino)cyclohexyl)carbamate

MS (ESI m/z): 548 (M+H)

RT (min): 1.69

2nd Step

Ammonium formate (0.2 g) and 10% Pd/C (0.2 g) were added to a methanol (10 ml) solution containing tert-butyl((1S,2R)-2-((5-cyano-3-fluoro-6-((5-(3-nitrophenyl)pyridin-3-yl)amino)pyridin-2-yl)amino)cyclohexyl)carbamate (87 mg), followed by reflux with heating for 30 minutes. The reaction mixture was cooled to room temperature and filtered with Celite, the solvent was distilled away under reduced pressure, and a yellow solid of tert-butyl((1S,2R)-2-((6-((5-(3-aminophenyl)pyridin-3-yl)amino)-5-cyano-3-fluoropyridin-2-yl)amino)cyclohexyl)carbamate (90 mg) was thus obtained.

MS (ESI m/z): 518 (M+H)

RT (min): 1.32

3rd Step

The following compound was obtained as described in the 2nd step of Example 5.

tert-Butyl((1S,2R)-2-((6-((5-(3-aminophenyl)pyridin-3-yl)amino)-5-carbamoyl-3-fluoropyridin-2-yl)amino)cyclohexyl)carbamate

MS (ESI m/z): 536 (M+H)

RT (min): 1.18

4th Step

The following compound was obtained as described in the 2nd step of Example 1.

6-(((1R,2S)-2-aminocyclohexyl)amino)-2-((5-(3-aminophenyl)pyridin-3-yl)amino)-5-fluoronicotinamide

MS (ESI m/z): 436 (M+H)

RT (min): 0.70

Example 44

The following compound was obtained as described in the 3rd step of Example 5.

6-(((2S,3R)-2-amino-6-hydroxyhexan-3-yl)amino)-2-((5,6-dimethylpyridin-3-yl)amino)-5-fluoronicotinamide

¹H-NMR (DMSO-d₆, 300 MHz) δ: 12.20 (d, 1H, J=6.6 Hz), 9.38 (s, 1H), 8.25-7.86 (m, 6H), 7.55-7.43 (m, 1H), 7.40-7.25 (m, 1H), 4.45-4.25 (m, 2H), 3.49-3.34 (m, 1H), 2.82-2.67 (m, 2H), 2.63 (s, 3H), 2.39 (s, 3H), 1.80-1.32 (m, 4H), 1.25 (d, 3H, J=5.9 Hz).

MS (ESI m/z): 391 (M+H)

RT (min): 0.51

Example 45

1st Step

N,N-diisopropylethylamine (3.4 ul) and di-tert-butyl dicarbonate (4.4 mg) were added to a tetrahydrofuran solution (1 ml) containing tert-butyl((2S,3R)-6-amino-3-((5-carbamoyl-6-((5,6-dimethylpyridin-3-yl)amino)-3-fluoropyridin-2-yl)amino)hexan-2-yl)carbamate (7 mg), followed by stirring at room temperature for 15 minutes. The solvent was distilled away under reduced pressure, the residue was purified by silica gel chromatography (ethyl acetate) and used in the subsequent reaction.

2nd Step

The following compound was obtained as described in the 3rd step of Example 5.

6-(((2S,3R)-2-amino-6-aminohexan-3-yl)amino)-2-(5,6-dimethylpyridin-3-yl)amino)-5-fluoronicotinamide

¹H-NMR (DMSO-d₆) δ: 12.20 (s, 1H), 9.40 (s, 1H), 8.26-7.34 (m, 11H), 4.40 (s, 2H), 3.49-3.34 (m, 1H), 2.62 (s, 3H), 2.39 (s, 3H), 1.86-1.50 (m, 4H), 1.26 (d, 3H, J=6.6 Hz)

MS (ESI m/z): 390 (M+H)

RT (min): 0.35

Example 46

1st Step

Sodium triacetoxyborohydride (10.6 mg) was added to a mixture of tert-butyl((2S,3R)-6-amino-3-((5-carbamoyl-6-((5,6-dimethylpyridin-3-yl)amino)-3-fluoropyridin-2-yl)amino)hexan-2-yl)carbamate (7 mg), chloroform (1 ml), and a 35% formaldehyde aqueous solution (6.0 ul), followed by stirring at room temperature for 15 minutes. The solvent was distilled away under reduced pressure, the residue was purified by silica gel chromatography (ethyl acetate:methanol=9:1) and used in the subsequent reaction.

2nd Step

The following compound was obtained as described in the 3rd step of Example 5.

6-(((2S,3R)-2-amino-6-(dimethylamino)hexan-3-yl)amino)-2-((5,6-dimethylpyridin-3-yl)amino)-5-fluoronicotinamide

¹H-NMR (DMSO-d₆) δ: 12.17 (s, 1H), 9.95-9.70 (m, 1H), 9.45-9.25 (m, 1H), 8.30-7.84 (m, 5H), 7.55-7.25 (m, 2H), 4.45-4.35 (m, 1H), 3.49-3.34 (m, 1H), 3.07-2.95 (m, 2H), 2.73-2.62 (m, 9H), 2.39 (s, 3H), 1.82-1.58 (m, 4H), 1.26 (d, 3H, J=6.6 Hz)

MS (ESI m/z): 417 (M+H)

RT (min): 0.43

Example 47

1st Step

Acetyl chloride (1.2 μl) was added to a mixture of tert-butyl((2S,3R)-6-amino-3-((5-carbamoyl-6-((5,6-dimethylpyridin-3-yl)amino)-3-fluoropyridin-2-yl)amino)hexan-2-yl)carbamate (7 mg), dichloromethane (1 ml), and N,N-diisopropylethylamine (3.4 ul), followed by stirring at room temperature for 15 minutes. The solvent was distilled away under reduced pressure, the residue was purified by silica gel chromatography (ethyl acetate:methanol=9:1) and used in the subsequent reaction.

2nd Step

The following compound was obtained as described in the 3rd step of Example 5.

6-(((2S,3R)-6-acetamide-2-aminohexan-3-yl)amino)-2-((5,6-dimethylpyridin-3-yl)amino)-5-fluoronicotinamide

¹H-NMR (DMSO-d₆) δ: 12.19 (s, 1H), 9.38 (s, 1H), 8.20-7.78 (m, 7H), 7.55-7.25 (m, 2H), 4.45-4.30 (m, 1H), 3.49-3.34 (m, 1H), 3.05-2.90 (m, 2H), 2.65 (s, 3H), 2.39 (s, 3H), 1.80-1.30 (m, 7H), 1.24 (d, 3H, J=6.6 Hz)

MS (ESI m/z): 432 (M+H)

RT (min): 0.53

Test Example 1 Syk Enzyme Assay

Table 21 shows the results of a test performed according to the test method described in “syk enzyme assay” in Test Example 1. In addition, the following are standards for evaluating IC₅₀ of Syk-inhibitory activity used in Table 21.

A: Up to 10 nM B: 10 to 50 nM C: 50 to 100 nM D: 100 to 1000 nM

The set of numbers (XYZ-xyz) given in each Example number column indicates the corresponding Example number (Example XYZ-xyz) in Table 21.

TABLE 21 002-001 A 002-002 C 002-003 A 002-004 A 002-005 B 002-006 A 002-007 B 002-009 B 002-010 C 002-011 D 002-012 D 002-013 A 002-014 A 002-015 A 002-016 A 002-017 B 002-018 A 002-019 B 002-020 B 002-021 B 002-022 B 002-023 A 002-024 A 002-025 A 002-026 A 002-027 A 002-028 A 002-029 B 002-030 A 002-031 A 002-032 A 002-033 A 002-034 A 002-035 B 002-036 C 002-037 A 002-038 A 002-039 B 002-040 B 002-041 A 002-042 B 002-043 B 002-044 B 002-045 B 002-046 A 002-047 B 002-048 A 002-049 B 002-050 B 002-051 A 002-052 A 002-053 A 002-054 B 002-055 A 002-056 B 002-057 A 002-058 A 002-059 B 002-060 A 002-061 A 002-062 A 002-063 A 002-064 D 002-065 A 002-066 A 002-067 B 002-068 A 002-069 A 002-070 A 002-071 B 002-072 B 002-073 B 002-074 C 002-075 B 002-076 C 002-077 C 002-078 B 002-079 C 002-080 D 002-081 B 002-082 A 002-083 A 002-084 A 002-085 B 002-086 B 002-087 B 002-088 A 002-089 B 002-090 A 002-091 A 002-092 A 002-093 A 002-094 B 002-095 A 002-096 B 002-097 A 002-098 A 002-099 A 002-100 A 002-101 A 002-102 B 002-103 A 002-104 A 002-105 B 002-106 C 002-107 A 002-108 B 002-109 B 002-110 A 002-111 B 002-112 A 002-113 A 002-114 A 002-115 B 002-116 C 002-117 A 002-118 B 002-119 A 002-120 A 002-121 D 002-122 A 002-123 A 002-124 A 002-125 A 002-126 A 002-127 B 002-128 D 002-129 D 002-130 D 002-131 A 002-132 B 002-133 A 002-134 A 002-135 B 002-136 C 002-137 A 002-138 C 002-139 A 002-140 A 002-141 A 002-142 A 002-143 A 002-144 A 002-145 A 002-146 A 002-147 A 002-148 B 002-149 B 002-150 B 002-151 B 002-152 B 002-153 B 002-154 B 002-155 B 002-156 C 002-157 D 002-158 D 002-159 D 002-160 B 002-161 C 002-162 D 002-163 B 002-164 C 002-165 B 002-166 D 002-167 B 002-168 B 002-169 B 002-170 B 002-171 C 002-172 B 002-173 B 002-174 C 002-175 A 002-176 A 002-177 A 002-178 A 002-179 C 002-180 C 002-181 C 002-182 D 002-183 A 002-184 A 002-185 A 002-186 A 002-187 A 002-188 A 002-189 A 002-190 A 002-191 A 002-192 A 002-193 A 002-194 A 002-195 A 002-196 A 002-197 A 002-198 A 002-199 A 002-200 A 002-201 A 002-202 D 002-203 B 002-204 A 002-205 A 002-206 A 002-207 A 002-208 A 002-209 A 002-210 A 004-001 D 004-002 B 004-003 B 004-004 B 004-005 A 004-006 A 004-007 A 004-008 A 004-009 A 004-010 B 004-011 B 004-012 A 004-013 A 004-014 A 004-015 D 004-016 A 004-017 B 004-018 B 004-019 B 004-020 A 004-021 D 004-022 B 004-024 C 004-025 A 004-026 A 004-027 B 004-028 A 004-029 A 004-030 A 004-031 A 004-032 A 004-033 A 004-034 C 004-035 A 004-036 A 004-037 A 004-038 A 004-039 A 004-040 A 004-041 C 004-042 A 004-043 D 004-044 A 004-045 B 004-046 A 004-047 B 004-048 B 004-049 A 004-050 B 004-051 A 004-052 B 004-053 A 004-054 A 004-055 A 004-056 A 004-057 A 004-058 A 004-059 A 004-060 A 004-061 A 004-062 A 004-063 A 004-064 D 004-065 A 004-066 A 004-067 A 004-068 A 004-069 A 004-070 A 004-071 A 004-072 A 004-073 A 004-074 A 004-075 A 004-076 A 004-077 A 004-078 A 004-079 A 004-080 A 004-081 A 004-082 A 004-083 A 004-084 A 004-085 A 004-086 A 004-087 A 004-088 A 004-089 A 004-090 B 004-091 A 004-092 A 004-093 A 004-094 A 004-095 A 004-096 B 004-097 A 004-098 B 004-099 A 004-100 A 004-101 B 004-102 C 004-103 B 004-104 B 004-105 B 004-106 A 004-107 B 004-108 D 004-109 A 004-110 A 004-111 A 004-112 A 004-113 A 004-114 A 004-115 A 004-116 A 004-117 A 004-118 A 004-119 A 004-120 A 004-121 A 004-122 A 004-123 A 004-124 A 004-125 A 004-126 B 004-127 A 004-128 A 004-129 A 004-130 D 004-131 B 004-132 B 004-133 B 004-134 B 004-135 B 004-136 A 004-137 A 004-138 A 004-139 A 004-140 B 004-141 A 004-142 B 004-143 A 004-144 A 004-145 A 004-146 A 004-147 A 004-148 B 004-149 A 004-150 D 004-151 D 004-152 D 004-153 D 004-154 D 004-155 A 004-156 A 004-157 B 004-158 B 004-159 A 004-160 B 004-161 B 004-162 A 004-163 A 004-164 A 004-165 A 004-166 A 004-167 A 004-168 A 004-169 A 004-170 A 004-171 A 004-172 A 004-173 A 004-174 A 004-175 A 004-176 A 004-177 B 004-178 B 004-179 A 004-180 B 004-181 A 004-182 A 004-183 C 004-184 B 004-185 A 004-186 A 004-187 A 004-188 B 004-189 C 004-190 A 004-191 B 004-192 C 004-193 C 004-194 B 004-195 A 004-196 A 004-197 A 004-198 A 004-199 A 004-200 A 004-201 A 004-202 A 004-203 A 004-204 A 004-205 A 004-206 A 004-207 A 004-208 A 004-209 A 004-210 A 004-211 D 004-212 B 004-213 B 004-214 B 004-215 A 004-216 B 004-217 A 004-218 A 004-219 A 004-220 A 004-221 A 004-222 A 004-223 A 004-224 A 004-225 B 004-226 A 004-227 A 004-228 B 004-229 A 004-230 B 004-231 B 004-232 A 004-233 D 004-234 B 004-235 A 006-002 D 006-003 D 006-005 D 006-006 D 006-007 C 006-008 D 006-009 D 006-010 C 006-011 D 006-018 C 006-020 D 006-021 B 006-022 D 006-023 B 006-024 D 006-025 D 006-026 A 006-027 D 006-028 D 006-029 D 006-030 C 006-031 D 006-032 C 006-033 B 006-034 A 006-035 A 006-036 D 006-037 C 006-038 A 006-039 A 006-040 A 006-041 A 006-042 D 006-044 B 006-045 B 006-046 B 006-047 A 006-048 D 006-049 A 006-050 B 006-051 B 006-052 A 006-053 A 006-054 A 006-055 A 006-056 A 006-057 B 006-058 B 006-059 A 006-060 A 006-061 A 006-062 A 006-063 A 006-064 B 006-065 A 006-067 C 006-068 A 006-070 A 006-071 A 006-072 B 006-073 A 006-074 D 006-075 A 006-076 A 006-077 B 006-078 A 006-079 A 006-080 A 006-081 A 006-082 A 006-083 A 006-084 A 006-085 A 006-086 A 006-087 A 006-088 B 006-089 B 006-090 D 006-091 B 006-092 A 006-093 A 006-094 B 006-095 D 006-096 B 006-097 A 006-098 A 006-099 B 006-100 A 006-101 B 006-102 B 006-103 A 006-104 A 006-107 A 006-108 B 006-109 A 006-110 A 006-111 A 006-112 A 006-113 A 006-114 A 006-115 D 006-116 A 006-118 D 006-119 B 006-120 B 006-121 A 006-122 A 006-123 A 006-124 A 006-125 A 006-126 A 006-127 B 006-128 B 006-129 A 006-130 B 006-131 A 006-132 A 006-133 B 006-134 B 006-135 A 006-136 A 006-137 B 006-138 B 006-139 B 006-140 C 006-141 D 006-142 A 006-143 A 006-144 A 006-145 A 006-146 A 006-147 A 006-148 A 006-149 B 006-150 B 006-151 B 006-152 B 006-153 A 006-154 A 006-155 A 006-156 A 006-157 A 006-158 B 006-159 A 006-160 A 006-161 A 006-162 C 006-163 A 006-164 B 006-165 B 006-166 A 006-167 A 006-168 A 006-169 A 006-170 A 006-171 A 006-172 A 006-173 A 006-174 A 006-175 B 006-176 A 006-177 A 006-178 A 006-179 C 006-180 A 006-181 D 006-182 A 006-183 A 006-184 A 006-185 B 006-186 A 006-187 A 006-188 A 006-189 B 006-190 A 006-191 B 006-192 B 006-193 A 006-194 B 006-195 A 006-196 B 006-197 B 006-198 A 006-199 A 006-200 A 006-201 A 006-202 C 006-203 D 006-204 A 006-205 A 006-206 A 006-207 A 006-208 A 006-209 A 006-210 A 006-211 A 006-212 A 006-213 A 006-214 A 006-215 A 006-216 B 006-217 A 006-218 A 006-219 A 006-220 A 006-221 A 006-222 A 006-223 A 006-224 B 006-225 B 006-226 A 006-227 A 006-228 A 006-229 A 006-230 B 006-231 A 006-232 A 006-233 B 006-234 A 006-235 B 006-236 A 006-237 A 006-238 A 006-239 A 006-240 A 006-241 A 006-242 A 006-243 B 006-244 A 006-245 A 006-246 B 006-247 A 006-248 A 006-249 A 006-250 A 006-251 A 006-252 A 006-253 B 006-254 B 006-255 A 006-256 A 006-257 A 006-258 C 006-259 A 006-260 A 006-261 A 006-262 A 006-263 A 006-264 A 006-265 B 006-266 A 006-267 A 006-268 A 006-269 B 006-270 A 006-271 A 006-272 B 006-273 D 006-274 A 006-275 A 006-276 A 006-277 A 006-278 A 006-279 A 006-280 A 006-281 A 006-282 A 006-283 B 006-284 A 006-285 A 006-286 A 006-287 A 006-288 A 006-289 A 006-290 A 006-291 B 006-292 A 006-293 A 006-294 B 006-295 B 006-296 A 006-297 A 006-298 A 006-299 A 006-300 A 006-301 B 006-302 B 006-303 A 006-304 A 006-305 B 006-306 A 006-307 A 006-308 A 006-309 A 006-310 A 006-311 A 006-312 A 006-313 A 006-314 A 006-315 A 006-316 B 006-317 A 006-318 B 006-319 B 006-320 C 006-321 A 006-322 A 006-323 A 006-324 A 006-325 A 006-326 A 006-327 A 006-328 A 006-329 A 006-330 A 006-331 A 006-332 A 006-333 A 006-334 A 006-335 A 006-336 A 006-337 B 006-338 B 006-339 B 006-340 A 006-341 B 006-342 A 006-343 A 006-344 A 006-345 A 006-346 A 006-347 B 006-348 B 006-349 A 006-350 A 006-351 A 006-352 A 006-353 A 006-354 A 006-355 A 006-356 A 006-357 B 006-358 A 006-359 A 006-360 A 006-361 A 006-362 A 006-363 A 006-364 A 006-365 A 006-366 C 006-367 B 006-368 A 006-369 A 006-370 A 006-371 A 006-372 B 006-373 A 006-374 B 006-375 A 006-376 A 006-377 A 006-378 A 006-379 A 006-380 B 006-381 B 006-382 B 006-383 A 006-384 A 006-385 A 006-386 A 006-387 A 006-388 A 006-389 A 006-390 A 006-391 B 006-392 A 006-393 B 006-394 A 006-395 B 006-396 A 006-397 A 006-398 A 006-399 A 006-400 A 006-401 B 006-402 A 006-403 B 006-404 A 006-405 A 006-406 A 006-407 A 006-408 A 006-409 A 006-410 A 006-411 A 006-412 A 006-413 A 006-414 A 006-415 A 006-416 A 006-417 A 006-418 A 006-419 A 006-420 A 006-421 C 006-422 A 006-423 B 006-424 B 006-425 B 006-426 D 006-428 C 006-429 A 006-430 A 006-431 B 006-432 B 006-433 A 006-434 C 006-435 A 006-436 B 006-437 B 006-438 B 006-439 B 006-440 B 006-441 B 006-442 A 006-443 A 006-444 C 006-445 A 006-446 B 006-447 B 006-448 C 006-449 C 006-450 D 006-451 A 006-452 A 006-453 A 006-454 A 006-455 A 006-456 A 006-457 A 006-458 A 006-459 A 006-460 A 006-461 A 006-462 A 006-463 A 006-464 A 006-465 A 006-466 B 006-467 B 006-468 A 006-469 A 006-470 B 006-471 A 006-472 A 006-473 A 006-474 A 006-475 A 006-476 A 006-477 A 006-478 A 006-479 A 006-480 A 006-481 D 006-482 A 006-483 A 006-484 B 006-485 A 006-486 A 006-487 A 006-488 A 006-489 A 006-490 C 006-491 B 006-492 B 006-493 B 006-494 B 006-495 A 006-496 A 006-497 A 006-498 A 006-499 B 006-500 B 006-501 B 006-502 A 006-503 A 006-504 C 006-505 A 006-506 A 006-507 A 006-508 A 006-509 A 006-510 A 006-511 A 006-512 A 006-513 A 006-514 C 006-515 A 006-516 A 006-517 A 006-518 C 006-519 A 006-520 A 006-521 A 006-522 A 006-523 A 006-524 A 006-525 A 006-526 A 006-527 C 006-528 B 006-529 D 006-530 A 006-531 A 006-532 D 006-533 B 006-534 D 006-535 C 006-536 D 006-537 B 006-538 A 006-539 A 006-540 A 006-541 A 006-542 A 006-543 A 006-544 A 006-545 A 006-546 A 006-547 A 006-548 A 006-549 A 006-550 A 006-551 A 006-552 B 006-553 A 006-554 B 006-555 A 006-556 A 006-557 A 006-558 A 006-559 A 006-560 B 006-561 A 006-562 A 006-563 A 006-564 D 006-565 D 006-566 D 006-567 B 006-568 C 006-569 B 006-570 B 006-571 C 006-572 B 006-573 B 006-574 B 006-575 B 006-576 A 006-577 A 006-578 A 006-579 A 006-580 A 006-581 A 006-582 A 006-583 A 006-584 A 006-585 A 006-586 A 006-587 A 006-588 A 006-589 A 006-590 A 006-591 A 006-592 A 006-593 A 006-594 A 006-595 A 006-596 A 006-597 A 006-598 A 008-001 B 008-002 B 008-003 D 008-004 A 008-005 A 008-006 A 008-007 A 008-008 A 008-009 A 008-010 A 008-011 B 010-001 A 010-002 B 012-003 D 012-004 B 012-005 B 012-006 B 012-007 D 012-008 B 012-009 A 012-012 B 012-013 B 012-014 D 012-015 C 012-016 D 012-017 D 012-018 D 012-019 C 012-020 D 012-021 A 012-022 D 012-023 D 012-024 D 012-025 B 012-026 D 012-027 C 012-028 D 012-029 D 012-030 D 012-031 B 012-032 C 012-033 B 012-034 D 012-035 D 012-036 B 012-037 C 012-038 B 014-001 A 014-002 A 014-003 C 014-004 B 014-005 A 014-007 C 014-008 D 014-009 A 014-010 B 014-011 B 014-012 C 014-013 B 014-014 A 014-015 C 014-016 A 014-017 A 014-018 B 014-019 A 014-020 D 014-021 D 016-001 D 016-005 D 016-008 D 016-009 B 016-011 D 016-012 D 016-014 D 016-015 D 016-016 D 016-017 B 016-018 D 016-020 D 016-024 D 018-001 D 019-019 D 020-002 D 022-002 D 022-003 A 022-004 D 022-005 A 022-006 C 022-007 D 022-008 D 027-001 A 027-002 B 027-003 A 027-004 A 027-005 D 027-006 D 027-007 B 027-008 B 027-009 B 027-010 B 027-011 B 027-012 C 027-013 B 027-014 B 027-015 D 027-016 D 027-017 B 027-018 C 027-019 B 027-020 B 027-021 B 027-022 B 027-023 C 027-024 B 027-025 B 027-026 C 027-027 B 027-028 B 027-029 B 027-030 B 027-031 A 027-032 A 027-033 A 027-034 B 027-035 B 027-036 A 027-037 B 027-038 B 027-039 B 027-040 B 027-041 A 027-042 A 029-001 C 029-003 B 029-004 A 029-005 A 029-006 A 029-007 B 029-008 B 029-009 D 029-010 D 029-011 D 029-012 A 029-013 B 029-014 C 029-015 C 029-016 A 029-017 A 029-018 A 029-019 A 031-001 D 031-002 D 031-003 D 031-004 B 031-005 D 031-006 D 033-002 D 033-003 D 033-004 C 033-005 D 033-006 D 033-007 D 035-001 A 035-002 A 035-003 A 035-004 A 035-005 A 035-006 A 035-007 A 035-008 A 035-009 A 035-009 B 037-001 A 037-002 A 037-003 A 037-004 A 037-005 A 039-001 A 039-002 A 039-003 A 039-004 A 039-005 C 041-001 A 041-002 A 041-003 B 041-004 C 041-005 C 041-006 C 041-007 D 041-008 B 041-009 B 041-010 A 041-011 A 041-012 A 042-000 A 043-000 A 044-000 B 045-000 D 046-000 D 047-000 C

The concentrations of test compounds were adjusted to 100 nM. The test compounds were examined using Profiler Pro kits (Caliper) in terms of activity against each of 170 types of kinases excluding Syk. As a result, highly selective compounds (Example 6-296, Example 6-368, and Example 6-395) having kinase inhibitory rates of 75% or more with respect to only 0 to 2 types of kinases were obtained. A compound (Example 6-157) having a kinase inhibitory rate of 75% or more with respect to 12 types of kinases was also obtained. Further, an inhibitor (Example 6-373) having a kinase inhibitory rate of 75% or more with respect to 24 types of kinases was obtained.

Test Example 2 TNFα Generation Assay

Table 22 shows the test results obtained by the test method described in “TNFα generation assay” in Test Example 2. In addition, the following are used in Table 22 to denote criteria for evaluating IC₅₀ in TNFα generation assay.

A: Up to 65 nM B: 65 to 130 nM C: 130 to 200 nM

TABLE 22 002-001 A 002-003 B 002-004 C 002-005 C 002-007 B 002-013 B 002-014 B 002-015 C 002-017 C 002-020 B 002-024 C 002-025 B 002-030 C 002-032 C 002-037 C 002-038 B 002-041 B 002-042 C 002-048 C 002-053 B 002-054 B 002-055 C 002-056 C 002-057 B 002-058 B 002-059 C 002-060 B 002-066 C 002-073 C 002-097 C 002-100 C 002-110 C 002-113 C 002-114 A 002-115 C 002-117 B 002-118 C 002-123 C 002-125 B 002-126 B 002-131 B 002-134 B 002-137 C 002-139 B 002-140 C 002-141 B 002-142 C 002-144 C 002-155 B 002-160 C 002-163 C 002-165 B 002-169 C 002-170 B 002-172 C 002-173 C 002-175 A 002-185 A 002-186 B 002-187 A 002-188 B 002-189 B 002-190 C 002-191 B 002-193 C 002-196 B 002-197 C 002-198 B 002-199 C 002-200 A 002-201 B 002-204 B 002-205 B 002-206 A 002-207 B 002-208 B 002-209 B 002-210 B 004-002 A 004-003 A 004-004 B 004-005 B 004-006 B 004-007 B 004-008 A 004-011 C 004-012 A 004-013 A 004-014 C 004-016 B 004-017 B 004-018 B 004-019 C 004-020 C 004-022 B 004-023 B 004-024 C 004-025 A 004-026 A 004-027 C 004-028 B 004-029 C 004-030 C 004-031 C 004-032 C 004-033 C 004-035 C 004-036 B 004-037 B 004-039 C 004-040 C 004-042 B 004-043 B 004-044 C 004-046 C 004-049 C 004-050 C 004-051 C 004-053 B 004-054 B 004-055 B 004-056 C 004-058 B 004-059 A 004-060 A 004-061 A 004-062 A 004-064 A 004-065 B 004-068 B 004-069 B 004-071 C 004-072 C 004-073 B 004-074 B 004-075 C 004-076 C 004-077 B 004-078 B 004-079 A 004-082 C 004-089 B 004-091 B 004-092 B 004-093 C 004-094 C 004-095 C 004-096 B 004-097 B 004-103 B 004-104 C 004-105 C 004-106 C 004-109 C 004-113 C 004-114 B 004-117 C 004-118 B 004-123 C 004-125 B 004-127 C 004-128 B 004-129 B 004-132 B 004-134 C 004-141 B 004-143 B 004-149 C 004-159 B 004-160 C 004-161 C 004-162 C 004-163 A 004-164 C 004-168 C 004-172 B 004-181 C 004-188 B 004-190 C 004-191 B 004-195 B 004-196 C 004-197 B 004-198 B 004-199 C 004-201 C 004-213 B 004-214 C 004-215 B 004-217 B 004-218 B 004-219 B 004-220 B 004-222 C 004-226 C 004-227 C 004-228 B 004-229 B 004-235 B 006-026 A 006-035 A 006-040 A 006-043 C 006-044 A 006-046 C 006-049 A 006-050 B 006-051 B 006-052 B 006-053 A 006-054 B 006-055 A 006-056 A 006-057 B 006-058 B 006-060 A 006-061 A 006-062 A 006-063 A 006-064 C 006-065 B 006-068 C 006-070 B 006-072 A 006-075 A 006-076 A 006-078 C 006-080 C 006-082 B 006-083 B 006-087 B 006-092 A 006-093 A 006-094 B 006-096 A 006-097 A 006-098 A 006-099 A 006-100 B 006-101 B 006-102 B 006-103 A 006-104 B 006-107 A 006-108 B 006-109 B 006-110 B 006-111 B 006-112 B 006-113 A 006-114 B 006-116 C 006-117 A 006-119 C 006-121 C 006-122 B 006-123 C 006-124 C 006-125 B 006-126 A 006-128 C 006-129 A 006-130 B 006-132 C 006-133 C 006-142 A 006-143 C 006-144 B 006-145 B 006-146 A 006-147 C 006-148 C 006-153 A 006-154 B 006-155 B 006-156 C 006-157 B 006-159 C 006-160 B 006-161 A 006-163 B 006-165 B 006-166 A 006-167 A 006-168 A 006-169 A 006-170 B 006-172 B 006-173 B 006-174 A 006-176 B 006-177 C 006-178 A 006-180 C 006-182 C 006-184 B 006-185 B 006-186 A 006-187 C 006-188 B 006-190 A 006-192 B 006-193 A 006-194 B 006-195 A 006-196 B 006-198 B 006-199 B 006-200 B 006-201 C 006-204 B 006-206 C 006-207 A 006-208 B 006-209 B 006-210 A 006-211 A 006-212 C 006-213 C 006-214 B 006-215 B 006-216 B 006-217 A 006-218 B 006-219 B 006-220 A 006-221 B 006-222 B 006-223 A 006-224 A 006-226 B 006-227 C 006-228 C 006-229 B 006-232 C 006-233 C 006-234 B 006-236 A 006-237 A 006-238 A 006-239 A 006-240 A 006-241 B 006-242 B 006-244 B 006-245 B 006-247 C 006-248 B 006-249 A 006-250 C 006-251 A 006-252 B 006-253 C 006-255 B 006-256 B 006-257 A 006-258 C 006-259 A 006-260 A 006-261 A 006-262 A 006-263 A 006-264 A 006-265 C 006-266 A 006-267 A 006-268 A 006-269 B 006-270 A 006-271 A 006-272 B 006-274 B 006-275 A 006-276 A 006-277 B 006-278 A 006-279 B 006-281 A 006-282 A 006-284 C 006-285 B 006-286 A 006-287 B 006-288 C 006-289 A 006-290 A 006-291 C 006-293 B 006-294 B 006-295 C 006-296 B 006-297 B 006-298 A 006-299 A 006-300 A 006-301 B 006-302 C 006-303 C 006-304 C 006-306 B 006-307 B 006-308 B 006-309 B 006-310 B 006-311 B 006-312 B 006-313 B 006-314 A 006-315 A 006-316 C 006-317 C 006-318 C 006-321 C 006-322 A 006-323 B 006-324 C 006-329 A 006-330 A 006-331 B 006-332 A 006-333 B 006-334 B 006-335 C 006-336 C 006-338 B 006-342 A 006-343 B 006-344 A 006-345 B 006-346 C 006-348 B 006-350 B 006-351 B 006-352 A 006-353 A 006-354 B 006-355 B 006-356 A 006-357 B 006-358 A 006-359 A 006-360 B 006-361 B 006-362 C 006-363 B 006-364 B 006-365 B 006-368 A 006-369 A 006-370 A 006-371 B 006-372 B 006-373 A 006-374 C 006-375 B 006-376 A 006-377 A 006-378 B 006-379 C 006-380 B 006-381 B 006-383 A 006-384 A 006-385 B 006-386 A 006-387 B 006-388 B 006-389 B 006-390 B 006-392 B 006-394 B 006-395 B 006-396 B 006-397 A 006-398 B 006-400 A 006-401 C 006-402 C 006-403 C 006-404 C 006-405 C 006-406 B 006-407 C 006-408 C 006-409 C 006-410 B 006-411 C 006-412 C 006-414 B 006-415 B 006-416 B 006-417 B 006-418 B 006-420 B 006-429 B 006-430 B 006-431 B 006-432 B 006-433 B 006-434 A 006-435 B 006-442 A 006-443 B 006-444 B 006-445 B 006-446 C 006-447 C 006-449 C 006-451 A 006-452 A 006-453 A 006-454 B 006-455 B 006-456 C 006-457 C 006-458 C 006-459 B 006-460 B 006-461 B 006-464 B 006-465 C 006-466 B 006-468 A 006-469 A 006-470 B 006-471 A 006-472 B 006-473 A 006-474 B 006-475 C 006-477 C 006-478 B 006-480 C 006-483 A 006-484 B 006-485 B 006-486 C 006-487 C 006-488 B 006-489 C 006-493 C 006-494 C 006-495 C 006-496 B 006-497 B 006-498 B 006-499 C 006-500 B 006-501 C 006-502 B 006-503 B 006-505 C 006-506 C 006-507 C 006-508 B 006-509 B 006-510 B 006-511 A 006-512 B 006-513 B 006-515 C 006-516 A 006-517 B 006-519 B 006-520 A 006-521 B 006-522 A 006-523 A 006-524 A 006-525 B 006-526 A 006-531 B 006-537 B 006-539 C 006-541 C 006-543 B 006-544 B 006-545 B 006-546 C 006-547 B 006-548 B 006-550 C 006-551 C 006-552 B 006-553 C 006-554 C 006-555 B 006-556 B 006-557 C 006-558 B 006-559 B 006-563 C 006-564 B 006-565 B 006-572 C 006-575 C 006-576 A 006-577 A 006-578 B 006-579 B 006-580 C 006-581 A 006-583 A 006-584 B 006-585 A 006-586 B 006-587 B 006-588 A 006-589 B 006-590 C 006-591 C 006-592 C 006-593 B 006-596 B 006-597 B 006-598 C 008-001 B 008-006 A 008-011 B 010-001 A 010-002 C 012-005 C 012-008 B 012-009 B 012-013 C 012-031 B 012-036 B 014-001 A 014-002 A 014-005 A 014-009 A 014-010 B 014-013 C 014-014 C 014-016 B 014-017 C 014-019 B 027-020 C 027-030 C 027-033 C 029-016 C 035-001 B 035-002 B 035-003 B 035-004 B 035-005 C 035-006 C 035-007 B 035-009 C 037-001 A 037-002 A 037-003 A 037-004 A 037-005 B 039-001 A 039-002 A 039-003 A 039-004 B 041-001 C 041-012 C 043-000 B 044-000 B

Test Example 3 Intracellular Phosphorylation Signaling Assay

THP-1 cells induced to differentiate by IFNγ were collected as described in Test Example 2 and incubated with test compounds for 30 minutes. Thereafter, the cells mixed with the compounds were seeded on a human IgG coating plate, followed by incubation at 37° C. for 45 minutes. Then, a cell lysate was prepared using AlphaScreen SureFire Lysis buffer (PerkinElmer). Subsequently, ImmunoPure Lane Marker Reducing Sample Buffer (Thermo) was added, followed by treatment at 95° C. for 5 minutes. Thus, Western blot samples were prepared, followed by SDS electrophoresis for protein separation, and the samples were transferred to an Immobilon FL PVDF membrane (Millipore). The membrane to which the proteins had been transferred was incubated in Odyssey Blocking buffer (LI-COR) at room temperature for 1 hour for blocking treatment. Subsequently, the proteins were reacted overnight with primary antibodies [SLP76 Antibody, AKT Antibody, Phospho-AKT (Ser473) Antibody, MEK Antibody, Phospho-MEK (Tyr128) Antibody, Phospho-p38 (Thr180/Tyr182) Antibody, Phospho-JNK (Thr183/Tyr185) Antibody (Cell Signaling Technology), Phospho-SLP76 (Tyr128) Antibody, p38 Antibody, and JNK Antibody (BD Biosciences)] at 4° C.

On the following day, the proteins were reacted with fluorescent-labeled secondary antibodies [IRDye 680 donkey anti-rabbit IgG, IRDye 680 donkey anti-mouse IgG, IRDye 800CW donkey anti-rabbit IgG, and IRDye 800CW donkey anti-mouse IgG (LI-COR)] at room temperature for 1 hour and detection was conducted using an Odyssey Infrared Imaging System. As a result, it was revealed that the addition of the compounds causes inhibition of phosphorylation of SLP76, Akt, Mek, p38MAPK, and JNK2, which are molecules located downstream of Syk, as shown in FIG. 1.

Test Example 4 Osteoclast Differentiation Assay

RAW264 cells which are mouse macrophage-like cell line were seeded on a 96 well plate (3,000 cells/well), to each cell of which RANKL (R&D) (final concentration: 150 ng/ml) and a test compound had been added, and were cultured for 4 days, followed by staining of tartrate-resistant acid phosphatase (TRAP), which is an osteoclast marker. FIG. 2 shows an example where a compound that was able to inhibit osteoclast differentiation was used.

Test Example 5 Antibody-Dependent Phagocytosis Assay

THP-1 cells (2×10⁵ cells/ml) which are human monocyte-like cell line were cultured in the presence of 10 ng/ml IFNγ for 2 days, so that the cells were induced to differentiate into macrophage-like cells. THP-1 cells that had been induced to differentiate were collected. The cells (5×10⁴ cells/well) were reacted with test compounds having given concentrations at room temperature for 30 minutes. Thereafter, Escherichia coli (Life Technologies) labeled with a pH-sensitive dye (pHrodo) was subjected to opsonization using an anti-Escherichia coli antibody (Molecular Probes). Then, the resultant was added to THP-1 cells mixed with test compounds that had been induced to differentiate, followed by incubation at 37° C. for 3 hours. At the time of addition of opsonized Escherichia coli, cell-permeable fluorescent dye (Calcein AM) were simultaneously added thereto, and phagocytosis of opsonized Escherichia coli in viable cells was quantitatively determined using an IN Cell Analyzer.

The test results obtained by the above test method are listed in Table 23 below. In addition, the following are used in Table 23 to denote standards for evaluating IC₅₀ upon phagocytosis inhibition.

A: Up to 1 μM B: 1 to 3 μM C: 3 to 6 μM

TABLE 23 002-001 B 002-134 B 004-008 A 004-013 B 004-017 C 004-031 B 004-042 B 004-060 B 004-079 B 004-120 A 004-228 B 006-021 B 006-038 B 006-049 C 006-050 C 006-052 B 006-054 B 006-060 B 006-087 B 006-098 A 006-157 A 006-165 B 006-173 B 006-177 B 006-211 B 006-219 B 006-249 B 006-257 B 006-263 B 006-270 B 006-278 B 006-301 B 006-311 B 006-322 A 006-342 B 006-368 A 006-375 B 006-376 B 006-377 B 006-383 B 006-384 A 006-395 B 006-433 B 006-468 A 008-005 B 008-006 A 008-007 C 008-009 C 012-008 B 014-001 B 022-003 B 022-005 A 029-012 C

Test Example 6 Ames Test

Four Salmonella typhimurium strains (TA100, TA1535, TA98, and TA1537) and one Escherichia coli strain (WP2uvrA) were used for the Ames test.

A solution containing a test compound (0.1 ml) was added to a test tube. 0.1 M Na-phosphate buffer (0.5 ml) was added to the tube for no metabolic activation (S9(−)) or an S-9 mix (Kikkoman) (0.5 ml) was added to the tube for metabolic activation (S9(+)). Further, a precultured bacterial cell suspension (0.1 ml) was added to the tube, followed by shaking at 37° C. for 20 minutes. Thereafter, 2-ml top agar (a solution prepared by mixing 5 mM L-histidine and a 5 mM D-biotin preparation solution at a volume ratio of 99:1 in a Bacto™ Agar aqueous solution for salmonella, or a solution prepared by mixing a 5 mM L-tryptophan aqueous solution and a 5 mM D-biotin preparation solution at a volume ratio of 99:1 in a Bacto™ Agar aqueous solution for Escherichia coli) was added, followed by sufficient stirring. The content of the tube was poured onto a minimal glucose agar plate medium and cultured at 37° C. for 48 hours.

The number of colony was counted by using an auto colony counter. In addition, the measurement value was defined as the average of colony counts for two plates.

Test results were obtained for different doses. When the average number of revertant colonies per plate for a test compound was at least two times or less than two times that for a negative control (DMSO solvent alone), such test compound was determined to yield a positive or negative test result, respectively. In addition, a test substance was comprehensively assessed to yield a positive test result when an increase in the average number of revertant colonies correlated with dose dependence or reproducibility.

Compounds listed in Table 24 were tested by the above test method. As a result, each compound was found to yield a negative test result.

TABLE 24 002-082 002-085 002-086 002-088 002-090 002-093 002-097 002-100 002-125 002-127 002-131 002-134 002-137 002-155 002-204 002-206 002-208 002-209 004-143 004-149 004-153 004-157 004-158 004-172 004-188 004-195 004-196 004-198 004-199 004-219 006-125 006-129 006-134 006-141 006-142 006-146 006-149 006-150 006-153 006-154 006-156 006-157 006-161 006-165 006-169 006-170 006-177 006-180 006-190 006-191 006-192 006-193 006-194 006-195 006-196 006-199 006-207 006-208 006-210 006-214 006-219 006-220 006-221 006-234 006-237 006-238 006-248 006-249 006-270 006-278 006-312 006-356 006-368 006-373 006-375 006-377 006-383 006-388 006-392 006-395 006-400 006-416 006-418 006-429 006-431 006-434 006-435 006-464 006-466 006-468 006-471 006-484

Test Example 7 Micronucleus Test Using Culture Cells

CHL cells (from Chinese hamster lung) were seeded on a 96 well plate (5000 cells/well) and cultured at 37° C. at 5% CO₂ for 24 hours. Thereafter, CHL cells were divided into a no metabolic activation (S9(−)) group and a metabolic activation (S9(+)) group. Phosphate buffered saline (hereinafter abbreviated as PBS(−)) or thawed frozen S-9 mix for a chromosomal abnormality test (Kikkoman) was added to each group. Test substances were also added, followed by culture at 37° C. and 5% CO₂ for 6 hours. Then, the plate was washed with PBS(−) and a culture solution (100 μl) was again added thereto, followed by culture at 37° C. and 5% CO₂ for 18 hours. Cells were fixed with ethanol, followed by removal of PBS(−). 100 μL of PBS(−) containing 2 μg/mL Hoechst 33342 (Invitrogen) and 2 μg/mL CellMask (Invitrogen) was added each cell, and the cells were stained at room temperature for 30 minutes. Cells were washed once with PBS(−), PBS(−) (100 μL) was added thereto, and image analysis was performed using an IN Cell Analyzer (GE) for detection of cells having micronuclei. At least 1000 cells were analyzed per well for calculation of the frequency of micronuclei. In addition, a cell toxicity test using CellTiter-GloBuffer (Promega) was conducted at the same time as the micronucleus test in order to assess the mutagenicity of each test substance according to the criteria described below. Dunnett's statistical analysis was conducted for a statistical significance test.

Compounds listed in Table 25 were tested by the above test method. As a result, each compound was found to yield a negative test result. The following are assessment standards.

Positive: Statistically significant increase and dose relationship Negative: No significant increase False positive: Significant increase and no dose relationship or

-   -   Significant increase and strong cell toxicity (survival rate:         50% or less)

TABLE 25 002-134 002-155 002-186 002-203 002-056 004-143 004-198 004-216 004-219 004-228 006-144 006-154 006-177 006-195 006-200 006-201 006-211 006-219 006-220 006-237 006-257 006-267 006-268 006-270 006-278 006-281 006-285 006-286 006-290 006-296 006-311 006-313 006-322 006-330 006-332 006-342 006-350 006-356 006-368 006-373 006-376 006-383 006-384 006-386 006-392 006-416 006-429 006-431 006-432 006-433 006-434 006-435 006-446 006-451 006-452 006-459 006-461 006-471 006-483 006-484 006-495 006-506 006-507 006-508 006-522 006-523 006-524 006-526

Test Example 8 Mouse Type-II-Collagen-Antibody-Induced Arthritis

The compound synthesized in Example 8-1 was tested to examine effects upon mouse-type-II-collagen-antibody-induced arthritis. An anti-type II collagen antibody mixture (Chondrex) was intraperitoneally injected into 7-week-old female BALB/c mice (Charles River Laboratories Japan, Inc.) (1.5 mg per mouse) (Day 0). An LPS solution 0111:B4 (Chondrex) (50 μg) was intraperitoneally injected thereinto three days later (Day 3), thereby inducing arthritis. Swelling scores were determined for four limbs of each mouse once daily from Day 3 to Day 14. Specifically, evaluation was carried out using a twelve-point scale for the sum of the scores for the four limbs for each mouse: 0 point: no change; 1 point: mild erythema/swelling on the carpal region or the ankle/calcaneal region; 2 points: obvious swelling on the carpal region or the ankle/calcaneal region; 3 points: severe swelling over forelimbs or hindlimbs. The compound synthesized in Example 8-1 was intraperitoneally administered at 30 mg/kg/day twice daily on consecutive days (from Day 0 to Day 13). The bone destruction score was determined based on soft X-ray images of four limbs taken on Day 14. Specifically, the osteoporosis score (0: no change; 0.5: an osteoporosis image of a joint and the vicinity of the joint) and the bone erosion score (0: no change; 1: a partial bone destruction image of a joint and the vicinity of the joint; 2: a complete bone destruction image of a joint and the vicinity of the joint) were determined for the following evaluation sites:

forelimb: the 2nd to 5th interphalangeal joints, the 1st to 5th metacarpophalangeal joints, and the carpal region; hindlimb: the 2nd to 5th interphalangeal joints, the 1st to 5th metatarsophalangeal joints, the ankle region, and the calcaneal bone. The bone destruction score was obtained as the sum of the both scores to calculate the total score for four limbs (the maximum bone destruction score: 105 points per mouse). The compound synthesized in Example 8-1 was found to have almost completely inhibited the increase in the swelling score and the increase in the bone destruction score.

Test Example 9 Mouse Type-II Collagen-Induced Arthritis (Prophylactic Administration Test and Therapeutic Administration Test)

The compounds synthesized in Example 8-1, Example 4-17, and Example 6-49 were tested to examine effects upon mouse type II collagen arthritis. To 2 mg/mL bovine type II collagen solution (Koken Co., Ltd.) dissolved in 0.1 mol/L acetic acid, an equal amount of Freund's complete adjuvant (Wako Pure Chemical Industries, Ltd.) was added to prepare an emulsion. A portion of the emulsion was intradermally injected into the tail bases of 7- or 8-week-old male DBA/1J mice (Charles River Laboratories Japan, Inc.) at a dose of 0.2 mL per mouse (antigen amount: 0.2 mg/mouse) on Day 0 and Day 21 twice, so as to induce arthritis. Each compound was administered once daily from Day 21 to Day 34 in the prophylactic administration test (1 to 30 mg/kg/day), and administered once daily from Day 27 to Day 35 in the therapeutic administration test (25 mg/kg/day). Arthritis scores for four limbs for each mouse were determined starting from Day 21. Specifically, the total score of four limbs of a mouse was designated as the individual arthritis score (12 points at a maximum per mouse) based on the following: score 0: no change; score 1: swelling of 1 or 2 digit joints or mild swelling of the carpal region/the ankle region alone; score 2: swelling of joints of at least 3 digits or obvious swelling of the carpal region/the ankle region; and score 3: obvious swelling over forelimbs or hindlimbs.

The compounds synthesized in Example 8-1, Example 4-17, and Example 6-49 strongly inhibited the advancement of arthritis after the onset, and the compound synthesized in Example 6-49 strongly inhibited advancement of arthritis in the therapeutic administration test as well.

Test Example 10 Rat Type-II-Collagen-Induced Arthritis

The compounds were tested to examine effects upon rat type II collagen arthritis. To 3 mg/mL bovine type II collagen solution (Collagen Gijutsu Kenshu-Kai) dissolved in 0.05 mol/L acetic acid, an equal amount of Freund's incomplete adjuvant (Wako Pure Chemical Industries, Ltd.) was added to prepare an emulsion. A portion of the emulsion (0.5 ml) was intradermally injected into the tail bases of 7- or 8-week-old female Lewis rats (Charles River Laboratories Japan, Inc.) (Day 0). Each rat was subjected to the same treatment on Day 7 after the initial inoculation so as to induce arthritis. Each test compound was orally administered from Day 7 to Day 20 once daily. At a given time during the period from Day 7 to Day 21, the rat hindlimb volume was determined using a plethysmometer (UGO BASILE), and the result was designated as an arthritis index. The following compound group inhibited hindlimb swelling by 85% or greater compared with the control group in the case of oral administration at 10 mg/kg/day: the compounds of Example 4-17, Example 6-49, Example 6-117, Example 6-157, Example 6-249, Example 6-322, Example 6-375, and Example 6-395.

Test Example 11 Mouse Thrombocytopenia Model

Test compounds were tested to examine effects upon mouse thrombocytopenia. Each test compound was administered to 5- to 7-week-old female CD1 mice (Charles River Laboratories Japan, Inc.). One hour thereafter, an anti-mouse CD41 (Integrin can) antibody (SCB) (1 μg (200 μl)) was intravenously administered to each mouse so as to induce thrombocytopenia. Four hours after administration of the anti-CD41 antibody, blood sampling from the saphenous vein was performed. The number of platelet was counted by using an automated hematology analyzer.

The following compounds were tested by the above test method, and as a result, improvement of the number of platelet (50% or more improvement) was observed:

Example 4-228, Example 6-165, Example 6-168, Example 6-177, Example 6-211, Example 6-249, Example 6-257, Example 6-263, Example 6-268, Example 6-296, Example 6-301, Example 6-311, Example 6-322, Example 6-342, Example 6-368, Example 6-375, Example 6-377, Example 6-383, Example 6-384, Example 6-395, Example 6-433, Example 6-435, and Example 6-468.

INDUSTRIAL APPLICABILITY

The nicotinamide derivative or a salt thereof of the present invention has excellent Syk inhibitory activity and thus is useful as a pharmaceutical composition for treatment of Syk-related diseases.

The claimed embodiments of the present inventions are described below.

(1) A nicotinamide derivative represented by the following formula (I) or a salt thereof:

wherein R¹ represents a halogen atom; R² represents a C₁₋₁₂ alkyl group optionally having at least one substituent, a C₂₋₁₂ alkenyl group optionally having at least one substituent, a C₂₋₁₂ alkynyl group optionally having at least one substituent, a C₃₋₈ cycloalkyl group optionally having at least one substituent, an aryl group optionally having at least one substituent, an ar-C₁₋₆ alkyl group optionally having at least one substituent or a heterocyclic group optionally having at least one substituent; R³ represents an aryl group optionally having at least one substituent or a heterocyclic group optionally having at least one substituent; and R⁴ and R⁵ each independently represent a hydrogen atom, a C₁₋₁₂ alkyl group optionally having at least one substituent, a C₂₋₁₂ alkenyl group optionally having at least one substituent, or a C₂₋₁₂ alkynyl group optionally having at least one substituent. (2) The nicotinamide derivative or a salt thereof according to (1), wherein the substituent optionally possessed by the C₁₋₁₂ alkyl group, C₂₋₁₂ alkenyl group, C₂₋₁₂ alkynyl group, C₃₋₈ cycloalkyl group, aryl group, ar-C₁₋₆ alkyl group or heterocyclic group, represented by R², is selected from the following substituent group α₁₋₁, wherein

the substituent group α₁₋₁ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl group optionally having at least one substituent; a C₂₋₆ alkenyl group optionally having at least one substituent; a C₂₋₆ alkynyl group optionally having at least one substituent; a C₃₋₈ cycloalkyl group optionally having at least one substituent; an aryl group optionally having at least one substituent; a C₁₋₆ alkoxy group optionally having at least one substituent; an aryloxy group optionally having at least one substituent; an acyl group optionally having at least one substituent; a C₁₋₆ alkylsulfonyl group optionally having at least one substituent; an arylsulfonyl group optionally having at least one substituent; a heterocyclic group optionally having at least one substituent; and a group represented by the formula -Q¹-Q²-NR⁶R⁷ (wherein R⁶ and R⁷ each independently represent a hydrogen atom, an amino-protecting group, a C₁₋₆ alkyl group optionally having at least one substituent, a C₂₋₆ alkenyl group optionally having at least one substituent, a C₂₋₆ alkynyl group optionally having at least one substituent, a C₃₋₈ cycloalkyl group optionally having at least one substituent, a C₁₋₆ alkoxy group optionally having at least one substituent, an aryl group optionally having at least one substituent, or a heterocyclic group optionally having at least one substituent, or R⁶ and R⁷ may form a cyclic amino group optionally having at least one substituent, together with the nitrogen atom to which they bind; Q¹ represents —NH—, a C₁₋₆ alkylene group optionally having at least one substituent, a C₂₋₆ alkynylene group optionally having at least one substituent, a C₂₋₆ alkynylene group optionally having at least one substituent, or a bond; Q² represents a group represented by —C(═X⁷)— (wherein X⁷ represents an oxygen atom, a sulfur atom, or a group represented by ═NR²⁹ (wherein R²⁹ represents a hydrogen atom, a C₁₋₁₂ alkyl group optionally having at least one substituent, a C₂₋₁₂ alkenyl group optionally having at least one substituent, a C₂₋₁₂ alkynyl group optionally having at least one substituent, a C₃₋₈ cycloalkyl group optionally having at least one substituent or a C₁₋₆ alkoxy group optionally having at least one substituent)), a C₁₋₆ alkylene group, or a bond).

(3) The nicotinamide derivative or a salt thereof according to (1) or (2), wherein the substituent optionally possessed by the C₁₋₁₂ alkyl group, C₂₋₁₂ alkenyl group, C₂₋₁₂ alkynyl group, C₃₋₈ cycloalkyl group, aryl group, ar-C₁₋₆ alkyl group or heterocyclic group, represented by R², is selected from the following substituent group α₁₋₂, wherein

the substituent group α₁₋₂ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a C₂₋₆ alkenyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a C₂₋₆ alkynyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a C₃₋₈ cycloalkyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; an aryl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a C₁₋₆ alkoxy group optionally having at least one substituent selected from the following substituent group β₁₋₁; an aryloxy group optionally having at least one substituent selected from the following substituent group β₁₋₁; an acyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a C₁₋₆ alkylsulfonyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; an arylsulfonyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a heterocyclic group optionally having at least one substituent selected from the following substituent group β₁₋₁; and a group represented by the formula -Q¹-Q²-NR⁶R⁷ (wherein Q¹, Q², R⁶ and R⁷ each have the same definitions as those described in claim 2), wherein

the substituent group β₁₋₁ consists of a halogen atom, a cyano group, a nitro group, an oxo group, an optionally protected carboxyl group, an optionally protected hydroxyl group, an optionally protected amino group, a C₁₋₆ alkyl group optionally having at least one halogen atom, a C₃₋₈ cycloalkyl group optionally having at least one halogen atom, a C₁₋₆ alkoxy group optionally having at least one halogen atom, an aryl group optionally having at least one halogen atom, and a heterocyclic group optionally having at least one halogen atom.

(4) The nicotinamide derivative or a salt thereof according to any one of (1) to (3), wherein the substituent optionally possessed by the C₁₋₁₂ alkyl group, C₂₋₁₂ alkenyl group, C₂₋₁₂ alkynyl group, C₃₋₈ cycloalkyl group, aryl group, ar-C₁₋₆ alkyl group or heterocyclic group, represented by R², is selected from the following substituent group α₁₋₃, wherein

the substituent group α₁₋₃ consists of a cyano group; an oxo group; an optionally protected hydroxyl group; an optionally protected amino group; an aryl group optionally having at least one substituent selected from the following substituent group 131-2; a C₁₋₆ alkoxy group optionally having at least one substituent selected from the following substituent group β₁₋₂; a heterocyclic group optionally having at least one substituent selected from the following substituent group β₁₋₂; and a group represented by the formula -Q¹-Q²-NR⁶R⁷ (wherein Q¹, Q², R⁶ and R⁷ each have the same definitions as those described in claim 2); wherein

the substituent group β₁₋₂ consists of a halogen atom and an optionally protected amino group.

(5) The nicotinamide derivative or a salt thereof according to any one of (1) to (4), wherein R² represents a C₁₋₁₂ alkyl group having, as a substituent, an optionally protected amino group or a heterocyclic group optionally having at least one substituent, or a C₃₋₈ cycloalkyl group having, as a substituent, an optionally protected amino group or a heterocyclic group optionally having at least one substituent. (6) The nicotinamide derivative or a salt thereof according to (1), wherein R² is a substituent represented by any one of the following formulae (II) to (V) and (VII):

wherein R¹⁰, R^(1l), R¹², R¹³, R¹⁶, R¹⁷, R¹⁸, R²⁰ and R²¹ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent, R¹⁴, R¹⁵, R¹⁹ and R³⁰ each independently represent a hydrogen atom, or a C₁₋₁₂ alkyl or acyl group, each optionally having at least one substituent, X⁸ represents an oxygen atom, a sulfur atom or ═NR²³ (wherein R²³ represents a hydrogen atom, or a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl or C₁₋₆ alkoxy group, each optionally having at least one substituent), R²² represents a heterocyclic group optionally having at least one substituent, X⁹ and X¹⁰ each independently represent an oxygen atom, —NR³¹— (wherein R³¹ represents a hydrogen atom, or a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, acyl, C₁₋₆ alkoxycarbonyl, aryloxycarbonyl or heterocyclic oxycarbonyl group, each optionally having at least one substituent), or a methylene group (wherein either one of X⁹ and X¹⁰ represents a methylene group, and when m3 is 0, X¹⁰ represents a methylene group), m1 and m3 each independently represent an integer from 0 to 2, m2 represents an integer of 1 or 2, wherein R²⁰ and R²¹ may be different from each other when m2 is 2, n represents an integer from 0 to 4, R¹⁶s may be different from one another when n is 2 to 4, and wherein R¹⁰ and R¹¹, R¹² and R¹³, R¹⁷ and R¹⁸, and R²⁰ and R²¹ may each together form a C₃₋₈ cycloalkyl or heterocyclic group, each optionally having at least one substituent. (7) The nicotinamide derivative or a salt thereof according to (6), wherein R² is a substituent represented by the following formula (II-1):

wherein R³² and R³³ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from the following substituent group γ₁₋₂, wherein

the substituent group γ₁₋₂ consists of a halogen atom, and C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl and heterocyclic groups, each optionally having at least one substituent.

(8) The nicotinamide derivative or a salt thereof according to (7), wherein R³² represents an alkyl group; an alkyl group substituted with a cycloalkyl group; a cycloalkyl group; or a cycloalkyl group substituted with an alkyl group, each containing 3 to 5 carbon atoms in total, or an alkoxyalkyl group containing 2 to 4 carbon atoms in total. (9) The nicotinamide derivative or a salt thereof according to (7), wherein R³² represents a methyl or ethyl group substituted with a heterocyclic group. (10) The nicotinamide derivative or a salt thereof according to any one of (7) to (9), wherein R³³ represents a hydrogen atom, or a C₁₋₆ alkyl or C₃₋₈ cycloalkyl group. (11) The nicotinamide derivative or a salt thereof according to (6), wherein R² is a substituent represented by the following (III-4):

(12) The nicotinamide derivative or a salt thereof according to any one of (1) to (11), wherein R⁴ and R⁵ each represent a hydrogen atom. (13) The nicotinamide derivative or a salt thereof according to any one of (1) to (6), which is represented by the following formula (I-1):

wherein R²⁶ is a substituent represented by any one of the above formulae (II) to (V) and (VII), and R³ has the same definitions as those described in claim 1. (14) The nicotinamide derivative or a salt thereof according to any one of (1) to (13), wherein the aryl group or the heterocyclic group of the aryl group or the heterocyclic group each optionally having at least one substituent, represented by R³, is a phenyl, pyridyl, pyridazinyl, quinoxalinyl or indazolyl group. (15) The nicotinamide derivative or a salt thereof according to (14), wherein the aryl group or the heterocyclic group of the aryl group or the heterocyclic group each optionally having at least one substituent, represented by R³, is a pyridyl, quinoxalinyl or indazolyl group. (16) The nicotinamide derivative or a salt thereof according to any one of (1) to (15), wherein the substituent optionally possessed by the aryl or heterocyclic group represented by R³ is selected from the following substituent group α₂₋₁, wherein

the substituent group α₂₋₁ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl group optionally having at least one substituent; a C₂₋₆ alkenyl group optionally having at least one substituent; a C₂₋₆ alkynyl group optionally having at least one substituent; a C₃₋₈ cycloalkyl group optionally having at least one substituent; an aryl group optionally having at least one substituent; a C₁₋₆ alkoxy group optionally having at least one substituent; an aryloxy group optionally having at least one substituent; an acyl group optionally having at least one substituent; a C₁₋₆ alkylsulfonyl group optionally having at least one substituent; an arylsulfonyl group optionally having at least one substituent; a heterocyclic group optionally having at least one substituent; and a group represented by the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein R²⁴ and R²⁵ each independently represent a hydrogen atom, an amino-protecting group, a C₁₋₆ alkyl group optionally having at least one substituent, a C₂₋₆ alkenyl group optionally having at least one substituent, a C₂₋₆ alkynyl group optionally having at least one substituent, a C₃₋₈ cycloalkyl group optionally having at least one substituent, a C₁₋₆ alkoxy group optionally having at least one substituent, an ar-C₁₋₆ alkyl group optionally having at least one substituent, an aryl group optionally having at least one substituent, a heterocyclic group optionally having at least one substituent, or R²⁴ and R²⁵ may form a cyclic amino group optionally having at least one substituent, together with the nitrogen atom to which they bind; Q³ represents —NH—, a C₁₋₆ alkylene group optionally having at least one substituent, a C₂₋₆ alkenylene group optionally having at least one substituent, a C₂₋₆ alkynylene group optionally having at least one substituent, or a bond; and Q⁴ represents —C(═O)—, a C₁₋₆ alkylene group, or a bond).

(17) The nicotinamide derivative or a salt thereof according to (16), wherein the substituent optionally possessed by the aryl or heterocyclic group represented by R³ is selected from the following substituent group α₂₋₂, wherein

the substituent group α₂₋₂ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a C₂₋₆ alkenyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a C₂₋₆ alkynyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a C₃₋₈ cycloalkyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; an aryl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a C₁₋₆ alkoxy group optionally having at least one substituent selected from the following substituent group β₂₋₁; an aryloxy group optionally having at least one substituent selected from the following substituent group β₂₋₁; an acyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a C₁₋₆ alkylsulfonyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; an arylsulfonyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a heterocyclic group optionally having at least one substituent selected from the following substituent group β₂₋₁; and a group represented by the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein Q³, Q⁴, R²⁴ and R²⁵ each have the same definitions as those described in claim 9); wherein

the substituent group β₂₋₁ consists of a halogen atom, a cyano group, a nitro group, an oxo group, an optionally protected carboxyl group, an optionally protected hydroxyl group, an optionally protected amino group, a C₁₋₆ alkyl group optionally having at least one halogen atom, a C₃₋₈ cycloalkyl group optionally having at least one halogen atom, a C₁₋₆ alkoxy group optionally having at least one halogen atom, an ar-C₁₋₆ alkyl group optionally having at least one halogen atom, an aryl group optionally having at least one halogen atom, and a heterocyclic group optionally having at least one halogen atom.

(18) The nicotinamide derivative or a salt thereof according to (17), wherein the substituent optionally possessed by the aryl or heterocyclic group represented by R³ is selected from the following substituent group α₂₋₃, wherein

the substituent group α₂₋₃ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected amino group; a C₁₋₆ alkyl group optionally having at least one substituent selected from the following substituent group β₂₋₂; a C₃₋₈ cycloalkyl group optionally having at least one substituent selected from the following substituent group β₂₋₂; an aryl group optionally having at least one substituent selected from the following substituent group β₂₋₂; a C₁₋₆ alkoxy group optionally having at least one substituent selected from the following substituent group β₂₋₂; an aryloxy group optionally having at least one substituent selected from the following substituent group β₂₋₂; an acyl group optionally having at least one substituent selected from the following substituent group β₂₋₂; a C₁₋₆ alkylsulfonyl group optionally having at least one substituent selected from the following substituent group β₂₋₂; a heterocyclic group optionally having at least one substituent selected from the following substituent group β₂₋₂; and a group represented by the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein Q³, Q⁴, R²⁴ and R²⁵ each have the same definitions as those described in claim 9); wherein

the substituent group β₂₋₂ consists of a halogen atom, an optionally protected hydroxyl group, a C₁₋₆ alkyl group optionally having at least one halogen atom, a C₃₋₈ cycloalkyl group optionally having at least one halogen atom, a C₁₋₆ alkoxy group optionally having at least one halogen atom, an aryl group optionally having at least one halogen atom, and a heterocyclic group optionally having at least one halogen atom.

(19) The nicotinamide derivative or a salt thereof according to any one of (1) to (18), wherein R³ represents a pyridyl group optionally having a substituent selected from the following substituent group α₂₋₄, wherein

the substituent group α₂₋₄ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from the following substituent group β₂₋₃; and the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein Q³, Q⁴, R²⁴ and R²⁵ have the same definitions as those described above); wherein

the substituent group β₂₋₃ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -Q⁵m4-R³⁶ (wherein Q⁵ represents a C₁₋₆ alkyleneoxy group (wherein the R³⁶ side is an alkylene group), R³⁶ represents a hydrogen atom, or a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl or heterocyclic group, m4 represents an integer from 1 to 3, and Q⁵s may be different from one another when m4 is 2 or 3), aryl, or heterocyclic group, each optionally having at least one halogen atom.

(20) The nicotinamide derivative or a salt thereof according to (19), wherein R³ represents a pyridyl group represented by the following formula (VIII-1) or (VIII-2):

wherein R³⁷, R³⁸, R³⁹, R⁴⁰, R⁴¹, R⁴², R⁴³ and R⁴⁴ each independently represent a hydrogen atom, or a substituent selected from the following substituent group α₂₋₆; wherein

the substituent group α₂₋₆ consists of a halogen atom; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy or heterocyclic group, each optionally having at least one substituent selected from the following substituent group β₂₋₅; wherein

the substituent group β₂₋₅ consists of a halogen atom; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, and m4 have the same definitions as those described above), aryl or heterocyclic group, each optionally having at least one halogen atom.

(21) The nicotinamide derivative or a salt thereof according to (20), wherein R³ represents a pyridyl group represented by the following formula (VIII-3) or (VIII-4):

wherein R⁴⁵, R⁴⁶, R⁴⁷ and R⁴⁸ each independently represent a hydrogen atom, or a substituent selected from the above-described substituent group α₂₋₆. (22) The nicotinamide derivative or a salt thereof according to (21), wherein R⁴⁵ represents a 5-membered ring heterocyclic group optionally having at least one substituent selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, and m4 have the same definitions as described above), and R⁴⁸ represents a halogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group. (23) The nicotinamide derivative or a salt thereof according to (21), wherein R⁴⁵ represents a halogen atom; or a C₁₋₆ alkyl or C₁₋₆ alkoxy group optionally having at least one halogen atom, and R⁴⁶ represents a 5-membered ring or 6-membered ring heterocyclic group, each optionally having at least one substituent selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, and m4 have the same definitions as those described above). (24) The nicotinamide derivative or a salt thereof according to (21), wherein R⁴⁷ and R⁴⁸ each independently represent a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy or heterocyclic group, each optionally having at least one substituent independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, and m4 have the same definitions as those described above). (25) The nicotinamide derivative or a salt thereof according to (19), wherein R³ represents an indazolyl group represented by any one of the following formulae (IX-1) to (IX-6):

wherein R⁴⁹, R⁵⁰, R⁵¹, R⁵², R⁵³, R⁵⁴, R⁵⁵, R⁵⁶, R⁵⁷, R⁵⁸, R⁵⁹, R⁶⁰, R⁶¹, R⁶², R⁶³, R⁶⁴, R⁶⁵, R⁶⁶, R⁶⁷, R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷ and R⁷⁸ each independently represent a hydrogen atom, or a substituent selected from the above-described substituent group α₂₋₆. (26) The nicotinamide derivative or a salt thereof according to (25), wherein R³ represents an indazolyl group represented by the following formula (IX-7) or (IX-8):

wherein R⁷⁹, R⁸⁰, R⁸¹ and R⁸² each independently represent a hydrogen atom, or a substituent selected from the above-described substituent group α₂₋₆. (27) The nicotinamide derivative or a salt thereof according to (1), wherein the formula (I) is represented by the following formula (I-2):

wherein R⁸³, R⁸⁴, R⁸⁵ and R⁸⁶ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent, R⁸⁷ has the same definitions as those of R³ described in claim 1, wherein R⁸³ and R⁸⁴, and R⁸⁵ and R⁸⁶ may each together form a C₃₋₈ cycloalkyl or heterocyclic group, each optionally having at least one substituent. (28) The nicotinamide derivative or a salt thereof according to (1), wherein the formula (I) is represented by the following formula (I-6):

wherein R⁹⁴ has the same definitions as those of R³ described in claim 1. (29) A pharmaceutical composition comprising the nicotinamide derivative or a salt thereof according to any one of (1) to (28). (30) The pharmaceutical composition according to (29), which is for use in the treatment of a Syk-related disease. (31) The pharmaceutical composition according to (29), which is for use in the treatment of a disease selected from the group consisting of rheumatism and idiopathic thrombocytopenic purpura. 

1. A nicotinamide derivative represented by the following formula (I) or a salt thereof:

wherein R¹ represents a halogen atom; R² represents a C₁₋₁₂ alkyl group optionally having at least one substituent, a C₂₋₁₂ alkenyl group optionally having at least one substituent, a C₂₋₁₂ alkynyl group optionally having at least one substituent, a C₃₋₈ cycloalkyl group optionally having at least one substituent, an aryl group optionally having at least one substituent, an ar-C₁₋₆ alkyl group optionally having at least one substituent or a heterocyclic group optionally having at least one substituent; R³ represents an aryl group optionally having at least one substituent or a heterocyclic group optionally having at least one substituent; and R⁴ and R⁵ each independently represent a hydrogen atom, a C₁₋₁₂ alkyl group optionally having at least one substituent, a C₂₋₁₂ alkenyl group optionally having at least one substituent, or a C₂₋₁₂ alkynyl group optionally having at least one substituent.
 2. The nicotinamide derivative or a salt thereof according to claim 1, wherein the substituent optionally possessed by the C₁₋₁₂ alkyl group, C₂₋₁₂ alkenyl group, C₂₋₁₂ alkynyl group, C₃₋₈ cycloalkyl group, aryl group, ar-C₁₋₆ alkyl group or heterocyclic group, represented by R², is selected from the following substituent group α₁₋₁, wherein the substituent group α₁₋₁ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl group optionally having at least one substituent; a C₂₋₆ alkenyl group optionally having at least one substituent; a C₂₋₆ alkynyl group optionally having at least one substituent; a C₃₋₈ cycloalkyl group optionally having at least one substituent; an aryl group optionally having at least one substituent; a C₁₋₆ alkoxy group optionally having at least one substituent; an aryloxy group optionally having at least one substituent; an acyl group optionally having at least one substituent; a C₁₋₆ alkylsulfonyl group optionally having at least one substituent; an arylsulfonyl group optionally having at least one substituent; a heterocyclic group optionally having at least one substituent; and a group represented by the formula -Q¹-Q²-NR⁶R⁷ (wherein R⁶ and R⁷ each independently represent a hydrogen atom, an amino-protecting group, a C₁₋₆ alkyl group optionally having at least one substituent, a C₂₋₆ alkenyl group optionally having at least one substituent, a C₂₋₆ alkynyl group optionally having at least one substituent, a C₃₋₈ cycloalkyl group optionally having at least one substituent, a C₁₋₆ alkoxy group optionally having at least one substituent, an aryl group optionally having at least one substituent, or a heterocyclic group optionally having at least one substituent, or R⁶ and R⁷ may form a cyclic amino group optionally having at least one substituent, together with the nitrogen atom to which they bind; Q¹ represents —NH—, a C₁₋₆ alkylene group optionally having at least one substituent, a C₂₋₆ alkenylene group optionally having at least one substituent, a C₂₋₆ alkynylene group optionally having at least one substituent, or a bond; Q² represents a group represented by —C(═X⁷)— (wherein X⁷ represents an oxygen atom, a sulfur atom, or a group represented by ═NR²⁹ (wherein R²⁹ represents a hydrogen atom, a C₁₋₁₂ alkyl group optionally having at least one substituent, a C₂₋₁₂ alkenyl group optionally having at least one substituent, a C₂₋₁₂ alkynyl group optionally having at least one substituent, a C₃₋₈ cycloalkyl group optionally having at least one substituent or a C₁₋₆ alkoxy group optionally having at least one substituent)), a C₁₋₆ alkylene group, or a bond).
 3. The nicotinamide derivative or a salt thereof according to claim 1, wherein the substituent optionally possessed by the C₁₋₁₂ alkyl group, C₂₋₁₂ alkenyl group, C₂₋₁₂ alkynyl group, C₃₋₈ cycloalkyl group, aryl group, ar-C₁₋₆ alkyl group or heterocyclic group, represented by R², is selected from the following substituent group α₁₋₂, wherein the substituent group α₁₋₂ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a C₂₋₆ alkenyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a C₂₋₆ alkynyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a C₃₋₈ cycloalkyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; an aryl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a C₁₋₆ alkoxy group optionally having at least one substituent selected from the following substituent group β₁₋₁; an aryloxy group optionally having at least one substituent selected from the following substituent group β₁₋₁; an acyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a C₁₋₆ alkylsulfonyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; an arylsulfonyl group optionally having at least one substituent selected from the following substituent group β₁₋₁; a heterocyclic group optionally having at least one substituent selected from the following substituent group β₁₋₁; and a group represented by the formula -Q¹-Q²-NR⁶R⁷ (wherein Q¹, Q², R⁶ and R⁷ each have the same definitions as those described in claim 2), wherein the substituent group β₁₋₁, consists of a halogen atom, a cyano group, a nitro group, an oxo group, an optionally protected carboxyl group, an optionally protected hydroxyl group, an optionally protected amino group, a C₁₋₆ alkyl group optionally having at least one halogen atom, a C₃₋₈ cycloalkyl group optionally having at least one halogen atom, a C₁₋₆ alkoxy group optionally having at least one halogen atom, an aryl group optionally having at least one halogen atom, and a heterocyclic group optionally having at least one halogen atom.
 4. The nicotinamide derivative or a salt thereof according to claim 1, wherein the substituent optionally possessed by the C₁₋₁₂ alkyl group, C₂₋₁₂ alkenyl group, C₂₋₁₂ alkynyl group, C₃₋₈ cycloalkyl group, aryl group, ar-C₁₋₆ alkyl group or heterocyclic group, represented by R², is selected from the following substituent group α₁₋₃, wherein the substituent group α₁₋₃ consists of a cyano group; an oxo group; an optionally protected hydroxyl group; an optionally protected amino group; an aryl group optionally having at least one substituent selected from the following substituent group β₁₋₂; a C₁₋₆ alkoxy group optionally having at least one substituent selected from the following substituent group β₁₋₂; a heterocyclic group optionally having at least one substituent selected from the following substituent group β₁₋₂; and a group represented by the formula -Q¹-Q²-NR⁶R⁷ (wherein Q¹, Q², R⁶ and R⁷ each have the same definitions as those described in claim 2); wherein the substituent group β₁₋₂ consists of a halogen atom and an optionally protected amino group.
 5. The nicotinamide derivative or a salt thereof according to claim 1, wherein R² represents a C₁₋₁₂ alkyl group having, as a substituent, an optionally protected amino group or a heterocyclic group optionally having at least one substituent, or a C₃₋₈ cycloalkyl group having, as a substituent, an optionally protected amino group or a heterocyclic group optionally having at least one substituent.
 6. The nicotinamide derivative or a salt thereof according to claim 1, wherein R² is a substituent represented by any one of the following formulae (II) to (V) and (VII):

wherein R¹⁰, R¹¹, R¹², R¹³, R¹⁶, R¹⁷, R¹⁸, R²⁰ and R²¹ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent, R¹⁴, R¹⁵, R¹⁹ and R³⁰ each independently represent a hydrogen atom, or a C₁₋₁₂ alkyl or acyl group, each optionally having at least one substituent, X⁸ represents an oxygen atom, a sulfur atom or ═NR²³ (wherein R²³ represents a hydrogen atom, or a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl or C₁₋₆ alkoxy group, each optionally having at least one substituent), R²² represents a heterocyclic group optionally having at least one substituent, X⁹ and X¹⁰ each independently represent an oxygen atom, —NR³¹— (wherein R³¹ represents a hydrogen atom, or a C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, acyl, C₁₋₆ alkoxycarbonyl, aryloxycarbonyl or heterocyclic oxycarbonyl group, each optionally having at least one substituent), or a methylene group (wherein either one of X⁹ and X¹⁰ represents a methylene group, and when m3 is 0, X¹⁰ represents a methylene group), m1 and m3 each independently represent an integer from 0 to 2, m2 represents an integer of 1 or 2, wherein R²⁰ and R²¹ may be different from each other when m2 is 2, n represents an integer from 0 to 4, R¹⁶s may be different from one another when n is 2 to 4, and wherein R¹⁰ and R¹¹, R¹² and R¹³, R¹⁷ and R¹⁸, and R²⁰ and R²¹ may each together form a C₃₋₈ cycloalkyl or heterocyclic group, each optionally having at least one substituent.
 7. The nicotinamide derivative or a salt thereof according to claim 6, wherein R² is a substituent represented by the following formula (II-1):

wherein R³² and R³³ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from the following substituent group γ₁₋₂, wherein the substituent group γ₁₋₂ consists of a halogen atom, and C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl and heterocyclic groups, each optionally having at least one substituent.
 8. The nicotinamide derivative or a salt thereof according to claim 7, wherein R³² represents an alkyl group; an alkyl group substituted with a cycloalkyl group; a cycloalkyl group; or a cycloalkyl group substituted with an alkyl group, each containing 3 to 5 carbon atoms in total, or an alkoxyalkyl group containing 2 to 4 carbon atoms in total.
 9. The nicotinamide derivative or a salt thereof according to claim 7, wherein R³² represents a methyl or ethyl group substituted with a heterocyclic group.
 10. The nicotinamide derivative or a salt thereof according to claim 7, wherein R³³ represents a hydrogen atom, or a C₁₋₆ alkyl or C₃₋₈ cycloalkyl group.
 11. The nicotinamide derivative or a salt thereof according to claim 6, wherein R² is a substituent represented by the following (III-4):


12. The nicotinamide derivative or a salt thereof according to claim 1, wherein R⁴ and R⁵ each represent a hydrogen atom.
 13. The nicotinamide derivative or a salt thereof according to claim 1, which is represented by the following formula (I-1):

wherein R²⁶ is a substituent represented by any one of the above formulae (II) to (V) and (VII), and R³ has the same definitions as those described in claim
 1. 14. The nicotinamide derivative or a salt thereof according to claim 1, wherein the aryl group or the heterocyclic group of the aryl group or the heterocyclic group each optionally having at least one substituent, represented by R³, is a phenyl, pyridyl, pyridazinyl, quinoxalinyl or indazolyl group.
 15. The nicotinamide derivative or a salt thereof according to claim 14, wherein the aryl group or the heterocyclic group of the aryl group or the heterocyclic group each optionally having at least one substituent, represented by R³, is a pyridyl, quinoxalinyl or indazolyl group.
 16. The nicotinamide derivative or a salt thereof according to claim 1, wherein the substituent optionally possessed by the aryl or heterocyclic group represented by R³ is selected from the following substituent group α₂₋₁, wherein the substituent group α₂₋₁ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl group optionally having at least one substituent; a C₂₋₆ alkenyl group optionally having at least one substituent; a C₂₋₆ alkynyl group optionally having at least one substituent; a C₃₋₈ cycloalkyl group optionally having at least one substituent; an aryl group optionally having at least one substituent; a C₁₋₆ alkoxy group optionally having at least one substituent; an aryloxy group optionally having at least one substituent; an acyl group optionally having at least one substituent; a C₁₋₆ alkylsulfonyl group optionally having at least one substituent; an arylsulfonyl group optionally having at least one substituent; a heterocyclic group optionally having at least one substituent; and a group represented by the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein R²⁴ and R²⁵ each independently represent a hydrogen atom, an amino-protecting group, a C₁₋₆ alkyl group optionally having at least one substituent, a C₂₋₆ alkenyl group optionally having at least one substituent, a C₂₋₆ alkynyl group optionally having at least one substituent, a C₃₋₈ cycloalkyl group optionally having at least one substituent, a C₁₋₆ alkoxy group optionally having at least one substituent, an ar-C₁₋₆ alkyl group optionally having at least one substituent, an aryl group optionally having at least one substituent, a heterocyclic group optionally having at least one substituent, or R²⁴ and R²⁵ may form a cyclic amino group optionally having at least one substituent, together with the nitrogen atom to which they bind; Q³ represents —NH—, a C₁₋₆ alkylene group optionally having at least one substituent, a C₂₋₆ alkenylene group optionally having at least one substituent, a C₂₋₆ alkynylene group optionally having at least one substituent, or a bond; and Q⁴ represents —C(═O)—, a C₁₋₆ alkylene group, or a bond).
 17. The nicotinamide derivative or a salt thereof according to claim 16, wherein the substituent optionally possessed by the aryl or heterocyclic group represented by R³ is selected from the following substituent group α₂₋₂, wherein the substituent group α₂₋₂ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a C₂₋₆ alkenyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a C₂₋₆ alkynyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a C₃₋₈ cycloalkyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; an aryl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a C₁₋₆ alkoxy group optionally having at least one substituent selected from the following substituent group β₂₋₁; an aryloxy group optionally having at least one substituent selected from the following substituent group β₂₋₁; an acyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a C₁₋₆ alkylsulfonyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; an arylsulfonyl group optionally having at least one substituent selected from the following substituent group β₂₋₁; a heterocyclic group optionally having at least one substituent selected from the following substituent group β₂₋₁; and a group represented by the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein Q³, Q⁴, R²⁴ and R²⁵ each have the same definitions as those described in claim 9); wherein the substituent group β₂₋₁ consists of a halogen atom, a cyano group, a nitro group, an oxo group, an optionally protected carboxyl group, an optionally protected hydroxyl group, an optionally protected amino group, a C₁₋₆ alkyl group optionally having at least one halogen atom, a C₃₋₈ cycloalkyl group optionally having at least one halogen atom, a C₁₋₆ alkoxy group optionally having at least one halogen atom, an ar-C₁₋₆ alkyl group optionally having at least one halogen atom, an aryl group optionally having at least one halogen atom, and a heterocyclic group optionally having at least one halogen atom.
 18. The nicotinamide derivative or a salt thereof according to claim 17, wherein the substituent optionally possessed by the aryl or heterocyclic group represented by R³ is selected from the following substituent group α₂₋₃, wherein the substituent group α₂₋₃ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected amino group; a C₁₋₆ alkyl group optionally having at least one substituent selected from the following substituent group β₂₋₂; a C₃₋₈ cycloalkyl group optionally having at least one substituent selected from the following substituent group β₂₋₂; an aryl group optionally having at least one substituent selected from the following substituent group β₂₋₂; a C₁₋₆ alkoxy group optionally having at least one substituent selected from the following substituent group β₂₋₂; an aryloxy group optionally having at least one substituent selected from the following substituent group β₂₋₂; an acyl group optionally having at least one substituent selected from the following substituent group β₂₋₂; a C₁₋₆ alkylsulfonyl group optionally having at least one substituent selected from the following substituent group β₂₋₂; a heterocyclic group optionally having at least one substituent selected from the following substituent group β₂₋₂; and a group represented by the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein Q³, Q⁴, R²⁴ and R²⁵ each have the same definitions as those described in claim 9); wherein the substituent group β₂₋₂ consists of a halogen atom, an optionally protected hydroxyl group, a C₁₋₆ alkyl group optionally having at least one halogen atom, a C₃₋₈ cycloalkyl group optionally having at least one halogen atom, a C₁₋₆ alkoxy group optionally having at least one halogen atom, an aryl group optionally having at least one halogen atom, and a heterocyclic group optionally having at least one halogen atom.
 19. The nicotinamide derivative or a salt thereof according to claim 1, wherein R³ represents a pyridyl group optionally having a substituent selected from the following substituent group α₂₋₄, wherein the substituent group α₂₋₄ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent selected from the following substituent group β₂₋₃; and the formula -Q³-Q⁴-NR²⁴R²⁵ (wherein Q³, Q⁴, R²⁴ and R²⁵ have the same definitions as those described above); wherein the substituent group β₂₋₃ consists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -Q⁵m4-R³⁶ (wherein Q⁵ represents a C₁₋₆ alkyleneoxy group (wherein the R³⁶ side is an alkylene group), R³⁶ represents a hydrogen atom, or a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl or heterocyclic group, m4 represents an integer from 1 to 3, and Q⁵s may be different from one another when m4 is 2 or 3), aryl, or heterocyclic group, each optionally having at least one halogen atom.
 20. The nicotinamide derivative or a salt thereof according to claim 19, wherein R³ represents a pyridyl group represented by the following formula (VIII-1) or (VIII-2):

 wherein R³⁷, R³⁸, R³⁹, R⁴⁰, R⁴¹, R⁴², R⁴³ and R⁴⁴ each independently represent a hydrogen atom, or a substituent selected from the following substituent group α₂₋₆; wherein the substituent group α₂₋₆ consists of a halogen atom; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy or heterocyclic group, each optionally having at least one substituent selected from the following substituent group β₂₋₅; wherein the substituent group β₂₋₅ consists of a halogen atom; and a C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, and m4 have the same definitions as those described above), aryl or heterocyclic group, each optionally having at least one halogen atom.
 21. The nicotinamide derivative or a salt thereof according to claim 20, wherein R³ represents a pyridyl group represented by the following formula (VIII-3) or (VIII-4):

 wherein R⁴⁵, R⁴⁶, R⁴⁷ and R⁴⁸ each independently represent a hydrogen atom, or a substituent selected from the above-described substituent group α₂₋₆.
 22. The nicotinamide derivative or a salt thereof according to claim 21, wherein R⁴⁵ represents a 5-membered ring heterocyclic group optionally having at least one substituent selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, and m4 have the same definitions as described above), and R⁴⁸ represents a halogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group.
 23. The nicotinamide derivative or a salt thereof according to claim 21, wherein R⁴⁵ represents a halogen atom; or a C₁₋₆ alkyl or C₁₋₆ alkoxy group optionally having at least one halogen atom, and R⁴⁶ represents a 5-membered ring or 6-membered ring heterocyclic group, each optionally having at least one substituent selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, and m4 have the same definitions as those described above).
 24. The nicotinamide derivative or a salt thereof according to claim 21, wherein R⁴⁷ and R⁴⁸ each independently represent a hydrogen atom; a halogen atom; or a C₁₋₆ alkyl, aryl, C₁₋₆ alkoxy or heterocyclic group, each optionally having at least one substituent independently selected from among a halogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl and -Q⁵m4-R³⁶ (wherein Q⁵, R³⁶, and m4 have the same definitions as those described above).
 25. The nicotinamide derivative or a salt thereof according to claim 19, wherein R³ represents an indazolyl group represented by any one of the following formulae (IX-1) to (IX-6):

wherein R⁴⁹, R⁵⁰, R⁵¹, R⁵², R⁵³, R⁵⁴, R⁵⁵, R⁵⁶, R⁵⁷, R⁵⁸, R⁵⁹, R⁶⁰, R⁶¹, R⁶², R⁶³, R⁶⁴, R⁶⁵, R⁶⁶, R⁶⁷, R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷ and R⁷⁸ each independently represent a hydrogen atom, or a substituent selected from the above-described substituent group α₂₋₆.
 26. The nicotinamide derivative or a salt thereof according to claim 25, wherein R³ represents an indazolyl group represented by the following formula (IX-7) or (IX-8):

wherein R⁷⁹, R⁸⁰, R⁸¹ and R⁸² each independently represent a hydrogen atom, or a substituent selected from the above-described substituent group α₂₋₆.
 27. The nicotinamide derivative or a salt thereof according to claim 1, wherein the formula (I) is represented by the following formula (I-2):

wherein R⁸³, R⁸⁴, R⁸⁵ and R⁸⁶ each independently represent a hydrogen atom, or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, aryl, C₁₋₆ alkoxy, aryloxy, acyl, C₁₋₆ alkylsulfonyl, arylsulfonyl or heterocyclic group, each optionally having at least one substituent, R⁸⁷ has the same definitions as those of R³ described in claim 1, wherein R⁸³ and R⁸⁴, and R⁸⁵ and R⁸⁶ may each together form a C₃₋₈ cycloalkyl or heterocyclic group, each optionally having at least one substituent.
 28. The nicotinamide derivative or a salt thereof according to claim 1, wherein the formula (I) is represented by the following formula (I-6):

wherein R⁹⁴ has the same definitions as those of R³ described in claim
 1. 29. A pharmaceutical composition comprising the nicotinamide derivative or a salt thereof according to claim
 1. 30. The pharmaceutical composition according to claim 29, which is for use in the treatment of a Syk-related disease.
 31. The pharmaceutical composition according to claim 29, which is for use in the treatment of a disease selected from the group consisting of rheumatism and idiopathic thrombocytopenic purpura. 